<SEC-DOCUMENT>0001628280-20-012738.txt : 20200814
<SEC-HEADER>0001628280-20-012738.hdr.sgml : 20200814
<ACCEPTANCE-DATETIME>20200814170815
ACCESSION NUMBER:		0001628280-20-012738
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200814
DATE AS OF CHANGE:		20200814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		201106468

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20200630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:fc80af1c-b60e-447a-a71f-0452a1e7408c,g:c711355c-b1ef-45b3-aa25-450d0075a667,d:60c789aa695e441494b09d48a21e5c74--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:cpix="http://www.cumberlandpharma.com/20200630" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20200630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGFibGU6YzBmZjJhZTk2NWEzNDhlMWE2YTE0ZjIxMjRmNzY0NjYvdGFibGVyYW5nZTpjMGZmMmFlOTY1YTM0OGUxYTZhMTRmMjEyNGY3NjQ2Nl81LTEtMS0xLTA_2ffdc9d7-cf6a-460b-a32b-5be67c58f44f">2020</ix:nonNumeric><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGFibGU6YzBmZjJhZTk2NWEzNDhlMWE2YTE0ZjIxMjRmNzY0NjYvdGFibGVyYW5nZTpjMGZmMmFlOTY1YTM0OGUxYTZhMTRmMjEyNGY3NjQ2Nl82LTEtMS0xLTA_8cbcdc30-3385-447f-a85b-3e981243b978">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGFibGU6YzBmZjJhZTk2NWEzNDhlMWE2YTE0ZjIxMjRmNzY0NjYvdGFibGVyYW5nZTpjMGZmMmFlOTY1YTM0OGUxYTZhMTRmMjEyNGY3NjQ2Nl83LTEtMS0xLTA_0aab578f-e96d-42d4-b786-2a2cd91ef98e">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGV4dHJlZ2lvbjoxMWRiY2U4YjRjNjA0MjZjYWJkYTgxYTExMzcyYTQ1Zl83OQ_39c3d227-99c9-4a3e-9b81-11d4d3b34bba">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGV4dHJlZ2lvbjoxMWRiY2U4YjRjNjA0MjZjYWJkYTgxYTExMzcyYTQ1Zl84MA_232b9f05-c017-4589-af8f-700ae47d624d">0001087294</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20200630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="iaafea39242fe45dfbb5917478334e41d_I20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic125e85e38194740b3b6e42596d48565_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4cd51a619a04cf88ce903ca6be458df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3afa198dbba942a8a7bb26d3c8157c4d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b29c2b729c047069c2f8e4ed4afac13_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77939a55b3504e7ea9bf84d21f5ab999_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i614de951b5564e1aa4a9b1cd5dd0b630_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b0a727080d249279283aba5d6854990_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23c7a1f4a90472a8b17ffd7485c2576_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f01311cc044c44bc525d43248d6c74_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f88a5961fc427a9c998030dc46f114_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea30b21c62f403ea68c6689d93cd21d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974df3aa74f74bdda4d426ab248294a8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f525b0defd4b22ab5cb985179a3531_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2d8f136b4c4979a189712441c7cf09_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c307de3b4e5439ebd106206ec278efd_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4d219a9d4941c3950eb19706eb7a5c_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8bcdfaca924879b5b43dd5bddd703a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i067cca3f781144dd860b28147290813f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae43656c3c484911bf5d613a8a8e45be_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555b1189aac24c028c9886b3795085a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f2d546729f4a7388d0da7c59afeefd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0768144df9f74550ab2219166aa29003_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9594a27a8953498781fa2c5b518d8690_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b35cee38dff4f04bdb57a8e96d4e329_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a024f6a04f4471a56faa5a162c173b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c893f1703e4ba7b7c6c8a4e8d3796d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17bd2f5664584e4e961c165808307967_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab2bd5c666b24aa0b832eb6b9d845d8c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45bf4110d4a5466bb3c612fbfef3c696_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66d5c13fd94d4f238dd81f8caf9f3403_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c7c34335f54f47863478492f5a0e20_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f61c1f6404247408b4f8f98b89594d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabb40a61c7844cbe9615cb5fbe8dba63_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="i5f3a745bf4174278a74c0d5a8fa02da3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea52a7e581244558e3b890ffe46b51c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia322c6d2a6df4e9fa5ed3bb2684d5ddc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9323653bab9c4287addb88df384f442e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd57a040d73460c9eb5b7058fff5111_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41ac3abceec4ba59776f3a5132e11cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e21e374e0f74f1598291e91e92c3d51_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92c97dcff25b433083d6b0f9f881f774_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia08b7430594741ebaab75913bbcae614_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id509d7930bbf4bd694189ff99605fa09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5669834e215b45b99cc41e3d665e69a1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68a865edbbc4fa68606bf229911a560_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b378ebb06a479bbf879faf98e19814_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc949d2f070b4f25affead2a375d491e_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf47d357fe2412f8af2acff2342ebb6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc40475e1a9d4a6bb5ec18bfe4e3e1b3_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6b3dd0ec548447582e12cdbcd66e63b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd0d5dd3b844bdaa5729899189c6770_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd91fba54ac84e0a8c8bd5e8f448455f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a5687dc8d944909b67b606cb812cce_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e3f32cd85cd4f9e996353f5f78ff1b7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ca879e8d4a47f39f75644f1ed2d685_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea199d488f3d4c6fbdc6df78ea63c963_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285e24ce4de04744ab32c8c31fb15880_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdbdea3b95045f39274bd68ed525b3e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810c3828a9d245e9a17ec124b2f9b2e8_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6deafdc7c3545129085c07232f96d65_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de4abd6721c4ddfae052da0cb09699a_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566675b7d46442779736a5e02fec5bb6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fe634f61a1e4a5a9ad7dcfe2f238132_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia147af4d03624f11ac640a8b4886b751_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i217c307695d149f3a072f507e80428e0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1febb70c5d54883bd12e7f1136868a7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aaf60aeada144d6b60fa49b4caff778_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1b0b04c6a4448c9bdd40023c85de9c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i410438689ecc46098ef7e58bf86b9e48_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918c1048efdc4eeaa992c0bef857728b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia46fcc7519ab4d55866e429c4169b5c6_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338997cfd24048679aea6c8ed87a43ce_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7262f7e4e1134261beeed2cb335a5dc1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17b3c50fbe874b3196c15fa2ac7f84ee_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i798cb1e7aeb14bf4a99ccd87345abcd7_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9476294995c8476c8cf46424d7813e1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4c685386484241a88e1c0f981bdbb1c0_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90f8ddce573e405db035f43203edac82_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34205ca5f1bd40e4bc73ff67fce99b21_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70788808c3514d7cb738bf570ee8ecab_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326c4e1bbd4143b0991323596e8218e2_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4932bbb650d149da92ef6f0570dbee67_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1abd143533634e079845141c8834cf0d_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2811f76482b0428a8411c4d8087350fc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576c01f880e64cda9a7bae358c95e641_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3072a59195c43eb83bc07add8758654_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09748a76bfe44299df7ff1fe1acec07_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c8bad9e0024da2b5f4ecd513ca3279_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23ab79d4c84449990786e49b3945c33_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf877f310c4d446597ea48ad1a455784_I20181017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a59ea378ede42c9b6cecb1b250655ca_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814c31ba70e6430d9e51bcc5840e4ac9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc647785e8e346e4a56e83e0cc7fa9ca_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7363b185835a4fefb0d6e62a0ebf0dfc_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8648009ac16482485d4df4b4a6b9fa6_I20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53b0f9aa7b34fdab1a8da61d4eedd27_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a665abb669e4b8294fe2d11afdae64b_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c77d503275442c7bd85a5f3a65d371a_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id334b396a4b3435091868e865fabd32c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf017760b38441c1af2d35a25e124e99_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89bcb77f46a4517a75030c3a28c5b4f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if905a7f82f44495396e2179b4d0584ba_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4c0cae1876488cbb05cfd3be1ad10d_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3a989ff74234cd4a92b992a22f309d6_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ecb77eacf14a63afd0516b29399c0a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575e7871cbfc48ecb68373ff71bde4cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484fde4f0aac43cf954b8569b221802d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0967848cdd484daebc2c83c3e623f456_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb806d70ebf248d28f3e9175478166e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb4e69141de4966aa42c82e466f9e01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i60c789aa695e441494b09d48a21e5c74_1"></div><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:3pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIz_8f7a5473-8676-4bb6-8de8-528197d11a85">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6NWIzNmM5ZDA2YTBhNDdjM2JmNWI3ZTFjZGIzYmQxN2YvdGFibGVyYW5nZTo1YjM2YzlkMDZhMGE0N2MzYmY1YjdlMWNkYjNiZDE3Zl8wLTAtMS0xLTA_8b7755ea-b1d1-433f-be8a-0ee65127bccd">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY183Njk2NTgxMzk2NDkw_481ea127-a63d-40a5-8627-16f24f7947fa">June 30, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6Y2JiYTkwYzc0NjcyNDFkNDhjZjhhZGFkYWNkYTM1OGMvdGFibGVyYW5nZTpjYmJhOTBjNzQ2NzI0MWQ0OGNmOGFkYWRhY2RhMzU4Y18wLTAtMS0xLTA_8d62b07a-872b-4891-b8d6-4a11e1080b48">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number: <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDE5_98424cee-fdbc-4819-a2af-b99b34fdeb2a">001-33637</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIw_259c198b-a3d4-4ca2-b2b5-54f55b45f3fb">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified In Its Charter)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:47.632%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.725%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8wLTAtMS0xLTA_bc122903-834d-4367-ab29-b46681ab1063">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8wLTItMS0xLTA_8dcbc135-6378-4045-88f4-8f93b37e3e67">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(State or Other Jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Incorporation or Organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV81_eaa3b693-f336-4d8e-a55b-316f1be50bbc">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV85_1974e986-1a73-439d-a19d-7f52598a3471">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV8xMw_a39332c3-b251-4005-bd62-f120298ebbde">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV8xNw_f498b3e4-57f9-447d-a34f-0a3c0ad7693d">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTItMS0xLTA_b03a056d-e70f-48ac-9798-74c4a1680c6e">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIx_1cd3885b-ef55-4e34-930d-a515573645c3">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDI1_6028160f-7285-4ef6-aa61-e2f11fd4e500">255-0068</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDI2_efa46a27-864b-48ab-9dd9-cd9fe775eb4c">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;"> <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIy_9f712e0f-d252-4e5b-a171-b6d111bcb5b0">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:21.391%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.285%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:40.836%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.431%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:24.023%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.434%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ODhkNTUxZDhmMTI4NGE3MzlhYzlmNTliNzQ1NjVjMDIvdGFibGVyYW5nZTo4OGQ1NTFkOGYxMjg0YTczOWFjOWY1OWI3NDU2NWMwMl8xLTAtMS0xLTA_4eb8eabd-1880-4681-ba12-98500bc36899">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ODhkNTUxZDhmMTI4NGE3MzlhYzlmNTliNzQ1NjVjMDIvdGFibGVyYW5nZTo4OGQ1NTFkOGYxMjg0YTczOWFjOWY1OWI3NDU2NWMwMl8xLTUtMS0xLTA_5fb8e25e-c134-452a-a9af-1e503904ffea">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Emerging growth company</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ODhkNTUxZDhmMTI4NGE3MzlhYzlmNTliNzQ1NjVjMDIvdGFibGVyYW5nZTo4OGQ1NTFkOGYxMjg0YTczOWFjOWY1OWI3NDU2NWMwMl8yLTItMS0xLTA_197ac007-1fc7-4504-96a0-3dcec352095e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDE2_b76d841b-fcf1-4a63-b117-ccdc9db9c540">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:22.594%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.727%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.315%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of exchanged on which registered</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding&#160;at August 10, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTAtMS0xLTA_ba2584f6-67cd-47df-9f9b-8a95a1c6f016">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTItMS0xLTA_5653a83c-689e-48c0-b8b9-637d6f3033a0">CPIX</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTQtMS0xLTA_81de71d1-7c80-4826-a604-d21b12342df9">NASDAQ Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iaafea39242fe45dfbb5917478334e41d_I20200810" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTYtMS0xLTA_1bbffb76-e43d-4ec7-94d0-88967a844ea0">15,138,623</ix:nonFraction></span></td></tr></table></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:9pt;"><span><br/></span></div><div id="i60c789aa695e441494b09d48a21e5c74_7"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:81.431%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.569%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_10">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_13">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_16">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_19">2</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_22">3</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_25">4</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_28">5</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_64">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_64">15</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_85">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_85">26</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_88">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_88">27</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_91">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_91">28</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_94">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_94">28</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_97">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_97">28</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_100">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_100">28</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">Item&#160;</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">5</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103"> Submission of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">Matters to a Vote of Securi</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">ty Holders</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_538">28</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_103">29</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_106">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i60c789aa695e441494b09d48a21e5c74_106">30</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i60c789aa695e441494b09d48a21e5c74_13"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i60c789aa695e441494b09d48a21e5c74_16"></div><div style="text-align:center;margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:58.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.618%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMy0xLTEtMS0w_45a35764-059b-4f47-a497-975f8e4f263d">27,373,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMy0zLTEtMS0w_2788aabe-68e1-4a24-9b74-74f7b932f5a5">28,212,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNS0xLTEtMS0w_e6bbbba7-d974-4e6d-85ae-f55e884a7e77">7,924,338</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNS0zLTEtMS0w_6947ada6-43e3-4f7f-b018-a1f621027208">7,843,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNi0xLTEtMS0w_5f512f0d-085c-48aa-aceb-2b797505730e">7,627,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNi0zLTEtMS0w_a352cb8e-6cc3-4461-bcd7-1b76e49b9c6b">8,871,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets of discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNy0xLTEtMS0w_2f2da8ac-81f2-4c69-8769-dab1c02b376e">744,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNy0zLTEtMS0w_dc41afc1-9f9b-4af9-841f-920fab8d4ac7">2,477,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOC0xLTEtMS0w_abffb8bd-dcce-4938-8224-e7b9498b9b42">2,085,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOC0zLTEtMS0w_937f187c-9e42-452b-aa19-f1996b93fe93">2,757,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOS0xLTEtMS0w_c31522aa-23af-48d8-ac79-a4edcb59a615">45,754,978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOS0zLTEtMS0w_c2b8532d-3717-4877-967e-daa6eb3f38f4">50,163,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTAtMS0xLTEtMA_22cc3628-9703-4da6-b4a0-73abfc9b95f7">15,640,060</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTAtMy0xLTEtMA_6a37075b-7d70-42d7-9fb4-c14c1ecc28bf">15,554,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTEtMS0xLTEtMA_2db2048b-fc2f-4396-94fb-94028547558a">631,534</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTEtMy0xLTEtMA_96c4a9b4-7d02-4974-ac9f-8fa710c965d9">747,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTItMS0xLTEtMA_04090e35-ee7e-4e6d-9186-d413888b631f">29,151,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTItMy0xLTEtMA_3082f3e8-7634-4e92-b553-8aeec4ebce1b">30,920,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTMtMS0xLTEtMA_7ec1bb0d-3b96-42cf-ba18-200693bf3091">882,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTMtMy0xLTEtMA_b859387c-1999-4931-843d-7f63fb676dd2">882,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTQtMS0xLTEtMA_ef56e9d2-2aa9-4119-9d5c-883232f6d03f">21,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTQtMy0xLTEtMA_8a321429-ad51-485a-b929-d3f358b9bdc7">21,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTUtMS0xLTEtMA_c54cc707-d4ee-4ee3-acf5-246af1343bc2">2,502,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTUtMy0xLTEtMA_3db1809b-d664-4ce0-a8a1-8238e56c2776">2,960,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTYtMS0xLTEtMA_8f53143c-651a-4f76-b5ec-d0af5b4ddb24">2,939,003</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTYtMy0xLTEtMA_a4c6a6d0-3192-4711-b44c-d6840916388a">3,298,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTctMS0xLTEtMA_84dd56cf-f2d2-4863-a78d-7254ec0c3dc0">97,523,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTctMy0xLTEtMA_1928abf1-78f4-4426-bd19-7b7be419c91d">104,549,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjAtMS0xLTEtMA_ae940ed5-bcbf-4ada-aca1-ec843785170f">10,829,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjAtMy0xLTEtMA_4ffd2074-9d2a-4298-a17e-6c153277f1bc">9,993,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities of discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjEtMS0xLTEtMA_baa122eb-76f8-49de-89dc-bf5105b231a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjEtMy0xLTEtMA_574046c8-e08a-4d0b-9fb0-f837cfe605c9">1,918,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjItMS0xLTEtMA_1432e6f2-6556-4c39-8c53-06c625ac0309">967,656</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjItMy0xLTEtMA_5a2e48b8-3813-44bc-9a01-7b2a88650a64">920,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjMtMS0xLTEtMA_4b7cca68-f79c-4d91-9ee5-0d2afc12e875">10,866,765</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjMtMy0xLTEtMA_2ce438e9-d8fe-4c44-b492-2d00a15d6c0e">11,317,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjQtMS0xLTEtMA_ad73d889-f5f3-42ef-81a1-00c895b9b873">22,664,403</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjQtMy0xLTEtMA_892fefdf-277b-4a97-9548-2cac2b0f9a62">24,150,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjUtMS0xLTEtMA_df59a5e0-bc88-4955-8c26-63a3793ca958">17,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjUtMy0xLTEtMA_759e868c-b9a6-471f-a589-dad8e9981bc2">18,500,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease noncurrent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjYtMS0xLTEtMA_712ac865-6ed0-45a5-b17f-fdb01752e7c9">1,580,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjYtMy0xLTEtMA_0881241b-29f5-4b18-9bb0-df85b2ac52c4">2,076,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjctMS0xLTEtMA_9ab85973-4962-46cd-a1a1-e4e8cd883189">7,867,679</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjctMy0xLTEtMA_ee733389-0ec9-410e-8223-afa2ff31f479">8,737,323</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjgtMS0xLTEtMA_d35f8c3b-5d48-4bfc-8c1b-ddbf1823c23c">49,112,285</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjgtMy0xLTEtMA_d12c537b-adfa-47c1-83b4-12484990d9a5">53,464,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjktMS0xLTEtMA_61703df2-1a87-4e73-b2b1-0120a3a9dae8"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjktMy0xLTEtMA_be09bcdd-6cf3-4148-a609-68df3a1dd711"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzE3_2225b63b-9bcf-4af3-821e-0d2184f86880"><ix:nonFraction unitRef="usdPerShare" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzE3_a4e4c83a-dbe7-4751-b5a0-3c1617e9db9e">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzMx_2b433daf-e9c7-4732-b8f8-4702168f5264"><ix:nonFraction unitRef="shares" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzMx_d11eb078-a47a-4aef-8fb8-a6f464f68dc4">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzUz_1f14ce9e-c278-4a2e-b6f0-3c5b3e72c1f5"><ix:nonFraction unitRef="shares" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzUz_e788bc35-c006-48a3-8c25-9d5b82af950b">15,181,276</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzYw_52748fb3-1ad4-4f3d-8641-a4d1d0d01574"><ix:nonFraction unitRef="shares" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzYw_b6212445-d447-4ac2-a7ef-5270a4a87225">15,263,355</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMS0xLTEtMA_8d8a0ef0-f72a-45a9-b396-de50a58d8301">49,246,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMy0xLTEtMA_2278584a-3891-4e6c-aa16-c1daee92834a">49,914,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings (deficit)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzMtMS0xLTEtMA_926ff970-add8-4afb-8b82-3f3fc09775a8">765,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzMtMy0xLTEtMA_9cf7c9c0-5452-4166-9ac7-63da2a1d9360">1,208,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzQtMS0xLTEtMA_1716b61c-9999-494a-9dcd-b08adcb84ecf">48,480,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzQtMy0xLTEtMA_4a22e606-c812-41c0-97a7-ee4edb3c8577">51,122,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzUtMS0xLTEtMA_88bcf5bb-d9e7-42e6-bd1c-006aea399c7c">69,459</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzUtMy0xLTEtMA_5da19772-e335-4882-bbb3-44515b8c242b">37,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzYtMS0xLTEtMA_28e8f101-cb6f-42a2-8326-f9196ff219bc">48,411,170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzYtMy0xLTEtMA_ddc62e8c-0369-4d3c-bcb6-33085831bad0">51,085,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzctMS0xLTEtMA_d8558806-143e-41d6-a341-bf41b10790ab">97,523,455</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzctMy0xLTEtMA_e1770913-1cc4-4f6a-834a-77c887e75d4c">104,549,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:46.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.433%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi0xLTEtMS0w_ba7c553f-eed2-4cd4-a193-2044217e5336">9,598,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi0zLTEtMS0w_54af28d3-13b4-44d7-a883-d93cd0e5baa2">9,417,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi01LTEtMS0w_9f4d465a-27bc-4a89-be96-e0dcf42cc456">17,928,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi03LTEtMS0w_3e28b82d-549b-4bb1-95fd-d229e2f1adf0">18,147,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC0xLTEtMS0w_7eb6e345-2861-43f0-9cc5-5e21c29aa891">2,609,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC0zLTEtMS0w_415129b2-781c-483a-bdca-a3f685d52774">1,792,293</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC01LTEtMS0w_04741f64-78d4-47f5-8464-763bb8093049">4,244,163</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC03LTEtMS0w_04b55b8d-7bab-4f6e-a24f-2707600164f4">3,451,082</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS0xLTEtMS0w_4a196e8d-05bb-493e-9812-0931009200bc">3,865,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS0zLTEtMS0w_9a99c557-6da5-41c0-8588-46128cdae033">3,982,379</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS01LTEtMS0w_d42a560b-402c-4c6a-9e03-76d77c0f6744">7,573,082</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS03LTEtMS0w_675d85d8-abbc-4c3e-9f8c-5c604c3c61da">7,419,311</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi0xLTEtMS0w_05f4d381-db99-4309-b75a-51f2a80632fb">1,421,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi0zLTEtMS0w_72d43d51-7b8e-4879-8204-09b63022a5d7">1,716,169</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi01LTEtMS0w_c24d612c-4781-4bfb-8fc4-3f1d10dd299a">3,144,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi03LTEtMS0w_57cdfa45-ae93-4514-a8be-be6c04126208">3,115,856</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy0xLTEtMS0w_5cd35ce2-6c5e-46c6-b644-9abed7a7070f">2,190,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy0zLTEtMS0w_a737bc78-3a8c-4546-bcb6-11121de635f8">2,270,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy01LTEtMS0w_a4fbbb29-6393-42f2-8c86-c4c42d7a693a">4,227,048</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy03LTEtMS0w_7ee15fdc-5906-483f-a8fc-4659a893e43a">4,807,057</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC0xLTEtMS0w_efea4058-0e06-41ff-aecd-c6f94ad43cec">1,091,485</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC0zLTEtMS0w_173f34f1-2dca-4d8b-968a-e70c7701c82e">1,029,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC01LTEtMS0w_8b98ff6a-bbda-4dcb-aa4c-d30ad22def48">2,167,524</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC03LTEtMS0w_d535a06f-4002-4e54-92a3-64fb99c104a3">2,051,353</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS0xLTEtMS0w_54ee58f1-13fe-42b0-8c04-e18a141fcd8d">11,179,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS0zLTEtMS0w_dc448f6f-79da-4ca1-b1ff-b4aa6bc36b98">10,790,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS01LTEtMS0w_512d6111-203b-45a6-a3a0-4136ecda27ff">21,355,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS03LTEtMS0w_a113c92b-4b73-4977-a2e3-6855dd6f0cad">20,844,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtMS0xLTEtMA_c22e8956-fcbb-4a9d-a2f5-e8f99da21779">1,580,962</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtMy0xLTEtMA_bec90bed-3df2-426a-88b1-ad40d2b6adc8">1,373,424</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtNS0xLTEtMA_f313fae4-55b9-4a4d-9179-50212dd36545">3,426,963</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtNy0xLTEtMA_279e4c67-1595-42a4-b6e4-26554d2752ca">2,697,356</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtMS0xLTEtMA_38f92c91-198c-4c80-a60a-438e8af8276c">28,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtMy0xLTEtMA_6db2ab99-1ded-4498-9d69-7ea8649fb1ff">130,565</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtNS0xLTEtMA_b132dac2-ea35-4b2c-8983-0cce54f1255e">58,549</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtNy0xLTEtMA_81151ae9-b3f9-462a-becd-07a1905dfd22">246,426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItMS0xLTEtMA_5c9793b0-bee6-4ccf-8ce4-778cacef5e75">119,455</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItMy0xLTEtMA_74edd79f-fa4b-4292-8178-aee81be87e68">91,200</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItNS0xLTEtMA_b73230f7-5351-49d1-9e1a-36ae523d2277">152,520</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItNy0xLTEtMA_8a2b44b7-5fce-439b-8518-3ef3da3eef06">152,111</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtMS0xLTEtMA_d40199fe-7bee-4a4c-81ab-b5cf46729bbd">1,671,756</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtMy0xLTEtMA_0b05aca9-30fa-4863-b7c4-54818d68dc46">1,334,059</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtNS0xLTEtMA_51ce4990-be53-4264-9391-8e78d528c9c3">3,520,934</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtNy0xLTEtMA_1343216f-75b9-481f-8a1f-4b75e521b206">2,603,041</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtMS0xLTEtMA_c3e62040-184d-4e13-ab62-0abc2846324e">7,455</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtMy0xLTEtMA_ca879612-d404-4eee-863f-9a28b0b91610">4,462</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtNS0xLTEtMA_fcd955f1-9949-4081-84f5-71353adb773b">41,695</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtNy0xLTEtMA_f7596934-d280-406a-9e18-fc894cf45419">76,966</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtMS0xLTEtMA_fe5f238f-6cd6-4d6d-a14f-73d2c313fd5d">1,679,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtMy0xLTEtMA_7022d629-37e8-4fc5-9ae6-73158992adb8">1,338,521</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtNS0xLTEtMA_38fea491-9bd3-4479-855a-8ee560ecd7ce">3,562,629</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtNy0xLTEtMA_0924735d-6ec3-43ee-9186-832222077ec3">2,526,075</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtMS0xLTEtMjM5_3156a832-dc41-4c64-94eb-23879b385c9d">738,622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtMy0xLTEtMjM5_c259318c-0c67-462c-900d-7486e1c1cc01">771,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtNS0xLTEtMA_ef9a550e-9843-4b82-a289-b1acc3baef2c">1,556,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtNy0xLTEtMA_dffa6539-d223-44ab-a29b-846f5c5e28d0">1,918,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctMS0xLTEtMjU1_c43c4214-2f8f-4427-8cd8-d621013b619a">940,589</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctMy0xLTEtMjU1_83fe752c-c574-473b-952b-f14514351e60">566,812</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctNS0xLTEtMA_c6e54a07-1487-44eb-82d3-97a81632a148">2,005,734</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctNy0xLTEtMA_ac5f50de-ca45-4991-8d76-2251dc1932d9">607,230</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtMS0xLTEtMA_9edcca95-ce25-466e-a31c-753c62a114c7">22,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtMy0xLTEtMA_a648f629-2831-4f27-b1f7-1026422b7c40">17,305</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtNS0xLTEtMA_16f50ad7-a515-44cc-8025-c644af4e00f7">31,839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtNy0xLTEtMA_c41d323e-2291-4475-833e-3b9eaf2d0b29">16,155</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktMS0xLTEtMA_f4630e2a-378a-41a3-91c2-93090749741b">918,275</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktMy0xLTEtMA_d0a9d967-fa20-40dd-9d9f-1304af105ed6">549,507</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktNS0xLTEtMA_8b777266-d406-423c-8476-0d6a4a3bcba6">1,973,895</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktNy0xLTEtMA_4fb35814-c7d0-4e91-ab23-b7e5a9e76b90">623,385</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Continuing operations - basic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtMS0xLTEtMA_abd325e2-8252-43b1-86d1-b8749953d724">0.11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtMy0xLTEtMA_09f73400-5315-4019-9d90-591667824f69">0.09</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtNS0xLTEtMA_3c9260d4-d934-4e76-b8b8-c88c2e95a79a">0.23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtNy0xLTEtMA_eef66a90-6d77-4908-a7a2-7bca435b3569">0.16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Discontinued operations - basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItMS0xLTEtMjQ3_2beed848-5a31-4769-bd87-0ce5974c8b74">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItMy0xLTEtMjQ3_fd31ae8f-0e35-4eb0-bc70-84128c8ed65b">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItNS0xLTEtMA_add614b1-2f68-4955-8db4-0ab5b81ad401">0.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItNy0xLTEtMA_35ed696a-07ea-4be7-b813-3a765aa63bca">0.12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtMS0xLTEtMjUy_7035bc9c-9572-43a4-95a1-be683c97a164">0.06</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtMy0xLTEtMjUy_a1d5eb5e-44af-4cfe-96d0-d02247f5686c">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtNS0xLTEtMA_b65a6570-453a-4ac2-a93c-8f15e98a570c">0.13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtNy0xLTEtMA_f22e42ed-b048-47f1-aa80-881ac2c731f1">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Continuing operations - diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtMS0xLTEtMjU4_9d604fea-d417-42b3-b882-204ee1ada50b">0.11</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtMy0xLTEtMjU4_7bc1cf7e-13da-4c7b-b988-67de312cc0b4">0.09</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtNS0xLTEtMA_fcf701b2-529d-4f9c-8b3b-51573a0b983b">0.23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtNy0xLTEtMA_2efa0001-4e18-4a35-82f0-ba4a2b1e9a08">0.16</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Discontinued operations - diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtMS0xLTEtMA_a9723415-7dc5-4252-bfb2-b453684de3f6">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtMy0xLTEtMA_e6f92aa5-9051-45c9-8f6e-2b05111a3875">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtNS0xLTEtMA_daaeb67b-9cd4-4d63-957f-9809bcbccbee">0.10</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtNy0xLTEtMA_951c3169-494b-400a-a54b-dd0ce49448ee">0.12</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctMS0xLTEtMjU4_305f8ab3-a858-4549-bda8-9e53010c8676">0.06</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctMy0xLTEtMjU4_f2d44f11-028b-4534-9878-d44401fa3ccd">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctNS0xLTEtMA_9d5dd155-90a8-4941-919d-0ff48adc599b">0.13</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctNy0xLTEtMA_bdff32ba-407d-46e2-9ae0-d7472a4853a4">0.04</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktMS0xLTEtMA_aa209967-83b2-48cd-86c7-e381f010e476">15,241,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktMy0xLTEtMA_74ef3cc9-dcdd-4f84-8f85-349fa4dff825">15,523,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktNS0xLTEtMA_90310ade-0d34-458f-ada0-d7e650387e0a">15,241,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktNy0xLTEtMA_cc409c1d-0df6-48bf-93e2-b996cfa4d47c">15,497,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtMS0xLTEtMA_72900226-7db4-4353-a385-f7512f61af53">15,241,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtMy0xLTEtMA_3d8a0b28-bba3-4c9f-8be6-2a3f8ba2b72e">15,523,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtNS0xLTEtMA_677426b1-99e7-4dae-a9cb-9ff74c8e3048">15,241,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtNy0xLTEtMA_41ec238e-8e09-4b53-9dc4-229c8376b150">15,497,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:65.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.791%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMy0xLTEtMS0w_f184c818-265e-46f4-845c-4030425906e8">2,005,734</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMy0zLTEtMS0w_2bfe29f2-6ae5-466f-8fe5-3e33d0f0efb4">607,230</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNC0xLTEtMS0w_ae23e87c-d871-4e90-bef5-2c220ab36f5e">1,556,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNC0zLTEtMS0w_d0baef70-73dc-4372-95d7-d1170d8b8217">1,918,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNS0xLTEtMS0w_101ff3b3-2dcc-4d61-96d5-ce527717627f">3,562,629</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNS0zLTEtMS0w_1d9c529e-70a1-412a-9943-ca29a29ba6a1">2,526,075</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNy0xLTEtMS0w_5c494c6e-0076-4e34-8708-1ef753fcf886">2,334,669</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNy0zLTEtMS0w_efc71b37-996e-4f96-8836-f2360e0ba560">2,174,397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOC0xLTEtMS0w_c608478e-9dbc-409c-b7e5-7607a7a574b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOC0zLTEtMS0w_ddb3eeff-3300-4257-898b-2f713dfcca14">43,605</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOS0xLTEtMS0w_b4f65d58-148f-44f6-ad0c-bef418596b0c">542,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOS0zLTEtMS0w_21021b25-0cc7-4875-a10c-30f2675e6b66">760,982</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTAtMS0xLTEtMA_a24eb312-3694-4523-895f-17d6bdc61e5d">645,571</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTAtMy0xLTEtMA_9c75bfe2-25f6-4e32-a923-02cf88074737">321,894</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTEtMS0xLTEtMA_f12bbdef-4a77-4425-aca7-4883885be455">22,973</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTEtMy0xLTEtMA_8a973e41-ed73-4b6a-880e-c936735b3f1b">28,111</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash investment gains</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTItMS0xLTEtMA_521b07db-3b29-494d-9feb-01b4e0c24761">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTItMy0xLTEtMA_ef537131-f356-499a-9d64-168e72c0c2d7">125,804</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTQtMS0xLTEtMA_0621ab25-4ad3-43f5-94a8-c16dcb15db1e">80,421</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTQtMy0xLTEtMA_b19ebbe7-b4e0-4c4a-b3d4-25f240fcb5c0">652,652</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTUtMS0xLTEtMA_3d2cc731-7f3e-4c19-be02-9f1ac7a3bf63">1,158,916</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTUtMy0xLTEtMA_c45e2fe7-0d32-4d31-8a6f-e13b353f4433">883,545</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTYtMS0xLTEtMA_88efc2dd-f3e3-4c1c-aec9-34abe89f22f6">1,017,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTYtMy0xLTEtMA_41ec1cd6-e399-412c-811d-106f5b7f2fe4">141,577</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTctMS0xLTEtMA_1bddaf13-636a-4c38-abbf-09f3a0952fd8">2,413,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTctMy0xLTEtMA_47ffe0de-ea3c-40c1-ad1d-6bb0f49dd5e4">163,530</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTgtMS0xLTEtMA_d4d1421d-9a9e-4b74-b31c-2f2aafe8bb39">869,644</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTgtMy0xLTEtMA_9cf40498-ded8-4d83-a630-949702efefb2">342,940</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTktMS0xLTEtMA_48b725f8-e8dd-4346-b438-9415f1e37234">2,332,634</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTktMy0xLTEtMA_ae5b286f-8992-4bee-b0a9-5fa842687652">100,678</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjAtMS0xLTEtMA_f08ae70c-646c-4465-b6c2-e2dffb3ca5df">1,371,437</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjAtMy0xLTEtMA_6d100912-81fa-471b-896f-a851c9a671f9">1,565,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjEtMS0xLTEtMA_f8466796-03d4-4469-b8c4-fc4d7e8984a7">3,704,071</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjEtMy0xLTEtMA_feb5cdb4-94de-48c0-8226-ede36984fd21">1,464,926</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjMtMS0xLTEtMA_82543bfb-7419-48c3-94af-9a3a0d71688a">50,883</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjMtMy0xLTEtMA_dbe5e46a-eee2-4107-a020-14ca7d2833ac">89,070</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjQtMS0xLTEtMA_790d0af5-977d-4877-95d0-ca2961e8cd9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjQtMy0xLTEtMA_dc7e408d-48ba-488f-af61-25f3d000ae7e">9,627,191</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjUtMS0xLTEtMA_1de798ea-8e17-4b8e-af96-975817c1d2e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjUtMy0xLTEtMA_731b6745-c90c-41f0-b45f-666425c7b505">8,563,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for acquisition</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMS0xLTEtMTU5_eed5fb87-c4ea-4047-a64f-636778c85267">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMy0xLTEtMTU1_b5d5c844-f732-4a87-b6f9-698b2499d19b">5,000,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMS0xLTEtMA_99620e10-444a-4f2b-a20a-0ed4fdc52a58">722,131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMy0xLTEtMA_4eb95868-0ce9-41b8-bf4b-260f13873a08">395,005</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjctMS0xLTEtMA_c9e507ce-932d-4579-b553-eb465ec47ab1">773,014</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjctMy0xLTEtMA_ba86d840-6a2c-45b7-8855-8b084a635558">6,547,278</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings on line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzAtMS0xLTEtMA_7a26c7d2-2372-4ab8-ac4b-8eb1a7014932">35,500,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzAtMy0xLTEtMA_84ea42b8-4ab3-4b3c-8209-2607b3812ac6">36,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments on line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzEtMS0xLTEtMA_b31084d6-2307-41ed-8750-b89acfcd04ed">37,000,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzEtMy0xLTEtMA_6f477b12-fdb7-4ab9-8818-d6d0cf73da7b">36,000,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzQtMS0xLTEtMA_d187486d-80f2-4498-8e66-65362dd3a1e4">260,735</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzQtMy0xLTEtMA_2c48ff4a-0fbf-4e7d-a81b-5dd92a3d4fec">684,738</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzctMS0xLTEtMA_4e1b846d-ffca-4f6b-aa40-551adcedfbe2">800,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzctMy0xLTEtMA_d0b815cb-c825-4e12-8815-afc554d116c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzgtMS0xLTEtMA_f5774306-a3b7-4af9-9e2a-8ec3cbafd432">1,209,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzgtMy0xLTEtMA_4c5751d7-0dbd-4e27-ba11-aa0bf53cfcf2">1,220,690</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzktMS0xLTEtMA_93bf8cbb-6fda-4391-84cb-4b72c2609dde">3,769,955</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzktMy0xLTEtMA_b5493b47-4983-41ae-8519-aa6ca5cc31db">1,905,428</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDAtMS0xLTEtMA_eecabd6f-83b6-4b42-9f12-8f4fb97ddfc5">838,898</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDAtMy0xLTEtMA_87ddb0da-eb0f-49c4-9e5e-568c69203bc8">6,987,780</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDEtMS0xLTEtMA_6105bab4-2857-484e-a6c2-5b5b6de5bab1">28,212,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDEtMy0xLTEtMA_8fbb827f-2492-40fe-bb93-db59b3fde792">27,938,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDItMS0xLTEtMA_c51ee85f-baff-4f91-bd60-0184d8c426bc">27,373,737</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3afa198dbba942a8a7bb26d3c8157c4d_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDItMy0xLTEtMA_fc02f74d-d79b-4835-a795-608e899a618c">20,951,180</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:3pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4b29c2b729c047069c2f8e4ed4afac13_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi0xLTEtMS0w_18a73489-8cf1-43a0-b2de-7c57565e52dd">15,481,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b29c2b729c047069c2f8e4ed4afac13_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi0zLTEtMS0w_f1bf4610-7ee5-4d81-984e-5075e2e5c2e9">51,098,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i77939a55b3504e7ea9bf84d21f5ab999_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi01LTEtMS0w_0a55e708-5a8b-4d64-85b4-ea207714e238">4,746,154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i614de951b5564e1aa4a9b1cd5dd0b630_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi03LTEtMS0w_527c26de-c7bd-41ac-9535-576e7e260370">274,266</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi05LTEtMS0w_b64fd22f-e8a7-43cd-8bfa-96d239ad3f78">55,570,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMy0xLTEtMS0w_a6fd185d-dfaf-4e22-abfa-d8c4e235791e">187,486</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMy0zLTEtMS0w_e5c9ed1e-4207-4a93-814a-452594413aed">364,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMy05LTEtMS0w_e0baed9d-042f-4f5e-88a7-f6107225bc28">364,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNC0xLTEtMS0w_ea310078-1a62-4f6f-9406-25a46753bc59">121,466</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNC0zLTEtMS0w_473d6ef4-f3c2-4247-9c59-ddd48972be32">703,790</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNC05LTEtMS0w_032883bf-6076-4d92-a0c8-2a2781337968">703,790</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie23c7a1f4a90472a8b17ffd7485c2576_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNS01LTEtMS0w_08f68fc5-7755-440a-bf1d-113670b08e71">73,878</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43f01311cc044c44bc525d43248d6c74_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNS03LTEtMS0w_612308b2-20f9-4ba6-a5e3-89bd21a7edd9">33,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNS05LTEtMS0w_bd1eda36-0054-4d32-be12-9d39fac24198">40,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi0xLTEtMS0w_ac458db4-e765-414c-bb9a-2ab8dca89e61">15,547,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi0zLTEtMS0w_cf2e5cf8-e65d-4360-99c2-02e925f9e49e">50,759,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ea30b21c62f403ea68c6689d93cd21d_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi01LTEtMS0w_5e4e8e09-cd2a-4997-9e57-5ccebf9af18a">4,672,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i974df3aa74f74bdda4d426ab248294a8_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi03LTEtMS0w_992b1cf8-544c-4cba-bccc-8615d524593a">240,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2f525b0defd4b22ab5cb985179a3531_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi05LTEtMS0w_38f4a3ec-d623-4d4e-adfb-fa3edfacf86e">55,190,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span><br/></span></div><div style="margin-bottom:21pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC0xLTEtMS0w_400e4cc6-7934-4d20-a4e6-1130efb352e9">15,547,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC0zLTEtMS0w_25759df2-2df1-44fe-b85d-3072c0de2377">50,759,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ea30b21c62f403ea68c6689d93cd21d_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC01LTEtMS0w_7a126c70-b272-42d2-9d25-03f4b996b69b">4,672,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i974df3aa74f74bdda4d426ab248294a8_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC03LTEtMS0w_d7bfe884-5482-455c-950e-915feb131efe">240,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2f525b0defd4b22ab5cb985179a3531_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC05LTEtMS0w_381f8e71-d1ca-48b6-8a8b-6a84c9d72232">55,190,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi0xLTEtMS0w_d7f16b24-e8e2-4987-933e-7cd3b8b71fa0">8,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi0zLTEtMS0w_79d82a04-69fd-44fd-ac07-b89ffe57216f">396,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi05LTEtMS0w_f1c8041d-4fb5-42fe-ad2c-a55cafcb5fb5">396,548</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi0zLTEtMS0zMDEw_88885973-2511-4dbe-a3fa-a325c0a322d3">685,805</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2d2d8f136b4c4979a189712441c7cf09_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi03LTEtMS0yOTk4_d3f7c132-9585-4817-9cbf-c749c26f4afb">114,195</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi05LTEtMS0zMDAw_1f31cb3c-5570-4ee2-9566-9c0632a12b6f">800,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMy0xLTEtMS0w_dc55abf5-a1f5-4b2e-a8e3-52643525136a">84,447</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMy0zLTEtMS0w_bde2fe07-e06f-48d6-b694-bb345f319eff">531,746</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMy05LTEtMS0w_79ce3fdd-de6d-4657-934b-315783fa8436">531,746</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8c307de3b4e5439ebd106206ec278efd_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNC01LTEtMS0w_ab7ee01c-8c64-46a1-97df-0849ed2ac9ef">549,507</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2d2d8f136b4c4979a189712441c7cf09_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNC03LTEtMS0w_5f7bbe9d-f3af-45b5-8fda-b21e2878de42">17,305</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNC05LTEtMS0w_6a17b8cb-3537-41f3-ae14-e033756ad428">566,812</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8b4d219a9d4941c3950eb19706eb7a5c_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS0xLTEtMS0w_98a26d29-a139-4fb4-a2e6-6e882cb9ad8c">15,471,070</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b4d219a9d4941c3950eb19706eb7a5c_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS0zLTEtMS0w_0eb9f0b7-3244-44c2-8b1d-08920e28854c">49,938,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3a8bcdfaca924879b5b43dd5bddd703a_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS01LTEtMS0w_a7a5a978-928f-48d9-9bcb-872d99d9d34f">4,122,769</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i067cca3f781144dd860b28147290813f_I20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS03LTEtMS0w_65397588-b585-438d-994a-d22fd0a2385d">372,306</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3afa198dbba942a8a7bb26d3c8157c4d_I20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS05LTEtMS0w_a842e492-74c6-48f7-94ce-281cc0aa66c0">53,688,717</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:12pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings (deficit)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iae43656c3c484911bf5d613a8a8e45be_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi0xLTEtMS0w_394b4751-f07f-4120-b625-405f8f20b041">15,263,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iae43656c3c484911bf5d613a8a8e45be_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi0zLTEtMS0w_1ff1e977-92f0-410d-8b99-aac26818f0e7">49,914,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i555b1189aac24c028c9886b3795085a2_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi01LTEtMS0w_e62e6507-cde5-4333-a68e-9ec3e812d659">1,208,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib4f2d546729f4a7388d0da7c59afeefd_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi03LTEtMS0w_652285ae-cc82-475f-9355-5f1ddf7d0ac0">37,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi05LTEtMS0w_e5893db9-a5e4-4f07-8f9a-ca83a51a1403">51,085,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMy0xLTEtMS0w_430ac57f-65aa-4c25-af09-6c8af531de87">219,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMy0zLTEtMS0w_ea5fc642-bad8-4534-9506-4da14a2d9822">264,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMy05LTEtMS0w_a730a6f7-9007-480d-b28d-9c9da1876c95">264,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNC0xLTEtMS0w_4db927ac-5473-4778-9bb0-1f813e7b874d">164,866</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNC0zLTEtMS0w_8ee972b3-911d-490a-a3fe-dea87df39ea3">441,624</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNC05LTEtMS0w_a6e40a0e-8def-4d15-a18e-b0d4e524cc63">441,624</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9594a27a8953498781fa2c5b518d8690_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNS01LTEtMS0w_30b53eb8-4de1-431f-8258-12e291908b49">1,055,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4b35cee38dff4f04bdb57a8e96d4e329_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNS03LTEtMS0w_b94c795d-0e85-4d54-bac9-9416c57fdd79">9,525</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNS05LTEtMS0w_08c4dd5f-6011-4586-bf14-6ff4574ef3fc">1,065,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi0xLTEtMS0w_22e6e5f1-60be-4416-bef5-1d2786817d31">15,318,539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi0zLTEtMS0w_00806a6c-dac1-46ba-b36d-d6d2f190e3cc">49,737,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9c893f1703e4ba7b7c6c8a4e8d3796d_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi01LTEtMS0w_41672f51-1e4a-4f35-8af5-2d6e57951767">152,775</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i17bd2f5664584e4e961c165808307967_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi03LTEtMS0w_bd68f069-ac48-4dd0-8bcf-a770f6822807">47,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab2bd5c666b24aa0b832eb6b9d845d8c_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi05LTEtMS0w_7395ba81-da8d-48cd-aa7e-ca61a92a14f5">49,843,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC0xLTEtMS0w_3ab11a68-7ee7-466d-853c-6e445f55ec9f">15,318,539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC0zLTEtMS0w_23d3291a-5e38-4358-aa39-f260eafce729">49,737,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia9c893f1703e4ba7b7c6c8a4e8d3796d_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC01LTEtMS0w_a9fcf70b-62ea-4d67-86c7-b83a70d81363">152,775</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i17bd2f5664584e4e961c165808307967_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC03LTEtMS0w_e3f64020-2e73-4239-bfbd-3425a4b0162f">47,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iab2bd5c666b24aa0b832eb6b9d845d8c_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC05LTEtMS0w_b27e819a-bcef-4721-a84a-fe860ca122d5">49,843,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMS0xLTEtMS0w_bc95cf52-6fa0-4aa9-930d-1b1c112751dc">4,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMS0zLTEtMS0w_93b434a0-7c32-42c3-960f-13fb47277801">278,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMS05LTEtMS0w_015404c7-70a1-4d53-8dd8-d817a661dc06">278,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNC0xLTEtMS0w_6a3dcbb5-3464-4879-970c-cf2afd67b739">141,463</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNC0zLTEtMS0w_ca68a778-5826-4d55-9d9b-ba994d4a7131">769,648</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNC05LTEtMS0w_b04aba61-3ced-4852-b731-61b398706590">769,648</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i45bf4110d4a5466bb3c612fbfef3c696_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNS01LTEtMS0w_07fd6fd1-4936-4e61-978c-3a406d4656e5">918,275</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i66d5c13fd94d4f238dd81f8caf9f3403_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNS03LTEtMS0w_8745eae6-0719-4842-8d8e-1099e8671998">22,314</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNS05LTEtMS0w_b022045d-addb-4e5a-8ab9-79043768d9cc">940,589</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i08c7c34335f54f47863478492f5a0e20_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi0xLTEtMS0w_b1a9f929-19f1-4884-b2d0-ef725832da01">15,181,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i08c7c34335f54f47863478492f5a0e20_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi0zLTEtMS0w_33cf519f-4cfe-414e-ae3b-503c9a1b35d1">49,246,129</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2f61c1f6404247408b4f8f98b89594d2_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi01LTEtMS0w_d39fd368-a65c-4419-974e-186aea0ab766">765,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iabb40a61c7844cbe9615cb5fbe8dba63_I20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi03LTEtMS0w_d08231fc-16a1-49dc-9a61-02ac0434bfa7">69,459</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi05LTEtMS0w_b6a4dc11-c6aa-4adf-ad1f-f158f09433b8">48,411,170</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="30" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i60c789aa695e441494b09d48a21e5c74_31"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(1) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMTA_fa8d9a22-13f0-41f9-b2c9-84a17cb08f42" continuedAt="i1535c6bf8d7a4e8cbc74e9d52a458149" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i1535c6bf8d7a4e8cbc74e9d52a458149" continuedAt="ie17286b0482447b7874905c40e46423f"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;2019 Annual Report on Form 10-K&#8221;). The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Discontinued Operations</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reclassification of prior period amounts</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the condensed consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the condensed consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the 2019 periods presented. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's corporate, sales and Cumberland Emerging Technologies (&#8220;CET&#8221;) employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><ix:continuation id="ie17286b0482447b7874905c40e46423f" continuedAt="ib370195800bf448ebf77da3f39328d2f"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMDM_1329f866-5f69-4dea-8145-34052f589e8a" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMDY_04dfacbe-1b81-4234-b737-41359699f08f" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><ix:continuation id="ib370195800bf448ebf77da3f39328d2f" continuedAt="i557c029a1bdb4f39bb59579921db1c8b"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMDg_483af090-16d5-46ce-a2cb-06cd655f0282" continuedAt="i47b50bbe277f4ae1a2a5c14c01e101d6" escape="true">Operating Segments</ix:nonNumeric></ix:continuation></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i557c029a1bdb4f39bb59579921db1c8b"><ix:continuation id="i47b50bbe277f4ae1a2a5c14c01e101d6">The Company has <ix:nonFraction unitRef="segment" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTAyMDA_5e756bdc-3352-45a6-8547-51e8f0060456">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div id="i60c789aa695e441494b09d48a21e5c74_34"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(2) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RleHRyZWdpb246MzhlYzgzNDVhODZhNDZlNDg0OWQ3ZDNiNjE0Y2MyMmVfMzQzNQ_dfafb04d-63f0-4303-866f-d734ee4b0df5" continuedAt="i081d856f24ab464b927d8902897e2a85" escape="true">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i081d856f24ab464b927d8902897e2a85"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of June 30, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of June 30, 2020 and December 31, 2019, all trading securities were investments with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RleHRyZWdpb246MzhlYzgzNDVhODZhNDZlNDg0OWQ3ZDNiNjE0Y2MyMmVfMzQ0MA_0bcf7712-877e-4eb0-aa4a-bf7ca0c92f26" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:27.368%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.162%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5f3a745bf4174278a74c0d5a8fa02da3_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC0xLTEtMS0w_774da53a-8b98-4433-9b5b-e69866bbe2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idea52a7e581244558e3b890ffe46b51c_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC0zLTEtMS0w_5a8b3e9f-47b5-444d-9bf6-8435ab0221d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia322c6d2a6df4e9fa5ed3bb2684d5ddc_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC01LTEtMS0w_cd194fc6-ad52-44f4-ae07-fdf76bcb800b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9323653bab9c4287addb88df384f442e_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC03LTEtMS0w_771fa954-3f6a-4a4f-9cd8-5ee37f2d5827">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dd57a040d73460c9eb5b7058fff5111_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC05LTEtMS0w_1ebfc308-6867-4b93-a789-34dbe117afca">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if41ac3abceec4ba59776f3a5132e11cf_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC0xMS0xLTEtMA_88dc8203-c0d8-4e5c-947e-c9f5abaa42f6">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e21e374e0f74f1598291e91e92c3d51_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi0xLTEtMS0w_3858d978-86d2-42a0-ab99-4a9519f5af5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92c97dcff25b433083d6b0f9f881f774_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi0zLTEtMS0w_b55bb3a0-34a3-4e12-a69f-645b660fc50b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi01LTEtMS0w_fe83860e-c2f5-4865-a624-891dbda27b83">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia08b7430594741ebaab75913bbcae614_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi03LTEtMS0w_9ff39fee-40ed-4ecb-8a46-bd2544397d6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id509d7930bbf4bd694189ff99605fa09_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi05LTEtMS0w_ed59e4b8-d86b-4e73-84b6-626810f438dc">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi0xMS0xLTEtMA_2bd1745a-261f-431a-88b1-b82305b2b094">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(3) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfNDI5_78945fbf-b839-48c9-bca1-280eb68a429a" continuedAt="ib9b9e5335df54955b3568f0224383abf" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ib9b9e5335df54955b3568f0224383abf"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfNDMz_fa9e69b3-0dba-4236-88d5-c2c0cf1f281b" escape="true"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:justify;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:58.087%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.446%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMy0xLTEtMS0zMjc_fe5f238f-6cd6-4d6d-a14f-73d2c313fd5d">1,679,211</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMy0zLTEtMS0zMjc_7022d629-37e8-4fc5-9ae6-73158992adb8">1,338,521</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNC0xLTEtMS0zMjk_3156a832-dc41-4c64-94eb-23879b385c9d">738,622</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNC0zLTEtMS0zMjk_c259318c-0c67-462c-900d-7486e1c1cc01">771,709</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNS0xLTEtMS0zMzE_9edcca95-ce25-466e-a31c-753c62a114c7">22,314</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNS0zLTEtMS0zMzE_a648f629-2831-4f27-b1f7-1026422b7c40">17,305</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNi0xLTEtMS0zMzM_f4630e2a-378a-41a3-91c2-93090749741b">918,275</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNi0zLTEtMS0zMzM_d0a9d967-fa20-40dd-9d9f-1304af105ed6">549,507</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfOC0xLTEtMS0zMzU_aa209967-83b2-48cd-86c7-e381f010e476">15,241,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfOC0zLTEtMS0zMzU_74ef3cc9-dcdd-4f84-8f85-349fa4dff825">15,523,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMTAtMS0xLTEtMzM3_72900226-7db4-4353-a385-f7512f61af53">15,241,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMTAtMy0xLTEtMzM3_3d8a0b28-bba3-4c9f-8be6-2a3f8ba2b72e">15,523,628</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:58.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.618%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:58.087%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.446%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMy0xLTEtMS0w_38fea491-9bd3-4479-855a-8ee560ecd7ce">3,562,629</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMy0zLTEtMS0w_0924735d-6ec3-43ee-9186-832222077ec3">2,526,075</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNC0xLTEtMS0w_ef9a550e-9843-4b82-a289-b1acc3baef2c">1,556,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNC0zLTEtMS0w_dffa6539-d223-44ab-a29b-846f5c5e28d0">1,918,845</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNS0xLTEtMS0w_16f50ad7-a515-44cc-8025-c644af4e00f7">31,839</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNS0zLTEtMS0w_c41d323e-2291-4475-833e-3b9eaf2d0b29">16,155</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNi0xLTEtMS0w_8b777266-d406-423c-8476-0d6a4a3bcba6">1,973,895</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNi0zLTEtMS0w_4fb35814-c7d0-4e91-ab23-b7e5a9e76b90">623,385</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOC0xLTEtMS0w_90310ade-0d34-458f-ada0-d7e650387e0a">15,241,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOC0zLTEtMS0w_cc409c1d-0df6-48bf-93e2-b996cfa4d47c">15,497,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOS0xLTEtMS0w_65e54301-d1f5-465f-8653-a1929d7465d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOS0zLTEtMS0w_5961758d-4fa7-440a-af53-d0c3ff2fb34d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMTAtMS0xLTEtMA_677426b1-99e7-4dae-a9cb-9ff74c8e3048">15,241,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMTAtMy0xLTEtMA_41ec238e-8e09-4b53-9dc4-229c8376b150">15,497,989</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and 2019, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfMjUz_5ab50bd2-92ff-485f-9622-46019bce8116">199,210</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfMjYw_85e31b96-3e7a-471b-a83f-ed28ecdef599">13,500</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i60c789aa695e441494b09d48a21e5c74_40"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(4) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMjIwNg_0a4e55c3-6fc8-4d57-8b31-d0b2becd7adf" continuedAt="ic2e84739cfc2408d83e4b5e24fc777f2" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="ic2e84739cfc2408d83e4b5e24fc777f2"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. </span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMjIwNQ_f4c108ad-c7c3-4d75-aa0f-9b1ef6ae0102" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:38.409%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.202%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.202%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.824%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.202%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.205%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5669834e215b45b99cc41e3d665e69a1_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy0xLTEtMS0w_7b598c76-4e7b-4d29-bb89-e73b6ba4aa48">595,310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if68a865edbbc4fa68606bf229911a560_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy0zLTEtMS0w_96aaf91c-be8f-450e-b666-3d499abd3879">983,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i02b378ebb06a479bbf879faf98e19814_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy01LTEtMS0w_94b70b0f-64b5-4cc1-824c-bd172fd26208">1,308,711</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifc949d2f070b4f25affead2a375d491e_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy03LTEtMS0w_5f143aa3-70b4-4d20-8c52-513fb98afa49">1,832,976</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iddf47d357fe2412f8af2acff2342ebb6_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC0xLTEtMS0w_83e57bed-f84f-445f-8678-28b210900142">10,948</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc40475e1a9d4a6bb5ec18bfe4e3e1b3_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC0zLTEtMS0w_444ad37f-95c8-46e4-8543-a6c323c84091">478,604</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6b3dd0ec548447582e12cdbcd66e63b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC01LTEtMS0w_60030ab4-442f-4f33-9024-4176938f4764">124,371</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffd0d5dd3b844bdaa5729899189c6770_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC03LTEtMS0w_339e8c77-8598-4446-af4f-b3c242b530fb">678,141</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idd91fba54ac84e0a8c8bd5e8f448455f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS0xLTEtMS0w_d670cf34-b160-4dcd-986a-47d8d8a7a363">3,477,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0a5687dc8d944909b67b606cb812cce_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS0zLTEtMS0w_ab7824b2-9bd1-4b55-af88-476a34bc414f">3,476,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7e3f32cd85cd4f9e996353f5f78ff1b7_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS01LTEtMS0w_75fcabec-e8c6-43d4-853c-df374d73c375">6,771,433</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i06ca879e8d4a47f39f75644f1ed2d685_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS03LTEtMS0w_5be3944f-e040-483f-ae91-fa24d26bc147">6,785,050</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea199d488f3d4c6fbdc6df78ea63c963_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi0xLTEtMS0w_1f3e8816-2a9e-4a4e-8592-6981f08e6b59">174,159</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i285e24ce4de04744ab32c8c31fb15880_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi0zLTEtMS0w_150dea6a-6f89-40c0-87d1-10038705bd92">212,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fdbdea3b95045f39274bd68ed525b3e_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi01LTEtMS0w_364a5bb1-e135-40b3-8c7b-46d58de6b4d4">382,016</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i810c3828a9d245e9a17ec124b2f9b2e8_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi03LTEtMS0w_08157a82-d9c3-4b2a-afe8-410e935de76d">499,202</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if6deafdc7c3545129085c07232f96d65_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy0xLTEtMS0w_06eb3c1c-005d-45d8-ab0b-c4b16f8eddd0">1,166,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9de4abd6721c4ddfae052da0cb09699a_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy0zLTEtMS0w_ce1fac6f-bbc9-452d-97e9-0516d8fd83e8">1,054,718</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i566675b7d46442779736a5e02fec5bb6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy01LTEtMS0w_95c78c9b-c275-4515-ac1b-a6c1f902ac76">2,261,286</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4fe634f61a1e4a5a9ad7dcfe2f238132_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy03LTEtMS0w_f02a1466-598f-44b5-bd97-9fe096ad4d78">2,372,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia147af4d03624f11ac640a8b4886b751_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC0xLTEtMS0w_cb9b727b-9a82-4f86-82ee-f69eee92523e">3,299,507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i217c307695d149f3a072f507e80428e0_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC0zLTEtMS0w_498892b3-252c-43c9-83ce-3ef09b979665">2,599,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id1febb70c5d54883bd12e7f1136868a7_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC01LTEtMS0w_bea5d148-cdb3-41db-92d1-c3952a7480eb">5,721,708</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0aaf60aeada144d6b60fa49b4caff778_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC03LTEtMS0w_a11fa1f4-74f6-4b06-a66f-055c7b21884f">4,659,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7c1b0b04c6a4448c9bdd40023c85de9c_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS0xLTEtMS0w_81e68e15-f0bb-4501-a5ef-b714288137c6">874,213</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i410438689ecc46098ef7e58bf86b9e48_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS0zLTEtMS0w_8571687d-ea54-40d6-90f6-a51815caa505">612,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i918c1048efdc4eeaa992c0bef857728b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS01LTEtMS0w_2c21b533-58fc-463d-96ae-31465234821a">1,359,386</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia46fcc7519ab4d55866e429c4169b5c6_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS03LTEtMS0w_600411fc-2122-48ee-965e-661545e156bf">1,319,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtMS0xLTEtMA_bbdb38e9-520c-4345-a416-c244b47710bc">9,598,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtMy0xLTEtMA_ed5c4504-6410-4988-baaa-a9a58a2c50d9">9,417,443</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtNS0xLTEtMA_841a106b-3f93-40a9-9d56-282f429d9cc7">17,928,911</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtNy0xLTEtMA_1076c2c2-c9ce-4d18-ae48-7ceb756c03e4">18,147,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i338997cfd24048679aea6c8ed87a43ce_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzI1Nw_4589d807-4bec-4f3c-b44e-3e66dfc65e1d">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7262f7e4e1134261beeed2cb335a5dc1_D20190401-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzI2OQ_1a28d511-6229-49ad-a226-e757e1ad9a49">0.2</ix:nonFraction> million for the three months ended June 30, 2020 and 2019, and $<ix:nonFraction unitRef="usd" contextRef="i17b3c50fbe874b3196c15fa2ac7f84ee_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzM3MQ_6586c077-4624-4356-be65-f9b004cc96c1">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i798cb1e7aeb14bf4a99ccd87345abcd7_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzM4MA_d194376b-a54b-4bc3-b797-1b5c2afdac00">0.8</ix:nonFraction> million for the six months ended June 30, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i60c789aa695e441494b09d48a21e5c74_43"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(5) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMjAwOA_2dc766d3-9fd4-48e7-b34f-ddb34d933fee" continuedAt="i2565eeff01aa43deb689a707c69ec06d" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i2565eeff01aa43deb689a707c69ec06d" continuedAt="i0d5986a0381e4263861524250b48bb9d"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at multiple locations. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods inventory. Cumberland also maintains API for its Vaprisol brand which is classified as raw materials inventory.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><ix:continuation id="i0d5986a0381e4263861524250b48bb9d"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consigned inventory represents Authorized Generic product which is shipped to the Company&#8217;s distribution partner and stored until sale.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  The Company also has obtained $<ix:nonFraction unitRef="usd" contextRef="i9476294995c8476c8cf46424d7813e1d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMTY2Nw_d40e0c83-547c-403d-8a79-1bc1e6275b34">0.4</ix:nonFraction>&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMTgzMA_110b0283-bbec-4fca-824b-6d899edddac5"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMTgzMA_850af5a8-40ec-493e-bdb8-a1a13d2de61c">15.6</ix:nonFraction></ix:nonFraction>&#160;million. The Company did not have any finished goods included in the non-current inventories at June 30, 2020 or December 31, 2019, respectively.  </span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMjAwOQ_9c105609-bfe4-49d0-b4e3-a8c878cd0ef3" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:56.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.681%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.531%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMi0yLTEtMS0w_7fc567f6-7319-4576-9073-51e496f0a22e">19,660,890</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMi00LTEtMS0w_b8a382ef-9713-44c7-a4bb-e451e9167384"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMi00LTEtMS0w_e343d231-e1e1-4df5-97aa-fcc5ae2efee8">19,345,723</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMy0yLTEtMS0w_e578d5d0-04b3-4e57-840b-771ab5ce67b2">219,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMy00LTEtMS0w_70ac0bc7-2024-4d5a-8bd0-3dc1526f07b9"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMy00LTEtMS0w_70cd88c3-6f62-4279-806d-030381016f53">416,468</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNC0yLTEtMS0w_88ece921-cc2c-4252-8ce2-340df428c53f">3,387,212</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNC00LTEtMS0w_15cd3541-2225-4cc2-bc74-4e9a568c8946"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNC00LTEtMS0w_54385687-7a26-46ab-a16e-310757d9608d">4,664,055</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNS0yLTEtMS0w_5db88ec8-1422-4bad-814e-550bf2d7d300">23,267,330</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNS00LTEtMS0w_21ed4384-c1df-47c6-b43b-edd803f3d7d7">24,426,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNi0yLTEtMS0w_a9a5ff7b-f763-4af2-aa18-21ea84736f8f">15,640,060</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNi00LTEtMS0w_c5023be1-5fbf-4a3f-967e-b94d0d7ba2c4">15,554,992</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNy0yLTEtMS0w_62a55928-4162-458e-adec-c14ca881002c">7,627,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNy00LTEtMS0w_1b134590-94f1-4416-879c-bbf6e99954ff">8,871,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="i60c789aa695e441494b09d48a21e5c74_46"></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(6) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTgwNw_fd5fac62-9d3c-4d80-8dbb-1fa7878bbc3b" continuedAt="i0d7ec49f5c3d4bbabd71c3ce2f09648f" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i0d7ec49f5c3d4bbabd71c3ce2f09648f" continuedAt="i84f53229b0314789ac2e4cd31833bfad"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTY0Mg_ed54b9dd-baf1-4e27-b716-ccefd81b351e">7.42</ix:nonFraction>%. The weighted-average remaining lease term at June 30, 2020 is <ix:nonNumeric contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTY5Nw_837ff8a1-8708-480e-be0b-5df563adddd6">2.5</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lease Position</span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTgwOA_92a8bb7b-ebad-4b92-ad06-5c722af5c780" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.742%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.399%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmZiZWQ2MGIzZmQ4NDQxNTdhODk2ZGQ4MmNkZDhhMDhlL3RhYmxlcmFuZ2U6ZmJlZDYwYjNmZDg0NDE1N2E4OTZkZDgyY2RkOGEwOGVfMS00LTEtMS0w_c54cc707-d4ee-4ee3-acf5-246af1343bc2">2,502,850</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmZiZWQ2MGIzZmQ4NDQxNTdhODk2ZGQ4MmNkZDhhMDhlL3RhYmxlcmFuZ2U6ZmJlZDYwYjNmZDg0NDE1N2E4OTZkZDgyY2RkOGEwOGVfMS02LTEtMS0w_6230fc23-35f9-4bdf-90cd-6234d140e4e8">2,960,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:61.742%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.408%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:15.399%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfMi00LTEtMS0w_1432e6f2-6556-4c39-8c53-06c625ac0309">967,656</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfMi02LTEtMS0w_49e9e429-5830-442e-870a-e41e6f69ff96">920,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNC00LTEtMS0w_712ac865-6ed0-45a5-b17f-fdb01752e7c9">1,580,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNC02LTEtMS0w_b8c6b5b9-3ff7-416b-a285-9b8d4fde3763">2,076,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNS00LTEtMS0w_17954716-2dd1-429e-8b84-5c8fbf1e92a9">2,547,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNS02LTEtMS0w_9ec86735-1e8b-4b9b-ac06-df015d402988">2,996,903</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTgwOQ_292956c4-0541-46a8-bb22-d1deaf670914" continuedAt="iae46e162d03049dfa8eb9b925b7b79f1" escape="true"></ix:nonNumeric><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div><ix:continuation id="i84f53229b0314789ac2e4cd31833bfad"><ix:continuation id="iae46e162d03049dfa8eb9b925b7b79f1"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%;"><tr><td style="width:1.0%;"></td><td style="width:76.078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.971%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Maturity of Leases Liabilities at June 30, 2020</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfMS0yLTEtMS0w_391c2b0b-7dde-45ba-9138-334bb5db4d58">566,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfMi0yLTEtMS0w_adb33da0-38f6-448f-b4e4-86d68dbc4b9a">1,144,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfMy0yLTEtMS0w_9548c0d2-87bc-4635-8082-c08f612c0117">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNC0yLTEtMS0w_adf294ec-6d3a-4f17-b5e4-7abade5d2eaa">92,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNS0yLTEtMS0w_bfab4e4a-df7c-46fa-b103-d7e8dd43883c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNi0yLTEtMS0w_decf3634-d155-4fbf-8c13-793b75d23e12">2,823,393</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNy0yLTEtMS0w_188ed9a3-b129-439e-94c3-92ef7e0e6a6b">275,534</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfOC0yLTEtMS0w_f49e190f-a0e3-4a90-a4cd-3663f148a3e8">2,547,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div id="i60c789aa695e441494b09d48a21e5c74_49"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(7) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNzY5NjU4MTQwNDU1NA_a54d6881-0aa9-412f-9e09-b9c9d9a6a31b" continuedAt="iafe32021826c4862ac8455cf20e2688b" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="iafe32021826c4862ac8455cf20e2688b" continuedAt="i288d64dc4af84465a72c2616c1f22957"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i4c685386484241a88e1c0f981bdbb1c0_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTMx_7fd8d095-2609-4a17-b5c3-c7cd7287528e">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i90f8ddce573e405db035f43203edac82_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjky_d9193204-f279-4511-817a-6fb459a101d2">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2020 and June 30, 2019, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i34205ca5f1bd40e4bc73ff67fce99b21_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzk4_3737717c-67e3-4226-8762-75f4ffadff74">306,329</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i70788808c3514d7cb738bf570ee8ecab_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDEy_8ac3a402-41f3-4b0d-8b74-cfad6de933be">205,913</ix:nonFraction>, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i70788808c3514d7cb738bf570ee8ecab_D20190101-20190630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDY0_886dc398-247f-4358-880e-6a38b36ead85">1.2</ix:nonFraction> million during both 2020 and 2019.  </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i326c4e1bbd4143b0991323596e8218e2_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfOTcz_994e3ce8-1fff-4401-9f77-281650a48c32">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the six months ended June 30, 2020 or June 30, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020, and June 30, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i4932bbb650d149da92ef6f0570dbee67_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTY0OTI2NzQ0NjU1Ng_a99f2753-46b3-47fd-8441-c93cd00dfb63">229,141</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i1abd143533634e079845141c8834cf0d_D20190101-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTMxNA_4d0c2bbd-b652-45ee-a49d-05febc13aef9">222,469</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <ix:nonNumeric contextRef="i2811f76482b0428a8411c4d8087350fc_D20200101-20200630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNzY5NjU4MTQwNDU1NQ_fdcac782-5db8-4a58-bbf4-a738562b0302">one-year</ix:nonNumeric> anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cumberland Emerging Technologies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a $<ix:nonFraction unitRef="usd" contextRef="i576c01f880e64cda9a7bae358c95e641_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTkyOA_336163ef-d63d-45ef-b9e3-d76b45467535">1</ix:nonFraction>&#160;million investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="i576c01f880e64cda9a7bae358c95e641_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjIxNQ_2004345a-499a-4113-b7ec-eb2e852b3d05">1</ix:nonFraction>&#160;million investment in CET.  Cumberland purchased additional CET common shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="ib3072a59195c43eb83bc07add8758654_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentCashContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjMwNQ_ebf5987f-a179-4046-ae59-d46c144453ea">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="if09748a76bfe44299df7ff1fe1acec07_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjMzNg_b7a526fc-598a-4989-85c7-422bdd1c55af">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $<ix:nonFraction unitRef="usd" contextRef="i69c8bad9e0024da2b5f4ecd513ca3279_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjUzOA_612a2db0-725f-450c-8a93-16a6f2f8033d">0.8</ix:nonFraction>&#160;million that was funded during 2020.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><ix:continuation id="i288d64dc4af84465a72c2616c1f22957"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2020.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ie23ab79d4c84449990786e49b3945c33_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzc1NQ_46bbabef-9556-4543-8db1-0a4aaeb0d4e7">12.0</ix:nonFraction> million with the ability to increase the principal amount available for borrowing up to $<ix:nonFraction unitRef="usd" contextRef="ie23ab79d4c84449990786e49b3945c33_I20200630" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzgzOA_9c00adb2-0c10-4cc8-a789-50918ed89fb8">20.0</ix:nonFraction> million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $<ix:nonFraction unitRef="usd" contextRef="icf877f310c4d446597ea48ad1a455784_I20181017" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDA3OQ_b009f4e0-6be9-42bb-ba87-a9650cba8219">20.0</ix:nonFraction> million.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i9a59ea378ede42c9b6cecb1b250655ca_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDI2Ng_16922523-aced-48af-b145-a01c97663139">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i814c31ba70e6430d9e51bcc5840e4ac9_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDI3Mg_6fdac87e-d616-44c9-8538-c1a357cc4b4d">2.75</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="ie23ab79d4c84449990786e49b3945c33_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDMwOQ_e88bc2b7-07cf-46b1-a4e1-41a8121d5f95">2.92</ix:nonFraction>% at June 30, 2020).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="icc647785e8e346e4a56e83e0cc7fa9ca_D20200101-20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDM0Mw_85c6e493-9547-4511-8876-fe43a1d48878">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of June 30, 2020 and December 31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDU3OQ_df59a5e0-bc88-4955-8c26-63a3793ca958">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTY0OTI2NzQ0Njc0NA_759e868c-b9a6-471f-a589-dad8e9981bc2">18.5</ix:nonFraction> million in borrowings outstanding under our revolving credit facility, respectively. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Paycheck Protection Program Loan</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i7363b185835a4fefb0d6e62a0ebf0dfc_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTA5OTUxMTYzMzAzNg_9a75751a-38ab-4433-8b31-b9fae997fc9d">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The PPP is administered by the U.S. Small Business Administration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan matures April 14, 2022, and bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="ia8648009ac16482485d4df4b4a6b9fa6_I20200420" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTA5OTUxMTYzMzM0Nw_7c7353b7-2b57-43b3-b414-e16a4f5f0729">1.0</ix:nonFraction>% per year, payable monthly commencing during November 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As result, the Company has recorded the $<ix:nonFraction unitRef="usd" contextRef="i7363b185835a4fefb0d6e62a0ebf0dfc_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzg0ODI5MDcwNTc0Ng_9a75751a-38ab-4433-8b31-b9fae997fc9d">2,187,140</ix:nonFraction> as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. Cumberland will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.</span></div></ix:continuation><div id="i60c789aa695e441494b09d48a21e5c74_52"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(8) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81Mi9mcmFnOjM2Nzc2ZGRiY2U5MDQxZGQ5NjhjZTJiNzEyNmExMDA1L3RleHRyZWdpb246MzY3NzZkZGJjZTkwNDFkZDk2OGNlMmI3MTI2YTEwMDVfNzY5NjU4MTM5NzcwNg_92d0500c-5837-450e-b73f-10879bfded7b" continuedAt="i7e5a5220f3be4383b8e45a6cbcb7d457" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i7e5a5220f3be4383b8e45a6cbcb7d457" continuedAt="i993426469958441b92ca0e01b517cc2a">As of June 30, 2020, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="ie53b0f9aa7b34fdab1a8da61d4eedd27_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81Mi9mcmFnOjM2Nzc2ZGRiY2U5MDQxZGQ5NjhjZTJiNzEyNmExMDA1L3RleHRyZWdpb246MzY3NzZkZGJjZTkwNDFkZDk2OGNlMmI3MTI2YTEwMDVfMTA5OTUxMTYzMDk2NQ_67053f3e-dda7-4a10-8fca-a3f758795eec">56.3</ix:nonFraction> million in federal net operating loss carryforwards including approximately $<ix:nonFraction unitRef="usd" contextRef="ic125e85e38194740b3b6e42596d48565_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81Mi9mcmFnOjM2Nzc2ZGRiY2U5MDQxZGQ5NjhjZTJiNzEyNmExMDA1L3RleHRyZWdpb246MzY3NzZkZGJjZTkwNDFkZDk2OGNlMmI3MTI2YTEwMDVfMTM3Mw_dd031b47-53b6-4572-bed5-e17cced0be5a">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i993426469958441b92ca0e01b517cc2a">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</ix:continuation> </span></div><div id="i60c789aa695e441494b09d48a21e5c74_55"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(9) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81NS9mcmFnOjBhYzMxZWE2ZGU2NDRhYWRhZDE1Y2UzOTk0NzNmMGI4L3RleHRyZWdpb246MGFjMzFlYTZkZTY0NGFhZGFkMTVjZTM5OTQ3M2YwYjhfOTc4_db92be01-c221-416c-b7f2-93ae6f872d4e" continuedAt="ie33bda60f1cc41178920077b9c35bb83" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="ie33bda60f1cc41178920077b9c35bb83"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 10 do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span></ix:continuation></div><div id="i60c789aa695e441494b09d48a21e5c74_58"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(10) <ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNjAxNw_7203ab7d-23b6-4420-b77a-07578befa81e" continuedAt="i385aece8d92649bba882eb976c19543c" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="i385aece8d92649bba882eb976c19543c" continuedAt="i3cdc22efe46c42a38774dec576574fe7"><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  The Company expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i6a665abb669e4b8294fe2d11afdae64b_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTIxNg_be37664a-1a78-4633-bc42-aa87218257d8">20.0</ix:nonFraction> million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i2c77d503275442c7bd85a5f3a65d371a_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTI1OQ_21a094a4-418a-4ad9-ad9d-3fb062c0b3e7">5.0</ix:nonFraction> million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i6a665abb669e4b8294fe2d11afdae64b_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTM2Mg_072e89ed-dee6-418f-8533-5f9dfb344fe8">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNjAyMQ_196accdc-78e4-43d3-af22-10988f92658c" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.631%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.369%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfMi0xLTEtMS0w_db173078-2e64-46f3-8750-2e8e99656624">20,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfMy0xLTEtMS0w_9d99b243-5e5c-453d-b2c7-a430bb8da810">5,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfNC0xLTEtMS0w_5ff4ebf2-d6b9-466c-bddc-0803a0f79f7d">9,182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfNS0xLTEtMS0w_d515a442-6565-4001-826f-223330760f7c">34,182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM1NA_9d54fa5d-8970-40d3-a08a-3b398638ba08" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMC0xLTEtMS0zMDIx_5e8bbbda-2daf-4012-82b7-998bad624b89">6,624,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMS0xLTEtMS0zMDIx_ee99872d-ae75-476c-a3b9-d156d3045dc0">3,970,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMi0xLTEtMS0zMDIx_d8bb1c0e-7f36-4162-8378-d8a1e733c867">1,827,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMy0xLTEtMS0zMDIx_896c693e-bdf0-40d9-a7a8-4f01fc9dc022">9,129,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfNC0xLTEtMS0zMDIx_d90adcb3-cebe-46b9-894f-287de9d6ca99">21,550,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfNi0xLTEtMS0zMDIz_0061b7ba-4cc7-45e5-8b83-1ea2b6832660">11,750,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfNy0xLTEtMS0zMDIz_645cec66-4673-4447-8843-a30896ae42e0">882,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfOC0xLTEtMS0zMDIz_7ecb250e-adee-46e2-8c4e-222b765c302d">12,632,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfOS0xLTEtMS0zMDIz_1c2d4c2c-6a20-4c33-84cd-2feecea54425">34,182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><ix:continuation id="i3cdc22efe46c42a38774dec576574fe7" continuedAt="i86219e62021e4164b0fc097f8fbdf0ce"><ix:nonNumeric contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNjAyMg_6430a94b-f385-4213-b742-745affae06a7" escape="true"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iaf017760b38441c1af2d35a25e124e99_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfOS0xLTEtMS0w_22d2c679-c7ad-4a15-94f5-e2d5937ecb76">8,633,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTAtMS0xLTEtMA_d821a267-a3a6-471e-8158-c4a30267d135">260,735</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTEtMS0xLTEtMA_1b77001b-0150-437a-841c-4678fa1491de">645,571</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTItMS0xLTEtMA_567d0a9c-bbf9-49f6-9492-214f759a46da">573,279</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance at June 30, 2020</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTMtMS0xLTEtMA_11f3ee84-d435-4ee1-ba1e-7c05460cdddd">8,300,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="id334b396a4b3435091868e865fabd32c_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM5Nw_314973d0-cd01-4a93-a179-918b495d7a82">8.3</ix:nonFraction>&#160;million was classified as other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib89bcb77f46a4517a75030c3a28c5b4f_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM1Ng_0c3bf241-57be-4aa9-96d2-1c7ebc8a0a55">2.8</ix:nonFraction>&#160;million and other long-term liabilities of $<ix:nonFraction unitRef="usd" contextRef="if905a7f82f44495396e2179b4d0584ba_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM3MA_31809291-7706-41e9-ae88-157e5ce3c1b8">5.5</ix:nonFraction>&#160;million on the condensed consolidated balance sheet as of June 30, 2020.  </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RediTrex</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, the Company announced an agreement with the Nordic Group B.V.&#8217; ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="ief4c0cae1876488cbb05cfd3be1ad10d_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMjk0NQ_0cefc811-286c-4a63-ae9d-8a2471c50423">100,000</ix:nonFraction> at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="ief4c0cae1876488cbb05cfd3be1ad10d_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMjk5MQ_0b46feb6-5d65-4a77-88f3-e523e805c9a8">0.9</ix:nonFraction> million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="if3a989ff74234cd4a92b992a22f309d6_D20161101-20161130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzAxOQ_0209d9fd-dcae-4f23-b9a9-ed4289cce88d">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name.  The <ix:nonFraction unitRef="shares" contextRef="if3a989ff74234cd4a92b992a22f309d6_D20161101-20161130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzQ3Mw_0209d9fd-dcae-4f23-b9a9-ed4289cce88d">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i46ecb77eacf14a63afd0516b29399c0a_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzU0Nw_fae2757a-f3d9-4aee-a962-e5d2802f4987">0.9</ix:nonFraction> million on the vesting date. The FDA approval also resulted a $<ix:nonFraction unitRef="usd" contextRef="i575e7871cbfc48ecb68373ff71bde4cb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzY0OA_65b0d0ae-dcde-4db3-bb5a-eb21b2e4dcd4">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and is recorded as an other current liability at both June 30, 2020 and December 31, 2019.  During the three months ended June 30, 2020, Cumberland recognized $<ix:nonFraction unitRef="usd" contextRef="i484fde4f0aac43cf954b8569b221802d_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMjc0ODc3OTA4MjQzMw_eb22077f-cf12-4f2f-b777-c9a8777bd5b3">0.5</ix:nonFraction>&#160;million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">   </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ethyol and Totect </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $<ix:nonFraction unitRef="usd" contextRef="i0967848cdd484daebc2c83c3e623f456_D20191001-20210930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNDYwNA_931cac8f-fbc0-4cd3-953b-346f8343fc2b">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first two quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="ibb806d70ebf248d28f3e9175478166e3_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTY0OTI2NzQ0ODAxNw_cb4f5f74-f473-408c-b1fe-8b0cb779cea7">1.5</ix:nonFraction> million during the six months ended June 30, 2020 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as discontinued operations and will record each future quarterly installment over the two year period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As there are no expenses associated with these payments,  approximately $<ix:nonFraction unitRef="usd" contextRef="ibb806d70ebf248d28f3e9175478166e3_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTY0OTI2NzQ0ODA5Mw_cb4f5f74-f473-408c-b1fe-8b0cb779cea7">1.5</ix:nonFraction> million in discontinued operations income was recorded during the period ended June 30, 2020. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Products provided $<ix:nonFraction unitRef="usd" contextRef="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNTExMA_ac04229b-d2c6-4789-aaa7-01aafe7f7640">5.3</ix:nonFraction>&#160;million in revenue, with $<ix:nonFraction unitRef="usd" contextRef="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzQxMQ_89d720f1-8be5-480d-95c9-503c8251b034">3.4</ix:nonFraction>&#160;million in direct expenses resulting in $<ix:nonFraction unitRef="usd" contextRef="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNTE1MQ_b48896ce-d0f4-411a-bafc-2625723b28cb">1.9</ix:nonFraction>&#160;million in discontinued operations income during the six months ended June 30, 2019. These direct expenses do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Those sales and marketing individuals who supported the Products have subsequently shifted their efforts to support other Cumberland brands.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="i86219e62021e4164b0fc097f8fbdf0ce" continuedAt="i8445dbd393ff46f587616d2eb7dd2ae9"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019 current assets of discontinued operations included $<ix:nonFraction unitRef="usd" contextRef="i8bb4e69141de4966aa42c82e466f9e01_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNTU4Ng_18541aa5-07f0-4bb1-9099-4446e596e1ec">0.5</ix:nonFraction>&#160;million in remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">inventory for the Products sold and returned to Clinigen as part of the transaction. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, and December 31, 2019, </span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8445dbd393ff46f587616d2eb7dd2ae9">the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.</ix:continuation>  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure regarding forward-looking statements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ significantly from the results discussed in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the 2020 COVID-19 pandemic. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and other filings with the SEC.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div><span><br/></span></div><div id="i60c789aa695e441494b09d48a21e5c74_67"></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Business</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;margin-bottom:8pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our portfolio of FDA approved brands includes:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Acetadote</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Caldolor</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of pain and fever;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Kristalose</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Omeclamox</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) infection and related duodenal ulcer disease;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vaprisol</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vibativ</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and</span></div><div style="text-indent:-18pt;padding-left:72pt;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">RediTrex</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">methotrexate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Aspirin-Exacerbated Respiratory Disease. We have also completed initial Phase II clinical studies with ifetroban in patients with Hepatorenal Syndrome and patients with Portal Hypertension.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has both product development and commercial capabilities, and we believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing, and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Growth Strategy</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland's growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently market six FDA-approved products in the United States and expect to market our seventh product, RediTrex, before the end of 2020.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through our international partners, we are working to bring our medicines to patients in their countries. Our clinical team is developing a pipeline of new product candidates largely to address unmet medical needs. We also look for opportunities to expand the approved use of our products for additional patient populations through clinical trials, through new presentations, and through our support for select, investigator-initiated studies. Through our active business development initiative, we are pursuing the acquisition of additional marketed brands and late-stage development product candidates in our target medical specialties. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, we are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. CET partners with academic research institutions to identify and progress promising, new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="text-align:justify;margin-top:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Specifically, we are seeking long term sustainable growth by executing on the following:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">        </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Support and expand the use of our marketed products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will continue to explore opportunities for label expansion to bring our products to new patient populations.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As examples, we have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Selectively add complementary brands.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In addition to our product development activities, we are also seeking to acquire products and late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs, as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ represents the largest product acquisition we have completed.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leverage our infrastructure through co-promotion partnerships.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We also look for strategic co-promotion partners that can complement our capabilities and enhance the opportunity for our brands. Our co-promotion arrangements with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc allow us to expand current promotional support for Kristalose across the U.S.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">     </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Build an international contribution to our business.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We have established our own commercial capabilities, including two sales divisions to promote our approved brands in the U.S. We have also entered into agreements with a group of international partners to register our products and make them available to patients in their countries. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The acquisition of Vibativ resulted in several new international partners and market opportunities.  We will continue to support and selectively expand our network of international partners, while assisting with the registration and commercialization efforts in their respective territories.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Manage our operations with financial discipline.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. Our goal is to maintain a healthy financial position, with favorable gross margins, and a strong balance sheet. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">www.sec.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  In April 2020, we issued our inaugural Environmental, Social and Governance (&#8220;ESG&#8221;) report which is also available on our website.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RECENT DEVELOPMENTS</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2) strain of coronavirus that causes COVID-19, a respiratory illness. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has remained open for business, as we are considered to be essential by the United States Department of Homeland Security. We have implemented measures to address the impact of the novel coronavirus on our business and taken appropriate action to protect our employees, secure our supply chain, and support the patients who can benefit from our medicines.  All our corporate, sales and CET employees have been provided the opportunity to work remotely, and those who wish to work at our offices are encouraged to follow the health guidelines outlined by the Centers for Disease Control. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, their contact has largely shifted from in person to telephonic and electronic communications. Travel across the organization and attendance at medical meetings have largely been discontinued. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third-party organizations around the world to supply components, manufacture and distribute our products. We are aware that we may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on our future results as of the date of this filing.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continue to monitor the coronavirus situation both in the U.S. and internationally in order to maintain our employees&#8217; safety and well-being, while also keeping our business operating.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Acute Care Product Special Supply Arrangements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, Cumberland announced an initiative to expand the availability of Vibativ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> along with special financial arrangements for hospitals and clinics to help ensure supply during this unprecedented health care crisis. In addition, we sponsored a national program with infectious disease experts to provide information on the management of complicated respiratory infections resulting from COVID-19.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also in March 2020, we announced an initiative to expand the availability of Caldolor</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> with special supply and financial arrangements, including favorable pricing and payment terms for hospitals and clinics to help ensure timely access to Caldolor during this health care crisis.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, in April 2020, the Company announced a third COVID-19-related initiative. This initiative increases the availability of Vaprisol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to hospitals and clinics including special supply and financial arrangements, with favorable pricing and payment terms, to help ensure timely access to Vaprisol during this health care crisis.</span></div><div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Vibativ Clinical Manuscripts</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In May 2020, Cumberland announced a new study published in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Drugs - Real World Outcomes</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, detailing the positive clinical outcomes that resulted from treating patients with bacteremia or endocarditis with Vibativ. This publication is a sub analysis of The Telavancin Observational Use Registry (TOUR&#8482;), a study conducted to record population characteristics, prescription information, and real-world clinical outcomes of patients with Gram-positive infections treated with Vibativ. The analysis suggests Vibativ is a promising and viable option for patients with bacteremia or endocarditis, including those with MRSA or another S. aureus pathogen.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, in May 2020, we announced the publication of two studies confirming the continued in vitro potency of telavancin. Both publications were part of continued surveillance of telavancin activity since 2011.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The first publication tested a global collection of 24,408 Gram-positive clinical isolates, and the second publication tested a U.S. collection of 15,882 S. aureus isolates. Both studies documented the sustained in vitro antimicrobial activity and spectrum of telavancin&#8212;many years after its clinical approval&#8212;against Gram-positive clinical isolates collected worldwide over 7 years, from 2011 through 2017.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, Cumberland reached an agreement to acquire Vibativ from Theravance Biopharma and assume global responsibility for the product.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Environmental, Social and Governance (ESG) Activities</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, we released our first Sustainability Report. This report describes the Company&#8217;s activities pertaining to Environmental, Social and Governance (&#8220;ESG&#8221;) matters, otherwise known as corporate sustainability. It includes details about Cumberland&#8217;s community involvement, ethical marketing, and drug safety.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our board appointed Caroline R. Young, former president of the Nashville Health Care Council, as the company&#8217;s first ESG board director. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The report notes that, during 2019, Cumberland provided nearly 4 million patient doses of products, safely disposed of over 9,700 pounds of expired and damaged products and had no product recalls. We also had no product listings on the FDA&#8217;s Safety Alerts Database and no products identified in the FDA Adverse Event Reporting System during 2019.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Paycheck Protection Program</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The PPP is administered by the U.S. Small Business Administration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the date of funding we have used the loan amount for such qualifying expenses.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from our PPP loan, we currently do not foresee doing so. We will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Ifetroban Phase II Clinical Programs</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have completed three pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure, 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients suffering from Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. A follow-up Phase II study is currently underway for this asthma indication. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are currently evaluating ifetroban in two pilot Phase II studies of 1) patients with Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 2) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy. This rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Enrollment in our clinical studies declined during the first and second quarters of 2020 due to the COVID-19 pandemic. While enrollment of new patients is currently limited, we are working to ensure that patients already entered into a trial continue to receive their study drug. We are awaiting further study results before deciding on the best path for approval for ifetroban, our first new chemical entity.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">New Hospital Product Candidate</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol-reducing agent for use in the hospital setting. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA. A Phase II study has been initiated and patient enrollment completed. We are now evaluating the results from this study and will then determine the next steps for this product development program.</span></div><div id="i60c789aa695e441494b09d48a21e5c74_70"></div><div style="margin-top:8pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2019 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accounting Estimates and Judgments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, fair value of contingent consideration liability, share-based compensation, research and development expenses and intangible assets.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Three months ended June 30, 2020 compared to the three months ended June 30, 2019 </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended June 30, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.707%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,598,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,417,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,609,982&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,792,293&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">817,689&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,865,406&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,982,379&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(116,973)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,421,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,716,169&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(294,667)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,190,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,270,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(79,554)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,091,485&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,029,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61,777&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,179,139&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,790,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">388,272&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,580,962)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,373,424)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(207,538)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,661&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">130,565&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(101,904)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,455)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(91,200)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28,255)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,671,756)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,334,059)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(337,697)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,455)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,462)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,993)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,679,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,338,521)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(340,690)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.780%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.254%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">595,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">983,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(388,163)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">478,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(467,656)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,477,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,476,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(38,367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,166,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,054,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111,851&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,299,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">700,227&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874,213&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">612,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">262,178&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,598,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,417,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net revenues for the three months ended June 30, 2020, were $9.6 million compared to $9.4 million for the three months ended June 30, 2019.  As detailed in the table above, net revenue increased for three of our marketed products: Vibativ, Caldolor, and Kristalose during the quarter. There were decreases in Acetadote, Omeclamox-Pak and Vaprisol.   We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated not-compete provisions, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date. The second installment of $0.8 million due from Clinigen was recorded during the three months ended June 30, 2020, as discontinued operations.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vibativ revenue was $3.3 million for the three months ended June 30, 2020, an increase of $0.7 million over the same period last year.  The 26.9% increase was a result of improved sales volumes.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Kristalose revenue increased slightly during the second quarter of 2020, when compared to the prior year period.  The increase was primarily the result of increased sales volumes for the product.  </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vaprisol revenue was $0.2 million for the second quarter of 2020, and this slight decrease of net sales compared to the second quarter of 2019 is primarily due to lower sales volumes.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Omeclamox-Pak revenue decreased $0.5 million for the second quarter of 2020, compared to the second quarter of 2019, primarily due to a decrease in sales volumes.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a decrease of $0.4 million in the product's revenue when compared to the prior year period as a result of lower sales volumes. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Caldolor revenue was $1.2 million for the second quarter of 2020, an increase of $0.1 million compared to the same period last year. The improvement in net revenue was the result of an increase in international shipments of Caldolor when compared to the prior year period, which were partially offset by lower domestic shipments of the product, significantly impacted by COVID - 19 and a reduction in elective surgeries.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of products sold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">st of products sold for the second quarter of 2020 and 2019 were $2.6 million and $1.8 million, respectively. Cost of products sold, as a percentage of net revenues, were 27.2% during the three months ended June 30, 2020, compared to 19.0% during the three months ended June 30, 2019.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase in sales of Vibativ.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling and marketing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Selling and marketing expense for the second quarter of 2020 decreased $0.1 million compared to the prior year period.  This decrease is primarily attributable to decreases in direct sales promotion costs and travel expenses.  There were partially offsetting increases in salaries and royalty costs during the quarter. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Research and development costs were $1.4 million for the second quarter of 2020 and $1.7 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  The decrease in costs were primarily the result of decreased study activity as well as decreases in the costs of our medical science liaison activities partially offset by increases in our annual FDA user fees.     </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  General and administrative expense for the second quarter of 2020 decreased to $2.2 million from  $2.3 million during the second quarter of 2019 as a result of decreases in advisory and professional fees as well as a reduction in non-cash stock based compensation during the period.  These decreases were partially offset by increases in salary and business development legal costs.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended June 30, 2020, and three months ended June 30, 2019, totaled approximately $1.1 million and $1.0 million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Income tax expense for the three months ended June 30, 2020, was comparable to the income tax expense for the three months ended June 30, 2019.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div><span><br/></span></div><div id="i60c789aa695e441494b09d48a21e5c74_76"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Six months ended June 30, 2020 compared to the six months ended June 30, 2019 </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the unaudited interim statements of operations for continuing operations for the six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.707%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,147,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(218,392)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,244,163&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,451,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">793,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,573,082&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,419,311&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">153,771&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,144,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,115,856&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,201&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,227,048&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,807,057&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(580,009)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,167,524&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,051,353&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">116,171&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,355,874&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,844,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">511,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,426,963)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,697,356)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(729,607)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,549&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">246,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(187,877)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(152,520)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(152,111)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(409)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,520,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,603,041)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(917,893)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(41,695)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76,966&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118,661)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,562,629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,526,075)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,036,554)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.780%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.254%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,832,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(524,265)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124,371&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(553,770)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,771,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,785,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,617)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">382,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">499,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(117,186)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,372,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(111,313)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,721,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,062,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,359,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,522&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,147,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(218,392)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net revenues for the six months ended June 30, 2020, were $17.9 million compared to $18.1 million for the six months ended June 30, 2019.  As detailed in the table above, net revenue increased for our marketed product Vibativ during the first six months of 2020. The overall 1.2% revenue decrease was the result of decreases in our other products. We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and associated non-compete provision, Cumberland is receiving $5 million in financial consideration paid over the two-years following the return date. The first two installments totaling $1.5 million due from Clinigen was recorded during the six months ended June 30, 2020, as discontinued operations.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vibativ revenue was $5.7 million for the six months ended June 30, 2020, an increase of $1.1 million over the same period last year.  The 22.8% increase in net revenue was a result of improved sales volume for the product.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Kristalose revenue was $6.8 million during the first six months of 2020, consistent with the prior year period.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vaprisol revenue was $0.4 million for the first six months of 2020, which is a decrease of net sales of $0.1 million compared to the first six months of 2019 primarily due to lower sales volumes.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Omeclamox-Pak revenue decreased $0.6 million for the six months ended June 30, 2020, compared to the six months ended June 30, 2019, primarily due to a decrease in sales volumes.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. There was a decrease of $0.5 million in the product's year to date revenue for the six months ended June 30, 2020, when compared to the prior year period as a result of lower sales volumes, partially offset by improved net pricing. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Caldolor revenue was $2.3 million for the first two quarters of 2020, a decrease of $0.1&#160;million compared to the same period last year. There were lower domestic shipments of the product, that were significantly impacted by COVID - 19 and a reduction in elective surgeries.  These lower domestic sales were partially offset by an increase in international shipments of Caldolor when compared to the prior year period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of products sold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">st of products sold for the first six months of 2020 and 2019 were $4.2 million and $3.5 million, respectively. Cost of products sold, as a percentage of net revenues, were 23.7% during the six months ended June 30, 2020, compared to 19.0% during the six months ended June 30, 2019.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the increase in sales of Vibativ.    </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling and marketing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Selling and marketing expense for the six months ended June 30, 2020, increased $0.2 million compared to the prior year period.  This increase is primarily attributable to increases in salaries as well as an increase in the non-cash expense related to the decrease in the fair value of Cumberland owned life insurance.  These increases were partially offset by decreases in royalty costs, direct sales promotion costs and travel expenses.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Research and development costs were $3.1 million for both the first six months of  2020 and for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  We experienced a decrease in study activity offset by increases in our annual FDA user fees.      </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  General and administrative expense for the six months ended June 30, 2020, decreased to $4.2 million from $4.8 million during the six months ended June 30, 2019 as a result of decreases in advisory, legal and professional fees.  We also experienced a reduction in non-cash stock based compensation during the period.  A portion of these decreased costs were related to 2019 expenses related to our acquisition of Vibativ. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the six months ended June 30, 2020, and six months ended June 30, 2019, totaled approximately $2.2 million and $2.1 million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Income tax expense (benefit) for the six months ended June 30, 2020, as a percentage of loss from continuing operations before income taxes, was 1.2%, compared to (3.0)% for the six months ended June 30, 2019.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><span><br/></span></div><div id="i60c789aa695e441494b09d48a21e5c74_79"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Working Capital</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our primary sources of liquidity are cash flows provided by our operations, the proceeds from the Paycheck Protection Program loan, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At June 30, 2020 and December 31, 2019, all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our liquidity and working capital as of June 30, 2020 and December 31, 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:57.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.561%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,373,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,212,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,373,737&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,212,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital (current assets less current liabilities)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,090,575&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,012,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit availability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our net changes in cash and cash equivalents for the six months ended June 30, 2020 and June 30, 2019:</span></div><div style="margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:57.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.561%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,704,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,464,926&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(773,014)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,547,278)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,769,955)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,905,428)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(838,898)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,987,780)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net $0.8 million decrease in cash and cash equivalents for the six months ended June 30, 2020, was primarily attributable to cash used in investing and financing activities.  Cash provided by operating activities of $3.7 million was positively impacted by decreases in  inventory of $1.2 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $2.9 million.  Cash used by investing activities was the result of additions to intangibles of $0.7 million and equipment of $0.1 million.  Our financing activities included the net repayment of $1.5 million on our revolving line of credit, the $1.2 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of subsidiary shares. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net $7.0 million decrease in cash and cash equivalents for the six months ended June 30, 2019 was attributable to cash used in investing and financing activities, partially offset by the $1.5&#160;million in cash provided by operating activities.  Cash provided by operating activities of $1.5 million was positively impacted by the decrease in inventory of $0.8&#160;million as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $2.9 million.  Cash used in investing activities included the $5.0&#160;million payment to Theravance as part of the acquisition of Vibativ. Cash used in investing activities also included net cash invested in marketable securities of $1.1 million and additions to intangibles of $0.4 million.  Our financing activities reflected the $1.2 million in cash used to repurchase shares of our common stock. </span></div><div style="text-align:justify;margin-top:11pt;"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021, as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 7 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018, we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  We were in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2020. We expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Paycheck Protection Program Loan</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. For a summary of the material terms of the Paycheck Protection Program loan, see Note 7 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">UUnder the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the date of funding we have used the loan amount for such qualifying expenses.</span></div><div id="i60c789aa695e441494b09d48a21e5c74_82"></div><div style="margin-top:12pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020 and 2019, we did not engage in any off-balance sheet arrangements.</span></div><div id="i60c789aa695e441494b09d48a21e5c74_85"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. The Company did not have any investments classified as marketable securities at June 30, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 2.92% at June 30, 2020). As of June 30, 2020, we had $17.0 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exchange Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the six months ended June 30, 2020 and 2019.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. Controls and Procedures</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, the Company&#8217;s management has concluded that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended June 30, 2020, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="i60c789aa695e441494b09d48a21e5c74_94"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Legal Proceedings</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i60c789aa695e441494b09d48a21e5c74_97"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A. Risk Factors</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the three months ended March 31, 2020, and other reports that may be filed by the Company.</span></div><div id="i60c789aa695e441494b09d48a21e5c74_100"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchases of Equity Securities</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity, by month, during the three months ended June 30, 2020:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.654%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.449%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Shares (or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Purchased (1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Price&#160;Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">per&#160;Share</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(or Unit)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Total&#160;Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Shares (or Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;as&#160;Part</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">of Publicly</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Announced Plans</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">or Programs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Maximum&#160;Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(or Approximate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Dollar Value) of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">that May Yet Be</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;Under</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">the Plans or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">April</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,144</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.96&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,144</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,117,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,078</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.81&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,078</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,953,582&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,241</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38,241</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,823,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,463</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">141,463</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Of this amount, 3,235 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div id="i60c789aa695e441494b09d48a21e5c74_538"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;5. Submission of Matters to a Vote of Security Holders</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At its meeting on May 5, 2020 our Board of Directors determined to hold future non-binding shareholder advisory votes on executive compensation every three years until the next non-binding advisory vote on the frequency of shareholder votes on executive compensation, which is required to occur no later that the Company's 2026 annual meeting of shareholders. Such determination is consistent with the previous recommendation of the Board of Directors and the preference of Company shareholders, as represented by their votes at the annual meeting of shareholders on May 5, 2020.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6. Exhibits</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.717%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.461%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:73.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">A</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">men</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">dment Nu</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">mber 2 to</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm"> t</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">h</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">e A</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">mended and Restated 2007 Long-Term Incentive Co</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm">mpensation Plan.</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101-amendment2l.htm"> </a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit102-amendment2d.htm">Amendment Number 2 to the Amended and Restated 2007 Director's Incentive Compensation Plan.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">Payment Protection Program</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm"> Note</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm"> dated</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm"> </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">April 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">, 2020,</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm"> by and between </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">Cumberland </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">Pharmac</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">euticals Inc. </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">Pinnacle Bank</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit103-form147_716ba.htm">.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2020q2-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2020q2-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2020q2-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><div id="i60c789aa695e441494b09d48a21e5c74_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%;"><div style="margin-top:12pt;margin-bottom:6pt;"><span><br/></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%;"><tr><td style="width:1.0%;"></td><td style="width:7.388%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.080%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.184%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.769%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.307%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.172%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.184%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.516%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumberland Pharmaceuticals Inc.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-amendment2l.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if064ca9ea6b14d56ba983f11c9c12dab_1"></div><div style="min-height:72pt;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div><div style="text-align:right;margin-bottom:8pt;"><font><br></font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;">AMENDMENT NUMBER 2</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;">TO THE CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;">AMENDED AND RESTATED 2007 LONG-TERM INCENTIVE COMPENSATION PLAN</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), a corporation organized under the laws of Tennessee, originally adopted the Cumberland Pharmaceuticals Inc. 2007 Long-Term Incentive Compensation Plan on April 18, 2007,  amended and restated by that certain amended and restated 2007 Long-Term Incentive Compensation Plan, effective as of April 17, 2012 (the &#34;Plan&#34;)&#59;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, under Section 12 of the Plan, the Board of Directors of the Company (the &#8220;Board&#8221;) may, at any time, amend the Plan as permitted by applicable statutes, except that it may not revoke or alter the Plan in a manner unfavorable to the grantees of any Incentives awarded under the Plan or any Incentives then outstanding, nor may the Board amend the Plan without shareholder approval if such approval is required by any applicable law or regulation&#59;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, the Board has determined that it is advantageous to the Company to amend the Plan to allow Incentives to be granted after April 18, 2020, the date currently specified in Section 12 as the last date upon which an Incentive may be granted under the Plan&#59; and</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, capitalized terms used and not defined herein shall have the meanings set forth in the Plan.</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">NOW, THEREFORE, the Plan is hereby amended as follows&#58;&#160;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">The last sentence of Section 12 of the Plan is hereby stricken in its entirety and replaced with the following&#58; &#8220;No Incentive may be awarded under the Plan after the earlier of the following dates&#58; (a) the date that no shares of Stock remain available for issuance through the Plan, or (b) April 21, 2026. However, awards made on or before such date may extend beyond such date.&#8221;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Except as expressly set forth in this amendment, all other terms and conditions set forth in the Plan shall remain in full force and effect. </font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">IN WITNESS WHEREOF, the undersigned Corporate Secretary of the Company hereby certifies that the foregoing Amendment Number 2 to the Cumberland Pharmaceuticals Inc. Amended and Restated 2007 Long-Term Incentive Compensation Plan was (i) approved by the Board of Directors and (ii) approved by a majority of the holders of all of the Company&#8217;s outstanding common and preferred stock.</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Dated&#58; May 5, 2020</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Jean W. Marstiller</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Corporate Secretary</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-amendment2d.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ice321abc3db34d239ebb0d6bd3425ff2_1"></div><div style="min-height:72pt;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div><div style="text-align:right;margin-bottom:8pt;"><font><br></font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;">AMENDMENT NUMBER 2</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;">TO THE CUMBERLAND PHARMACEUTICALS INC.</font></div><div style="text-align:center;margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;">AMENDED AND RESTATED 2007 DIRECTORS&#8217; INCENTIVE PLAN</font></div><div style="text-align:center;margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), a corporation organized under the laws of Tennessee, originally adopted the Cumberland Pharmaceuticals Inc. 2007 Directors&#8217; Incentive Plan on April 18, 2007, as amended and restated effective as of April 17, 2012 (the &#8220;Plan&#8221;).</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, under Section 11.1 of the Plan, the Board of Directors of the Company (the &#8220;Board&#8221;) may amend the Plan at any time, to the extent permitted under Section 11.1(a) and (b)&#59;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, the Board has determined that it is advantageous to the Company to amend the Plan to provide that Awards may be granted thereunder until April 21, 2026&#59; and</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">WHEREAS, capitalized terms used and not defined herein shall have the meanings set forth in the Plan.</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">NOW, THEREFORE, the Plan is hereby amended as follows&#58;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Section 11.2 is hereby stricken in its entirety and replaced with the following&#58; &#8220;No Award may be made under the Plan after the earlier of the following dates&#58; (a) the date that no shares of Stock remain available for issuance through the Plan, or (b) April 21, 2026. However, Awards made on or before such date may extend beyond such date.&#8221;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Except as expressly set forth in this amendment, all other terms and conditions set forth in the Plan shall remain in full force and effect. </font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">IN WITNESS WHEREOF, the undersigned Corporate Secretary of the Company hereby certifies that the foregoing Amendment Number 2 to the Cumberland Pharmaceuticals Inc. Amended and Restated 2007 Directors&#8217; Incentive Plan was (i) approved by the Board of Directors and (ii) approved by a majority of the holders of all of the Company&#8217;s outstanding common and preferred stock.</font></div><div style="margin-bottom:8pt;"><font><br></font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Dated&#58; May 5, 2020</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Jean W. Marstiller</font></div><div style="margin-bottom:8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;">Corporate Secretary</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-bottom:0.08pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103-form147_716ba.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit103-form147_716ba</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit103-form147_716ba001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E                                                           U.S. Small Business Administration                                                                          NOTE           SBA Loan #             7054927105          SBA Loan Name          Paycheck Protection Program Loan          Date                   4/14/2020          Loan Amount            2,187,140.00          Interest Rate          1.0%          Borrower               CUMBERLAND PHARMACEUTICALS INC.          Operating Company           Lender                 Pinnacle Bank          1.  PROMISE TO PAY:             In return for the Loan, Borrower promises to pay to the order of Lender the amount of              Two Million, One Hundred And Eighty-Seven Thousand, One Hundred And Forty and 00/100 Dollars Dollars,             interest on the unpaid principal balance, and all other amounts required by this Note.         2.  DEFINITIONS:             &quot;Collateral&quot; means any property taken as security for payment of this Note or any guarantee of this Note.            &quot;Guarantor&quot; means each person or entity that signs a guarantee of payment of this Note.            &quot;Loan&quot; means the loan evidenced by this Note.            &quot;Loan Documents&quot; means the documents related to this loan signed by Borrower, any Guarantor, or anyone who             pledges collateral.            &quot;SBA&quot; means the Small Business Administration, an Agency of the United States of America.        SBA Form 147 (06/03/02) Version 4.1                                                                   Page 1/7      Compliance Systems LLC 2020 ITEM 716BAL1 (93/2020) Page 1of 7                                    www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit103-form147_716ba002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E          3.  PAYMENT TERMS:             Borrower must make all payments at the place Lender designates. The payment terms for this Note are:             Maturity: This Note will mature in 2 years and 0 months from date of Note.                           Repayment terms:                           The interest rate is 1% per year.  The interest rate may only be changed in accordance with SOP 50 10.                           Borrower must pay principal and interest payments of $  $123,084.34                                 every month, beginning seven months from             the month this Note is dated; payments must be made on the        14      calendar day in the months they are due.                           Lender will apply each installment first to pay interest accrued to the day Lender receives the payment, then to bring             principal current, then to pay any late fees, and will apply any remaining balance to reduce principal.                           Loan Prepayment:                            Notwithstanding any provision in this Note to the contrary:                           Borrower may prepay this Note.  Borrower may prepay 20 percent or less of the unpaid principal balance at any time             without notice.  If Borrower prepays more than 20 percent and the Loan has been sold on the secondary market,             Borrower must:                           a. Give Lender written notice;                           b. Pay all accrued interest; and                           c. If this prepayment is received less than 21 days from the date Lender receives the notice, pay an amount equal to 21               days' interest from the date lender receives the notice, less any interest accrued during the 21 days and paid under               subparagraph b., above.                           If Borrower does not prepay within 30 days from the date Lender receives the notice, Borrower must give Lender a new             notice.                           All remaining principal and accrued interest is due and payable 2 years and 0 months from date of Note.                           Late Charge:  If payment on this Note is more than    15       days late, Lender may charge Borrower a late fee of up to                                   5.0      % of the unpaid portion of the regularly scheduled payment.        SBA Form 147 (06/03/02) Version 4.1                                                                     Page 2/7      Compliance Systems LLC 2020 ITEM 716BAL2 (93/2020) Page 2 of 7                                   www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit103-form147_716ba003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E          4.  DEFAULT:             Borrower is in default under this Note if Borrower does not make a payment when due under this Note, or if Borrower             or Operating Company:             A.   Fails to do anything required by this Note and other Loan Documents;             B.  Defaults on any other loan with Lender;             C.  Does not preserve, or account to Lender's satisfaction for, any of the Collateral or its proceeds;            D.   Does not disclose, or anyone acting on their behalf does not disclose, any material fact to Lender or SBA;             E.  Makes, or anyone acting on their behalf makes, a materially false or misleading representation to Lender or SBA;             F.  Defaults on any loan or agreement with another creditor, if Lender believes the default may materially affect                  Borrower's ability to pay this Note;            G.   Fails to pay any taxes when due;            H.   Becomes the subject of a proceeding under any bankruptcy or insolvency law;             I.  Has a receiver or liquidator appointed for any part of their business or property;             J.  Makes an assignment for the benefit of creditors;             K.  Has any adverse change in financial condition or business operation that Lender believes may materially affect                  Borrower's ability to pay this Note;            L.   Reorganizes, merges, consolidates, or otherwise changes ownership or business structure without Lender's prior                  written consent; or             M.  Becomes the subject of a civil or criminal action that Lender believes may materially affect Borrower's ability to                  pay this Note.         5.   LENDER'S RIGHTS IF THERE IS A DEFAULT:              Without notice or demand and without giving up any of its rights, Lender may:             A.   Require immediate payment of all amounts owing under this Note;            B.   Collect all amounts owing from any Borrower or Guarantor;            C.   File suit and obtain judgment;            D.   Take possession of any Collateral; or            E.   Sell, lease, or otherwise dispose of, any Collateral at public or private sale, with or without advertisement.         6.   LENDER&#8217;S GENERAL POWERS:              Without notice and without Borrower's consent, Lender may:              A.  Bid on or buy the Collateral at its sale or the sale of another lienholder, at any price it chooses;             B.  Incur expenses to collect amounts due under this Note, enforce the terms of this Note or any other Loan                  Document, and preserve or dispose of the Collateral. Among other things, the expenses may include payments                  for property taxes, prior liens, insurance, appraisals, environmental remediation costs, and reasonable attorney's                  fees and costs. If Lender incurs such expenses, it may demand immediate repayment from Borrower or add the                  expenses to the principal balance;             C.  Release anyone obligated to pay this Note;             D.  Compromise, release, renew, extend or substitute any of the Collateral; and             E.  Take any action necessary to protect the Collateral or collect amounts owing on this Note.       SBA Form 147 (06/03/02) Version 4.1                                                                     Page 3/7      Compliance Systems LLC 2020 ITEM 716BAL3 (93/2020) Page 3 of 7                                   www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit103-form147_716ba004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E          7.  WHEN FEDERAL LAW APPLIES:             When SBA is the holder, this Note will be interpreted and enforced under federal law, including SBA regulations.              Lender or SBA may use state or local procedures for filing papers, recording documents, giving notice, foreclosing              liens, and other purposes. By using such procedures, SBA does not waive any federal immunity from state or local              control, penalty, tax, or liability. As to this Note, Borrower may not claim or assert against SBA any local or state law             to deny any obligation, defeat any claim of SBA, or preempt federal law.          8.   SUCCESSORS AND ASSIGNS:             Under this Note, Borrower and Operating Company include the successors of each, and Lender includes its successors              and assigns.          9.  GENERAL PROVISIONS:             A.   All individuals and entities signing this Note are jointly and severally liable.             B.  Borrower waives all suretyship defenses.             C.  Borrower must sign all documents necessary at any time to comply with the Loan Documents and to enable                  Lender to acquire, perfect, or maintain Lender's liens on Collateral.            D.   Lender may exercise any of its rights separately or together, as many times and in any order it chooses. Lender                  may delay or forgo enforcing any of its rights without giving up any of them.             E.  Borrower may not use an oral statement of Lender or SBA to contradict or alter the written terms of this Note.             F.  If any part of this Note is unenforceable, all other parts remain in effect.            G.   To the extent allowed by law, Borrower waives all demands and notices in connection with this Note, including                  presentment, demand, protest, and notice of dishonor. Borrower also waives any defenses based upon any claim                  that Lender did not obtain any guarantee; did not obtain, perfect, or maintain a lien upon Collateral; impaired                  Collateral; or did not obtain the fair market value of Collateral at a sale.        SBA Form 147 (06/03/02) Version 4.1                                                                     Page 4/7      Compliance Systems LLC 2020 ITEM 716BAL4 (93/2020) Page 4 of 7                                   www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit103-form147_716ba005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E         10. STATE-SPECIFIC PROVISIONS:            The following provision applies when a borrower is a resident of WISCONSIN:            Each Borrower who is married represents that this obligation is incurred in the interest of his or her marriage or family.            The following Confession of Judgment provision applies when a borrower is a resident of DELAWARE:            WARRANT     OF  ATTORNEY/CONFESSION        OF JUDGMENT.     In addition to any other remedies Lender may            possess, Borrower knowingly, voluntarily and intentionally authorizes any attorney to appear on behalf of            Borrower, from time to time, in any court of record possessing jurisdiction over this Note and to waive issuance and            service of process and to confess judgment in favor of Lender against Borrower, for the unpaid principal, accrued            interest, accrued charges, reasonable attorney fees and court costs and such other amount due under this Note.             The following Confession of Judgment provision applies when a borrower is a resident of MARYLAND:            WARRANT     OF  ATTORNEY/CONFESSION       OF  JUDGMENT.    Borrower  authorizes an attorney to appear in a            court of record and confess judgment, without process, against Borrower in favor of Lender for all indebtedness owed            in connection with the loan, including but not limited to service charges, other charges and reasonable attorney's fees.             The following Confession of Judgment provision applies when a borrower is a resident of OHIO:            WARRANT     OF  ATTORNEY/CONFESSION        OF JUDGMENT.     In addition to any other remedies Lender may            possess, Borrower knowingly, voluntarily and intentionally authorizes any attorney to appear on behalf of Borrower,            from time to time, in any court of record possessing jurisdiction over this Note and to waive issuance and service of            process and to confess judgment in favor of Lender against Borrower, for the unpaid principal, accrued interest,            accrued charges, reasonable attorney fees and court costs and such other amount due under this Note.            WARNING: BY SIGNING THIS PAPER YOU GIVE UP YOUR RIGHT TO NOTICE AND COURT TRIAL. IF            YOU DO NOT PAY ON TIME, A COURT JUDGMENT MAY BE TAKEN AGAINST YOU WITHOUT YOUR            PRIOR   KNOWLEDGE      AND  THE   POWERS   OF  THE  COURT    CAN  BE  USED  TO  COLLECT    FROM    YOU            REGARDLESS      OF  ANY   CLAIMS    YOU   MAY    HAVE    AGAINST    THE   CREDITOR    WHETHER      FOR            RETURNED     GOODS,  FAULTY    GOODS,  FAILURE    ON HIS  PART  TO  COMPLY    WITH  THE   AGREEMENT            OR ANY OTHER CAUSE.             The following Confession of Judgment provision applies when a borrower is a resident of PENNSYLVANIA:             WARRANT     OF  ATTORNEY/CONFESSION        OF JUDGMENT.     Borrower irrevocably authorizes and empowers            the prothonotary, any attorney or any clerk of any court of record, upon default, to appear for and confess            judgment against Borrower for such sums as are due and/or may become due under this Note including costs of suit,            without stay of execution, and for attorney's fees and costs as set forth in this Note and knowingly, voluntarily and            intentionally waives any and all rights Borrower may have to notice and hearing under the state and federal laws            prior to entry of a judgment. To the extent permitted by law, Borrower releases all errors in such proceedings. If a            copy of this Note, verified by or on behalf of the holder shall have been filed in such action, it shall not be necessary            to file the original Note as a warrant of attorney. The authority and power to appear for and confess judgment            against Borrower shall not be exhausted by the initial exercise thereof and may be exercised as often as the holder            shall find it necessary and desirable and this Note shall be a sufficient warrant for such authority and power.            The following Confession of Judgment provision applies when a borrower is a resident of VIRGINIA:            IMPORTANT     NOTICE:   THIS  INSTRUMENT     CONTAINS    A  CONFESSION     OF JUDGMENT     PROVISION            WHICH    CONSTITUTES     A WAIVER    OF  IMPORTANT     RIGHTS   YOU   MAY   HAVE   AS A  DEBTOR    AND            ALLOWS THE CREDITOR TO OBTAIN A JUDGMENT AGAINST YOU WITHOUT ANY FURTHER NOTICE.            WARRANT     OF  ATTORNEY/CONFESSION        OF JUDGMENT.     In addition to any other remedies Lender may            possess, Borrower knowingly, voluntarily and intentionally authorizes to appear on behalf of Borrower, from time to            time, in the District Court of Alexandria, Virginia and to waive issuance and service of process and to confess            judgment  in favor of Lender against Borrower, for the unpaid principal, accrued interest, accrued charges,            reasonable attorney fees and court costs and such other amount due under this Note.             The following Oral Agreements Disclaimer provision applies when the borrower is a resident of MISSOURI:            Oral or unexecuted agreements or commitments to loan money, extend credit or to forbear from enforcing repayment of a            debt including promises to extend or renew such debt are not enforceable, regardless of the legal theory upon which it is            based that is in any way related to the credit agreement. To protect you (Borrowers(s)) and us (Creditor) from            misunderstanding or disappointment, any agreements we reach covering such matters are contained in this writing, which            is the complete and exclusive statement of the agreement between us, except as we may later agree in writing to modify it.         SBA Form 147 (06/03/02) Version 4.1                                                                     Page 5/7      Compliance Systems LLC 2020 ITEM 716BAL5 (93/2020) Page 5 of 7                                   www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit103-form147_716ba006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E         10. STATE-SPECIFIC PROVISIONS (CONTINUED):            The following Oral Agreements Disclaimer provision applies when the borrower is a resident of OREGON:            UNDER     OREGON     LAW,    MOST    AGREEMENTS,      PROMISES     AND   COMMITMENTS        MADE     BY            [BENEFICIARY]/ US CONCERNING LOANS AND OTHER CREDIT EXTENSIONS WHICH ARE NOT FOR            PERSONAL,     FAMILY,    OR   HOUSEHOLD       PURPOSES    OR   SECURED     SOLELY     BY  GRANTOR'S/           BORROWER'S RESIDENCE MUST BE IN WRITING, EXPRESS CONSIDERATION AND BE SIGNED BY [AN            AUTHORIZED REPRESENTATIVE OF BENEFICIARY]/US TO BE ENFORCEABLE.             The following Oral Agreements Disclaimer provision applies when the borrower is a resident of WASHINGTON:           Oral agreements or oral commitments to loan money, extend credit, or to forbear from enforcing repayment of a            debt are not enforceable under Washington law.            The following provision applies when the borrower is a resident of  ALASKA:            The Mortgagor or Trustor (Borrower) is personally obligated and fully liable for the amount due under the Note.            The Mortgagee or Beneficiary (Lender) has the right to sue on the Note and obtain a personal judgment against the            Mortgagor  or Trustor for the satisfaction of the amount due under the Note either before or after a judicial            foreclosure of the Mortgage or Deed of Trust as under AS 09.45.170-09.45.220.             The following Oral Agreements Disclaimer provision applies when the borrower is a resident of IOWA:            IMPORTANT:     READ   BEFORE   SIGNING.  The  terms of this agreement should be read carefully because only            those terms in writing are enforceable. No other terms or oral promises not contained in this written contract may            be legally enforced. You may change the terms of this agreement only by another written agreement.             The following Oral Agreements Disclaimer provision applies when the borrower is a resident of UTAH:            This is a final expression of the agreement between the creditor and debtor and the written agreement may not be            contradicted by evidence of any alleged oral agreement.        SBA Form 147 (06/03/02) Version 4.1                                                                     Page 6/7      Compliance Systems LLC 2020 ITEM 716BAL6 (93/2020) Page 6 of 7                                   www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit103-form147_716ba007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit103-form147_716ba007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">DocuSign Envelope ID: E7C3AEA6-A740-4BF5-BA8D-743B58722B0E            11.   BORROWER'S NAME(S) AND SIGNATURE(S):                 By signing below, each individual or entity becomes obligated under this Note as Borrower.                                                                                                  4/14/2020                 ______________________________________________________________              _______________________________                  Signature of Authorized Representative of Borrower/Borrower                 Date                  A. J. KAZIMI                 ______________________________________________________________              _CEO______________________________                  Name of Authorized Representative of Borrower                               Title          SBA Form 147 (06/03/02) Version 4.1                                                                                                       Page 7/7        Compliance Systems LLC 2020 ITEM 716BAL7 (93/2020) Page 7 of 7                                                                   www.compliancesystems.com </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>a2020q2-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib54954fc94384033af9f9011ee9eafc4_1"></div><div style="min-height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, A.J. Kazimi, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:49.395%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.698%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.264%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>a2020q2-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i56a4c39a8c934e0d8fcb1a335c04bf02_1"></div><div style="min-height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Michael Bonner, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:49.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.258%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.264%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>a2020q2-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i55905550d4c8416182b3837ca960c32a_1"></div><div style="min-height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended June 30, 2020 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:38.888%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2020</font></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">August 14, 2020</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cpix-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:fc80af1c-b60e-447a-a71f-0452a1e7408c,g:c711355c-b1ef-45b3-aa25-450d0075a667-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20200630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20200630">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecurities" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities">
        <link:definition>2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecuritiesTables" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2107103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2111104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2312303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2413405 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2114105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2315304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2118106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2319305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2420408 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2421409 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2123107 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2126108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2427413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2128109 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2129110 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2330306 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
        <link:definition>2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
        <link:definition>2433416 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2434417 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentCashContribution" abstract="false" name="SubsidiaryInvestmentCashContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" abstract="false" name="SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cpix-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:fc80af1c-b60e-447a-a71f-0452a1e7408c,g:c711355c-b1ef-45b3-aa25-450d0075a667-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200630.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d498008-9d5f-49cf-9644-966f9aaa9583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040ef1d7-5992-4399-be63-3c58c803df2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d498008-9d5f-49cf-9644-966f9aaa9583" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040ef1d7-5992-4399-be63-3c58c803df2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6dba4ded-3e7d-4c81-999a-2f5f1cfff78a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d498008-9d5f-49cf-9644-966f9aaa9583" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6dba4ded-3e7d-4c81-999a-2f5f1cfff78a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_61d3e02b-f95a-41ba-85db-77e93111024d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d498008-9d5f-49cf-9644-966f9aaa9583" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_61d3e02b-f95a-41ba-85db-77e93111024d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e373a416-b13d-47c5-a968-71788d636ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d498008-9d5f-49cf-9644-966f9aaa9583" xlink:to="loc_us-gaap_OtherAssetsCurrent_e373a416-b13d-47c5-a968-71788d636ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d9803a41-d0d7-46ec-abe7-d14ef7330ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0d498008-9d5f-49cf-9644-966f9aaa9583" xlink:to="loc_us-gaap_InventoryNet_d9803a41-d0d7-46ec-abe7-d14ef7330ded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8fb459fe-0c1b-4f2d-9c14-03be70568b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_eacd565d-7568-47ac-83f3-3e92331cc1ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8fb459fe-0c1b-4f2d-9c14-03be70568b95" xlink:to="loc_us-gaap_Liabilities_eacd565d-7568-47ac-83f3-3e92331cc1ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bdfd4f42-6280-4ddc-8cb2-def289301255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8fb459fe-0c1b-4f2d-9c14-03be70568b95" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bdfd4f42-6280-4ddc-8cb2-def289301255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2337329e-b1bb-4334-8109-fb35e566a9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8fb459fe-0c1b-4f2d-9c14-03be70568b95" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2337329e-b1bb-4334-8109-fb35e566a9e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_51e728ba-1b1c-42f1-8d10-bb98953302aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_51e728ba-1b1c-42f1-8d10-bb98953302aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6605fe96-1bfd-4431-9706-d25ec5b1afed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6605fe96-1bfd-4431-9706-d25ec5b1afed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4502001c-3f0e-4b6f-9651-494fd601b826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_Goodwill_4502001c-3f0e-4b6f-9651-494fd601b826" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_3ed8a919-fec1-4449-aa1c-0fe7f36919c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_InventoryNoncurrent_3ed8a919-fec1-4449-aa1c-0fe7f36919c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fe0b27af-57aa-43d3-8cc0-b66eb6f139b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_AssetsCurrent_fe0b27af-57aa-43d3-8cc0-b66eb6f139b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cbc2190a-cf5b-4f50-8796-4cbad2c97e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cbc2190a-cf5b-4f50-8796-4cbad2c97e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8449ce05-e7c2-4956-867c-e08067e10643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8449ce05-e7c2-4956-867c-e08067e10643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21866138-9cf9-4bab-beff-b7aef71dee7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_51ee3b94-6ab4-42fa-972e-dccb44ee8c9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21866138-9cf9-4bab-beff-b7aef71dee7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_74f77893-fa54-4ac1-aff0-45e802db8f71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_adc58471-95c8-4d6e-b684-002ecb25aafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74f77893-fa54-4ac1-aff0-45e802db8f71" xlink:to="loc_us-gaap_LongTermLineOfCredit_adc58471-95c8-4d6e-b684-002ecb25aafc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ee029882-9c49-4e20-b2e6-a4a6ed00ac11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74f77893-fa54-4ac1-aff0-45e802db8f71" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ee029882-9c49-4e20-b2e6-a4a6ed00ac11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52eaa835-e07c-44b4-84ff-b0a199ba895f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74f77893-fa54-4ac1-aff0-45e802db8f71" xlink:to="loc_us-gaap_LiabilitiesCurrent_52eaa835-e07c-44b4-84ff-b0a199ba895f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_0e1cdb4d-023d-4298-b2ca-4cfa777aa12b" xlink:href="cpix-20200630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_74f77893-fa54-4ac1-aff0-45e802db8f71" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_0e1cdb4d-023d-4298-b2ca-4cfa777aa12b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02b624a0-e3a8-493a-a72d-d45a1d6d8e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cff8088-0fdf-47ed-84d9-91154be2b2fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02b624a0-e3a8-493a-a72d-d45a1d6d8e5a" xlink:to="loc_us-gaap_StockholdersEquity_2cff8088-0fdf-47ed-84d9-91154be2b2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e3104213-a1e2-4497-8da7-277f4df445b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02b624a0-e3a8-493a-a72d-d45a1d6d8e5a" xlink:to="loc_us-gaap_MinorityInterest_e3104213-a1e2-4497-8da7-277f4df445b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_43d4ba6b-a8ab-481d-b84e-778526f2985b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5740537b-ee57-4aa0-a3d0-8599dc93b564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43d4ba6b-a8ab-481d-b84e-778526f2985b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5740537b-ee57-4aa0-a3d0-8599dc93b564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4a1e9406-c7ed-4bb4-b312-ce58fda0e598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43d4ba6b-a8ab-481d-b84e-778526f2985b" xlink:to="loc_us-gaap_AccountsPayableCurrent_4a1e9406-c7ed-4bb4-b312-ce58fda0e598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aab195dc-ed6e-4de8-8642-b5a3813be2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43d4ba6b-a8ab-481d-b84e-778526f2985b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aab195dc-ed6e-4de8-8642-b5a3813be2e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_5932957e-dffc-431d-8400-e41a1200d1d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_43d4ba6b-a8ab-481d-b84e-778526f2985b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_5932957e-dffc-431d-8400-e41a1200d1d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cb1a958c-b656-4c6e-aaef-5b94358d16d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_243ac781-28af-42d4-8bd6-1931aff49dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb1a958c-b656-4c6e-aaef-5b94358d16d6" xlink:to="loc_us-gaap_CommonStockValue_243ac781-28af-42d4-8bd6-1931aff49dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fdd57f8e-b81f-420c-9935-664817489335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cb1a958c-b656-4c6e-aaef-5b94358d16d6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fdd57f8e-b81f-420c-9935-664817489335" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fa9332f5-27ff-4f94-8f57-2df69a795755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_767dce5b-9cb1-4778-a352-1813a4a3fbfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fa9332f5-27ff-4f94-8f57-2df69a795755" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_767dce5b-9cb1-4778-a352-1813a4a3fbfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_17bd1f8c-a710-4c98-9ec2-a95d69eb7387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fa9332f5-27ff-4f94-8f57-2df69a795755" xlink:to="loc_us-gaap_CostsAndExpenses_17bd1f8c-a710-4c98-9ec2-a95d69eb7387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_41d34bbc-2f19-491f-b4a9-eadc6716e100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_efce75ce-fa38-4cf4-a95e-f2bdb7a2198b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_41d34bbc-2f19-491f-b4a9-eadc6716e100" xlink:to="loc_us-gaap_OperatingIncomeLoss_efce75ce-fa38-4cf4-a95e-f2bdb7a2198b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6539ae39-300e-4f5c-b08a-15d764d61192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_41d34bbc-2f19-491f-b4a9-eadc6716e100" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6539ae39-300e-4f5c-b08a-15d764d61192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_19b83dd6-d3fc-49ff-8806-a45fd13bf56b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_41d34bbc-2f19-491f-b4a9-eadc6716e100" xlink:to="loc_us-gaap_InterestExpense_19b83dd6-d3fc-49ff-8806-a45fd13bf56b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_81b8c06a-ed86-4a30-9281-79f391657286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_db47bf05-2112-4052-99b8-e637939e7045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_81b8c06a-ed86-4a30-9281-79f391657286" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_db47bf05-2112-4052-99b8-e637939e7045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ae19950-8418-4a74-9b1f-5393fe1533d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_81b8c06a-ed86-4a30-9281-79f391657286" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ae19950-8418-4a74-9b1f-5393fe1533d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c1f8c3f4-bb39-4247-ac82-e84ac246ecb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_62c93b88-f838-4f50-ac6b-c482f47ee752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c1f8c3f4-bb39-4247-ac82-e84ac246ecb4" xlink:to="loc_us-gaap_ProfitLoss_62c93b88-f838-4f50-ac6b-c482f47ee752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d4ccc1de-98de-4d46-8d35-1d0cf044f7ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c1f8c3f4-bb39-4247-ac82-e84ac246ecb4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d4ccc1de-98de-4d46-8d35-1d0cf044f7ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_870105d1-a158-4cd9-ae7a-d1258682207b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_075a7df1-8f69-474b-9cfc-dbc07b858a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_870105d1-a158-4cd9-ae7a-d1258682207b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_075a7df1-8f69-474b-9cfc-dbc07b858a3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d201650d-e8c4-4bf1-bd80-4bc4e3b3a567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_870105d1-a158-4cd9-ae7a-d1258682207b" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d201650d-e8c4-4bf1-bd80-4bc4e3b3a567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c13f0e71-09fc-46bc-bb0a-63e7f3e1bf9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_870105d1-a158-4cd9-ae7a-d1258682207b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c13f0e71-09fc-46bc-bb0a-63e7f3e1bf9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dbc5aa65-91aa-4515-ab19-83b9563a5505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_870105d1-a158-4cd9-ae7a-d1258682207b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dbc5aa65-91aa-4515-ab19-83b9563a5505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d33045ce-3b66-4d9f-b281-b8c8c7719fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_870105d1-a158-4cd9-ae7a-d1258682207b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d33045ce-3b66-4d9f-b281-b8c8c7719fde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c64364d6-0d42-4322-9c01-1a0a614c7a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1dd41159-5b2c-4cc4-925f-c8cac8b81354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c64364d6-0d42-4322-9c01-1a0a614c7a6a" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1dd41159-5b2c-4cc4-925f-c8cac8b81354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_187ca8e4-c3b7-4608-bbc2-1c5214b2ee41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c64364d6-0d42-4322-9c01-1a0a614c7a6a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_187ca8e4-c3b7-4608-bbc2-1c5214b2ee41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33f04003-90f9-4303-a23d-473c0d235825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_bf8a0913-8f39-40b1-827f-4e6a9be888dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33f04003-90f9-4303-a23d-473c0d235825" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_bf8a0913-8f39-40b1-827f-4e6a9be888dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0e924223-bf53-41de-b8c9-5a8400accddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33f04003-90f9-4303-a23d-473c0d235825" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0e924223-bf53-41de-b8c9-5a8400accddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_aeeb753b-896c-4a4b-83a9-3e9b11b9a691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33f04003-90f9-4303-a23d-473c0d235825" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_aeeb753b-896c-4a4b-83a9-3e9b11b9a691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fad52afe-6fad-40c0-9fd6-9951b60c81af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33f04003-90f9-4303-a23d-473c0d235825" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fad52afe-6fad-40c0-9fd6-9951b60c81af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_5babb033-bdad-4d0b-b897-3e0956c31d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33f04003-90f9-4303-a23d-473c0d235825" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_5babb033-bdad-4d0b-b897-3e0956c31d44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_f6bccdb9-a085-4441-aa2c-95dfd0a854d8" xlink:href="cpix-20200630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_f6bccdb9-a085-4441-aa2c-95dfd0a854d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fbf719e1-547f-4656-b696-d0bcd0c01ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fbf719e1-547f-4656-b696-d0bcd0c01ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_993c977e-efe5-497f-901f-5870f2e5a65f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_993c977e-efe5-497f-901f-5870f2e5a65f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f499d455-85b4-4778-b528-39e989b64e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f499d455-85b4-4778-b528-39e989b64e97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_274b3a08-b221-4904-a57b-2a7ac54e198d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_274b3a08-b221-4904-a57b-2a7ac54e198d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_101c62c3-f7d5-4059-92aa-6a042d9aa0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_101c62c3-f7d5-4059-92aa-6a042d9aa0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d4237177-89a0-4a89-a61a-fffc7b42232d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d4237177-89a0-4a89-a61a-fffc7b42232d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_15bf0693-15cd-4a1e-9c5c-2499f6115378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_15bf0693-15cd-4a1e-9c5c-2499f6115378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_093f5605-3d70-447c-9b49-9356252102dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_093f5605-3d70-447c-9b49-9356252102dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b60c2970-efff-4bb9-be16-372478df05b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b60c2970-efff-4bb9-be16-372478df05b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8eb5f68d-e5ec-4948-8b39-a1c6a91ecc49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_ShareBasedCompensation_8eb5f68d-e5ec-4948-8b39-a1c6a91ecc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5ce0c48e-da5b-4d2a-91ca-ee69573396ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_7c82bd10-9965-4075-a696-2f8c43424472" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5ce0c48e-da5b-4d2a-91ca-ee69573396ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3cb376-47b9-4f4a-953a-84c156e966c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_907445f2-6126-4a45-bee0-c7f2674401e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3cb376-47b9-4f4a-953a-84c156e966c6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_907445f2-6126-4a45-bee0-c7f2674401e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_609799a4-ab50-4700-8a7d-fb0c3a0c0ea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b3cb376-47b9-4f4a-953a-84c156e966c6" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_609799a4-ab50-4700-8a7d-fb0c3a0c0ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08666a52-2117-43c4-9cd2-4f5a9eb3e09c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12103971-7b35-4372-88de-05362e3834c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08666a52-2117-43c4-9cd2-4f5a9eb3e09c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12103971-7b35-4372-88de-05362e3834c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d7d5a62-c453-428c-b687-d8a65716342f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08666a52-2117-43c4-9cd2-4f5a9eb3e09c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0d7d5a62-c453-428c-b687-d8a65716342f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c96c98b-4565-45ec-ad51-85be5e77d8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_08666a52-2117-43c4-9cd2-4f5a9eb3e09c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c96c98b-4565-45ec-ad51-85be5e77d8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd41092f-7b4c-40e1-af42-21237cec95b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11425e0f-bd78-48e2-b677-dc767bbe88bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd41092f-7b4c-40e1-af42-21237cec95b4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11425e0f-bd78-48e2-b677-dc767bbe88bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ecab8a60-f092-4f27-ae54-8fbb2bdca7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd41092f-7b4c-40e1-af42-21237cec95b4" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ecab8a60-f092-4f27-ae54-8fbb2bdca7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4ed20f8f-82bb-4927-9339-f9f4ba22cecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd41092f-7b4c-40e1-af42-21237cec95b4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_4ed20f8f-82bb-4927-9339-f9f4ba22cecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_656c1a86-ab52-423c-b486-20890857cf58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd41092f-7b4c-40e1-af42-21237cec95b4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_656c1a86-ab52-423c-b486-20890857cf58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7b679b74-b2e4-4651-bb9d-6e804097fe03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd41092f-7b4c-40e1-af42-21237cec95b4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7b679b74-b2e4-4651-bb9d-6e804097fe03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_730da42c-0176-4507-be2d-4235e7b70933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eddd10c8-06f3-4aae-befb-9223cccc6bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_730da42c-0176-4507-be2d-4235e7b70933" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_eddd10c8-06f3-4aae-befb-9223cccc6bf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd0c012a-98ec-41df-802e-8720300b2b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_730da42c-0176-4507-be2d-4235e7b70933" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_bd0c012a-98ec-41df-802e-8720300b2b5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200630.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200630.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e31ed5c0-79b7-4d25-bb84-57942846cbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d582c1fd-b4c4-4161-9b92-2ee398340441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e31ed5c0-79b7-4d25-bb84-57942846cbb0" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d582c1fd-b4c4-4161-9b92-2ee398340441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2c119fef-aba9-426f-9125-1f2278577bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e31ed5c0-79b7-4d25-bb84-57942846cbb0" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_2c119fef-aba9-426f-9125-1f2278577bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_25572b85-8134-4180-9d8c-9d281cba4590" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e31ed5c0-79b7-4d25-bb84-57942846cbb0" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_25572b85-8134-4180-9d8c-9d281cba4590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e1a5ef01-03a4-41d2-bfa7-15ed4ab7cea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_f2196ac3-83a7-4bd4-b637-1bf28551c9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e1a5ef01-03a4-41d2-bfa7-15ed4ab7cea3" xlink:to="loc_us-gaap_InventoryNoncurrent_f2196ac3-83a7-4bd4-b637-1bf28551c9de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_b5ce5794-ad5e-4452-9a18-9c38bc56762a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e1a5ef01-03a4-41d2-bfa7-15ed4ab7cea3" xlink:to="loc_us-gaap_InventoryGross_b5ce5794-ad5e-4452-9a18-9c38bc56762a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200630.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bfaaaad4-5e42-4db2-ab9b-ff991fd57ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c8f0b6a-cbe6-4f44-83f7-c664aa26a011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bfaaaad4-5e42-4db2-ab9b-ff991fd57ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c8f0b6a-cbe6-4f44-83f7-c664aa26a011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0c44d91e-09c2-4689-8ee2-3ca0327d1cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bfaaaad4-5e42-4db2-ab9b-ff991fd57ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0c44d91e-09c2-4689-8ee2-3ca0327d1cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_60bffa75-cb3b-4065-8ad7-594d3e74cb39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bfaaaad4-5e42-4db2-ab9b-ff991fd57ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_60bffa75-cb3b-4065-8ad7-594d3e74cb39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3eccf9a6-856c-4821-9c8f-242911862445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bfaaaad4-5e42-4db2-ab9b-ff991fd57ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3eccf9a6-856c-4821-9c8f-242911862445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e6a01f1b-ff90-4a90-8447-21f77482f93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bfaaaad4-5e42-4db2-ab9b-ff991fd57ccf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e6a01f1b-ff90-4a90-8447-21f77482f93a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3407c492-aa21-4727-9cde-7f6e74ffd918" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0980b2f4-9506-4ca1-b05d-2b9e803e1766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3407c492-aa21-4727-9cde-7f6e74ffd918" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0980b2f4-9506-4ca1-b05d-2b9e803e1766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f6b27a65-9d81-4202-9f98-338fa38c6ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3407c492-aa21-4727-9cde-7f6e74ffd918" xlink:to="loc_us-gaap_OperatingLeaseLiability_f6b27a65-9d81-4202-9f98-338fa38c6ac7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200630.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200630.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200630.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e92f476f-ad3d-4c09-9102-e49bee9e1bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1a2626d8-3888-4150-b70d-2ae91b17e9ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e92f476f-ad3d-4c09-9102-e49bee9e1bf7" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_1a2626d8-3888-4150-b70d-2ae91b17e9ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4fad8c09-536a-4d49-babb-d6a99cdc4c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e92f476f-ad3d-4c09-9102-e49bee9e1bf7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4fad8c09-536a-4d49-babb-d6a99cdc4c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_d14ae102-3bb8-4df9-bb7f-81d2128820b0" xlink:href="cpix-20200630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e92f476f-ad3d-4c09-9102-e49bee9e1bf7" xlink:to="loc_cpix_PaymentsForContingentConsideration_d14ae102-3bb8-4df9-bb7f-81d2128820b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_895bbcab-3469-4baa-99e1-f7522c0764d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_e01eec17-ef45-4e8b-b304-ccaf62b95247" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_895bbcab-3469-4baa-99e1-f7522c0764d5" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_e01eec17-ef45-4e8b-b304-ccaf62b95247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_44c34733-f1e9-44d7-a7a3-5ebb445950a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_895bbcab-3469-4baa-99e1-f7522c0764d5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_44c34733-f1e9-44d7-a7a3-5ebb445950a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c82601b-19cc-4c63-935f-46a8a03654a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_17f492a4-bf06-4e43-8db9-bdef8f01dce8" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c82601b-19cc-4c63-935f-46a8a03654a8" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_17f492a4-bf06-4e43-8db9-bdef8f01dce8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_65bf91c1-b311-435d-93d6-411d90eb0a28" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c82601b-19cc-4c63-935f-46a8a03654a8" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_65bf91c1-b311-435d-93d6-411d90eb0a28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_02949bf6-e408-42ce-a16b-57c83a2215d9" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c82601b-19cc-4c63-935f-46a8a03654a8" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_02949bf6-e408-42ce-a16b-57c83a2215d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_93b4c9fc-63ac-4d5f-bce3-9d00aea24476" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0c82601b-19cc-4c63-935f-46a8a03654a8" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_93b4c9fc-63ac-4d5f-bce3-9d00aea24476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_0d9f10b5-1e1c-4b25-a6c0-0e00630e5717" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2396465c-d92b-4e2c-b564-5aac34145b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_0d9f10b5-1e1c-4b25-a6c0-0e00630e5717" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2396465c-d92b-4e2c-b564-5aac34145b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_06392c61-f8b3-45f2-8d59-f30cc92fe070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_0d9f10b5-1e1c-4b25-a6c0-0e00630e5717" xlink:to="loc_us-gaap_Goodwill_06392c61-f8b3-45f2-8d59-f30cc92fe070" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cpix-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:fc80af1c-b60e-447a-a71f-0452a1e7408c,g:c711355c-b1ef-45b3-aa25-450d0075a667-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200630.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="ieb1eb1a12b2e41e68de7827d3261b9ae_CoverPage"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="if89884057b484221ae2c950f2a6cbe96_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i7f8ea6a5c02e48a3b72f25f0b4e499de_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="if7b5fbff1216457fb5bc93be7499620d_CondensedConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="ia7481079cbf3498f9190a721838ceb31_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i06332d1b0ba6469994f896dee014aaef_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_351d0622-44e8-4a59-b4d5-33cde32325fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_351d0622-44e8-4a59-b4d5-33cde32325fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3954b7e-48ad-44fd-9d2c-36c052a8af66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3954b7e-48ad-44fd-9d2c-36c052a8af66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dcfe42d3-fe20-4a3d-b6ce-521ea9f3958a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dcfe42d3-fe20-4a3d-b6ce-521ea9f3958a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ae09fcc3-7969-4851-8930-e931435d61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ae09fcc3-7969-4851-8930-e931435d61ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0bfcb3ae-8d6b-4aac-bf4a-5f1ba6d62afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0bfcb3ae-8d6b-4aac-bf4a-5f1ba6d62afd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_a72b2603-f2dd-4c28-9d68-f19048227977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_a72b2603-f2dd-4c28-9d68-f19048227977" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ea9aa1cd-9e94-4945-883a-195fb4a3075a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ea9aa1cd-9e94-4945-883a-195fb4a3075a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb558d9c-048b-4f99-91aa-b8df5a500d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb558d9c-048b-4f99-91aa-b8df5a500d48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d3eb064-f39f-4ea6-b7e3-0d74007e78bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_ProfitLoss_2d3eb064-f39f-4ea6-b7e3-0d74007e78bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ded6f9a3-f80c-4ea4-9276-80e5600d8705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd74536a-99d6-41c4-8865-5e669b9d30a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_351d0622-44e8-4a59-b4d5-33cde32325fe" xlink:to="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:to="loc_us-gaap_EquityComponentDomain_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:to="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdb4d380-0cfd-4b12-a0e7-3182945f7aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:to="loc_us-gaap_CommonStockMember_bdb4d380-0cfd-4b12-a0e7-3182945f7aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_be8c43ba-7fdf-42f3-a426-c62e5adf62ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:to="loc_us-gaap_RetainedEarningsMember_be8c43ba-7fdf-42f3-a426-c62e5adf62ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_63ece99e-c0d6-4042-bd63-7b0b11a00b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:to="loc_us-gaap_NoncontrollingInterestMember_63ece99e-c0d6-4042-bd63-7b0b11a00b6b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i5f1fc4974ef34015917f332863d13104_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="i9679ee5c39f64820b379046d71ca4f24_OrganizationandBasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended" id="i162eb49bc4f1438991c9c1bd40cef1ca_OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended" id="i15533ab5ccb9408bbcabda09f76ebe3b_InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended" id="ic2dc814759bd4a6ca4af5afa6b42572c_InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="ibc88a095fd2c441b840811947ed00c4f_InvestmentsinCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b82cc007-43f4-4e4f-804d-27e68add75c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_458071b4-b745-4212-ace9-65dcb96f2b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b82cc007-43f4-4e4f-804d-27e68add75c1" xlink:to="loc_us-gaap_TradingSecurities_458071b4-b745-4212-ace9-65dcb96f2b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b82cc007-43f4-4e4f-804d-27e68add75c1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_136cd899-ed07-4378-b66f-a649c037be6b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_136cd899-ed07-4378-b66f-a649c037be6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d24959de-3158-4f26-b66b-2af952ccdab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d24959de-3158-4f26-b66b-2af952ccdab4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c2903387-0fe2-4f14-b3c9-0a32dc15d5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c2903387-0fe2-4f14-b3c9-0a32dc15d5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ad4e69-6291-4370-9276-f22d108ff3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ad4e69-6291-4370-9276-f22d108ff3e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f25f7777-0810-442a-a32a-08e5bfbfa149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ad4e69-6291-4370-9276-f22d108ff3e9" xlink:to="loc_us-gaap_CommercialPaperMember_f25f7777-0810-442a-a32a-08e5bfbfa149" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="i579c5285f3b0431db20c79e8e9b90418_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="i5c0f3f9cfe0a4c9bb281a5c16381aa6d_EarningsLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="i53b8d095d1d645308d60c73cafc48560_EarningsLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" id="i083bf568ec2146249de883cd6d328846_EarningsLossPerShareDetailsTextual"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200630.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="ic222f90248b840e1ac8436b9801e841e_Revenues"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="i05b4503038da4103a0764aa91dbcfaa5_RevenuesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="i7dc2032c9e8c4d1c89d0c381e64d25cf_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bf8e15f1-267a-40d8-98de-20069c6f4bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a0ead38b-6bc7-4862-a517-c1cd5de4d415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bf8e15f1-267a-40d8-98de-20069c6f4bcf" xlink:to="loc_us-gaap_RevenuesAbstract_a0ead38b-6bc7-4862-a517-c1cd5de4d415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_2301d44e-8852-4f64-a45d-4a232859cc29" xlink:href="cpix-20200630.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a0ead38b-6bc7-4862-a517-c1cd5de4d415" xlink:to="loc_cpix_ProductsAbstract_2301d44e-8852-4f64-a45d-4a232859cc29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0b55c81-ebc1-4457-ba30-2108f51e1380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_2301d44e-8852-4f64-a45d-4a232859cc29" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0b55c81-ebc1-4457-ba30-2108f51e1380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bf8e15f1-267a-40d8-98de-20069c6f4bcf" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:to="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a4b94af-c301-49d1-85a6-86fdfa5051b4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:to="loc_srt_ProductsAndServicesDomain_8a4b94af-c301-49d1-85a6-86fdfa5051b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:to="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_a4f0ae2b-ed35-4733-b4bd-6b6f80d535df" xlink:href="cpix-20200630.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_AcetadoteMember_a4f0ae2b-ed35-4733-b4bd-6b6f80d535df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_4e98f3ab-96b8-4313-b316-857bf243cee1" xlink:href="cpix-20200630.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_OmeclamoxPakMember_4e98f3ab-96b8-4313-b316-857bf243cee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_8071ca4d-d9e0-42ca-bb6e-cc81172848f1" xlink:href="cpix-20200630.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_KristaloseMember_8071ca4d-d9e0-42ca-bb6e-cc81172848f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_5c7de8bf-ad84-4cae-aef6-b515dd43eb3f" xlink:href="cpix-20200630.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_VaprisolMember_5c7de8bf-ad84-4cae-aef6-b515dd43eb3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_be90ec7b-66ad-4b3b-844e-af98ceadc920" xlink:href="cpix-20200630.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_CaldolorMember_be90ec7b-66ad-4b3b-844e-af98ceadc920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_2d154cdf-aa18-4bff-add9-842d9110994b" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_VIBATIVMember_2d154cdf-aa18-4bff-add9-842d9110994b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_64972a01-4d66-45d8-8ebc-0f4d7c9fc1a9" xlink:href="cpix-20200630.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_OtherProductsMember_64972a01-4d66-45d8-8ebc-0f4d7c9fc1a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a6362b13-70a4-4e97-b1cd-131d271b83f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_us-gaap_GrantMember_a6362b13-70a4-4e97-b1cd-131d271b83f8" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200630.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="ic267005f4c744dd98b3ee299f9bedf3f_Inventories"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="id3be775ca3894070a07b4a31c7ae53d5_InventoriesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i32286c8edc144aad82305b443c3c8104_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_5c7992ed-6455-49c3-af57-796904bfcefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_2afb57e4-5c09-44fb-a400-fe0d2626dfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_5c7992ed-6455-49c3-af57-796904bfcefe" xlink:to="loc_us-gaap_InventoryNoncurrent_2afb57e4-5c09-44fb-a400-fe0d2626dfbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_5c7992ed-6455-49c3-af57-796904bfcefe" xlink:to="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b34de9-0f79-48c7-9769-fed647badcd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c9b34de9-0f79-48c7-9769-fed647badcd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e88dfddc-9849-4192-85dc-a5a1318cb738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e88dfddc-9849-4192-85dc-a5a1318cb738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_0dbc91e8-87fd-4f83-b056-f89800a8475f" xlink:href="cpix-20200630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e88dfddc-9849-4192-85dc-a5a1318cb738" xlink:to="loc_cpix_IfetrobanClinicalMember_0dbc91e8-87fd-4f83-b056-f89800a8475f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="i37384dbc74da40d28a036450ca9f3a49_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200630.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="ieae45b264a7147859b164044242fbb2d_Leases"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="i87971e9d70824471bf24b5fc78848c1c_LeasesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ie555618da60247f48afea037c34664d3_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="iebbc6ec93ca14c61980d6498710c21f6_LeasesLeasePositionDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="i1546f50097404799bd1d42fb6aaa3984_LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended" id="i399b75ee518c45358ce753c42ce02294_ShareholdersEquityandDebt"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i310a13a370144be8b8cc822dde4598ac_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00b3a2c6-e1da-453a-b885-834eed79cbfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:href="cpix-20200630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00b3a2c6-e1da-453a-b885-834eed79cbfe" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53b4234e-9b6e-49af-bc93-063160e9e683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53b4234e-9b6e-49af-bc93-063160e9e683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_55f6565b-22ee-4b52-8a72-36b9bd83af52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_55f6565b-22ee-4b52-8a72-36b9bd83af52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_aa0e28a9-94de-4fc6-b3b3-38417b6f92a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_aa0e28a9-94de-4fc6-b3b3-38417b6f92a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_6c1b329b-e2d5-43d3-b443-10b4b2363b76" xlink:href="cpix-20200630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_6c1b329b-e2d5-43d3-b443-10b4b2363b76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b41bee03-a21e-429e-b739-84fe7b013919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b41bee03-a21e-429e-b739-84fe7b013919" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57bfe1fc-ce65-4f2f-995d-13a206685c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57bfe1fc-ce65-4f2f-995d-13a206685c51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d02f183a-aef3-4230-803b-d887683d8bb0" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d02f183a-aef3-4230-803b-d887683d8bb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_68949bff-5abf-400b-a6d7-3127470a1490" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_68949bff-5abf-400b-a6d7-3127470a1490" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_e8687289-c155-4b81-9e92-2e56973c0a5e" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_e8687289-c155-4b81-9e92-2e56973c0a5e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_14c9d46e-d509-4fac-abfa-6b08284b2e0c" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_14c9d46e-d509-4fac-abfa-6b08284b2e0c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00b3a2c6-e1da-453a-b885-834eed79cbfe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_849b4fa5-dc6b-4d06-ac12-ef978ef305c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:to="loc_us-gaap_EquityComponentDomain_849b4fa5-dc6b-4d06-ac12-ef978ef305c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cff5ef0e-ab48-411c-9455-c34094d20558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:to="loc_us-gaap_EquityComponentDomain_cff5ef0e-ab48-411c-9455-c34094d20558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_37c8cfcb-1bc7-4d19-aa65-63d55b343cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cff5ef0e-ab48-411c-9455-c34094d20558" xlink:to="loc_us-gaap_CommonStockMember_37c8cfcb-1bc7-4d19-aa65-63d55b343cde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69249f60-b00a-4ce1-9222-edb07f27165c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_69249f60-b00a-4ce1-9222-edb07f27165c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8943820a-cf95-4858-9da5-4860d4552c9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8943820a-cf95-4858-9da5-4860d4552c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3494dbb7-7809-479f-991d-8b95a72681d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8943820a-cf95-4858-9da5-4860d4552c9b" xlink:to="loc_srt_DirectorMember_3494dbb7-7809-479f-991d-8b95a72681d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4efcc61f-2ff2-4103-ad73-1d740c5a0a91_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4efcc61f-2ff2-4103-ad73-1d740c5a0a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3140837-6377-4958-ad09-1b2395b97929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3140837-6377-4958-ad09-1b2395b97929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_afca9be7-fa2f-4379-9b47-ea257767706e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3140837-6377-4958-ad09-1b2395b97929" xlink:to="loc_us-gaap_RestrictedStockMember_afca9be7-fa2f-4379-9b47-ea257767706e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae93f62-57ad-4a7f-a4e7-e99e6f644470_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ae93f62-57ad-4a7f-a4e7-e99e6f644470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ad1c9910-d1c3-4fe0-b0fa-8353316ffe16" xlink:href="cpix-20200630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ad1c9910-d1c3-4fe0-b0fa-8353316ffe16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_08b8438d-3975-4835-ab28-3a0b8169f47c" xlink:href="cpix-20200630.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_08b8438d-3975-4835-ab28-3a0b8169f47c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i6eaf9b0b2582401b940ab031419ec647_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8368877d-6894-40d8-a5b0-de1d799c9e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8368877d-6894-40d8-a5b0-de1d799c9e0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_3785fb24-f3aa-4a95-8f34-0b7763f4d3e1" xlink:href="cpix-20200630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_3785fb24-f3aa-4a95-8f34-0b7763f4d3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1fd5351a-0af1-4d2d-a2fe-ba5a78ed1e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1fd5351a-0af1-4d2d-a2fe-ba5a78ed1e30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_ed3e5c3c-ddec-4eaf-836d-a57337693097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LongTermLineOfCredit_ed3e5c3c-ddec-4eaf-836d-a57337693097" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_a92eb21e-935e-4f0d-94a0-42389622cd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_a92eb21e-935e-4f0d-94a0-42389622cd1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b43ee10c-5970-4b60-aeb8-28a56f4e34ea" xlink:href="cpix-20200630.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b43ee10c-5970-4b60-aeb8-28a56f4e34ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ce71e21b-17b7-472f-835a-49efd34ecac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ce71e21b-17b7-472f-835a-49efd34ecac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_4451f1ed-ccfd-40b2-affc-00c8881a39cc" xlink:href="cpix-20200630.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ce71e21b-17b7-472f-835a-49efd34ecac9" xlink:to="loc_cpix_PinnacleBankMember_4451f1ed-ccfd-40b2-affc-00c8881a39cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_048c394c-b67f-473d-9d42-258abda02420_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_048c394c-b67f-473d-9d42-258abda02420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_51e81cd0-92da-4318-91ec-4bb03b97a2d1" xlink:href="cpix-20200630.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:to="loc_cpix_SecondAmendmentMember_51e81cd0-92da-4318-91ec-4bb03b97a2d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d5d672bf-1402-43db-b3e6-fee2eca0491c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:to="loc_us-gaap_LineOfCreditMember_d5d672bf-1402-43db-b3e6-fee2eca0491c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:to="loc_us-gaap_CreditFacilityDomain_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b3273465-9920-43b6-985f-ae5d5d11ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:to="loc_us-gaap_CreditFacilityDomain_b3273465-9920-43b6-985f-ae5d5d11ac06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_31890d7e-d5df-4985-8a88-c5a786ac877a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b3273465-9920-43b6-985f-ae5d5d11ac06" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_31890d7e-d5df-4985-8a88-c5a786ac877a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36911f5c-a355-4e7e-9268-6845d80110c6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:to="loc_srt_RangeMember_36911f5c-a355-4e7e-9268-6845d80110c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:to="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_affd4d66-f25e-4ffc-a538-4795996e15df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:to="loc_srt_MinimumMember_affd4d66-f25e-4ffc-a538-4795996e15df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c42a9276-6063-4b58-b6b3-b0ce5715f81a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:to="loc_srt_MaximumMember_c42a9276-6063-4b58-b6b3-b0ce5715f81a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200630.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="ib93e2f3b30bd4b46b5e094e49ed213ac_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200630.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="i802c502c2c64485b94a389106417b903_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_df71f64a-03bf-479d-b44c-ba0a0fd6aa49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0c9498fe-48f3-429f-a382-81f3a01421e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_df71f64a-03bf-479d-b44c-ba0a0fd6aa49" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0c9498fe-48f3-429f-a382-81f3a01421e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_df71f64a-03bf-479d-b44c-ba0a0fd6aa49" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_59fc095b-d7e2-404d-8abc-939b11e60c31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_59fc095b-d7e2-404d-8abc-939b11e60c31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3ada6a95-7a95-4752-8bfc-7ff2fc8ad528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3ada6a95-7a95-4752-8bfc-7ff2fc8ad528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e85b34fa-de6f-4ab7-8cea-a8957fbc1e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3ada6a95-7a95-4752-8bfc-7ff2fc8ad528" xlink:to="loc_us-gaap_DomesticCountryMember_e85b34fa-de6f-4ab7-8cea-a8957fbc1e2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200630.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" id="i38c4e116ca7b4139be6f5730f9e482af_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRights"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended" id="i7ed7f2089c1e46c6a0b4295aaca34eb6_AdditionsandReturnsofProductRights"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended" id="i017e172f95be46dca10c179d2cb3996a_AdditionsandReturnsofProductRightsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i0b6cd9d742e242a2a0d3007949ffa642_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_620dcf37-0b9f-4709-a013-7d441ea69d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_620dcf37-0b9f-4709-a013-7d441ea69d51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_35fb8715-9d17-40ba-8b86-d0a2603a3090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_35fb8715-9d17-40ba-8b86-d0a2603a3090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_270439c3-dabc-409d-b0fa-de9cacba5a11" xlink:href="cpix-20200630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_270439c3-dabc-409d-b0fa-de9cacba5a11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_12dfe63e-5c01-436e-806a-b8e3237e5598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_12dfe63e-5c01-436e-806a-b8e3237e5598" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8031228b-44d7-4f67-b109-cdbdaa529045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8031228b-44d7-4f67-b109-cdbdaa529045" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_61e65f37-c92a-47d4-aa01-255f0c2d0391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_61e65f37-c92a-47d4-aa01-255f0c2d0391" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_4c1050e2-9076-46af-9e0c-e1252a774b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_4c1050e2-9076-46af-9e0c-e1252a774b32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_4ba227ae-0185-4926-853a-16c08338ff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_4ba227ae-0185-4926-853a-16c08338ff0f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e574fa77-d245-4360-8321-d7cf79cea363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_Revenues_e574fa77-d245-4360-8321-d7cf79cea363" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_94f3da56-f063-46ef-b867-57250005b18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_OperatingExpenses_94f3da56-f063-46ef-b867-57250005b18f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ae8ab429-e368-4683-8f29-6196330e6a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ae8ab429-e368-4683-8f29-6196330e6a2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_6f739c6c-58dd-4d7a-a2dc-c489819f9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_6f739c6c-58dd-4d7a-a2dc-c489819f9ae3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5c39804-3423-4ef7-a242-8a3eed9c4974_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f5c39804-3423-4ef7-a242-8a3eed9c4974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_f365f5d1-3b87-42e7-ac83-ce3ab71c6eea" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:to="loc_cpix_VIBATIVMember_f365f5d1-3b87-42e7-ac83-ce3ab71c6eea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_2ce59de2-aa1a-47f3-9c9c-ae7c2853d027" xlink:href="cpix-20200630.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:to="loc_cpix_MethotrexateMember_2ce59de2-aa1a-47f3-9c9c-ae7c2853d027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8218aabc-bc73-44f7-b17c-312fe6e130dc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8218aabc-bc73-44f7-b17c-312fe6e130dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_84fb2d2e-8cb3-4724-8cc9-fd17fdf5a18c" xlink:href="cpix-20200630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_84fb2d2e-8cb3-4724-8cc9-fd17fdf5a18c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_c38bd25b-1ea8-4af9-91c9-3c5c19a84c7b" xlink:href="cpix-20200630.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:to="loc_cpix_NordicGroupBVMember_c38bd25b-1ea8-4af9-91c9-3c5c19a84c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_cee24cab-c332-4641-ae57-ff394c21f2fe_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:to="loc_srt_ScenarioUnspecifiedDomain_cee24cab-c332-4641-ae57-ff394c21f2fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c464403a-dd35-46b6-bb96-2ac19062c72b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c464403a-dd35-46b6-bb96-2ac19062c72b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c3f5bdb0-12cf-4274-bbc8-0c0f3220b281" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c464403a-dd35-46b6-bb96-2ac19062c72b" xlink:to="loc_srt_ScenarioForecastMember_c3f5bdb0-12cf-4274-bbc8-0c0f3220b281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_feb0c415-8f86-4f81-af81-79c0162722a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_feb0c415-8f86-4f81-af81-79c0162722a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10c47009-bffb-4e5a-9709-9ca8a7b3f216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10c47009-bffb-4e5a-9709-9ca8a7b3f216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bae8e9e0-6146-4b8a-8eb9-74d3d0b7af56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10c47009-bffb-4e5a-9709-9ca8a7b3f216" xlink:to="loc_us-gaap_RestrictedStockMember_bae8e9e0-6146-4b8a-8eb9-74d3d0b7af56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2683dfe3-dc35-42d7-bc49-3dca02bc3898_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2683dfe3-dc35-42d7-bc49-3dca02bc3898_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a27bd2ad-7e16-4cb1-8127-f0436f84df91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a27bd2ad-7e16-4cb1-8127-f0436f84df91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_83df4979-04e0-41ef-896b-461a90c5643c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a27bd2ad-7e16-4cb1-8127-f0436f84df91" xlink:to="loc_us-gaap_SubsequentEventMember_83df4979-04e0-41ef-896b-461a90c5643c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_924337e0-c989-4efa-bad1-be94cab5e7f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_924337e0-c989-4efa-bad1-be94cab5e7f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_f14257a5-58e7-4cfe-ac85-ed5efc25f366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_f14257a5-58e7-4cfe-ac85-ed5efc25f366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_78d20f24-d6c6-48d1-b7b9-be4ab5504c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_78d20f24-d6c6-48d1-b7b9-be4ab5504c78" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended" id="i0c028b6cec34457fb750f15e24615ed8_AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5aa8a978-378d-4cd9-a613-07a368a68750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5aa8a978-378d-4cd9-a613-07a368a68750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_3d1fdb38-e8dc-40d7-acf1-0663a1241c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_3d1fdb38-e8dc-40d7-acf1-0663a1241c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_d499df9a-f4f8-4e5d-a521-0c5168c132e4" xlink:href="cpix-20200630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_cpix_PaymentsForContingentConsideration_d499df9a-f4f8-4e5d-a521-0c5168c132e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3573b688-6195-404d-9354-e7e386305f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3573b688-6195-404d-9354-e7e386305f13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a9c62f2-060c-400b-8f0d-0183d74159e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a9c62f2-060c-400b-8f0d-0183d74159e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40323ec1-4d85-4157-9197-e407fccba483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40323ec1-4d85-4157-9197-e407fccba483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d8cfe890-ed78-4ae2-b2c3-c5237b19ae86" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40323ec1-4d85-4157-9197-e407fccba483" xlink:to="loc_cpix_VIBATIVMember_d8cfe890-ed78-4ae2-b2c3-c5237b19ae86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended" id="ia379548ee87a464a8993d1699adf4838_AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_621d3496-2b64-4580-a752-538e900a2452" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_621d3496-2b64-4580-a752-538e900a2452" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8bb9050e-c8ae-4598-b1bf-558eeb0144d4" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8bb9050e-c8ae-4598-b1bf-558eeb0144d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_aa836224-c510-4247-b227-fddb02c1b23a" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_aa836224-c510-4247-b227-fddb02c1b23a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_f2babad2-aa74-4861-ad63-80b0132d7c9d" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_f2babad2-aa74-4861-ad63-80b0132d7c9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_019d54d7-f548-49ec-bf06-5da0dfea216d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_019d54d7-f548-49ec-bf06-5da0dfea216d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c496da0c-b2a4-4ed1-93be-1deaa2f4eb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c496da0c-b2a4-4ed1-93be-1deaa2f4eb64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80ed69fc-9f6d-41a1-95f7-da652aa1d629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_Goodwill_80ed69fc-9f6d-41a1-95f7-da652aa1d629" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_a6b024e8-8104-4a27-a7e0-2419f98a7ebe" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_a6b024e8-8104-4a27-a7e0-2419f98a7ebe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_68c39855-d31e-4623-b34f-8e6b563be67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_68c39855-d31e-4623-b34f-8e6b563be67e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0a606aa-ea96-4318-9945-c0f8c7dd1fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0a606aa-ea96-4318-9945-c0f8c7dd1fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_1956b536-322a-4787-8412-2342c66fd8f5" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0a606aa-ea96-4318-9945-c0f8c7dd1fdc" xlink:to="loc_cpix_VIBATIVMember_1956b536-322a-4787-8412-2342c66fd8f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="ic88627958a59497ea5aaedb6d5274612_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_00e30228-c692-4627-b762-79defb94777b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00e30228-c692-4627-b762-79defb94777b" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4081302d-bc38-4b25-b81c-4e988d27013d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4081302d-bc38-4b25-b81c-4e988d27013d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_7271b560-0892-4a02-b4d3-52a7030d761a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_PaymentsForRoyalties_7271b560-0892-4a02-b4d3-52a7030d761a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cba67ce0-6122-4d1f-aada-a0b14819f006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cba67ce0-6122-4d1f-aada-a0b14819f006" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b43c95f8-ee52-4fcd-88ac-bc515e004a05" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b43c95f8-ee52-4fcd-88ac-bc515e004a05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_42f474c3-3981-424f-9a22-271c65ec3838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00e30228-c692-4627-b762-79defb94777b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25c12f38-95ee-4c9a-9b6d-d96538508433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25c12f38-95ee-4c9a-9b6d-d96538508433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_5b293211-1e50-4a83-930e-1fb93d205a16" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25c12f38-95ee-4c9a-9b6d-d96538508433" xlink:to="loc_cpix_VIBATIVMember_5b293211-1e50-4a83-930e-1fb93d205a16" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cpix-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:fc80af1c-b60e-447a-a71f-0452a1e7408c,g:c711355c-b1ef-45b3-aa25-450d0075a667-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15e8f24a-9c13-44ae-8340-57d7143a7e60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_2a28ed92-d3c0-4005-92c9-e1c5276ae483_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_b34a6734-58b1-4412-87fe-7202ca5d4aa2_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20200630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0fd73ad2-ae04-48b0-b62c-d0e7ae5bf7c5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ddbfa39a-2ba9-4655-b8ea-7df8a8adc21c_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_b37cc278-4568-4eee-9bc1-9a216ad12b5c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_445bec72-45a1-4aa3-a18e-e1452e22fd04_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ab7416ea-fc79-4f66-9683-6ccbde78cee2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1ad8e65c-41a8-4ab7-b579-8c265b3d49b4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_2965bf35-8952-42e9-98ac-58fef8b6d3c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5a5f4051-f84f-47ff-90af-3e42ed01b7f4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_cc21b83a-44b7-400b-912e-3c27a70e6dfe_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_94948a7b-26bb-48ea-9012-5a2fc54bffca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_a79b0347-d061-4427-8c6a-6c41ef0e979c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fb2fb5ba-72aa-4572-8d7e-703159ab9bc0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_77723856-cce1-430f-aa20-6af82d2a4a8e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9ce56d4a-66fd-47dd-abfe-7f43f73f742f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c6f386a1-a9ab-406f-9983-882f055ddad6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_eaf4d940-b798-43fd-bb50-44404d9b996a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_e9ffe92a-5319-4d1e-bff9-bad2c1d0b4d8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7b3f1339-8e93-45c3-9b5f-460437b994c6_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_9a371e2e-8088-4c6b-b639-569fc2cdd9a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c34dcf81-47eb-45e0-a376-7387dd804e6d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_7eab66e8-668f-415e-ac23-c8d5a0093676_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20200630.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_b290a6af-5a5f-4c2e-92f9-5c14c3918092_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20200630.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_86d3906e-4607-4bfc-9a0d-cb5acdb17749_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f0f1287-3619-4b11-ba1b-4f9005312266_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_8ef9730b-bd60-4e8d-bff3-5902800cb4c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_c79d85b8-0874-4281-8e73-1dd57580b290_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_23038a05-72f4-4b2b-9d94-46a3a008fd58_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4f6f2535-5901-4d71-b825-c2494a0bb37b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2a0a9266-775e-4690-95e2-d14c03b12496_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_cafb39c8-fed2-4a65-86d9-2fcac25bf999_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:to="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_688fa396-3df9-4f99-a44c-63e4f4ee0295_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_750f82fc-82d0-453a-a223-a208e58bb678_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_c5fafe93-f93b-49b6-a8f0-1117f799f2f9_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20200630.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_17754faa-ef72-48c0-a9c2-819d57404e2f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_103c850a-7e5b-4e1b-869d-3572cbf894f5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1ce281db-a638-434d-bbcc-5e2698e9245c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_1a9eb0e7-a7d1-48be-be71-434d78c2f65e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b9e86823-903c-4d96-b22a-fcbbe6aafa13_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fb08d5a9-fe65-420e-b8d0-dc960d2f804b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_7e7b641c-02aa-4029-afe1-8888286f60f3_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_92fcf647-0246-4254-8728-b86e59de304d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_374abe46-3956-485b-98e6-6ee7b6874a22_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_5cfcf650-2395-4e62-8ca0-b62be3264cff_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20200630.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_3cf13b55-4590-41dc-a7c0-0af82c57d726_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_dae49cab-35de-4605-89d5-ea80143419f4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9eb528cc-4e58-4ae1-9650-5f968588fe3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_aa9f6239-df7e-40f3-832b-fec804bf0b24_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_ffb2b3cc-9a08-4f27-84bc-36932c18a14d_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_42843cfb-db41-493b-a482-e3edd7c777df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8113aabb-87ed-45e2-a939-656ce4253690_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ef53c14-35eb-4113-a1d6-3727224fadc0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4789d414-a839-41e8-bf41-3cb7ac2512ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_87428231-dd8c-4bd3-8a58-8a315273bd49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8050bda6-f0d5-4fc3-9fdd-686d2997044e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_758fc9ce-9bf9-487b-962c-ffed9988fe53_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_358aad12-aa0b-48d8-9a5c-304d61da0b86_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_76c3d67a-2a59-4672-8ca6-e12319fde29a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_4561e0f8-769c-4518-b51f-7f719ade2ca7_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ee1deb40-c2d6-4d2e-9a34-b722feb3cb32_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c26d8c45-da90-42d8-a77d-4b3c4796878c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5add3d69-de37-4f20-ae42-28a1dbbb1883_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_68cb095f-ed64-4cab-b2a1-c18539f35cb4_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_07c4c81d-78cb-47ff-bf6d-58f0667d0039_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20200630.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_515bb64c-29fd-4328-959c-00a2eaa4d8ad_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20200630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_2c19a8a7-133c-4f88-8efb-9f5ad366598a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_dfd468a3-30ac-423a-8a9c-e450795eeab7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70061c6e-96c2-4fb9-b06c-ce8bb852c68e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a804d14b-6428-495d-9e2f-8f932d6a38cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f56dbbee-a80c-4087-bcf9-011fd8750f88_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_569874b5-1d84-4599-bfda-18510c7b637c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f1d37486-a70e-4d93-bfc8-f36a6ab13a94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0e8d6a9e-1321-4130-8851-aa1dd80f40d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eae18d10-e5e2-4391-bf5a-d2c5b6b017ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_858ca1e6-88fd-44ad-948d-29d9c0616ddf_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_0a3f5a10-897d-4297-99d7-a72cd7359108_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_fc3030f5-eeff-4c46-8993-8bc90108ea24_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20200630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_2ddac694-b5f0-474d-a5bb-423625b2bf94_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_7213b8eb-78c0-41f6-a680-32e8cb3839a9_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment through purchase of shares of CET Stock</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_bb7cfee6-f58e-4663-a701-92343a9ff5b3_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20200630.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b9db8c83-c5fe-4906-a52b-ff2f1b4cf2cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_84fd1abb-87f7-4f75-9feb-1e01564dd826_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_fb3db31e-1cbe-4303-9462-0776438a627a_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20200630.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_17c80e2c-0691-4992-aeba-c280a8ec6ff3_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d894a68e-2f61-435f-94d0-32a02c1f1e31_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e69a343-b301-4fa5-922a-d53a7a9c8ee3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_18df8732-0aec-45bb-b0bb-5819ba567c07_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_6180545b-e5f8-4f35-a963-3f1dc4f3498e_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20200630.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_1d2557a2-9fe2-454e-b8d8-a802b4dda730_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_86309454-47fc-44b0-968a-81fa420b1e52_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_518f079a-aa05-4405-9d89-2afca6c4a13f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_783dba8e-6194-4f69-9cf5-e2db04d923e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_08630e74-f7a2-4324-92f0-f37c9133cf95_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20200630.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d91b1d13-066b-4786-bed8-876cfc9a544d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6eb1da75-55f8-4a6e-99d6-abca2fcc3141_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c9a8f9e6-4fcd-4eb4-8037-7f849141af56_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d6726964-575f-49b6-b548-2edf01b14646_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_edaa60f2-b413-4d41-98ba-7ebcd3b3572b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_8eccc803-b590-4002-88bc-022647d6abed_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20200630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c9cc39d3-711a-4e06-aac7-4a81c42bc6cc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f2dc9463-d465-4673-95eb-813660abc00b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ac1f52a8-0710-44cf-9f72-ef645429f8d8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cfc99571-8617-46ff-9bac-296073188c40_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5c6c5b56-4bc9-4c78-a180-96e4c0e9e1be_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_70d5c407-84ab-487f-b51f-be366434a77f_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8fa82c77-6a57-45c4-b7c0-b2bcbcd3905a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_a1e520f4-d4e8-4e98-9fbb-d2a5ce34ec08_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_2fc0e24e-8846-4a83-867f-ebc188f64b48_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8a6fb364-505d-4b23-9c7e-6a0cf4717d4d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_5b755934-c4d5-42ba-a2ac-687c6bc96678_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0141ecdf-f131-4985-b39b-6420d601899b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_a90a4e51-f7e3-4fe4-b88a-ecefdf396c41_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_505ac287-8588-42ab-bcc0-95968176d0c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_2cd9eac6-712a-4815-8568-95e2107bf046_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4184057d-a00d-4a05-9568-6c2f4cb71c49_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_36a6d8d2-5efe-4ecf-a028-0ce245a75d76_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_bde830e7-871b-411b-a8a2-327c08ea2c47_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_fe042e16-65fe-444e-b22d-01b15b58caf1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_461ecce6-9e39-4d17-88f3-49c4d8e74e7f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_3621a7e6-de54-46aa-982a-06efbc53b8ba_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_b2815488-be1f-41d2-beb0-492e988cd945_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20200630.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_49f2b2c8-681a-4eb8-be0b-8bbb098eb720_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_38af34e0-c270-43fa-960b-e662f57b91a5_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7e80faa9-46d4-4430-9147-5917ecea32bb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fbb5ad4e-a0cf-4b88-b509-cc4673cfa9c8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Leases Liabilities at June 30, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6662a1ae-974c-4305-bb4f-1819d2889349_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d16fc69d-4c8a-441b-aa2c-92c90850b687_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89db6870-9f5c-4e94-b6de-c706f7714034_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d985885c-e565-43d0-8e83-dc382d2b3520_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_4a27675b-d64d-4586-9471-f98a75aaf60f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b96e58da-97ab-46d6-aeaa-7dd6cba8426b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_201b5472-8a42-435c-ac45-ef11f8ff98b2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8f83a7e7-c39d-46ff-8582-cd103ea5c41d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_f63be4da-6b73-4fb0-aee7-811fefe1a48f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_99a8dde7-1a50-44e6-9eb5-d0dc205bc29a_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20200630.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ca698b4d-7848-4a99-9ba7-2cda9e6b411d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_e166df70-41ef-4645-8902-d9504b35f7e7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2f2d0380-1218-43c2-805f-763fa1ae197f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_210f4a0e-a898-4275-ba70-8c6e8e5a93ef_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7e98f6c-25d9-463d-b08a-c8916a09768e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4c505516-862a-4dc0-ab26-9f2267b06fe5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_33ce2843-88d8-4cfe-bdd5-b4650de8751c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_d7b368d0-f1b6-4fe2-931d-c8f5890c0ee8_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7e179c71-3dee-460c-9284-0837807256b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_86f9371c-198f-4fc6-a4f2-c5508882688a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b6494915-525a-4585-970f-72ed4fb172e1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_46f1a119-22f1-4df2-91aa-4eeb967c3590_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a5579268-af84-4f22-be88-555429c3bfc6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_d895b515-ddaf-4ccc-9386-04ab578dfd69_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20200630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1379483a-6f1c-4fb4-b91f-9ee749071aa3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d298429f-9f2a-4e42-ab93-6becef735d6c_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_375d9abf-b7a1-452a-a32d-1dbc59f67064_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5f8bdb75-c750-46a6-bbbe-6c642c25a2da_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_186afcdb-9530-4f05-bb1a-86e025c00da2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1be4e43-242f-405f-b300-926211485dd0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_a02c5c07-6f43-4655-9889-b9071c53ac7a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e437d536-11ae-472a-b2c5-3f9bd66948f9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_511d59e6-8273-4154-a7cb-11e58df72431_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_200b4743-e89c-47c5-94a4-a28b305e752b_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20200630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a6c563a9-801e-470a-848b-39220e650438_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b0f74846-1805-45d1-821f-2862a279b358_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_ec9062e8-b664-4117-b2d5-ce628561f172_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_0a027e94-f702-4233-9411-c3917a4d9197_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20200630.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_803bdf75-35f4-457a-b024-bec6fd3e5fb9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_814f7a71-b188-4d79-988e-c49e8ea6fdbb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_e67dbfd5-8e2d-474f-89f9-b0d4c4433e03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_f624b08a-9b74-4738-9905-244b7a925609_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b6e58946-347c-452f-8deb-b68331cf3a7a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_92d00597-7ba5-48cc-a531-1ab56f8fb75a_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20200630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_8c2a61bb-0983-4678-8c29-47bbbfcc0c1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_57a24516-52c3-4acc-82a2-9ce992c9cb3b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_d90cae29-8893-4d67-8e8d-cacf5474158c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_2e2e09c4-8fb9-45d3-85b6-8b75e3c54ffc_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20200630.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_98defec0-d63f-4c70-b5a7-59359d2dba2d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e8402301-75c5-4ac0-92b9-20bb6d3db09a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_503e18cb-3bde-4955-b4ee-2e29c6629301_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8a45ebbb-c3d9-405b-9f73-a8598c2d4b5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5eb66bb1-ad2b-4157-9539-2b0d0d32f9b0_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_49962a53-85b0-48fd-b309-ea6800c0b8c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_2ed8ab7e-d6b4-4766-bf76-91558765f371_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7dda6ec6-c8d3-454a-b2f2-64e9f5709e97_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_188d3a9b-4dc8-4fa8-a058-d27a6f0c0a31_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7f0da986-3c64-4d05-983b-da10fc5b7850_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ee7c3829-1f5e-40eb-b167-d683bcca9631_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f3442789-251f-4753-92a5-50b9754fa7e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_31cc8be8-4ac3-46ef-9b24-874d889fa835_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_9dae7fb3-4762-4b91-9800-cc0c69104203_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_0e42744b-667d-416e-82dc-284066b4709f_totalLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_85f69c75-3840-45b4-b6b2-40a48df9867b_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20200630.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_f2e1548a-e0c4-4261-8295-3ee6ae319ee5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4f393677-bb2e-4096-bace-42874b9c5416_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_12fba981-d07a-430e-bf0d-e9c07579e04f_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_f3395e6d-89e0-4cb9-aaab-114396387235_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b1f1c95e-727a-443c-a8a9-b8dbcb73569f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_df95a070-66a9-4fb1-982f-1a3294e62e1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_24383f22-874d-4f1f-a5b2-1fea25823efe_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1f10fa96-be11-4a58-b9bf-e3e82c657998_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9a3a0c2c-8b0d-4f9e-b2cb-a78e1228a376_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c51d77b8-8b7f-4b97-8619-025c6c2587b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_92595d2f-6939-4d68-b78c-9b7887e07261_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_698086f9-7d7c-45bb-a2bc-9ce241ff3cbb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bde0d6b5-f924-4f4e-9825-668784818935_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_12dd1f48-80e8-489f-a744-27075f852736_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a5d1fff7-c4dc-474f-9e4d-ff8785289530_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_1d0c856b-4bc2-408e-9d82-41c01ca1c222_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_dfd2ed41-492b-447c-9374-1365a9189a04_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b1fa8bf1-2ec5-487a-b4bb-4b72fd8d7b11_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1eb2c0cc-dcf3-4a74-89fb-dbdde32185be_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7307dc1d-fb72-4aa7-b393-6ae2fcca9eca_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1eb500e7-28ef-4e30-a570-e13b677a9b83_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_1a7f4d69-df18-42e6-8bff-e964359cafd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_336268ad-269d-4bf0-a859-bf5d89b3c65d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a1bccb80-6128-418c-a983-0f2af78124fe_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4ff2fe1e-127b-489d-83c5-0a7c1424397b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1ac8de31-235a-4bc4-baf3-757f7913f957_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b14126dc-502e-4579-9c5f-4ac8a25076d8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_986ab166-ae03-4990-8956-fe18279a8a9d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2e0b552e-dfaf-4c3a-8d3a-11a93b576f21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_7e0df2f6-b116-487a-9fb1-2c725b43ff96_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for return of shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_b83fbcf1-2f6f-4c38-b43f-bef256f684bf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_b88891c7-d0ba-4f2f-b82f-cdb3174db16a_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_aba0269d-6041-4026-b840-7f9b32ef6c14_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e74fb1fc-c3a1-47f5-a081-426b4d0d6ba4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6b5386de-2c03-451d-85be-39acb1a1686a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_12d57526-fd0b-485b-84f3-114ce75bde7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8a86ef6b-9e3c-4f4c-9ffb-92c052771ebf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_78eb2993-453b-4c69-baea-b5e70220da96_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross, Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed9a89dc-8a4b-4626-8036-8b8bae4a3494_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_3c26a687-3e2b-4224-9f49-441b50e78295_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_444acf8c-548e-4c05-bccd-04d734143d64_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_9a71234e-d043-42c5-95e3-cd8b5edc9e9c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_9241ad87-31a7-44ca-9793-472278899b61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4c8dc824-7299-4897-85f6-6642ccdfb8f3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b07ace1f-dce9-4114-9387-ebeabd7256b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_71c4f87a-cffa-4fe9-ab83-08143c91b86d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b12880a-d39c-4400-9da1-20e6a8bd256c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_82b558b3-9263-4dfa-8acd-b6fadf4084ed_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_639d341f-ad28-482d-963a-a6e6114d0c0c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_63325fd2-6380-4eff-b173-c3428a8aacec_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d8f03c03-a4f9-4dfb-9aac-daa979c50400_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5719e23c-74f9-4e00-b2c6-0ee3bc00a296_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_be9e8008-36a8-4193-a979-de1d98adc69b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_b76bbf9a-3de2-43be-abc5-ffc9b0e6e154_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_57743b89-1071-480b-8e68-a3805cf0c265_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_d75147d7-416e-4629-b5f3-5144cd578209_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_194b925b-aaaa-49b9-9405-57f39009de14_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20200630.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ec501780-15e3-4f92-882f-eaf21801a27a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4d18bc2-b29d-4a8a-8628-104954293fb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6950a533-1688-4f4c-a194-e0cccc744514_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b895325b-b9ac-4243-92bb-9101a4ba2781_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_9729fcb4-1b5f-4768-be01-55323ab4f31a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e00ea884-44de-4df6-b0c1-5b5421ecf498_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7aa1f897-6a0e-43ec-9613-ff713b77f040_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9c0af0b2-30e3-440b-941c-6861d80608aa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3ac81acf-fcf9-4efe-a1b9-a52ed005c65e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_005c4b5c-baf5-49b0-aefe-78cbdc46dd14_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fdef22e-7c2c-4f89-8174-de8721aa7f0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_c30a4bb7-596a-4b20-84f3-dfd1f4a70214_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_b70cd9c2-f865-4e2b-80d7-ee092df63ca5_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_58aed06f-a1da-4e5c-b078-b79404b4c205_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_89fe5a8f-564e-48cb-805b-1788f1d29fef_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3acc0001-74d3-46ab-8f89-41b1f31f302f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_cb3bc3ee-f352-4e6f-9009-6db262b1c81b_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_e49450ea-c873-449e-b95c-dcbddb05eeb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3615bbef-040c-4e8d-99bf-3b6fbcce258b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8fa15c26-4cd7-4dd7-b044-0bf36c419c96_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_4a08f884-7207-4a14-8ce4-06e9e5983b1e_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5ed89440-1c21-48ad-8253-c079cee2ea32_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c1b46cd2-32dd-433b-8aee-5de19dc4ec43_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_5fb223be-df7b-47e3-8434-4fd72fae466a_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_d266517e-4d64-4a6b-9c08-60b9c17f6536_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c9357ac2-f6e9-48d7-a073-e5c55db78b2e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20200630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_cd24c8e9-f988-45d0-a736-d130813a1082_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_917a32f9-50ef-4d91-9e5b-7ac361fa402f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_b9234a02-49c0-4b40-8b95-c78e7615aac8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_f5803ec6-687f-4b77-8408-4db5b3ae64e0_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20200630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23c5e8be-b4ee-426e-b81f-c31fbb7b27c4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b513be6c-18d3-448e-8c27-f3066c2357d6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c1dbde99-d403-44a7-ba2d-c6b5780079b8_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_59fd089b-2bc9-485b-bf60-7fd3d9f5da76_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7cc9612-cd49-41fb-8075-169ab9d43e3e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_1ea27d03-af50-49d0-aa7c-bb1a8f4fa1a5_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20200630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_446d5461-59ff-46e5-b696-77e36926a89d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7c117224-b40f-4711-8986-aa5ab2014db3_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b4cf8332-4fd1-4ca1-88df-25b573d900f8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_7b363d55-8dd9-4e43-bd87-a1400d9f16fe_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b9584d3c-7f8d-4013-8199-8219aa1e007a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_630a758a-7f04-499c-8560-5c375cb642ae_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_aa4e76cc-fe11-4672-9514-2f0ebacf4e71_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20200630.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_dd51e1e8-34b5-4ad6-90b7-9dda09bccf99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0da23ea9-c404-4215-bfda-4a993ae97e2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_46e3bdfd-de18-4c24-a0d6-86c70c474d75_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_2fb830cc-e9e3-4427-844d-10f04f2566a3_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ec297dce-562f-48cb-891a-bd0e69367902_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b12ec1e-a0d5-47f9-8bd5-b224e13f14a6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_809a4087-fd5c-4846-a5ac-403ce0b0e227_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a297e2f8-8d4d-478b-af6b-d73116ca44d8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4053563f-0e3b-469d-b924-0f270ad333df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_9949af59-f470-4019-82ed-dbc7d914a96b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_76a7337c-b93a-4932-8594-6a7d4166c483_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9072097f-8105-4fa2-81bc-9a599e8218bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d154b1a-077c-466b-9f2f-1b207a79b03a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9f4e22dd-e6cc-4e07-89d0-2601b79b5c31_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_84b58805-2bcf-468c-ac75-17177abee5da_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7ae8f7aa-0ba3-475b-a0a0-ca3f98adc76c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_bf4f4db8-3130-4b92-baff-f6b6eecdefcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_73f983c0-a2d7-4ae1-81e6-fabc72aebee1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_7a41aa38-e029-407f-aac4-34a3b192fce7_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_2acff980-466c-4c0b-aa51-bdeae0b34b31_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_7df3c71f-b5c8-4f6c-a527-7eb5054971c8_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_b2a2a2a5-e989-4373-90f3-59bbbb7c16bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d819bb81-203a-4ccd-bb58-302b4a9e4b25_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_f487b190-7616-4644-bc15-ef20a09c4d12_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20200630.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_9befd140-e21e-402c-be98-a2f371f6e7ae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_5e0f9e5e-1505-46b1-bed7-eb06a17b52df_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_cae90bf2-36a8-4d33-b6f5-4da94a130b0d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_de255108-4190-4734-b4d6-bd61bd9a6100_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dde701e2-db9f-4404-8955-05b537fa6201_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_089a6a55-3151-44a5-abe9-080db81bbc83_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20200630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_48ad2abe-975d-4ae6-8e75-97f760d3f39a_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_376a0add-4ade-482e-8aa9-57e41149be4c_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:to="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_50df036f-00da-4312-b504-53f23f9f0682_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_68c56804-c086-4df9-af7e-65c9d8befb54_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cpix-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:fc80af1c-b60e-447a-a71f-0452a1e7408c,g:c711355c-b1ef-45b3-aa25-450d0075a667-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_48a85bff-bed0-4ec1-81e1-fa5d2a3f33fd" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_DocumentType_48a85bff-bed0-4ec1-81e1-fa5d2a3f33fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2660ffb0-87ec-4216-83b2-0cf8f090254a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_DocumentQuarterlyReport_2660ffb0-87ec-4216-83b2-0cf8f090254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_de56e3c7-ad01-4a39-ab06-17eb569662c8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_DocumentPeriodEndDate_de56e3c7-ad01-4a39-ab06-17eb569662c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0a566b76-e14d-4ed3-b071-6bb62d19004a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_DocumentTransitionReport_0a566b76-e14d-4ed3-b071-6bb62d19004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6be73030-bdc8-461a-81a4-d794cad5a584" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityFileNumber_6be73030-bdc8-461a-81a4-d794cad5a584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_59282d74-be27-4d95-bd32-a1cdd3094627" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityRegistrantName_59282d74-be27-4d95-bd32-a1cdd3094627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd565100-a4f4-4ef5-8456-c7bce6145f84" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityCentralIndexKey_fd565100-a4f4-4ef5-8456-c7bce6145f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1348d601-f148-491b-a452-01bff06ecef0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_CurrentFiscalYearEndDate_1348d601-f148-491b-a452-01bff06ecef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ff642113-3e82-498a-9e4b-ef17e4552843" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_DocumentFiscalYearFocus_ff642113-3e82-498a-9e4b-ef17e4552843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_93dc46f2-5ecc-4f1c-b686-b4792f9abb62" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_DocumentFiscalPeriodFocus_93dc46f2-5ecc-4f1c-b686-b4792f9abb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3e02ee8a-dcd4-4cbc-94a5-0fedbac0e751" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_AmendmentFlag_3e02ee8a-dcd4-4cbc-94a5-0fedbac0e751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ab3f1bed-4e4e-406d-81df-eaebdd8c8d73" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ab3f1bed-4e4e-406d-81df-eaebdd8c8d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5abcd9ef-5257-4fdc-9ea0-49abc530453a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityTaxIdentificationNumber_5abcd9ef-5257-4fdc-9ea0-49abc530453a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2b1e8c61-e62a-4f7e-b552-51e6b0be7a64" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityAddressAddressLine1_2b1e8c61-e62a-4f7e-b552-51e6b0be7a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_faf85cb3-4356-41c8-81c2-f6cba47c8829" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityAddressAddressLine2_faf85cb3-4356-41c8-81c2-f6cba47c8829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_102b244d-b0e0-4309-ac08-ffe74d73b31a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityAddressCityOrTown_102b244d-b0e0-4309-ac08-ffe74d73b31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b8fef3b5-9c95-456c-8484-64e9a0d6dbe8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityAddressStateOrProvince_b8fef3b5-9c95-456c-8484-64e9a0d6dbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_24b957d0-ba17-48e2-9291-82dc551e1d5c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityAddressPostalZipCode_24b957d0-ba17-48e2-9291-82dc551e1d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e3edc991-6a2e-416a-acf8-19ed531b971b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_CityAreaCode_e3edc991-6a2e-416a-acf8-19ed531b971b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_479627b5-5840-4e4a-8785-bcca4ddc6dfc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_LocalPhoneNumber_479627b5-5840-4e4a-8785-bcca4ddc6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_942a0c44-a9f5-4b1f-87c9-d239868a5887" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityCurrentReportingStatus_942a0c44-a9f5-4b1f-87c9-d239868a5887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d30cfe06-0076-4095-be90-dce0d6f09ae4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityInteractiveDataCurrent_d30cfe06-0076-4095-be90-dce0d6f09ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_02acc88d-bb75-446d-86c2-76dd074378fb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityFilerCategory_02acc88d-bb75-446d-86c2-76dd074378fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_30f783f5-7459-49f3-9cff-1b7cc4e451d5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntitySmallBusiness_30f783f5-7459-49f3-9cff-1b7cc4e451d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d0019d45-63cb-4fbb-9a26-c669ef97d4ac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityEmergingGrowthCompany_d0019d45-63cb-4fbb-9a26-c669ef97d4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_aa783791-b028-423d-bfd2-48bf2376a475" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityShellCompany_aa783791-b028-423d-bfd2-48bf2376a475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f6ffed63-767f-478c-863a-ba45ef29de02" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_Security12bTitle_f6ffed63-767f-478c-863a-ba45ef29de02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0682a3cc-f754-446c-962b-dbf03ab3a22b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_TradingSymbol_0682a3cc-f754-446c-962b-dbf03ab3a22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7a4bd6e2-591b-4e25-b4d9-a2074eb1f5e9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_SecurityExchangeName_7a4bd6e2-591b-4e25-b4d9-a2074eb1f5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a97815ed-3e7e-4d4a-8a22-4610f880f059" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20c17f37-a0ad-4f32-b636-bf08b9591b15" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a97815ed-3e7e-4d4a-8a22-4610f880f059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b74a2a37-93f3-413c-a55c-2da8fef7d49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b74a2a37-93f3-413c-a55c-2da8fef7d49e" xlink:to="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbcfa236-cd91-451b-ab04-7a7fe6527544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fbcfa236-cd91-451b-ab04-7a7fe6527544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9b6e2d29-e206-4722-9ad6-feec81b102ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9b6e2d29-e206-4722-9ad6-feec81b102ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_743c337f-44ae-4f5d-923c-decc8e13d7c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:to="loc_us-gaap_InventoryNet_743c337f-44ae-4f5d-923c-decc8e13d7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a7b71f1-2e6d-44d4-bc51-55d803777d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a7b71f1-2e6d-44d4-bc51-55d803777d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5670f944-7aaa-48bc-8362-f565cc44799a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:to="loc_us-gaap_OtherAssetsCurrent_5670f944-7aaa-48bc-8362-f565cc44799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_10b52589-fba2-4e8b-82eb-b8442215693d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_da5582ab-7896-48d2-a5f6-ad38cc4431d7" xlink:to="loc_us-gaap_AssetsCurrent_10b52589-fba2-4e8b-82eb-b8442215693d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e1d83cb6-2b97-4802-9b79-558f1a3c4bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_InventoryNoncurrent_e1d83cb6-2b97-4802-9b79-558f1a3c4bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b9a3abbd-c268-4921-bd95-55fe09fd8907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b9a3abbd-c268-4921-bd95-55fe09fd8907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72863f17-c3ef-4c94-a284-011eb718ec5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_72863f17-c3ef-4c94-a284-011eb718ec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1359d320-ec41-4b5f-9b72-0b8fff11af1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_Goodwill_1359d320-ec41-4b5f-9b72-0b8fff11af1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5488d5bf-ac38-4498-9848-4eb150ae65c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5488d5bf-ac38-4498-9848-4eb150ae65c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5cac21aa-189c-437c-a506-ab19606826ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5cac21aa-189c-437c-a506-ab19606826ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f5682523-a8a0-4ead-aa5d-193baf58190a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f5682523-a8a0-4ead-aa5d-193baf58190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_41964c31-8a76-48cf-9248-1064e2a91d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6456bba4-b86b-463c-a937-389d786d2d22" xlink:to="loc_us-gaap_Assets_41964c31-8a76-48cf-9248-1064e2a91d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b74a2a37-93f3-413c-a55c-2da8fef7d49e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9173f32a-aceb-40dd-8146-e71a0235e1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:to="loc_us-gaap_AccountsPayableCurrent_9173f32a-aceb-40dd-8146-e71a0235e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed4a9cb1-5210-4e05-ba65-8dee990b781e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ed4a9cb1-5210-4e05-ba65-8dee990b781e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac667e07-6d49-447b-9983-2f4658d52b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac667e07-6d49-447b-9983-2f4658d52b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5703bde0-33e8-4aa2-89a5-162024c9be56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5703bde0-33e8-4aa2-89a5-162024c9be56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_147b86f5-b960-4140-88fa-a43f63fb541b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8032def-1354-442d-bc8a-3778809b7bca" xlink:to="loc_us-gaap_LiabilitiesCurrent_147b86f5-b960-4140-88fa-a43f63fb541b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_00b78ca4-f2d9-43b6-94b2-9c4552b1f224" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_LongTermLineOfCredit_00b78ca4-f2d9-43b6-94b2-9c4552b1f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df97c021-1e57-4d45-98b0-449a56487158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df97c021-1e57-4d45-98b0-449a56487158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_7ac39a08-467a-4fbd-b55f-bac3816b36eb" xlink:href="cpix-20200630.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_7ac39a08-467a-4fbd-b55f-bac3816b36eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7038c5c5-be7b-4991-a4b3-363ba910e461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_Liabilities_7038c5c5-be7b-4991-a4b3-363ba910e461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8e2e6237-645c-47ff-b575-0247263cd3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8e2e6237-645c-47ff-b575-0247263cd3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7c76d834-3304-4722-b359-be3c00875f15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7c76d834-3304-4722-b359-be3c00875f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_874b8e05-30cc-4caa-9a77-ff9e16dccd2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7c76d834-3304-4722-b359-be3c00875f15" xlink:to="loc_us-gaap_StockholdersEquityAbstract_874b8e05-30cc-4caa-9a77-ff9e16dccd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8993ae52-83be-4a09-8b7c-96fbcdba2339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_874b8e05-30cc-4caa-9a77-ff9e16dccd2e" xlink:to="loc_us-gaap_CommonStockValue_8993ae52-83be-4a09-8b7c-96fbcdba2339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38b0eb8e-c252-4045-8758-cf1df06e452c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_874b8e05-30cc-4caa-9a77-ff9e16dccd2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38b0eb8e-c252-4045-8758-cf1df06e452c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e6450c3c-b7da-4d9e-b5e7-5391c9a4d3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_874b8e05-30cc-4caa-9a77-ff9e16dccd2e" xlink:to="loc_us-gaap_StockholdersEquity_e6450c3c-b7da-4d9e-b5e7-5391c9a4d3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b65131d2-1601-4a3e-a209-41aa12b3a14b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7c76d834-3304-4722-b359-be3c00875f15" xlink:to="loc_us-gaap_MinorityInterest_b65131d2-1601-4a3e-a209-41aa12b3a14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8a1b2e2-b0af-40aa-9445-3cd101b8decf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7c76d834-3304-4722-b359-be3c00875f15" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8a1b2e2-b0af-40aa-9445-3cd101b8decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0c51df9-aa6a-4ead-b4dd-5f706ad9df38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7863ee59-3247-4b31-8a84-cf7a95b94215" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e0c51df9-aa6a-4ead-b4dd-5f706ad9df38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_841b1f7f-37f9-49ef-8006-431cd0c7e319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_6bcb5816-351c-449a-b3e3-1274282d2041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_841b1f7f-37f9-49ef-8006-431cd0c7e319" xlink:to="loc_us-gaap_CommonStockNoParValue_6bcb5816-351c-449a-b3e3-1274282d2041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_72d3d148-31ac-485f-be8f-ae88c723147d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_841b1f7f-37f9-49ef-8006-431cd0c7e319" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_72d3d148-31ac-485f-be8f-ae88c723147d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f527fef8-5a7e-42e6-914d-63e74f5d5627" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_841b1f7f-37f9-49ef-8006-431cd0c7e319" xlink:to="loc_us-gaap_CommonStockSharesIssued_f527fef8-5a7e-42e6-914d-63e74f5d5627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f7faf10c-8b35-4c25-979b-39b8c555a9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_841b1f7f-37f9-49ef-8006-431cd0c7e319" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f7faf10c-8b35-4c25-979b-39b8c555a9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6283881-d633-4f6e-a369-e6f6e4765839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e6283881-d633-4f6e-a369-e6f6e4765839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cf2ec0df-5ff9-4fbb-a286-87257a3490ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cf2ec0df-5ff9-4fbb-a286-87257a3490ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cc1c48b8-ffa9-4386-8b98-eed5aef5d4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cc1c48b8-ffa9-4386-8b98-eed5aef5d4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d034a67f-7930-4f10-ab9c-c8d84bb4bb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d034a67f-7930-4f10-ab9c-c8d84bb4bb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_502ce00f-54e7-4800-97d3-7b17b3d444b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_502ce00f-54e7-4800-97d3-7b17b3d444b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cb7d6c5d-95eb-4b2d-a8f2-94e3531eec15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cb7d6c5d-95eb-4b2d-a8f2-94e3531eec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4ec42d52-f3b1-41ed-b4e6-528cf07057e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_CostsAndExpenses_4ec42d52-f3b1-41ed-b4e6-528cf07057e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_95a07373-0fcc-42ca-83b4-1c48368d2e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_cc96936e-2e7a-4479-8a60-7b32fc966d9e" xlink:to="loc_us-gaap_OperatingIncomeLoss_95a07373-0fcc-42ca-83b4-1c48368d2e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b6c7fc7f-6596-4f71-a6f6-609e1602b842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b6c7fc7f-6596-4f71-a6f6-609e1602b842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_129c387e-aced-46c1-9411-cb13fed6fc62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_InterestExpense_129c387e-aced-46c1-9411-cb13fed6fc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1d8c5ebe-3620-44d3-8636-21aa1975b543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1d8c5ebe-3620-44d3-8636-21aa1975b543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b789761-0443-4a43-82d8-b8eb48eb1651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b789761-0443-4a43-82d8-b8eb48eb1651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b50eb9b9-6315-45a6-99f4-582d4ce9b92c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b50eb9b9-6315-45a6-99f4-582d4ce9b92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9d5b1cd4-aac9-4d2c-844a-79c46dd96016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9d5b1cd4-aac9-4d2c-844a-79c46dd96016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d8826411-576e-4b00-8897-0c2a162a6d36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_ProfitLoss_d8826411-576e-4b00-8897-0c2a162a6d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_77453b55-e241-497a-9173-27f2bff7303f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_77453b55-e241-497a-9173-27f2bff7303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84ddf591-8a79-45dd-a07e-38333fbee83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_NetIncomeLoss_84ddf591-8a79-45dd-a07e-38333fbee83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b027e3cb-ce3d-41df-982f-461f7f98dd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b027e3cb-ce3d-41df-982f-461f7f98dd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_545bd1c7-4789-4430-bc18-78a7c327d0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_545bd1c7-4789-4430-bc18-78a7c327d0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9d85d48a-582d-4d06-ad41-825881b61e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:to="loc_us-gaap_EarningsPerShareBasic_9d85d48a-582d-4d06-ad41-825881b61e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_052c325f-bf88-4d25-a462-2de742cf9aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_052c325f-bf88-4d25-a462-2de742cf9aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e2fb8ae5-771c-420b-ba0c-b840243ed2ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e2fb8ae5-771c-420b-ba0c-b840243ed2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7aa30745-1a36-4ac7-90c8-922bc02c8e27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e31e619d-ad9f-4069-9863-0f47f6794c42" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7aa30745-1a36-4ac7-90c8-922bc02c8e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dd4253d4-2592-4c9c-869f-85c2a999de74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d99928c-05fd-4a37-ad26-59acab3d80f3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dd4253d4-2592-4c9c-869f-85c2a999de74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c72adba-9af7-484b-b2d9-4ec46d9aef5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dd4253d4-2592-4c9c-869f-85c2a999de74" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c72adba-9af7-484b-b2d9-4ec46d9aef5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2032ca5b-5bc6-42b4-be4d-2a2b7ff91787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dd4253d4-2592-4c9c-869f-85c2a999de74" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2032ca5b-5bc6-42b4-be4d-2a2b7ff91787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c108cad9-1d6c-4f55-98ac-378a721782d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c108cad9-1d6c-4f55-98ac-378a721782d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_14a0422d-1189-48ab-a265-95a228ae1304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_ProfitLoss_14a0422d-1189-48ab-a265-95a228ae1304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8e0f3498-be4d-4876-97a9-58b52e1531f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8e0f3498-be4d-4876-97a9-58b52e1531f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e53e70ec-9ccc-43ad-a849-b9ad06130598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e53e70ec-9ccc-43ad-a849-b9ad06130598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0d7225b3-9dde-4baf-8c02-021d6f270453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0d7225b3-9dde-4baf-8c02-021d6f270453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b5470d88-39e8-42f0-8c4c-2f399c345cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b5470d88-39e8-42f0-8c4c-2f399c345cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_584ad662-ed44-4974-bc56-ff10feaae65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_ShareBasedCompensation_584ad662-ed44-4974-bc56-ff10feaae65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_dcbc5938-cd89-4b98-a7e3-a958aab643b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_dcbc5938-cd89-4b98-a7e3-a958aab643b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c19bdad7-cf3f-4cb7-a9ea-c9bfd5e2d501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c19bdad7-cf3f-4cb7-a9ea-c9bfd5e2d501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_ebe91e54-73c0-4dc6-8353-d36c74c7e995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_ebe91e54-73c0-4dc6-8353-d36c74c7e995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_83a64a21-9948-4d88-b067-c2d3fedf4fea" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_581f127e-7442-4fcb-aef8-94bcc77ee22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_581f127e-7442-4fcb-aef8-94bcc77ee22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8e1954c3-21c2-4800-8ba4-9bfdff482e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8e1954c3-21c2-4800-8ba4-9bfdff482e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_294fc2ca-15fe-4e2a-9eb9-3a7b82e5e356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_294fc2ca-15fe-4e2a-9eb9-3a7b82e5e356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_fada0eaf-f297-47de-96dc-045d522d3750" xlink:href="cpix-20200630.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_fada0eaf-f297-47de-96dc-045d522d3750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4945bc43-1fa1-44be-9c51-d8df613b19e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b5359675-7e38-4169-aa39-6e4b8e69f82b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4945bc43-1fa1-44be-9c51-d8df613b19e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f148f6f-bcf1-4a76-bde7-7b6498f37bbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_0f148f6f-bcf1-4a76-bde7-7b6498f37bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1dcf32a2-1b29-445c-9f37-01c468d8e52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1dcf32a2-1b29-445c-9f37-01c468d8e52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19689600-3ee7-4cbb-93f2-9552f0693efe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2cbd2479-097c-4dda-81b5-5992e97e3540" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19689600-3ee7-4cbb-93f2-9552f0693efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c108cad9-1d6c-4f55-98ac-378a721782d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37201f21-1952-4cd3-929a-415c5ab1cea0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_37201f21-1952-4cd3-929a-415c5ab1cea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_93a5226b-90c2-4416-bbbb-dfad71f70e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_93a5226b-90c2-4416-bbbb-dfad71f70e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_731f0fc4-d50b-4c99-9cef-920876875a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_731f0fc4-d50b-4c99-9cef-920876875a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6482da96-b02d-4740-bdd4-b0c121a15cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6482da96-b02d-4740-bdd4-b0c121a15cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7e058a91-e98d-4aab-8f6c-5d0a32ada512" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7e058a91-e98d-4aab-8f6c-5d0a32ada512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8af5b68-e553-42f6-a475-3975f4a254d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85037b51-b38f-46ff-9666-3e4a6cc2407e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c8af5b68-e553-42f6-a475-3975f4a254d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c108cad9-1d6c-4f55-98ac-378a721782d3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_98878bb3-f2fa-4cca-91c8-4d4a7b99b834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_98878bb3-f2fa-4cca-91c8-4d4a7b99b834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_5e3517df-17b2-4579-af78-a1bbb83081b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_5e3517df-17b2-4579-af78-a1bbb83081b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e58d9388-313d-423c-a5f8-d4628bb57de8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e58d9388-313d-423c-a5f8-d4628bb57de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_afb9a0bd-83d5-43d8-a12f-d28e14ef47e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_afb9a0bd-83d5-43d8-a12f-d28e14ef47e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_141ef494-593d-42bb-aeea-fcb3f9196adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_141ef494-593d-42bb-aeea-fcb3f9196adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56ae5905-b90d-40e8-85f2-c0197a5e6374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_56ae5905-b90d-40e8-85f2-c0197a5e6374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aaece7c0-87b5-4fca-8228-ebf7975fddc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_aaece7c0-87b5-4fca-8228-ebf7975fddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_beaf5cb6-995c-4c83-84c8-0044150924a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_beaf5cb6-995c-4c83-84c8-0044150924a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3e2fa31-d4f9-4f03-9c02-80384fbd40c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8f212ec5-9ab1-48c8-a89a-783ce86c8445" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3e2fa31-d4f9-4f03-9c02-80384fbd40c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200630.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_85451dee-3353-4845-8e21-4c1c4981b1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_85451dee-3353-4845-8e21-4c1c4981b1ac" xlink:to="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4b2b5c2-75ac-43f8-aa9f-d29d2228d2c2" xlink:to="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bdb4d380-0cfd-4b12-a0e7-3182945f7aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:to="loc_us-gaap_CommonStockMember_bdb4d380-0cfd-4b12-a0e7-3182945f7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_be8c43ba-7fdf-42f3-a426-c62e5adf62ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:to="loc_us-gaap_RetainedEarningsMember_be8c43ba-7fdf-42f3-a426-c62e5adf62ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_63ece99e-c0d6-4042-bd63-7b0b11a00b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_64b9d12c-7645-4f20-b635-860cf56c1ee6" xlink:to="loc_us-gaap_NoncontrollingInterestMember_63ece99e-c0d6-4042-bd63-7b0b11a00b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_351d0622-44e8-4a59-b4d5-33cde32325fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0ee0df13-5cc0-4087-8d8d-125c42ffe9dd" xlink:to="loc_us-gaap_StatementLineItems_351d0622-44e8-4a59-b4d5-33cde32325fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_351d0622-44e8-4a59-b4d5-33cde32325fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3954b7e-48ad-44fd-9d2c-36c052a8af66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3954b7e-48ad-44fd-9d2c-36c052a8af66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dcfe42d3-fe20-4a3d-b6ce-521ea9f3958a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dcfe42d3-fe20-4a3d-b6ce-521ea9f3958a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ae09fcc3-7969-4851-8930-e931435d61ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ae09fcc3-7969-4851-8930-e931435d61ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0bfcb3ae-8d6b-4aac-bf4a-5f1ba6d62afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0bfcb3ae-8d6b-4aac-bf4a-5f1ba6d62afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_a72b2603-f2dd-4c28-9d68-f19048227977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_a72b2603-f2dd-4c28-9d68-f19048227977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ea9aa1cd-9e94-4945-883a-195fb4a3075a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ea9aa1cd-9e94-4945-883a-195fb4a3075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb558d9c-048b-4f99-91aa-b8df5a500d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_eb558d9c-048b-4f99-91aa-b8df5a500d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d3eb064-f39f-4ea6-b7e3-0d74007e78bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_ProfitLoss_2d3eb064-f39f-4ea6-b7e3-0d74007e78bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ded6f9a3-f80c-4ea4-9276-80e5600d8705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ded6f9a3-f80c-4ea4-9276-80e5600d8705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd74536a-99d6-41c4-8865-5e669b9d30a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_41dd2320-a327-43bd-9034-082f9457c1b7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd74536a-99d6-41c4-8865-5e669b9d30a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21004c85-faf9-439c-ae9d-0f807d0a8fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_81d32562-8d1c-465b-b821-4527ce93244d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21004c85-faf9-439c-ae9d-0f807d0a8fe6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_81d32562-8d1c-465b-b821-4527ce93244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fe9ea26-3176-4ae2-a982-5eebab505d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf474aed-2f57-4efb-9112-a36936e253a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fe9ea26-3176-4ae2-a982-5eebab505d81" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf474aed-2f57-4efb-9112-a36936e253a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b662b7f1-6b4a-4b15-a92d-fa0090309e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fe9ea26-3176-4ae2-a982-5eebab505d81" xlink:to="loc_us-gaap_UseOfEstimates_b662b7f1-6b4a-4b15-a92d-fa0090309e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3b585437-bf69-4e55-80c7-936db976dafc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7fe9ea26-3176-4ae2-a982-5eebab505d81" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3b585437-bf69-4e55-80c7-936db976dafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_479329c2-4109-4e7e-9188-21328807a4bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2ed34003-b32e-4306-8e83-a124c71c63d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_479329c2-4109-4e7e-9188-21328807a4bc" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2ed34003-b32e-4306-8e83-a124c71c63d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0e9d2fcf-ef8d-4b31-85ae-020269d32940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_21559951-f69b-430b-b184-943b5858cef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0e9d2fcf-ef8d-4b31-85ae-020269d32940" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_21559951-f69b-430b-b184-943b5858cef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b4ee3b56-ce9b-4c00-a5fd-2021ef4b8dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_babdf3ea-28f4-43ae-bc94-5fd7e248b110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b4ee3b56-ce9b-4c00-a5fd-2021ef4b8dec" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_babdf3ea-28f4-43ae-bc94-5fd7e248b110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9a4f00e2-0a53-49e9-8b6c-492a7e6a880c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9a4f00e2-0a53-49e9-8b6c-492a7e6a880c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_136cd899-ed07-4378-b66f-a649c037be6b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d24959de-3158-4f26-b66b-2af952ccdab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d24959de-3158-4f26-b66b-2af952ccdab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c2903387-0fe2-4f14-b3c9-0a32dc15d5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee18bbd7-31a5-495a-9dc2-146e01f991d6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c2903387-0fe2-4f14-b3c9-0a32dc15d5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ad4e69-6291-4370-9276-f22d108ff3e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d9bcfbc7-f8f1-4b44-86f0-76fbfed80a53" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ad4e69-6291-4370-9276-f22d108ff3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f25f7777-0810-442a-a32a-08e5bfbfa149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1ad4e69-6291-4370-9276-f22d108ff3e9" xlink:to="loc_us-gaap_CommercialPaperMember_f25f7777-0810-442a-a32a-08e5bfbfa149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b82cc007-43f4-4e4f-804d-27e68add75c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e225c5c2-fe95-4f09-94cb-c617d4578af3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b82cc007-43f4-4e4f-804d-27e68add75c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_458071b4-b745-4212-ace9-65dcb96f2b22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b82cc007-43f4-4e4f-804d-27e68add75c1" xlink:to="loc_us-gaap_TradingSecurities_458071b4-b745-4212-ace9-65dcb96f2b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a88f8d91-cf3d-4668-a11d-fada64b1f215" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9e4c1cc1-7ec5-42a4-a32f-4cc0006a01c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a88f8d91-cf3d-4668-a11d-fada64b1f215" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9e4c1cc1-7ec5-42a4-a32f-4cc0006a01c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9f5886f9-9011-4233-b6f1-77cdff016601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c8e33f77-39a6-4f22-b94b-579742ce33d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9f5886f9-9011-4233-b6f1-77cdff016601" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c8e33f77-39a6-4f22-b94b-579742ce33d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_def641bd-321e-4c7f-b88e-603598711126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_82fa7178-8301-47aa-882f-be0524da6c45" xlink:href="cpix-20200630.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_def641bd-321e-4c7f-b88e-603598711126" xlink:to="loc_cpix_NumeratorAbstract_82fa7178-8301-47aa-882f-be0524da6c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_47d7fced-25b4-43f3-914c-e063fdaba0f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_82fa7178-8301-47aa-882f-be0524da6c45" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_47d7fced-25b4-43f3-914c-e063fdaba0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3a265845-cc09-48e0-8c0a-d03f65fb6552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_82fa7178-8301-47aa-882f-be0524da6c45" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3a265845-cc09-48e0-8c0a-d03f65fb6552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1f8afde0-db2d-48ae-9264-e6f67863bfd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_82fa7178-8301-47aa-882f-be0524da6c45" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1f8afde0-db2d-48ae-9264-e6f67863bfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_312c2fbc-9bcf-4539-b049-71adcecb1636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_82fa7178-8301-47aa-882f-be0524da6c45" xlink:to="loc_us-gaap_NetIncomeLoss_312c2fbc-9bcf-4539-b049-71adcecb1636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_e9d183c1-c8cd-4e77-8931-a20539cebc17" xlink:href="cpix-20200630.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_def641bd-321e-4c7f-b88e-603598711126" xlink:to="loc_cpix_DenominatorAbstract_e9d183c1-c8cd-4e77-8931-a20539cebc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d1be49c3-4def-4cac-aff0-0210299b487c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_e9d183c1-c8cd-4e77-8931-a20539cebc17" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d1be49c3-4def-4cac-aff0-0210299b487c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b89b53e-a218-4e8b-a44c-bfbcba3f4d27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_e9d183c1-c8cd-4e77-8931-a20539cebc17" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1b89b53e-a218-4e8b-a44c-bfbcba3f4d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_371d631a-593d-41a6-9ad8-150aae38ae60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_e9d183c1-c8cd-4e77-8931-a20539cebc17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_371d631a-593d-41a6-9ad8-150aae38ae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200630.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_024e1b3d-7a96-48c1-9162-952f5c0b5395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_820b229c-536d-41c7-8351-410479256b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_024e1b3d-7a96-48c1-9162-952f5c0b5395" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_820b229c-536d-41c7-8351-410479256b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200630.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_72720301-dbbf-4b25-9f38-45d41b266660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_9b24cc40-a194-4b31-8fae-72cbbc0efca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_72720301-dbbf-4b25-9f38-45d41b266660" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_9b24cc40-a194-4b31-8fae-72cbbc0efca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2f1ab584-e592-49d3-8d9a-322885af63bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_9c59c056-ccb2-43fc-a2ef-c7445978452a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2f1ab584-e592-49d3-8d9a-322885af63bf" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_9c59c056-ccb2-43fc-a2ef-c7445978452a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2e237068-e824-4516-87ab-ca9019303a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2e237068-e824-4516-87ab-ca9019303a34" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:to="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8a4b94af-c301-49d1-85a6-86fdfa5051b4" xlink:to="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_a4f0ae2b-ed35-4733-b4bd-6b6f80d535df" xlink:href="cpix-20200630.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_AcetadoteMember_a4f0ae2b-ed35-4733-b4bd-6b6f80d535df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_4e98f3ab-96b8-4313-b316-857bf243cee1" xlink:href="cpix-20200630.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_OmeclamoxPakMember_4e98f3ab-96b8-4313-b316-857bf243cee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_8071ca4d-d9e0-42ca-bb6e-cc81172848f1" xlink:href="cpix-20200630.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_KristaloseMember_8071ca4d-d9e0-42ca-bb6e-cc81172848f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_5c7de8bf-ad84-4cae-aef6-b515dd43eb3f" xlink:href="cpix-20200630.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_VaprisolMember_5c7de8bf-ad84-4cae-aef6-b515dd43eb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_be90ec7b-66ad-4b3b-844e-af98ceadc920" xlink:href="cpix-20200630.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_CaldolorMember_be90ec7b-66ad-4b3b-844e-af98ceadc920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_2d154cdf-aa18-4bff-add9-842d9110994b" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_VIBATIVMember_2d154cdf-aa18-4bff-add9-842d9110994b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_64972a01-4d66-45d8-8ebc-0f4d7c9fc1a9" xlink:href="cpix-20200630.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_cpix_OtherProductsMember_64972a01-4d66-45d8-8ebc-0f4d7c9fc1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a6362b13-70a4-4e97-b1cd-131d271b83f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_927adfa5-1143-4a0d-8d73-89fd05624293" xlink:to="loc_us-gaap_GrantMember_a6362b13-70a4-4e97-b1cd-131d271b83f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bf8e15f1-267a-40d8-98de-20069c6f4bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8f258c9f-9326-45a1-a256-6a6e4a0964a1" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bf8e15f1-267a-40d8-98de-20069c6f4bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a0ead38b-6bc7-4862-a517-c1cd5de4d415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_bf8e15f1-267a-40d8-98de-20069c6f4bcf" xlink:to="loc_us-gaap_RevenuesAbstract_a0ead38b-6bc7-4862-a517-c1cd5de4d415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_2301d44e-8852-4f64-a45d-4a232859cc29" xlink:href="cpix-20200630.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a0ead38b-6bc7-4862-a517-c1cd5de4d415" xlink:to="loc_cpix_ProductsAbstract_2301d44e-8852-4f64-a45d-4a232859cc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0b55c81-ebc1-4457-ba30-2108f51e1380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_2301d44e-8852-4f64-a45d-4a232859cc29" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d0b55c81-ebc1-4457-ba30-2108f51e1380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200630.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_568ba355-9608-47f3-a476-4236feca7f56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_27ea73d5-a183-47a1-8a92-0dfd7b047329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_568ba355-9608-47f3-a476-4236feca7f56" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_27ea73d5-a183-47a1-8a92-0dfd7b047329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_246e5c14-802a-45f7-8878-d18801be4e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6def0c49-f364-4aed-9d8d-612b8cf9f795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_246e5c14-802a-45f7-8878-d18801be4e92" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6def0c49-f364-4aed-9d8d-612b8cf9f795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2c54c390-6653-426e-9be2-a1bd5a00c46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2c54c390-6653-426e-9be2-a1bd5a00c46b" xlink:to="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e88dfddc-9849-4192-85dc-a5a1318cb738" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c9b34de9-0f79-48c7-9769-fed647badcd0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e88dfddc-9849-4192-85dc-a5a1318cb738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_0dbc91e8-87fd-4f83-b056-f89800a8475f" xlink:href="cpix-20200630.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e88dfddc-9849-4192-85dc-a5a1318cb738" xlink:to="loc_cpix_IfetrobanClinicalMember_0dbc91e8-87fd-4f83-b056-f89800a8475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_5c7992ed-6455-49c3-af57-796904bfcefe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_7f033ee3-5d74-4540-8d33-4fb3e8d02301" xlink:to="loc_us-gaap_InventoryLineItems_5c7992ed-6455-49c3-af57-796904bfcefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_2afb57e4-5c09-44fb-a400-fe0d2626dfbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_5c7992ed-6455-49c3-af57-796904bfcefe" xlink:to="loc_us-gaap_InventoryNoncurrent_2afb57e4-5c09-44fb-a400-fe0d2626dfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_cc402485-cef0-4aa5-af0c-1e2d27a93ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_cc402485-cef0-4aa5-af0c-1e2d27a93ead" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d38269b7-1d81-4be3-b4d3-b403875b237b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d38269b7-1d81-4be3-b4d3-b403875b237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_3e828ade-5c80-4d3a-9bfc-2be1fb27a33b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_3e828ade-5c80-4d3a-9bfc-2be1fb27a33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9d13bc25-5f5c-45b0-99f1-4dbb71ac2549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9d13bc25-5f5c-45b0-99f1-4dbb71ac2549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_fcc53592-eab5-41fc-afb4-d38c53790258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:to="loc_us-gaap_InventoryGross_fcc53592-eab5-41fc-afb4-d38c53790258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_9b1637ed-fe7f-46b7-8ea5-07bd59b435a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:to="loc_us-gaap_InventoryNoncurrent_9b1637ed-fe7f-46b7-8ea5-07bd59b435a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_af48f2ed-6b78-4eea-8142-0cd0c768d35a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_8596569c-3a6e-4bb6-914d-fbcc211e0c3c" xlink:to="loc_us-gaap_InventoryNet_af48f2ed-6b78-4eea-8142-0cd0c768d35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9e6e270c-5326-4d61-b1d2-af2ca517a5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_31fabab9-4843-404b-86e9-9456985ca2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e6e270c-5326-4d61-b1d2-af2ca517a5e6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_31fabab9-4843-404b-86e9-9456985ca2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4e231fc7-130d-4362-8fe0-d8b54b07810b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_74ce5457-80d7-4393-a475-fff3be8e1e3a" xlink:href="cpix-20200630.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4e231fc7-130d-4362-8fe0-d8b54b07810b" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_74ce5457-80d7-4393-a475-fff3be8e1e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_55af3820-d701-4e60-90bd-db0a50ede710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4e231fc7-130d-4362-8fe0-d8b54b07810b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_55af3820-d701-4e60-90bd-db0a50ede710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_23bb6c8d-e062-401d-bdcb-b6554cc1b32f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e7115346-5cef-43ad-a9a7-c43e2c3dca6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_23bb6c8d-e062-401d-bdcb-b6554cc1b32f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e7115346-5cef-43ad-a9a7-c43e2c3dca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9a98a5c7-eaa0-42ce-9906-930565004f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_23bb6c8d-e062-401d-bdcb-b6554cc1b32f" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9a98a5c7-eaa0-42ce-9906-930565004f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b3d890a5-b084-4f9d-8d8d-9007f17ec098" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95d6d153-3b3e-4fde-8e08-975c2f8dee53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3d890a5-b084-4f9d-8d8d-9007f17ec098" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95d6d153-3b3e-4fde-8e08-975c2f8dee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6719f7b7-1088-4c88-8159-f534ae419552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3d890a5-b084-4f9d-8d8d-9007f17ec098" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6719f7b7-1088-4c88-8159-f534ae419552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5cb1a66d-09d3-4f80-8735-dea1019efd71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3d890a5-b084-4f9d-8d8d-9007f17ec098" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5cb1a66d-09d3-4f80-8735-dea1019efd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_d5db7f40-6872-4d56-a2db-08a429949363" xlink:href="cpix-20200630.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3d890a5-b084-4f9d-8d8d-9007f17ec098" xlink:to="loc_cpix_LeaseLiability_d5db7f40-6872-4d56-a2db-08a429949363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e180b053-403f-40c6-8ed0-b1277b0d7535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e180b053-403f-40c6-8ed0-b1277b0d7535" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d97b8e1f-1675-4496-96e9-4bdcead0c470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d97b8e1f-1675-4496-96e9-4bdcead0c470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d9a1a26f-5bcf-4e4c-a620-4f67c2567b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d9a1a26f-5bcf-4e4c-a620-4f67c2567b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd17de2a-2950-4ede-894a-297ab34735c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bd17de2a-2950-4ede-894a-297ab34735c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_db4ec526-54ee-429a-ab6d-149af3b01bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_db4ec526-54ee-429a-ab6d-149af3b01bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8e347d1a-6558-43cf-bab6-6a7cc1468a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8e347d1a-6558-43cf-bab6-6a7cc1468a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_becf1fee-1cf6-4c5c-95c5-343d759a069e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_becf1fee-1cf6-4c5c-95c5-343d759a069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c121fc8-77f7-49a0-be19-1445b8835802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4c121fc8-77f7-49a0-be19-1445b8835802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f6562e95-ff5a-4f93-b68c-754dbb096898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d0fb2b13-dc7b-4ef6-9610-e6c264eeba2e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f6562e95-ff5a-4f93-b68c-754dbb096898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200630.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_da3aa903-5143-4c10-8cf6-0f579fab34ae" xlink:href="cpix-20200630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1243b54f-601d-4736-95f4-0459797d3453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_da3aa903-5143-4c10-8cf6-0f579fab34ae" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1243b54f-601d-4736-95f4-0459797d3453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_5ec044ea-0bef-4205-a73c-c154b270b0d8" xlink:href="cpix-20200630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_5ec044ea-0bef-4205-a73c-c154b270b0d8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cff5ef0e-ab48-411c-9455-c34094d20558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_849b4fa5-dc6b-4d06-ac12-ef978ef305c1" xlink:to="loc_us-gaap_EquityComponentDomain_cff5ef0e-ab48-411c-9455-c34094d20558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_37c8cfcb-1bc7-4d19-aa65-63d55b343cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cff5ef0e-ab48-411c-9455-c34094d20558" xlink:to="loc_us-gaap_CommonStockMember_37c8cfcb-1bc7-4d19-aa65-63d55b343cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8943820a-cf95-4858-9da5-4860d4552c9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_69249f60-b00a-4ce1-9222-edb07f27165c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8943820a-cf95-4858-9da5-4860d4552c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3494dbb7-7809-479f-991d-8b95a72681d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8943820a-cf95-4858-9da5-4860d4552c9b" xlink:to="loc_srt_DirectorMember_3494dbb7-7809-479f-991d-8b95a72681d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3140837-6377-4958-ad09-1b2395b97929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4efcc61f-2ff2-4103-ad73-1d740c5a0a91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3140837-6377-4958-ad09-1b2395b97929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_afca9be7-fa2f-4379-9b47-ea257767706e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3140837-6377-4958-ad09-1b2395b97929" xlink:to="loc_us-gaap_RestrictedStockMember_afca9be7-fa2f-4379-9b47-ea257767706e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6ae93f62-57ad-4a7f-a4e7-e99e6f644470" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ad1c9910-d1c3-4fe0-b0fa-8353316ffe16" xlink:href="cpix-20200630.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_ad1c9910-d1c3-4fe0-b0fa-8353316ffe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_08b8438d-3975-4835-ab28-3a0b8169f47c" xlink:href="cpix-20200630.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8cf695e-c96c-4c09-90cb-257dedb96369" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_08b8438d-3975-4835-ab28-3a0b8169f47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00b3a2c6-e1da-453a-b885-834eed79cbfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e8bc0840-05d1-4272-9b54-17e593072515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00b3a2c6-e1da-453a-b885-834eed79cbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:href="cpix-20200630.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_00b3a2c6-e1da-453a-b885-834eed79cbfe" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53b4234e-9b6e-49af-bc93-063160e9e683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_53b4234e-9b6e-49af-bc93-063160e9e683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_55f6565b-22ee-4b52-8a72-36b9bd83af52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_55f6565b-22ee-4b52-8a72-36b9bd83af52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_aa0e28a9-94de-4fc6-b3b3-38417b6f92a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_aa0e28a9-94de-4fc6-b3b3-38417b6f92a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_6c1b329b-e2d5-43d3-b443-10b4b2363b76" xlink:href="cpix-20200630.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_6c1b329b-e2d5-43d3-b443-10b4b2363b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b41bee03-a21e-429e-b739-84fe7b013919" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b41bee03-a21e-429e-b739-84fe7b013919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57bfe1fc-ce65-4f2f-995d-13a206685c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_57bfe1fc-ce65-4f2f-995d-13a206685c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d02f183a-aef3-4230-803b-d887683d8bb0" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d02f183a-aef3-4230-803b-d887683d8bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_68949bff-5abf-400b-a6d7-3127470a1490" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_68949bff-5abf-400b-a6d7-3127470a1490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_e8687289-c155-4b81-9e92-2e56973c0a5e" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_e8687289-c155-4b81-9e92-2e56973c0a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_14c9d46e-d509-4fac-abfa-6b08284b2e0c" xlink:href="cpix-20200630.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_fe84484a-fca7-43b8-8c39-c0159ec13a06" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_14c9d46e-d509-4fac-abfa-6b08284b2e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_b2f5b8b0-bfc3-4c9c-88f0-5518c1b8bccc" xlink:href="cpix-20200630.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_b2f5b8b0-bfc3-4c9c-88f0-5518c1b8bccc" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ce71e21b-17b7-472f-835a-49efd34ecac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_71f7e7b0-799b-4d0d-a4cd-ff26e8755bb3" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ce71e21b-17b7-472f-835a-49efd34ecac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_4451f1ed-ccfd-40b2-affc-00c8881a39cc" xlink:href="cpix-20200630.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ce71e21b-17b7-472f-835a-49efd34ecac9" xlink:to="loc_cpix_PinnacleBankMember_4451f1ed-ccfd-40b2-affc-00c8881a39cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_048c394c-b67f-473d-9d42-258abda02420" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_51e81cd0-92da-4318-91ec-4bb03b97a2d1" xlink:href="cpix-20200630.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:to="loc_cpix_SecondAmendmentMember_51e81cd0-92da-4318-91ec-4bb03b97a2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d5d672bf-1402-43db-b3e6-fee2eca0491c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14885591-4c4d-436a-9a48-e8b0a48efea4" xlink:to="loc_us-gaap_LineOfCreditMember_d5d672bf-1402-43db-b3e6-fee2eca0491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b3273465-9920-43b6-985f-ae5d5d11ac06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_71f5cc30-d7db-451c-a4eb-3c573dbbb3cb" xlink:to="loc_us-gaap_CreditFacilityDomain_b3273465-9920-43b6-985f-ae5d5d11ac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_31890d7e-d5df-4985-8a88-c5a786ac877a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b3273465-9920-43b6-985f-ae5d5d11ac06" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_31890d7e-d5df-4985-8a88-c5a786ac877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_36911f5c-a355-4e7e-9268-6845d80110c6" xlink:to="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_affd4d66-f25e-4ffc-a538-4795996e15df" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:to="loc_srt_MinimumMember_affd4d66-f25e-4ffc-a538-4795996e15df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c42a9276-6063-4b58-b6b3-b0ce5715f81a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d108327c-5abd-4b93-9a8f-f6964082dab5" xlink:to="loc_srt_MaximumMember_c42a9276-6063-4b58-b6b3-b0ce5715f81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_544f3ae7-07e4-4bc6-b272-663372f0d057" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8368877d-6894-40d8-a5b0-de1d799c9e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8368877d-6894-40d8-a5b0-de1d799c9e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_3785fb24-f3aa-4a95-8f34-0b7763f4d3e1" xlink:href="cpix-20200630.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_3785fb24-f3aa-4a95-8f34-0b7763f4d3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1fd5351a-0af1-4d2d-a2fe-ba5a78ed1e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1fd5351a-0af1-4d2d-a2fe-ba5a78ed1e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_ed3e5c3c-ddec-4eaf-836d-a57337693097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LongTermLineOfCredit_ed3e5c3c-ddec-4eaf-836d-a57337693097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_a92eb21e-935e-4f0d-94a0-42389622cd1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_a92eb21e-935e-4f0d-94a0-42389622cd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b43ee10c-5970-4b60-aeb8-28a56f4e34ea" xlink:href="cpix-20200630.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_f61fd2ec-e186-4d0e-8eda-73ce77a26e8c" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_b43ee10c-5970-4b60-aeb8-28a56f4e34ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef7aa40-3a85-4b77-8175-702a26a10327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0065ae04-a5a3-46e8-b9b7-0c02f6fd1d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6ef7aa40-3a85-4b77-8175-702a26a10327" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0065ae04-a5a3-46e8-b9b7-0c02f6fd1d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200630.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aeb7ea8b-c01e-4a2a-9177-af7b649f284a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aeb7ea8b-c01e-4a2a-9177-af7b649f284a" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3ada6a95-7a95-4752-8bfc-7ff2fc8ad528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_59fc095b-d7e2-404d-8abc-939b11e60c31" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3ada6a95-7a95-4752-8bfc-7ff2fc8ad528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e85b34fa-de6f-4ab7-8cea-a8957fbc1e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3ada6a95-7a95-4752-8bfc-7ff2fc8ad528" xlink:to="loc_us-gaap_DomesticCountryMember_e85b34fa-de6f-4ab7-8cea-a8957fbc1e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_df71f64a-03bf-479d-b44c-ba0a0fd6aa49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1ca97dac-6ce5-4667-812b-82760e8d05c3" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_df71f64a-03bf-479d-b44c-ba0a0fd6aa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0c9498fe-48f3-429f-a382-81f3a01421e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_df71f64a-03bf-479d-b44c-ba0a0fd6aa49" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0c9498fe-48f3-429f-a382-81f3a01421e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200630.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e1e6bc2-31b6-4ebe-8bb0-5fe1c7f4ca92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_05c348ca-7604-4436-96e0-942a26c8f0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e1e6bc2-31b6-4ebe-8bb0-5fe1c7f4ca92" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_05c348ca-7604-4436-96e0-942a26c8f0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_72741d32-6a02-4616-aa17-115b7602b743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1cd046d8-a48c-49f4-932d-1686ad64f092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_72741d32-6a02-4616-aa17-115b7602b743" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_1cd046d8-a48c-49f4-932d-1686ad64f092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_96121d81-f2f6-4551-a178-eb3614e6ab9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3ec82a2c-6d90-4d01-adbc-8ef6bd49db82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_96121d81-f2f6-4551-a178-eb3614e6ab9b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_3ec82a2c-6d90-4d01-adbc-8ef6bd49db82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c5c997d0-bb70-477e-b94e-a21236d0ce90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_96121d81-f2f6-4551-a178-eb3614e6ab9b" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c5c997d0-bb70-477e-b94e-a21236d0ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_ec7065f7-e000-4476-975d-ae5d7a36aaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_96121d81-f2f6-4551-a178-eb3614e6ab9b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_ec7065f7-e000-4476-975d-ae5d7a36aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_55b76c23-e67c-4bc0-9cd3-3dfe5e21574d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_55b76c23-e67c-4bc0-9cd3-3dfe5e21574d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f5c39804-3423-4ef7-a242-8a3eed9c4974" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_f365f5d1-3b87-42e7-ac83-ce3ab71c6eea" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:to="loc_cpix_VIBATIVMember_f365f5d1-3b87-42e7-ac83-ce3ab71c6eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_2ce59de2-aa1a-47f3-9c9c-ae7c2853d027" xlink:href="cpix-20200630.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_920242de-46ab-40a3-83bf-487103c5ad1b" xlink:to="loc_cpix_MethotrexateMember_2ce59de2-aa1a-47f3-9c9c-ae7c2853d027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8218aabc-bc73-44f7-b17c-312fe6e130dc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_84fb2d2e-8cb3-4724-8cc9-fd17fdf5a18c" xlink:href="cpix-20200630.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_84fb2d2e-8cb3-4724-8cc9-fd17fdf5a18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_c38bd25b-1ea8-4af9-91c9-3c5c19a84c7b" xlink:href="cpix-20200630.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33a5a074-1297-4334-b168-5917cb644d09" xlink:to="loc_cpix_NordicGroupBVMember_c38bd25b-1ea8-4af9-91c9-3c5c19a84c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c464403a-dd35-46b6-bb96-2ac19062c72b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_cee24cab-c332-4641-ae57-ff394c21f2fe" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c464403a-dd35-46b6-bb96-2ac19062c72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c3f5bdb0-12cf-4274-bbc8-0c0f3220b281" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c464403a-dd35-46b6-bb96-2ac19062c72b" xlink:to="loc_srt_ScenarioForecastMember_c3f5bdb0-12cf-4274-bbc8-0c0f3220b281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10c47009-bffb-4e5a-9709-9ca8a7b3f216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_feb0c415-8f86-4f81-af81-79c0162722a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10c47009-bffb-4e5a-9709-9ca8a7b3f216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_bae8e9e0-6146-4b8a-8eb9-74d3d0b7af56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10c47009-bffb-4e5a-9709-9ca8a7b3f216" xlink:to="loc_us-gaap_RestrictedStockMember_bae8e9e0-6146-4b8a-8eb9-74d3d0b7af56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a27bd2ad-7e16-4cb1-8127-f0436f84df91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2683dfe3-dc35-42d7-bc49-3dca02bc3898" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a27bd2ad-7e16-4cb1-8127-f0436f84df91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_83df4979-04e0-41ef-896b-461a90c5643c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a27bd2ad-7e16-4cb1-8127-f0436f84df91" xlink:to="loc_us-gaap_SubsequentEventMember_83df4979-04e0-41ef-896b-461a90c5643c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_924337e0-c989-4efa-bad1-be94cab5e7f1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_f14257a5-58e7-4cfe-ac85-ed5efc25f366" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_f14257a5-58e7-4cfe-ac85-ed5efc25f366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_78d20f24-d6c6-48d1-b7b9-be4ab5504c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_d2666656-d3a5-4930-b3e5-d5e3d35cf32d" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_78d20f24-d6c6-48d1-b7b9-be4ab5504c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c383fa7e-5451-4196-ab48-d2021d56bf3c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_620dcf37-0b9f-4709-a013-7d441ea69d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_620dcf37-0b9f-4709-a013-7d441ea69d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_35fb8715-9d17-40ba-8b86-d0a2603a3090" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_35fb8715-9d17-40ba-8b86-d0a2603a3090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_270439c3-dabc-409d-b0fa-de9cacba5a11" xlink:href="cpix-20200630.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_270439c3-dabc-409d-b0fa-de9cacba5a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_12dfe63e-5c01-436e-806a-b8e3237e5598" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_12dfe63e-5c01-436e-806a-b8e3237e5598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8031228b-44d7-4f67-b109-cdbdaa529045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8031228b-44d7-4f67-b109-cdbdaa529045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_61e65f37-c92a-47d4-aa01-255f0c2d0391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_61e65f37-c92a-47d4-aa01-255f0c2d0391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_4c1050e2-9076-46af-9e0c-e1252a774b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_4c1050e2-9076-46af-9e0c-e1252a774b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_4ba227ae-0185-4926-853a-16c08338ff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_4ba227ae-0185-4926-853a-16c08338ff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e574fa77-d245-4360-8321-d7cf79cea363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_Revenues_e574fa77-d245-4360-8321-d7cf79cea363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_94f3da56-f063-46ef-b867-57250005b18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_OperatingExpenses_94f3da56-f063-46ef-b867-57250005b18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ae8ab429-e368-4683-8f29-6196330e6a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ae8ab429-e368-4683-8f29-6196330e6a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_6f739c6c-58dd-4d7a-a2dc-c489819f9ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4b2d68e4-3600-4b7c-8453-7c126b5cd87c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_6f739c6c-58dd-4d7a-a2dc-c489819f9ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_56db5ef9-bd6b-4168-9128-f02d1ecc92f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_56db5ef9-bd6b-4168-9128-f02d1ecc92f6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40323ec1-4d85-4157-9197-e407fccba483" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3a9c62f2-060c-400b-8f0d-0183d74159e1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40323ec1-4d85-4157-9197-e407fccba483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_d8cfe890-ed78-4ae2-b2c3-c5237b19ae86" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_40323ec1-4d85-4157-9197-e407fccba483" xlink:to="loc_cpix_VIBATIVMember_d8cfe890-ed78-4ae2-b2c3-c5237b19ae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0cac1fab-cd53-4fca-9aae-9d6339ad2808" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_5aa8a978-378d-4cd9-a613-07a368a68750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_5aa8a978-378d-4cd9-a613-07a368a68750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_3d1fdb38-e8dc-40d7-acf1-0663a1241c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_3d1fdb38-e8dc-40d7-acf1-0663a1241c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_d499df9a-f4f8-4e5d-a521-0c5168c132e4" xlink:href="cpix-20200630.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_cpix_PaymentsForContingentConsideration_d499df9a-f4f8-4e5d-a521-0c5168c132e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3573b688-6195-404d-9354-e7e386305f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_db31824c-3266-47a6-8048-bde6499f3ce3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3573b688-6195-404d-9354-e7e386305f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_fdb57cea-9904-4e39-846f-cc7056a3b5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_fdb57cea-9904-4e39-846f-cc7056a3b5e8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0a606aa-ea96-4318-9945-c0f8c7dd1fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bad72f9e-cddd-46e9-ad8d-f74b036ab3e4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0a606aa-ea96-4318-9945-c0f8c7dd1fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_1956b536-322a-4787-8412-2342c66fd8f5" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0a606aa-ea96-4318-9945-c0f8c7dd1fdc" xlink:to="loc_cpix_VIBATIVMember_1956b536-322a-4787-8412-2342c66fd8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29aa8c25-cb21-4829-993d-638cf2a91f55" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_621d3496-2b64-4580-a752-538e900a2452" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_621d3496-2b64-4580-a752-538e900a2452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8bb9050e-c8ae-4598-b1bf-558eeb0144d4" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_8bb9050e-c8ae-4598-b1bf-558eeb0144d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_aa836224-c510-4247-b227-fddb02c1b23a" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_aa836224-c510-4247-b227-fddb02c1b23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_f2babad2-aa74-4861-ad63-80b0132d7c9d" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_f2babad2-aa74-4861-ad63-80b0132d7c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_019d54d7-f548-49ec-bf06-5da0dfea216d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_019d54d7-f548-49ec-bf06-5da0dfea216d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c496da0c-b2a4-4ed1-93be-1deaa2f4eb64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c496da0c-b2a4-4ed1-93be-1deaa2f4eb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80ed69fc-9f6d-41a1-95f7-da652aa1d629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_Goodwill_80ed69fc-9f6d-41a1-95f7-da652aa1d629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_a6b024e8-8104-4a27-a7e0-2419f98a7ebe" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_a6b024e8-8104-4a27-a7e0-2419f98a7ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_68c39855-d31e-4623-b34f-8e6b563be67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e5796db3-79e9-45a2-99ea-f02a88fd8d64" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_68c39855-d31e-4623-b34f-8e6b563be67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200630.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_44ff7553-34b4-4f9d-b4f1-600ec154d894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_44ff7553-34b4-4f9d-b4f1-600ec154d894" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25c12f38-95ee-4c9a-9b6d-d96538508433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5e02178-2b1a-44f4-bc49-7d1ecbbdaa98" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25c12f38-95ee-4c9a-9b6d-d96538508433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_5b293211-1e50-4a83-930e-1fb93d205a16" xlink:href="cpix-20200630.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_25c12f38-95ee-4c9a-9b6d-d96538508433" xlink:to="loc_cpix_VIBATIVMember_5b293211-1e50-4a83-930e-1fb93d205a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_00e30228-c692-4627-b762-79defb94777b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0af53947-af82-4056-b965-4b21112a7432" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_00e30228-c692-4627-b762-79defb94777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_00e30228-c692-4627-b762-79defb94777b" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4081302d-bc38-4b25-b81c-4e988d27013d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4081302d-bc38-4b25-b81c-4e988d27013d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_7271b560-0892-4a02-b4d3-52a7030d761a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_PaymentsForRoyalties_7271b560-0892-4a02-b4d3-52a7030d761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cba67ce0-6122-4d1f-aada-a0b14819f006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cba67ce0-6122-4d1f-aada-a0b14819f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b43c95f8-ee52-4fcd-88ac-bc515e004a05" xlink:href="cpix-20200630.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_b43c95f8-ee52-4fcd-88ac-bc515e004a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_42f474c3-3981-424f-9a22-271c65ec3838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_847b9740-82ce-45b4-acec-b742db77391f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_42f474c3-3981-424f-9a22-271c65ec3838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exhibit103-form147_716ba001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
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M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%96J^)]"T.=(-5U2VLY
M9%WJDKX)7.,_I0!JT5SG_"PO!_\ T,5A_P!_:/\ A87@_P#Z&*P_[^T ='17
M.?\ "PO!_P#T,5A_W]H_X6%X/_Z&*P_[^T ='17.?\+"\'_]#%8?]_:/^%A>
M#_\ H8K#_O[0!T=%<Y_PL+P?_P!#%8?]_:/^%A>#_P#H8K#_ +^T ='17.?\
M+"\'_P#0Q6'_ ']H_P"%A>#_ /H8K#_O[0!T=%<Y_P +"\'_ /0Q6'_?VC_A
M87@__H8K#_O[0!T=%<Y_PL+P?_T,5A_W]H_X6%X/_P"ABL/^_M '1T5SG_"P
MO!__ $,5A_W]H_X6%X/_ .ABL/\ O[0!T=%<Y_PL+P?_ -#%8?\ ?VC_ (6%
MX/\ ^ABL/^_M '1T5SG_  L+P?\ ]#%8?]_:/^%A>#_^ABL/^_M '1T5SG_"
MPO!__0Q6'_?VC_A87@__ *&*P_[^T ='17.?\+"\'_\ 0Q6'_?VC_A87@_\
MZ&*P_P"_M '1T5SG_"PO!_\ T,5A_P!_:/\ A87@_P#Z&*P_[^T ='17.?\
M"PO!_P#T,5A_W]H_X6%X/_Z&*P_[^T ='17.?\+"\'_]#%8?]_:/^%A>#_\
MH8K#_O[0!T=%<Y_PL+P?_P!#%8?]_:/^%A>#_P#H8K#_ +^T ='17.?\+"\'
M_P#0Q6'_ ']H_P"%A>#_ /H8K#_O[0!T=%<Y_P +"\'_ /0Q6'_?VC_A87@_
M_H8K#_O[0!T=%<Y_PL+P?_T,5A_W]H_X6%X/_P"ABL/^_M '1T5SG_"PO!__
M $,5A_W]H_X6%X/_ .ABL/\ O[0!T=%<Y_PL+P?_ -#%8?\ ?VC_ (6%X/\
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M*0?_ !%'_"W?'?\ T'?_ "4@_P#B*X_;\H]/6F[: .R_X6[X[_Z#O_DI!_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*!VH ^0;NWDMKF2"5=KQL58?2H,5Z9\8O"_]EZV-5MHPL%W]X <!J\U/Y$4
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M+%<VL N',@&PQDX# @G]<5':>)8+R6P\NQO%@U+)M;ED7RW&PN#PVY<JI(R
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M':V[@="3CGZ4ZY\9Z=;ZS<Z.MM?SWMO")3%%;$EP3CY<XS]?N^] &^2%4LQ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M< 4 >>?&R*%_""RN!YJ2C83U'(S7S[7HWQ4\<Q>([M-.L)=UI;MDO_?->=4
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MCGFM>YU*R\0:QI=OI5Q'>QVER;FYG@8/'&HC=0-XXW%F'&<X!-=(1D8/2@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;X__ /(#TG_KY?\
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MQAHQU735DMSMN[5O-A8=21V_+-<./CUIN/\ D%W'Z?XT-\==-. VF7&#]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#"J%OK@5;HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \G^/O_(#TG_KY?\ ]!KPU6QS
M7U_J&DZ;JR)'J6GVMZB'*+<0K(%/J-P.*H?\(;X6_P"A:TC_ , 8O_B: /EB
M34+N>$0RW,KQ#^ N=OY4HU&\1PPN9=R+A6WG(%?4W_"&^%O^A:TC_P  8O\
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MKZ[@D:6*XE21NKJY!/XU]4?\(;X6_P"A:TC_ , 8O_B:7_A#?"W_ $+6D?\
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M\(;X6_Z%K2/_  !B_P#B: /E074Z@*)7P#N^\>OK3'D:5B[L68]23R:^KO\
MA#?"W_0M:1_X Q?_ !-'_"&^%O\ H6M(_P# &+_XF@#&^$7_ "3'2/\ MM_Z
M.DKLZ@L[*UT^U2ULK:&UMX\[(H8PB+DY. .!R2?QJ>@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?
MQSX0\3^(M3M[C0_$DFE0QP['B2>1-S;B<X7CH0/PKN** /(?^%8_$'_H?)__
M  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/
MQ!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+
MG_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?
M^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_
M / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8
M_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y
M_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_
M (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__
M  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/
MQ!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+
MG_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?
M^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_
M / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8
M_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y
M_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_
M (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__
M  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/
MQ!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+
MG_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?
M^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_
M / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8
M_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y
M_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_
M (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__
M  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/
MQ!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+
MG_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?
M^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_
M / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8
M_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y
M_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_
M (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__
M  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/
MQ!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+
MG_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?
M^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_
M / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8
M_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y
M_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_
M (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__
M  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/
MQ!_Z'R?_ ,"Y_P#&O7J* /(?^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+
MG_QKUZB@#R'_ (5C\0?^A\G_ / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* /(?
M^%8_$'_H?)__  +G_P :/^%8_$'_ *'R?_P+G_QKUZB@#R'_ (5C\0?^A\G_
M / N?_&C_A6/Q!_Z'R?_ ,"Y_P#&O7J* ,GPMIM_H_ARTL-4OFO[R$,)+AG9
MB^6)'+<]"!^%:U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !163X@7S8[&!F<1SWB)(%<KN7#'
M&1SV%+_PC6D_\\)/_ B3_P"*H U:*RO^$:TG_GA)_P"!$G_Q5'_"-:3_ ,\)
M/_ B3_XJ@#5HK*_X1K2?^>$G_@1)_P#%4?\ "-:3_P \)/\ P(D_^*H U:*R
MO^$:TG_GA)_X$2?_ !5'_"-:3_SPD_\  B3_ .*H U:*RO\ A&M)_P">$G_@
M1)_\51_PC6D_\\)/_ B3_P"*H U:*RO^$:TG_GA)_P"!$G_Q5'_"-:3_ ,\)
M/_ B3_XJ@#5HK*_X1K2?^>$G_@1)_P#%4?\ "-:3_P \)/\ P(D_^*H U:*R
MO^$:TG_GA)_X$2?_ !5'_"-:3_SPD_\  B3_ .*H U:*RO\ A&M)_P">$G_@
M1)_\51_PC6D_\\)/_ B3_P"*H U:*RO^$:TG_GA)_P"!$G_Q5'_"-:3_ ,\)
M/_ B3_XJ@#5HK*_X1K2?^>$G_@1)_P#%4?\ "-:3_P \)/\ P(D_^*H U:*R
MO^$:TG_GA)_X$2?_ !59MKH6GOXCU&W:.4Q1P0,B_:), DR9/WN^!^5 '3T5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%97_"-:3_ ,\)/_ B3_XJC_A&M)_YX2?^!$G_ ,50!JT5
ME?\ "-:3_P \)/\ P(D_^*H_X1K2?^>$G_@1)_\ %4 :M%97_"-:3_SPD_\
M B3_ .*H_P"$:TG_ )X2?^!$G_Q5 &K165_PC6D_\\)/_ B3_P"*H_X1K2?^
M>$G_ ($2?_%4 :M%8VFPI9>(+ZR@+BW2TMY%C:1F 9GF#'DGJ%7\A6S0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 96N?ZS2_\
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MN* .QO?$FA:;<FVO]:T^TG4 F*>Z1& /3@G-6KB^M+2R:^N;F**U1=[3.X"
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M@_[^#_&@"Q15?^T++_G\@_[^#_&C^T++_G\@_P"_@_QH L457_M"R_Y_(/\
MOX/\:/[0LO\ G\@_[^#_ !H L457_M"R_P"?R#_OX/\ &C^T++_G\@_[^#_&
M@"Q15?\ M"R_Y_(/^_@_QH_M"R_Y_(/^_@_QH L457_M"R_Y_(/^_@_QH_M"
MR_Y_(/\ OX/\: +%%5_[0LO^?R#_ +^#_&C^T++_ )_(/^_@_P : +%%5_[0
MLO\ G\@_[^#_ !H_M"R_Y_(/^_@_QH L457_ +0LO^?R#_OX/\:/[0LO^?R#
M_OX/\: +%%5_[0LO^?R#_OX/\:/[0LO^?R#_ +^#_&@"Q15?^T++_G\@_P"_
M@_QH_M"R_P"?R#_OX/\ &@"Q15?^T++_ )_(/^_@_P :/[0LO^?R#_OX/\:
M+%%5_P"T++_G\@_[^#_&C^T++_G\@_[^#_&@"Q15?^T++_G\@_[^#_&C^T++
M_G\@_P"_@_QH L457_M"R_Y_(/\ OX/\:/[0LO\ G\@_[^#_ !H L457_M"R
M_P"?R#_OX/\ &C^T++_G\@_[^#_&@"Q15?\ M"R_Y_(/^_@_QH_M"R_Y_(/^
M_@_QH L457_M"R_Y_(/^_@_QH_M"R_Y_(/\ OX/\: +%%5_[0LO^?R#_ +^#
M_&C^T++_ )_(/^_@_P : +%%5_[0LO\ G\@_[^#_ !H_M"R_Y_(/^_@_QH L
M457_ +0LO^?R#_OX/\:/[0LO^?R#_OX/\: +%%5_[0LO^?R#_OX/\:/[0LO^
M?R#_ +^#_&@"Q15?^T++_G\@_P"_@_QH_M"R_P"?R#_OX/\ &@"Q15?^T++_
M )_(/^_@_P :/[0LO^?R#_OX/\: +%%5_P"T++_G\@_[^#_&C^T++_G\@_[^
M#_&@"E;_ /(VZA_UX6O_ *,N*U:Q[.6.;Q7J#Q2+(OV&U&5.1_K+BMB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$$4<_P#9
ML<L:R(U\@97&0?E;M5O^QM*_Z!EG_P!^%_PJOKG^LTO_ *_T_P#06K5H I?V
M-I7_ $#+/_OPO^%']C:5_P! RS_[\+_A3+O6(K:^%C'!/=77E><T4 &4CS@,
M2Q Y(( SDX.!Q5.?Q;806%G>F"[:*]N?LL0$6&\W<5"E201DJ>OXXH O_P!C
M:5_T#+/_ +\+_A1_8VE?] RS_P"_"_X5%::[:76I/IC++;WR1^;Y$Z;69,XW
M*>0PSQP3BI;G5[*SU.RTV>8)<WV_R$_O[!EOTH /[&TK_H&6?_?A?\*/[&TK
M_H&6?_?A?\*N5FZ3KMOK%Q>0V\%PAL9C!,95  D !*C!.>"#D<4 3?V-I7_0
M,L_^_"_X4?V-I7_0,L_^_"_X5=HH I?V-I7_ $#+/_OPO^%']C:5_P! RS_[
M\+_A5VFNQ1&949R!D*N,G\^* *G]C:5_T#+/_OPO^%']C:5_T#+/_OPO^%0Z
M-X@L->MIYK!G9[:5H9H77;)'(IP5(/0U8TW4$U.T%S'#+$A9E E !RI(/ )[
M@T -_L;2O^@99_\ ?A?\*/[&TK_H&6?_ 'X7_"KM% %+^QM*_P"@99_]^%_P
MH_L;2O\ H&6?_?A?\*NT4 4O[&TK_H&6?_?A?\*/[&TK_H&6?_?A?\*NT4 4
MO[&TK_H&6?\ WX7_  H_L;2O^@99_P#?A?\ "KM% %+^QM*_Z!EG_P!^%_PK
M*M-)TP^*-30Z=:E5MK8@>2N!DRY[5T59%G_R-6J?]>UM_.6@"U_8VE?] RS_
M ._"_P"%']C:5_T#+/\ [\+_ (5=HH I?V-I7_0,L_\ OPO^%']C:5_T#+/_
M +\+_A5VB@"E_8VE?] RS_[\+_A1_8VE?] RS_[\+_A5VB@"E_8VE?\ 0,L_
M^_"_X4?V-I7_ $#+/_OPO^%7:* *7]C:5_T#+/\ [\+_ (4?V-I7_0,L_P#O
MPO\ A5VB@"E_8VE?] RS_P"_"_X4?V-I7_0,L_\ OPO^%7:* *7]C:5_T#+/
M_OPO^%']C:5_T#+/_OPO^%7:* *7]C:5_P! RS_[\+_A1_8VE?\ 0,L_^_"_
MX5=HH I?V-I7_0,L_P#OPO\ A1_8VE?] RS_ ._"_P"%7:* *7]C:5_T#+/_
M +\+_A1_8VE?] RS_P"_"_X5=HH I?V-I7_0,L_^_"_X4?V-I7_0,L_^_"_X
M5=HH I?V-I7_ $#+/_OPO^%']C:5_P! RS_[\+_A5VB@"E_8VE?] RS_ ._"
M_P"%']C:5_T#+/\ [\+_ (5=HH I?V-I7_0,L_\ OPO^%']C:5_T#+/_ +\+
M_A5VB@"E_8VE?] RS_[\+_A1_8VE?] RS_[\+_A5VB@"E_8VE?\ 0,L_^_"_
MX4?V-I7_ $#+/_OPO^%7:* *7]C:5_T#+/\ [\+_ (4?V-I7_0,L_P#OPO\
MA5VB@"E_8VE?] RS_P"_"_X4?V-I7_0,L_\ OPO^%7:* *7]C:5_T#+/_OPO
M^%']C:5_T#+/_OPO^%7:* *7]C:5_P! RS_[\+_A1_8VE?\ 0,L_^_"_X5=H
MH I?V-I7_0,L_P#OPO\ A1_8VE?] RS_ ._"_P"%7:* *7]C:5_T#+/_ +\+
M_A1_8VE?] RS_P"_"_X5=HH I?V-I7_0,L_^_"_X4?V-I7_0,L_^_"_X5=HH
M I?V-I7_ $#+/_OPO^%']C:5_P! RS_[\+_A5VB@"E_8VE?] RS_ ._"_P"%
M']C:5_T#+/\ [\+_ (5=HH I?V-I7_0,L_\ OPO^%']C:5_T#+/_ +\+_A5V
MB@"E_8VE?] RS_[\+_A1_8VE?] RS_[\+_A5VB@"E_8VE?\ 0,L_^_"_X4?V
M-I7_ $#+/_OPO^%7:* *7]C:5_T#+/\ [\+_ (4?V-I7_0,L_P#OPO\ A5VB
M@"E_8VE?] RS_P"_"_X4?V-I7_0,L_\ OPO^%7:* *7]C:5_T#+/_OPO^%']
MC:5_T#+/_OPO^%7:* *7]C:5_P! RS_[\+_A1_8VE?\ 0,L_^_"_X5=HH I?
MV-I7_0,L_P#OPO\ A1_8VE?] RS_ ._"_P"%7:* *7]C:5_T#+/_ +\+_A1_
M8VE?] RS_P"_"_X5=HH I?V-I7_0,L_^_"_X4?V-I7_0,L_^_"_X5=HH I?V
M-I7_ $#+/_OPO^%']C:5_P! RS_[\+_A5VB@"E_8VE?] RS_ ._"_P"%']C:
M5_T#+/\ [\+_ (5=HH I?V-I7_0,L_\ OPO^%']C:5_T#+/_ +\+_A5VB@"E
M_8VE?] RS_[\+_A1_8VE?] RS_[\+_A5VB@"E_8VE?\ 0,L_^_"_X4?V-I7_
M $#+/_OPO^%7:* *7]C:5_T#+/\ [\+_ (4?V-I7_0,L_P#OPO\ A5VB@"E_
M8VE?] RS_P"_"_X4?V-I7_0,L_\ OPO^%7:* *7]C:5_T#+/_OPO^%']C:5_
MT#+/_OPO^%7:* ,:PMX+7Q3J$=O#'"GV&U.V-0HSYEQV%;-95O\ \C;J'_7A
M:_\ HRXK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,K7/]9I?_7^G_H+5JUE:Y_K-+_Z_T_\ 06K5H Y77]&?4M?%WHFKMINO
M6EJF<C?%-"S/M61.XW*W(Y&?I6%J>JW6M>%] GGMXK*\'B.&"01?-'YJS,K,
MOJ"03^?UKN[K2--OIO/N["WGE"A!))$&8*,G&>N.3^=-GT72;FWAM[C2[.:&
M#'E1R0*RQXZ;01@?A0!RV+BR^*MBE[.NHR7=A*L)1/+-FJD%BRC.0QP-Q[C%
M5_$=KJ6K6-YK^GVL4DMG.EQI\IFPVR G("[>0^9._(9?2NTM])TVT$HMM/M8
M1,-L@CA5=X]#@<TZ'3;"VLC8P65O%:D$&!(E6/!Z_*!B@!NEZC;ZOI=KJ-JV
MZ&ZB65#[$9P?>N?\%,/MWBGD<:W+G_OW'71V=A9:=;_9[&T@M8<D^7!&$7)[
MX Q5)O"_AYW=VT'36>0Y=C:1DM]>.: ,I;X:[XMN]->[GBM$T^.>T-O,T1EW
M,P>0,I&0,*!VYSWK AUJ^U+P];&[O[@7ZZ1/<,$F-NFT.52<LO)8A00O3DYQ
MQ7>SZ1IERD*3Z?:RI;KMA5X5(C&,87C@8XP*6?2M-NIH9KC3[6:2 $1/)"K&
M,'LI(X_"@#C["2YUS6=*AN-4O5BN_#PN)EM[@QYDW1C<-O0\GD8].F0=[P1?
M7.I>"]*N[N5I9Y+==\C=6(XR??BKT>A:/"Z/%I5DC1Q^4C+;H"J?W1QP/:I[
M6QL[&V%K9VD%O ,XBBC")SUX'% '$MIEWIJ-XKT*(RW45S<I?6B?\OL(GDZ?
M]-%ZJ?P]JGMM3@OM/T)(+JX4:@;J>*%)3 )4!)W.X^90H8' Y)(XXR.PM;*T
ML8C%9VL-M&6+%(8P@)/4X'>HI])TVY6%+C3[698',D0DA5A&WJN1P?<4 <-H
M]]>ZK#X/$^JW9^UQW,=SY4Y7S=BG&XCG/3GKWZ\TR.:^M=*BO!JVH22V7B+[
M#'YERS!X/M/EE7'\9VGJV3P,$5W2:)I$<D4D>EV:/ S-$RVZ QEN25..">^*
M:= T8PF$Z18F(R>:4^S)M+_WL8Z^] '*PWESJU[=S?V^MA=:?JS1- 6<YC5]
MJ(8]P#!UP0<$Y;CI7=52.CZ8VI+J3:=:F]4;5N3"OF =,;L9Z5=H **** "B
MBB@ K(L_^1JU3_KVMOYRUKUD6?\ R-6J?]>UM_.6@#7HHHH YM/&UHT%Y<-I
MFII!82M%=2^4K"%E +9"L2< @\ UT$$\5U;QW$$BR12H'1U.0RD9!'X5PNBZ
M9J&K#Q79PZE':6EQJ\\4H%MOEP8XPVURV!P<?=.*=>VEJ=2NM%L[5!'H^EPI
MYMW>.@C3#[6C51][ ^9\CHHH [RBO-X-2;3K'PMXRU"662*>S$%^VYB-[1Y2
M3;G&<J5/^^*LZ7ICIXIL](U4/]GDTQ[W[.TK%'N&E^<=?F\M2J@=@<]>: .M
MFUJ.#Q#;:-);3![J&26*;Y=A";=PZY!^8=JTJX"33-/NO$WARRBO+B\LE@U'
MYFF8EAYD?R;NI53\HYZ*.M9EC-J,VKV.A\7.GQ7FHQQ175V\:RF.7"(SA6+;
M5)(4]<>U 'J59NJ:RFE7-A#+;32+?7 MUD0KM1R"1N!(/8] >E<4AU"*_P!.
MT>]O4.F3:S-%*L%S(XB AWI;M(RJ2-_;Z+VQ5KQ#;6^GRV46C2>?*NNP?Z-)
M*WE0.8F^4'!V@C#$#/7IS0!WM<]_PF$'VF_@&E:FQTY@MR5B1MF5W X#9/RD
M'@&H?!1AFM;J:99$U=9F348I)"?+ESG"C. A&"N.H/<YK.T^TU*\\6^+X;+4
M8K.-YX%<FV,C\VZ<J=P _$&@#L+&]MM2L8;VSE6:WN$$D<B]&4]*L5PEQX;L
M=.\1^&-$MWN%LA8W22H)V7S@@BV[L$=V)XQU].*Q;6-K#X8C5[>29==@NS&F
M9W9Q*+C8(,$\KMXVGMS[T >F6NH6MY-=0V\H>2TE\J88(V/M#8YZ\,#QZU9K
MR?5E32[G67MF%O)/XBM[5G:Y:+$3Q1EQN&2,C.2 2 2>U7]>.LZ#:ZR]E+;V
M"&PC9K6TNI)FA_>A6F7<BA/W9?IW3/8T >@WU];:;8SWUY+Y5O;H9)'()VJ.
MIP.:!=JUZ+40S',7FB7RSY>,XQN_O=\>E<3XTT;1K;PYJ?V2:193I$[BW29F
M251M(E89Y8'@,>NX]>V1XIN5TC6&AT2[>!?[, O##.Q,(:XMPS=3M81OG/4!
MLT >JT5PNK6\5AXB73=-+BTN=)N);N%96*J4*^5)UX8DD9[]\XJMHD)LO^$%
MO8[BX:?4K?9=O).S><#:EP""<<,HQ0!UNM>((=#DM$FL[J<WDP@B,"J09""0
MIRPZ@'VXI^FZ]:ZC>SV'ESVU[;JKR6]PFUPC9PPP2&'!&036-X]69O\ A'%M
MY$CE.MP['="Z@[).H!&?S%0ZYX=:#2]?UV_O6NM0?2WBC>)#"D*(K.H4!B<[
MN<DF@#LJ*\ZT[2+=O%>B0WC3R0W6BF9C+<.1=3@IG<"<'"L2!V_ 55L[JXO-
M;L=&NKF9]#_MF]@C9I6Q*(XU,<1?.64.9  3SL YQ0!Z?17E6J6\0?Q&;6\N
M<VNK6,$$BW#DPJQA#JISV)88_"M*\TZQCUG7;/3[4(;.TCFGFO+^4>665B&B
M')!P.7R.0* /0Z*\\L(SKVH>$Y+^:9_M^B22W:K,R"=@(<;@".[$U5M;=[;P
M_9:H+N[>[M=>%I%(]PYQ +KRO+(S@C;Z\T =UKFNPZ!;17%Q;7,T<LJQ P*I
MPS$*H.2.I(%:,;F2)7*,A8 E6QE?8X[US7C\@>'[<G@?VE9_^CTJ+QQJJ0)H
MU@MX88]0U**&X:-RI,/.X;A]T$[%/(X8T =917G.NWT>A:UJUA;I.^F-96S2
M017#1K#<//L4;^?+5EP6QV&<<U8B2:WUW6]'E$,5N=(6Y-O;3.R1R!G 89P5
M) &<8S@&@#OJ*\]T: V+^!KR.XN&GU&#9=O),S><#;%QD$XX91CTKT*@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,JW_Y&W4/^O"U_P#1EQ6K65;_ /(VZA_UX6O_ *,N*U:
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M+I&F373W<NG6DEPZ;'F:!2[+C&"<9(QQBG6FF6%A$\-E8VUM&_WDAB5 W;D
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MJG_@INO_ (W0!KT5D?\ "2V'_/OJG_@INO\ XW1_PDMA_P ^^J?^"FZ_^-T
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MH UZ*R/^$EL/^??5/_!3=?\ QNC_ (26P_Y]]4_\%-U_\;H UZ*R/^$EL/\
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M_A);#_GWU3_P4W7_ ,;H_P"$EL/^??5/_!3=?_&Z ->BLC_A);#_ )]]4_\
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M5/\ P4W7_P ;H UZ*R/^$EL/^??5/_!3=?\ QNC_ (26P_Y]]4_\%-U_\;H
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MH **** "BBB@ HHHH **** "BBB@ HHHH RK?_D;=0_Z\+7_ -&7%:M95O\
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M# I#&C*%9%('(!'% %#P_"MOH-G ES<721QA4GN?]9(HZ$_48K1HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LBS_P"1JU3_ *]K;^<M:]9%G_R-
M6J?]>UM_.6@#7K#UGP]<:IJMIJ-OK$]C):(RQJD4<B@MU;#@\XXSZ9]36Y10
M!PWAGP[K-EI>@:?J1D=+:XENIPVS$6T,(TRO7+/O[_=K>US3[J[UK0+B"+?%
M9WCR3MN V*89%!YZ\L!QZUMT4 <-XF\&:K<6NIS:;J]S)+?W,,KVQBAP0KI@
M!V&<*!D#/;W.=:*VU2TO-6U,V[WUU#:16UF&9$-R44NS=@NYWP>GW/3%='10
M!Q'AVTU26YEDUS0;_P#M#4(FCN=0EF@,<*8)\N-5D)5,\<#)/)]FV.EZW<V7
MA_0;S3'MX]&GB>>],B&.985(C\L!MQ+':3D#'-=S10!PEF=>NO$']J:WX7OY
MGBE*V4:W%OY-HAXWX\S+.1U;''0>Y?:3K<6G:[X=M=,>6/5[F:2&^$B"*))N
M9-X+;LJ2V  <\>]=W10 R*-884B7[J*%&?04^BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RK
M?_D;=0_Z\+7_ -&7%:M95O\ \C;J'_7A:_\ HRXK5H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,K7/]9I?_7^G_H+5JUC>)+:"
M[33K>YB2:)[Y R.N0PVMU%._X13P]_T!+'_P'7_"@#7HK(_X13P]_P! 2Q_\
M!U_PH_X13P]_T!+'_P !U_PH UZ*R/\ A%/#W_0$L?\ P'7_  H_X13P]_T!
M+'_P'7_"@#7HK(_X13P]_P! 2Q_\!U_PH_X13P]_T!+'_P !U_PH UZ*R/\
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M_A0!KT5D?\(IX>_Z EC_ . Z_P"%'_"*>'O^@)8_^ Z_X4 :]%9'_"*>'O\
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M @;[S#JH/0D=P#FM6N+AM[?7;G3]-T.W6#0M%NUF:Z'262,G$<6>H#?>;IU
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M_A);#_GWU3_P4W7_ ,;H UZ*R/\ A);#_GWU3_P4W7_QNC_A);#_ )]]4_\
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MU3_P4W7_ ,;H UZ*R/\ A);#_GWU3_P4W7_QNC_A);#_ )]]4_\ !3=?_&Z
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M7_QN@#7HK(_X26P_Y]]4_P#!3=?_ !NC_A);#_GWU3_P4W7_ ,;H UZ*R/\
MA);#_GWU3_P4W7_QNC_A);#_ )]]4_\ !3=?_&Z ->BLC_A);#_GWU3_ ,%-
MU_\ &Z/^$EL/^??5/_!3=?\ QN@#7HK(_P"$EL/^??5/_!3=?_&Z/^$EL/\
MGWU3_P %-U_\;H UZ*R/^$EL/^??5/\ P4W7_P ;H_X26P_Y]]4_\%-U_P#&
MZ ->BLC_ (26P_Y]]4_\%-U_\;H_X26P_P"??5/_  4W7_QN@#7HK(_X26P_
MY]]4_P#!3=?_ !NC_A);#_GWU3_P4W7_ ,;H =;_ /(VZA_UX6O_ *,N*U:P
M]+O(K[Q-J$T*3JOV&U&)X'A;_67'\+@']*W* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#*US_6:7_U_I_Z"U:M96N?ZS2_^O\
M3_T%JU: "BLRZUVWM-<M-'DAG-Q>*SPE5!4JN-Q)SQC(_/C-:= !13$ECD9U
M1U9HVVN ?NG .#^!!_&GT %%%% !13%D1W=%=69#A@#RIQGG\#65=>)+>UUH
MZ0;.\ENA;FY"Q1A@8P=I8<^O&.OM0!L453TK5K+6]/CO]/F\V!R0#M*D$'!!
M!Y!![&K,DJ0IOD=44$#+' Y.!0 ^BBB@ HHHH **** "BBB@ HHHH *R+/\
MY&K5/^O:V_G+6O619_\ (U:I_P!>UM_.6@#7HHHH **P[3Q7I^H>)Y=!LRTT
MD,#RRSJ/W:LKJI0'NPW<XZ=.M6]:UB/1K2.5H9+B:>98+>"+&Z61NB@G '0D
MD] #0!HT5SG_  EZQV=Z;G3IH+^SFA@>S+J2S2L%B(8'&UBW7M@\<5-#XG6:
MUB_T-EO9+TV1M?,!PZGYSN'50H+9QT]Z -VBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#*M_^1MU#_KPM?_1EQ6K65;_\C;J'_7A:_P#HRXK5H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,K7/]9I?_ %_I_P"@
MM6K65KG^LTO_ *_T_P#06K5H Y36,'XE>'!G!^QWG_M.L2VGOHK2TU#^UK^2
M5/$CV6'N&*-"9VCVE>C<="<D=L5W<NEZ=/>)>S6%M)=1\).\*EU^C$9%0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH RK?_ )&W4/\ KPM?_1EQ6K65;_\
M(VZA_P!>%K_Z,N*U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#&\1SI;)ITT@D94OD)$<;2-]UNBJ"3^ J3_A(['_GAJ?_ (*K
MG_XW1KG^LTO_ *_T_P#06K5H RO^$CL?^>&I_P#@JN?_ (W1_P )'8_\\-3_
M /!5<_\ QNM6B@#*_P"$CL?^>&I_^"JY_P#C='_"1V/_ #PU/_P57/\ \;K5
MHH RO^$CL?\ GAJ?_@JN?_C='_"1V/\ SPU/_P %5S_\;K5HH RO^$CL?^>&
MI_\ @JN?_C='_"1V/_/#4_\ P57/_P ;K5HH RO^$CL?^>&I_P#@JN?_ (W1
M_P )'8_\\-3_ /!5<_\ QNM6B@#*_P"$CL?^>&I_^"JY_P#C='_"1V/_ #PU
M/_P57/\ \;K5HH RO^$CL?\ GAJ?_@JN?_C='_"1V/\ SPU/_P %5S_\;K5H
MH RO^$CL?^>&I_\ @JN?_C='_"1V/_/#4_\ P57/_P ;K5HH RO^$CL?^>&I
M_P#@JN?_ (W1_P )'8_\\-3_ /!5<_\ QNM6B@#*_P"$CL?^>&I_^"JY_P#C
M='_"1V/_ #PU/_P57/\ \;K5HH RO^$CL?\ GAJ?_@JN?_C=9=IK]F/$VI2&
M'4<-;VX &FW!/!EZC9D=>]=3619_\C5JG_7M;?SEH =_PD=C_P \-3_\%5S_
M /&Z/^$CL?\ GAJ?_@JN?_C=:M% &5_PD=C_ ,\-3_\ !5<__&Z/^$CL?^>&
MI_\ @JN?_C=:M% &5_PD=C_SPU/_ ,%5S_\ &Z/^$CL?^>&I_P#@JN?_ (W6
MK10!E?\ "1V/_/#4_P#P57/_ ,;H_P"$CL?^>&I_^"JY_P#C=:M% &5_PD=C
M_P \-3_\%5S_ /&Z/^$CL?\ GAJ?_@JN?_C=:M% &5_PD=C_ ,\-3_\ !5<_
M_&Z/^$CL?^>&I_\ @JN?_C=:M% &5_PD=C_SPU/_ ,%5S_\ &Z/^$CL?^>&I
M_P#@JN?_ (W6K10!E?\ "1V/_/#4_P#P57/_ ,;H_P"$CL?^>&I_^"JY_P#C
M=:M% &5_PD=C_P \-3_\%5S_ /&Z/^$CL?\ GAJ?_@JN?_C=:M% &5_PD=C_
M ,\-3_\ !5<__&Z/^$CL?^>&I_\ @JN?_C=:M% &5_PD=C_SPU/_ ,%5S_\
M&Z/^$CL?^>&I_P#@JN?_ (W6K10!E?\ "1V/_/#4_P#P57/_ ,;H_P"$CL?^
M>&I_^"JY_P#C=:M% &5_PD=C_P \-3_\%5S_ /&Z/^$CL?\ GAJ?_@JN?_C=
M:M% &5_PD=C_ ,\-3_\ !5<__&Z/^$CL?^>&I_\ @JN?_C=:M% &5_PD=C_S
MPU/_ ,%5S_\ &Z/^$CL?^>&I_P#@JN?_ (W6K10!E?\ "1V/_/#4_P#P57/_
M ,;H_P"$CL?^>&I_^"JY_P#C=:M% &5_PD=C_P \-3_\%5S_ /&Z/^$CL?\
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M ,\-3_\ !5<__&Z/^$CL?^>&I_\ @JN?_C=:M% &5_PD=C_SPU/_ ,%5S_\
M&Z/^$CL?^>&I_P#@JN?_ (W6K10!E?\ "1V/_/#4_P#P57/_ ,;H_P"$CL?^
M>&I_^"JY_P#C=:M% &5_PD=C_P \-3_\%5S_ /&Z/^$CL?\ GAJ?_@JN?_C=
M:M% &5_PD=C_ ,\-3_\ !5<__&Z/^$CL?^>&I_\ @JN?_C=:M% &5_PD=C_S
MPU/_ ,%5S_\ &Z/^$CL?^>&I_P#@JN?_ (W6K10!E?\ "1V/_/#4_P#P57/_
M ,;H_P"$CL?^>&I_^"JY_P#C=:M% &5_PD=C_P \-3_\%5S_ /&Z/^$CL?\
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M3WJQ+XOU:V\/^))FDL+R?1T5H;RV0B&8LN=I7<?F7N W<4 =U17,:?+KLE[
M)O%&C7,98%X8;/:[CN ?-.#^!JC9:MX@U-]4GCU[2;&*SOY[9(;BS+?+&Q +
M-YJ]O:@#M:*X[2/%U]JG_"+N\$,0U;[2+@*"0?*4X9"?X21D9[$5TFLZG#HN
MC7>IS\QVL32$=V(' 'N3@?C0!=HKF- U_4[G1=235HX8M8TS=YZ1J0ARF]&
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M=L?O&SZR>U0Z7X5U.]DT9-2:ZTZ'1M(@@A:WG4,T[(!+R,\*%"^^3CBN\HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH RK?_ )&W4/\ KPM?_1EQ6K65;_\ (VZA_P!>%K_Z,N*U
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*US_
M %FE_P#7^G_H+5JUE:Y_K-+_ .O]/_06K5H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "LBS_Y&K5/^O:V_G+6O619_\C5JG_7M
M;?SEH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,JW_
M .1MU#_KPM?_ $9<5JUE6_\ R-NH?]>%K_Z,N*U: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#&\1W$5JFG3SN$C2^0LQ[?*U2?
M\)-HO_00C_(_X4:Y_K-+_P"O]/\ T%JU: ,K_A)M%_Z"$?Y'_"C_ (2;1?\
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MPDVB_P#00C_(_P"%:M% &5_PDVB_]!"/\C_A1_PDVB_]!"/\C_A6K10!E?\
M"3:+_P!!"/\ (_X4?\)-HO\ T$(_R/\ A6K10!E?\)-HO_00C_(_X4?\)-HO
M_00C_(_X5JT4 97_  DVB_\ 00C_ "/^%'_"3:+_ -!"/\C_ (5JT4 97_"3
M:+_T$(_R/^%'_"3:+_T$(_R/^%:M% &5_P )-HO_ $$(_P C_A1_PDVB_P#0
M0C_(_P"%:M% &5_PDVB_]!"/\C_A1_PDVB_]!"/\C_A6K10!E?\ "3:+_P!!
M"/\ (_X4?\)-HO\ T$(_R/\ A6K10!E?\)-HO_00C_(_X4?\)-HO_00C_(_X
M5JT4 97_  DVB_\ 00C_ "/^%'_"3:+_ -!"/\C_ (5JT4 97_"3:+_T$(_R
M/^%'_"3:+_T$(_R/^%:M% &5_P )-HO_ $$(_P C_A1_PDVB_P#00C_(_P"%
M:M% &5_PDVB_]!"/\C_A1_PDVB_]!"/\C_A6K10!E?\ "3:+_P!!"/\ (_X4
M?\)-HO\ T$(_R/\ A6K10!E?\)-HO_00C_(_X4?\)-HO_00C_(_X5JT4 97_
M  DVB_\ 00C_ "/^%'_"3:+_ -!"/\C_ (5JT4 97_"3:+_T$(_R/^%'_"3:
M+_T$(_R/^%:M% &5_P )-HO_ $$(_P C_A1_PDVB_P#00C_(_P"%:M% &5_P
MDVB_]!"/\C_A1_PDVB_]!"/\C_A6K10!E?\ "3:+_P!!"/\ (_X4?\)-HO\
MT$(_R/\ A6K10!E?\)-HO_00C_(_X4?\)-HO_00C_(_X5JT4 97_  DVB_\
M00C_ "/^%'_"3:+_ -!"/\C_ (5JT4 97_"3:+_T$(_R/^%'_"3:+_T$(_R/
M^%:M% &5_P )-HO_ $$(_P C_A1_PDVB_P#00C_(_P"%:M% &5_PDVB_]!"/
M\C_A1_PDVB_]!"/\C_A6K10!E?\ "3:+_P!!"/\ (_X4?\)-HO\ T$(_R/\
MA6K10!E?\)-HO_00C_(_X4?\)-HO_00C_(_X5JT4 97_  DVB_\ 00C_ "/^
M%'_"3:+_ -!"/\C_ (5JT4 97_"3:+_T$(_R/^%'_"3:+_T$(_R/^%:M% &5
M_P )-HO_ $$(_P C_A1_PDVB_P#00C_(_P"%:M% &'IE[;7_ (GU":UE$L?V
M&U&X>OF7%;E95O\ \C;J'_7A:_\ HRXK5H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,K7/]9I?_7^G_H+5JUE:Y_K-+_Z_T_\
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M%2V1@GC<:VO#.H?\) 6UU/M$5N\*0QP2.V PYD)7ID,=F<9_=GUH Z&BBB@
MK(L_^1JU3_KVMOYRUKUD6?\ R-6J?]>UM_.6@#7HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH RK?_D;=0_Z\+7_ -&7%:M95O\ \C;J'_7A:_\ HRXK5H ****
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MBB@ HHHH **** "BBB@ HHHH **** ,K7/\ 6:7_ -?Z?^@M6K65KG^LTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &5;_ /(VZA_UX6O_ *,N*U:RK?\ Y&W4/^O"U_\ 1EQ6
MK0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 96N?
MZS2_^O\ 3_T%JU:RM<_UFE_]?Z?^@M6K0 4444 %%%% !1110 4444 %%%%
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M^*K7HH R/[>;_H#:I_WX'_Q5']O-_P! ;5/^_ _^*K7HH R/[>;_ * VJ?\
M?@?_ !5']O-_T!M4_P"_ _\ BJUZ* ,C^WF_Z VJ?]^!_P#%4?V\W_0&U3_O
MP/\ XJM>B@#(_MYO^@-JG_?@?_%4?V\W_0&U3_OP/_BJUZ* ,C^WF_Z VJ?]
M^!_\51_;S?\ 0&U3_OP/_BJUZ* ,C^WF_P"@-JG_ 'X'_P 55&WU&>+6[V];
M1]2\NXAA10(1D%"^<\_[0KI:* ,C^WF_Z VJ?]^!_P#%4?V\W_0&U3_OP/\
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M^*K7HH R/[>;_H#:I_WX'_Q5']O-_P! ;5/^_ _^*K7HH R/[>;_ * VJ?\
M?@?_ !5']O-_T!M4_P"_ _\ BJUZ* ,C^WF_Z VJ?]^!_P#%4?V\W_0&U3_O
MP/\ XJM>B@#(_MYO^@-JG_?@?_%4?V\W_0&U3_OP/_BJUZ* ,C^WF_Z VJ?]
M^!_\51_;S?\ 0&U3_OP/_BJUZ* ,C^WF_P"@-JG_ 'X'_P 51_;S?] ;5/\
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MU3_OP/\ XJM>B@#(_MYO^@-JG_?@?_%4?V\W_0&U3_OP/_BJUZ* ,C^WF_Z
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M?] ;5/\ OP/_ (JM>B@#(_MYO^@-JG_?@?\ Q5']O-_T!M4_[\#_ .*K7HH
MR/[>;_H#:I_WX'_Q5']O-_T!M4_[\#_XJM>B@#(_MYO^@-JG_?@?_%4?V\W_
M $!M4_[\#_XJM>B@#*TY9;C5;K4V@D@CFMX85CF7:X*-*22.F/W@QSV-:M%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!HW=[<#[T#\?(N?F!P,G(/(% &G%XB-Y:37^G6$MY90LZ^:C@-+M)#&-3]X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HA;P";SA#'YO]
M_:-WYU+10 U41"Q1%7<<M@8R?4TZBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#[4 3T45%/<06L1FN)HX8QU>1@H'XF@"6BHH+B"ZB$MO-'-&>CQL&!_$5+0
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M<6=Q%<0L2!)$X921P1D>] $]%%% !1110 4444 %%%% !1110 4444 %%%%
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M(S P1.3DLJX]23@D@'G%,A\'6D%E86B7]\8]/NS=PDF/.\EB<G9R/G;\_I@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#92!,;CM(SGMCO6'!+K>B-/;:#!*UA-*\L<5[ITQ:V9R68*5/S+DD@'&,]:
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M+G_6Q-NRI]N>@YZ@Z5E_: OKU;J1'M0R_9B(RK#CY@>3NYP<\=3Z4 7J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM]*G?QW*1 \\,,4MN=PRDHB^\GHV['(YR<5=OMK>(=:N-.CB;4[O08Y-/E1
M7DEQ,"R,!UY49^E 'H8(.<$''6C<,9R,>M>9G_A&K_0M6U+3+RY>0Z/+#<0-
M$D:1D#*B0!%_>!N!SGK4UPFE:1IOAZ]8"#2+N/-_<Q(LBF;RU$;29# CAQDC
M@XH ]&R!SFH!?6QU#[ )5-R(O.,8/(3. 3]3_(UP%W:6=CINGC2-2AFBB6ZD
MM[;6%7R+J)BA94.!MQT0XZ$]5-7-&6R_X3FQNI=/%F]UH-N8(Y8\R*X9MRYQ
MG<JE03UQ0!W1( R3@45RVN311>,]/76!'_8\EG*L9G \H7.Y?O9XR4R!G_:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,J71GD\30:U]JQY-L]L(?+R"K,K$YSURHK5HHH **** ,O7-&?65LE6
MZ^S_ &2[CNA^[W;V0Y /(X]?Z5ITM% !1110 5EZ[H[:S#:1K=?9_LUW%= ^
M7NW-&VY0>1QD<UJ44 (.G-+110 4444 %%%% !1110 5#]FC^U_:3EI A123
M]U202!]2!GZ"IJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K+UO1VU@606Z\C['=I=#]WNWLG0'D<<\]ZU** "BBB@ HHHH *
M*** ,[3M*DL[F>YNM0GOIY251YE1?*CR2$4* ._)ZG ]!6C110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/H^F:A?WFDS+'81K*VV13YBG.=I]1CD''6N<\17EA/;^$8(-3#QQZJD2W2R
M&39&Z%P>XW<9]:O>-[5-+^'&O))>R3>=&[*\[ L2V,+GC/3CVH T]0\60:/<
MZ;'J=LUO#J)VK<!PR1-Q@/TQDD#/(R>M:5QJ$L.JP6$=KYAGBDE$ADP%V%00
M>,_QC]:Q[\:5JMSI>GWDEO/!>V<R^67!\P$)T_\ K>E9V@KJFD^*X-#U,O/;
MV5C.]G?N?];"7BPKG^^F,$]Q@T :VF>*)M6L4NK32)W#W4EOM,B@KLW!F)Z
M97 [G/2C2O%$^KQB:#1YQ"+F2V>0RH=CH2I) YV[AC(SUJE\-[F"7PQ.8YHV
M"7]T6(8' ,S$$_AS1\.;F"70;YHYHW"ZG=LQ5@< RL03^'- %RU\8V<NBWFK
M7<$EK!:7+VVTD.\DBMLPH'7+<#U]JL7.OR::L$VK6+6EK/(L8F$H?RF8X42
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *:$4'(4?E3J* $  S@ 9.3[TM%% !2$ ]0#]:6B@!
M!@#%)L7^Z/RIU% #=B_W1^5*0#P0#2T4 -VK_=''M2D ]0*6B@! JCH ,^U
M51T &?:EHH 0*!T 'TIJQ1HS,D:JSG+$#!/UI]% ";0#G SZT%0>H%+10 Q(
MHXRQ1%4L<MM&,GWIP 48  'H*6B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S=:;4D@M3IA ?[9")\I
MNS"7 ?\ 3OVH TJ*X]M=UNVCTK1[@QC6-4O+E%E>/"Q01NQW[1C)V;<>N03G
MON"UU2WO;1DU)[FUW,+E9XXPV-AVE2H7^+&1@_48.0#4HK,M_$.EW5S!;Q7)
MW708V[-&RI-CKL8C#<<\'D<CBN9;6]73P_-<_P!H.9H/$'V/>8T^>'[2(]I&
MW'W3U&#0!W-%9DOB+2X+W[))<$2"=;8D1L465@"J%@-H8@CC/<>HJ"S\4V-W
M<:G$5GA739O*=Y874,=JGC(ZY< #J>H&"* -JBL6;Q=HEM!=37%T\(LY$CN%
MD@D5HB_W,@C(!SP>GO0_BW1DB:1IYP$1Y'7[++N1$.&8KMR%![XY[4 ;5%<_
M+J5RWC/3;:WO-]C=Z=-/Y852I96CVL#C/1SWQ3/#DOB22>V_MEE,9TR)Y1Y0
M4_:2S;O_ !W;D=J .CHK*OO$FEZ??/8SRS&Y2#SS%%;R2,4SC("J<\^GO3+/
MQ7HM_=6EO:W9D:]C+VS^2XCE &XA7(VE@.2N<C!R.* -BBLS_A(=,%]#:&X9
M7GD:*)S$PCD=<[E#XVDC!XSV/H:9:^)](O'"07#N6@-Q&?)<"6,'!9#CYADC
MIGJ/44 :U%8VG^+-%U2XM8+.Z=VO(C+;L8'5)5')VL0 2.XSD>E6K+6;'4)4
MCMGD?S(O.C8Q.J2)D#<K$8(Y'3U!Z4 7Z*S-2\0Z9I,CQWD[*T4/GRA(G?RX
M\XWMM!P,@\GT/H:AOO%>CZ=<36]Q<2F:"$3R)';R2$1G.'&U3E>#DC@8YH V
M:*SH=>TRXU&#3X;@O<7%O]JB B?:\7'S!\;2.1W[BK%KJ%M>VK7-NSM$C,I)
MB93E20< C)Y!Z=: +-%8-IXU\/WUS:P6]\6:\)$#&"14D89RH8KC=Q]W.?:I
M(/%^AW)F\N\;; )/-=X)%1/+.'!8K@$$].OM0!M45DMXFTF-;HS3R0FSA\^9
M)8)%=8_[^TKDKP>0#C'--L?%>BZC>FSMKS]]Y/GJ)(GC#Q]V5F # =R"<4 ;
M%%9'_"4Z0'D5KB1#';FY^:"0;XAU=?E^8#VSU%49O'>D*MF;875R+R>.)&2T
MEV_.NX'.WGY0>!DY'L< '2T5EQ^(]+EBU"59Y NF$B[W6\BF/ W="N3QSQGB
MEUS7(-#\/7.LS132101>9L6-MQXX!&,K[YZ=Z -.BLBZ\4:59(6N9I8]L/GR
M V\F8H\D;W&W*C(/)QT)Z"J,FMR67C&_ANKQCIL.E1787RPVQFD=21M&YLA1
MQSUXH Z6BLV[UZPLH/.G:<#RC,RK;2,Z(.K,H7*CZCL:K7'C#0[=RANI)&%L
MMT!#;R2;H3T<;5.1[CICF@#;HJ&&[M[BRCO89D>VDC$J2@_*4(R#GTQ6?;>)
MM(N]YCNBJK;?:]TL;QAH?^>@+ 97W'MZB@#6HJI9ZG;7TLD4/FAXE5V62%X_
ME;.TC<!G.T]/2HY=9LHKHVS/(9%E2%RD3LJ.V"JLP& 2&!Y/<>HH OT5FMX@
MTQ+V&T:=E>>5H(G,3>6\@SE ^-N[@\9Z@CJ*:/$>E&[BM1<,7F9UB(B?;*R9
MW*K8PQ&#P#V/I0!J45E0^)=)N(;":*Y9H]1=DM6\EP)& )(Z<'"MUQTJE<>,
M-%N+"]\C49X/)BFWW"6<C>04.UCRA&Y20=I^N,4 =%16$/%%G'JT.E%;N9VL
MOM1F6V=@RY4#A5YSDDXX'3J<5:MO$.F7EA9WUO.\EO?2>7;LL$GSMSVVY'W3
MR<#B@#3HK#\5ZV^B:;"\(D\VYNH;=72%GV!Y%5CP",@$X!ZG'!Z4V+6+;2()
MUU#5+B[$?[]G>T8-;Q-]T2;%XQ@\D XZ]": -ZBLBY\4Z/:WPLI+EVG:-)56
M."23<C'"L"JD%<]QP.]6-4UO3M&\C^T)S#]ID\N+]VS;FP3MX!YP#QWQ0!?H
MK&MO%FBW=D;N&[8JMP+8QM"ZRB4]$,9&[/MCIS2_\)5HXAMY3<R!;FY-HG^C
MR9$P.-C#;\ISZXH V**RK_Q)I6F/*MY</%Y+QQR,8'*JS_=&X#'.1WX[U6D\
M::%"ETTD]PILR/M"&SFWQ@C.\KMR$Q_%C'O0!O45G7NNZ=80^;-,S((O.)AB
M:7;'_?.T' Z\^Q]*IW'C/0;8RAKN1_)@2X?R;>23]TV2'&U3E>#R.!WH W:*
MQU\2V<GB"'2(DFD::U^TB9(F,94D!<,!C!R>>@P/6KUYJ-M8M$D[MYDQ(CCC
M0N[X&3A0">!WH M45S6N>++>#0(;[397E^TW45LLB0.QC+2JCY7'##)PK#.1
MC!Z5:FU!O#OAV]U34+NZOX80TZ;K;;*J8R$( '3GD@8'7H30!MT5R4GB9X?$
MUBTDUR+"YTN6<VHM69_,5XP"JA=YX9O;'/2M,ZYI]Y=:*UMJCJFH%WMT2'*W
M2B-FP6*_+@#=U!R,4 ;5%4;76;*\N5MX'D=G5V1O*<(P1@K88C!P2.]8GBS5
M]7T*^LKRP1KRT =[RS"+N,2@9:,XSN&<X)YQVH ZFBL6+4O[1U33)M/U#S-/
MN[66?"*I5]IC Y(R/OG(]NU31>(]*FN(8$N&S<EA YB<),5ZA&(PQP">#R!D
M9H U**Q-+\56&IV,MXJ7$*)</;JLD#AG8.R_*,9)^4\#)'?%7]-U6SU:&26S
ME+B*1HI59"C1N.JLI (/3\Z +E%9DWB+2[><Q2W)4"80-+Y;&-9#C"E\;0>0
M.3U..M,C\3:5+JKZ7'/(UW'+Y+H+>3Y&*[AN.W !'().#VH UJ*S]1US3]*?
MR[J5Q)Y33%(XFD81KC<Q"@X R.:KW'BK1[:=(&N)))9+;[5&D-O)(9(N/F7:
MIW=1T^O:@#8HK*@\2Z1<SV$$%T9'U*(S6I6)RLJ 9)W8P,#J"015VTOK>^$I
MMV=A#*T3EHV7YE."!D#.#QD<4 6**R9O$^D02JCW#G?.;=62!W5I1U0, 03P
M>/8^AH;Q/I"6DUV]RZPP70M)6,$GR2D@!2-N1RRC/3D<T :U%9DOB+2X;W[(
M]R?,^T+;%A&Q196 *H7 VAB".,]QZBH/^$NT/[3/;F[=7MG=)RT$@6(HF]MS
M%<*-O()/.#C- &U16.?%6CK;W<[W$D:64*SSA[>166-@2'VE<D<'D#L:1/%F
MD2_:1'-,[6UO]I9!;29>+^\F5^<=LKF@#9HK&L?$UE>:-9:@8[A&O(!,L @=
MI,;0QPH7) W ;@,<CGD5)_PDFE-80WL-PUQ#/$9HS!$\C%!U;:H)&.G(Z\=:
M -6BH+:]MKRQCOK:=)+:6,2)*#\I4C.:IV_B'3+JXB@BG??/&98-T+J)T'4H
M2,/P0>,\$'I0!IT5R^@:I>>(+^XNTO;BWAM+Z:$VK6N(Y(UR@^9E!#;ANZ\=
M"*9KGBG-CXEMM/-S;7FD6;2B<VYV[PC/CYE*XX'7KDX]: .KHK%TSQ)I]Y']
MG^T2&YBM5GD!@<;TQRZ?+AQGNN12:?KU@NCV,QU":_\ /MS,DPMV+S(N-SE$
M7@<CL.HH VZ*J7+M=:4\UI<M"7BWQ2JH)'&0<,*YGPYXHO=5T:XL=3(LM=M;
M43-L VS1E<K*@(P5/0CL<CCB@#L:*R(-9AM=/LQ>3RSW4ML)F6*$NY&!N;:@
MX&3CI[=:BD\6:=]NTJVMS+<KJB-)%-#$[IL4=<@'G) QVZG'< W**S1X@TPW
MT-GY["2X=HX6,3".1USN57QM)&#QGL?0UI4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <[XET:\N=2TG7-,1);W29'(@=MHFCD7:
MZ@]FQ@C/&15V1KW5[.:U:QGTY)HG1WG>,N-RD#:$9AD$YR3V[YXU:* .-LM#
MU2ZTWPWIM]9_9FT.>.26X$B,DHBC9%V8.[YL@G<!@9]J@?1-8;0+JU&G/YTF
MO?;E7S8^8OM ESG=C.T8QZUW-% '#:QI7B&_N[@MIQE$6JVUU;,EPB(T*-&2
M-N>9/E;);MT/047V@:S<)XAMXK)-]Q?P:A:R2R*89B@A/EL,[N3&1R .E=S1
M0!Q&I:3J&I>'+P6_A:WTV[N'M\PQR0^8^R4.2S@A<  X&<\GI5SQ)8ZUJ-Y+
M#;V1DLKC37B7;.L1CG.?]8<Y*XQ@#(SG(Z$=710!R6EZ9JD6K^'KBXL&CCLM
M*>UG(E1MCGR\#KS_ *L]/45UM%% &!+9WJ^.5U-;-WM%TQH/,5TY<R!L8)!Z
M#KZUB:3H6KV>E^$+>73W\S2IW:ZQ+&0H,<B9'S<\N#QV!KNJ* .(T/1-3L N
MFW/AW3Y&LYF>WU:0HP<9)5MN-X?!P3]3D]#'I6E>((]6TC4KS2W\VWL)[>Z_
MTI"/,)C(**#M5#M. ,>X'4]W10!P^CZ)J]G;>#HIM/<'25D2[(EC.S,10$?-
MR,G/';\JM^%M%U#2M21XX+BPTV2V)EL)IDE2&<LI_<D$E4^]D$@=,#TZVB@#
MCO%FEZYJLNJ6EO9^?:W6EM#;NDZQ!9B'SYG.YAR-HY7KG&<AT>G:M_;%U=R:
M8X271([1<31G]ZK2$C[W^V!GID'ZUU]% '#W.DZA:^$_#9@*6FN:6L%M&)"&
M#;E$4B_*3E<9?_@ /&#796=K%8V<-I""(X4"+DY. ,<^]0G2=/;55U5K.$WR
MQ^4MP4&\+SP#^)_.K3*'0J<X(P<$@_F* //O#NGW6M^$O#]L+-XXK/4!=M<,
MZ;2(Y78!0#NR3@<@<$\],W#X<U:\\(ZSIWD?9;N;4Y;VW\QU*R S^:H)4G&<
M 'T]ZZW3].L]*LUL[& 06Z$[8U)PN>3C/2K5 '$>(["[OH-3UVYLY+%;?0;J
MW\J1T9W9QN/W"1M&WUY)Z<4CZ#=^)K+26>W>P2VTN:'S796+--"(QMVD_*!E
MN<?P\=<=C>6=OJ%I+:748E@F4K(A) 93U!QVIUO;Q6MO';PKMBC4*BY)P!T'
M- ''V.F:G+I$T5WX5L;.^ALY(!<1/$S3L5V_NR,%5/4[B/3!ZB6YTK5!X;\+
M(FGR27&E7-N]Q;K)'NPD3(Q!+;3R0>O3\J["B@#E-1TJ2;QG;26TJ+#?09U*
M'.=PA93&P^I;8<]5^E:7C#3KG5_"&JZ?9H'N+BV=(U) W-C@9/ J[9:3I^G3
MW,]G9PP2W<GF3O&@!E;U)[]3^9JY0!Q'B"P\0:W!J%NNE.L%YI1B@4W"1F.8
MA\B7!^;JN ,J#G/J*VI>'M?NM<CUBTM6@N;/3K=;=6F1HY)HWD)C<;NA5\9[
M'D'CGT"B@#C=0L=5?7X]7/AN+48;RRCM[BTFEBWVSHSD$%OE93O(..> <=JF
MBTF_MO$#SQZ6B6PT9;15MF18UD#,VU5)!"\@ X'X5UE% &%H%EJ%AX&LM/:!
M(M0MK%80DK!E\Q4P,E2<KD?E7/V>CZ[]LCO;K1?-9]$EM)XI[I&#RDJ=N <*
MC8( 7 &>0*[VB@#F_"VDWVDW-W$6NDTLQQ_9;>\E666%OFW*&!/R ;< DGK^
M-74-%U!_$[:EID$]G.;F$2S+,AM[N !=WF1DYW@;E!"YX7G'3KJ* .+T/1+^
MQN1IU[X=L9X[:[::#5G,;$J7+ [<;Q( <9Z=\^MGPG:Z[I5G;:'?:;%Y-@2B
M:AYRL)HQG:53[P8@@'.!U.3TKJZ* .!T_1M>MK;0+)])^72-2DDEF^T1XDC*
MR@.HSG'SC(.#['J+D.CZI_PA/B+3&L'2ZOI+XP(9$^<3,Y4Y#8&-PSGT[UV5
M% '+6EAJ-KXFTV]:P<P?V2+25A(G[EPZM\W/(P#]W//IUI-!TE[;Q)J*),CZ
M9:S&:UC'_+*:90TB_ADD8[3&NGEBCGA>&5%>.12KJPR&!X(-0V&GV>E6<=G8
M6T5M;Q_=CB7:HH RO%ME>W]A9QV-JUP\5_;SN ZKA(Y%<_>(["J3Z;JEGJNO
MO'8F\M]9C1XCYB#R7$?EE'R1\O .5SWX]>KHH Y+0= O=%U^R5H7FM+;18K$
MW6Y<&1&)/RYW8_"I/&TCQ3^&GCA:9AK4>(U(!;]S-TR0/S-=352\TRSU"6WD
MNH?,>V?S(26(V-_>&#UZ\^] '+7.D:U'>WVK6ED=VH:A TUJLB+*+>./82K9
MVAR?0YV]P>C;;P],OAC7[#556P6:\FN[>X,^_P OD.CYZY4J#SSP:[:J=]I.
MGZFT#7]G#<FVD\R'S4#;&]1F@#FKS2M6OO!4*O:^=JEY=6]Y=*K*@4K(CD?,
M1]U$"CZ"GWFE:G+J/BJ9+!RFI:=%!;'S(_F=5D!!^;C_ %@Z^AKKJ* .%&C:
MM97MG=-X>@U6&?38+2XMYI(@]N\>[D%L@J=YS@YXJQ_8NHPZCJS1Z6B0SZ-%
M:0K;M&L?F+YF54$@A?G &0.AKLJ* ./T;2]4L-8T6>;3W,<>BK8SL)$_<R*R
MG)^;D$ XVY[9Q6AJ]A?IXHTS6[.!KN."&6VGMU=5<*Y4AUW$#@H,C(X-=!10
M!Q%SX<U./1YQ!:&6>]UU-2>%9$'DH)$;&20"=J9X[D\]ZZ+Q-8W&J^%-4L;9
M/](NK.6.-&('S,A !/3K6K10!RMG:ZH_B33-2ETJ:&&#2I+>0-+&661FC(&
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M+.YC62"3C@Y;#(V.1STZ5Z!10!0A2]CT&..Z59[U;95E$.%5Y-N&VYP ,YK
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ML4@6-%A5"K Q\_,74C)8<9R/8 ':45P\%_JWV#7=0N/$;6Z:?=W%O%YEM&R
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M .QHJII37;Z7;&_D@DNQ&!,]N28V<<$KGMFK= !1110 4444 %%%% !1110
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M?:V+2M C!YB#([NSN^!@99B2<"K-% %:#3[:WO)[N)7$UQCS29&(;'3@G _
M5'+HVFSPWD,ME$\=^=URA7B4X R?? '/M5VB@#/CT/3H[>X@-N94N8O)F,\C
M2L\>"-I9B3CD\9[GUJK<^#] O(+2&?3PPL@1 PD<.@/4;@=Q!]":VJ* *D6F
M64%XEW%;K'+' +="I("Q@Y"A>G4>E6Z** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%5+75-/OG1+2^MYV>+SE$<H8LF<;ACMD$9]: +=%%%
M!1110 4444 %%0W5W;V-K)=7<\<$$2[GDD8*JCU)-/BECGA2:)@\<BAE8="#
MR#0 ^BBF2RQP1/--(L<: LSN<!1ZDT /HJ&TN[>^M(KNUE6:"90\<B'(8'H1
M4U !3)8HYX7AE0/'(I5E/0@\$4^B@"KIVFV6D6266GVT=M;Q_=C08 JU110
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJW]H6?\ :/\
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MZ\KR)'MY2GFQYSM;UQDX/49ZT <UX,U.YN=)T70;29;9HM$BNGF,>\G<=J@
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MS6\MPKK<6KE[>XB<I)$3P<$=B.H.0>XID&A6\>JC5)YI[N\6$P)),5&Q"02
MJ@#D@<D9H P]+\2ZC>1^$YIFA UBW=[E0F &$1<%3GCGZTS3_$>JS:K9VCSV
MTPOK"><2I"3"DD93_5G(+IA^O?&0:T+7P1I%JUF5>\=+ O\ 9HWN6*QJP*E
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M>./EY&* .EO;^"P6+S2Q>=_+AC09:1L$X ^@)]  2:I0^)=.N((WA,KRRS/
MMN(R)?,3.]2#TQ@Y)..G/(JOXFT[4YKG3-4TA(I[K39V<VTK[%F1T*L V#AN
M<@U7O-.UJ?5=(UXV\)GLS,DMBDN?W4@4?*Y !8% >< Y(SP"0!FLZ_\ :[+3
M+K2KR6(?VQ!:7,>T*W^L"O&X(R#],?B#3K36VL-9\2'4KR22UM+BW2!2H)7S
M(UPBA1SEF 'UZU3N?#6HA&N8H%>>ZUR'498A( (HTVC;GH6(3/ID]>,E]WI7
MB!;W7[G3X5C-[<VTD69@K21HJK(N1G8Q"G![9[&@"]J/C&VM-/DN(;6XEFAO
M8K*:$IAHG=E'//3#@C&<Y'X7+[Q-I^G1/-<^<D,)07$@C)6W+8(#^GW@3C.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JWNFV.I",7MI#<B%Q)&
M)4#;&'1AGH?>K5% "=*6BB@ K/N] T:_O%O+S2;*XN5  FEMU9QCIR1FM"B@
M!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LW6H=0FBM/[/G:)DO(7FVX
M^>(,-Z\^HK2HH X?4[_6?#^C:=)J\MW+9B\G_M&YMES(D6Y_*/R\A,;<D<@
M?2GZG>S1>!-;U?2]?DO(E0SV-PDBL8@$'R$@<_,&^]SSSR*Z74!JBWEM+81P
M30*KBXBED*%L[=I4@'D8/7CFN7G\&7IT7Q+!806EH^N8$=J)2(H/EVER0OWF
M/) &.G-  =>DCUK0+72=7>_EO6'VRU=E=5BV$M)NQE2#CC/.>E:7C75=3T_3
MP=&4/<P#[9,OK!&P+J/=N@]1N]*AU/P]JNN#18+E+.SBTVYBN7FBF:25B@^Z
MH** #W.?PK0M]%:\U"_N]9L[9VE94M]DK/B$#A2"HP=Q8]_O>U $FHRW.KZ%
M:W.B713SY;:99%Q\T)D0OU_V,U-H4.HP6EP-2G::5KR=HRV,K$9&\L<?[.*H
M>#M)U/0M,ETN]%N;:&>0V1BE9V6$L2J-E1R,X[UT- '.-XWTU$:5K6_$$=Y]
MCEF^SG;%)N"C/.<$D#@'WQD59A\56$@OQ/'<6CZ>4$L=Q'M8A^(RN"<[CP.^
M>,"L6;PSK,FB:E9!+,2W6L+?1DSMM$8E23!^3[WR8].>M/U;PMJNIW^MSQR6
ML'VR*T:U<N7VRV[LXWKM^Z2<<$\#I0!IIXOTYFNXFCN$N;1XD>WVJSL93B/:
M58J03QG/'?%$OC#3K>REN9H;M/(O5LIHO*W/'*Q7&=I((^=3D$]?7BJ<]AXH
MN](.(M.L;KS8BT%M,P6:-6RX,NP,NX<# ./4YXSW\)ZTMIJ%O#!IL:76K6]_
M&B3,H54\HLOW/6/ /?.>.E &]'XLL&CO#+%<6TMG/'!)#.@5RTA CQSC#%A@
MDCOG%:=E>?;$D)MYK=HI#&R3  YP#G@D$<CO7.76@:C<:EK<LUCI]W::G]F7
MR)IF^9$X<'Y.#@Y!&>0.E:?AC2+G1=/FM9IY'A-PSVT4DIE:"(@8CW'DX()]
MLXR<9H YW6_$U]>>&=4NXH;K3FL-4BMU9'7+ 31HP.TDG.YN!ZCDUT,/BFP<
M7_GQW%J]@R"6.>/:Q#_ZLK@G.X\#OG@@5B7OA?6I=*U?3H19,EYJJWL4CS,#
MM\U)""-AP1LQU.<]L<OU7PKJNIW^MSI):P?;8[-K5RY?;+;N7&]=OW22!P3T
MH WM+U^TU6\N[*-)(;JSVF6*3:3M895@5)!!P>A[<XKG]7UY;'Q9/8:Y?76E
M6DT<8TRZC.R%FP=^YL$;\]G^7 ''/._HD>J"-I=4M;&TD("B*S8N#ZL6*CKV
M&./4YX@U&TU*[.H6ESIMEJ6GW!'DQS3%2!L (8;2,;@3D<\]* &KK@TE=,TF
M]6ZOM1FL]^^"+(F9 H<YX&26!].>U,M/&FFW@L'2WO4AOI3 DTD&U$F!(\MN
M<YRI' (SWJEI7A;4=)N?#@$L-Q#I%E-;RN\C!F:39C:,'@;,<GIBH(O#&LQZ
M)IMF4LS+::PU^_[]MI0RO)@'9U^?'3M0!NQ^)K*34(;3RKA5N+B2VBG9 (WE
MC!W*.<_PMR1@[3STKEKC4-1C\,:[,NI77FVNOK#')YGS",S1+L^F&/ JY_PC
M?B"74[&\NOL,TUEJ<D_VAIWWR0LKJJ@;/DVAE&T'!QG(ZE9_#&LRZ%K%BJV8
MFOM6%[$3.VT()$?!^3K\F._7K0!T/B626#PSJ=Q!*\,T%I++'(AP595)!_,5
MR$?B*=+3PRVGZS)>ZE?O +FS=E=71E!E8\90KU!!'I@UV.NVESJ'AZ^LK98_
MM%U;21+YCD*"RD9) )P,^E<Y>^%]8U;PSI6@W"65LEF;<R74<[22+Y6.8QL&
M"<=2> 3UH V;OQ78V5OJT\T-R!H[*+H!5) *A@1SR,$'UJQ+KENE_)9QP3SO
M!+%%,T04B)I,;=P)!QA@<@']#7.Z]X9UJ]/B6VLELS!KD2%99965HF6,(5*A
M3D':#G/&3P:LZEX<O]0UJ/4DA@LKZ*6$I>VUPP)B&TR1R+M&\'Y@,^HZ8Y )
M_P#A)]-T^'5KV1M1D2VOUMYE="WENP0 (.R?,I^I-6X?%.GO_: GCN+1]/V>
M:D\>UB'^X5 )SN(('?/&!6+?^&=:N;'78(DLMVHZE#=PEIV ")Y60WR<']UV
MSU]J=JWA75=4O]:G1[6W%[!:?9G+ERDL#EQN7;]TD@=>@Z4 :B>,-,+W4,JR
MPW%J\2- Y3<QE.V,J0Q4@GCKQWQ5DZ_"K10M:7*W,TKQ1VS; [%1DD9;;C&.
M_>LUM-U?4=(E@U72=(/FE$DLTD+1R*#\S%R@(/=1C@CD\\4E\(7!TI-,O8%U
M"R6XDDA26Z;S[-?E\L1RXR2OS=Q@-C)QR ==:7"WEG!=*DD:S1K($D7#*",X
M([&N9UCQ!>V'BJP92!HRS"PNF[B>50R'Z#"#/_30^E;6DVVH:?X?MK:ZG%]?
M0PA6D=R!(P]6QG\<9/7%8EWX.&I>#[FRN[:W_M:YB=GE65MOGD[MX;&0 V".
M.,8H W[[4X;2XAM DL]U<*S1PP[=Q5<;F^8@ #(Y)ZD5S/AGQ2MOHUHNH&_N
M9[W4+N" M&7?Y))"JMZ':N,>WI4XTKQ)'J>E:VR6,]_!9M9WL/GLJ2*2K;T;
M9P=RY((Z'K5>Q\,ZW!_9?FI9?Z'JUS>R;9V.4D\W 'R=1YGZ4 :*^-].\CSW
ML]0CCCNA:W+/  +:0L% <YZ$L.5SU&>M.G\1:?IU[KMQ*U^YTV"*2YCVDHJD
M.08Q[@')Z<"LV\\,:S<:)KMDB68DU'4UNXB9VP$#1G#?)P?W?;/6I=5\.ZQ?
M/XG,:6BC6+"*V@W3M\C*K@EODZ?/VSTH U8/$]G=75Q:?9[V&6.V^TJ'AP98
MNFY._!XP<'D5!IWB*Q72-.^RB^OC<67VF)7*M.\2XRS9(R?F'3DU&ND:L/$,
M.I>3:>6FE-:,OGMGS"P;/W/N\8SUYZ5E_P#"'7LGAC2]*N[2UDGT^S\N*Z@N
MGCEMY@,!T<*#M/<>PX- &P/%)_MN]LVTZX%M:64=T9AM)(??_"&S_!CIG.<X
M'-/M/%UG>V=O=0V5_P"7=>4+;?!M\XR*6 4DXX"G)) &.^1FF=!UF+4KFX$M
MM=B[TF*TFED=HV\U-_S8"D88OGKQCH:1=%UV#PIH6FPFU,M@(8[R'[0RQW$:
M)MQO"Y )VMC'.,'CJ 2W'C%2=,^Q:?<3?;+Z2SE5MBM"\8?<I!;!;*'H<=>>
MF9X=>TVWN=:EDGO ;2>..9)@2%=E4(L2]?FROU+5C6OA36;.*V,2:?NM=;FO
MXXQ*RH8Y!(,?<^4CS!Q@].M2W_A+4[^?7)A+;0R7=[;7EDV]F >%4 #C;P"4
M[9QGVH UKGQ;864=_P#;(+JWFT^#[3+ R!G,7/SKM)!'!'7C'.*GT[Q'::CJ
M3:>L%U!-Y N(_/BVB6,G&Y>>QP#G!Y%8^L^'-3UL:G>M';V]W=:2^FPQ&8LJ
M[R2S,P7UQ@ =CZ\3_P!F:O;:W#JPBL@MOI#VI5[A@/,RK YV?=RN">O.<4 =
M+(ZQ1M(YPJ L3Z 5BV_BRQGW V]W$?L7VZ,/&,RP_P!Y0"3GD<'!Y'%6[674
M+_P^LCJEG?S0'&,LL;D<'D9(S@X(S7,V7AK7XKV*]FAT_P \Z5)93M]I=VED
M)4B0L4R<D'CL/7I0!MZ9XLL-4N;*".WNX?[0M?M-K)/%M650%) YZ@,/;T)K
M3O[Q-/L)KMU+")"P1>KGLH]R< >YKF]-\/:M:2>%?-2TVZ-9-;7!6=B6)1$!
M7Y.?N9YQUK7UBQNM2NK&#R8)-/67S+H/*59L [  %.<-ANHY44 4?!VJ:A=1
M:AIFLNC:IIMR4F*<!T?YXV'MM./^ U._B[3T: K%<R07-TUI#/'&&1Y5)!4<
MYZJPSC!VGGIFJ?#MWI_C.WU;1X;:.SEMC;WT;RLK/\V491M()'/4C@USNE3R
M QWT=C87VF_VA)=6J0ZEM9&=V 982GW\,?D+=2< 'H ==-XLTR"\A@?S/+GN
M3:)<#:4\[)&S&=WW@5SC&1C-0P^-=.FEA46U\D<MZUCYSP81)@Q4*3G/+# P
M#[XJKI&B:WI5[-9"/3I=--T]Q#=,3YZ*SES&5VX)R2 V[@<X[55'AG6_[,%O
MY=EYHU[^T_\ CX;;Y?G>;MSL^]V]* -Z3Q':)<K&L-S)$UU]D-Q'&&C6;IM/
M.>O!., \$TV#Q/:W%C=W26UT/LEU]DDA95$GFY5< ;L=67'/.>*HZ/I?B#1[
MVYL8S9OI<UW)<QW!D;SHU=R[1[-N"<DX;=T.<'I45M9VNH>.);_3KZ*>S\I)
M+R.)@Z&X7<D9R.,[2V1VV(: .BO]1M]-M1<7)8!G6-$499W8@*H'<DD#_P"M
M67=^)T2RU7R;2=;_ $V RO:R[0V"I*OG=M*\'H>Q'7BI?$^CW&L6%M]CE2.[
MLKN*[@\PD([(?NMCD @D9[51N]!O[^?5M3>."*\O=-%A!#YI*J/G)9F"^K]@
M>%]^ "QX7CN)-+@U6>6_>6YM(S)!/*KJS[<ET&2%W9Z9 ]A6)<>)[S4=(T35
M1%=6*R:QY+Q1L&\V,/(NTA22?N#/OTR*ZS1+:XLM$LK2Z6,36\"1/Y;%E)50
M,@D#T]*YB#PSKD&EZ78;;%ET_5C=[_/8&2+?(W39PWS@8Z<=>: -NW\4V$]I
M/,T<\$D%S]E>WF4+)YI (7KCD$'.<8Y)&#5C1]<M-:%R+</'+:2F&>*3&Y&P
M".A(((((()%<Y>^%M:GFU*Z@:R2=M4CU"S61V9'VQ"(I(-HP" >1GK[5TNCQ
MWZV[2:A;VEM*Y'[BU8LJ >K$ DGZ #CZD R?#]Q=2^,/$MK-=S2V]E+;K;QN
MV1&'B#M]>3WS3GUB+0CK%[?S7<UO#?1P1JH+^6'CB( 'IOD/)]<4Y-+U+2_$
M^I:I90PW=OJ:1&2-Y?+>*2-=H(X(*D8]"".]0ZQH.J:AX?O((_LOVZ^O(;F1
M6E81QA&C^4-M)/RQ 9P,DD\=* )KKQ/83:;K2S1ZA:'3H-UP%CVS+&RDB1,$
M]@Q!ZC;R!3H?$3?V_;:4EG,;9M.^UFYD=.F5 )^;/'.>^>E4M1\/ZO=W/B62
M-+0+K&FI:P[IVRCJL@RWR=/WG;/3WJ0^'=0DU.UF<6_D/I)T^Z E;<F2#N3Y
M?F[CG'K[4 7(/%^ES7L-LS/ +B![B"67:$E10"Q&"2, @X8 XK.FUN:]\7^'
M?LPO8+.\BN'Q)A8YU" JV <YYSAL'GI3+#P[KD^@S:#JHTZ*$6CVHO;7)DG4
MH4!*E1M.#D\G)'I3K+2/$3:AX?FOX+!1I*213/'<,3*&0(&4;..F<$_C0!9\
M9:M/HXT^YD%TND^:PU":U4EXEV_*3CD+NZD<\#Z&O)KK:1X;NM8LKQ]=M9KJ
M,6CB1&\I'V)@GC.')]^1GN:W=0&J+>6TEC'!-;A)!<12R%"V=NTJ0#R,'KQS
M7,R>"KK^RM=2RBM;.34KJ"YALU<^5&8F1CD@<%RIS@8''6@#<O?%-II[2_:+
M:Z5;<1&Y<(I$'F'"[OFY]]N[%1IXG"ZWK%I=6CV]II<,<CW#%2#N#,3@'.,
M8 &>N>U9'B#PYXBUL:E&XL)([B*$VOF3OBU9<%E"[,')!^?@X/3M5C4?"^I:
MC=:XK26T4.KVD*>:KL6AEC#8^7;AER0<Y'3IS0!H?\)CID<MU#<B6VFMHDF,
M<FP[T9MH*E6(^]@<D8)YQ6K97GVP3 VTUNT,GELLP&2=H;(()!&&'?UK!BL-
M>N])GAU/3-%\QD$301LS1W(W#>6)3*C:#@8;DY/2K?A?19]#@NK<R.+1YMUI
M;/,93;IM *[CSC<"0.<"@!UWXIT^S$\LB3&TM9A!<7:J#'"_ P><X!(!(! [
MG@XSK^YO-5\83Z%_I]K;QV"3)/:S*C*[2,/,^]R/DP 0>^14,OA743IFMZ$K
M0-8:K<R3+<%R'A64YD4KCD@[MISW&<8K3M]*OH/&4VIA(!8MI\5HG[TF0%'=
MLD;<8^?'7M0!IZC>#3M.EN2IE:-<(G0R.>%7ZEB!^-8_@_5;VZL+RPU=Q)JF
MEW#P7)08\P?>1P/0J1CZ&KNK6%SJ5_8Q-!!)IT;F6X#RE69@"$PH4@@$YZCD
M#TK.C\/7FF>,QJNDP6J6%Q:B&\B:9E9V5LHX&T@D D<GH: 'Q>.=-EAM)Q::
M@L%Y.]O'*;<X$JLR[" <Y)0XP#[X/%6K?Q5836US+)'<6\MM<"VDMYU"R>8P
M!4#G'(8$'.,<G&#6+;^&=9BT/2K)DLS+9:NU[(1.VTH97? ^3K\^/PZTFH>%
M-9N;O5KR!K..:74(+ZS$CLZL8XQ&4D&T8! /3/7VH TF\<:4D3M)'=+)'>)9
MRPB,.T<CXVYVD@@@@@@G/UXJ2WURSN==A25=1LY_L$LYAN5\N,(LBJ689QN!
MQ@^A/K5*_P!(UW4M.LRUIIMO<17]O<M!',VQ5C8,?GV9+'Z #W[V=4T"[U/Q
M']I;RELI-*GL9")#Y@,C*<@8Q@;?7O0!9C\463L#)!=0PO:M=Q3/%\DD2X)(
MP20<$'# 'GI4VG:];ZC>O9""XM[A8$N DZ@%HW) 88)[J1@X(]*RM/L?%R>'
MWTN>>PMI[>T:"VNX79S*X7:CLI7Y,<$XSD^W!ATO0M;L-9?5?LNGI(^EK;M&
M+EW+3*S,&9R@+;BPR3R,=Z .OHJ. RFWC-PJ+,4'F*ARH;'(!/49J2@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JK%IFGPW;7<5C;1W+YW3+"H<_5L9JU10 4444 %106T%JA2W
M@CA5F+%8T"@D]3QWJ6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHKF?$]Y>:??0W4T-[+I"PL)FL'(DMWSQ(RCEEQ
MGIG'.0: .FHKBS>-)KVF117E]J%I+HK3;K68CS65HP),!AR0Q_/I5G1M>N)?
M \-Y=7D?VV1WMQ))A3&_F%5\P< ,HP6&/X30!U=%8?A#59-4T%/M$RS7=F[6
MMRZG(>1#C=_P(8;_ (%67YL\_B76[-FU-T2>W2%X+@A;?>BY.-W3)SC!'X4
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M4,.#RV A;TR!TQ6C?SW$?B[2(4N)!!-!<&2$8VL5V8/KGDT ;5%%% !1110
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M*]QN18$_AVX_B<JH]@WI0!U]%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP)! (\LXR,9(SP:S8]$UB*PL;9K;S&2^-[),9UW#_26E*2  !OE;C:,!^>,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit103-form147_716ba002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
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M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA"W)M7<VKA4E!P58XXYX]*@\(:K%KL&HZBD$D!>]PT,JX>)UAB5U/N&!%5_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J-EHNF:;(9+*P
M@@8DG*(!C)R<>F3Z5>HH @M[.VM&F:W@CB-Q(992B@;W( +'U. /RJ>BB@ J
MKJ&F6.JV_P!GU"TBNH<@^7*NY<]C@U:HH KW%A:75DUE<6Z2VS+M:)QE6'H1
MW%,GTNPN=/\ [/GM(I;3:%\AURF!T&/2K=% %4Z;9'3O[.^RQ_9-FSR-OR;?
M3'I[4MMI]I9V0LK:W2&V4;5B0851Z =JLT4 5;?3;&T@A@M[2*.*W;="BH,1
MG!&5]."1QZFH?[!TGS;F7^SX/,O!MN'V<S#T8]_QK0HH RXO#6AP+$L6E6J+
M"P>-1$,(0<@@=L'FK=OI]I:3S3V]ND<EPVZ5U'+G&,GU. !5FB@")+>&(RF.
M)4,S;Y"HQN; &3[X _*H;'2K#3!*+&TBMA,Y>3REV[V/4GU/O5NB@".>"*YA
M>&9 \;C#*>A'I5>#2-.MM..G06<,5F008$7"8/48]*N44 9<7AG0X$B2+2K5
M$A8-&HB&$(.00.V#S5BWTG3[2]FO;>SBBN9\>;,JX:3'3<>_XU<HH S4\.Z-
M&@2/3;9$$OG!50 !_P"\ .A]ZM36%I<1SQS6T;K<#$P*_P"L&,8;UXXJQ10!
MG?\ "/:/Y$$ TVW$=L"(%" >3G&=G]WH.E/_ +%TPV#V!L(#:R-ODB* J[9!
MRWJ<@')]*O44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M161_PD^E?\]+G_P#F_\ B*/^$GTK_GI<_P#@'-_\10!KT5D?\)/I7_/2Y_\
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M/^$GTK_GI<_^ <W_ ,10!KT5D?\ "3Z5_P ]+G_P#F_^(H_X2?2O^>ES_P"
M<W_Q% &O161_PD^E?\]+G_P#F_\ B*/^$GTK_GI<_P#@'-_\10!KT5D?\)/I
M7_/2Y_\  .;_ .(H_P"$GTK_ )Z7/_@'-_\ $4 :]%9'_"3Z5_STN?\ P#F_
M^(H_X2?2O^>ES_X!S?\ Q% &O161_P )/I7_ #TN?_ .;_XBC_A)]*_YZ7/_
M (!S?_$4 :]%9'_"3Z5_STN?_ .;_P"(H_X2?2O^>ES_ . <W_Q% &O161_P
MD^E?\]+G_P  YO\ XBC_ (2?2O\ GI<_^ <W_P 10!KT5D?\)/I7_/2Y_P#
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M7/\ X!S?_$4 :]%9'_"3Z5_STN?_  #F_P#B*/\ A)]*_P">ES_X!S?_ !%
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M75+^$W\E]<6\:A-H;9(P4>@.U>A.3[T =315./5K*6[%JDQ:1F9%PC;69?O
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M 4444 %%%% !1110 4444 %%%% !1110!E>%O^12T?\ Z\(/_1:UJUE>%O\
MD4M'_P"O"#_T6M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQUWQ=<Z7=K9&QTNUF4"%7#;%F(7G@+Q@X&>F".X!Z!3)I4@A>:0X2-2S'&<
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MS@7<\;21Q8.65<9.>G&1^=6JXJ\AU.7Q/X:@GU&'[:+.^26ZMXA@D&$953D
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MMQJ<43+<W*J)2)&VMM& =N=N<<9QG%7J* *(T>R76FU@+)]L:$0E_.?:4!)
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MBBB@ HHHH **** ,KPM_R*6C_P#7A!_Z+6M6LKPM_P BEH__ %X0?^BUK5H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(
MF_Y'&R_[!]Q_Z,AK7K(F_P"1QLO^P?<?^C(:?XBUR/PYH\NJ36TMQ#"5#K$1
MN&Y@H/)'<B@#4HK(_P"$A2'5[72[ZRGM)KT-]F=RK1R,HR5RI.#CGD#/8UKT
M %%%% !1110 4444 %%%% !1110 45!9WEO?VRW-K*LL+YVNO1L$C(]N*GH
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MBN?C\4B?QF- AM=T(@D=KK=QYB%=R =\;QD^N1V-=!0 4444 %%%% !1110
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M&>] 'G,-EHUQ%XSNI6C>:TNIS$QF.8@UN@)'/&3N'U'M2VT-C8:;X3N@L?\
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M6Q:)%N=825G$I/F[H7!;)/.2$Y]<>M8*_P!EP6#ZC'/$MQ;>*ML<WG9,<9N
M& .>%*$Y[$5ZM4-Q=VUH$-S<10^8XC3S'"[F)P%&>I)[4 <1IUWI-[K%W::R
MSKKMOJS26Z*2)GCW?NMA[Q[,9'3[Q/6LK5'M!H_B;;<!4B\1V[%EE(**3;AC
MD'@?>'YUZC@9W8&>F:S/$.C-KNG+9BY%N!/%,6\O?DHX<#J.ZB@#B=0CT[1;
MO7IK!7;0WM;8W"V\Y$8N&E()W<X&S:7Q_">>M4]3N[9/#?CJUAN;9H2D4D*6
MZ[(CNB3)1<D8)'4=3DUZHBA4"X7IS@8'Y5'#=VT\TL,-Q%)) 0)41P3&3T#
M=/QH S?$U[;P>$M1NV\Z6 6KL3:R;7*D=58=/KVZUY_J-U8+8>+X(;FS\B;1
MX)K=;/*Q,^)02G/S'(0%AU( Z\5ZQ28Q0!YMJ,HTW5-1'AN1!=W/AUIE6&3<
MTTH;Y7Z_,^TG!Y)JUIMWX>F\9^')]&FMB)M.N4<QL-Q;]T0'[[_O9SSZUZ!3
M0JCHH'T% '+^)7@C\9^%&DD5&-Q< Y?'!@<#]2!^-<G;'2[?3[348IXEN(?%
M#QI-YWS)$UPP*@D\*4/(Z$<UZM10!YHTD&FV'BH6<*QW$.L+)<I;QCS1:$PE
MR !G:5W_ %^:H=77P\VB7-]I>JF:VN;^Q9C&5B@C82J&*;0,-MR6], G%>HT
M@ 48  'H* //M9BT/3M;;1]4DCL-'N;$&Q9D#1>:SN9=K,#M?YD(QZ<5'JA^
MPW$,T<J:M'!;VL<UE??+>@ _)+$>[$GE2!DC\*]%(!QD XY&:"H)!(!(Z''2
M@#DO"D=C;>*_%$"Q0Q79O1(%5 '\MHHSG_=+9^IS6;JMCH=WXO\ $5OK,B",
MZ=;2(KS%<-^]RRC/WAQC'3/O7H%9-MHK0>([[5VN5D%Y%%'Y)BQL$>[:0<_[
M;9XH \[U2Z<^&Y;35CLUJW\.QR[KHEG+ .<Q+U#@@%WSQ@<<9'1ZDTFG:GI_
MB+3(%NQJML+&7:,@RL,PR'_9+95CZ$'M7;8K.;2YI=9%]<:A++;QX:"SV($B
M?:5+;@-S<$\$X&?I@ Y9M'T6W\;66D3K"]LFA2(\4K85\21\LN<$GYF_7M6/
MHCV-OI_@G44G3[9)>/;23--EVBV2@(23]T$)@= <>M>FQW=M-<2V\5Q%)-!C
MS8U<%H\YQD=LX/7TJ:@#SGP])IFI7=FU]?S0^(;.>07ENB*LC9W!Q(<9,6#D
M'.!A<<X%4-&_LRVTKPKJ$,T2W3:S- \OFY8Q,9\H<G[I^0X]2#WKU3 R3@9/
M>EH \TM(;&/2]2LK6ZL=.O5U^8*L\0\IOG=HXY0,81@./PQ77>#Y_/\ #RD6
M"63)/,C11ONB+"1MS(>Z$Y(]N.U;A (((!!Z@T<*O8 #\J /-;%WNM"T>:(A
M?%,>IHMV,XFSYA\X/WV;,G'3 7':MSPQ'IG_  FOB@VT=KYJ7$.TQJNX PIN
MQC_:SGWS74VUQ:WD0N+2:*>-B5\R)@P."01D>A!%34 <5XSM]*N]2MY4U)-*
MUNR*&*[+ %8SN/*DX=,@Y!Z>V:Z3P]>WFH^'[&\U"W^SW4T*O+& 1AB/0\CU
MP>1FKTD,<I0R1JY1MRY&=I]13Z /*+]GTK6VN_"UQ=)=R-,TFBW47F+(YF0,
M%4C*!N7W XP,\#-=3XIO;>'Q;X:+LP%K<3/,0C$1JT#J"2!W) KJ3;Q&Y6Y*
M#S40HK>BD@D?FH_*DCN[::XEMHKB)YH0#+&K@L@.<9'49P>OI0!RGB;Q#93W
M\GAZXDN+:T*#[;.EM*YD5A_JD*J>H^\W8' Y.5GEUC0=1T^/3]1M[BPLY+6.
M6(2!X592"-@*XY '*^XXKJJ* .2\+:A(-!T_2=2$L-S>+<+:*T.Q_(1L*S
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M2:R=.L]%\;Z?;2Q16UO<P/#"DF%1FCC+;0#W;.1ZYKU"21(HVDD=411EF8X
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M;KR/6NR\+71O?"FDW+S><\EE$7?=G<VP;LGUSG-:M% !1110!E>%O^12T?\
MZ\(/_1:UJUE>%O\ D4M'_P"O"#_T6M:M !1110 4444 %%%% !1110 4444
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M\EOO,?)<$$-A.1AFZ8ZU:MO#T$%]:WDUU<74MDCI;F;9E ^,\A03P,#/\^:
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M7"=#]W()Z$@CH.AYJY8Z+#I^IWU]!//_ *=()9(&8&,/M52PXSDA5ZDCCC%
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M#J.H036EQ+/;W<<JB6,R,6=0=N"I)Y!!K>LK-+*T6W622;J7DF;<\A/4L?\
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MK$N]&CTO1)_#]G8WVHQ:JTXW2,K1VYD)8[SD$+EB0?F;CKG%=%8V<6GV,%G
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ML42_:+,PO%/;2]U96)R/1@,'%21>$+6)=*5=0O=NDV[6T )C^9&4*=WR<G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR#\QY!!]^M5[*_UJX\+Z1=QR2ZEY,-R+JU6[:&XE19-@E5P1N90O0GG=ZXH
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M67*AAO!S\JD$+G^+..!C8\'7-[>: XOI7F,-U/!%<,?FFB21E5R?7 Z]\9H
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MHK>XGOX&N9Y'R[12E8D9PRG)7=WY*CK0!Z+6?J>KPZ7/8Q30S/\ ;K@6\;(
M0KD$C=DYQA3TS4'A])K70Q$VIG5VA:15N-I!< G"Y).XC[N[/..><UQL-VNJ
M:1X/UJXO9)+NYU9//5IFV*Y63<FS.%VG@<9_,Y /2:*\_L]6:77]#F@U*>2U
MO[V\BD>:Y(,JJLA \K[J!650I&#QSC)JWIS7D>JS^$[BZO7EANQ>)<M<2;VL
MR=RC?G/WQY9'IDT =)KNMVWA[2WU*\CF>WC*AS$H8KDA1QD=R!Q5Z-B\:LT;
M1DCE6QD?D2*YCXF$#P!J)) &Z#K_ -=DK<U6_P#L-A(\.'N7C<VT74RN$+
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M%%% &5X6_P"12T?_ *\(/_1:UJUE>%O^12T?_KP@_P#1:UJT %%%% !1110
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M9&5&W(-O) <9!(^IJ]INJ:G<^,-8T^:. 6=G'!Y>V0[AN#G.-O).!GD8P.M
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M.X*K%'&SY1A^",].0.E3Z7XGGU.PL95T^..ZN+N2VGMFN"3;E-V\D[>2-O3
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MN70;1\Y*#.",;1R:TF\7S6K7#ZAH]S#;16AN5G1)"N00/*)9% <Y&,$@\^E
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MGKWQQ6KINFWFGQ6%N=062WM+7R'C$ 7S6& KYR2, 'COFM.B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_ "*6C_\ 7A!_
MZ+6M6LKPM_R*6C_]>$'_ *+6M6@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH RO"W_ "*6C_\ 7A!_Z+6M6LKPM_R*
M6C_]>$'_ *+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,B;_D<;+_L'W'_ *,AK7K(F_Y'&R_[!]Q_Z,AK7H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\+?\ (I:/_P!>$'_HM:U:
MRO"W_(I:/_UX0?\ HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH R)O^1QLO^P?<?\ HR&E\2:Q<:#I#ZC#8&]6(KOB
M23:Y!8#Y1@[CSTXI)O\ D<;+_L'W'_HR&CQ//%;Z.&FD5!]IM^6..DR$_H"?
MPH :_B&*XT*UU?24BO8+J2)$S*8_]8ZI_=/(+<CV-:WF*I5795=NB[NOT]:X
M?5=(O-"U>"?1XO.T?5M0MGNK=.EM+YR-YR?[+8PP]<&H-26.:+Q=9:K'G5)7
M:3321^\=/+7R?)/4E7!^[T8DGK0!W":C:2:C-IZ3*;F"-))$!^X&)VY^NTU9
MW+G&1^=<-I^EP2^+[^SUNTCEGOM(M5=C#D2,!()2&QCN,GW'M67:PZKIPTO4
MUTWS;C0Y&T>0>6 UTK$HC@_W0?).?]IZ /1I9;@7=NL20M ^[S7:3#+@?+M&
M/FSSGD8]ZR+WQ1$EOIUUIZ1WEO>ZB+)I!)C8=[(6'!W<J>XK)NM,L=+\6>$[
M2..(&*&ZC=@@&[*#K_O-N/U)K!M8[&'POI5A+"L,T?B(K<H8RA ^T2D;CCH%
M(^@(]10!ZAYL9C,@D78,Y;/ Q[U!/J5G;W-I;R7""6\=D@7/+E5+'\ %//T]
M:X+R;2*;7M/M+V+2XDU>&2U(B#0(_DH3N3@;"ZL#Z-[BB,QR3>&;K4=)MK=(
M-1NXI6MXC)"Y9),.G&=KN<@>IH ]%$B&0QAUW@9*YY ^E)YB;@N]=QS@9Y..
MM>;QW=J^O:5=10/;%-;N4N(S"[2KN24?O'_VB%(7H!@<XXJVD&FVVF6=[%'!
M'<Q>)VVR@ ,D)G;(!ZA"ASZ8.: .^\2:VVA:9]KCACG82Q(8VEV$*\BIN'!S
M@L../K5^.6X-Y<)+'$L"*IB=9,LV<[MRX^7&!CDYYZ5YIJES;2>']7MM3B_X
MG<6LI*0\1,AC^T)L9.,[/+P 1].]7M86S=OB H2,^=IL3*NW[\GE2 8'=MQ7
MWR1WH ]#61')"NK$8R >F>E"R(Y8(ZL5.#@YP:\\BAL;;68182K9_:_#4PEF
MMURS2 IM8XY9P-Y'?@TOA";1M1UW2KH76G)>6^EBV6WCSYDC\'?\RC!50>F3
M\S<X'(!Z$\B1+ND=4&<98XH9U3[S!>_)Q7)>+9;5];MK.XMLO+87 CFDB:5#
MDJ#&B#@R'KD] #P<\8>F)8:A=>!_M\<<W_$GECN1<)]Y@D0 ?=UY#XSW!H ]
M)#J0"&!R,C!ZTH(/0YKS2PM8X/!FG>(+2%9;KP]>7#; ,L;;S9 T8_[9$,OT
M&.M=UH=C]ET\R2PK'<W;M<7  &=[G.#Z[1A?^ T :'F('";UW'.!GDT;UW;=
MPSG&,\UY7_9FFW6DZG'810KKT&ORBQ,8Q+%BX_A[A N[./EX/<5H)ID5P/&<
M^DVT)U>&YD>Q=5&]"UNBDQ^A)W#(ZD<]* /0UD1BP5U)4X;!Z'WIVY?4<^]<
M/9PV.HZUX>GT:&,0+:2QZE&J  1% %CE']X/C //#>]3>&-+:WNGT&YM!]CT
M*Y>2VD=!B19!F+![E59P?<*: .JMIYC#*]ZL,)25U&R7<-@/RDD@8)&,CM2R
MRW NK=84A>!RPE=I,,N!QM&/FYZ\C%>>6$<7]A^7:7]OI\T.NWDEJ9XPUNWS
M285QQA65N"/;':K=E)')JO@VX>PAT^?%VAB3E4&T@;3_ '&/*^Q% '?"1#(8
MPZ[P,E<\@?2D\Q-P7>NXG &>2>M><6,<MUH.C1*NSQ/:ZFANN,3*?,/G,_<H
MR9YZ$%0.U5)(-,ATJ_O(8H%NK?Q,K0R*!NCC\],E3V4KNZ<$9H ]-OI+F*RE
MDM(XI9U7*)-)L0GW;!Q^52M(B9WNJXZY.*YOXBI%-X#U(.JR9C!C&,DMN&,>
M]8>LVND7WB+Q,T\-M.KZ+$R;@&5I!YOS#L6 *<]1D>M 'H,DB11M)(ZHB LS
M,<!0.I)K$;Q,CZCH<5K$DMGK$<DBW!D(*A8]X^7'<8[_ (4FF9U'P%:A_P#2
M'ETU0X;YBS^7@@^^?UKC]*33;BW\!VLD,?EI;R+<QO'M7>+<*0P(P?FXYZD8
M[4 >BW,TX2%[1(95>50Y>3: AZD8!R?0<9]:F\Q/,\O>N_\ NYY_*O,[<VB:
M-IL8\H+9^*G$ &/W47G.1CT7:1[8Q6K:,]OXQC\AK?4K:?4)\JR;;NPDVN&)
M(^]$<$#./O+C/% &[XG\2_\ ",1VMU<69FL99A%-+&Y+P\%BVS;RH"DGG(]*
MMW6J21SZ:+2&&Y@U"38)O/P%'EM(&&%.X$(>_<5!KLMLM_HL=P\85[Q@5<C!
M!@E7GVR0/Q [US]GI6H>'?%&F:1"C3:$]U)<6CDY-HWDRAH3_LG=E?3D4 =O
MYB>9Y>]=^,[<\X]<5!::A:WTES';3+(;68PR[3G:X4,1^ 85Y]''+=>&XK;:
M$\66^JAVXQ+N\_YG]3&8B>?N[>.V*+A?L-MXF2WLY!+'K,<]PD%OF1K3$);;
MQ@@X8X[X;CK0!Z0DB2KNC=74]U.14$&H6MS>W-G#,KS6NWSE4YV%@2 ?? S^
M(K$\)1Z2\U_J&CW%S<0WC1N[O&(XBX!'R*%7G&-QQZ=P:YW68)X;[QHFFVK#
M49HX)(?*B(>2/8OF[6 ZG##@]?>@#T1)$DSL=6P<'!S@^E5Y=1MHK^/3_-0W
M<L32QQ%L$JI )/H,L!7-6"VESXRL+[P_Y0L3I\B7I@ "=5\I2!T<?/P>0,U)
MJT=I!\1-(NKJ!-CV,\:RM%D>9OB*\XX( 8Y[ &@#5\.:T=<T:"^EA2WEE:4&
M%9-V-DC)P<#/W?3O6IYB>9Y>]=^,[<\X]<5YAI,=A!I?A:_C6*.\.M3+)-C$
M@B8SY!/4*<IQTY'K5W018WVH6L&HRWZ>(+"^DDDB6$*22S L7V<Q%3W;'0#L
M* /0F944L[!5')). *0R(L?F%U"8SN)XQ]:YGQ=>+IVJ:)=W\;-I"2R"Z8(7
M6-RF(F8#/ .X9[$@UG.+"QU/0GBMVB\.%KD@S!O+29L%'(;[JG]X%S@<\=10
M!W&Y< [A@]#GK5>[U*SLH8IKBX14FF2",Y^\[L%4#UY/\Z\[DLH8AIZ7*)]@
M;Q,[62N.%M3$P./2,N3[$$=B*;<6]C%8ZG#';Q?8[+Q/;3"-(P5BA)AWD*!P
MN=^<<=: /3MZ;MN]<GMG_/H:%D1RRHZL5.& .<'WKA;&ST>;QAXCN381SM!#
M;3VT:1X<,L;9*#C#=!Z@D5E:3-8OJ-JZQ)'97'AV6)HQ VQ65HR$=V'SNH+9
M8XYSP,T >G"2-NCJ>,\&E+JN<L!CKDUY]IOA:QU#X<:;=:;96XUB"UMIXY2@
MW-/"H(5SUZ[E(/0'V%;-HVEWWA^Y\0:W9*D&J>7(\<L1=EB!41*0 2><-[%O
M:@#JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,KPM_R*6C_]>$'_ *+6M6LKPM_R
M*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ,B;_D<;+_ +!]Q_Z,AK7K(F_Y'&R_[!]Q_P"C(:UZ "BB
MB@ HHHH **** "BBB@ HHHH **** *NI6$6J:;<6$SR)'<1F-FB;:P!&.#56
MRT>>&6*2^U6YU P'=$)8XT"G!&[Y%&3@D>G/2M2B@ HHHH SM0TDZC=P227U
MPEO%_K+1-HCF.01NXSP1T!&>AXSG0.<<=:6B@#,T/1O[%AN8A=-<?:;F2Y8L
MH!#.Q9AQVR>*TZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH H:KICZI%'$NH75I&K$RBW*@RJ1@J
M202![C!]ZNHBQQK&BA44 *H& !Z4ZB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M RO"W_(I:/\ ]>$'_HM:U:RO"W_(I:/_ ->$'_HM:U: "BBB@ HHHH ****
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MH8H^X%3M '#*><="/3) -VBL+4/&6CZ9<7=O.]TTEBJ/<"*TD?RU;)W'"_=
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MN" R+C"J./EX/KZUU]C86FF6BVEC;I;P)]V.,85?H.U3LJNI1U#*PP01D$4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?\BEH_P#UX0?^BUK5
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#(F_Y'&R_P"P?<?^C(:UZR)O^1QLO^P?<?\ HR&M>@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #C/'%<+!XEOK(:7-?WDS+I=R]GKA+80$L4BD/L3AN.,'GM0!Z-5=+Q&N;B
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M44 5+G2[*[O+>\N(!)/:DF&0DYC)ZX^O?UIC:+IK37DKVB.]\GEW);)$RXP
MP/! !('IFKU% &?'H.DQ/:.FGP*UDI6W8)S&#R<?B,_7FHK7PQH=C<7-Q::7
M;P2W0(E>-=I8'KTZ9[XZUJT4 9L/A[28/L?E62)]AS]E )Q#GKM&>,]/I4]U
MIEE>W-O<W, DEM6W0N2<QGH2/?'%6Z* ,W_A'=(^SS6YL8S'/+Y\@.3NDSG?
MG.0V?XNM22:+ILVGR6$MG');2MND1QNWMD'<2>2<@<GG@5>HH HQZ-IL5TUR
MEG&)7A$#'L8QT3'3;[=*BT_PWHNE6T]M8Z7;00W (F18QAQSP<]N3QTY-:=%
M &*GA/1+;2+K3++3+6"WNAB5/+RK>F><D#L,UJ6ELEE9P6L98I!&L:ECDD 8
M&3Z\5-10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 97A;_D4M'_ .O"#_T6
MM:M97A;_ )%+1_\ KP@_]%K6K0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &1-_P CC9?]@^X_]&0UKUD3?\CC9?\ 8/N/
M_1D-'B#6)]'_ +-,,,<BW=_%:R%V(*!SC('<T :]%107,%U'YMO-',F<;HV#
M#/U%5=;OY=*T2]U&&))FM('F\MW*A@JDD9P<=/2@"_17,6/BVX:_T6UU'3XX
M%UN RVLD$YD 8('*N"JXX/49_"M];^R?S=MW WD_ZW$@.SZ^GXT 6**@%Y:E
M8V%S"5E.V,AQASZ#UIUQ=6]I%YMS/'!'G&Z1PHS]30!+16/J.LS6>NZ)8Q11
M20:G)*C2[SN7;$SC Z'.WKFG>']6GU9-0-Q#'"UI?2VP$;%@0N.<D#UH UJ*
MA-W;"Y%J;B(3L,B(N-Y'KCK0;NV6Y6U:XB$[#<(BXW$>N.M $U%0_:[;[3]E
M^T1>?C=Y6\;\>N.M,;4;%" U[;J3G ,J\X.#W]>* +-%1K/"\KQ)*C21_?0,
M"5^H[4VWN[:Z5FMKB*94.UC&X8 ^AQ0!-16)::_]L\5S:3#]GEMDLUN%GBEW
MDL7*E3C@8Q[UI233KJ4,2M;B!HG9PSD2[@5QM'0KR<GZ4 6:*@2^M))!&EU"
M[E2X59 25!QG'IGO5;3]=TS5+.6\M+R)X(7='DWC VL5)SZ9!P>] &A14"WE
MJT*3+<PF*3A'#C:WT/>D:_LE$):[@'G_ .JS(/WG^[Z_A0!8HJ%[RUCG6WDN
M8DF896-G 8_AUJK8Z[I>I132VM[#)'!*8G<.,;@<>OKP/6@#0HI&8*I9B H&
M22>!4"7UG+;M<QW4+PJ<&19 5!^O2@"Q14<5Q!.TBPS1R&-MKA&!VGT/H:R(
M?$'VCQ:-'@^SRV_V)KCSHY=S!U=5VD#@?>H VZ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 97A;_D4M'_Z\(/_ $6M
M:M97A;_D4M'_ .O"#_T6M:M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9$W_(XV7_ &#[C_T9#6O61-_R.-E_V#[C_P!&
M0UKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,4^KRW4]LMVR^;$ZX"E]G&&P<8^8#!]* -&X\81E-)DL;*>X34;M[8\*IB9
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M10VQM);*Z?8-F059&VM@CD=.0:KZWX9OM22,I;007T-O_HE]:3&%K:8LQ*G
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MU,QC==X.YBF6R'SNZ\=^M;\&G:A_PF*ZK)#$EL=.6V;$N6#ARW3'(YQG/X4
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M6PD(BM;"*ZAC^T-B.8QR9<#/WLJG/^-=5(1JO@ O,%NC<:9N;(W!V,>?QYH
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M\D)U(]!SD4R^O+*VTC4-4T#5Q<VD[6WVU;!=L5O%Y@#L "=KE"<XYP,G'!H
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M.,\C!]:O44 065I'8V<=M$698QC<QRS'J6)[DG)/N:D:&)VW-&C-ZE1FGT4
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M,@TZB@!C0Q,,-&A^JBA88E8LL: D8)"BGT4 1QPQ0C$42(,8^50./\DUE2:
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M:.VS!,\]WGR+90OF/A2QZD 8 [GT'4U!?>)+/3M#BUB[@NXK:39D-"0\98@
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MBBB@#*\+?\BEH_\ UX0?^BUK5K*\+?\ (I:/_P!>$'_HM:U: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R)O^1QLO^P?<
M?^C(:UZR)O\ D<;+_L'W'_HR&KFIWO\ 9VFSW0C,KHO[N,'F1SPJCW+$#\:
M)8+NWNGF2"9)&MY/*E"G.Q\ X/O@C\ZI2^(M*@&HF6Z*C2P&N_W;_N@1D'IS
MP,\9KEM#6;PUXTCMIX)XH->@R\DNW#WL8)=AM8XWJ2?JM)K'W?B)_P!@U?\
MTF>@#NH94GA2:,[DD4,IQC((R*?67&\L?A2.2"3RY4L@R/@'!"9Z&N;L=8UL
M:3X>EN-3\^;7HX>3%'$(3Y#2-M.TC+$#J".N ,C !W%%<7<WGB:P;2K6ZU.
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M1YBF)69-^Z0;#\ISCY=O0_AI>)-;FT;PI)JD8B,V(E# [HU9V5-WNHW9]\4
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MT5%;.TMM%(^PNR MY;97)'8]Q4M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 97A;_ )%+1_\ KP@_]%K6K65X6_Y%+1_^O"#_ -%K6K0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1-_R.
M-E_V#[C_ -&0U;U#2[74UA6Z64B&02IY<SQX8="=I&<>]5)O^1QLO^P?<?\
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ML%XX]2* -BBJ6CW[:KI%IJ+0B$74*3*F_<55@",G YYJWO3?Y>]=^,[<\XH
M=15*VU>RO-3N].MYUDN+((9U4Y"%]V!]<+G'N*MJZOG:P.#@X/0T .HK"UWQ
M5;Z1J5EI,%O)?:I?Y\BUC8+\HZNS'[JC!YYZ' I9M<U"SG\B\T@(QMY9UEBN
M-\1V '9N*@ACG^[CCO0!N45C^%_$,/B?P_::O#$;<70<B)V!8!7*_P!*UMZ;
M_+WKOQG;GG% #J*:74=6 YQUHWKOV;ANQG;GG% #J*:74.$+ ,>0,\FE!!)
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MZML+@>?%$RF380'D5,]#G!8<5J9&<9YH 6BDS1D#O0 M%)GG%&1G% "T444
M%%96K:R^F7^E6XMEE34;G[/YGF8,9V,X.,<_=/<5J9&,YXH 6BDS1D>O6@!:
M*0D#J:AO)GMK.:>.,2-&A8(6V@XYZX- $]%<M'XT*:!9:_>::8=,N_+)ECF#
MM"'(52ZX'&2,X)ZUU&0* %HI,T9H 6BD!!Z4M !12$@=3BC- "T4A.!DTM !
M165H6LOK"WYDMA;M97LEJ0)-X;9CYLX'7/2KMW?6UDL37$JIYTJPQY/+NQP
M/7_ &@"Q129&<9YJIJVI0:-I-WJ=SN\FTA:5PHY( S@>] %RBJ-A<ZA-),M_
M8QVRJ5\J2.X\P2 CGL""#QT^AJZ2!U- "T44F<T +16-I6M7.KR17%O8*=-F
M\T+<^?\ ."CE1E,=&P2,$^^*V: "BDR/6H[FY@L[66ZN95BAA0O([' 50,DF
M@"6BF1RK+"DJGY74,"?0T^@ HHHH **** "BBB@#*\+?\BEH_P#UX0?^BUK5
MK*\+?\BEH_\ UX0?^BUK5H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLB9M5%G(2\JB(; QS_K-_"YYX/IQVUXUEXETC4--LM2@?S8F@F>%ED,8=<=
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M0@?ML$FW)/' -5-7M(5L]:FCCB?0XM6L)K<A0T4?SIY[)V"\\XXSN]Z].HH
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M>JDCI4E%00WMK<3S007,4LMN0)D1P6C)Z!@.G0]: /,O$=U93Z+XNM=8\O\
MMA+IFMDE'[PP#;Y1C[[<9SM[EL]:G\4ZC8RWNISP%(KNTOK%]\@+2E-T7SQG
M_EG%M)!/.26Z9Y](N)X+6!Y[F6.&*,9>21@JJ/4D]*=%+'/$DT3J\<BAD=3D
M,#R"#0!Q>HZ>UCXCGM[*US:>*8A'(ZICR9%^^Q]-T18C_:3WJ#4UCT_Q1FU6
MROK=;NUB>P90ES:, FQX2.J $$KC'#\]:ZJ+3S:7]QJ=]J<DZ -Y*S!$CM4.
M"P! &>@Y8DX'US?M[B"[MX[FVE2:&1=R21L&5@>X(ZB@#GO'\B1^&!O=5S>V
MF,GKBXC)_0$_A7,^(K^Q?5+Z>(I!=6>KV1=I 7F*9B!=3_RSBVDCN"2W3.#Z
M910!YK>&.RF\7FRMBMU]LMYW2"'$S6I6$RE>.A ?ZG/>M?1=1\+:7'J.O66K
M2'3YA%Y\GEA;='SM&%5!ASD!OPSBNSJ*YMTNK=[>3/ER#:X!QN'<?C0!G^)9
M8X_"NJ2/(JJ;.7!)X.4.*R?"WB/2(?".AVXU"WDNC:6\ MTD!D\S8J[=O48/
M7/3O75    # ':EH \ZTEM+U#5(H=3N[N'Q#9:C(\D*1JKLI=NK;,F$H1WQ@
M #H*SK--+MM,TK4(6@2ZB\2R1B8.-R0M/)E0<\(5(..G.>]>K44 >5:G>6$W
MA_44U4Q#7[?6HVD60?O53[4FPKW\ORR "./QK0D?3-0UV_L=8N[NWU>/4!/9
M+#&OFR1C!B,3%"=N.",X'S9QDFO1*6@#C/"%AI4VN:]=+%"]U;:M*86#9,:M
M$@) [ G</?'M2ZI::7>?$B*'4(X)8GT:42QS$%6_>H1N!X/ )Y],]J[*B@#R
MW0EL+?3_  5?H\:WC7;V\LY?,AB\N4!&)YV@A, \ X]:ETB]T^X\0Z#<6ZK$
MEQ->07$3*6FRP)V3OW8D9VD<>_6O3::P+(0&*DC 8=1[T <3HVE&VU>3PK)9
M@Z?87/\ :,,A0%6B<DQI_O+)OY](QZUI>-KS[!;Z9<W*LVEI?+_:&%+ 1;6P
M6 _A#["?I6MI.F2:=$YN;Z:_NI<>;<S*JLP'  "@  <\>I)[UH4 >>:BF@R2
MZ!'IQ!L+G6VFP6(C?,+ABF?X,D# X))'>JMM>:796MS8.L*V<?B1XX 6Q;6Z
MF/<I=1P4W;L+P"V.1BO3:* /*(&L9=-TFUNW3;!XGGBV,#&%A)FPN#T7E?E]
M"!WJYXE72-,U+4=%FN;&VAN-*BALENG,:V39D 9"1SSAB1SE5_#TNL:;0[O^
MU;B]M-9N+=+K;YL)B20 J-OR%AE>!TY&<G')H Y'46T1=1_LS6K[9I=UIL*:
M=<QQHT4I^?S"C;6"N25(QR>/05V;&.T\+_O9IMD=G@R71 D/R8R_^UZ^]7;2
MUBLK6.VA&$C'&>I[D_B>:GH \A*V[?#+139:A)=ZI;K \.E^9YRS2!A\CQ#G
M Y/;& :Z&_>UGU;Q):^(EC21[>-M/\SKL\OGR3UW"3/W><[?:N]I* //-+T^
M"_\ %=E;>(HXIK[^P;=[B.1N3.KDDD=V& ?_ *U4K>SMT\&:MJ.EP"6\@U&X
MCD> EI5M3=9=5QT!C&0!V)(ZUZC10!Q TO3M:\17-OI?D/HM[I)2[^S8\KS2
MP\MACC>%W>X 'M619OJEM+I6M#35-Q;HVAW"^5_K)!E5E_W-ZH,^C-7IM% '
MGVL6^CZ7JZ:)K<K6NDR::D-E)Y2F,R!G\T9*G$A!0Y&,XJ2RTO2;GQQ#9W0>
MY":+;L@O&_>NZ2,0SCCYP IZ9KO:6@#FO%UU907.CPWR)LFNF"RW&3;HPC;&
M]>C$YPH)'/.>.6?#N;?X/AA+,7M[BXB964J4 F?:N#TPNWCL,5U%% 'FR:A8
M0V6H_:BCQ2>*'7>[XACR 5>7'5,KT/!..1UJF!9MI$ N4B:"Q\4G<7AVI#"S
M$]#]U#D<=.17JM% 'G,C:5?:U?Z?J]U=VNJ)?+-8)#$HE>(;3%Y3%"0, @C(
M ^;.,DUO?$A('\ :L)DC8B!O*W@'Y^@QGO\ 2NHHH \^UN71(]92QU:5+71;
MO3E6QDBB0P^87?S0"5(#D%"",=/6J]\-*6^;1_$5[?0VD^FPQZ?/<QJTCX#!
MN2AVS9VGC#'CT%>DT4 <[XC&HQ> +I=+-T]XEF A<_OV&!NSC^/;GIWZ5F6R
MZ9<^*-/N-"^S'3)=/F&I+&!Y17Y/*#CINR7Z\X#5VM)0!ROPV2S7P=;/:I"K
ML\GFF-0"?WCXW8]NF>U<SJMQ8V>D^)-.D*1W4>NPW$<&WYDC9X/G [*?F&>G
M..]>HTE 'F.K66B7EYXTCN-AO$:.6P4.?,64VR%6B&?O%\=.3G'>NJ\26MQ<
M?#74(+R(3W?]E/O7;NS*(SR/?=TK1TW1FT_5=3OVNO-.HRK(R>7MV%4"#!S_
M '5'XUJ4 <%;W&E/K>GI?+:?V%-I(%HTBJ+<S[_W@Y^7<5V_@&QWK>\$1WD7
MA:W2\:1MKRB RYW^3O;R\YY^YM_#%;U+0 4444 %%%% !1110!E>%O\ D4M'
M_P"O"#_T6M:M97A;_D4M'_Z\(/\ T6M:M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 9$W_(XV7_8/N/\ T9#6O61-_P C
MC9?]@^X_]&0UKT %%%% !1110 4444 5M1O$T_3;J]D^Y;0O*V?103_2N6\'
M>(;W6Y8#<^(=(NG:W$LME;6S)(A('1C(<@$X) _*NHU**>?3+J*U6!IWB98U
MN%W1EB. P[KZUSEO::MJ^OZ+>7>B_P!DQZ2LA=FEC;S&9-FR,(3\G.<G'0<4
M :&N:E?KJ^GZ+I<D,-Q>)+-)<31F011Q[<X4$9)+J.OK4GAO5;G4K:[AOA%]
MLT^[>UF:($(Y #!@"21E64XR<'-4+Z+5VU'2?$4>CNT]O'-;W-@L\9D".5(9
M6)"D@H#C(X;VJYX6TZ\LK>_NK^(0W.I7KW30APWE A5521P2%09QQDF@#.U7
M0[B/5[C4WN(TM&O+:]>0D[XQ$FTQA<<[L#_OMO;-F#6[6SU.4WZ2"\F:%)2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'
M_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH R)O^1QLO\ L'W'_HR&M>LB;_D<;+_L'W'_ *,AK7H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?\BEH
M_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#(F_Y'&R_P"P?<?^C(:UZR)O^1QLO^P?<?\ HR&M>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,KPM_R*6C_]>$'_ *+6M6LK
MPM_R*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,B;_D<;+_ +!]Q_Z,AK7K(F_Y'&R_[!]Q_P"C(:UZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\
MHM:U:RO"W_(I:/\ ]>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH R)O^1QLO\ L'W'_HR&M>LB;_D<;+_L'W'_
M *,AK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH_
M_7A!_P"BUK5K*\+?\BEH_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#(F_Y'&R_P"P?<?^C(:UZR)O^1QL
MO^P?<?\ HR&M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KP
MM_R*6C_]>$'_ *+6M6LKPM_R*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,B;_D<;+_ +!]Q_Z,AK7K
M(F_Y'&R_[!]Q_P"C(:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'_HM:U: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R)O^1QLO\ L'W'
M_HR&M>LB;_D<;+_L'W'_ *,AK7H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?\BEH_P#UX0?^BUK5H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(F_Y'&R
M_P"P?<?^C(:UZR)O^1QLO^P?<?\ HR&M>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,KPM_R*6C_]>$'_ *+6M6LKPM_R*6C_ /7A!_Z+6M6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
MB;_D<;+_ +!]Q_Z,AK7K(F_Y'&R_[!]Q_P"C(:UZ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'
M_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH R)O^1QLO\ L'W'_HR&M>LB;_D<;+_L'W'_ *,AK7H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?\BEH
M_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#(F_Y'&R_P"P?<?^C(:UZR)O^1QLO^P?<?\ HR&M>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,KPM_R*6C_]>$'_ *+6M6LK
MPM_R*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,B;_D<;+_ +!]Q_Z,AK7K(F_Y'&R_[!]Q_P"C(:UZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\
MHM:U:RO"W_(I:/\ ]>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH R)O^1QLO\ L'W'_HR&M>LB;_D<;+_L'W'_
M *,AK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH_
M_7A!_P"BUK5K*\+?\BEH_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#(F_Y'&R_P"P?<?^C(:UZR)O^1QL
MO^P?<?\ HR&M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KP
MM_R*6C_]>$'_ *+6M6LKPM_R*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,B;_D<;+_ +!]Q_Z,AK7K
M(F_Y'&R_[!]Q_P"C(:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'_HM:U: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R)O^1QLO\ L'W'
M_HR&M>LB;_D<;+_L'W'_ *,AK7H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?\BEH_P#UX0?^BUK5H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(F_Y'&R
M_P"P?<?^C(:UZR)O^1QLO^P?<?\ HR&M>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,KPM_R*6C_]>$'_ *+6M6LKPM_R*6C_ /7A!_Z+6M6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
MB;_D<;+_ +!]Q_Z,AK7K(F_Y'&R_[!]Q_P"C(:UZ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'
M_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH R)O^1QLO\ L'W'_HR&M>LB;_D<;+_L'W'_ *,AK7H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?\BEH
M_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#(F_Y'&R_P"P?<?^C(:UZR)O^1QLO^P?<?\ HR&M>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,KPM_R*6C_]>$'_ *+6M6LK
MPM_R*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,B;_D<;+_ +!]Q_Z,AK7K(F_Y'&R_[!]Q_P"C(:UZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\
MHM:U:RO"W_(I:/\ ]>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH R)O^1QLO\ L'W'_HR&M>LB;_D<;+_L'W'_
M *,AK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH_
M_7A!_P"BUK5K*\+?\BEH_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#(F_Y'&R_P"P?<?^C(:UZR)O^1QL
MO^P?<?\ HR&M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KP
MM_R*6C_]>$'_ *+6M6LKPM_R*6C_ /7A!_Z+6M6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,34IFL_$EG>-;7,L(LYHB
MT$#2;6+Q$ [0<<*?RJ;_ (2"W_Y\=3_\ )?_ (FM6B@#*_X2"W_Y\=3_ / "
M7_XFC_A(+?\ Y\=3_P# "7_XFM6B@#*_X2"W_P"?'4__   E_P#B:/\ A(+?
M_GQU/_P E_\ B:U:* ,K_A(+?_GQU/\ \ )?_B:/^$@M_P#GQU/_ , )?_B:
MU:* ,K_A(+?_ )\=3_\  "7_ .)H_P"$@M_^?'4__ "7_P")K5HH RO^$@M_
M^?'4_P#P E_^)H_X2"W_ .?'4_\ P E_^)K5HH RO^$@M_\ GQU/_P  )?\
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MX2"W_P"?'4__   E_P#B:/\ A(+?_GQU/_P E_\ B:U:* ,K_A(+?_GQU/\
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MK5HH RO^$@M_^?'4_P#P E_^)H_X2"W_ .?'4_\ P E_^)K5HH RO^$@M_\
MGQU/_P  )?\ XFC_ (2"W_Y\=3_\ )?_ (FM6B@#*_X2"W_Y\=3_ / "7_XF
MC_A(+?\ Y\=3_P# "7_XFM6B@#*_X2"W_P"?'4__   E_P#B:/\ A(+?_GQU
M/_P E_\ B:U:* ,K_A(+?_GQU/\ \ )?_B:/^$@M_P#GQU/_ , )?_B:U:*
M,K_A(+?_ )\=3_\  "7_ .)H_P"$@M_^?'4__ "7_P")K5HH RO^$@M_^?'4
M_P#P E_^)H_X2"W_ .?'4_\ P E_^)K5HH RO^$@M_\ GQU/_P  )?\ XFC_
M (2"W_Y\=3_\ )?_ (FM6B@#*_X2"W_Y\=3_ / "7_XFC_A(+?\ Y\=3_P#
M"7_XFM6B@#*_X2"W_P"?'4__   E_P#B:/\ A(+?_GQU/_P E_\ B:U:* ,K
M_A(+?_GQU/\ \ )?_B:/^$@M_P#GQU/_ , )?_B:U:* ,K_A(+?_ )\=3_\
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M+?\ Y\=3_P# "7_XFM6B@#*_X2"W_P"?'4__   E_P#B:/\ A(+?_GQU/_P
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M1110 4444 %%%8UUJ&I-XA_L^R^RB*"&&:?SU;<ZR2.I"D'"D!">0<D@<=:
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M;ZXCD,T6S&V5E5MC;TW*#AMK<C/0UHT4 8</@_1($VI;/@+L&9G.%^3"C)Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit103-form147_716ba003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
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M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M![AXT++%'C=(0/NC) R?<U3OM76S:V@%M+-=W:L8K92H8[5RV23@8R!UZD4
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M&YM+:\B\JZMXIX\YV2H&&?H: .)\1I/8>)O"T\U\VJ![P11V4BJK1EE(,Z[
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M13+^\2]\4ZSI>I7+V\5MIT<EI&)C%O#;_,D!!&2"%&>WXFNIM[*TLRYM;6&
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M*-;6%M"8RQ0QPJNTMC=C XS@9]<4^WL+*TEEFMK2""28[I7CC"F0^K$=?QH
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M,DK.YPA(RQ.3SZUK'2M-:"* Z?:F&#_51F%=L?\ NC''X5:90RE6 ((P0>]
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M'[1C'G>6-^/][K4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW6?<A=4$A;?M!V[#G[N>V*B\(+(NN^*1+!' _P#:$9*1ON7F",Y!P.O7IWH
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MDM8GN(A#,R R1A]P1L<C/?![U+0 4444 %%%% !1110 4444 %%%% !1110
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MMH]NNJB1=*O)+E"]OR^X.-IPPQPYY]?RJQ;^&[RT:_,6IPG[=?F[=7M=RD%
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MG9@-W!'UY/H.*L1>'Y=-?1[Z;4%>/0[&2 JEHQ:52JY. Q.<1KP >_KQTM%
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M]P0,G# \YSUJK;^$WL)-)N;'4-EWIUD+%Y)H=ZW$0Q]Y0P(.5R"#W/6NCHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDW $KG8VWZ\]>* .OHJM8V[VMMY3W<MV=[MYLNW=RQ.. !@9Q^%6: "BBB@
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MQR>OO1)IEG+J,6HO#FZA0I'+N.54]1UZ'C\A5NB@"A::'IEC-YMK:)$P9F4
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MX&WK0!W<UU;VVWSYXXM^=N]PN<#)QGV&:B34]/EMH[F.^MG@E8)'*LJE78G
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M;64ULFGVTJ7T<ENR;(S&%\D@CYCOP0!G[N?3(!UMO?V=VY2VNX)V"AB(Y Q
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M_MY"L$#RD*LBLQPH)X J?6=2EUC2+[3-'AO!>7%G-Y<LEM+ J'80OS.H&2Q
M Z]3VH V(]4TZ43&._MG%O\ ZXK,I\O_ 'N>/QI\&H65U,\-M>0321@,Z1R!
MBH/0D \9KA)$L=7T+4+R+1M62^32);5X[FWD&S(XB5<8<[NFW.,=1GELEC="
MXL%TBRGMKF3PW<6ZRBV>,+.?+*!FP #D,>?ZT =/<^(@OBG3-)M9;2>.Z$PG
MVR;I(RBY P#QSZ^AK534;&2>6W2]MWFA&9(UE4L@]2,Y%<+;2F\O/"@L].O;
M6:TM9[>7S+*11;.8@H#$KC&X=>G3UJ3PY%:74&G)J&DZJFI:3;/#,)XG\N/*
M;7P<;9 Q P!D\@]J .FO=?1;K3H=-:WO3=72Q3>7,"8HVC=P_'^YQZUHQ7]G
M/.UO#=P23("6C20%EP<'('(YK ^'UA%9^#=+W6!M;M;9$G$D!CDW#.0<@'J3
M^=4O"<=[:ZI;V\?FW6F?8W,3W=NT5Q8?,G[EF( <'MQGY/3&0#K+F_L[,J+J
M[@@+?=\V0+GZ9H>_LH[M;22[@2X?[L+2 .WT7.3T-<GXNBO$U2>ZTLS/="Q1
M)+.6V:2WOTW/B(,!\L@)/.>C#/'-9VN-=3W=V$TN]@>#6K.X9(+1Y!,BF+,Q
M?!!P!C:F"-IR#S@ ZS_A(["[74X-/O[/[58!E8S2 1J^T'+8.=H+ $^N1UJ^
M^HVEND0NKVVB>101NE"AO]W)Y%<5J<$S:=X[LWT^Z>6[5I;8"V=A)FV15VD
M@G<",#D8HU5+Z-DN]+6X>Y^PV\4VGW-JYAO4!.%5L I(I9N_'!([T ;EWXBF
MGUVYT;2)K W=K#'*RW+G$I9FR@VG*D!"2<'J.*V[6_L[W?\ 9+N"X\O ?RI
M^W/3..E<I=&9/$WBB4:9<W:R:5$D4?E.JW#*)2T8?&,_,!P>]8D]OJ=^U_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,[4M&AU2[L;F6XGC:PF\Z(1E0"VTKSD'/#$
M?C6C110 4444 %%%% !3)(UEC:-\[6&#AB#^8I]% #41(T6.-0B* %51@ >@
MIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4<<$<3R.BX:1MSMG))J2B@ HHHH H6^CP0
M:I/J)GN9II<A5FF+)"#C(1>B@X&:OT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9VDZ-#HYO##<3S?;+AKF3SBIP[=<8 XX'%:-%
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M)X4UF73;^W>6Q\R[U>/4!AG 159&*YV\GY,9QW_"@#=37X9]1FL[>WEF^SW
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M*YFN+6S,DSVSA##N4E<-D'=P3@=A[C,>BZZ5T33+6."XU"]&EPW,RQLNX*5
M!)8C+,0V/7!SBH[[P]JR:OK%SILUH]OK5NJ3I<,RM#(J% RX!W C&0<=.M,T
MKPWJNB7=I>6TEI/+_9L5E=Q.[(I,6=CJ=I/<@@C\: +9\::7)8VUS:,;@W4#
M3QQ[TC;:#@@[R #G(QZ@^F:(/&5A>PPR:?!/=-+9B\$2[5D\LDKPK$9(*D$#
MICW&<ZW\(ZKH+:?<:#>6KS00/!=1W:L(Y@\AD++MR5(=FP.>#BI]?\+WVN1+
M'.;1YDA'D7REHIK6?+$NFT$E>5PI8?=Y)SF@#:UW6(M T>XU2>"::*W&YUA
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M;)A3MYQNSSCI619>%=;AU+3+VYNK&:6QNII))RKF2X216 +'L0& "]!C@]J
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M*KJ5=0RD8((R#3J* &1Q1PH$B140=%48 I]%% !1110 4444 %%%% !1110
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MVX@N_MEJ]G<VMVMHT$DB\NRAE.[.,%6S[8-7-$UV/63=QB$Q2VDOER88.CY
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MVW=LD1@RDCN,CFLO5O"UWK46I3W$MO%>WNG?V>FS<4B0DEFR0"221QQC ^M
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M5/W<@@C!':L=_"UZB:U96]Y#]BULL\Q92'@=T"2%!R""!D D8/KTK:NM//\
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MC_6^;LQ]>,_I45WX-U5M-U/2+34+1;"]O!=QF6)FDA8RK(R<$ C()!Z\X]Z
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3
MI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I, ]12T4 %%%% "%0>H!^M+110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:@MHTVG:?<&"YG5_F4@@.RICE5)P>0>#@''-?4/&C63ZN4TB>>+2 CW$@E0
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MEG:F"0:E#93YEP"#*@)1@/F5E;&[C&3W%6IM7M_"<5QC2G@M1-$TV9SMWRD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO(-C:BZ61Y/EFC.?F'' !4@^G'6L;4? UW/!?65GJ,,=G<6<-M LT!=[<1@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MJKJ.I6>DV;WE_,(+>/[\A4D+[G'04 6J*SKO7M,L;6WN;JY,,-RP6)VC;YV/
M0=.I[#O6@#D C//J,4 +1110 45GW6N:=97R6-Q.RW,BETB$3LSJ.I& <@=\
M=*GL=1L]2A:6RN8YT5BC%&SM8=5(['V- %FBBB@ HHHH **** "BD) &2< 5
M535+.359-+67-W%$)GCV,,(3@'.,'D'OVH MT444 %%%5-4U2ST;3Y=0OY?)
MMH1ND?8S;1] ": +=%-=@B,[=%&3@9J.TNHKVTANH"S13('0LI4D$9'! (_&
M@":BBDR,X[T +114-U=065NT]Q((XU(&3SDDX  [DD@ #J30!-1573]2M-4A
M>6TD9ECD:)P\;(RN.H*L 0?PJU0 4444 %%%% !1110 454NM4L[*[M+6XFV
M37CF.!=A.]@"Q&0,#@$\^E26UY!>"4P,Q\F5HGW(RX9>N,@9'N.* )Z*** "
MBBB@ HI"0H)/0<U6TW4K35[);RQE\V!F9 VTKRK%6&" >""* +5%%% !1110
M 445434[.35)=,27-W#$LKQ[",(20#G&#R#T]* +=%%% !15235+.+5(=,>7
M%W/&TD<>P_,JXW'.,<9'?O5N@ HHHH **3(SC/-+0 4444 %%%,EE2"%Y9"0
MD:EF(!)P/8<F@!]%1V\\=U;17$1)CE0.A*E201D<'D?0U)0 4454DU2SBU2'
M3'FQ=SQM)''L;YE7&XYQCC([]Z +=%%% !1110 4454U'5+/2H8YKV7RDDE6
M)3L+9=B HX!QDD"@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9]/2NWO- TZ^U*+4IXYOM<*%(Y8[F2,JIZ@!6 YP*2/PYH\5K>6WV%'CO_\
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M<UU4GAK29[:XM[BW>=+F)89#-,[L44DJ Q.1@DG@]>>M1IX2T1?M6ZT>4WD
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M7\5^;=/M,,30QR8Y5&()'_CH_P F@#)LKFY\06EU>:9JTD-M/'&MI*(HW"G
M9G (YZ[<'H5-;]9-WX>L9?#;Z%;P+#:%-B1J[(%YSG*D'KSC(ST[UIPQ^3"D
M6]GV*%W,<DX'4^] #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,\1ZN
M^@Z!>:JELMS]DC,C1F39N4=<'!YH TZ*@LYI+FRAGEC6)Y$#%%?<%R,XS@9_
M*IZ "BBB@ HK%OM=N+3Q3IVBK8I(E_'+()S/M*"/&?EV\_>&.:(-=N)O%USH
M1L45+>V2X-P)\DAF( V[>N5/>@#:HID<T4N[RY$?:<-M8'!]#21313#,4J2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(,?(N"> .<]!CGN:* .!U"*]36K.VLXK1[VTTE8+M/M_D.48X !,;!E^1B.
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M/DEF4X^12". .?05U]% $%E-+<6-O//"8)9(E=XB<F-B,E?P/%3T44 %%%%
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M5HF7R\@DL=P/F>@QCOUH\5_;3K_AE+>XBC1KY_E>(O\ ,()>3AAD8[>O.>U
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M?[-$-C:;+*VNY4E5I'3>S*\>5;!(V'##CV.> #HY+VUANH;66YB2XGSY43.
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MVD N)5DMI%;RNF\#;DKGJ1T[XH JS^"--NA??:+F]EDOC$\DC3 ,LD>-LBX
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M5Z$CI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHJE<ZSIMF]PES?0Q-;1>=,KN 43^\1Z>]00>)-'NHGDMKY)PC!"(E9F+%=P
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ML'C-E=!@D=Y'&ZNJD@Y1R%VG.!GG-=S10!PM_I5YK>AWEQ8Z#/IU\?(8K>S
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M:V_VII$4JWD&7&W<<\L2"3C.,]3U/8T4 <_XITXZ@]EM%]!+"7>*^L3E[=\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#,Z,6W;?0Y_/VYKK** .?\2:=JDFH:7J^D1PSW&GO('MII/+$T<B@-AL'##
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MR,)U]3Z<UE:=X<\1V^C:=I4\%O);16,L$L1N2JK*6RLAPIWKMXVGO^!KOJ*
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M 02HZ!5SU(# GIG!]:O+H=Y=:KXF6YC\FTU>!(8IE<%AB,H21VZY'T[5TU%
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M*\/ZM96WA"&6V0G1@ZW1$H[Q-&"OKRV>W%,_X1W6/[/GVVT0G77_ .TXXWF
M#Q[PVW(!PV/PKMZ* .2U.P34?%MB]K=0B22$Q:I!&V[=$C!U!],.=O/57:MG
MQ-IDVL^&-2TRW95FNK9XHRYPNXC S[5=@L;2UFFFM[6&&6X;=,\<85I&]6(Z
MGZU/0!R]MI^L6?B#^VOLD<@O+)+>YMDG&871F*$,0 5(8Y]#TS6EX8T=M \/
MVVFO(KO'O=ROW=SN78#V!8@>U:U% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '&:M9V>H?$,V.H7$PMI='+F'[4\:L1+C. 1T'/'IGM6!;WPDT&PLM4O
M'>[_ +,NGA>\EPCQ^9B)P.KRE0N#D8!)ZGGMY_#QN?%8UF>:"6 6GV86KV^X
M_?W;MQ;&<_[-;#11NRNT:LR9VDJ"5SZ4 <$E])9Z/X:\8*\MZOV.*WU!8V+E
M]Z* ^.F\284GKAB.U=CI.GFSTE+:<!I7!>?!R"[<L![9) '8 "HKC2KBYU&%
MC>A--A"-]A2 #=(IRK%\YP#M.T#JHYZBM2@#RJP33QX4\-VD<D<<G]O^7,D<
MFUU.^8 '!RIQ^-6=0D2T\.^*;2&ZDBBL-8@$ $[#RU;R25Z_=)9^#QR:]&:T
MMG^_;Q-R6Y0'D]32&RM#G-K"<G)_=CDT <?JD\UIXJ>X=8=1LGO[:%O+<K<V
M$A";0!_'&V0Q Q]YCSBNB\1O$FF1"9D"M>VJ_,>#F>/BKXM+99A.+>(2J,!P
M@W =,9ITL$,X FB20#H'4'% '"3V-YX4U2UTFWB>;0;^_A>UQS]AE$@9HS_L
M-@E?0\=ZAU"YDNM(\4S33/%KEA>N++:Q$B*-OD!!_=?C@<,2<YKT,JI4*5!
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M S>7-%Y<@CD#%U)8<$+T.",UOVIE_M4/#H3V8E3%Q<2M%\P7.U0$<DG+'D\
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M7$<$EJ51I"9-NP@JQ7!W#G/&#FH9O&=I;Z?=7DEC=E;*\%G=*GEDPL=N&)W
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M>YM]/2PNXIP_E2(A)5E(&0P+-U&#GM6M'H^IQ^*(]7>6WG":<;5LL4+.7#Y
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MLB)&NV-%1?11@4Z@#E[_ ,-7M_;Z].YMX[[5[(62J)&,<*!6&=VT%CER>@Z
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MYK. N#T.>F* ):*9%+'/$LL,BR1L,JR'(/T-/H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*ZN8K.TFNIVVQ
M0H9'/H ,FI:I:IIJZK:"V>YG@42*Y,)7+%2& .X'C(''?ITH XW0KV72_&L;
M77VI5\1PEY1/!(@BNDR0@+ #'EG:,=?+%=_67KF@V^O0VL=Q<7$)M;A;B)X"
MH82+T.2#ZFK=O9F"ZGN#=W$WG!!Y<C HFT8RH &,]30!9HHHH XKQ+<O9^/M
M)N8K&6]:/3+QO(BV[GP8^!DBHO#5R/#_ (#GUB&2&X34+TW%O!"?W5N9Y%18
MAG'"L>>G.>E=-<:%!<Z_:ZTUS<+/:QM'&BE=FUL;@1MSS@=^U57\'Z7)#J5L
M3/\ 8]38O/:!QY8<XRZ\94Y /!Z\T 4Y]?UW3#.NH:?&%FGMX+"<[4#O*VPA
MU#L<*3G.1D<=:CU'Q#K.F2^((6>RF;3-*%_"_D,H8_O,JPW_ /3/J".M73X-
MLIM(ET^]OM1O?,V[;FXN,S1;3N4HP  ((SG&3WS5"QT)_P#A)]6MKW[==V=W
MI<5JUS<\F8@R;QD  ?*XZ #KWS0!<&NZB^L6]D@M0ESH[WJDQME9%:,8/S<K
M\YXZ\=:S;/Q'KE[9^&4L5TZ!]8L9)6WPN5B=44C ##Y?FQCVZUK6GA"WM;F"
MY_M/49IX+1K1))9$/[MB#C 4#(VCG';G-/L_"5I8MI!AO+O&CQ-%;J60@JP
M(;Y>> !VZ4 45U[Q!=N\NFZ?%<Q6M[]EG3Y5WA2%D8,9 5(.2 5/ ]^-'Q;J
M-SI.@/>VR02,DT*LDZ%E(:15XP1R-V1]*9_PB-DNL3ZC%=WT*73B2XLXYL03
M/Q\S+C.3@9P0#W!J]K6D0ZYIK6%Q+-%$[HY,) 8E6##D@]P* .?U37]>AN_$
M<5FVGJFCVT=S$9878R J[%3AQ@_)C/;T/:6WU_6'U>VMI?L7EZCIKWEL%C;,
M++L^5CN^<$..0%Z5H3>&+:>7597O+K=JT"P7&"G"J"HV_+P<,WYT#PQ;BYLK
MA;V[$EE:M:Q$%/N-C.?EZ_*OY?6@#"T[Q+XAO(_#DS'3@NNP-\HA?,#B,R;L
M[_F& ?EX[?-WJQ9^*M2F@ALI(89-1?4+BR+PIA&$0)+A&<<D <;NY/.,5I6O
MA.SM$T=(KN[VZ,"+8%D/!4I\WR\_*2*AF\$:?/:R0M>7RR->M?1W$<BI+!,V
M=Q0A>AR>""* (8->UL7-AI.H6<-IJ%Y/.%D.&1H(@#Y@57."=RC:6XY/.,'&
MT^_OM*TW4I=MI-(_B<0S;HCM(>2-=RC/!YSR3BNDN/"5I<16A^VWR7EG*98K
M]909]Q&ULDJ5(( !&W& .*C_ .$,LOLDUN;Z^(GOEOW8NA)E4A@?NX RH./:
M@"MJGB6_T_54C'V5X6U."S\I$9V"2;1N9P<*V6SM(Z#WR*T'B#4[)]>FN9H[
MKR]7CLK6(1[=I=80O);&!O)(XR<\C/&E/X*L)YIW-Y?(L]XE]Y:2@*DZE3O'
MRYYVC(.1Z 4^?P=IUTNJQ3S7+V^J.LDL&\!4D 4!U(&X-\BGDGD4 6-&N=;E
MN[V'5;)8H8RAM9UVJ901\P*AVP5(ZYY!K%U'7O$JW7B!-/&FE-&"2*LL;EIE
M,>\KPV >HW?I70:1HZZ3$RF]O+Z5@ 9[R7>Y S@< #N>W?FL&VT6;4/$OB7[
M2U];65]Y* *H5+A!$%?DJ2.<C@@^G8T 1:GXROH-,.JVJ6WD"VMKE+<HTDC+
M(?FWD$"/@X4D')!Z]*OW?B"^TW7=0L;W[/Y7V/[3IQ2)@TI!VLARV"P8IP,9
MW"GWW@C3+Y[[]_>6\-_%''-!!(%3]V $8#&00 !C...11<6)U?7+**YTR=8=
M&F\Y+R=E(G;9@!<')Y.XD@<H/P *L^J^)!J]SI22Z8LT.F1W?FFWD*[RS*5V
M[^F4X.>,]ZBT[Q5J<LN@W5ZMH+/6K-YO*B1M\#+&),[B<,",\8&..3WW9=!A
MEU>XU3[5<I/<6HM6"E-H0$D8!7KEB<^]5K?PG9VPT<)=7171D,=LK%""I7:0
MWR\_+QV_.@"GI>L^(]4;3KN+3XAI^H6YE,C!?]')7=&>)"7!Z'Y0>_'2JFB>
M*-;OAX<N+L6(AUR&3Y(HG#0NL9<-DMR#M(Q@8]36KI7A"ST9BMI?:@(%+&WM
MGG#1VQ;(^0$>YQG(&:+/PC9V,6D1PWEYMT8M]F#,AX*E2&^7D;21_P#7H ;X
M(N]0O_#JW6HW*7$CW%P RQE2,32#U/' P.PXYZU0O/%M\FAZCX@MH[=K+3KM
MXGMV0^9)'&^QV#9P#U(&#P!GKQO:+HL6AVTMM;W$\L+RO*B2E2(MS%BJX .,
ML>N3[U5;PG8,]VHEN%M+Z?S[BS#+Y4DF02>1N&2 2 0#Z<G(!G0Q3WGQ#U&*
MXDMYK0Z7!F&2W)#(TDO'+8SQR<<\<"K_ (AU6^TZ14LWM4'V:64;XVED=UQ@
M!%((7DY;.!P.,U=BT6*+7Y]9%S.9YX5A>,E=FQ22H QG@L>_>H=1\.6NI:FF
MH/<74,HMVMG$,@42Q,<E6XSU[@@^] &+'?'5?$7@[4FC$;7>F7,Q4'.W<D+8
M_6KO@4 :#< =/[2O?_2B2K%GX4M+&327BN[PG28&M[<.ZG*,%!W?+SPJCMT^
MM7-'T>'1+1[:"::5'F>8F4J2&=BS= .Y)H Q)/$FH0:Y9VS_ &62"ZU&2S*1
M(S>6 CLA,F=I;Y.5QQG';FD?%'B!+(WQ&G-'#K)TZ2(1."Z^=Y08-N.TY(.,
M&M9/!5A')$R7E^$@O6O88A,-L3MNW <9P=[=22,\$4\^$+,V+V9O;S8]_P#;
MR=R9\W?YG]WINYQ0!FR^+-1TR35;*^%K<75M<VL-O)%&T:-]H.%W*68_*<D\
M\@=J76O$^K:)+JUFXM)I[72WU*VE\E@C!#AD9=W7.,$'H>G'.G=>$=/OIM2D
MNI;B7^TUC$JEE 4Q_<92 ""#SG-2MX:LYXKM;Z6>^DO+7[)++,5#>5SE1M50
M.6)SC/3T& "C>:_J,.JRVD0M=G]CM?(6C8D2*P&#\W*\^QJMI?B#6[B[T6.Z
M:Q":UIK7$7EPOF"151N<M\RG?TXQC&3UJ[%X-MDF\^35-2FF^Q-9&225"3$3
MZ!0,\#G'UR:GMO"]K:SZ3*EW=,=(@:"W#%,%& !#?+SPJCMT^M '/:;XIU*R
M\':-JFI3!XKQ6:YO1:M(+?.2-ZJV<$_Q# '3 ZUU!U<6OA4ZS<O%<"&R-S*U
ML<H^U-S%/8X.*JZ=X5CTNSMK6UU2_6.U#I$"8SA&(.P@I@@8X)&?>M"TTBQL
MM&CT>*$&S2'R?+?G<N,$'Z\T 8HU[58+C11=?96BUI"B&.)LV\OEEUS\WSK@
M$'[IXSWXH0>,M25=(-[]C1Y+^2RU)$A?]RRML5E._ !8QCG/WP:W]/\ #5KI
MYL_](N;E-/4K9I.RL( 1MX(4$X7Y06).,TV[\)Z3>)JRRQ/_ ,3<+]I*M@Y5
M0%*^A& <^HH H7>MZC%_8T[+9R0:AJOD)^Y8,L)#E'!W'YB$SG'1N@JE+XHU
MV&WOKYA8&WT_6%LI(Q$^^6-GC3(.["D>9GH<^W?I-0T.VU'^SPTDL"Z=.L\*
MP[0-RJ5&<@\8)&/>J,O@^SFLKVT:^O?+OKQ;R7#)D2!E88.S@91>/;ZT 9^L
M^*M1M)-72SCMUFTZ>".*VFC9GN1)M^9<,.[$#&>4.>O&QXEU*]T7PI?:G 8'
MNK2W,N'0E&*C)& P(!^M<]<:=J4GB"_G/_"06L\DH\E[-[=X'0*JJV9 =I."
M2./H>IZN?3AJ6A/INJ$3?:+?R;DI\H8E<,1Z=\4 8VI>(-1M-7N[.$6I2+1V
MOXR\;$AU;&TX;D'\#56V\5ZE:RV$VK"U:TOM)DO\6\;!XC&J,PR6(8$/Z#&.
M_6KZ^#;;S7FEU/4IYGLFL6DDE0DQDYZ!0,^^/UYJ5/"=D'T]I+BYF73[5[2-
M)"A5XF #!OEYX51VZ?7(!AS7=]>:[X-U.\:W6*X\^811H<Q;K9V W9.[@\G
MY'X#0TK6_$.JG3;Z#3XAINH0F1G8*#;@KNC/$F7[ C:#]*FLO!=I92:<5U+4
M9(]+=FLXI)5*Q*5*E,[<E<' R21ZU)I7A"ST:4_8[V_%NK,T%H\P:&W)SRBD
M>YP"2!GI0 WP?J>L:WI%OJNHFR6&ZA#)%!&P96W$')+'(QCC''J:P-?NM1N=
M-\>P75U');VEMLBC$1&T& ..=Q_O'/'/MTKL-$TB'0=)ATVVFFEA@!$9F(+
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MGO\ 3..<9H T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@X(.0,FL#3IVDUWP_<)I]W:)#?7B36XM9"("ZR'YG()8LW)(.T9'3&:]'HH
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MWG75L\"I 3O8)&&9,#DY#9([YJWJMK:QZGXECM(Y;2UN- 3]Y:0$9<>;G &
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M['(XR$V'Z8->GT4 <;/I<]KXKN-)MX =+UTB\GQC$;1E1*".XD'EC\6K5\;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4PFR ^RZY!Y.HH>"%CP0^.O*%HSZ;E]* -[5-;LM)T&?6IY-UI!#YNY.=X[
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MQZ&@#O58,H92"",@CO2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !115+5]6M-#TV74;YG2VA&9'1"^T>N!S
M0!=HK/AUFWFN(8/)NHVG)$;26[JI(!;&2,#@&M"@ HHHH **H7FKPVMZMBD,
MUU=-&9?)@ )5,XW$D@ 9X'.3S@'!J33=1@U6R6[MQ(L;.Z8E0HP*L5((/(Y4
MT 6Z*S[K6(+35[32Y(IFFO$D>)E4%?D + G/7D?G3M&U:#7-,CU"V25(I'=
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M,$\<T 7Z*R4\0P2R:I%#9W<LVF2+'+$B+N<LH8;>>>&!YQ6M0 4444 %%%%
M!14$]R89K>,6\TOGN5+QJ"L>%)RW/ XQWY(J>@ HHID<L<R;XW5UR1E3D9!P
M?U% #Z*** "BL_5=8M](^R?:(YG%W<QVR&-00KN<#.2,"M"@ HHHH **@GN3
M!+;QBWFE\Z386C4$1\$Y;G@<8[\D54O]=M-/ELXW$DOVRZ%HC1 $+)@G#<\=
M#^5 &E1110 4444 %%17,QMK66<0R3&)"_E1 %WP,X4'&2>U5[S4X+&PENYE
MD/DP&=X5 ,@4#)XS0!=HJ"QNX]0L+>]B#".XB65 PP0& (S[\U/0 444R.1)
MHQ)&X=#T93D&@!]%%4)M7@AURVTAXYO/N89)HWVC9A"H89SG/S#M0!?HHHH
M**8TB(R*[JK2':@)^\<$X'X G\*CM;DW*2,;>:#9(T>)5 +;3C<,$_*>H]J
M)Z*** "BBB@ HIK,J(7=@JJ,DDX %*K!U#*<J1D$=Z %HHHH **** "BBB@
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M2P'!P<\/CI7H%U:6][;O;W<$<\+_ 'HY4#*WU!JN^BZ5+:K:R:9:20*^\1O
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M8#=.H'>G#1]+&I_VF-.M?MV-OVGR5\S&,?>QGIQ0!822&[@8Q2K)&V5+1/\
M@<$="*\Z?5=0TR...:ZO)9/#NHM_:3M</^]M'8;'89Y.V0-_VR85WFE:5:Z1
M;R0VL4<2R2M*RQ($7<>N%' Z#^?4U/)9VLJSK);Q.+A=LP9 ?,&,8;U&..:
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M-2U73?%+R12:4TL44,SNV]2")0Q8E.N"!@'([BNY32-,CEAF33K19+=-D+K
MH,:^BG' ]A4,7AS0X+>>WBT:P2&X.Z:-;9 LA_VAC!_&@#B_%236R^([ W]Y
M-!+X>:[*RW#'$H9AE?[H(QE1A3Z5W&EM;QV-O;Q3[V$(;:TI=L>N22<9I?[&
MTKS?-_LRT\SRO)W^0N?+QC9G'W<=NE.MM+TZR='M+"VMVCB\E#%$JE8\YVC
MX7/./6@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6TB$TC21E4*'J0QX..^.E0V_B.RN9[.)8KI!?DBUD>W8)+A"^<]OE4GYL$T
M:U%5[Z^M=-LY+R\F6&"(99V[=A]23P!WJF=>MXV@^T6MY;K<R+'"TL! 9F.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>;:=/JNF^'KC7X+V1KV36W6\LGC0B7-P(0F<;@0NTC!QP.*
M])JI_9=A]L-Y]DB\\L&,FT9+ 8#?7'&>N.* +*NK%@K E3A@#T/O3J@@L[:U
MEGE@@CB>X?S)F10#(V ,GU. *GH *Y_Q[QX"US_KQE_]!-=!4%Y96NHVS6U[
M;QW$#_>CE4,K?4'K0!#8SQ0:39-*X4-'$BY[D@ "N3\-V^IW*>)1IVH0V_\
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M%=6GA?0(H/(CT:R6(?\ +,0*%ZYZ8Q5I-*T^/4&U%+.%;QQM:<(-[#T)ZXH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCW#&TG:!QCI@=:N7=W<V&HZ;H1U1KJ.[FN1YTDIA;*[62$R+DD@.>>"=GU!
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MY?\ CT8,N4EC[JX(&[G -:OBS59-*T^T99?(CN;Z&WFGZ>4C-@G)Z>F>V<T
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M'8GD5>HH I)I&GQW-S<I:HLUV,3R#AI!VR>]-70]+72_[+6P@%CVM]@V#G/
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M >N: 'T5"EY:R0"=+F%H6.!(K@J3G&,_6F_;K/RVD^UP;%?86\P8#>F?7VH
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M<=VT>'R5<$J@V(WS$*>N!T_#3NM2G'AN75+:V*3?93.D-T"A4[=VUQU!'<4
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M7RI?-1TSPP; R".>G>N+M[JX\'ZO>WSL7\.75ZT4Z=182<!7'I&<X(['!]J
M/0**Y:PO[71X!#:V\;W&HZI/# BG:K89VR2 <*%4]CV ZU6UCQ=J$-CJ%O!:
MPP:C87EK#.K2ED,<SJ%=#MYR"1R!@@]<<@'945S>I>*KJS>[CM-(EOI;#8+F
M*#S&)9E#%4Q&0Q"L#SMSFM35M8ATC26U"5'8914CQAG=V"JO/3)8#VH T**Y
MJ_\ %=QI<U_:W>G1_:K6P>_B6.X)2>-.'&XJ"&!QQ@YR/?&IHM_>ZC:"YN[!
M+1)%5X0)_,+*R@Y/ VG)QCGZT :-%<Y'XIE_MRSTV>P2%KV2:.-3< RH8PS
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M6CE74,0V[<>QXQR#5VYUNXE\37&@):3QHMA]H-TC)QN)4$?-D ;2.F<]L<D
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M,@CKD5'J_BBPT;[09UEE%J@DN3%M/DJ<\D$@G@$X4$X[<B@"7P_H<.@6,EK
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M)R<X]\UO6.HV>IQ/)9SB41N8Y!@AD<=58'D'V-/N[RWL8//N95BCW!03W8G
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M^-VWZXH'B/1R9@=0B3R8?/8R90>7TW@G[R_[0R* .=NO#&MSZ+K-DJ60DO\
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MR11>>3?[D;,2^2[CGL<A?7[P]:N6NK6-[-Y-O/O<IYB_*0'3.-RDC##GJ.*
M+E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN6*GIG<%&<?=],5VVJ:;IFKFWCOSO-O<++"JW#1D2KR#\I&2.N#1JNG:9K,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC"H8_+?82A5@01D 9)/4UN?$6*&;P?.LJ!V$\!0 98$2IDKCG.W/3MFNHHH
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M"12#^\'Z*>>&K(2RU+28K.XBT]Y6\*7;6JX0;[NWD. %_P!V-HS]<^E>FT4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$,6QH7A8LCJVX\AF)Z>GXZ>CZ?J%E&3J>K/J4Y 4/Y*Q* /]D=SW/L.E:5%
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MT-0+XMT!V*+J<);R1, ,Y9#CE>/FZ@8&3FL;5M/O=8OI]6AL+B#9HT]IY4@
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M]TI25<]>>77IGO4JZ)=2V%Y#?Z=?VYEUR6Z@GM94\V!65MLJ[6/^Z5(Z-T-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=,U"_;3KG;8:@+&1-R9W$H-W7IEQTR: .DHHJ*.XAFEEBCD5GA8+(H/W20"
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ML!D?:""1@G)'J<$5Z.;.U)8FVB)8 ,=@Y Z#\*=Y,6]W\I-T@P[;1EAZ'UH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,E\1:3!=R6LUWY<D,
MBQ2%XV54=ON@L1M!.1CGG-:=<7_9,/B#Q!XET^>X9+26:V,J(!F4(BD@,>V1
M@XY[9%,75;QM?;[/<7D:-]NB<3H[A'0CRR5 V@<$J!R5Y))- ';TA(52S$
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M9\LB,A_O=")4]^O Q45]XZMH[&X>UM9Q/'&^WSD&P2*KG8V&SG]V_3CCKR*
M.KHKF9/&^G68"77FNY2:0&.-5R(S)D!2Y;.(FYZ=.1D"ICXQL469WM+U4MHI
M9;EO+4B (95.[#'J87 QD<#D9% '045S]QXCDNO#HU31XM^9_*?='YQC4/M=
MMD;?/C!.%;D<C--M_%UJ+-3<_O[A+7[1)]C4NCJ$W%TR<E3T&><\>] '145R
M\OCNRMQ)+/97$<"PPRQN7B_>&0R  ?-C_EF3G.#V[9FC\:Z=+/'&EM=F.1T5
M9MB[#N=8P?O9QN=1T[^QP =%16 ?$ZW7AV/5[&!U62ZAA"W"@'#S(C'"GKAC
MWX(P1P11>Z[=P1:OY4<.^TNX+: L"1^\6+EAGG!D/ QP/QH VGMXI)XYV7][
M%D*XX(!ZCZ' X]AZ"I:RII]5M]#>:>XT^&ZB9C+.R.85C#'YMN<YV#.W=P>Y
MQ6-:>)-;N+BVCDMK2%Y62W:"17#+,UJ9\ELG"Y 4K@GJ<]J .NHKC)/%.L0H
MQ(L9%@6:5IEA<+<)&\:?(-_R\NXW$L/E!Q@U>U_7=2L9=3CL3:K]ALH+H&:)
MGW[WE5EX9<?ZM<'Z]<\ '2T5R-_XBU>RDU>(/:R2:=;AD_T"8)(Y0-DN'*J,
MG[O7'>IO#OBFZUS69+9X(H[=+**0X!WB8JK.O7&!O ^H/- '45%!;Q6R%8EQ
MN8LQZEF/4DUSLVM:Q;6>J3;[&X%E<QPJZPO&#G:7XWMG&\#J.0?2J6I>,+^U
MNM36(6X2UWK$DEM*69E,8)W X?[Y^48/3D\X .THKCO^$QNXX--,B6Y>>]>*
M<F-HSY*RK%N",=R-F2,E6S@9J]<ZUJA\.7&I6JVZO;75TDFZ&27]W%)(B[44
M@ECL3/( RQ[8H Z.BN>UGQ!=V-C:26T,3S3VYG<X,BHH* D;3\P!D!XZA3]:
MIP^)-5EL]/O0+1K>:]-G(1!(#(1<-%N&6Q&-J[ANW9)"]2,@'6T5R-[XEU>T
MLTOUCLI8I-/DO! JOO55A+[F;. -^U,8[YSQBI9-;UN-2JFPDD@OOLC@0N#<
M,?+("+O.WY6<DDMC;G&,X .IHKD[#Q/J$US#]ICMC!.T;*(T8,BO))& 26.3
ME4.<#J>.]/D\37\/B34+9K<2:?8L1(8[=PR*($EW&4ML)+-MVX!Z'.,T =31
M7-1^.])D".([GRV5F:0*K*A42D@D,<\02<KD<#GD5877I-5T!M2T;8I1V$GG
M1&8J%^]M2)OG;T ;O^% &[16"/%$-OH>F:A?1-OO;=9G6WPRQC:&9LD\J,]L
MGTS4FFZG?:CIE_</Y-F\-W-%$TL>Y52-RN6 ?G[I[K].,D VJ*S]"N[J_P!$
MM+R\$8FGC\S]VA0;3RORDD@[<9&3SFM"@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HJ&YNH;.(2W#[$:1(P<$_,[!5''JS
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M'\V!B[&8L)@<L7_Z>'/3/O6HV@V3Z>EDS7)1)/-63[2_F*_J'SGN1Z8K2HH
MR[CPYI=S96EE);D6]F@2%$D9<( !M.#R, <'KBIVTBR?3;G3S&WV>[,IE4.0
M6\PDOSU&2QZ5=HH 15"J%4  #  [4M%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit103-form147_716ba004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
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M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ+)=[MD3VYD!?C *YY]*YCP-K^DVGP^T82ZA;>8MLD?E"52Y?H$"YSN)P,4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FA%#%@H#-
MU..33J* &JBJ254#<<G ZFG444 %%%% #2BD%2HPW48ZT.B2##HK#T89IU%
M$9@A*A3$A"] 5'%(;: ]88S_ ,!%2T4 1F"$J%,*$#H-HXIY /49Q2T4 ->-
M)!AT5@/[PS1Y:%-FQ=G]W'%.HH B%O I!$,8(Y!"BE$$(;<(4SUSM&:DHH :
MZ)(,.BL/1AFFK!"IRL* ^H45)10 Q(HH\[(T7/7"@9I%@A1@RPHI'0A14E%
M#&AB=MS1(S>I49IOV:W_ .>$?_? J6B@!K(KKM90R^A'%-%O I!$,8(Y!"BI
M** &)&D>=B*N>N!C-"11QDE(U4G^Z,4^B@!I12&!48;J,=:=110 P1HK%U10
MQZD#DTAMX223#&2>ORCFI** &K&B*55%53V XI$BCCSLC5<]=HQ3Z* (C;P,
M23#&2>22HI3!"0 8D(7H"HXJ2B@"+[- 3DP1_P#? I3!"R;&B0I@C:5&,'J*
MDHH C6"%81"L2"(#&P*-N/I4E%% !1110 4444 %%%% !1110 4444 %%%%
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M;26&#XDI<65]_:MO+8.+RYE<.+%5.5"N,*H8]5Z\9KO** //M8M;KQ#X;O\
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MC*B3_;SG.>>M+HTFAZC9)?0:E+]NBTZ6*_MP@C(.SYOM' .0XX).22>HS7I
M50<A0/H*4  D@ $]?>@#CO!L^A:+X/T6^DN(8)M2M[:W>5I"?-F"8"'W'S#V
MQCM5CXBPV\GAE)KF*-XX+ZUD9I%!$:^<@8\]!M)S[9KI+FUCNT6.;)17#E>S
M$'(S[9Q_^JIJ /,M8BT>\OO&1)MV2WT>W>V ;"HRQS%2HZ9&5P>V1CK5Z._M
MI?$EG=27VUYO#$C2RQR98'=&=P'][AC^%=_10!QO@IW@U&ZL98K&X9;2%EU'
M3SB.XC!<+O7^&3DD\G(^E6M7T_3/$&N7NC7DJ%I+&)E".!)&P=R'7N&'!_\
MUUTX4+G: ,G)P*6@#SG[3XI33O%%K+$[:S8Z;!%#<Q#'VI=TY$J#LQ4GC^\*
MMF'3K[6=.;P\D,MC<Z=<#4(H@&1TVKY?F#^_N)'//WO0UW5 4+G  R<G ZT
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M%]T(68$-GKECVK6H \YTI]/U+5HXM1OY8?$%GJ<C/;I$!,Z[VP,D9:$QD>P
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M:[*FA5 P% '7 %.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L7Q=J=YHOA:_U2Q,/
MGVD1E F0LK8[8!!_6MJL#QS;7-[X+U2RL[>2XN+F QQ1QC))/\OQH V+(S-9
MPM<NCRL@+LBE5S[ D_SJL-=TLW1MOMT0EVLX#' 8+]X@G@X[XZ=ZJP:I=3Q6
MUK%I5]"\@"O+-&%6$ <DG/)XP,9Y([5@^%[*XMXM.M-4\/WBWFC(4^V23F2'
M 0KNB&XDEACC:,9/H 0#I+/Q)HNH7,5M9ZG;SRSH9(U1\[U'7'KZ_3FL[7?$
MGV6_TJVT^ZA8W&HI;3J8RV1SN"MTR",$<D>U8>C:9J%KIO@R%].N89-/FE^T
MCR_]2&BD4$]CRXZ9J.RL]9AT+P_I$^BW;76DZG&\\J[3'(H+_O%8MSD-D]\Y
MS[@';RZUIL-XEI+>1I,[^6H8X!?&=N[INQSC.<5'9>(='U*Z^RV.I6]Q,59@
MD;AB0K;6/X'BN8T[3[J*^FTO4]"O+HQZB]W;WOGDVVUI3('(W\.NXC 7D@>N
M:U_!5K/9Z7=Q7-I);R-J%S*!(N"RO*S*?R(H U;W6-/TYBMY=)$57>^<_(N<
M;FQ]U<]S@5#>>(]%T^?R+O5+:&7:K[&D&=K' /XDUC26U[8^(=?>>QFO+75H
M(_LYB7< RQE&B;^[D\@GY?F/-5O#NBWND:_I4-S!),MKH2V;W07*"4.&*@]<
M8'7ITH VO%>NGP]I4=Y\B(]S'"\\BEDMU8X,C 8R!]1R14,M]K,%AJ5VEW8W
M5O%9BXL[A(3M=@'+!L/@C 7!!'6M#69IHH(533FU"&67R[F%55OW95LG#$ X
M..._3K7)6F@OICZ]_8EI>0:/=6#+%9.K &Z.[)C1N5&, YP,GT' !;_X2C5[
M/0- UFZ-E<)JIMEDMHH6CD!F /R$NV[;GICD \BMGQ7K-SH>ARW5C;?:KSGR
M8/[^T%F_)%8_4 =ZXY_#ES+X3T2UTG0I+#Q!:QVZF_\ +6+[.RA1(6;.7! 8
M8&<YKK6M[C5/$4[NUY9Q6<0B@D5$VRECF0C<#Z(!P.AZ@T :UA>P:EI]O?6K
M[X+F)98V]589%5+WQ)HNG330W>IV\4EN@>5"^60'H2!]#_.LCP1;7FCQ7VA3
MVUPMG:7+FPN)%P)(6.0OU4DCH.,8I+RUN3XOU:[^QS-!+HZ6\<@C)#R!I"5'
MX,OM0!MVVO:3>7WV&VU"":X,?FA$<'*\<CL>HZ>M)#X@TF<N(KZ-]D1F.,X,
M8."Z_P!Y0>XR*Y2PL-1MH?!JC39C)IUC)%<!DPL;F%5 8^A8=1GUI= M-4&N
M:'>7.CW5N(M.FMKA2(TB@<F,A416X0;6 XR1CK0!UT6L:?-;VMQ%=(\-XP2W
M=<D2DY(QZ\ G\*EFO[6WNX+2:=8Y[DD0HW!D(!) ]2 ":YOPUI5Q9:S>6+%&
MTW2YF-B <E3* Y4CML#,!_LR5:\3P70U/0=2@M)KJ.QO'::.  N%>)T! )&0
M"PS0!J)K6G20F:.Z611,8,("S>8.2FT#.X $D8XP:237--BLX[M[M/)D4NC*
M"V5'5L 9P.YZ"N/ATF[GMKE;VRU/3Y&UF>ZM[NU(:2#<#M?"YW*<E2,$'/IS
M2K!K]I=:=J6J:9=7ZRV;VURFG/Y3QOYI99"@91\ZD;AG@T =S'<P36JW44T;
MP.GF+*K J5QG.>F,=ZR=2\6:5IVEW=^TK2+:QJ[1K&P8ALA,9'1B#@].*DBL
M8[3PH]G'I82-;9U6P1\\$']WG/4YQP<9Z5R=SHFM/X<UK3+3[7?6;V<7V,7J
M!+A7#$F'<<;P!T)[M@$\T =E<:_I5KCS[V./*ASN!^12<!FX^4$Y&3@4R/Q!
M92>(+C106$]O"DKL5(7YMW&<>BDYZ5ROBJWUC6(-:MX=$N46[TQ5MVB$:M*P
MWY65MV>,C:HX^8YSVL:GI>J:CJ6LI%93P#5M$2WBF8KMBD'FY5\'C[Z],]?:
M@#J;/6-/O[A[>UNDDF1!(4Y!*'HPSU4^HXIU[JECIV/M=PL9*E]N"2%'5B!R
M%&1D]!FL+PVKWEY'>W7AZ\T^\@@,,LUW/YG4@E(SO;*Y&<\=!^#Y8KS3O&UQ
MJ4EM-=6-[8QPJT*[S"Z,QVE>N&WYSTR.<4 :-YXET.P5&NM5M8A)$9D)E'S1
M\?,,=1R.:K^+=4N]+\,7&HZ=)$)(_+*LZ;P59@#CD=CUYKGM#T"^TC4?"\4]
MI(ZV5K>+,ZKN6!I75D3/L 5R/3T-;WC>VN;WPE>6MI;R7$\IC"1QC).'4G]
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M6:AKFE:5(L=_?P6[NA=4D<!BHZG%-37])EL8+Z&^BF@N21"T1WF0@$D*!R2
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MW22PSY\IHLOOQG. N2<8.?3'-5_[7M)M0L_)U>V$4UJ]QY! +2I\I60-GY5
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M]L;9IF5=Y4C&>F-V.^.O-5SX8=],73Y=6N)X/LGV219HT?S$[,>/O =_S!H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4)+&80*H^<C;@@?7@?7%:]Y8VFH6S6U[;17,+=8YD#J?P--L]/L]/0I:6T4
M;[VQ0-WU]: ,_P +7EE-X/TRXMI(Q;)9QC.0!'M4 @^F,$'TQ6)/&TGQ0LX[
M&<6P&@.5_=@X7SDP-IZ?_6KI!H6D+=M=KIEJ)W;>T@A7+-_>/J??K2W&AZ1=
MW?VNYTJRGN-NWSI+=&?'IN(SB@#&U/3K;4M&BT;6-5<WHNQY=Y;GRVBG^:2,
MCLIVXX]P.X-9D5Q="35?#'C)K>\A^PJYU*%?+,D+.4_>#^%@<GCCJ:ZS^P](
M^R_91I=F+?S/-\H0+L+XQNQC&<=Z='H^F1030)86XBGQYJ^6,28Z;O7\: .4
MM1X@\/ZU9Z!=WJZM9WT<RV%[(,7%LZQDX?'##'&[KGK5WX;LD'@*Q@D_=2V8
MDBND<X,<BNV\-Z'//XYK?M-(TVQF,UI8V\$FW;NCC (7T'H/:DN-&TRZF::X
MT^VED?&]GB!+XZ;O7'O0!YM;0W$?A+2)%(BBNO%2360D4D+$TK%#C(X/)[9!
MKI?"B_\ %4:T=8(_M_Y5< ;8GM@3Y;1+UVGODDA@>>E=->:7IVHB,7UA;70B
M8-&)H5?81T(R.#3I=-L)[J&ZELK>2XMQB&5XE+QC_9.,C\* .$A2\\)6MA>Z
M1=KJGA>\GA"64_,ML)'&PQ-_$ Q'RGI^9KNM2O5T[3YKMEWF-?D0'EV/"J/<
MD@#ZU#;Z#H]I)');:7:0M%S&4A4;#TR..#[U8O-/LM1A$-]9P7408,$GC#J"
M.AP1UH X=(;SPMXFTC4KN".*'45^P7\J2[A).Q+I(1@8RY<>P8"M+7O#XUW7
MKMK>?[+J5G:6TME=KUADWS]?53T([BNDO=,T_4H5AO[&VNXD.Y4GB5U4^H!%
M+#IUC;W+7,%E;Q3LH1I4B56*CH"0,X% '&V>L3ZOI/BB2]M&L[VVL/(NX6Z+
M(J2$[3W4@@@^AJ2YN+2W^"\"W>&$^BQ0QQXR9)&A 15'<EB,8KKY["SN5F2X
MM()EG4+*LD882 9P&!ZCD]:@MM#TBRD22TTJRMWC&$:*W12OT('% $7AV&XL
M/"NF0:@V+BWLXEG+'HP09R?PZUQVN"_AMX/&J60W6=U]K+B7YS9L-A3;CC]W
MAR,\-FO0;BW@NX'M[F&.:&0;7CD4,K#T(/!J$Z;8-I_]G-8VYL]NS[,8E\O;
MZ;<8Q0!@Z]I<6NW]G=:1K#:?K$%N9;6XC =)86(RK*?O+D+],@UFQ./%>AMI
M^O8TS5+?53;QW-D^!]IC3<LB$^JY&#[BNJ.@:,8XH_[*LPD*[8@L"CRQZ+@?
M+^%/;1M+>SCLWTZU:VB;>D)A4HK<\@8QGD\^YH Y>PO]9@DUK0M>-O=7-MI_
MG1ZA FSSHCO #K_"P(;@<=?QQ;!VM+?X;W]R<:=';-%(Y^[',\(6,M]>0#VS
M7H4>CZ;%;S6Z6%N(9_\ 7)Y0(D_WO7\:?'I>GQ6!T^.PMDLR,&W6%1&1Z;<8
MH Q]?U&]L_$GA^SMWB$%_/(DH>+<R[8V;*G/!."/QK*O=&N_M%SXCT$+_:]E
M=2JT6<+>0Y!:)O?NI[&NJM]&TRTF2:"PMXY8QM1Q&-R#T![#V%2VMA9V/F?9
M+2"W\UM\GE1A-[>IQU- ''6RZ9XN\*0-+<7-@UYJ<LEE*OR2P3AG8=>XPPQW
MJUHEWJXU'4_#OB">)YX;-94U6U_=,\3%U!8=$<$,1CCJ?KTD^EZ?<P^3/8V\
ML7F&78\09=YSEL'OR>?>DBTG3H+>>WBL8%BN 1,@C&)01@[O7CCGM0!/;(L=
MK$BRM,JHH$CMN9QCJ3W)]:EID44<$*0PHL<<:A411@*!P !V%/H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,WLR^8#LXQZCD&HH[W4[RR:*RMI8=0M=0876E75\W[[$()2*8'IAE< \=<@
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MR!2OI&F2/,\FG6CM<#$S- I,G^]QS^-<\?&LQT_[3%IT<SIJZ:;($N/E)9E
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MT)%26UE:641BM+:&WC)R5BC"@GZ"IZ* *D&DZ;:QR1V^GVL*2C$BQPJH<>X
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MIUE5],LV69MTH,"D.WJ>.3]:<^E:=)<PW4FGVKSVXVPRM"I>,>BG&1^%6Z*
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M)J[10!1DT/2);I[J32K)[B0@O*UNA=B.F3C)Q4ATRP-^-0-C;&\"[1<>4OF
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M/--- L("/O)(5>?D52<@#/2MJB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM &I15"RUB&\O9;+R+B"YAC61XYH]ORDD @]#T/0FK] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX;2VCMK:)(88E"1QH,*J@8  ]* ):*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M85:&+5;2Z0Q1$J$'D,[K@=,!SD=L]J /4<CGD<=:RO$>M/HGAZXU:W@2Z\@
M[#+M!!(&<@'UZ5Q>HZGIAU;Q+<I US:74.G$O&K+&X\Q\NS <H,J6QU'%5[^
M:-/#WC6W1P4>XADB"0M&C;HXLE%]"0?7.">>M 'J!=%8*6 8] 3R:4D*"6(
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MCUJ_I TZ3Q=)<WT4+B[T2V99GC#!R/,$AW8]" ?J* .MAU-8Q8P:B88+Z\!
M@CEWC*J2V#@9 QUQW%6+:6X<W'VF**,)*5C*2;MR8!!;@;3R>.>W-><:'%:#
M3_ 5Q=VZ.D<$L,C-%NVOL^53QUR#@>M.,RV>G:O)"'^PQ>)3)>+;('(MRB_-
MMP<J'P3P?NGTH ]*\V/R_,WKLZ[L\?G3@01D'->?/:Z8-/2XT36&A2XU'[1!
M+>PK]DDE\I@R;<+A".X_BZ<BNF\+SF7PK!*]BMAQ)F&$Y48=N4/]T_>7V(H
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MMQTQCG/?I4RNK$A6!*G!P>AKAO$$-Z/%6O\ ]CH5OY?#JF(QC#,_F2 $?[6
M /H*=9K87>MZ!=:(L26ZVDR:DJ@ +%L&U)1V8/V;G[_O0!V-G+<26J/>1Q0S
MDD,D<F]1@G&#@9X'I3;K4;2S2%YYT47$JQ1<_?9C@ >OK] :\UTN'3IM,\$Q
M3I"R+?72.KXX0K+A3[$E1@\'(]:=Y6GKIRIY,+65AXJ.%"!D@@8GH.R%C]*
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M@6+[,F(J<\MCH!S@5WEE?6NHV_VBSF6:+>R;EZ;E8JP_ @B@"Q1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9-]HL]QJB
MZC::M<V4OE"%T14='4$D<,#@Y)Y'7OG%:U% %>SLTLH3&KO(S,7DD?&Z1CU)
MP /R %6*** "L4:!<Q7]S/;:W>00W4GFRP;8W ; !VLRD@8 XYQVQ6U10!';
MP16MM%;P($BB0(BC^%0, ?E4E%% !1110 4444 %%%% !1110 4444 9FFZ-
M]BNY+VXO);V\DB6 SRJJGRU9F PH ZN<G'/%:=%% !1110!5U&UFO+&2WM[V
M:RE;&V>$*63!!X# CG&.1WIUC9QV%HEM$694R2SG+.Q.68GU)))]S5BB@ HH
MHH **** "BBB@ HHHH **** *>IV4]_;+#;ZC<6#!PQEMPA8@=5^8$<_2I[:
MVBL[6*V@7;%"@1!G. !@5+10 4444 %%%% !24M% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HJ!+VTDF>%+J%I$.&19 67G'([<U/0 4444
M%%0R7=M$Y22XB1AU5G -2JRNH92&!Z$'@T +1110 4444 %%%% !1110 444
M4 %%%% !14<T\5NF^:5(D+!=SL ,DX Y[DD"I* "BBB@ HIKNL:%W8*JC)9C
M@ 5$M[:.8 EU"QN%W0XD!\T8SE?48YXH GHHJ.*X@N-_DS1R^6^Q]C [6ZX.
M.AY''O0!&;"S-\+\VD)NPGEBX\L>8$SG;NZX]JL444 %-DC26-HY$#HPPRL,
M@BG44 06=E::?;+;65M%;0)]V*) JCZ <5/110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !114<D\,+1K+*B&5MB!F WM@G ]3@'\J )****
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M;_Z]:K^&4N$E:[O[BXN7M&LUN&5 T<;?>P ,;C@9..PX%))X722PT>T_M&Y
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M9I+B)55@\1!0@8(ZCG(.<_3&K=63W&G_ &47D\3C:1<(5WY4@YY&.<<\8Y-
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MZEP(/)\["[\8QGIC./:LJ'P; NA0:'/J=]/IT,8B-N2B"1!T5F50Q'T(SWH
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M;!GU2R^R7"2O'@<+(H/RN!DD C!P>16E573[(V-MY37,UU(3NDGF(WR-ZG
M'0<  <5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=U;4=0M_
M&>B:9!<A+74([AYE\L%@8PI&T]L[N<YZ5NW-S#:0F:=]B @9QDDDX  ')))
M '6N;U^WU$^,]"U&UTJXN[:QBN5F>)X@09 @7 9QG[IS3/$,>M:Q9+-:Z/(A
ML+J*>.UN)D5KL#<'4%6(7AAC)ZB@#5;Q5H:0":34$B7[0+8B561EE/\ "RD
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M,@6%O+5&24%ONC8#E=W7O6KH=E>6WBC7IY[)XK>Z: P393;($C"G #$CGU%
M%VWUF*&VM8M1E(O62%9PD3%5D?  ) (7+'C)JOXSU&\TKPS<7UA,(IXI(@&*
M!N&D52,'V-9NM:3J,FOOJ&DQ75K>"2%?,#JUM=Q C=YB$\%06P0 >F,]M#QM
M97FH^%;FSL+9[FXD>+;&K*O"R*Q.6('0&@"XNI6PUR[@;5$_T:V226U* "$9
M;]X7]QQCMMIC^*-&B2Y>:\\G[)$)IA+$Z,(ST8 @$KQU&16#K>AZIJ^LZV8+
M9X(KW14M89Y&7;YH>1MI .<?.!G'K4%W8:AJWAS52/";6.I3:;+:#?-&[R,W
M\*-N^YGDYQVP* .GM_$NC74EPD-_&3;0^?*6!4"/^^"0 5X/(R*M6FHVU[))
M'"TF^(*762)XR <XX8#T-<M=:;?S:L)Y-$FN+8Z!+:21-)&H>0E3Y9^;N 1G
MISUK0\*Z?J.G3WD,TUU+IP6/[']M*M/&?FWH6'+*/EP3SR>HY(!IWNNZ9ISN
MEU<^7Y04RL$9EB!Z%V (0'U;%07WBG1-.FG@NK]5EMXQ+(BHSE4.<-A0>.#]
M.]8TVF:G;3^)[3["]Y#K(,EM*&7:&:(1E'R00!M!S@\'UXJ"WT/4K"]NX19S
M7,2^'X+".X#)^^E3?G@MD9W#D^] '73W]M;Z9)J3R@VL<)G,BG(* ;LCUXK'
MT6XUC7-&AU@W261NXQ-;6PB#HB-RGF$_,Q(P3M*]<>]/TK29+CP%:Z)J,3V[
MOIJVEPA()4^7L;D$@]^]5_#DFK:1HMKHU_I,\L]C$L"3P,ABF11A6R6!7@#(
M(^F: -%=9CT_3[8:Q($O?LRRW*0QM)LP!N;"@X7.>3Q52\U:X/B?0H+.[C>P
MU""=VVJ&#[54JP;T^;M4*6NIZ9XLO-2>S>]M]1LX8SY#+F&2/?\ +AB/E;>>
M?7KBL[2/#NI:-/X4MVMFFCTZWN5N98W7;$TF"%&2"0#D<#H!0!IZ!K['29Y]
M7N@TBZE<6D96/E]LK*JJJC).%[9/!J>Y\7:;#_9QA\ZX6_N6MT,4#G8RABP8
M8R&&TC;U]N#6';66NVFEJBZ1*2VMSW$R*T1F$#O(P:,EL _,H)R" 3CUJ"TT
M36K2.TD.DS/]E\0SWGEBXC9FAD$H# EN<;USDYZT =A-KNFV]Y':RW.R2240
MJ2C;#(1D)OQM#>V<U57Q?X?9Y4&IQ9A\SS"0P";/O9.,<9_'M6'8:3?6^I7.
MG7WAY;R)K][NWU!IE,2J\ADRRD[MZDD# YP.G6EM[#6[;PYXCC@TK_3+G4)K
MBVCG,;+*CL#D#)&< X#=\9H T]>\0J/"^MW>DW7EWFFV[NRRPE6C8)N&4< X
M(Z'&*W+.1I;*"1SEGC5F/J2*X6ZT?6)K;Q8L>DW?_$VT^..V\^XC9V<(ZD-\
MY .6!ZXQ^5=A83W2FWM)+"6-%M59IF9,*XXV8!)SWST]Z -"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*XNK>TC\
MRYGB@3.-TCA1GZF@"6BJ]M?V5X2+6[@G(ZB*0-C\JL4 %%%% !15>2_LHK@6
M\EW DS=(VD 8_AUJQ0 4444 %%017EK/<36\-S%)-!CS8T<%H\YQN';.#U]*
MGH **** "BBB@ JGJ.E66JI"E[$T@@E6:/$C)M=>5;Y2.15RB@!*6BB@ IOE
MH9!)L7>!@-CD#TS3J:[I%&TDC!$4$LS'  '<F@"I=:397M]:WUQ$S7%F28'$
MC+L)&#P#CD<<]JNU'#-%<01SP2)+%*H='1LJRD9!!'4$5)0 4444 %%%% #=
MB&02%%W@8#8Y ],TZBH;FZM[.$S74\<$0ZO(P4#\30!-158ZC8BR2^-Y +5]
MNV?S1L;<0%PW3DD ?6K- !1110 45%;7-O>6Z7%K/'/#(,I)&P96'L1UIL]Y
M:VTL,4]S%%).VV)'< R'T4'J?I0!/1110 4444 %%%% !1110 445#<7EK9^
M7]IN8H/-<1Q^8X7>Q. HSU)/:@":BBB@ HHHH **** "BBB@ HJ#[9:_;?L7
MVF+[5L\SR-XW[,@;MO7&2.?>IZ "BBB@ HHHH **** "BBB@ HHHH **B>YM
MX[F.V>>-9Y59HXBP#.%QD@=3C(S]14M !1110 4444 %%%037EK;S0PS7,4<
ML[;8D=P&D/7"CO\ A0!/144]S;VJHUQ/'"KNL:F1@NYF. HSU)/ %2T %%%%
M !1110 4444 %%07=Y:V%LUS>7,5M GWI)G"*/J34] !1144ES;PS0PRSQI+
M.2(D9@&D(&2%'? !/% $M%%% !14%M>6MZ)#:W,4XB<QN8G#;6&"5..AY''O
M4] !1110 4444 %%(2 "2< =Z@M[ZSNRPMKN"<K]X1R!L?7% %BBBB@ HIDD
ML<,;2RNL:(,LS'  ]2:2WN(;NW2XMIDFAD4,DD;!E8'N".HH DHHHH ****
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M:A:+:2QH4VK&H(4+E200&;N>OTH J+KUWK<EQ9Z>L$!ATZ*YF,Z&3+2ABJ
MC@!3D^XXK(\,:QJ*^&-%TG28%>Y31HKEF= PYRJC!=.,J<G)[>M;J^#[6*X@
MN+;4+ZWFCM5M)'C9/](B7[H<%",C/#  ^]0KX$L(;?3DM=1U&TFTV'[/%<P3
M*)'B_N/\N&'&>E $*:UXGN=9M=,%K86,\NFBZE2<-(8G#JK+E&P1R<'_ /57
M6UDP>'K:WUB'4XKBY$D-L;81EE960G<<DC<26&<YSFM:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU2:-K7][& X6-$)/S<<H3SZBM2XTZ_O?%D]RUE-!:7&D?9//WQYCD+%N@;/
M/4=_SH TK;Q%IDTMO;BZ+27"GR9#"ZI.5'S;&(PWK@$Y'(R*BMO%^AW:R-#=
MN4C5V=V@D51M?81DKC=N(&WJ<C YK%L]#U6XTKPYI=[9&W;0YXY)+A9$*3")
M&5=F#GYLC.X# S[9CCT'6G\%S6<=H+?4(-3:^@CFD4I-BY,RJ2I.,C Y[^U
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M.2"U/FQ_.XC=2#\W'+C\ ?;-&[M]0?4VBL]*NIG.D16>H+;7, =<[L*0YP"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)&DL;1R*&1P592,@
M@]15?3M-LM)LTL]/M8K6W3.V.)=H&>M6J* "BBB@ HHHH IV.DZ?IDEQ)8V<
M-N]U(99VC0 R,>Y/?J?SJY110 4444 %%%% %+4M(T[5XT34+.*Y$;;HRZ\H
M?4'J/PJ:SLK73X!!:0)#'G.U!C)]3ZGWJ>B@ HHHH **** "BBB@ HHHH SK
M[P_I&I72W5YI\,UPB[1*5PVWT)'4>QXJ]%%'!$L4,:QQH-JH@P%'H!3Z* "F
MNB2QM'(H9&!#*1D$'M3J* *NG:;8Z39I9Z=:Q6MNF=L<2[0,]:M444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCTVUBNVD$ZJ)(G#ME??"' [^W=TOA2<#6K2VODCL-;9GG1HR7B9U"R%#G'S
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MZG::O9+>6,IE@9G0,5*\JQ5A@@'@@B@"W1110 454O=3L]/FM8;J4QO>2B&
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MK8H 6BBD!! (.0>] "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]];;I8BZYWE0RF+" _W@0S'CW%;3Z)ISWUM>FU"SVL9BB9&*A4X.TJ#@C(!
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MBSW;(TV)I%5F3&UMH8 ,,#Y@,^]6K31-/L;RZN[>%EEO,>>3*[!\# ^4D@8
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M/Y%Q$6# ' (*L.H((/8^U &M13$FBD0R)(C(.K!@11YT7_/1.N/O#KC/\N:
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MAI%4Y P3CD]*59$9F574LOW@#R/K0 ZBF)-%(&*2(P4X8JP.#0LD;L51U8@
MD YQGI0 ^BLB[UMK?Q)IVDI%%(EXLN^42_-&44'&W'?(YS^%:B2QR,5216*G
M! 8$B@!]%,>6.-E5Y%4N<*"<9/M0\L<>=\BKC&<G'7I0 ^BH;F;R(&=?++XP
MBR/L#-V&<'^1JGX=U5M<\/6&JM"(3=P+*8PV0N1TSWH TJ*8LL;,$612Q&0
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MGV!KIJ* .8\/P@>*M:NM/*_V3/' 5,?^K>?#;V3''W=F2.I]P:R=46VM-?\
M%QF@"27&DQM _DGY\),&P0.N2H]R0.]=[10!YM!;K:W.CG1ECAOKGP[.A=,
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MUN+R&*:9@B(S@$L>@^IP<#OCB@#F'TAK3Q5>Z3%9!M-UT+=RL$&R-DP)E/\
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MT_U&63N.5?)'7!]*]-M[RVNFF6WG24P2&*4*<[' !*GWP1^=34 <]XTDN/\
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M&>9BDMI/;%@6&59"N0>?:KDL8EB:,LRAA@E6P<?4=*(XTAB2*) B(H5548
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M-[W5KK43"=T0F2)0IP1N^11DX)Z\<]* -2BBB@ HHHH **** "BBB@ HHHH
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MS7OD0?97T]YQ)(JXCE"[E "R$LA&?0C&<]J9IFN:W/>Z+#=7%J4UK3'N$\J
M@P2*L9SDL=P/F=,#I6A8^#-.T^RFLX;J_:!XFBCCEN2ZVZ-P5C!R!QQGD@=#
M4]OX8M+:XTN=+FZ9M*@:"W#,N-C  @_+SPJC/M]<@',Z'K.NKX>\)L+RWF?5
MW*3/- 2P)B=\Y##/*\^N>U2OXC\0VVF7UY+<64@TK5%LYE%NP-RA>,9^]\A
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M[;G!(ZAF.2,=>F*GF\*Z>][:WL$EU:W%M$8/-@F(:6,G)5R<[N<G)YR2<YH
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M D5K([/LX=< 9W \%>HKG;;PSKUA::5='2[*]GLWNXYK*68$/'-+Y@96*X#
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MI(HV\\_ZP?D?:G6?A?4AX<LO#%S&/)L;Q)!?!P1)$DGF+@?>#G 4\8ZG)Z4
M;^@Z^NN2Z@JVLT L[MK<&1,;MH7)^N2>/3%27_B+3].:X$S2E+0*;J2.,LL
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M)L+[2R.#SP1P1G(]*LZWX9U+7+[6P46VCU'28[2.7S P$BL['/?;\X&<>O%
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M$B7/V5H&C(E$W79M]<<YZ8YSCFJ7A74KG4-1U])YYY([:^$<*SH$:-?*0E<
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M2[OF^7J?D/)YJA\0HH'\/027 &R+4;1BQ. H\] 3GZ$U@ZK;VMSJ'C*:&XD
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MD',Y&=G.>1T .>1SWKF]/N)9=.\(:GI]S++?WDR1WX,A)E4QL9MZ^J,./[O
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M31M]Y)%#*?J#26]K;VD(AMH(H(AT2- JC\!4M% %>&PL[>-XH+2"))#EU2,
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ME_UB",;7^HQS3A:6PMOLHMXA!C'E!!LQZ8Z5-10 @  P!@5%;V=K:!A;6T,
M<Y81H%W'U.*FHH @M[.UM-_V:VA@WG<_EH%W'U..M'V*TP@^RPX1]Z#RQ\K?
MWAZ'WJ>B@"N;"S.S-I ?+)*?NQ\ISGCTYIO]F:?MV?8;;;G./*7&?7I5JB@!
MDD4<T312QK)&PP589!'TJ%M/LF9F:S@)<88F)?F^O'-6:* *[6%FXB#6D#"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*X99FM3/DMDX7("E<$]3GM0!UU%<9)XIUB%&)%C(L"S2M,L+A;A(WC3Y!O\
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M+N:UGN&66! S@0NP&<8&0,%CN7"@YY'%57\9Z"@RUY)C9O+"VE(4;=QR=O!
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MFTBR?3;G3S&WV>[,IE4.06\PDOSU&2QZ5=HH 15"J%4  #  [4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %35-/BU739
MK&9Y(TF7&^(@.ASD,"01D$ CBLB/P1I442Q(]P$2\2Z4;E^4J"-G3[AW-D=?
MF/-=%10!S/\ P@>E_8K.U%Q>*+*.9(I Z[SYF?F)V\E<_+Z=\U=/AN(?8Q%?
MWD(LE"0B,H-J!54IG;G!V@GOUP16S10!S:^!].$<B-=7C!XVB&63Y$(P%'R]
MNV<GUS5>7P';7-]?&>[N!:7*2%8T9=P>3[1O8Y7L+A@OZYQ7644 <O<^ -*N
MYVFDN+L$I,O!3CS1,&P2N1_Q\/P#CY5SG'-B;P=93/=_Z9>)'?1RQW,:.FV5
M7,AP?ESP9GQ@^F<XKH** .>B\&V,+P.)IG$"2J(ML<<;^9NW A$& =_0<?*I
M()&:C@\&6YT_3;>ZN[AGL[8POY;*!*S(5D8DKNY+$GD D#(.*Z6B@#G(O!6G
MQ7_VTSSO-NB<L5C!9D\O!)"9Y\I<C..3@#L1>"K"#[(([N\5;0PE1N3YO*55
M7)VY'"X)&,AF'0XKHZ* ,*;PM'.\SR:G?$SA#)S& TB;=LA 3[PV+Q]WKQ4/
M_"#Z9]CEM3<7965'5VWKD[X_+8_=ZX)/U]N*Z.B@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit103-form147_716ba005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
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M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %2/5+&;4I=-CNHWNX8Q))$IR44G )]*8^LZ?'>_8WN0)=ZQGY3M5V&54
MMC 8C& 3DY'J*RH_^2F7'_8&B_\ 1TE<I=^</AGXF8Y^W'5IC[^;]H7R\?\
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MJ]A)8WT9EMY1B2,.R[AZ$J0<>U&FZ9::181V%C&T5M$,(AD9MH] 220*MT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(V*E<J1D'!Y'XT 9W_"6>&_^AATO_P #8_\ &C_A+/#?_0PZ7_X&Q_XUKT4
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M73K-[R[E$5N@R\F"0H]3CH/>HKG6+"T6$SS,K3@F*,1LTC@=2$ W8'&>.,T
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MATO_ ,#8_P#&C_A+/#?_ $,.E_\ @;'_ (UKT4 9'_"6>&_^AATO_P #8_\
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M<W-PNWS)7#*PZC 'R*, =!5I_#T4NO\ ]KS74LCFS-F\#*OEO&3DY&,Y)]Z
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M[VM]$L5Q"40@@#!9>/E8^OL,8(S5O5]%M=9T*XT>?>EM/%Y1,;891VP?; H
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M>>%?&.DW<JBZTF%E:>-,">)XBRY'9L'!QZ>]=CI$4D>EVWG2B5_*7Y]@7C'
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MEM;F">PN&P)XBV[Y6_A;(ZG@X]L'7UWP_8^(]';3=20R(<,L@P&1QT8>A_\
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MBBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH
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M[>_?3XR\D*3@=.Q(S@]>U>9V%OKEWK&J26MK>0S7OAD1VY-O)&!( H" MSD
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M'F9O[;]T<2?OE^3G'//'/%<_\2=$DUKP;=?95/VVQ(N[5E&6#ISQ[D9'U(K
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MM+=<@9Z4 >CS:KIUNTBSZA:Q-%S('F52GUR>.H_.I'OK-)8XGNH5DD7<BF0
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MD.B:7,NG31W2>*Q,[_9V#K ,'<>,[>?I0![!:^)M(O-9O=*AO(FN+%5,WSC
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M4K&7SO+O;=_L^3-ME4^7CKNYXZ'K7/>$_&%QXLFDN+;3XDTU6D03?: 9%92
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M,C.&'8U:H RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH
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M=QQ^'- %RBBB@ HHHH **J)JEC)J<FF)<HUY%&)7A!RRJ3@$^G-6Z "BBB@
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M=62*1<+G&!(C;>IZ<'TK5FN(;<(9I4C\QQ&FXXW,>@'N:;>7MKI]L]U>3I!
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M(![C8@_WJ[/0=5B\57%CJL6##!9+)@<@32]1]552/^VE:4&@65OXDN]>1?\
M2KN".!_3"D\_4_*/^ BDT'0+3P[I\MG8#:DMQ+/R.A=B<?0# ^@H Y?QVO\
M;9N;*"::.?2HEN+8Q1.P-WD,@RH(R%'?_GJ#VK1O=9B\0_"N_P!5A  N=)G9
ME_N-Y;!E_!@1^%;>D:;)IEO+')=&Y>69YFE9 K$L<\X].@]@!6/:^#&M-&U?
M28]4?[-JKS.Z^2/W/FYWB/G@<\ YQ0!S5H9/$%YX/TAX3IS:9;V^HI/*1ONE
M5 "D6W(P>-P)!QCBMG7GGC^)^@-;0+-)]ANOE:38,93O@UI7'A"*YT33;!KV
M6.YTHH;.^B4++'M 'N#D#!'0^E.N_#5S=Z_9ZT=59+FS@:%%6!=A#?>)!/7@
M?E0!9MSJES:ZC*;2WL=1),4!<F1" N4)(QN&6;IZD=JU(1*((Q.RM*%&\H,*
M6QS@>F:S/[)O66\>36)C//#Y4,BQ*HMNOS*O<DD$YS]T5IPHT<$:/(9650&=
M@ 6..IQQS0 ^BBB@ HHHH **** "BBB@#*\+?\BEH_\ UX0?^BUK5K*\+?\
M(I:/_P!>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)J6F""VU]4^S30W'F>6SA2JN"JX^\.1FMGQ/XBM/"NA3:M>@M'$54(IY<DX
M'\_P->8PP7.C7G@[6]32;5M&2RAA$94L=-G\M<MM7T*]P2,'N!7;:W!%XQEO
M=,AFM9+6"V,;&0DCS)!]]<==HQ@^K,.U &_J6J-:Z#/JME"EXL<!G5/,V"1
MN[@X/4=.*P=$\?P:_P"&[_4K2RV7VG!S<Z?-+M=-N3UV]P#VZY':N>\&:W*G
MPYU;1-5)2[TF&:W0L#B:/!"%/[W/RC'^SZT_QWX8NK>[/C#PLPWSQ&'488^5
MN(6&"X ZD#D_0'L<@'1>)/%VH>&],U#4Y]%CDM+ Q*6%V0TI?;G:-G0%\9)'
M0UIZ-JU_J)A>YTQ+>"XM4N(I8[@R YQ\I!5<$ CUK!^+@,GPYU&WC!>:5HA'
M&HRS8E0G [\ FNB\-.K^&-+VL#BTB4X[$( 1]: 'Z[K=CX<T>XU749"EO ,G
M:,LQ/ 4#N2:Q;WQC=:5X?@\0:EHQAT^38TOEW&^:!'("LR;0.XR Q(SWJ#XI
M^'[WQ'X)GM=.0R7,,BSK$.LFW.5'O@DCZ5F>+M8@U[X;?V7IB-<:G?QPPK8H
M/WL;!E+;UZH%P<DX'2@#9UOQL=+UG1-/M;&*\36_^/:<7)11]WDC8>/F'2MK
M3;^^N;NZM[RQBMQ"$,<L-QYJ2Y+ C)52"I7D8[UYGXBTEM.UKX>Z7+,['3T\
MNYFB8CRN(QG</NC(.#[5Z;H>F?V/I,=CY\EP(WD82R-N9@SLP+'N>>30!H5B
M^'_%&G^))=2CLFR=.NC;OSG=@?>'L3D#Z4_Q'J'V/3Q;QSK#<WKB"%V.-A;J
M_MM&3]<#O7!K#-X'^*D%QY<2:;K4 BN$M@2D#+@*Q'89QR?[S>E '0Z[XXO]
M 6S>ZT)-E]?&T@'VPAOO$!V&S@'&>IX-:R:MKCWGV3^P8E<2,#(;P^5L"H0P
M;R\G)8C&/X37*_%O,C>'%C!=H]325PHSM0=6/H/>O0FFB2'SFD01 ;MY8;<>
MN: .2\+>.+WQ3IT>I6VAJEJ;S[-+_I>Z2/I\^W9@CYAWJ[IGBR3Q!<Z@NA6,
M=U;6$AA:YFN#$LLHY*IA6R!QR<=1C-<[\%(VB\%W5M,KQ2_;9&*,"K!2J8.#
MSZ\^U,^&NSP3IVJ:!KTBV4\%XTT<DIVI<1E5 9"?O?=Z#D9% &T?B#:S>$+_
M %^TLF>337,=W9RR;'B8'!&0"#UX]::?'YM8]!N-2TL06FNA!!-#<>88V< J
M'4JN/O=1GO7%0:/>VO@#QIJ]W;RVYUV<R6MM(I$A7>2#MZY._IZ#-)%!<Z1+
MX-US44GU;18K6*)H"I8Z=/L7+;5ZX([@D8/?% ';ZO\ $"'0/%MOHNJV!@M;
MG CU 2YC!.<!AM&WIZG'6M:]UJ[LUU5_L$3QZ?;^>I^T$&488XQL^7[I]:S=
M3TS1O&,NK:1<R1S)+#"R.A!9&&[#J?49'YX/6L'0+;6M*\(^)],U^3S)K*V:
MVMYC_P MHO+;80>_WL#OQCJ* -W1?&6H:YH-CK5MHL/D7;D>5]M)E1!)Y;/M
M\O! //7I4DWC-[3QW!X7O=-6W%U&9+:[-QE90 > -O#<$8S_ #%<C\/9[+P_
MX2T_4[FZG-[%:W%N=.9F+;FGW)M3^'.!DXQR#VK4^,EJ&\-VE_;!O[4L;M)+
M1HN9!SS@=<< _@* .SM=0FN-0O8C;QI:VI"BX$N=[8R1MVC& >3D\\=CC#F\
M=QK'I-O;Z>UQJFL*9+6S63;B+DB1V(^4;1GH3U'.*FU!E'@J&SLI"9-1"6J2
M*<G=*<2/GU +L3Z@USNO:=+X>^*6D>)7@=M&^R?9))(T+"U.& R!T7D<_6@#
ML!JVH6U]!;ZEIT,$,D;NUU#<EXX]HS@Y52#C)], UGZ;XON==TFZU?1](^T6
M$+.L32W'ER7&W[Q1=I&.PR1D]<5=O[FS\2Z1?Z5IUTL_VNSEB^T0G?'&64J,
ML.,\]!SQ7+^ M6A\+^!/[*UA3::CI;3*UK(,239=G4H/XP=V 5S0!I7OQ"@'
M@Z'Q/I&GOJ5L[%9(?,\N6,@$G(VGI@Y]N>:T;'Q7#K.DZ;J>D11W,%]*(G#S
M;&A."2" IR1@\<=JY+P#H\WA3P?ID&LD6\][J9N/)EX,:F/: 1VZ GTW8-20
M^%+[PE\0K)](S_PC^J7!>:W R+:8(Q&/0'M^784 ;L/C.ZN?&&J>&X=+MQ-I
ML*S//+>%$92%(Z1G'#C\C4.K^.;W14TD7>A*LVI7C6@C^U_ZMP^T-G9RI&#G
MKSTKESI*ZY\6?%=N;F>VCN[%(X9XI"BNX2(%<CAAD'(]C6C\6E$NH>%U&\B+
M45DE,><QIE<L<<@=>: .L?Q!<V(OIM4L(X;2TM7N/M%O<&8.$)WK@JI##%,T
MOQ%>ZE!I=XNFPM9ZETE@NO,,(*%AO&T>FTX)P36=!JFF:3HUWI,#2:S'!;75
MW,23*'0R%MA;HS$.1CV.:YS3?#Z>'/%VES^"M5FFL+Z?%]IC,6$,>,EV!Y7'
M3YOFS@9/(H ZNT\8S:I87VHZ7IT=W:V<SPLHNL3':<%MFW '<#.2.<9XI]UX
MNFMO'MKX4_LU6:ZMS<+<?:, (-W5=O7Y#WKA-8TBT9/^$L\'WL^EZ_(X,FF+
MG_2'+88",\D$Y.>5(YXZUL7[LWQST>XD "II1BE=?N)(3*=N>F>1Q[B@#IK/
MQ6=8UK4--T2S2Z732$N+B:<Q1^8<_(N%8L1@Y.!CWJ"V\;I?:-JUS:V#'4-&
M9UO+"27:RE<YVL 00=IP<<X[5@^!(1X+U?Q!I>MR+:">Z^TVMS,=L=Q&<]&/
M&X<9'7FJFA6,\3^-/%%TCVMGJA=+-95*M*HW8;:>><C'KS0!TNB>/H/$'AF\
MU2QL]MY8[OM-A-+L>,C/?:>H'''J.U=8A8HI<!6QR%.0#]:\V\:^%KJSU0>+
M?###%VODZG!'RLT3\&0 =2.I^@/KGTN@#G[KQ4G_  E*^&M-MA>7Z0^?<%I/
M+CMTXQN;!.3D8 '<=*-.\5)>:[>^'[BV%KJMH@E$1EW1S(<897QG'(SD9'O7
M-6MG)X8^+NIZIJ.8].UBV AO&_U:2#;E&;HI^4XSUXHL+.36/BY=>)X?DTFP
ML_LZW3<).^.=I[@9.3TXH TM \<:CXDT:[U*PT*#_1;A[<P27Y5Y'50Q"_N\
M<[N,D5U\,AF@CE*E2ZAMI[9'2O+/A1HWVFSDNI)[F":SUF:X%NSLJR(T00,4
M/7J<'VKU>@#F?%GBZ3PO>:5 -.6Z&IW MT;S]FQB0.1M/'-(?%\Z^/(_"C::
MF][?[1]H%QP%Y_AV=<BN0\5ZA<^*]<\.6L.FS6]W9:VPEMV(9UB1E_>L!]U2
M.1GTXS6CK)_L;XSV&L7_ .XTZXTXVXNG&(UDRQVLW0=NOK0!U.H:]=V$.LSG
M3XGCTN#SP?M)!E 4L1C9\IP#ZUB1?$@1^'-/\1ZAI#6^E7K[#-#/YK0'<5!=
M=HXR.H)JSK<R77AKQ3>1',%Q9O% ^/\ 7$0D97U!+8&.N.*X@)/J7P3TWPQ8
M6LMSJETX0P*AS"!,7+.>B# ')QUH ]$U;Q=;V6KV&BV$']H:EJ"^9%$LFQ$C
MP3O=\'"\'& 2<5:&J:G%JEM976E1JER'VW$-P712JYVME003],8!^E<,NAW/
MA#XA:/J]YNETS^S$L);L E8)$0+EO[JG:.3Q\QS6[%XGU.[^(:Z58RVUSH@M
M?/ENHH]X1N?D,@.T=![\T 3Z!XY75_%5]X=N].-C=6JL\;>=O6=5;:2O _SG
MTI+;QS]L\=2^%[?3<B.-I/M3SX#!3M;"[3_%D=>V:YS6](O;V^T+Q+X;9&OK
M?49K69@,@122OAF'H Q_!\T^RAAL?C<%CR+6+2A;K*WW=PQ\I;INXH WM)\:
MWVLZCK-C:Z1;))I%P()#-?%1(Q+ ;?W9ZE>_J*;XB\=W'AO2-.U2ZT*5X;I
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MBBN0\8>+[_PXUTT5E$(;>U$Z23MQ<MNPT: '(('.<'Z#K0!U]%<FOC2677M
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M!G6(*N<87ELMQVP.?:EC\>7BWOAQ+W1C96VN H9)G97@F&1L*E>YQ@\9STH
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M$4+T.PYR<\X&.],\4^/K[0(;N[7342WMHX)(DN3A[M9" ^W!RFS(!R#SZ<9
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MKRK6=<7Q1!\/M=-LL$ESJR@J#G;A]I /IE<U>\-6)UGXF^*)-6CAN3IUQ:O
M<MF%@K[-G/ P3D=": /2:IZMIYU32Y[%;RYLS,N!/;/LD3G.0?PJY7 7/Q*:
M""_U9;2,Z38:H-.DR3YK_P!Z0'H "1A<<CN* .WM8([&W2#S2[%B2\A&Z1B<
MD\8&22>@JQ7FL-D=;^,>KVNJQQ7-O:6L+PJ2W[K!5E*\\'=@GL:]*H RO"W_
M "*6C_\ 7A!_Z+6M6LKPM_R*6C_]>$'_ *+6M6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *R/"_\ R+]O_O2?^C&K7K(\+_\
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M5)?VR0%MOFM,H3/IG.,T &JV1U+2KJP$WDBYB:)GV[BH88.!ZX-<G'\,;-]
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MGN[55,BAQ]X[OE'J0%R<=,UH75Y:V,7G7ES#;QYQOE<(,^F30!, %4*H  &
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M3@CYB<\],U?\=&<^(-,CMM+O)II;6YB^V0QO(L89,;-H^7+''S-P.O/;NZ*
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MDYXZCCC-9]^B_P##0.FG:,_V23G'?]X,UVOAW0H/#6B0:1:SS306^1&TVTL
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MG/&TCD=^E=(X8HP0@-C@D9 /TKG;OPHB>!_^$;M;R_*11K'#+%,L<O!! +
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M.--O_P"W!+J%^%UUXGN@ICX\MLJ%^3C]:R;W0=0/Q1L&MGU""UM]%%I_:$<
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M *\(/_1:UJUE>%O^12T?_KP@_P#1:UJT %%%% !1110 4444 %%%% !1110
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MQ2#<CHP96'J".M>3W^F^)[SP/ M_:37MQ9:]'+YT=NRS7,"#;YI3&XGH.F2
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M7+)HDOA[Q7X7O;;3]2ET6UM9X$5HFFEMW<N06502-P8#IQT.,5K?"FRN]/\
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M#@XP:WWU73X[Y;%[ZW6Z8@"$R .202!CU(!/X&O)$\-ZU8>$O#L,NG7;2#Q
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MVAMP&ED\]=L8/0DYP ?6O.[G1=6N_$GB]=/L;J!+[1XX;61H&C21A&H* D
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M8;G5M/LI(XKR^M[>24 JDD@4G) [^Y ^I J*Y\0Z+9R3Q76KV,,ELH:9)+A
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M&MHK26:Z=$OL?9C]GD_>YY&WY>3CG'I0!KT5GV>NZ9?7;6=O>(;I5W&W<%)
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M67B*YD\5#2M1NI=/NA=2A+6:$"*[@ ;8T3XY;[A//9ABKEIX+LK'4IKFVO\
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MO"#_ -%K6K0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTW3GN1>",2"618T+ QC) YQG)]?Q73?B#>B;09-5AM_LVNVT\Z"!&#6YC&X
MDD[LK@=!S[4 >@45Q&C^+]:OM&B\336EH=$DM;FXE6,D2V_EEMHR3\^0O. ,
M']8+'QMXANM*_M"+1C>1SZ8]W%Y-O(JQRCD1%C]_*XY7&2#ZC !WU%><#XD7
M4GA"37;3R+U(IX8[@16S+):*<^87C+\XQP0P!R/0UV7AK51K>AP:@+JWNA,S
ME9;=2J,NXA?E))4XQD$\'- &K16)XDU6]TI;(VL<(BGN!%/<3$'R00<83(+L
M3@ #GV-<G9?$;5+SPSIMY]CMTN;S5QILLY1O)B&X#S"N<]#T)Z]^U 'H]1S3
M16\+33RI%&@RSNP55'N37$6GC#7YM-UJZ^SV$BZ;J7V-9L>3'Y:MAY26?!P#
M]T$<]S61J_C&YU/P5XL6]LK*[&DW20[989$2XC+C&Y-P96'7KVZ4 >H@@@$'
M(/>EKSV]\7ZW:ZU%HVG1:=%#_8(U%&DA<[" ?DP'&1\OMC/?',4_Q*O(= \.
MZK<6\5G;:I'(+F[,#RQ0R*<*,!@0"03U)P.,]: /1Z8\L<>-\BKGIN.*X)-6
MUJ\^*>G6(U"U^R_V.+O8D1=&W, V"'&2<?*W0 ]#SF'XY(I\!(Q4%EO(\$CD
M<-0!Z(DB2#*.K#U4YIU>6V]Q!I7Q=N+NY@.A(=-+)9* ?MP4,2Y*?*" #QG/
MRUHZ3\0=0N3X<NKVWMEM?$,TT4<<:MOMRK83+$X;/?@=: /0:*X;PMXD\5>)
M+B[VQ:5%;6&I2VD\A60,Z*."J[CSD@G)P<]L<UO#WC;Q'JF@S>(;RVTU--L#
M<_:UC$@ED$:$KY8)('. <GUH ]"HK@=*\<:K<WF@6]W':+_PD-K++;F.-O\
M1W494-\WS@C'3;S63_PM#6H-,AN;JVL4EM-2:TU>-87(MD# !Q\_?) SU(/I
M0!ZI17&7_B^]M;_1].4P&76)IWBG2V>0);H"4.Q6)9F&#D$#GI5*X\;>)(IO
M#%NVE6]O=:RTT4\%S&ZF-TP P.>%.0<$$XH [\G R:9#/%<1+-!*DL;?==&#
M _0BLY&U1/#,C:J+)M06"0RB!6: GG'!()&,9Y]:\_T/Q?J%AX1\'+I6GZ;:
MQZO=R6S0[)"D7[UAE3OS[G.>: /5:@GO+6VDCCN+F&)Y3B-9'"ESZ 'K7/\
M@CQ'?>(+;5$U%(!<:=J$MF7@4JD@7&&P22.OJ:YHVLVH?&#6X;N*VU".#3$>
M.WDCP&PRLB@EL*=V"6Z=>!0!Z917 Z+XWU:_\3VFBSI9!KW3VGW1(66WF4D%
M=P<B11CDJ1SD9'03^%O%VKZXKV=VME;ZI9Z@\%["L3D)"@R6'SYY. #TYZ4
M=O17G5C\2;VXM=*UB6WMQINJZHU@D*JWFQKT5RV<$Y!R,=/UNZ+XE\4:YKVJ
M6%O#I:V^E:D()I9%D5GAR<[0"?GP.IX_H =Q37=8T9W8*JC)9C@ 5SOBOQ+/
MHM[HVFV<<9NM7NQ LDH)6)!C<V 1D\C R*X7QQXHO=;^'>OVTABAGTS4_L5R
M8E8+.HD 5E^;Y<XY!STH ]8AO+6X@\^"YBEBSCS$<,N?J*>DL<F=DBMCKM.:
MSTTRVL='NXEM[=6G#RW'DQ;$ED8?,VW)Z^Y-<A\$D1?A]&P4!FN9=Q Y/(H
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MFK>.]5T'3=2EN]-\YXI8(K"X-O);Q7#2#D$-DC:0?J,=.M '=B1&<HKJ6'4
M\BG5YUX?CN8_C3JXO#;M.=*C+O;H45CN3G!)(_,]*]%H RO"W_(I:/\ ]>$'
M_HM:U:RO"W_(I:/_ ->$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH ****
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M(6VO]0M;G1U*6MW$Z"78>JME=I'/I_6KGBOQ1:Z!I=X\=Y9C4(+=IX[:9^7
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M=!TQ^-='110!E>%O^12T?_KP@_\ 1:UJUE>%O^12T?\ Z\(/_1:UJT %%%%
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MP><]/2KU<5-::C+\0FMH-3,%P-"C#W7DJS$^<W(4_*.?8\?G4>D^+-1U?3M
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M .O"#_T6M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5D>%_^1?M_]Z3_ -&-6O61X7_Y%^W_ -Z3_P!&-0!=U&Q74M.N+&26
M2)+B-HW:+&[:1@XR#V-5+708;/PV-!CNKDVZP?9TD)7S%3&, [<<#OBLCQ;X
MMO/#&LZ/"]K"VGZE.('N68@P-D=1T(P<_@:;'XPNX_B.?"=[;V\2/;F>WG5B
M6F&,[<=CPWK]WWH T(O"5K"NBJE]>8T0;;7)CZ;-F&^3GY>.WY\U'8^"K#3=
M0DN+:\OTM7F\_P#L_P __1EDSG<%QGKSC.,]JU-,N[B[BGFG$2QK.Z1%,_,B
MDKN.?4@_ASWK-\)^+K/Q9%?O:C:;*[> J3RR@_*_L"/Y&@#2UG2HM;TFXTRX
MFEBAN4,<AA(#%3U&2#52X\,V\[:?-]KNH[S3E*P7:%/,VD8*L-NU@0!U';(Q
M6+:^+=8OO%>MZ!;6=D9-*C5UDD=E$VX @=]O7KS4"_$9KSX;3^+[.P57MFV2
MVLK$@G<JG##_ '@<X]J -V\\(V%[HUQICSW*I=W N+B9&7S)I P8$DKCJJ\
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MS%FD4%0#C@8.[(YZ8H WFT&(^()-;6\NDN7MOLNT%-BH"6& 5ZY).<_I66?
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M;43*KS0SAC"R+D@XR/3]: .MHK#T37VOK&_O-0DT^""VNGC26"\65/+&,,S
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M.<LQ)R23ZDDFIZ ,KPM_R*6C_P#7A!_Z+6M6LKPM_P BEH__ %X0?^BUK5H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LCPO\
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MEW1N[<&1#AR0>?DY''ZFKDO@?2I;C69?-NT76TVW<22@(3@C<.,@\GN1STH
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MRSC< BN"6V\-CUP>N.G>N2ETG4X_BCJEXEM.MOJ&D"W@NHURB29'WCVQC/\
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MC?<<J^<@\;>1CKTKG_[+U&Z\0:]K,5E=164F@BRCC>!E>:8J" $(SQTSCO\
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MR.<*H'4D]A5"R\2Z'J-VEI9:M:7$[IYB1QS!BR^H]:9XK.?!NM'!&=/GZ_\
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M53*=IV%N@XR,U-IEA<:IX#N;-_#=S9ZW#HC::99X@GF;5PJJQ/S GGT'KTH
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M,<?:%)^4?5OG/T% '5-K.FIJ L&OH!=%@OE%QG<1D+]2 2!UP,U7'BC03.L
MUBS,K3BV$?G#=YO]S'K[5PVDZ#>)XCU;3M9T[4YDEUG^TK.YAP(#S\I9^Q4
M<9]@/71\$Z*4\3^*+O4-*=#<:CY]K+<6Y&Y06PRDCCDY]: .G\2^(K'PMHD^
MJW['9&,(@^](_91]?TK#U#QW'9>*](LO.L_[*U"VEFDN68@H4#=&SCJ,=*E^
M)^E7VL^ ;^RTZW:XN&,;+$GWF"NI./7@&LS4K>[N_B-X9U;^R[W[';6<PF9K
M=CY996"@@9Y/''49&<4 ;VK>)E2STJZTB^TN6&_NTC\RYGVJ\9)#>61U?L!]
M>*U/[9TS[?\ 8/ML)N=_E^5NYW[=VWZ[><=<<UY)9Z%K,/@#PQ82:3?"YLM<
M%Q/']G8F.,,Q+=.GS#]?2NDBTC5++XAK?Z0EV+.]O';4+2YA8PK@$">-R,9/
M' YYQR* .J\6ZAJVE:#)>Z-;PW5U&Z*MO*I/F[F"X!!&#S63H7C9O$WAN#4-
M.,$%W'<Q6][;3(S&)G=4.,$'OD9ZXQU!K=U^4QV4*K#/*3=0-B&)I" LJ,Q.
M <  &N5UGP5<6OC>Q\1Z'NC@N[F,:K;(,!P'#"3'^\!G\^YH Z^?7-*MKT64
M^H6\=QE08V< @M]T'T)[ ]>U45\7:4_BQ_#B3J;J.'?(2< ,2 $'J<$D^G\N
M"USPSK;VOB_2DLIY[K6M1@FLYE0F,Q[PW+]%V 8Y(]LULIHNKV_Q#U>;R)RF
MH:.EO!>JOR"0* 2Q['(SZT =I::SIM]<O;6E]#-,@)*(X)P#M)'J >#CH>*E
MO+^TL(U>[G2$.VU-QY8XS@#J3@'@>E<%\/-(FBATQ-4TK4[;4M'CE@WS86 *
MQ/W2/OYX]<$$YZ9V?&R7K7FAR66CRWKQW9+7,*AI+08P2H)"Y(XRV0,=.E &
MRWB31$TZ'46U6T6SG;9'.90$9O0'UX/'M3[/7M(U&&YFL]2MIXK4D3NDH*QX
M&>3V&.]>2MX=UQ/ADNDR:/>FZ37/-,7E;B8^<MQV]^^>,UI:EX>UK4;KX@QV
M=E<Q?VDEN;1GC*+/Y?WU!/'/(]\T =/#XW%YX]L=$L)K.[T^[M&G\Z/.]",\
M9S@@X!Z=#^-;'BCQ-8>%-):_OFSE@D40/,CGH/8>I[5QNEVVH77C[PWJ(T6_
MMK6UTC[-,\T!01OAAM.>P/'_ -:MGXI:5?ZOX1$6GVLES+%=Q2F.,98J#S@=
M^M '03^(M&M8XI)]2MD29#(A+CE!P6_W1W/05H"1#&)%8%"-P8'((]:\YUS3
M=2_X2C6M6-A=SV^J: ]K:JD1=DD./W; 9VYZY.!SSS77>#M-O-'\(:7IU^V;
MFWMU609SM/\ =S[=/PH >/%?A\VRW0UFR,#2^2)?.&TR8SMSZ^U6I-8TV)96
MDO85\J01."W(<C(7']X@@XZUYQJWP^U"YD\6V,(9=/G*ZAIZ+QFZ().,?[I7
M'HPK6UFTU>+PWH#OI#ZCJ;7L5Q=31+N>U<C+.JD@$J/E&[Y>!D4 ;6N>*8H?
M#@U31;_2Y-TRQK)>3[(>OS D=& SQ_\ JK577=):[N;1=0MS<6BE[B(2#=$H
MZEAV%>1W/AW7A\.M<TIM'OVNY]>-Q$GE[B\9V_-E>/X3STYXKL]>\.7TWCK3
M=:TI2MOJ-N]EJF5*D18W!CW#<;<]B%H Z>;7](MTA>;4;=%G021EG&"A( ;V
M7) STY%6[R<6UG-.6C3RXRVZ0X48'<]A7GFMZ+=CQ]J/VW3M1N]&U>PCMU:Q
M0-L*_P #?W0>3G@<CWQV][ 8?#,]O''(S+9M&J#,C$[, >I- %'1_$T#^'[&
M]UF^TZ.XNE=B;6;=$VTG)4^@&,GH/6M"37M)BFCADU"!9)0C*I;J'.$^FX\#
MU[5Y7!X<U:/P/H36\.J:=KVE07#0M';.ZL3(3Y3J!_$",'[O7-:FI:-KD>MV
M&K:9;7%OJ;):07]F(2]G<*%7<0WW5V'(Y/8$'/4 [R7Q+H<*73RZM:(MFXCN
M"TH'DL<X#>A.#UJ2]U[2=-56O-0@@5D$F6<<(3@,?1<]SQ7EWB?0]:(\=V4.
MC7MPVK2VDMK)#%N1U5P6Y]1Z=?PYJ[XLTW6+^2XM['P_=?O]!6(W<2#=,P((
MB;<1M P> -Q..W% 'H=YXAT;3Y8XKS5+2W>6,R1K)*%+J!G(]1QVIR:YI4FE
MQZFFH0-92D!)PX*N2< #U.>,=<\5P%OINHKXD\!74VEW@ATW3&CNV,#-Y3^2
M5 .,\[A_*L;2]#\1Z=X)T"X72;N272-8:YN+#RR)'0GAE!ZD GIZ_6@#U==>
MTE]/COTU"![:5_+CD5P0[]-HQR6X/'7BK5K=6][;1W5K,D\$J[DDC8,K#V(K
MSSQ%IUTEQX>UO1=#OH+*TO9I;JU@B G/F@#S?+YY'S<'GGM79>&-.MM+T5+>
MTM[FWA9WD6.Y;,@W,2<CMDDG';/;I0!/)KVDQ7R6,FH6ZW#R>4J%QR^,[/3=
MCMUJ"[\5^'K"6:&[UFR@DMV"RH\P#(3TR.HKS?6]*UR[U"0V_AN[MH;?Q+'=
ME8$#),G(:;).XLW'0!0/>I/$.BZI=:MX\EBTJ[D&H6UO':,(&/FE0@8 X]1^
MF: /2=4UNPTV)%FU"UMYIU8V_FMD-@9SC(R!W.1]:S_ ?B.Y\5^%+?5[N&*&
M69W4I%G:-K$=R?2N5M=/U33O%>C:M/IEY<VK^'UL=L<)9H)A@E6'\.>F3QSU
MK:^%-A>Z7X$M;+4+.:TN(I)-T<R[3@L2#^1H Z0ZSI@O_L!O8?M.\1^5NYW$
M;MOUQSCKCFB/6M,EO6LH[Z!KA-P,8<$Y7&X>Y&1D=1GFN(.CZI9_$--0T=+L
M6M[>G^T;2XA)APHXG1R, G XZYXY%5O VA7=HUM8:YIVJ?;M(O)IH;G&+=@^
M<N&'+$Y(V\GD>^ #ME\6^'7\O9K=BWF;]FV=3G8,M^0ZU8AU_2+FW@N(-1MY
M8;ES'#(CAA(PSD*1U(P?R-<E\+]"^Q:-=G4M):"\-_+*IN;?#[&  ()'3&1Q
MZGUJ;P5X;OO#U_JEG<J?[)L;IY=,&"21(H)Q_NC*^Y9Z -;0/$?VK0FU'5KS
M3% N&B62SGWQGYL*,GJQR.!_]:M%=>TE]/COTU"![:5]D<BN"';IM&.K<'CK
MQ7D^FZ)XBT_PQI-VFD7DCZ7KKW<]CY9$DD9QAE!ZD<]/6M_Q#IUU'=>'=;T7
M0[Z"QM+R>6ZM8(@)\R@#S?+YY^]P>?I0!Z):W5O>VT=S:S)/!*NY)(V#*P]0
M155]<TI+_P"P/J%NMSO$?EEQG>1D+_O$<@=35?PQIMMI>BQVUI;W%O 7>18[
MELN-S$G([9))QVSVZ5YQ>>%M>;2M5T-;:=KZ\\1"\BNPA\L0G!$A?H,8/&<Y
M[4 =8_C"_O\ QQ<^'-'&G_Z$(VF:Y9LRY/SA"O0JOJ#SZ5V5<3HUG=Q?%C7[
M^2SN$M+FVACAG:)@CLJJ& ./_P!==M0!E>%O^12T?_KP@_\ 1:UJUE>%O^12
MT?\ Z\(/_1:UJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !61X7_Y%^W_WI/\ T8U:]9'A?_D7[?\ WI/_ $8U &O17'^(M;UB
MU\=:%H6GW,,,&J13&1I(=Y0HA;(Y'ZUS=Q\0]>A\%7-^OV=M1T_6#I\K>5\D
MZ_WL9^4T >J45Q&K:YXAT6_TK2;NZM)+C6M1*1SPP$"W@ 4L "3ELG@G/TK-
M'Q%OEMWL)!$+U?$']D?:MGR;-V/-V]-V >.F>>G% 'I-%</JGB'7]!.F:9J#
M0276I:F\$5S F6^SC!#;3QYASC'3ZU2U?QCXDT+3M/N=8L);2V-S-%>7<4*R
M,JC'DN4R0 V?F'7@@8R* /1:*\[U+QQ?Z=K&F6]U=1P6%_:0M;:BD.^WGF;E
MPQZJ".F.F<G(Z>AG.#@9/;- "T5YWI/C76)O%>AZ==26TJ:F+E+A85W11/'N
M(\J0?>X !ZC.><CC-?QYXEAL[B_:XM7BL_$/]FF+[/@RQ^I;/!^@H ]0N[RU
ML+=KF\N8;:%?O23.$4?4GBG0S17,"3P2I+%(H9)$8,K*>001U%>;>*-?U'7(
MO&VG0RQV]CHMD$*&+<T[.K%B3GC&TXQ[$YZ5V7@K_D1M!_[!T'_HM: -K/..
M]+7G*ZOJ-M\2_$\\]ZTMKI&G+*EN$&"FS>5'H<]^II^B^-]5DO/"S7YBEB\2
M1SEHXX]OV9D.5VGJ1@@'.?7/:@#T.BL;Q=KI\->%K_6$B$SVT8*(>A8D*,^V
M2,US6L>)_$/AGPK?ZY<R6E_;O!;O8N%VL)' #;@.-H)R.^.,]Z .ZG@BN8_+
MF0.F02IZ'ZCO4E<!=^+M6TV^\0Z1+,D]QIVD?VC;W)B Y"C<K <$9(QT.,]>
MM0^'O&&O7GB#0+.^GMI(M:TMKDB.#;Y+@$@@Y.>E '<KJ^FMJ']G+J%L;SG_
M $<2KYG !/RYSP"#^-7*\8T+6)/#GAKQ!K3)#=7J^();>WEFA!,3OM#OGK@C
ML".@KJ=9\2^*=%TB]N9--N);>VO8@+D1IYK6I4EV"#C<I&,D8P<XX)H [ZBO
M-]3\?7=GI.C:HET9=(O/.$^I06N[RFW8B#H>@ X8#DD'!]?0+";[1I]M.94F
M\R)7\R/[KY .1[&@#/O-/T77=6B,LJ3WFE$YCBG(,8D'*NH/1@.AZXK8KSF/
M7;NTUCX@26\-I'/IEO'-'.L #R$1LP$A_B QCZ4_2/&NK76N>&;>Y:$P:II3
M7=P%CP0X5C\OH.!Q0!W-WJ5A8/$E[?6]L\[;8EFE5#(?1<GD\]JM5XQK6N:E
MXH\,>'==O)8E@N?$48BM4CQY2J7"_-G)/!SGU&,=][7O&GB"TNM=CMA'!<V%
MU!!8V)BW/=HYP7YY;U&W@8YS0!Z317GNL>)/$5MXGU;1[:^MT2QT0WXD>VW,
M77&0.< $^N<9J+1?&NN76K^$OM<ELUMK]O,9(8X=OELBY#!LDG)[=/YT >CT
M5P7AKQ;KWB.2TU&VM"^GW-W-#,BHH%M&.$<,3DMD?-VYX Q6+8>/_$CVFF:A
M<3VKPSZ]_9DD*V^"R''S;L\$>PH ]6SSBH;R]M-.M7NKVYBMH$QNEF<(JY.!
MDGCK7%^&KG4KOXH>*8[C4"\%F+=$B\L8V%78 >F"Q.>]7/BE>/I_@*]NU@M[
MCRWBS#<Q"2-P74<@^F<_A0!UP((R.12UYWK?BG7K;Q+J6EV%S;006NA-J*%[
M?>0RX^4<@8/OGK76>$]6FUWPKINJ7"JLUS KR!.!NZ''XT 7+[5]-TO9_:%_
M;6F_[OG2JF[H.,GW'YU<KSF]LVO?C=]GN6CN+=M$W&":(,A7S?ND'W&<T:5X
MUUB;Q3H>FW4MO(FIBYCN%@4-'"\>2OE2?Q<  ]1G(ZC  /1J*X/0_$NMWFKZ
MGX=O[F*/5K._149(0%>U(W;\'N5!Y[%D_'.G^(FIII]]X@58Q96>M_V<+0IR
M\0 W-NZ[^01V'3!ZT >B:A8Q:GIUQ87!<0W,;12;#@E2,$9[<5%H^DVVAZ7#
MIMGO^SVXVQJ[;BH],UR,>M^*-3\;Z]H&GW=E!#IQ@D26: L=K@,5X(]3S[>^
M1V6J7RZ9I5YJ#H76U@>8J.K!5)Q^E %JJ:ZOIKZA_9RZA;-><_Z.)5+\ $_+
MG/ (/XUP^C^-M7EN?"_VUXG3Q)'.2J18^S,O*;>Y&" <Y]<]J/A39B6+7+NY
M\N>:'6[E8Y'B&]&*IO8-U&X8R/:@#N+_ %;3-+"G4=1M;,/PIN)ECW?3)&:M
M1R)+&LD;JZ,,AE.0?QKSKXW?\BKI?_87B_\ 0)*[O5-1ATK3I[R;D11NX0'E
M]J%R![X4_E0!<HK@=$\3^)-3TR+4VM]UI=Z?+.TPC4);3+DHJ\Y92!@YR<CJ
M.E4/#OC?Q!>7GA&2^FM9(->6Y62*.#88S&3@ALG)/Y?SH ]#O=2L--1'O[VW
MM%D;:AGE5 Q]!D\FJ+>%]-:*ZM\3BUO)'DN+83-Y<C.<MD=0">H! ]J\O\4Z
M_J/BKP/<ZK-+'':+K:00VHBY5%(PQ;.=QSSVKK=0\6:[<^(=<T[0[0S2:-]G
MV6X0'[27Y?<Q(V@+P,=^3GI0!UVI:3::I9+:7",(T=73RV*%&4Y4C'I3M+TN
MST738-.T^$06MNNV- 2<#KU/)Y)-<<=<\4ZEXWUKP_IEU9VT=E%#-'+<0%RN
MX*2I (SU//;'OD=U(6$;% "P!V@G )^M #J*\[T7QKK%QXJT?3KE[>XCU*WG
M,PA4&..6/<<12?Q+P >HSGGBJ^E>,O$>IW.C)OBCN;^]GBO+ 0 M9QH>"><C
MCJ6ZY&,4 >F5!!?6ES//!;W4,LMLP6:-'#-&2,@,!T_&N!O/&NLV?B&PMW>V
M=+C6CI\L$(WQI&<;#O[2<Y*Y..,@9JF_B2^TS_A/KNSBLXKG3)H2DJVX#39R
M/WF/O<?2@#U&BO/])\5^(9/$3Z9,;:\>?05U*W1(O+VRG "9R<@D]3^E9+^.
M-3U/P'K]PFHO:ZG8VT:SV\EN(Y;>0L1)C_9.1@]1@YYP: /50<C(Z50NM>T:
MQN?LUYJ]C;SXSY4URB-CUP3FJ_A))D\*:7Y\_G,;2(@[-N!L&!_]>N,\5-<I
M\;/#+6<44LXLI]B2R&-3\DO5@K$?D: /1;6\M;Z 7%G<Q7$+=)(7#J?Q'%35
MXKH7B4^$=%\1+;KC7)=76*:V=/\ 1[9W9@"F#\R@*WIT7C'7I]2\9ZKIK>+=
M-$J2W.AP17%M<M&/WBLJL5=1@9!.,C'% 'H=%>>:AXA\5Z?\/9O%4UW8Y>SM
M9X($MS\C.5#;B3SD-GCH?IS)JOB;Q+HFB6E[=S64LNLW-K;VBQPD"UWJ2Y;G
MY^G'3GMCB@#OZ*\[O/%GB!;;Q796+Q27WAYDECE>($3Q,I8A@,#< #R,9P.*
MKP?$#4KG6[**.5?L&L6!.G2&(9-V%7*$]" Q(/3F@#TRBN"O?%>OS:[K.EZ-
M;FYGT5+;;%Y:_P"EN_+[B2-HV],=_7I2MKGBG4?&VL^'],NK.V2T@AGCDN("
MY3<%)4@'GJ>>V/?( .\J"[O+6Q@\^[N(K>+(7?*X49/09/<U-7 ?$Y+A]5\(
MK%<>6K:S" -F0&SPWOCTH [JUNK>^MH[JTGCN()1E)8F#*P]01UJ:O,K[QG?
M:9:>)+G2X+:UL?#5Q#;Q6:PA5FW/MDSC[O7C;CWS5Z7Q'XCU3QM<Z%H]Q:6\
M3Z6E[#)<P%C$25X.#SUQ[9SSC% '?U7O+ZST^W:XO;N"UA4@-)-($4$],D\5
M*HD\D!F4R;<%@.,^N*\9:ZU'4?A)XNO;^^:Y9[]E(9 #D/$,Y], #'08H ]G
M1TEC62-E=& *LIR"#T(-.KSC1_%VIZ3J-WIM^T5U:V7AU=3C$<?ELNU5RF<G
M.<]36OX1UW7]8DL;JZMO,T^^L1.\P146&;/W%YR5VGODY'7G% '845ROQ'\0
M:AX8\)2ZKIK1B>.5%Q(FY2&.#Q6?-XJU9/$?B_3EEB\K2+!;FU/EC(8Q[\-Z
MC/'TH [JBO-O#GC/7KW6O#$%_/;20Z]9S2,D4&PQ,@8@@Y.<[?I5#_A/_$EO
MX7N?$<T]K)#8:N;.2V%O@RQC&3NSP>>,#\Z /6*@%]:-?-8+=0F[2/S&@#C>
M$SC<5ZXSWK@?&OC76?#TFIS0/;;;&2W,4"#S/,C?[QE/6,Y^[R,^AQFG:GXC
M;1?B#KTK6=M*++0C=+((@)6PRX0OUVY/^<4 =S)J5A#?1V$M[;I=S#,=NTJB
M1QZA<Y/0_E5JO*$N]2U+Q?\ #W4]2N8YI+V&XG"QQ;!'NB!VCGD $=>>O/IZ
M/KUU-8^']1O+9@LUO:R2QDC(W*I(R/3B@#0HKS72O&NO+)X2NM0FMI[?Q#OB
MDAC@V&%@0%8')SUYJ]X8UGQ3XAU+4HA>V<5KI>K26LC&#,DT:Y&!S@'H<XYS
MVQR =K9WUIJ$)FLKJ&YB#%"\3AP&!P1D=Q4]>0Z?XOU33O %KJ.G0V%K--KA
MM'2.V"QLK9RQ /7(ZYK5E\?ZKH]CXQ-Z(;R;0IHDMW6+RPWFG # 'H#[Y- '
MH5Y>6NGVKW5[<16UO&,O+*X55YQR3QUJ96#*&4@@C((Z&O/?&%WKUAX'UN\O
MY-/U&R5+:2T,D ;S0S*'5TZ8!(*D<],U))K^OS^+7T"PN[6U@&B+?(S6P8H^
M0,#D#'],T =_5:ZU&QL9(8[N]M[=[AMD*RRJAD;T4$\GD<"N&TWQOJFL>&=!
MU &WM#?M-%=,@W2^8@(3RHR#NR1D^@].M86H>(;KQ1X1\$ZK?)&MS)X@B23R
MQA25=AG';( H ]?HI*YWQ5J]_IMS80VTT,$-SYHDDX>?<$R@C0@[N?O<<#GC
MK0!T=%><:7\0-1U/0_"@D\JWO-=N9899U3*HL;$$J#QN;Y<9R.3Q5^?7_$-G
MJ.@>&]0FM(=2U(W!ENX4W*%C4E-JMQN;C/ISZ\ '<45P.J^(/%NEZCX4TN9]
M/%[JIFBN]J%HU9,89>AZ-DCVP".M3-K?B'3_ !CHGAZ^O+:8WME-)<2Q0;?G
M4,5*YZ=%R#Z4 =Q25YGI?Q#U6\\,>'9IP@O=:OGMWDBC^XBL0=JDXW'@#/'L
M:NS^*_$<5WH6AW5NMC?:E>31O<O&&S#'@AU7) 9@1UZ$'CI0!VUEJ5AJ2NUA
M>V]VL;;7,$JN%;T.#P:?<7UI:2P17-U##)</LA61PID;T4'J?I7#_"\2+?\
MB\2NKR#7)@[*NT$Y.2!SBKGC>_>S\2>$XQ;VTRW.H;"9X0YC/'S(?X3S_*@#
MLZ3/.*\IU;Q[XEL+?Q'>1W%J8M$U-+=(VM_FF0L1@MGCCN!^5;#ZAJ+?&.X@
M:_86=IHQG6$1@C:9(]P^IP.?:@#OZ*X3PIXH\0>(TTS45M2;#41<"<JBA;/:
M2(BI)R^<$'(Z^@JEX9\7^)=1\'MXLOY;(V=I%<M-;1PD/,4!*D-G"\\8QV)[
M\ 'I%(3@9/2N L_$OB^XT-M1M=.^VK<:0+N%O+"JEP>?+4 Y9=IX[Y7KSQ@>
M)/&=WK'PNU*^L=4<,)H[>>)X1'-$&X=&QQR<X8=1QQ@T >OT5%;)-% J3S^?
M*/O2; N[GT%2T 97A;_D4M'_ .O"#_T6M:M97A;_ )%+1_\ KP@_]%K6K0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'A?_D7
M[?\ WI/_ $8U:]9'A?\ Y%^W_P!Z3_T8U '/^)]$U'4OB)X=OH+>Y%E9QSB>
MZ@=5,9=2%QDY/.,\$8ZYK0E^'VA2Z NBE;@6PN?M3D2_/++_ 'V;N?\ ZU;&
MI:WIVDX^VW/EL4:38J,[;%^\VU03M'<]!3)?$.DPV%O?-?1M;W0S T8+F7C/
MRA02> 2<#C!H -4T*SU>.U^U;_.LY5FM[A"!)&X_B'&.>X(P?2LZX\!Z!=:%
M-I$UL[Q3W!NI)=Y$K3D\R;O[WZ8XQ5V7Q1HD6GV]^=1C:WN49X7C!<NJC+$!
M03A0#GCCOBF3^+_#UL8//U:WC%S ;B%B3MDC )+ ]#P#0!7OO!.E:GI,-A>2
MWLS6\HFBNWN6,Z2#@,'[?3I^-37/A6SN;5;=[N]QY4D,CF;<TRR;=V_<#G[H
MQZ=L4Z+Q;H,[HD6HH[/:_:T4*V6A_OCCD<'\C4R^(](DTZVU".]22VNVV6[1
MJS&5N>%4#)/!Z#L: *4_@O2+BV2S83"R00C[('_=L(L;.HR.@R003WS6\Z+)
M&R.,JP((]167/XET>*RM;K^T8S'?<6IC!D,I_P!E5!)QW].^*S/ 'B6]\3Z3
M?W5Z;=FMM0EMD>W4JKHH4@\D]<GO0 :=\.O#^E3Z=/:K=A],=VMBUTY"[_O#
M&<8Z\#KDYSFFO\.=$DLYK1I+PQ3WOV]QYPR9_P"]G'OTZ5KW7B31[*_6QN;^
M..=I$BVD'"NX)56;&%8@' )!-<UI?Q!ABU_7[#7[RTM8=/NT@MG",I8-GEN3
M[#/ YH UM1\"Z/J=[>W<K743ZC"(;Q8)BBS@# + =Q[5L:9IUOI&F6^G6F\0
M6R".,.Y8A1T&35?4O$>D:0S+?7JQ%$$DF%9O+4G 9MH.T$\9.!3+[Q1H>F3Q
MPWNI0P/+"9X]Y.'0 DL#T/ H 0^&-+.OSZWY<@NKF$0SJ)#Y<J@8&Y>AXXJ#
M3?!FD:7=V=Q"LK_V>CI9)*^Y;97.6"]^>F22<<5(_C#P_'#',=2C9)+?[2"B
MLVV+IO8 ?*N>YQ4DOB?18+6&ZDOE$4\;21D(Q)1?O/@#(4=V/ H NZA86NJZ
M?/87L(FMKA"DB'N#6-:^!]'M]!FT27[5>6,J>7Y=U<,^Q <@)_=P<$8YX'H*
MOS^(M)MYUA>]4LR(_P"[5G 5SA"2H( 8],]>U:= &!_PANF-%J(F>XFFU* 6
MUQ<2./,:(#:$! P!CT&3U/-1V?@C2K&^TV]@DNA-I=N;>V)D!"QG/!&.>O4U
M8O\ QCX=TN>YM[_58;>6UV^:DF05W=.,<YSVJU)X@TF'4!8/>QBX+K'MY(#L
M,JI;& Q X!.30!EIX!T)='U#29$FFM-1F-Q.LDG/FG&74@ @\#VX^M6X/#%M
M;V<%NE_J!DMY Z7$EQODX5E )8$%<,>,8YJ63Q-HT5\ED]^@FDG^SKP=AE_Y
MY[\;=_\ LYS4B:]IDFH_8$N@UQYIAP$8KY@7>4W8V[@HSC.: ,X>!])32AID
M#7,%KY,D,B1N,2JYW-N!!&22>1@C/&*VXH$L;%+>SA4)!$$ABS@ *,*N?P J
ME;^)-'NKX64-_&\S.\:#!VNZ_>56QAB.X!)%56\;^&EF,+:O"LBW'V9E8,"D
MF<;6X^7G/7'2@#%\,>';ZXUGQ/J.N:=]E@UR.",VK2JYP(BL@)4],L0#QG&>
M*T=,\ Z/I5_87UO+>M/IT1A@:6<N%C.?EP1C&">E:>H^)=&TF1X[Z^2$Q;/-
M.UBL6\X7>0,)D]-V,U@ZAXSDTGX@_P!CWLL"Z6=,^V!Q$S2!MQ7'!.1@$\#^
M5 $K?#7P^8DMP;Q+:*[^UPVZ7++'%)S]T#H.?P[8YK%U'PWXJ.N:Q?Z;JFIV
M+SR[K:./RIHI $ 4DNP*\CD$<>]:^O\ C"6UOO##Z/-:W5CK-X('D*ELJ2.5
M((P>HY!K?&OZ4=1_L\7J&X\PQ;<''F!=VS=C&['.W.<=J ,P>#;:ZNI=3U">
M9M2O-/%E>/$X",A4;@HQP,C.>M%KX$TBSGTB:*2ZW:,K+9@R A WW@>.<YQS
M6W>ZC::=&CW<PC\QQ'&H!9I&/1549+'@\ =JQ-7\=:-IOA2;Q##/]K@0F-%C
M!RTO0(>/EYZYQB@"72_!NE:-?W%U8-=0I/*9C;"<^0LA_B"=,_7(Z>@JG'\.
M=#BLX+1'O!%;WOVZ,>:,B;CYNG/3ITJ9_'.F#7]/T=!,TUY$TK-Y+@(HX'&,
M\G\@/I6BGB31Y+_["E_&9_., &#M,H&3&&QM+@?PYS[4 );^'-/M?$-UKD E
MCN[Q56<+*0DA48!*],@<?_7IWB#0++Q-I+Z7J!E^S2,K.L;;2V#D#/U /X57
MD\9^'(KI[235H4N$N%MVB;(82,<!<8]NO2F'QOX:68PMJ\*R"X^S,K!@4ESC
M:W'R\^N.E $=QX)TRYU"XOY9KMKBYL382MY@&Z$C!&,<'C.>M:FC:3;:'I4&
MF69?[/;KMC$C9(&>F:9>Z_I6GW7V6[O4BEPI8$$A QVJ6(&%!/ SC-1KXFT9
MY[Z!;T&73E+W:;&S"/4\?Y'- #)/#%A+XD.ON\YO#;_9B-XV&+KMQCUYSUK.
MT[X=>']+GTZ:U6[#Z8[O;%KIR$W_ 'AC.,>PZY.<YK8U?6(M*\/76L%&DCM[
M=I@NT@M@9 QC(SQVX[US_A;Q5=WNC6^KZU=VBP7ZJ+:"""02B3DNH7DN, $8
MST- '1IH]C'K<NLK !>S0+;O)ZH"3C\S^@]*S9/!.BRW3RM%)Y,MX+Z2U#?N
MGG QO(QG/J,X)ZBKLGB/1XK.VO#?1O#=J6@,8+F0 9) 4$D <GCCO39_$VC6
MRQN]^C+)!]H5HU:0>5V<E0<+[GB@!MCX;L=/U^^UN%YS=Z@%$^YP58*,+@8X
MP!BM62-)8VCD4.C@JRL,@@]0:CN[RVL+22[O)T@@B&YY)&P%%4(_$VCRPWTH
MO-HTX9NU>-U> 8SEE(# 8YSC&* *NG>#-(TRZM)X!,QL$DCLDD?<MJKG+;..
M_3+9XXJSH'ARR\.1W4=B\Q2[G:XE$KALR-C<W3O@>W%-T[Q9H.K7J6=AJ<,\
M\D7G(BY^=/4$C!^G45SWBKQ\NGRZ<NAW=K<F74TLKE7B9A@_>VN" 2N,'&<;
MAF@#?\2>%=/\5VT-MJ;3F&"42HD3[/G (!SC/0G\Z?\ \([;R7L-U=W=W>-"
MKJD<\@,?S+M.5  )P2,GU-:-W>6UA:2W=W.D$$2[GDD.%4>YK/3Q1HCV5U>'
M4(TALWV7!D!1HF[!E8 @G/ QSVH IZ7X(TK1[*>RLYKU;:575(7N"R0!\[M@
M/ ZGGD\GU-1V?@'1K%]):![H?V,7-F#*"$WG+9XYS[UHOXGT:/3[F_DOECM[
M1PEP71E:%N.'4C*]1U'>G1>(M)FO6LHKQ7N$MOM1B"L6,7'SCCD<CI0!C7/P
MW\/W4=S WVM+6YNOM;VT=P5C$O=@!TS_ /JQ5VX\&:5/KO\ ;*O=P73QB*<P
MW#(+A1@ 28^]P!^5(GCOPO)&'BUB&7="\X6,,S%$SN. ,]C^56/#'B*W\3Z-
M%J5O&\:R9.QU((&3CG&#P!TS0 MGX:L;+Q%>:["\WVN]14FRXV%5 "@#'& !
M6I-"EQ!)#*NZ.12K#U!&#6=+XDT>#4ETZ6_C6Y>40A2#CS",A-V,!B.=N<T1
M^)-'EO\ ["E_&T_FF$#!VF0#)0-C:6 ZJ#F@#+TWX>Z#I-SIUS:+=B73=_V<
MO=.P ;JN,XQR>!@<GKFN;T7PUXSTTVK6^K:A$WVK?/:7(BEA"&3+_O-VYN"<
M$#)/9>W<+XCTEYY(4N]SQF13MC8J2@RX#8P2.X!.*S=#\=Z1K.DG4@[P1/<&
M")6C8M(=Q"[0!\Q.TG R10!$/AOX=642*EVK+??;D"W3@)+URHS@=O?@<\5-
M-X#TB==75Y+HKK3*UX/,'SE3D8XXZ]JWK.]M]0M5N;63S(F+ -@CD$@C!YX(
M(JC;^)M&NK^*QAOT>>??Y(P0LVPX;8V-K8P<X)Q0!2C\$:5'??;!+=&;[!_9
M^3*/]1C&WIU[YZYJ1O!NDS)J(NUFNWU*%8+B29_G,:CY1D =/7J>Y-!\;^&E
MG,#:O"L@N/LS*P8%)<XVMQ\O.>N.E1>+/%=KH>G7Z6]Y"-3M[1[E(7C:08 X
MW8^Z"1@$D<GC- &QIFG0Z3IT-C;O*\4"!%,KEVP!@<GV%9NH>$;#4O$%OKLM
MQ=QWUJAC@>*0*(U((( QSG<>N>M3^%M4GUGPMINIW019KJW6601@A02.<9)X
MIJ^*]#:WEN!?#R8HC,TGEOM,8.TN#C#+D]1D4 5$\!>'4TR]L39LXOY!-<3/
M*S2R2 Y#[R<Y!)(^I]33Y?!FE3VFIPSM/+)JVT7MPS@22A0 JY P  ,8 %7;
M;Q'I%W>6UG!?(\]W +B! #^\C(SN''(ID?B32;R[;3[/4(FNV5_*&TE7*\-M
M/ ?:>H!XQ0!'>>%=/OO"R>&[AYVL$C2+ <!RB$%03CM@?E4M[X<T_4=%ATJ[
M5Y8;?88G+8=&3[K CN*Y[P+\0+;Q!H^G_P!JW=K#JMZ\BI!$K*K;6/ SG!Q@
MXSGFNMO]0L]+LWO+ZX2"!,;G<\9)P![DGM0!5TS0+#2S>O&K2S:A)YEU-,06
MF.,<X & .   *BM_"VD6L.DQ16V%T<DVF3DJ2I4Y]<YS]<&H-4\9Z/I?A^]U
M@S--%9MY<D2HPD63LC*1E221U ZUC:OXZFL=3\+F)H$L=7,@N3-$P9-H4_*2
M1W;'0Y[4 ;5WX.TN[\0'7 UU;W<D8CG-O.T:SJ.@<#KT'Y5/:>&K&R\17>NP
MO-]KO$6.8%QL*J % &.,8%.@\3:+<Z2NJPZA$]HTGE+( <E\X"!<9W9[8S39
M?%6AP6MO<RZC&D-Q,8(W8,!YH."AX^5L@\'!X/I0!#H/AN+1-6UB]A+JFI3B
M4Q-(7PPW;GYZ;MW3T4?03ZUX;LM>GL9[N2=7T^<3V_EL!MD'1CP<_0\59TK6
M-.UNU:ZTR[CNH4D:(O&>-PZBJ\7B;1IM0BL8[]#/.SK#P0LK)PX5L;6([@$X
MH J7_@K1M1N+N2>.41W[QO>0(^([AHSE2PQGTZ$9QSFK,7AJQA\32>(8VF%[
M)!]G8;AL\OC"[<>H!J";QQX9MI)8YM7AC>"80RJP8>6^<8;CCGN>*MV/B/1]
M2N[FUL]0BEFM%#3*"1M4]&R>"/<9% &G7,MX!T0Z7J&EJ+F.SU&8S30K.=NX
MD$[?0$J/R]*TK+Q)H^HN4M+U96$1F50K R1@X+ID?.N1C*Y%10>+M N4LGAU
M.)TOY#%;, V)7!P5!QUS0!#;^#-*M]5;4<SRS/9"Q=9'!5X, ;2,>P.:D\/^
M$].\-)Y5A+=M"N?*AGN&=(03DA >G\_S-,N?&_AJSFGAN-6ABDMI!%,K!@8V
M)P-W' ]^E-NO&%A;>+K;PWB1KB6$S.P1BJ#("C@<Y)//08YH OZ]H5CXDT>;
M2M21GMYL9VMM8$'((/KD5FP^!M*AN-1N%GO6FU2W^SW<DD^]I%QMZD<''IZ\
M=JU]3U:PT>W6>_N5A1Y!&F02SN>BJHR6)] *Y3PYXZ^U2^(I=8N;:.QTFZ6*
M.XCB9?E.>6&3@\ =J -.S\#:1I]UI5U UUYFCQO': R A5;.X$8YR&(KFO!O
M@1IM-NX?$=I=PJ-6>\CM6F'E2CC86"D]#GC([9SQ7<6VOZ5=ZB-/@O$>Z: 7
M(BP03$<8<9'(Y%%AK^E:G<&WLKU)I-AD4 $!T#;2RDC##/&1D4 9&I?#OP]J
MUQJ,]U'<[M3*-<*ERZJ63H=H.,_7/4^M6CX.TI]8N-4E\^::YM/L4RRR;E>'
M &TYY[ YSGWJ_<:WIUIJD&F3W(2\N$9X8=K%I H).,#G !JF?&/AT:7%JAU6
M$64TODI.0=A?^[G'!X/7TH I6?P^T6SN=-N%EOI'TK=]D$ERQ$0/\('IV^AY
MSQ6MXCAFN?#6IV]M$TTTUI+''&N,LS*0!SQU--L_$NBWUM>7%OJ,+16)(N68
ME1%@9YSCC'?I7/VOC62_^(5IHUC+!/IEU8&Y#F%TD4\XY)&00 0<<@T 1^"?
M!D=KI&B76KPW0U#3(G6.WFE#1P.Q^9E SU&.YQVQ70:+X:LM :^:REN-U_,T
M\QD<-^\;JPXX_E[5);^)-'NI7B@O4D9$>3Y58AU0X8H<8?!X.W.#46G>+O#^
MK74%K8:K!<37"-)$B$Y95."?;D'\J ,T?#G0UT>/20]V+6*[^V(OFC(EQC.<
M9_#I5I?!.C%]8:9)9UUK'VQ)7R'(SM(P!M(SQBG:KXOL-*\2:=H4@D:XO SL
M5C8B- I(/ Y)( P.G)..^+HGQ!A.K:U9:_>6EL++4?LELRHR[AD@%N2!TZ\"
M@#3/@/2G\.2:!-<7\UE($4B6Y+,$4Y5 3]U00.F.@K$E\*7L_P 1WF:.^BTS
M^QQ8K>12JK%MP.#WQMR,XZ^^#6__ ,) T7BZ^LKC4-/CL;2P^T/$P=9XR",N
MQ/R[,'J/\:UM/U:RU3?]DE9S&%+*T;(0&&5.& /(YH QV\!: 8M)BC@FA72
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M?4H)WNVCU2X%S=#S0-[@D@].!D]!Z"M-O#.GMK\6N'SA?1VXMV=9"HE0'(#
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M!&'@5R3D+G;SD9 /;K4E]H5S)X_\*WMOH;0:;86\JR(BILMRRL$& <<'&<9
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M=QP,9)[UY/::#XDDUO0;V;PX]G%8ZI,[P0/$(HXVQ@J-V3T)+'KVXP*];HH
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M;@W<)!^4QO@D+[#*X_WO:NLU?3)M4-K'Y\*VL<HDG@E@\P3@=%/S# !P>AY
M_'#O? :/XOL/$6E7<&F26:&-H8K0%9E.<AL,.Q/;T]* .,GU'1]*^(OB\ZVL
MK:=!;Q;$CC=A&S*GW=OW"2>O')ZUL:'I&JZE\*+:T\07<CSW4\7D7"R[Y8HG
ME0*=X/7!/?H0/:MNW\"*/$^LZO>WL5W#K,(AN+0VQ4!0 !AMY]/3\J31?!>H
MZ%H9T:VUY9K6.Y2>W^T6A9H560/LR'&1D>W4_@ <MHVKW5C*/ ?BW$E[;75N
M;"Y?I=0^<G )_P!G/U&0>G.C+$G_  O>&WV_N#IGFF+^#?DC=CIGWKK-=\+V
M6O7&F7=QA;S3+J.XAF5>?E8%E^AQ^'!JE)X0N'\>KXK&IQAEM_LXMC;$C9S_
M !;^O/7'X4 <=J#:GX UUO%%LTUUH%Y<RP7]H#D6^)6564=AQQ[Y'<5+XJ\1
M-I?@:U;PY.L/]MZG-&MY#_#&97Y4]C@*!Z#IBO0;32&_LVZL-3E@OH;F25F4
M0%!MD8L5(+'/WB,UC'X>:3+X*C\*SO*]M!*\EO,#B2(EV92#Z@-CWH 76-"\
M+Z?HZV=Q>6VDR.NV.[>X$4KL.[.2"^>X).:UUU*_?Q"EE'IA?37M?.&HK,"N
M_. FWZ<YS6)KW@R_\3Z=8Z?J^LQ/%9W*7!DAM"DDI4$#)+D#.XYP/RK<.FWI
M\2C4QJTHLQ;>5_9^P;"^[._/KCCI^/:@#'^)_P OP]U65?EDBC5D<<%3O7D'
MM7$Z3=21>(O!'V>6?2!/I\9NI+AF6/4247Y5 RK-D]3@_,.^*])\5:$_B7P[
M=:.MVMJMT KR&+S" "#P,CTK$7X?&Y;0%U75?M-OH"(+:&&W\K>RA0&<EFS]
MT<#% &)KCGP!\1[37&\QM$U=3!,@!86\OJH[9P#@?[7M7=Z-IPM4GO)85BN[
MZ3SIE'\'HGX#&<=3D]ZS/&WA"3QC9VEI_:*V<=M<+< ^1YA9@"!_$./FKI(P
MX0"1E9\<E5P#^&30!YWXYU"_T#Q5#K%_HSZQX>^R>4Z(-WV63=EGVGC)&!DX
M],COB^/KVPE^$MEJ&AWTTL37Y,<[,PE0,TC%"2<\9QR>< UZ3)IFHIJUU>VN
MI1+%<HBFVFMRZJ5!&X$,#DYY^@KF]5^&$%_X0B\.6VHBTB%T;J646^XNYST&
MX!5^;@<\ 4 5M?O9=0^)VC^#59K?24MS<W$,1*>>0&*H<?PC:..AR<UORV7A
MNV\16*V]]9V%Y S$V,4RQB<,C+S$",D9R#C/!%/UCPFNJ:EI^M178M=9T\$1
MW2191U.<HR%LE3D_Q C)YJ'_ (1":X\:6OBF^U"-[FTMC;Q0P6Y1,'=R26)/
MWSTQ0!QEU+J7P_UU_$<;377AV_NYH+ZVR6%MB5U5E'88''XCN*F\<M:+\)I]
M0TME57OW>&>$X)5IV P1SC;@?0 5Z!:Z,3I5SIVJ207T-S)*SJ(2@*R,S%2-
MQSC<1GZ5@ZE\.TO/ D/A*VU(V]K%(6$KP^8Y7>74?>'3.,]\=J ,_P 5>&;O
M5K#2/["N&L=2M;%KB!HFV"5D,6%;U^\<9[GZT>%_%UKXDN(K^[M!%J^EV5RM
M[;E<,KJT>" ?7YL9Z98?7K;?2KZ&\L)FOX&2TMF@=!;$&3<4Y!W_ "_<'8]3
M^$</A:PM_%LWB.!1'<7-J;>X0#Y9/F4AOKA<'UX].0#D_AT8?$^@7?B;Q(8K
MN>XN7 ^TX,5M&N,*@;A1UYZGO75^&$TN*VNUTG58]1@>X,FY+D3^5D#Y-V3P
M,<9[8':J>D^$9O#8O+?0K^*'3[J0RBUN+<R"%R,'8P=?EX'!STZU9\&>%8?!
MV@+I4-T]R!(TC2.H7)..PZ#B@#GOBGIEO9^"M=UB+<+V1H"LVX[H@)(TPOID
M9SCKDU+=Z-9P?#J[U6%#'._A]B^TG#.(MP?'9@<\CGFM[QAX=?Q7X<N-%%X+
M2.X*;Y/*\PX5@PP-P[J*6?09Y_!K^'C>QAGLC9M<>0<;2FPG;NZX]Z /++V^
M(^ UNZV]VMT"K?;-I&29L$[\YZ<?I6OXSC6&+P"L0\L3W,$<NSCS%/EY#>H.
M3U]370S_  \FG^'L7@\ZP@AC8?Z0+3YB ^\#&_KGO4VM>!KG64T /J\41T1T
MD0BT)$K+MQGY^!\HXH P?%6J7'ACQC=7VNZ))J7AZYBBCMIXAN^PE1A@!T4E
MB3G@],'C%=UX;DLY?#E@^GW;7EJ81Y4[$EG7WSSGUSSG-0/H^IBYU)X]3MW@
MU @F"XM#(L?[M4./G&0=N2#Z_7-GP_HEMX<T*TTBS+M#:IM#.>6))))^I)-
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M^&K76PNFNKQHSVVZ>.)B=R!]P!ZD [>,T[5_A]I>H^#[;PW;2/9163K);2J
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M*Z1XBM'#;T!1)%Y88]\#C_;H ]3HKQ[P1NTBY\0>!;NV$5Q=R));(X#-Y<@
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M(EPD?SD;P.@.'/3O@U5U+1+*T^$(OH%$=_#8)>+?*<3&;:'+[_O9)R.O0XH
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M@W8WMW_"MB@#*\+?\BEH_P#UX0?^BUK5K*\+?\BEH_\ UX0?^BUK5H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LCPO_R+]O\
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MXB:"8RI-&55@X)4>I&,=J ,*^\#3ZAX7'ABYUIY-,4(JLUN/M 1""J[\[3C
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MJD+1I;I"(XU+,"6ZDD_+CD]SZUAZ#XUOM<D\01C3((6T25H?^/@L)F4M_LC
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MB0"I#%1@<D'C@CO3M7\63^&9-/?7K.&*TOI1 UQ;S%Q!(1D!@5&5X/S#TZ4
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M_P#PCSW,\-H84A9H]N\JN,<D$=AVJYHVF+HVD6NF1SR316L2Q1M(!NVJ !G
M Z"@#(^(/AP>)_!U]8K&'N43SK;CD2+R /KROXUYCK&KOKO@[P_XLL8$>_\
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MCI63XHT2]M/B-H?C"WMY;JUMXVM;N.%"[QJ0X#A1R1\_..>*CUW2[GQ?X_\
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M&3V(H N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_HI >(R%0P^;^(+NZ=#QCK5C[?XE>_\ $.EKJ\"MID45Q%<_8QN(=6.PKG&
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M6<F/=%,"I!3"8ZJO!STK2U5#;^'+R/,UPPM77.TO)(2I'11R2>P% ')VVO\
MB2WL_#&L7=W;7%IK+6]O/;);[3&TJ95PV>>>HZ<\>M.A\2:Y;Z3K6NWM[;R6
MVCW5W ;6.VVF?8<)\V[Y><>O?\+WA+0C-X9\/MJ$UVS:?;QLEK/$(_*E";>0
M5!.W+ 9^O)P:T['PK96=CJ=C+/<7MMJ<TLL\=QLQF3[^-JK@'/X=J *%SJNJ
MZ/?Z']INTN[?5I/L\H$07R92A963'\/!!#9/3FF:?KVK30ZEIUS+;KK%KJ"V
MT86$A6C;#))MW9(\O<QY_A-:5CX9AM&L?/O;F]7301:+<;?W?R[020!N(4D
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MP&W^S%\)NV;=O3;MZ<=*HVOA1+32=/TV/5]1,6G2*\+,8BQ"C"J3LY 'X^]
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M *\(/_1:UJUE>%O^12T?_KP@_P#1:UJT %%%% !1110 4444 %%%% !1110
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M"?.X]@53;_P(5R\UI/X8^,%SXAO8I&TK5K,0_:E0LMNX"</C[H_=]3Q\WL:
M.KFUZYTR:?\ MFRCMK2"T>Y:[BF,B$*0"N"H(/.<?3&><9UOXMU2\\)R>*+?
M28OL:HTR6SSD3/"N<MD# . 2%Y^M6?$4,7C#PQJ>D:=*7,]N0EP!^Z+YRJ[N
M_(YQG'>L#3=2ELOA:VC3V%VNKP63V8LO(8N[X*J1@8*G(.X<8H NZY\0FLO"
M]AXET?3?[3L;K/F+YA22( $L2,$<;2#Z8]*VK/Q&FKPZ3>:3Y,]EJ)8&1F(:
M,A2Q& .ORD$9&#6!X3T1_#'A_P /:-J*E[@R2R3J$+HF]'^4D @#Y@.>"<U6
MT7PC?>$O'Z1V#.WAV\\RX2+J+:8(1M]@03CUP!VH TM(\9:EK&M:[ID5A90M
MHTJQ-)+<L%E+%@#PAQ]WWZTFH>--5T[6-!TN;2($N-8W*0UPV('4@$?=^8<\
M'BN<\->'SJ?C;Q6]W'?6R2W\-Q:28DCCF\N1F]E<=.N>N15[X@VSW?CWPJ_V
M:\DMK9Y/M,MLDG[H-MQEDY'3L: .DN_%%SH^E:KJ>K648M;&))(I+64N)]Q*
MXY48(8 =^H-6;/6KV9[.2:SMFL[N)I!=6MR943"[L'Y1G/."/0]*QS?:?9^'
M9M%&FW>H:=9010S&2VD_>J\@3:H(R[!<DX[XK!T30W\*^+X/^$4U*:]T2XAF
MEO;1VWI;%5RG/8EL  _-P<Y[ '4:1XON=<TJVU>PT^&:RN+E82JW.9H5,@3<
MZ[<9 .XC/ ]:2U\6W5Q\0[KPHUE"JVUL+DW(E.64[>-N.#\_KVKC)=!M[._T
M_P 0^![BYL-0NYXOM.CD$ JQR^Y#RJCDG/RXZ8XK6L[6:3XW:M<O;W"V<^F?
M9UN/*8(S_N\@-C&>#^5 &_HOBRY\4F_GT*T@:RLY3!'/<2$?:9  3M !VKR/
MF.>O2JT'CR34_"=SJ^DZ89KVSF$%QITLFUUDW!=H(!SUXXY]JS/AW')X(TG4
M-"UN*6&2WNGEAE6%F2YC(&"A .3P?EZ\CBJ_@_1[W0]%U'5M4MI[>;5]6AN%
MM?++/'&)@V64 D'!8GT H W]$\<)XC\-1:IID$7VD7$5O<VLTA!A9W5.H'(^
M;(XY [&NL&<<]:\[UWP?=Z;XTL/$7A_<MK?WD"ZK;(."/,5A)CZ@9].O<UZ+
M0!S5GXKDUOQ#J.DZ+;Q/'I9"7-W,Y"^8<_(J@9.,')R,8Z&H++QN+VQUQ/L:
MP:IH8<W%J\F5<*"0ROCE3CKC([BLCPA8R^"_$_B*UU-)$M=0N!=6EWL+1N"6
MRI8#AAD<'KSBJ.FZ->O<^-O%$]K/!%J=O+!90O&PDE7:0&V8R,X7 (SR: .B
MT#Q;J^O^'+'6K?2[0+=NV;?[2WF!%D*,P^3!QC..*Z^O/?A7X?\ LWAW2;^X
M6[M[ZVAN();><R *'FW A&X7A1R ,YYS7>7<LL%E/-! ;B:.-FCA#;?,8#(7
M/;)XH YN^\6W=I\0K'PHME"ZWEN;@7)E(* ;^-N.3\GKWH\-^+;O7?$NMZ/)
M90P#2)!&TJREO-)+8.,#'W?>N<L/[0\1?%71->.FS6T=MI!%V'5ML$C&0>66
M(&6^8<5/X=#^&OB/XI?5(9X8=3>.:UF6%W24#=D J#S\PXZT :WB#QEJ'A_P
MI<:[)I]O-Y%V]OY*S,-P$ACW9V\<C.,?C3Y?&TFF:II-IK5@EO!K  M;J"8N
MH<X^1P5!7[PYY'/UK$^(5G>7'PPN+6*SN)+FZO6FC@2)FDVM.SC*@9!VD9ST
MJ/Q'I=YXPG\+:;8VEPL%BR3WMU+"T:1 !?E!8#<W!X'3C- '3CQ7)J/BFY\/
MZ+;QRO8H&O+J9B(XB>B #EF_$ 8-6?[5U>&348KK3H$^R6RS0S)*2D^=V1TR
MI&T<<]>]<QX>L)_!WC[Q%+J$<GV#6Y!<V]XJ%D5MSL48C[I^<XSP<5/I>K:]
M?W'B@:AY[:5;(R6$GV7;]H!#="%RV.!QZT :/@_QLOB.+5$O[1=-N]*E*7$)
MEW@+C[V<#CAOR]Z@\,^-K[Q)>ZY;#2XK0Z20N))B2Y.[ (V_+]WGKUK-D\,7
M<GQ LM9T[<FFZI8[-3!0C/E[>"#C!;"KZX#5#X*66T\3^.;BYMKF&*ZN!);N
M\#@3*#)DKQSU'3U% &EX?\<:OXC\,_VU9Z1:;M[JMJUTV]]G)V_)R<=JE\3>
M/9/"GB.UL]0TW.E3A-]_'(3Y)8L &7'^P3UZ ^F*Y7X;P0^'O#<6IZC::K'?
MVC7"_9!;3L9%?:1M3& 25'/'N:[BYL[+Q#>ZAI6J6K-'=:? LBE&VA@TI(5L
M8W+D'U'% %NYU74OM-U%86=M=JD,$L!\XCS/,=EY(!P %+9&>*QH/&.L77B_
M4_#,&E6;76GVRS[VNF"29"D*/DX^^.?:HOAWHFL>';O5M)U.5[BWM1"EA.1P
M\.9"!GV)(QV^F*IZ'#.OQMU^]:VG6UGLXXXIVA81NP6+(#8P>A_*@#OK662:
MTAEEB,4CQJSQGJA(Y'X5G>*=9F\/>'+S5X8$N#:)O,3N5W#/K@XJ2UUG[3K]
M[I/V"\C^R(C_ &EX\0R[AG"MW(_Q]*S?B(DDW@/5H(8I)IIH-D<<2%V8DC@
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MQ4%SJ=A92I%=WUM;R2<(LLJJ6^@)YJMX::X;PSIIN[-;*?[+&'ME&!$=H^4
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M/QIXPU;PXUZT%O:+%;6Z30^=F1KDEP'&%8%  1\Q!&2/;(!VU%</J/C#6?\
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MDSLCY&T8.<G//:@#T*.1)4#QNKH>C*<@TZN4^%__ "3C1O\ KBW_ *&U=70
M45YE>_$C6K32=9NQ;V#2:9K7]GJ#&^)$R1N/S\'BM34O%?B!?%VL:'IZ:<$L
M-/\ ML<D\3DMT^0X<=<]>,>AH [FBN!T[XA7.NOX;M-/MX;>YUF"6:9YE9TA
M$>X$!003ED/?@>M51\2M2NM#T&^L[.T6?4-3&G7,4NXJK9QN5@>!WY!Z^W(!
MZ117,>#/$E]KLVM6FHQVXGTJ_>V\RW5E611T.TDD'@]ZN^+_ !"/"WA>]UDP
M^<UNHV1YP&9F"C/MDC- &J+B SF 31F4<F/<-P_"I:\N2ZNX/BSI]_JS6[2?
M\(\T\AMHB@QEB1@L22.1G//'2MKPYXOUKQ ;"6.P5+;4H9F686LI2S=2=@=B
M0) 0.VWD8H [%+NVDN'MTN(FFC&7C5P64>XZBIJ\B^'\]S8>!+7Q EM:7%W)
M>-#)>3X5K>%Y,R.S%AOY X&#SWK4E^(VJQ^"]>U=;>T:[T;4?LOS1.J3+O50
MVTMN4_-TR>E 'H[NL:%W8*JC)9C@"DCECFC$D3K(AZ,IR#^-<?#XGOK_ ,3Z
MKH%Q#;?9HM*6Z1D1@Y+ 9!R2".3VKB/#NIZM;>%/ &GZ?>16\-]>7'F!XB^2
MDS$;L,,KSTXY'6@#V*_LTU#3[BRE>2-+B-HV:)]KJ",9![&FZ=81Z;9I;)++
M,1]Z69MSR'&,L>,G  _"K"[@@#D%L<D# )^E8?C?4+W2O!NIW^GS)#<V\!='
M9-V/H,]?0\_0T ;U%<#IOB;5+6#PCH*RVTU[J]H)3<R0MMBB6$-RN_+N<'G(
M'M6]X*\2MXIT-KR6%8;B"X>VG5"=N]>ZY[$$&@#H**Q_$NJ7FDV5O/:0PLKW
M*1SS3N%6WC/5\%ANQP-H.3FN+G^)6K1^!=4UM+:S-UIFIFS8/$X25<@!MN[*
MGYNA)Z?D >F45PTOC'6;'7-7T6]CL6N+?2VU&TEBC<)@=4<%LGGN".G3M572
M_'NLN_A>XU*WL3:>(2T>VW1P\#@X4Y+$$'/3 QZF@#T.BN'T/QQJ.N7=M<6N
MG-+IMQ>RVS>7;R%H$7A9&D^Z<D<C' (YXYAMO'>JCQ-HVF7UI:QC4IKB&:"/
M+/:M'@KF0,58D$$C (R/44 =]17$:'XF\4:YKFIV4%OI8M]*U/[//*_F*SPY
M.=H!/SX&>3BNWH A:ZMDN5MFN(EG<96(N S#V'6IJ\?L]0_L?4?&_B'5HK?4
M9-*O8VB!B*GS3E$*DL=JC=C'/UXKJ(?&>IQ:E/I-XEH;LZ,-3@ECC8(#@Y1E
M+$GD<$$<4 =Q17)>"=>\1>)=/LM7O;;3H-/N;=R5B+^;Y@? .#D!< ]R?Y5T
MM]-/;Z?<36MO]HGCB9HX=X7S& R%R>!D\9H L45PV@>-M1U3Q,=%G6S)DTL7
MB2PHV(I,[60G>1( ?XE(Z$?3,T/XC:[?Q^&KN\M=/%MK5W+:ND*N'0J<!@2Q
M'X8/3KSP >D37$-NH:>:.)2< NP4'\Z>#D9'2O(?'7B*]\3^"/$TB1VT6G:=
M?I:(I1C*[+(N7W9P!STQT)YKUBR_X\8/^N2_RH S9O#%I/XL@\2M<7(NX(/L
MZ("OE[,DD8VYZD]ZV:Y/6/$NJ'Q/-X=T*&U:]@TYKTFY!(D;<%6,888SG[Q/
MI5'4?&NK1ZCJ5A;6EK!-I&D?;[M9@TFZ3:&\I2",#&?FY^E '=4UW2)&DD94
M11EF8X %<(/'.J:EJ_AVUTF&SCBURR>?-RCLT+JI)&0PW#(]!GU%<WXF\3ZC
MXI^$VF:K)Y-LUQJ"17$2(Q5R'.,?-P/ER0<_48H ]=AGAN8A+!*DL;='1@P/
MXBI*\_N/$ESHVJ:IHF@:5#++ID4=Q/##:R-]JFE(9@NTGR^#G+9Y(].;*^.;
MEO&[>'YXX=/+-";>.ZA8-<QL 6*ONP&!) 4CL1G/% ';T5Q?A3QK<Z_KUUIE
MV+>TN;5Y1+8O$R3( PV,&+$.".O P2.W-=I0!E>%O^12T?\ Z\(/_1:UJUE>
M%O\ D4M'_P"O"#_T6M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5D>%_^1?M_P#>D_\ 1C5KUD>%_P#D7[?_ 'I/_1C4 -UC
MPQ::SJNFZI)<7-O=::SF%X&49#C#*<@\$>F#[UE7OPXTN_36TFO]0"Z[)')=
M!7C&#&VY0OR<#/UK5US5Y].OM*M[>33P;RZ$<JW5R(W*=_+!^\V<<?Y%B3Q#
MHD27#R:Q8(MJX2<M<H!$QSA6Y^4G!X/I0!E7'@BUDUBUU>UU._LKV"V%K)+
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M2UCBUBR=[P9MU6=29><?*,\\@CZB@";6=(L]>TBYTN_C+VURFUP#@^H(/J"
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M/4;6X-J<3^5*K>5_O8/'0_D: ,.X^'^EW6AZGI<MS=C^UKC[1>7",@DD;<&
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M[J'4K5X+?_72"9=L?&?F.>..>:='K.ERV<MY'J%LUO!Q++YHVQ_[Q[=1U]:
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M44 %%%% !1110 4444 %9'A?_D7[?_>D_P#1C5KUD>%_^1?M_P#>D_\ 1C4
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M$]N\:K/@<$D?+@@]<=/<9]6HH \[^'>F.(M,;4-/U:UU+2K=[5A/$(X A/\
M"=HWYP#U./RS:\<07T_B"Q2QT6YG:2SN(FOX%W&,,I'EX)"#)QEFSQTYY'<D
M@ DG '4FH+2^L[^-I+*[@N45MK-#(' /ID=Z /)H-(U,^&_ -M-I%]OL-1WW
M2-:N?*029RPQP,'O4%WH&N7?A7Q5#;Z9> R:^;U+=H&0W$&[/R@CYN@./;Z5
M[110!YB)M27Q]KFO6&CZ@L=QI"Q6DDMFZ!YOEV@@C(Y'.1V^E:>N:!<Z=K7@
MV>WBFN-,T<O%.(D+LI,859"HR3R.3V_&N[HH \7N?#FL?\(I8PW&F7DJ7'B<
MWPMU@=FAMB""64#*]<XZ\_6O8;2SM;*(QV=M%;QLQ<K%&$!8]20.]3T4 >(:
MIH6J3^%_%<,>BW[7%YK_ -H@7[')NDBW$AAQTQG\_>NCELKD>+_&-TN@W=W9
MW6EQI#$8)(DN2L8!0-@8/;CGTKTRB@#R_P &6&KIX\M;^^TJ]M[:;05M_P![
M!M2)@R_N^I( "D#<=QZGK6IX)T"]T77]6TEU']D6%T;FP)[&5?NCV52P^K9K
MM[FWCN[6:VF!,<R-&X!(.",'D=*KZ5I=MHUA'96ID,<8 W2N79L  9)Z\ #\
M* .7^(=A>7E[X9GMK.:YCL]5CN+CRHRY2->2<#^74]JY?6/#&O7^G>-+[3[2
M=(]1NX)+>U9"CSK&<NVP\\DY&1DX^E>NU5FU.PM[N.TGOK:*XE($<+RJKOGI
MA2<GH: /-O$&D7NJ>&[S6=&L-6>\N+JUN;NVO8Q&\_E C8L84=/ER0.<<9Q5
MOQ'IC:QI5EJFC:)>VJ_VQ!?:A!+;E)9@.&/E]21QQCGDC->D44 >1ZSHFL7.
M@^.[B&PNWBU:[@^PVX@?S)-CC>^S&0".Y SM^E2OI=T/%-Q<+I%YY!\*FUC8
M6;X\[:/D'R]<9'Z5ZA<WUG9>7]JNH8/-;:GFR!=Y]!GJ:GH \?LM/US3--\#
MZ@^GZGY.FK<0W<,%L6G@9\@-Y;*<C!ZX/'UKT?P]I4.E^&(=/T];FWB5'\D7
M)S(FXDC/IUSCMTK3DN[:&YAMI;B))Y\^5$S@-)@9.T=3@=<5-0!XI;Z5JT'A
M/PYI$FA:B;[2]>$UVRVKLNS<S;P^,,"".1GISVS=\5:3JHU?QQ'%I-]<?VM;
M6IM'@MV=7VA=PW#@$8/'7VKUZH+J^M+((;NZAMQ(VU#+(%W'T&>IH \QNM.U
M"'7M)N;RQU632KSP^NG3?9+8N\#'&Y64J2H.,9P#[\5WZ::8O"7]EVR2+ML3
M!$DSAG'R;0&/3/2M*>>&V@>>XE2**-2SR2,%50.I)/04L<D<T22Q.LD;J&5U
M.0P/0@]Q0!X]X<T[58[OP%'+HVI1#2FNTNWDM'"QER=O..G(YZ<]>#BMJNBZ
MI+HWBA8M%U!I[OQ"+B#%G)NDBW,0PXZ=?S]Z]JFFBMX6FGD2*-!EG=@JJ/4D
MU#%J5A/:->0WMO);)G=,DJE!CKE@<4 >;ZW8ZC;^(_&4LFF7MW'K.D;+"2&V
M>09$6"AP/D.><'&<>I JI!I^LZ<G@R^FT_4_LEI8R6EU';6V^:W=AC=L*G@\
M#..@^E>L07$-U"L]O-'-$XRKQL&5OH14E 'F-YX<2'Q/X)M8-*OY=,L$G$AG
MA:7RPW^K#D# YQP>@QFO0Y;**/29;&S@CAC\EHXXXU"JN0<  <"K=% 'C,^D
M:LWP5T_0SHVH&^MKW][!]E<G'FR,2..1@CGIS6E>:=?G5?B$\6F7ODZA8QI:
M;;23$S"/;A>.>3_6O5** /'[[1=731-$O=*M]1@UBSTB&UEMI+-VANT+$-"X
MQA2#DG=P00>,9KTW7'D7PW?$PR22M:NHB@0R,6*D8  R>:MW=_9:>BO>W<%L
MK'"M-($!/H,FIG=8T9W8*JC+,3@ >M 'GWQ \(3ZO''XH\.B2'58HBLJ!"C7
M,)&&4J1G< 3P1DCCTI/$FF:C#XSUC47M+FZM;[P_):6IAA:7;+D?NR%!VYZY
M.!SUKOK6[MKZ 3VEQ%<1$X$D3AU/XBIJ /+K'0=:T?5? ,]Y97-P-/M9X;EH
M4,AA9T(16QT R%STXZT[0]%NQK^HZ9K=GJS.NN'4[2>&,""3IM8R;>, <KGH
M< 9KT^B@#B/BM9WE_P"&;6"QL[BZE%_%(4@A:0A5SDG XKG?$6EW]UXE\:7,
M6E7LJ7FE1PVL@M'/F/A 54X]?Y>U>L5%:W=M?6ZW%I<17$+$A9(G#J<'!Y''
M48H \Q2TU+3]0\*W][H]]>Z8=!73;R".W=W@D*X<M'C.#@ GT!]LZ2:;)!\4
M="FL])N[;3;;23;@^0Q2$Y;:I89&<8[UZ%45Q<P6D#3W,\<$2?>DD<*H^I-
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MT>>[MK9XHY[B*)YWV1+(X4R-Z+GJ?84VVOK.],@M+N"X\IMLGE2!MA]#CH:
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M/+$]I-Y9=/[K<'(Y/O3=1\%Z5J-Q/,7N8&NK46ESY,@_?Q#HK%@3GMD8..]
M',7OQ'NTNM)DD1=,L-4L8Y;>YFB,D9G8_-&[9&T ="/4$\5)::GKK_$7Q:L,
MZW7]FVD?V:T,> ^4+J@.>"6(R><^W&.CU#P7I6HVPLI3.EALBC-FC+Y16,Y4
M<@D>A(() Q3Y?".FR:QJ&JK)=0W&I0>1<B*7:K@+M#8]0#QV[XS0!F^ ?%DG
MBB"Y:>X7[1;I&L]JT!BE@E^;>",G*\#:>O!!YI_C'Q!J>C2[+5K>*$V4\RR$
M>9*\J#(41]=N 26[>H[Z^E^'K32]0N]1226>\O BS3S;=Q5!A1\H _'J>YJM
MK/@[2M=U:/4[PW(F2V>V(AG:-7C;.0V.O4_US0!RM[\1=1M]#\/:M<0K:66I
M0,;F\2 RI#-T4%<Y"DY)YSCITKOH)Y)=*CN$\NXE: .OEM\LA*YX/H?6L1?
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MD1K&+&2\BV3+U)CYY*KGZ<\=34_C.VU*XUS138:.]RJ^<LE[#M\VW#)C:-Q
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MVLM*^S3O*@41OM(QUSC-=1X]@N[GPA>166DQZK.VS9;2<@G</FQD9QUQGM0
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MM&[*$$;..#N!YSZ8K6O[&74?&<&L:7:W%UI;>&FMX+E8RP=R'*CUR0P_$XH
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M>TN;!K+5F_YZHN"N?]X\'V%9UGX,UV/X8:QH;N6O?GMK/)V[X$D+*,_[66_
MKZ4 =NOB;16LY[S^T(A!;!6F=LC8K<JQ!&=I'0]#4NGZ]I.JW$EOI^H07,L2
M)(ZQ/DJK#*G\17!3Z1<:AX)U2XCT+4X-7N=-2SD6X;)D9<85%S]T<G<<<'ZX
M[/PC8)8>%]+B-F+:XCLXHIE:/:^Y5P0?7YL_GGO0!:U#7M*TFXAM]0OX;:6<
M$Q+*V-^.N/7_ .N*J1>,_#<XMC'K-JWVN3RX?G^\V<8]CD'KBL;Q=I]Y=^._
M"5Y!9336UA).UQ*B$K&'"A<_B#]*XL^'-;_X1":T72+O[2WB;[:$$1SY.W[_
M /\ 6Z^U 'JU[XBT?3KCR+S4(87#*K;CPA;[H8]%SVSC-.&NZ6VIS:8MXAO8
M(S)) ,EU48^8CTY'YBO-/'>AZ_K,OB.WL/#TR1SFV>.6 )B[*XRSDG)(!P%4
M>N><5T'BG1;^?Q-X?US2<V]W+FPO%8C<L+H6R<'JF&/7KCL* .UM;J"^M8[J
MVD$L,JAHW'1@>A'M7'Z'\0(9=6UFPUV[L;3[%J!M+8J"AD&2 6R3Z#G@5V<4
M:0Q)%$H1$4*JCH .@KQO6O#>N76C>,(8-(NVFU#6$GM0(R/,C#,=WL/KZT >
MJZCX@TC279+^_B@*!2^XG$88X4L1]T$\ G IYUS3!JJZ5]LC^W,GF+ ,EF7&
M=P]1[UYYX[TK6]8O-<AT[0)O*NK"'9<Q!0;EE96Q)N.1M&0%49R.>*U-:\.:
MM<1>%=9TF)K;5;#R[><2 $K"Z[7W 'G;R<>YH ZN3Q'I$5I%=/?1B*;<8S@D
MN%^\0,9P,')Z#O6A%+'/"DT,BR1R*&1T.0P/((/<5P/B;1+VR\8:/J%O87EY
MI$=@]A+'9G,D6<\XSR#P"?;Z5V6B6$.F:+:V5O;O;PPQA4ADDWL@[ GGG\3]
M30!G:5XSTG5]5U.R@F"KIIVO*_RJQ )<\] N.I]^U:.G:WIFK,R6-Y',RHLF
MT9!*'[K 'JI[$<&O/F\+ZY-;>.],2SEBDU6X,]I.2!'(N<[<YZGI[9YK1\/Z
M/J4WC73-6-I-9VEAH,=E,)E*%Y<DE #U X.>G'% '9:GJ^GZ- MQJ5W':Q.X
M022'"[CT&:CL?$&CZE'=26>HV\R69Q<,'XBXSDD]L \].*YSXIZ9?:OX7AM-
M/LY;N;[;$Y2-<X5<Y)K U#PSK.JZCX]CMK6: :K#;_8Y)%*+,8P-RY/3/3GU
MH [Z+Q-HL]K<7,=_&T=M$)I.#D1D9#@8R5/8C@]JP#X[74M"TW4M*GLK8W=\
ML3+J!91Y>YA@$?\ +0@ @?7KBLJU\/ZKJ7B 7\=I+:6\/AH:<PG7RR\YS\H!
MZ@9'S=..,UERZ'K3?#CPOI1T:\%WIVJ1RSIL!PBF0EN#T^9?KVH ],N?$&D6
M=\EC<W\,5P[K&$8]&;.U2>@)P< \G'%.;7-+74!I[7L0N2XCV9_C(W!,]-Q
MSMZXYQ7%Z9IE]8>+M<M-5T";4[+4KU+VSN0BM&C#H'+'Y=O'OP>#D9K:+X>O
M(?$&IZ?K.DW]RCZR=3L[N*7;!DD89CG@J!TYSTH ](GGBMH'GGE2**-2SN[
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M\T;4;^_U"2X:349@WF!1R-HSG'I@8Z#M7;7%O#=0/!/&)(G&&1NA'O0!F?\
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MI<5EIUS!]EN-1UE;.VO)1&S?9V(PY525WC..F.,XIW@-)8OB!XW2:;SI%EM
M9-H4M\C\D#C/T_3I0!VTNJ6$.H0Z=+>0)>3@M% T@#R 9)('4]#^56J\^\8Q
MS2_%+P?'!/Y$C1W8$FP-M_=]@>,_7]:SSXP\4S>"=7U&VFC>]T'49+>X<0KB
MYA4C+8_A8 YXXP.E 'J-5/[4L/[2_LS[9!]MV>9]G\P>9M]=O7'O5+0-1.LI
M+J<%T9M/G"?9054<;06.0,_>)&#T*FN7U)G3XX6S1[-Z^'V*[SA<^8^,GL*
M/0**\YT'Q?K%[XJTO3)[R.:'4;&5Y)(HU\N.5"W,+8&Y>,<[A[FLFY\>^)[+
M2[[SI0]]HNHE-1"0*%:VW*JLO'!)/'MDT >N5!>7UKIULUS>W$=O GWI)6"J
MOU)JKHMT]Y9?;'N?-BNI&>VRH7]T3\F, 9RHW<\\U0\>_P#(A:Y_UXR_^@F@
M"]:>(M$OYTM[/5[*>:1=R1QW"LSCU SDBM*O$"[0:=\/;[646WTNV*>3-:MO
ME,F5(#Y VK\O.W=W]JZ'4_'^KP6GB#6H2BVVBZFEDEF4&)E#;7+-]X$YR,$
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MS$B,N<M]<GUKI&8*I8YP!G@9/Y5PL7C]=.\+0ZEJ%U!J4UU?FU@:Q@D$>2W
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M"B1'6%HE"A7\PC*CDYP3TX)XJ(^%KT>+==@U/1+C4]-UB6*>&:*\,<<;+VD
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M2'//N<#V*FNTJ"U@M[.%+2W"HL:\)NR0">ISR<G/)ZG-3T 97A;_ )%+1_\
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MM",(@)..<GD\DDDG)H X;Q[XEUC2)M3^P:E&AM+*.>&&W17=#O 9IMRD!2"
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MQ(Y\OLIW,00.,9Z8'H*@E\ ^&Y=&ET?["Z6,LOFO D\@7=DGCYN!DDX&![4
M<Y/XRUK1=3\7VEU-'?\ ]DV<=S;'R0FUF4$@@=5!;N<X'6GZ5XFUE=;TC3;J
M^>Y75]#%ZTAC0-!-M+97"XV]L$'G'O750^%-(AU.]U'R'EN-0A$-T99&=94
M  *DXZ#%+8^%=&T]R]O;.'^S"U5WF=FCA'1%).5'/;'Z"@#B_#.I^*=<\ R>
M([W7EPEI=9MULXOWC+NVL3C'&,8Q@BLQ;[4M2_X5P#J,ML+WSFD6VCB1%9
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M$[SSEY&)7:H+NQP%STSVH YW3/%&O6NJ>$'O=1>_A\06;M/ 8(U\MU0,&3:
M>_.2>_3C%GPAXC\2^(H-.UI0&LKF2X6\20Q+'  2(MF#O)&!G/7=]*V/"/A"
MUTK3]+NKVS8:K9V@M]TD[2+%QAM@W%5S[ 5?L/!V@Z7>7%S9V/E-<,S/'YKF
M+<PP2(R=H)!QD#IQ0!QVA>+M:G\7>'[*?4$O+?4XKD3O%&OD,\>X@PG:&P-N
M"3P><9ZU=\&7WB;Q!>ZA)<:\%M=+U>6W,9M(RT\:C[I( QU!R!GD^U;UAX#\
M,:9/9SV6EB&6Q9FMW$TA*%NO);D=>#D<GU-7]'\/Z9H/VG^S+=H1=2F:8&9W
MWN>K?,3@GVH ;XG1G\+:J$F>%OLDIWIC(PI/<$<]/QKSCPUJ]]IOAGP1I5G.
MT9UF619;G8A>.-&SL7Y<<[NIR1S^'JMW:0WUG-:7"EH9D*2*&*DJ>",@@BLR
M/PEHD6F6FG16;);V4GFVV)GW0MZJV=PZGC.* //]1\=>(8_!U]<V]YLO=-UP
MZ>)_*0B>//&X%2 ?7 %>DZ19ZE:1W U/5!J#R3%XR+<1")"!\@ )R <\GGFJ
M4_@OP_<Z0FE36&ZT28S[!-(I:3GYV8-ECSU)-;:J$4*,X P,DD_F: .-\;ZW
MJ6F730V6HI"/[-N)TA@56N#(@R'.Y2HC !SR"3P,GBLA_%>OW=IX'DAU 6SZ
MT6CO-D*,&P!\PW X/7V]J[35/"FAZSJ,>H:CIZ7%S'"85=F8?(<Y4@'!')ZC
MO4*>"O#\:::B6+A=*8M9C[3+^Z).2?O<]!US0!PT?CS7;7P7=R/<K/?KK[:3
M#=21+\JX!WLH !(&1TQTK3\,Q30?&'Q)'/<M<NMC!^]=55FX7J% &?H!71'P
M+X<.DW>EBP86MY-]HE4SR,?-_O@EB0W Y%3Z9X3TK2M7FU:W6X:^N(Q'+-+<
MR.7  Z@G!Z#^E %+X@>(KCPSX9-[:E4EEGC@$K+D1!CR^#P< 'KWQ63XFU;Q
M'X7TU4.I)=?VEJL5M9W)B7?;Q.,G=@!2PP0.._X5V6IZ78ZSITNGZC;I<6LP
MP\;=#W[<@Y[BJ$?A#0XM'.D_8V>U)4XDF=W!7[I#D[ACM@\=J .*U?QCKEAI
MOC.UAO6,^A20-:W9B0L5D(RK#;M..><9K0\.:WK=UXUFT.\U62:&?1([U9!#
M&K0R$J#LPN,?,3AL]!72R^$-#GTV\T^:S:2"^D$MUNF??,P((+/G<>@XSBG6
MWA31K34O[1@MI$N_LPM?-%S+GR@  OWO8>^1GK0!Y=X2UNZT#X;Z$UM(_FZG
MJWV0R[8R8(RYW;"PQDX_B)'?M72ZWKGC'0])6YNK::2WM[^4SM 86N6L\?(Q
M !4$$_-QV'3)-=(/ WAL: =!_LT'3C)Y@A::1MC_ -Y26RI^A[FK(\+Z4MM%
M J7"B'=MD%U*)#N !W/NW-P .2>@]!0!P^M>--4L;;2=02_N7T.[L &U*WMT
M+1W!8@/*A4X7 Q@8YW8R0*]-5E= ZD%6&01W%8TO@_0I;9+4V;+;I EOY*3.
MJ-&A+*K*#AN23SSR:UIO-2VD^S*AE"'RU<X4MC@''09H \W7Q!JT$?Q!DANE
M272W5K:5;>(,,*Q^;Y?FZ ?-DXJ;2O%VLOXDT&&ZO&FM;OPZM_<1")!NEVDD
M@@9&<=,XK6\,>%KJ.X\1W6N6T(379%WVH;< H0A@2/4L?PK2T[P3X?TJ]MKV
MTLI%N;6+R8I'N97*Q\_+RQ!'/0]* /-[_5M3\1:)X.U[4+L-]M\0(5MEC4)
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M .O"#_T6M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%M(.IZ;J=A';W-O]L$)A=0!AANPR\=L]3^(!Z%D2Q9CDP'7Y77!Z]QVK@O
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M#+ DC ./6NAKD?AIH>H>'?"O]GZG:BWN!<22$!U<,&/!R"?I^%==0!E>%O\
MD4M'_P"O"#_T6M:M97A;_D4M'_Z\(/\ T6M:M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5D>%_P#D7[?_ 'I/_1C5KUD>%_\
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MPI]HM[C#(YR?WJ$#HV1QTZ8JQXQ\(VWC"XN[1V\F[AM(9+2X'6)]\OZ''/\
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M[NKE5=LY5MRX;.1@\C!XI9?">A3VT=O-8+)''.;D;I'),IZR$YR6]R<UL44
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MELFM[26T26\:\MOM,,<116,>!ACO90.H&,Y_(XI1>.M+N4TMK6WO;C^U1)Y
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M>VDCW 9R<%2&.<$G/8UA67AKQ%INDZ#=KI5K=W>FBXAGL))UQ+%*X;*L1M#
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M^\,9(QT(JU52.XO7U%H7L?+M!"KK<&4%BY)RA0=,#!SG'-6Z "BBB@ HHHH
M**** "BBB@ HHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'_HM:U: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\+_\
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M$\QI6.%"^M<!X;4-\;/%JL 0;6$$'O\ +'6OXZLEUG2)?#<!GC5K8R'R(7<
MCB)&V@X!8$_\ ]Z .IO;VWT^SDN[I_+@B7<[[2=H[DX[54M_$.D76C-K%M?1
MS6"!BT\8+!0.N<#(QWKDO"7B!]?^%EXMR3]ML+6:TN5;[VY4(!/U&/QS7/\
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MLG)Y/W<]_>MRPNH[W3[:[A#+'/$LB!NH# $9]^:X#XI?\C'X)_["Z?\ H<=
M'6VFL>'[#48_#]O<0VUVPW):E2C-WR,CG.#SWYJZ=7L4GN87G\MK2/S)S(I5
M8TY^8L1C'![]CZ5R?C?P</%-[/-9R?9M8L+:"6RN%."&#RG:3Z' Y['!]<YN
MC:D?''AK6[370^FW8AATZ[8KC;-O<!L>A++D?4=.: .XA\1:5-)'&MR4>5#)
M&LL3QF1 ,EEW 97'<<=/6JP\9^'VG@@6_)EN4\R",02;I5P3N4;?F& >1Z5R
M.B7_ (DT;Q'IOA?QA:PZA#<"1+#4HNIPA!#>ORG'(!YSSUI_B%0OQQ\**H
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MB,-[;=V/:@#V0>)](S )+EX?M+K' 9X)(A,S$!0A91N)R.GUZ4]?$>COK?\
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M=S*B+)!)E0&!0 %3NY!';KVH Z6ZT/3;RTO+6:U'DWS;[E49D\TE0IR5(/0
M?A5&?P5X>N=%AT::P9]/@;=';FXDVJ>?]KW-<K_PE=[%X_\ $&DZCK[V>FZ;
M;I-$RQPAR2J';ED.?O' Z]*[O2H;Z"P6+4KH75PKOF8($W+O.S(' .W;GWH
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MXRR#:",%E.#SSG-6/#_B#7-8U;Q+HD-W%<+882SU,1+@,P^ZP'RL1[ =#ZT
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M=S+(^)M@3<FX[<@<9Q@'Z5=H QCX3T9[FTN9X)KJ6Q;?;&YN99O*;CD!F//
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M%9?L\JRQ%NJ.O0@^O^)KGO 'BJ;Q3HT[WL8AU"SN9(+F$<;#DE?TX^JFNIH
MR]:\.:3XA2%-5M3<+ ^^-?-=0K>N%(Y]ZTD4(@49( P,DD_F:X'2M7\0:MXY
M\1Z&FLO#%IRH;4_9XFY8?Q_+DCGL0?>J0^(.J:C\-M7U6,I8ZQH\HBF$:!HV
M;<!G# \$$_B* /1-0T^UU2QEL;R,R6\RE9$#LNX'J"00<4S3-*LM&T^.PL(C
M#;1C"1^8S;1Z DDBN:\,ZCJ&M6VE74.O-=2"W@GU*W,<)0>9&3M!505(8 X)
M/%<[=^,=5MM<\66=QXC6T728U>Q$D4.97*YV$%<MDX'&#S0!WMAX7T;3;J]N
M;2SV2Z@2;HM*[B;.?O!B0?O'\S3;+PGH6GZ3/I-OIR"PN"3);.[2(3[!B<?A
M61IUYXEU;PM9ZO>S/I,RV4LD]O'"NYY ?D/S@[1M&<=?F]JH^"-:UO6?"MCX
MDU'5RT:O,U["8(PC1J' *X4$$$*>OK0!TT/A;1X9[68V\DS6?_'L+BXDF6'W
M4.Q /OU%7[^PM=3LI;*]@6>WF&UXVZ,*Y+PCK&L^-=%NM:%^=-CEF>.R@BB1
MPBKP&<L"6)/7!'2L*X^(NJWWPOOM=MG6RU;3;E;>=416C9BZC(# \$-^8H ]
M,NK6&]M)+6=2895*.JL5R#U&00:R8/!V@VVG0:?!9-':VT_VB&-9Y/W<F"-R
MG=D'YCT[G/6N;;Q3J]CXF\,V$5Z-4CUB'==P-&F^WX4[P4 PO)Z@_=/X>@4
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M1-AE0@':P'&X9ZC X/%=E0!E>%O^12T?_KP@_P#1:UJUE>%O^12T?_KP@_\
M1:UJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M61X7_P"1?M_]Z3_T8U:]9'A?_D7[?_>D_P#1C4 +XHT./Q'X:O\ 29,?Z3$0
MC'^%QRI_!@#7):A\.[N]\%:%8_:675M/G@FDNM_SK]U7PW^RH&/^N:UZ$2 "
M2< =2:@L[^UU"PBO[2836TR"2-T!.X4 <I\2/#E_KO@U-$T6S#N)(]H,BHJ(
MOU-4O%?AO5M5U'PG=6&E872KI+BZ!DC4X#(<#YN3\I]NE=5H_B?2->GN8-,N
M7GDM'V3@P2)Y;<\$LH&>#Q1J?B?2-'U&UTZ^N7BNKUMMO&+>1_,/ P"JD=Q^
M= '.SZ%J\GQ:MO$:V#?V?'9?9F<RINW'=SMW=.1[TWPSX>U7P/JVJ0VMBVI:
M1?S_ &B$P2(LL#'JK*[*",8Y![=.:[G(V[CP,9YXK%_X3#0OLLEX+UFM(WV/
M=+!(T(.<?ZP+MQGC.<>] &3X\TK6O$O@>[TVVL4%W<R(8XQ,N(U5U;YF) SP
M>F>N.>M9/BKPMK&JZ'X:MK'2@)].FAEN<R1KC8N" =W)KK[[Q7HFFW]E8W5X
M4GU#'V4+"[K-D@#:R@@]1W[BEA\4:/<:_)H,=RYU*)=[P&"1<+QSDKC'(YSW
MH U5)9 Q4J2,E3C(]N*XWQ#X7U!?&^G>,-&C2XFMXS!=6CN$,L9!&58\;ANZ
M' X%=!+XBTN!7,DTBE+@6NTP2;GE(SM48RQQSQD5/8ZM9ZC//!;M)YUN%\V.
M2)HV3=G&0P'7!H K2)<ZW:7%E>Z<]G97%N\4HFD0RMN&, (6 &"><_A7/>&-
M-\0>$/"\N@1Z?]O>V:3[%=1RHL;!B6&\,P92"3G /MFMK4_&>@Z/]H-_=RPI
M:R"*:3[),R*Y (7<%(S@COWI9?&&B06]U<3W%Q%'9HDDYDLYE*(^0K8*9(.T
M\CTH Q/#'A&Y\'>'=-TZ&!KZ<7GVF\DB=54$J5.-Q&0!M'O@GCI4VH>!U'C_
M $[Q3IA$+;V74(@<"4;"%?ZYQGUX/4<Z=WXV\/V.C6^LW5[)%87) BG:VEPV
M1D?PY&0.,U)>^+=%TZ_M;"[GGCNKP9@B^R3%I/H O7VH YWQ/X8N/%6DWMIJ
M?A])-0$LRV%^DL8"(7;RBQSN  QE0&_/I;\:>'M4U/X<'P]8J;V]:*",RNZJ
M&*,I+$D]]I]>M='I^L66J2W$-JTOFVQ42I+;R1,N1D<.H)S[4S5->TW1G@CO
M;C;-<MM@@C1I)93_ +**"3^7% &7>Z=?S_#B72$LV^VR:8;01%TX<Q[,YSC&
M?>E\#Z??Z%X)LM.OK-ENK1&5HT=&W_,2,'.._?%73XGTI6F222>.2W@-Q+&]
MK*'6,$ MMVY(Y[>A]*JP^._#<]K;7:ZBRVMV_EPW$MO+'$[9(QO90N<@]^U
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MV:0VDQ3S1G*A@F">#T/:GW7C+0K&TNKJ[N9[>*T95G,MG,IC+?=R"F<'UZ4
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M0TT9]&&FQ'3W.3;-DH#G/ )XYYXH XGQVLO_  LGP8EE)&LF)1$TBEU' QD
M@D?C6UK9DB^'&J6^H.C:M_8KFZ*]3A6&?IN+8_&MF3PAH,KVKR:>&>S4+;,9
M'S"!T"G/R_A4@\+Z,([N/[$"+Y56Y+2,3,!G 8DY(Y/'O0!Y9K8B;]GS1T8;
MIVDC%N!]XOO;I[[=U;%\+E?B[X)6])-T-,839_O^7)N_7-=W9>%]#T]H&MM-
M@0VV?(R-WDYZ[,YV_ABGW'AW2;O5HM6GM ]]",13EVW(.> <\#D\#U- '%?$
MM$B\3>!(XU"(NK(%4#  WQ4WXIQ/'K_A"=U"Z;_:JM=G'RE]T84M_P !##Z
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MKN#:P/:FUDC$L++L9)?G#+Z'.<_C6?!X8T6WDMW2R!%J<VZ2.SI ?5%8D+^
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M*E70=+CAM((;-(8K)MUO'"3&L9YR0%(&>3S[GU- 'EVC/J,WPZU_0=3B8?\
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M)*RYZ[@3@D^M #?"MM86GA;38-+N#<V26ZB&8GEQCJ?3Z=NE</XE\-7UD_\
MPF_AA<:K97-Q]J@4<740F?(([D#\Q[@5Z%IFCZ?HUE]BTZW%M;Y)$:,<*3UQ
MSQ^%26.GVNFPM#:1F.-G9RI=F^8G)/)/4DD^YH \D\6:@^K>&_"&KF-H]*N-
M7>>Y1CD)NF)7=] 7%;WQJ$DGAO2X;3<;]]4B^RA/O[MK]/Q(_2NZ;2=.;3GT
MUK*!K-\[K=D!0Y.3QTZG-06WAW2K6YAN8[7?-;J5A>:1I3"#U";B=H^F* .(
M^-$8B\%Z<NU5)U6(MM& 6*R$G\22:T_B]&@^&VK2!0';R 6QR0)EP/U/YUTV
MKZ#I>O11Q:K9K=QQMN1)"=H;UQG&>3S[T[4-%T_5K 6&H6_VFVXS'([$-CIG
MGG\: /,]8:1/%7PZ:]_Y!@MXPA;[HGVC&??.S%>JSI;/+;F<(9%D+0[CSOVL
M./?:6_#-59M!TJYTI=*N+&*>R0 )#*-X4#IC/3';TI;31=/L6W00OOVE \DK
MR.JGLK,25'L,4 >:_#J/5'UO7&LY8A:+KSFZ0H=[+\^,'.,9VY&/QKTNTU+2
MW,%G:W=ON:(M#"K@,T:G;N5>I7C&>E4HO!WA^W$XAT\1"Y.9@DKCS3ZM@\]3
MUJS;^'](M;NVNX-/ACGM+<6T$@7F.(?PCV_Q- &E1110!E>%O^12T?\ Z\(/
M_1:UJUE>%O\ D4M'_P"O"#_T6M:M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5D>%_^1?M_P#>D_\ 1C5KUD>%_P#D7[?_ 'I/
M_1C4 97C'Q;>>%=1TD-:POI^H7 MY;EV(-NQ(Y([C&3_ ,!--/B^[M_B/'X4
MO+>WCBN(#/;W"L=T@P?EQV/RMW[>]7?'?AX>)O!]_IJKNG*>9;_]=%Y7\^GX
MUQFK>%->O/#/AO6X\_\ "26US!)*Y7D*P1,,/]G:A;M]\]Z /1M-N[BZ6YEG
M$2Q).\<+)D;E4X).>GS C\,]ZS?"7BZS\6P7TEJ-IL[MX"I/)4'Y7]LC^1IV
MKQFUTFTT.T2<_:<6YF%N\JQQ@?,SE>F0-N<CEL]C7)6]CJGA7XKO=QVD]UIV
MM0@7CV=C)Y4,H^ZQQN[CKG^-J -BU\6ZQ?>*];T&VL[(R:5&KK)([*)MP! [
M[>OO4"_$9KOX;3>+[.P57MFVRVLK$@G<%.&'^\#G'M7.W'AK4]<\;^,!!_:>
MF_;8$%G=B.6*.5E505+8 *G!'/X5+.VH7OP7O=$/AN]LM2MU2 VL5C(%E(D4
M[TPN#G!)([Y]J .B?QU=V$WALZC80-;>(0@C>"0[H7<*0"I'(^<<@^O%;/B_
MQ/;^$?#\NJSQF7:ZHD8."Y)_PR?PKS^#2=4T#5?"_B'^SM0U6Q%G%;7%I+!)
M++I\FQ0SHA&5&1V'8CN*['5;)_%EQ?V9#V]I';-;?Z582_.7 +.A)7D84 \G
M(/X@&OJFIRQ>&Y]7TL17.RV-S$KDA95"[@ >V1T-<]H7CY]>\.ZE.EI'::QI
M2N;FPG)XVYZ'K@XQTX/X5D^#KK5K3X>:IH6K:9J*W%A'-!;M]BE/VB,@A=OR
M\\DCZ8J?QUX0N;B\C\5>' \5ZR>3>PJA4W,##:V5/\0'8\\#N!0!K>+/$^M>
M&-'U'5FL;26VLVB2,%V5IMVP%O\ 9 9B._2M?1K[5;QHY+RVMUMI[9)HI(68
MD,>JL#[$<]^:Q/BO;75]X O;*RM+F[N)GBV16\+2,<2*3PH.. :Z+0B?[ T\
M-')&RVT:LDB%&4A0""" 10!#XF\167A70I]6OMS1Q8"HGWI&/ 4?Y]:R-4\5
M:KH/AN#Q%J6GP-:MY;7-O"Y\VW5R "&/#D$@$87ZTWXG>&;OQ5X.ELK !KJ&
M59XHR<>85!!7/T8X]\5G>+KRZ\3> 1HVG:;>'4[\11O!);O&+<AE+EV(  &T
MC.><C&: -#6O&EQ9:_H%AI\5M<VVNJ6AG8L-@P"#@=00P]*W=+NM2GNKJ.]A
MMO)CV^3-;LQ#G+!U((X*E??K7GWB#P]<6OB#P-IZ6E_=6NE1>3=7-O!+M480
M9WJ.,X/0\5Z-HVEPZ+I<6GV[,T4);9O)) +$@$GDXSC- %ZN?\+>+[+Q5)J:
M6HVG3[HPD$_?3^%_H<''TJSXCGE6P6RMTG\V^?R/-BMWE$*G[S-MZ<9P<CDB
MN*;3]3\*?%2#4H+.:[L-6@\J]-C8R>7"PP%8@;@.B]^[4 :WB'QAK?A]M-\_
M3K,_VE?FUC7S&RBEL*[<=Q@X_6MJ.Z\2O=_9VL;)%$CYN-[E"@5"I QG)+,,
M?[)YKFOBC:WEY=^&OLEA>77V;4DGF-O;/((T!&22H-=Z\RQP&8ARH7=A4);_
M +Y SGVH X[P=XQUGQ9H\&K1Z=:QV[7?D31B1BZ+QEQQ@]1QZ9JWH?BJ[\6-
MJ$^APVZV-G,8(Y[@L?M,@ )P!]U>1SR>>E9'P>T^[L?!$MAJ-C=V<WVF0E+B
M!XB5(7D;@,]Z;\/;>?P-INHZ%K%O<@PW;S6\\5N\B7$94 ;2H/S?+]WKR* +
M;?$43^"=2UVTLU2\TJ3RKNRF;.UPP! 8=N<@X[$4K>/+RQ7PU/J-A UKXA$8
M1H)#O@=PI *D?,/F'((^E<LGA?5[3X=^*[NXL+G[?K]QYL5E'$TDB+YF1D*#
M@_,<^@ IUOH^JZ#>>$_$/]G:CJMG'916US8RPR2RV$FQ0SQH1E>1V';'<8 .
MHUWQ]-X9\6P:=JMBBZ3<$*-01C^Z9AP''X>O3GL16Q?ZQ?VD&LW"+:O'I]MY
M\/WLRC:6P3GC[N,C/7/M5>\TVP\42:OI=_:7)MKB*+#R6[Q@$ _,K,H&X$BN
M=T+1];T3P=XFTC5//O)(8'M[%XXF<S1>4=FT $GDXQVZ=J -?0?%6M:[H&FZ
MO!967^FMEK8.^]8Q+Y;L#C!QG..*?<>,+S3OB!;>&]1M8(;6^0O:78)_>G^X
M1T!SQU/;UKG? L/_  CGA:QO)-*U?^UUMI+9[5K*X(),Q9.J[4'<D8X/K6C\
M7]-N+_PS;2:=8W5SJ=K=));-:PN[Q^IRH..WX@4 =;::A/-=7\DODK86S%$E
M&<L0/GSVPIR,^H/3'.!<>.)T&BZ?;6"3:UK2>=%;LY1((CDAY#R>%'0#D@]*
MO:G$TOA&VTRTAF3[=Y5HP*,K(C<2$YY!V!SD]\>M8/B;1[W2_B/H_BZVLYKN
MPA@-K=1V\9=X1A@'"CDCY^P/W3ZT =-+J.K:;<0_VE#:-9%)'GO(2RB':A;!
M0YXX/S9[=.16;I'BG5?$6@7&O:780+:*7^RP3L?,N50D$Y'"9(( PW2M'4)8
M?$VDWVE6R7 CO+62)KAX&C2/<I ^\ 2>>@STYQQGF_!MW=>%O IT74M.O%U+
M3O-1(8[=Y!<99F4HR@@@[L=>,<XH LW7Q GN_!5OXE\/:>M[O<I+:2$AT*@E
ML$=<!2?<?E6EI7BU/$6E:7J.CF$QWD_DSQRY+0,$9F''<;?QR#6#X&\/W?@[
MPOI-IJ$,[7-QJ#7$R0PM*(=T3* Q4$#HN3TR:6/P9=>'?B19:CHVY=%U"5VO
M+91\L,HB?:P'8$D_0G'<4 7X/&&I7'C+6?#PALHETJ%9FN9"V&4A3R.V WJ>
ME,UWQCK6@G0X;G3K3[1JEZUHZAVVQD2;5<'^($$'&!6"OAM]<^)_BC[;9ZC!
M8WMJB07/DS1QLZK&.N & (/!X.*T/BE975]JGAC[/87MS';:@);AK:WD?RX\
MKDY0<< ].: .DEUV_P!.MM2OM0MH);*RMGF66U9B79"P="".""OK_*HM#\07
M^L6^EWT"V-U97Q_?-;.VZT/ELVTYSN^8!2?EP3T]*D%['HVDW.E:9I-_>6]M
M;SW!\^TE42%I-PA!<#>Q#MZ].>M8-GX3ATGQII>H^#OMUI#<2G^TK.6-UB2+
M!)SN P<\!3GD@C % &]I?C&[UZRO;[28K.?[).\1L6<B<*K8WGW/4+CGINS4
MESXKO8?B-;>%%MX#%/;&Y^T$G<J_-\NWN?EZY[]*Y'7?#<.IP1>(_#]IJ&C^
M*F=6,$<#HLKE@&)R,!2,G=G&.O)K6NK6^;XVZ?J#6-VUK'II@DN5M9#$)/GX
MW8QW'YT ;FE^*I_$FKZG::+%"MKIC^3)=SY82R\Y55&.!C[Q/I@57M/&\^I:
M-K3VMC''J^B.R7-E)(2K%<_=?CAMIP2.WXUF>"+"?P/J.N:9J4$XMI[G[3:7
M20O(DJ'C!*@X88'!Z\XS570=%O[2/Q;XDO;*ZB.LR,+6T$+--Y>6P6102"<C
MCM@T ;.@^/F\0>'+ZZAMH[75M-)%U8SD_*03WZX./3@@CWKLDW!%WD%L<D#
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MO)+2UMI$FN$M9&C0LL@ + 8[C\Z .XTR6]FL4?4((X+G<ZND;%EX8@$$\X(
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M@]<C(J#6=+U1/"WB[1I])OKG4[K6!<PO':O()8BRX96 QT!XSD9Z=: /3O\
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MOQ@ 8/?CI7L= %-]7TV.]6Q?4+5;ISM6 S*')QG 7.<XJ*X\0:+:/(ESK%C
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M;@-QV!\@>H%8>J6 U/P+K>H6%EK<E_?V=O#+;SVA4[T88545 3M&?F (QW]
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M **** "BBB@ HHHH **** "BBB@ HHHH *R/"_\ R+]O_O2?^C&K7K(\+_\
M(OV_^])_Z,:@#7HKD=?\1:S:>.-(\/:>;)(M2@E<RSPN[1E%)R,. >G3]:Q+
M3XE:A<:19PM;6ZZK<:U_9+N%;RE((S(%SGHPXSU_*@#TFBO.KSXAZG::=K/^
MA+//HVI);W,T,18"W)/[W9N^\ ,8SC)!Z<4[4OB'<6&E:-J/GVTNG7\DRS:E
M#:N\<6&Q$&3<"I(^\,D\'% 'H=%<'>^-M4?47TS2HH+FZMM*2])BA>9;F5L$
M(NT_*A!^\?4?B3>.[Z'QA;Z->0II272VSVWVJ%B)]V#*F\$!7&2HX(R.>HH
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M;WXB>(K2WU:\,>FM!I6L_8&00N&F3<1G._"GCT/7MCD ]1J$7=L;HVHN(C<
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MDVTCBWC5=P79N+,YXSSQSQQ574OB!K6EVVD/JU@NCB]AD6:XGMWDCCG#852
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M<F]PJ_*57<1U(SD\\],<U/#?C?Q'JGA4^*KZWTU-.M8KAKB*$2"60H"5V9)
MYX.?<T >B45P6D^-=6N-0T&SNUM WB"QDN(&2)L6\@!8 C=\R[<>AS^F/_PM
M#6X=,@N;JVL5EM-2:TUB-87Q;IN #K\_&<D#.<D'TH ]5HKC-0\7WMK?:+IX
M,/F:S-.\<\=L[B.W0$H=@8EF8;>>@R>*HWGC3Q-;'PQ"^F6MO=ZO-)!<07,;
MKL92 '4[N%(.<$$T >@U%/<06L)FN)HX8UZO(P51^)J#21J:Z;$-8:U:^Y\T
MVH81GDXQNYZ8S[YKB_B:+MM7\)10SQ)&^KQ@(\18;\\$_,,CGIQ]: .\AFBN
M(4F@E26)QE71@RL/4$=:DK@+35O$">*=6\)>'[31K6VTI(7@:2)T55<!BI"D
MY/S'D8Z>]5[[XD7UO:ZOK$4$!T[2=46Q:!D/F2KG#ONS@')&!CIUH ]'HKSS
M6_&GB"VUOQ+8V/\ 9RPZ-8K>1O) [.X*ABI^<#N>?TJ?1?&FKWGB?0[*[BM!
M:ZUIGVM$B1@\#8S@L3\W ]!U]LD [RHEN8&N'MUFC,R*&:,,-R@]"1U KC?B
M-J.IV=UX:MK"[2W2]U>"*7,9;=AP1G!'RY'(&,^HJFVL75AXT\4XM-.-Y8Z.
MMP+M8'5I2J@[6&\_+GTP>G)Q0!Z'17FNF^.?$M[=^&8Y%TQ1XA@E("PR?N&3
MG=]_YO\ =X],]Z=9?$B_?PO:W%S!!_:%QK/]E[XXV,8Y&9-@.3P?N@\F@#TB
MJ6K:9!K.ES:?<231Q3  M#(4<8((((Z<BJGAS4=2U"VNO[3LWMY(+IXHI#$T
M8N(A]V0*W(R#R/45Q.G^*]5TZZ\;ZQ?W$=U#I4XB2 1%<XR$"G=\HR>>">2<
MT >D6MLEI;K#&6(7))8Y+$G))/J22?QJ:N,T/Q=J$OB33M&U-;=VU+2DOXY(
M$*>6QSN0@DY&!P>M=G0!E>%O^12T?_KP@_\ 1:UJUE>%O^12T?\ Z\(/_1:U
MJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61X
M7_Y%^W_WI/\ T8U:]9'A?_D7[?\ WI/_ $8U '-^)]*O[[XF>'KRWCO(K:V@
MF66\MX\^4S*P7J"#SCJ".>:U8? &BP:-!IT?V@-;W@OH[HN#-]H!SYA.,$]L
M8QCM5G6?%VE:'K&GZ7=SJMQ?,V,G C0*3N8_4 #Z^U1Z?XE#7.M/J-[ID=EI
M\ZHDD,^6C4CGS<_=.?IW^I '6WA"SLHYOLUW=QW%Q=F[GN0R%Y7(((8%=NW#
M'Y<8JNO@/38M&&DV]U=P6ICFCE5/+(F$A!8L"A&01Q@#':KP\7^'&,@76[$^
M5$)7Q.O"'H??J/SJU_;FE?V?#J OX&M;@@0RJ^1(3V7'4\'@<\&@#(D\!:6-
M1L;^QN;W39[*V6T5K24+YD*]%?<#GZ]?R&)[[P?8:C<Q275Q=20Q7$=RELS*
M45T4*N"5W ?*,C=S^)K:MKF"]MH[FUF2:"50R21L&5AZ@BBYF%O;2S%D41H6
MW.<*,#O[4 84G@VQEU"._N+F\N)K=)TM]SH#")<[@K!0W )"Y)QFK/A?1I=!
M\/Q:;)<S2^6SE&EDWNBEB54MCD@$>V?:JNC>*K9M T^\US4M*@N+PN%:WN 8
M7(8C",3SVSSUS6QINJZ?K%L;G3;R&ZA5RA>)MP##J#[T <['\.]/B_M94U74
MPFLN7OD$D8$N221G9E0=Q'!'!JY_PA6D0C3#IXET^72D>.UEMR"RJX(8'<&#
M9R3R,YYJSXG\36'A72C?7S_>8)%&.LCGH/8>I[5C7WCN*P\:6NF37%DNDW&G
MF[^UL2"I#,N,YP1\OI0!8?X>Z-_9VD6%O+=VT.D7 N8/*=<M*#G<Q93DY_#F
MK^M>&+37-2TR_N+FYBETR4RP"%E"ECCE@5.>E7&UG3%L(;_[=";:XP(9%?(E
M)Z!<=2?059M;JWO;:.YM9DG@E7<DD;!E8>H(H S-5\-VFJ:E;ZGYT]K?6\;Q
M)<0%=Q1A@J0P(([CC@U"?!FB?\(K'X:^S'^SHRI"9RQ(</DGU)Z_4UG>+O%.
MIZ%XC\/Z79I:M'K,S0EYHV8Q$%!GAAG[_3CI3['QC+%XLNO#&M0PP7<4'VBW
MN(B?*GCQD\'E2,'C)Z'GU -R'1+&#7KC6XX\7ES D#MVVJ21^)R,_P"Z*S=&
M\%V&@WEQ+I]Y?1VT\IF^Q&4&!'/=1C/X$D=..!1H7B9)_#]K?:S>Z8D]P[J#
M93;XGVD_=/).%&3Z8/2G77C71;;6M-TL7<<DFH1F97#?(L>W*MGONXP/Q^H!
M/X:\,6GA:SGM;*XN98YYVG;SV4D.V,XPHZX%&M>&+/7-3TR_N;BYCETR4RP+
M$5"ECC.X%3GI4@\4:"9EA&L69E:?[.$$PW&7^YCU]JJ:%XC^UZ5>7^J7FF+%
M!=O$DMI/N0("-H8GHYST]QZXH SV^&>D-HE]HJWNH)I][<?:'@62,+&V<X3Y
M/E&<<>PJ]'X(TP:K?ZC/-<W+ZC:"TN8Y638\84+T"@@X'8T:OXYT+2M,@O\
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MKH=C+:7>GW-D;D3QYWJ02,9S@YQGH."/J>KNKF"RM9;JYD6*&%2[NW10.IH
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M2\4GF AU R6&.H Y)Z 4 8;_  XT-_#T&CJUW'Y%S]KCNTE G$W=]V,9_#'
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MO"W_ "*6C_\ 7A!_Z+6M6LKPM_R*6C_]>$'_ *+6M6@ HHHH **** "BBB@
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M#C=@ <\\FMZQ\):AK.D?8O%E_<W:VU\+BS?Y(Y<!0%+[<C@EL#)X(SZ"]<^
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M[2SE@J'(*X/&,$T 8WA[QIKFLVUIKBV+2Z9.US]IC5% MD3/ED-G+$[?F^O
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MR3.0><]/3IR<YJ'QIHFKZMJNE2Z?=7MI':K*7GM"C$,P4 &-B >,\C./3G(
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M:\X0G5X1)]H^S%6# K+_ '6X^4_7'0U#XL\5VVB:=?I;WD U.VM&N4A>-G&
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M10>?(8;9Y%1,L,DJ"!]UORJK%XRTF:U2Y1;WR98#/$YLI0LB ;OE)7!..<4
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MD@ANI%CCE\IB@8] Q ^7\: -6BF331V\$D\SA(XU+NS=% &2:PAXVT0^&_\
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MBEH__7A!_P"BUK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYA[QBM?1M&M="L39V;2F'S&D D?<06)9N?<DFG66EI97MY=BYGE>\<,XE*D
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MLH9+N42?V?J=M_JYR%)967^%L?@?2I/A26?P+!-.2;R6YN'NRWWC+YK9W>^
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M( QDD\D^] $M%%% !1110!E>%O\ D4M'_P"O"#_T6M:M97A;_D4M'_Z\(/\
MT6M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF94CB>4!F8] ![X./6O-/#7@O4=-UCPE'/ITKQ65M+=W,S8PL\A.$8]?DSD
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M?1/$5E8?V0QDUZ26XN+F(C;"ZH, @#GY549XR>>^* .DDD2&-I)75$099F.
M!ZDUGCQ)H9C$G]L6.PS>0#]H7F3CY.O7D<>]<_\ $*WU2Z?1([:UN+C3EO1)
M?K;Q^8V%P4RG\2YR2.G K.UCP\U_X8U7P]I^C:A]JO ;YKZ[* 239W#+ \.=
MH&T   CIS0!U>J^+M T6WNIKW5;93:$"6)9 T@8@D+M'.3@X%6)-?TJWLK>[
MN]0M;:.YC62,R3* 0V,$'.".1R..:X2_LM1UC2_"UM_PCES;(]Y'-J8\L!F:
M)<_/SG#,3RW/?ZOT[0KS5_$6MQ^(]/OY!/J*L@"@6\MM&<Q N>JCKL&"3C.>
M< '<3^(=%MGN4GU:RC:TQ]H#3J/)SP-W/&?>I+[5M/T^!9;J^MX%D4M&TCC#
M #)(YY '/%>6ZIX5UG5=,UB]FTJX>[US68XVCVC?!:(>'Y/7 QGT/;)JQXGL
M/$LNH^*3;:+<R^98P6.GN@#1I V/."]R23V'0'/09 .X\$ZSJ'B'PO;:MJ44
M,4MT69$A4J FXA<Y)Y(&>O>M,ZOIJS/";^V$D88NIE'R[?O9^F1GTS6==6=[
M8^!9+'18FCO(-/,5JA(#*P3"\]-WXXS7,06<P^'"BT\.7D>KV6F/;1&:(+()
M9 %D*\Y.3EB?_KT =O::UI=^<6FHVLY\OS<1S*WR9(W<'ID'GI38=<TFXBN)
MH=3M)([4 SNLRE8@1D%CG@8YS7!:_P"$;C2O!^CVFG::T\C26T6KO;1;II8%
MY9<=67.!C/0 =*=K.@W8GTI[+2K^Z@OM4%SJ?F;1)-L \H.. L8/\/8 9YH
MUF\:RR^(-;MX+S2X]-TVS0I<W#%%^TN,HC/NQC@YP,]NU:=CXLLC>Z;HM[>6
MDFLW4 DFBM7RB'9N.,\\]AUQSTYK@9-#U^^\+W,-UHUW]HUS7UDU *HRMN&S
M@#/W1M&"<=:ZWPW87S>/O$.JW]A+ K+%;6CL/D\I1SM/<$\\=,4 =7=7EK91
MB2ZN(X58[5,C 9/H/4^U5VUW2$2V=M4M MVI: ^>N)0!DE>>0!W%<GK=KK8\
M=W.I)8SW26^E&/250907#G#$GHI]2<?+ZUGZ5X'NK;5O#6C7D!GTW1]/FEGE
M*YCEGE;YHQGJ.?Q&1WH ] ;5-/33/[3:]@%CL\S[3Y@\O;Z[NF*IZ9XHTC5=
M(358+R-;225HHWD<*6()'3U.,@=<$<5G>-[2ZMOA[?:=H%@SR- MM#!;K]U&
M(5L >BDU@-I6KZ;XB@FM]-N9K?3=#%OI$07*BX.%)8]%;'4D]/6@#T*VNK>]
MMH[FUGCG@E&Y)(V#*P]01UKE;?QD^O:]?Z=X=NM-:+34C:6:=RPF)8;MFT_=
M5<Y;D;B!TYJ_X5TA?!W@JUL+J8/]BA>2>0=,DEVQ[ D_E7!66CZOJ7PUAGBA
MF+:_K(O-26($O]F=SNP!R1@*<#L30!Z<FNZ1)#/.NJ6ABMU#3/YR[8U/().>
M >Q[UC>*O&5MI/A:]U32KNSN[FW6(I%N\P$R$;,A2",@Y'MS7+Z[X>UR\M?$
MFI6UC(DVK^1I]E;*,&.W4@,[CL" 3CJ >?2M#Q'X6A@N_#]G::4SZ>MT+G4I
MX(-[2F)#Y8<+DMN)/;% '7Z1J]KJ.EK<I?V=R8E"W,MM*&C20 ;AG)P/J>E.
MAUS29[>>YAU*U>&V.)I%F4K'QGYCGC@UYIJ'AS7X;(WLEA.8=8UL7>H6=N@D
M>.W'W$90?F]6 ]JTM4T*]AU/0FL])OKNTN=1DO=1,I7S)954>49,855!_AZ
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M4KQ2:K9J\</GNIG7*1\?.>>%Y'/N*X>?1K_5?&NN0ZQ8Z@UG<10P6AMU B:
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MR/.L!+JEX(6)0!6*PG) YSUX').* /0ZBN+B"TMWN+F:."&,;GDD8*JCU)/
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M9;8)'J*:59+*A8W,Y/SMP1A5SQCKZ]JO-X@\1WWBS5])TI]/\C3!;^9-<(P
MW -)D@G)QT' Z^E ';45P^D^+=;\37MC=:/9JFES73AVEA;'V=,@N7) WLPX
M49P!SUK0\?>(;[P[H<$FEB)KZ[NX[:!)(R^XMGH 1S@4 =117GZ^/[W3_P#A
M*;W5(H)++1GBAMU@!#23,.4+=\,0"<>^*2]\9ZUIE_>VEV;7?;:$=0F*Q$K;
M3[L"/[WS C Y.<\].* .P30M.36I=8$+&\E559FD8K\HP"%)V@X)&0,\GU-7
M?)B$YG\M?-*[=^.<=<9]*P? Z:DGA.UNM9N_M%W>+]JD=EVE X#!3SC@<<8
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M59@P\Q5 /)+9/7@#W% 'L%%<3K/B_5)-3O\ 1=!M?/OK"W0RNL1D#3N/D0=
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M ..<]>:VK&^M=2LHKVRG2>WF7='(AR&%1W^K:?ICP)?7<=NUR_EQ!SC>WH*
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M@6X989648!91_P#J]JY>T\+^)8M3MM6M+J_L+ZYO%EU2W:='LF7/SE%W%N0
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M\-:;I6K7NIVB2K/>[/-W2$K\J[1@?3^OK1?^&M.U+6K;5[A9?M5K$T4;+(0
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M:16UD+-XXH5BZR1N<[D!;D[>2,]>E0W.BZ^;KQE=:?IDD$[VL=CIFTA0(54
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MY_3U]<HH 2O.?%FF^)Y_$^KWECICW4?]CFVL)!(H6-G/[S )SO/\A^%>CT4
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MG7='*26P5&<Y)QUZ8]#7<54U/5;'1K)[W4KI+:W0@-(YX!/2K*L'0.O(89%
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M%Y-OIK:IJ/FQ*Q1V)((8C((9NOH*ZS4/ 7AK5+B]GN]-#/?)&D^V5U!"8VX
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M)XZUV^K:18ZW9BUOX?-C6195PQ4HZG*L".00:J3^%-$NM,N-.GL1);W<HFN
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M'R"&+9SD8&.>,8''%%QX4T:[TZ^L+BT\R+46#73&1M\Q!!!+YSQ@8&<#ITH
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MMA;VZDD)N9N2<GEB3U- &%%K.L^(KO6H]"FM[9-+N!:1-,N1+*"#*6X.% .
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M?2Z79S7<MW) K3RV_P!G9SU\O).T>G)_EZ53D\+:)+HMOHS6""PMF5XX%9E
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M2?4"#<RJ2&?"A1SU' [>YJBG@WP_';Z;;IIRB'2F9K1/,<B,M][//S9_VLT
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M#%O=SMJ4*1V3!+EG)7RF/13G^+VZYXK'\9Z=J]_K?AMK*R^V6-K=O/=1^8J
M.%'E,<]@=QX!^G2N,?3M1M/"\5OJ6BW%SK5UK!U6XM[=U>4 ,?WFP$@I]U<$
MCECZ#(!Z2_BS08TN6DU.*,V:[KA'!5XAQRRD9'4=N]30^(M'GAN)H]1@:.U<
M1S-NQL<XPI]^0,=<\=:\]_LM?$_A&^?0!>3W.MZM&NJM=JL3VX1@6!0G "@
M8!)Y[UL>)_#U['XBT&;3--F?2[5I)+A;'RED\[8%21@Y 8@=SR.?:@#JH/$&
MDW%B;V*]C, F,&2"#Y@.-FTC.[/;&:@3Q=H$D=G(NJ0[+TN+<G(W[3ANHXQC
MG/2N1OO#%_9^(]%-GI5X-(MK64;+.>-I8KB0G<[-(1DE2/FSD'.#2:EX3U!=
M:MY-/T<16.AZ3*-.@252KW;YXR2"1T))QDCO0!V%MXM\/WC6:V^K6TC7SLEL
M%;F1EZX%3W6OZ597L5E<7T:7$LJPJG)^=ONJ2. 3@X!QFN"\.^!M4TG6/"ZO
M8AK;3;&2::9I5P+N3.Y2,Y.T=,#'ZFI_!WA[4;:S677=&NY]3M+F>[+33Q>3
M).<X= IRS$;0"W YP10!UA\8^'5)#:O;J1<_9<,2/WO]SZC(SZ9YI(?%=C=>
M+)/#MLDLEQ;Q&2XD\M@D9XVKG')().>G'4FN%T_P/K<5GX<2YL/-EDU-]2U=
MC*@V2 YC4\\CGG&?Y5U7@_2-3LM:\1ZCJMH(IM0OBT3^8K;X4&V/&,]L]<'V
MH K^*O%SZ)XQTFP-\+:Q\B6ZU ^3YA$:\+C )Y;.<=A723:]I5OI\-_)>Q"W
MN(_,A<9)D7;NRH')^7G@<"N-U7P[X@O==\2W$=DN_5;>/3[.X:5-D%N5/F,W
M.[.>0 .N/K59?"%_:^)GLI[&^O-(72XK"TD@FC1=@ \Q9"3N7<1R5YQQSTH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\
M]>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K(\+_\ (OV_^])_Z,:M>LCPO_R+]O\ [TG_ *,:@#7HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#*\+?\BEH__7A!_P"BUK5K*\+?
M\BEH_P#UX0?^BUK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "L@>%])!.R.Y0$EMJ7DRC).3@!\#DUKT4 9'_  C&E^EY_P"!
M\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/
M_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^
MEY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E
M^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_
M  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='
M_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=
M:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!
M\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/
M_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^
MEY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E
M^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_
M  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='
M_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=
M:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!
M\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/
M_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^
MEY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E
M^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_
M  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='
M_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=
M:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!
M\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/
M_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^
MEY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E
M^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_
M  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='
M_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=
M:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!
M\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/
M_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^
MEY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E
M^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_
M  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='
M_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=
M:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 9'_  C&E^EY_P"!
M\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^EY_X'S__ !='_",:7Z7G_@?/
M_P#%UKT4 9'_  C&E^EY_P"!\_\ \71_PC&E^EY_X'S_ /Q=:]% &1_PC&E^
MEY_X'S__ !='_",:7Z7G_@?/_P#%UKT4 16MM#96D-K;IY<,"+'&@.=J@8 Y
M]A4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+O4[2RD6
M*>1O,9"^Q(V<A1U8A0<#GJ>*MURWB6&-M52YM-6;2=4M[?,<TB[H)T+']VX/
M!Y&>"&&<C- &N?$&F>;#$L[N\]O]IC6.!W+1<?,, \<C\Q5J"^M+FR6]@N(Y
M+9E+B56!7 ZG-<7%=RS^(=(N;N0Z+,VA.)%4+B%V>(A,.#CH2!UXI^@M.GA:
MRT1X%2:ZN9A^^W1_:(1(SM(P()7S/3_;..!P =I;7$-W;17-O()(9D#QNO1E
M(R#^54Y->TZ*:YA:60O:$"?;!(PCR,C)"X QSGTK)\'2-8F_\.S!5;3IR;<*
M25,#_,H!(&=A)3VP/6HM/@DNO&.OF&^EA59[9FC55*RA8UW Y&>Q!P?K0!UE
M%<;'>:C+>(#/.E_'JTD<\!<A/LF6VMMZ!?+V$/\ WN,\D53T][B33O#LTNJZ
M@TE[>M%=[KEAE!'-P1_#SY8R,'.._- '?57GO[6VN;:VFF5)KIBD*'JY"EB!
M^ )_"N/T"\NEO=&,FH74WGR7D$JRRE@41SY1(/&< ?-U.>IS6WXA=5U;PYD@
M;=29C[#[-,N?IEE'U(H U;B_M;2XMK>>=4ENW,<"'J[!2Q _ $U3@\2:1<ZB
MNGPW>^X9V15\M\,R@D@-C!^Z>_:L'6(-;_X272+A]/M)$&J'RY5NGRL0@F !
M7R\+P22<G+8'3!&\J?:?$6=N(;"WVKQP9)#S^*JH_P"_AH T'GBCECB9P'DS
MM7J3CJ?H..?<>M06>J66H,5M9Q(0H<<$;E.0&7/WE.#@C(-85[#=7?B76[96
M*O)HT:69S@ LTP<CWSY>?H*Y_4+2^O\ 2H!ID4Z&U\/FVN5C4AU9FBS&!_?"
MQR<=1D>HH [Z/4;2:UDNHY@T$:EC*%.T@=2#T8<=1FFIJUB]V+19QYQ;9M*D
M#=MW;<XQNV\[<YQSBL&S:YFO;C38YS=:7*\ MY"JX50K-*GR@ KA4'L9".V*
MH16=R&@T[:WVR/Q%)=N<?\L2[R!_]THP7/J<4 =79:UI^H74UK:W >: !G0J
MRG:>C#(&Y3CJ,BDDUO3HF"R7(4DG/RGY0&V$L<?*-P(R< UB+=2G7[G5-/N$
MOK::P\M<QC]Q,' CC# #AB[$@\C:,\8K/U?3I+)?$5D(WE.H:-%:V/&3*X65
M"@]]SJQ_WL]C0!U3Z[ID>J)ICW:K=.=JH5."V,[=V-N['.W.<=JN03Q7,?F0
MN&4$J>Q!!P01V-<U/J&F3ZI8:5<3%I+&=';;"Y\V?&!@@8P"V2?7\:N:.9/^
M$I\0 ?\ 'OYEN1Z>9Y0W?^.^70!?M=9L+RWN9[>9GCM'9)OW; HRC+#!&<CT
MJS;W$=U;QW$+%HY5#(2I&0>AP>:YB]L;JV\4SVMO"[6&OQAKAE'RPR1X#D^F
M^/"_5:-3O+IO$LEA)>75D089+'R8799E!^=>#M/.00W0$'CK0!UE,\U?/,.&
MW!=WW#C&<=>F>.G6N(AENSI,UU#JLK7']J3PJEU<R+$\:R2E$++R@*[2'YSA
M1R#BFSZKJJQ/)9?;ED_L2"3[/(QDD1M^'..\FSGU/''- '>45PVH7=TMS)]C
MU&Y_LQ[RQ\F99F8Y9R)E#')*A0I.> 2?PV?#L]T^F:E#',;B6VO)X[8W,C-E
M0<H&;DD<XSR<>M &Q'?VLM_-81SJUS B22QCJBMG:3]=II)+^UBOX;!YU%S.
MC/'%W95QD_J*Y72/[0TSQ5J5SJ=G!#"FEP///'.\I8B2=BW^K7).3D#H N,Y
MP-349$/C+0SG_EA<_AD1X_/!_(T ;]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#?#<[I&O[M\,SG"X./7OV[XJ:77],AALYFN&*7Q'D%8G;>#CG@<#D<G Y'-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1_Q\/P#CY5SG'-B;P=93/=_Z9>)'?1RQW,:.FV57,AP?ESP9GQ@^F<XKH**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit103-form147_716ba006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
M8\T6HV6I?:+G4"@",F]B[B3.6+J<8Z_-SC% ';#4;$S30B]MS+ NZ5!*NZ,>
MK#/ ^M-O=3L]/LYKJXG41PP/<, <GRU&68#N/\17$V>CW+>'8]%/AU_[4BM+
MF&:^DPB[VC92ZO\ \M-[$<=LDG!&*L0_VM?ZG!<6^AS1FWT*>V"WZ!8Y)BT)
M\L\]#M//0_A0!N:?XCN+J[M8;O1+RRCO5+6TSLCJ<+NPVTG8<<\\=LYJ]#J]
MHUG:7%U-#:-=J#''+.F23V!!(8_0FN4T>SFAUK3_ .P]*UC28%<F_M[J0_95
MCV'A5+$;MVW!3 QG-9FGV,NE:>J:IH[7[-H$,/D_(6MBOF;PX8C:K9!W=/D/
MH* /0I-5TZ$(9=0M8Q(%*%IE&[=]W'/.<''K3-:U2/1-'N=2EB>5+=-Q1,9;
MG&!GCO7$Z-H+7FBSS3Z<)O-\,65O;L\8.7\N7<HSWR4_2MS7;&]NOAK)9""6
M6[:QC5HE^^6 7(^O!H T[+5-1GGVWFA3V,(4LT\MQ"RKCV5B:M)JFG2>;LO[
M9_) ,NV93LSTSSQ^-<M:PVA2ZBLM(\11336LJ*U]//)'RIXP\C#)Q@<4EOX6
MC;^P[5].$5NVBSVEZ40+@L(<*Q]<AS]<T =B]Q#&Y1YD5@A<AF (4=3]/>J%
MUKUC!:074,J7<4]U%;*\#JP#.X4<@]B>:XR;0?$&IZ!>W%_!(;]'MK;RUVEI
MX('#2,H;Y3O;>V#P0%!J2#1KV6>6[BMK]EDU"P8FXACAWB.3+.(T48P#@L>N
M!Z4 =TM_9M>-9K=P&Y49,(D&\#UV]:2+4+*>X-O#>023!=QC252P'K@'.*XF
MSTF\6'3=,_L>:/4;75?M,^H% $9/,9F<29RQ=#MV]?FP1@57T*TDO[#1X=/T
MJ6TN+:_FN);\Q@)LS("0V<L6R!M_/H* /0(KZSGN9+:&ZADGB_UD22 LGU'4
M54U#6H=.OX+.2)W>:VGN RXP!%LR/J=XQ]*XSPMH-_:WNB17-OJ"3Z<'^T.T
M,*1*2A5OW@7=*&)SC/H3R*Z'Q!875SKUE/! \D::;?1,RC@,_D[1]3M/Y4 -
MM?&3/;65[>Z)>V5A?>7Y5VSQ.B^9C9O"L64'(&<8!(SBNC26.5G6.17,;;7"
ML#M.,X/H<$?G7"H-2U;P=IOAE-$O[:40VT-S<7**D<2Q["Y'S98_*0 !U/:N
MSLVC:6[$=F]N1-AW:,+YQVK\XQU&,#)Y^7VH QXO$]]=S72V'AV[NHK6YDMS
M*)X4#,AP<!F!Q3M:\3W.B!I)?#]]- &1%EBE@_>,V %52X8G)QT[>G-<W:Z?
M#:WVJ?VAHWB.22749Y4>RN)TB9&?*D!)%'3VKIKJVN-2\4Z7+);R+8V=N]R-
MXX\]L*H/NJE_SH =<^(IOM\UCIND7&H3VRJ;G9)'&L)89";F(RV.<#CD9(S2
M_P#"2>=9V<UCI5]=2W@<B#8(VBV'#!RQ 4@\8SR>F1S5&*2Z\-:SJQ?2[V]M
M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3]>TK5-,;4[.\1[)02;A@43 ZG+ # P<FJT?B_0I+<7(O6%LQVI<-!(L3DG
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M-9BO(&>/R+1$4-:#'(8CDYZ\^E &O1110 4444 %%%% !1110 4444 %%%%
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M<3%IA .&QYA. N<=<G&* '?\)9X;_P"AATO_ ,#8_P#&C_A+/#?_ $,.E_\
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MW_T,.E_^!L?^-'_"6>&_^AATO_P-C_QK7HH R/\ A+/#?_0PZ7_X&Q_XT?\
M"6>&_P#H8=+_ / V/_&M>B@#(_X2SPW_ -##I?\ X&Q_XT?\)9X;_P"AATO_
M ,#8_P#&M>J$6MZ=-)?QQ7.]M._X^@$;]WQN].>!GC- %?\ X2SPW_T,.E_^
M!L?^-'_"6>&_^AATO_P-C_QK2MKB*\M8KF!BT4R"1&((RI&0<'D<>M2T 9'_
M  EGAO\ Z&'2_P#P-C_QH_X2SPW_ -##I?\ X&Q_XUKT4 9'_"6>&_\ H8=+
M_P# V/\ QH_X2SPW_P!##I?_ (&Q_P"-6]3U6QT:T^UZA.((=P7<5)Y)P!@
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M4,HQ@<#&.<Y.>>:EN_":ZAX?N-*O=5O9WNROGW;;/,8*00 -NU1QT [GN2:
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MN;FS22UMHUE$&4D*A]VUF&-RY'MR>#6I'X1L[>\T>>TN9[=-'C>.")=I5@X
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M+#E1[9W''JQJAHO@]-$*Q1:QJ$]G 2;6TF=6C@],'&6 SP"2!]0#0!%X-O\
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M$$S E-S%B!@#C+'DY//6H[#P[#97&J2/<S7,>JR&2>&4+L!*A3C !QM ')-
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M#:,#Y?UKHKJYALK2:ZN'"0P(TDC'LH&2:\Z^']TFF>(/&$U]'/!'=:F\T#/
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M6TFD:XDC?^)CL3<1\['<>F3Q[T /\'^-T\31:DMY9C3;O3)2EQ"TV\!<<-G
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M+^ @F4B?RVC *C.-ISRPKJ:P=>@L]1U&#2KS+17EI<0N I( ;8!ST!X.,^E
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M4FD:O=2O;6 ;<+>,D@H1V/3@>@/>L[P<MYH^I:M\-9P717,MO<<<6K\O^."
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M\8,,>_D=#E2N?<X]:U_&^DV6E?"GSK!%MYM-C@EM;B+Y71]R@L&'.3DY/?-
M'?27$$3;9)HT/7#, :6.XAE;;'-&YQG"L#7GOB"&'4_A/=>(;NUC.I7NDQ-+
M*R#(X!X]!EB?QK;\!Z38IX8T'5$MHTNQI:1&55 +*P1CGUY4?KZT =/)/#"0
M)943/3<P&:1+B"5ML<T;MZ*P)KS[XY*I\!(Q4$K>QX..G#5:U.Y-KHNNZ];Z
M&--U'28I(K9BB;V1HU)8[<@C)SC)^[]10!V[7,"S"!IXQ*>B%QN/X4LD\,1
MDE1">FY@*X#PQI%C>_!]I+J-9IKVTEN+BXD^:1I?F.\L><C P>V*XO6=4O-;
M^#&@W>H[I[B/5UA$S\M(JB0#D]?3WQ0![I'+'*NZ-U<>JG-/KS+0GCUGXOW-
MYI4/]E0Z9:^1?VL@$<ERY+ '8O! )7YO8>HKTV@#*\+?\BEH_P#UX0?^BUK5
MK*\+?\BEH_\ UX0?^BUK5H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "LCPO_R+]O\ [TG_ *,:M>LCPO\ \B_;_P"])_Z,:@#/
M^(6G7NJ^%'MK"V>XG^T0.(TQDA9%)Z^P-2:IX2@UKQ!I_B!K^\MKFQ0B!$5
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MH7$=M'::QIF[[58SD_+MS]#@X_ C%;_B/6U\-^&KO5K@"5K:$L%48$C] .^
M3^0H ECTR?9*;C4KB::2,QAMJJJ ]<*!C/N<UCZ/X$M]#\/_ -AV6J7HM?M
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D>%_\
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M2"<CCM@UZ5%+'/&LL,B21MR&1@0?Q%0?VII_VK[+]OMOM&[;Y7G+OSZ8SG-
M'"^-_!]S/J$/BKPX)(KQU$5]"J%3<0-PQ*G^(#L?0=P*Z+4XYM;UIM.5#';V
ML!+M<V4CQ3-("I"ME0=JY!Y/^L]JV9]2L+698;F]MX96P522558_0$TBZGI[
MW1M4OK9K@'!B$JE\^F,YH \]\ #4]!TO6_#-_8Z@UO9O*UA<FRE"S1G.0OR]
M<\X_VCZ4_P"&U[-X9^'_ -GU#2-76[ADE<6RZ;.7?)R /DQS]:[V35],BW>9
MJ-JFQMC;IE&UO0\\'VH@U?3+J416^HVDTA!(2.=6/'7@&@#-TSQ'-=Z\^B7>
MEW5M/':+.+ATQ#-PN\(?]DN!^=;U9::IH2WCS+J5B;AP$)^TJ3@=ASP/85?F
MNK>W5&GGCB$CA$+N%W,>@&>I/I0!'J#^7IUPVUWQ$WRQH78\=@.37GWPH\--
M;:%8W5_:7MEJ-C-,#'<I)&"CCLK8'H<@=J]!FU*PMKA;>>]MXIGY6-Y55F^@
M)S4WG1"'SS(GE;=V_<-N/7/I0!R&M:7+XQAUFV?=;6XB^R1BZL)=QQAS(A)7
M.7"] ?\ 5CUK,\(ZEJG_  KR.QUC2]3AO-/ECA"M8REI8PZE6 V\@*,'_=]Z
M[>/6])FD$<6J6;NQP%6X0D_AFI;K4;&Q95N[VWMRPRHEE5,_F: .+TKPM=:7
M\0]5U&(.NAWD<=\8Q&3NN/F&-N,\$L^,9R5]*YWPKI^HVGPD\2Z=<:5J,5Y<
M33F&!K*4/(&C0+@;>>0:]5M=2L+YREI?6]PRC)6*57('KP:2+5=.FF:"*_MI
M)5.UHTF4L#G&",^M 'E'B#3M2N?@CI.E0:5J+WT;QA[<6<N]=N[.1MX'(YKT
M=-?\RXT^SM;"_9KAL222V,T:0H$+$LS* "2 H&>IJ^NKZ8\C1)J-HSH"643J
M2,=<C-)#K&EW,HB@U*TED;HB3JQ/X T <'XSTN23XG>'M0M=-O9(L&+4)H+:
M1D,>?E#E1@CDY]NM=AK?B'^Q;S3(6TV[N(K^<0-<0IE+<L552_IEF _.M"ZU
M&QL65;N]M[<L,J)953/YFJ_V_1KYA(+ZTG^S?O/EG5@G;<0#CCU/2@#1HJO%
M?V4]LUS#=P20)G=*D@*KCKDCBG)>6LMM]JCN8G@P3YJN"F!UYZ4 <'X/TZX\
M$^(?$%IJ%O.;.^N/M5I=Q0M(C ELJQ4':PR.#UYQ6?9Z!J)@\<>([BRNHFUB
MWFAL;3R6,SKM8*2@&03\N >1SFO1;;6=+O/^/74K2?G'[J=6Y].#['\J8=?T
M8'!U>Q!'_3RG^- 'D=IX>UK3?#?A?7(M,U"_.F2%;S1;B&1B"7;$D<;#A@".
M0/0^M>SVUPMU;1W")(BR*&"RQE''L5(!!^M.66-X1,DBM$R[@X8%2.N<^E16
MNH65Z7%I>07!3&\12!]N?7!XZ4 6*\Y\>6%Q?_$'PM(NGWUQ:6KO]IE@MY66
M,-MQEE''3L:[U]2L([K[*][;K<?\\FE4/Z],YI(-4T^Z=DM[^VF9!EA',K%1
M[X- 'G]GI4EI\:9+F'3K]=/;3_(^T-!*T>_CC>1^N<5/\/[.?P)9ZIH6JVUS
ML2[:>VN(K=Y4N(RJ@8*@_-\OW3SS7<C4]/-J]T+ZV-NAP\HF78I]SG I!JNF
MFW-P-0M3"N"9/.7:,G YSCD@_E0!YKI?@O6)?!OB^YFMF@O_ !#(\T-HY 95
M#,R@^C'<>/I6]X:N7N?!FC:,+*]BO;;[,D\<]K)&(O*=2Y+, .BG'/.1[XZ?
M_A(-%_Z"]C_X$I_C5NXN8+2(RW,\<,8ZO(X4#\30!P/BWP]H_BBZOVU"POK'
M4K)]MG?VUO(3, H9<%00V&)&.O'!%8WB2PU^XT;P1%JEE?WE[:7*2W[0022F
M- R\LR _-MZ\YR#7J-MJNG7DGEVM_;3OC.V*96/Y TR76])AD:*75+.-U.&5
MKA 0?<9H Q=(NK;38FT:PL=2-I!#/.9YK.90"TFY8UW+EV^<],_=KS_P]X=N
M(O@_JMM=:1J<>J$R". V\X9L@;<)C![\X^M>QV]S;W<(FMIXYXSP'C<,I_$5
M#_:VFF<P?VA:^:N<Q^<NX8Z\9H \PNO#>JW7@[P7JEM87+7?AV5'GLGB:.5E
M#(6PK $D;!]<FM;Q_8S^/8-)T/3+>Y\HW:W%U<RV[Q+ @5EP=P'S'<?E'/'.
M*[RWO[*[C>2VNX)TC^^T<@8+]2#Q3K:ZM[R+S;6XBGCSC?$X89],B@#SYTN+
M;XURZK)I^H&Q&G>1]H2RF="_!P"JG/UZ4_XA7=[XB\#:S:6.DZBY$\,5NAL9
M1),0RLS!2N=O;) ^Z:[=-8TN19'CU*T=8AF0K.I"#ID\\4]-4T^2V>Y2^MF@
M0X>43*57ZG.!0!YWX@T:_P#&&G^%M%M;&ZAALS%-?7%Q \(B"H!M&\ LW7I[
M5Z=5%];TF)MLFJ62-C.&N$!_G4YO;1;7[4;J$6^,^:9!L_/I0!/7F^HZ4^I?
M&037.GZ@VFMIGV9YTBF2-GR?E+K@8P?7%=W_ &UI0A\[^T[/RBVW?YZ[<^F<
M]:2/6](FD6.+5+)W<X55N$))] ,T <;\3?"TDW@.VL?#^F@II]W'.+6V3DH
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M-M=2L+UBEI>V]PRC)$4JN0/7@T <#IFC7MQXP\4>,9[2Y@MKFU-K9PM"WFS
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M, J ;L#J<]33CX9MY6LA>7MW>Q6$JS6\5PR$*Z@A6)"AF(R<9)]3DT <EX2
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M7@437$NW<54850%   R>W?G- '!>$+"UU+Q]X]LKN%98)I(T=&'!!WUV?C8
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M.3VI^DZ7;:+ID&FV89;>W7;&K') R3C/XT ><7+1>"OBE?Q2P>9IGB>U9UB
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M$CNVX$(PX*J<'GYNIXKI/&"OX%\?6'BZSB+VFJ'['?P(0"[D?*PSQDX!_P"
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MDL<,TMLS(T@$?3C_ &6YH NZ%X[NIW\43ZR+6*T\/SO$3!&P:7:6&>6/)VC
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MX!% '6S>+]53Q]J'ATRV%O:V=B;PW,EN[D*-N00)!_>Z^W2NKTI]2:U<:JL
MN$E9=UNI".N?E8 DD9'7GK7G6J^'CJ?Q1U6ZU+2KR32KC3?LZ7"6KN!+\F"
M!GC!YZ5Z%I.H3ZDES++93VD:3E(5G38[H%7YB.P)+8]A0!RZ^+=7D\=:QX?:
M73[>VTVU6Y%R]L[D@A#@CS!_?_2K6NZSXLTGPS'>065C<ZFL\B/;K&^V5 7(
M9/FR"44''.<XKF[G0?MWQ0UZ^U/2KUM-N;2-+>Y6UD;$JB/!  SP5/MQ[UU[
M:I<7IL[B72[V!%U A$-NQ<1B,KO8#. 6/Y8]Z *^B^,?^$GTC3-0TF2",SW
M@NX9D+M"VTL0,,/3@GJ#5*+Q;K$WCK6_#S3:=;6^EVRW'VE[=V)4JC<CS!TW
M]?:HI/!,^D?$>RUW1B4TZ]E8ZC;+]U7V/MDQZ$G\"?0\9H\+'6OBAXCGU+3+
MD:;?6B1V]P\+!?,58QD'M@J>O!Q0!NZCXNU/2Y])T.6VM9=>U.>1 %W"&.)7
M($I&23E0#MSZ\BK&H>*KKP]XFTO2M86WEMM7)CM[J!&C,<H(&UE+-D'<,$'O
MT[U1\8>'[[_A,M"\6V%N]V-/)BNH(^7\HY^91W(W-QUZ5%XCTBZ\9^+_  ^]
MO;7$&FZ3*;FXN+B%HM[94JBJP#$_)R<8&>N>* );/Q3K]_XH\0:+$=-C_LA%
M>.1X'Q+D9P?G^7Z\_2FVOQ/M#\.AXLO+)HGWF$6RM_K)<X 5CV/7/;!ZXKG[
MCP?>^(/%GB]9(KZQCU&-!97>UT1V50"&QU4XQ@]NE/O?#NM^+OA=%HD^DG3=
M6TF96CB,8CBN-H9<J1\HR&/XCL#0!V?G^+TT,W[1Z:]X8_,%BL,@*\9V[]_S
M,/\ =&3QQUK,O/%VJP^/[GPZ)+""TAL3>&YDMW8JHZ@@.,_7]*V]/\03WEG"
M'TB_BOV4"6"6W9%1NY\PC85'L2<=!GBN*UWP^=5^*%[<:CI=Y+I,VF&U,Z6S
MN!)ZC SQZCB@#T/27U)[>4:HL'G)*51[=2J.G!5L$D@\\C/45D>%_&5MXFU/
M6+&)/+;3K@+'GK+$1P_T)#?@5]:2[U>^OM,N88M.O[437 M(I#;-O$9"[YB!
MT RP'?(_+F]1T;5?#GQ)TW7M.MI[ZWNH?LVHK;6Q 2,8"M@<'& <#GY/>@#3
MF\5ZXWCW4O#=NVFQ1VEC]L2>>%^?N_*V'&!\WWO;I5!_B3J4WPO;Q=;Z?!#/
M%,(GAF5F23Y@NY2"#CGWY!'O5:^T9;OXJ:IJ.J:#=7VD3::(%;[(SAI!LX'&
M0>",\?6LZX\/^*_^%/WNCW]M=7%W-=(;*U_ULD4(93M9AD#&#P3_ (  ]4TJ
MXN+O2+6YN#'YT\*R-Y:D*"0#P"2>_K7(:/XNUO5==U_37FTVU72;F.WCD:VD
M;S6=F5<CS!CD =^M:]CJ]Q#IFD6-OIE\9RL,4YDM71(% &\L2 #P"!C/)%<=
MH>A;/&?B/4M6TB_6.34(;K3YEM)&+&-V8XP.,@@<XZT >EZ;)>2Z;;OJ$<<=
MV4'G)'G:&[XSSBK58%MKVJ2W.EQ2>'KI([XS&65B%^R*I.S>.>6&._?C-;]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &5X6_P"12T?_ *\(/_1:UJUE>%O^12T?_KP@_P#1:UJT %%%% !1110
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M/!Y'(/6I-0U"TTNRDO;Z=8+>+&^1N@R0!^I% %FBBB@ HHHH **** "BBB@
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M]9$22W0(Z>2K .W4 %LY'/7\#0]:U)_$MA8SWDEY;7FF-<-))"B*TBL@+1X
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MM_LR*I)N/*1R1@_+GID C\ZO:EJGB#P[#J6H7+^?IZ6@:'[48O,CGWA?^68
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M92L3L&&00H)P&8 $D#/L, !K]W<6\EA%!>K;"><JZHF^>4!&(6,$$9R 22,
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MX7&GZXEQ/ ;=_,6,%_F"XR1\PZ9K?UK3]43QS'K.B17NZZN;:.^LKBV8PS(
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M8;\XR!DXS7G>CZ%J$.G?#^*;1;Q7L;RX>\#6;_NLR J6X],<^WM45]HVKR^
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M"T+0MLM0=VU<L2V.0=S=23C@8'0^'= O-(\=:QIR(!HDDB:I$.RRON79CTW
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MEAJ\FN^%[D>&]0TZTL=0N@UOY+,ENKXP=Q)8Y.26.%Z8KV*@#*\+?\BEH_\
MUX0?^BUK5K*\+?\ (I:/_P!>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH
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M<X ]2<D_4GG-2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M \I)620'A03SC]*J6VB7NEZ5X7MVLKC,.L27<D443.+:)_-(!V@@8WJ#[YH
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M)["Q2>.>)"JNK!2<J2<$$CG//M5GPQXEOK"?PMX>OX+:2UU324:VDB#!D*1
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MG;6]Q(DZMAPL6X@;2,$\G/KVYXF?68-6^(?@_71$84N-*GF=>I7Y&)&>^.:
M/3Z1F"J68@ #))[5Q7A?QEJOB";2[K^SBVGZD)]S1V\@^R;"0FZ0_*^X @X
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MX7R8W!A=03R2QW XZ<=>O&39^&>HZOJUGJU[J5[%.#J4T>T0E6!4(!@[B N
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MV-C!:)(\BP1K&KR8W$ 8&< #]*KW>N:387(MKS4K6WF:,RB.6958H 26P3T
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M[F!+@+&@4L&)Z<D #US[4 ,O/!ME=W$5TMW=07<=DUBUQ&4W20GLP*D9'4$
M5&W@/21+H;6\MS;+H6[[)'$R[26QN+94DDX]1WK6?7-*CODL7U&V6Y=_+6(R
M#<7QG;_O8[=:S;7Q*O\ :VM)?WFF16&G&,)(ER#(F0=WF@_=YX'3\: .AKG&
M\$V(FUN6"[NX1KB%;F-64H"5*EERN<X)ZDCGITK3L=?T?4[EK:PU.TNIEC$I
MCAF5CL/1L ].1^8JS=7MK8Q"6ZGCA0MM!=L9/8#U/M0!S6G_  _L].O]$O(]
M0NG;1(7AMU8)AE;<#NXZX;MCI5K0?!EGX<N9387U\MG)*9EL6D!AC<]2.-V/
M8DC\:VK&_L]3M5NK&YBN8'SMDB<,IQUY%4KOQ1H%C--#=ZS8P2P$"6.2=59,
M],C.10 GB7P[9^*=&?2[Z2>*%W5]T#A6!4Y'4$?I66/A]IBQZT@OM1QK:*EV
M6E5B=HQD$J<$Y.>O7C'&-ZZU?3K&".>ZOH(HI1F-VD&'&,DCU&.<^G-1W&OZ
M-:S)#<:K9Q221&9%>906C )+#GD8!.?:@#(M_ EA;7VFWL>H7XETRR^Q09:/
M'EX(Y&SD\]?85'9_#S2;#1[#3H+B[_XEMR;JTG=D,D3DY(^[@J>X(_I6S_PD
M6BD0D:I:D3HKQ8E'S*QPI'U/ ]34DVM:7;WPL9M0MX[DE1Y32 -EONC'8G!P
M._:@#$N/A]HUSX>O-'D>X_TVZ-Y/<AAYK3%L[^F/;&,8_.EB\!V,<VLS-J6H
MR2ZW;B"\=WCR1MVY7Y.#C/MSP!QC4O/$NA:=/+!>ZO96\T*AI(Y)U5E!Q@D$
MY[BIKG6M+L[:.YN-0MXX94\R-S(,.N,EAZC!!S0!BV'@+3M.U#2+V*]OFDT>
M!K>W5VC*E#G.["<\'VZ"K^@>&;/PVUX+&>Y,-W<-<&&1P4C9L;MN #C@=2>G
MUS0UWQ7)IVK^'8+(6UU::S.8C*"3@8!#*0<'.:U?$6I2Z3H-U>P/:)-&G[LW
MDOEQ;NVYNU %;6O"T&K:QI^L1W<]E?Z?N$<T(4[D8892&!!ZG'IFLJ+X::4G
MAB^T"6]O9K>]N?M3.S('CDR#E2%]AUS6]!KMABS@NK^S2]NK<3+"DP.\;=S%
M.[+P3GT%.'B#1FTPZHNJ6C6(;;]H$RE,YQC.<9SVH R8? 6F+=ZK=75U>WKZ
MQ L%X+ATPX"@ C:HP>.W [ <8O>'?#B>';-+6/4KZ]BB3RX1=2*?*3^Z-H&>
M@ZY/&!@5F>&_&7]L:SXAM;E[1;/2&B*74;85T<,26)) QM_G6O'XGT&5F5-9
ML2Z1^8R>>NX)C.[&<[<<YZ8H C\1>&;7Q&+)IYY[:>PN5N;>: KN1Q[,""/J
M.U91^&^DG1M6TDWVHFWU>Y%S<DR(7W[@W!*="0.N>GUK7C\5^'9I!''KE@[&
M,R@"X4_(.IZ]*L0ZYI5QIAU2'4;9[(9S<"4;!SC&?KQ0!DQ^!=,75+C4);B[
MG:ZL/[/FCD9-CPX Z!0<\=<U2M/AS;VTVBNVM:A(NANYLT(C&U6Q\I^7GICZ
M>E=#)XAT:&UCNI=4M(X))#$DCRJH+C@KD_Q<'CK4,GBO08]*N]375;:6ULLB
M>2*0/M/IQW/8=Z *FE>#++1M5NKRQOKZ*WNYS<26(D'D>9_> QN'TSC\.*L>
M'?#%KX:^W?9+FZF%]<M<RB<J<2-U(VJ.O'Y59T'6K7Q!HUMJ=HZE)XU=D#AC
M&Q4,4..XSS3FUS2DOUL6U&V%R[E%B,@W%AR5_P![';K0 FO:):>(M%N=(O\
M?]GN5"N8VPPP000?4$ UER^"X)=2T6_;4KQI=%1E@+[#OW#!+?*.P XQTK2N
M_$6B6$[P7FK6=O)&0'$LZKL)Y ))X)'0'K2W'B#1K1HQ<:I:1^8%*EIEP0WW
M3GT/;UH YZ/X9Z2OAPZ(]Y>.BWGVR&X#*LL,OJI Q^8[_2NGTZR:PM1$]W<7
M<A.7FN&!=ST[  =.@ _/-9KZ])'XMETV2?3ELH;$SR9GQ<(^[DE/[FWO^M6;
M3Q-H-_<PVUGK%E<33J6BCBG5BX&<X //0_D: )X[!X]8FU#[7(1-$D1@*KM
M4L00<9S\Y[U1_P"$2T?S]8D-L-FM(JWD0X5R PW#T)W<GU&>M6_[>T@32Q?V
ME;>9"',B^:,KL^__ -\]_3O5;PUXHTWQ58/>:=*K*DC*5S\P 9E5B.HW;<C/
M:@"OIG@O3M/O8;MYKB\EM[(6,!G*_NH1V&T#)[$GFJ7_  K?1_\ A&(_#_VJ
M_P#LUO/Y]K)YJB2V?<6^0A1W9NN3SUX&-'_A+M+D\3R>'(KJ(7L<.]BQX#D@
M!,?Q'J2!T_EF>"?'MKXETNV>_N+*TU&YDD6.T27YF"GJ 3GL: -.7PK'<)I_
MVC5M3EEL;D7/F^>%,S 8VN  -O'0 =_4YW:IMJ^G)?BP:^@%T2 (3(-V2"0,
M>I )QUP,U<H RO"W_(I:/_UX0?\ HM:U:RO"W_(I:/\ ]>$'_HM:U: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\+_\ (OV_
M^])_Z,:M>LCPO_R+]O\ [TG_ *,:@#5=@B%CD@#)P"3^0K@OA/87VF6&L0W]
MC<VCS:B\\8FA9-R$  @D>W2NWO+^RT^(2WUW!:QDX#S2! 3]33A=6S6GVM;B
M(VVSS/.#C9MQG=NZ8QSF@#QO4="U:71?$:Q:-?--=^)/M4(%J^YX=S$,..G7
M\_>MS4=&NYO&VOVVJ6&JW.EZ[%;F&2SB!7]V.$=B/W?S<]1TYZUZ+9ZC8ZC&
MTEC>6]TBG!:"57 /U!JS0!G:T&7P[>HJ2RN;5T544NS$J0  !D\UR<WA2XF^
M(MKX@LO,BTZ^L_\ B8HR%2S1E2H*GG)PO&.BMZUWE+0!Y+IN@:S<P?$*VBLK
MJVEU:=WLGEB:-9EW2' )&!D$#G'WJO:3I>I2^(-*OTL;JVMM-\."TN?,@9"\
MN#^[4$9;!P<C(XZUZ910!YQX(\,20_"V6SGTG[/J[6]U%^^@V29?<  2.A&W
MOC\JQIVCT3P5X-N]6AO;"XTF]"GSK=M@/).X#YL8 P0#U[\U[!5'4-(MM2FM
M;B4R1SVC,\$L3[60L-I]CD'N#0!YG;2Z?<>#YI/#ROXDN7UP7DXCAD0V<CG.
M]8R02%QQDX)))XR*HWNDW%IX3\7MK-KJ-JCZPMY#*\(;>"XPS!?E8<Y;;P.W
M85ZY8Z7;6$MQ/$&>>Z8-/-(V6D(&!GL !V&!^=&IZ7:ZO:K;W:L521)4*.59
M'4Y5@1Z$4 >62M8^+])\8OX>U<7NLZK%!(]I'$\(2.(J,+O W$@$$^X'ULZS
MH=_KO@O4;[3=/U:/5+F&V%S!>1B(R^4P.Q4 &<#/..>!R>GH]KI%O;7S7[-)
M/=M%Y/GS-E@F<[0!@ 9YX'/&>E7Z .;\)V\,LU]K*VNIV\^HB(W']H((V+(I
M7 0 8P,#.,'WQ7+>)-&U2/7_ !=,;*YNX]8TM(;%H8FD 8*%*$@?+S\W.!WK
MT6[OK/3XEEO;N"VC9MBO-($!;T!/?@_E55/$6ARR+''K6GN[,$55ND)+'H ,
M]?:@#A&\.WR^*O \.HV,UW#IU@T5Y+Y)DB60QX4$XP?F Y^A->CI'!96JQPP
MK%#$N%CBCX4#L% _05-10!X9IGAC4$\!75NF@ZC%XC&I>=82+ \;1J=GS&0X
M4# 88)_QKH;W2=:C\5*VOVVH7MIJ>BQV5S-IT0D"R#&]6X.U2=QR,=1[X]2I
M* /+M4T2]3Q=?O%I=[);+X6>RB<Q-)F7;PFX#!;'&?K52VTW7=,M/!.H/8:D
M8-/@FM[N*VM]\T#/D!MC*<C&.<'@>XKUVB@#S2_T!['4_ T.F:=J'V'39YGD
M\Q&D:%'(V[R!QWX[#K63KGAW7M0N?'?V&PN0;R6UEMP\3*MRL9.\*3P>QQW[
M5[#52TU33M0DDCLK^VN7B_UBPS*Y3KUP>.A_(T >>>,;5_$/@'4I]+\,ZA:Z
MCJ,ENT\;VK+)(ZD9R.N% ZX .>]5/'&GZMJ<FNVVG>'KP+<V%L?M,49/VLJR
MMAMQ^7:,C:HW$CGCBO6:* /-Y-(GOOB!X:N;O2;B2S@TGRIFEMRR)(0V%;C&
M?KTXJ[XK\/WEIXJT'5_#\:02/G3+A8P%"PLI*L /[F"<>RUW72L>VL=%3Q/>
M74%RKZG*JM-!]IW%=JA0WEY^4X(&<=_>@"_/9C^R9+*U B'D&*(#@)\N!^5>
M;V=K<W'P$;2X+2>6^6.2W-O'&6<2+,<@@=.E>I5!#96]O<33PQB-[@AI=I(#
ML!C<1TSC SU.!Z"@#EM U.YTWP?HFG)IE^U\L-O;2(UG(JPGY5=F8@#"C)Z]
MJP/#VB7B:W>Z9K=CJK/%KAU.UN(D MY,]',F.H&<KGD'&,UZ?10!XG?Z#J\F
MA^($BT>^,]SXD^U0@6S[GARQ#=.G7\_>MK6].U2WUWQJSZ9>WBZUIJK82PV[
M2#(C*E"0/E.><'&<<<D"O4:AMKRUO5=K2YAN%C<QN8G#!7'53CH1Z4 >61Z;
MK-@W@^]FT_4S9V^F-974=M;^9-;N1@DH0>#P,@=!5ZX\-"'Q?X,@BTJ\DTK3
MX)UD,\9E$6X'RPY (ZX^E>BW5Y:V,/GWES%;Q9 WRN$7)Z#)I]O<07=NEQ;3
M1S0R+N22-@RL/4$<$4 <9XUL ^I^#]-TZ%(C%JR3K'$H4)%$"7P!P!@C\Q3_
M (L6%[JG@2XLM/M)KJXDFCVQPQEB<-DGCV%=:+*W%ZU[Y8-PR>7YA))"]<#T
M&>3CK@9J5F5%+,P4 9))Q@4 >:G3[Q?%OC"[&A7-U9W>E1QP0M$\:7)6)04!
MP,'J/7TJAHFEZJWB%KO4=#U%;2?PPUHT8BV[6&/W2X)(X!"[CN/!/6O5;6[M
MKZV2YM+B*X@D&4EB<,K?0C@U-0!POP\T[5](N]1T^YDGNM+@CB6QN;NW:*;;
M\Q\L[@"0N?H,\>@DU>POH_BSH^KK93S60L'MVEB3<$<EC\W]T<CD\5VU% 'B
M>H:#J\FA^($BT>^,]SXD^U0@6S[GARQ##CIU_/WK>U#1KN;QMX@MM4L-5N=+
MUR*W:"2SB!7]V.$=B/W?S<]1TYZUZ=52UU33KZ:2"TO[:XEB_P!8D4RLR<D<
M@'CD$?A0!1\5PRS>"]7MH8I)YI;":*-$4NSLR%0..O)%<;+X>>/X+&TM]&D7
M59+%('C6V(F9MX)!XSC.3Z5Z5TJ!;^S>]>Q2[@:Z1=S0"0&15XY*]0.1^= '
MD>MW6FZ+J<*ZA=S:=+J/AE;*=KFTD=4SA3M"\[A@Y!XZ<\UJK9PW6N^ KK1A
M<:GI&GV\J->K"S*!MV*6XX.Y3QVQ7?3:);R:E)J,4T]M<S1K%*\3_?522H((
M(XW'D8/-6-/T^UTNRCL[*(101YVKDGDDDDD\DDDDGWH \@C\.ZVWPM6S_LF\
M%S;ZV+EK<PL'\K/55[]>U>P.6NK!RJ,AEC.%D&",CC([58HH \?L/#^MCX;Z
M#8OIMW'+I&KK/>6[1G,D8D<DJ.KX!!XZYXSBNO\ !FG7\/B3Q1JL\,L%GJ%T
MAM8Y4*,VU2&?:>0#D=1SBNQHH \Y\2:5JD?C==6T)+OSY9[>&\MI8&>VNHQ@
MB3?C:I3W/!&1SP<#Q-HFLD>.[*'1[ZX?5)[6:U>& LCJKY;YNF1Z=?;&:]EH
MH \PU+2[[_A,'DO['5;C2-5T>.T+64&]HR,9C<$$H#R<\<D<]<=KJVEW-QX)
MNM)L6>.X>P:"'>^6#;, %O7MG\:VJ3K0!YEX=TC5/[>\)S_8;JUAT72GBOS)
M"R9<J5V#(^?YOF^7(_2L'1- UBUT7PE%)H]['-::XUQ<C[,^8X]R_,>.F/Y>
MU>UDA5+,0 !DD]J@L[^SU&)I;&[@NHU;:7AD#@-Z9'?D?G0!B_$#3[K5? NJ
MV5C"TUQ+#\D:]6PP.![X%<O?V5[>7_P_E&E7ICT\'[5OMF_<_(B@L,<?,#^6
M?2O2J* /&(]"\0IX*N#!IMZLMKXF_M#[-Y)626  8*AA\W/.,'ITKTGPK9V\
M%O=W=O!?P_;[@W$@OE".SD $[,#;T Z#IZ8)WJ* .<O-*L?$@UK1]1M)S;SN
MI#O"RC(11N1B,9!'^17%2>#O%$?PVU_P\\CW5S#<H+5NGVBW0(0 ?H",>HQ7
MK%0W5Y:V,!GO+F&VB!P9)G"*/Q- 'G-QHFJZMK/BB_L[.XBM+K0/L4,<T31&
M:8IQA6P>.1GIS526SUN#0O ]]%IFIA-&S%>P109G4E%7>L9!SCYNW?\ &O58
MY$FB66)U>-U#*RG(8'H0>XIU &1X7TZWTO1$M[2&ZA@9WD1+H_O!N8DY'\.2
M2<=L]NE>:W6FZS/K%C-%X;OK.WL_$HN&BBCW(4)!,N22Q+8.<80#'X^PTA('
M4XH \?U_0]4N7^('E:1>2-J+V@LR+9CYVQQOVG'08S6H]CJ=CXP34[C3;VZM
M;SPZ+.(Q6[.8I>"488^3.#R<#GZUZ+:7UGJ$32V5W!<QJQ4O#(' ;TR._(JQ
M0!R/PNL[O3OA]IUC?6DUK<P&4/',A5AF1F'!]F%<=JGAG77TWQ!HR6ER]_J.
MNK=6URL;&/RB00YDQA=H!XSD=A7K]58-4T^YNWM+>_MI;B,$O#',K.N.N5!R
M* /.M5TS4(_$?CJ1M+NYTU;3X[>S>.W9UED$"KU X 8CDX'!YXIUOX>U?1O$
M'@::>TGNH]/L9;>Y>!=_EN8R #Z#) R>.*]&@OK2YEEBM[J&:2$XD2.0,4/H
M0.E3T >/:OINM76IA[?PW?6L%MXF2Z9(H]RRK_%-DDL2V/X0% ]ZMW^E:G)?
M?$-DTR\(U*");0BW?]\54J0O'/)'\^E>J]:6@#S'PYI6H6WC7PS</IMU#!;^
M'([6>1K=E5)ADE2<=:Z+QTMT3HSV>CS7TD=^K>?"I9[08Y<+D G&1\WRCN#7
M65!)>6L5U%:27,*7$X)BA9P'D ZX'4X]J .0^%VGW^EZ+J5KJ-E<6LO]IS2*
M)U WJ<8((X/0\CBN=U20+\1/&L0LKB[DN-'2&-((&E8LT:@#"@D G'/3CDUZ
MC=7EK8P&>\N8;>)2 9)7"*"?<UG6?A[3X-?N?$-O)*UU?1JLC^8"CH -N!CT
M Y% 'G<.@Z]H<OA6:_M=0N+6+3)+.Z6QC$TENSDGE<'C!520/X>O3.A-X:\K
MQKX/BCTF\DTJPM94<SQF41;@VP.0",YQ].*],HH \V\3Z'?6GBB/4/#-O<13
M*8+::R^S$VEU#D=P-J;.>N,8R#GKEZUX;UQ[/Q9I265Q->:OJL4]G.L;&/R]
MX8$R=%V@8Y(]J]8N+F"S@>XN9XX(4&6DD<*J_4G@4L,T5S"DT$J2Q2#<CHP9
M6'J".M 'F6O:/J,OC'Q'<#3[JXCF\-26D,ZV[,))R!A0<=35<:?JZ:/X=LX_
M#UX;A=(FMIKM8SOB)4CRB&(503C+$'C[OK7K-5$U33I;YK"._MGNUSN@653(
M,8SE<Y[C\Q0!Y=8:5JJ:7\/XY-)OE?3KIVN@;=OW2[N">.!79?$W_DG.M?\
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M"K% &5X6_P"12T?_ *\(/_1:UJUE>%O^12T?_KP@_P#1:UJT %%%% !1110
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M6,20R>27C8D .$.,E<9 ..2,FL_6?!-S8V.B:9X?NM0M;.QEFD:>-UF:,L.
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MW%W!K.AM:VNQ,E)2,;&!^Z#UR>.M '97OB71=.GCAO-2MX'EB,T>]L!T )+
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M"D[6<X120, GL#UKS3QQH/B'5YO$$%CX?D2.2>WDBDMR@%UMZNY)W%AG@
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M115>2\6._@LS#.S3([B18R8UVXX9N@)SP.^#0!8HHHH **** "BBB@ HHHH
M**KWMXME$DC0SRAY$CQ#&7(+'&2!T SDGL*L4 %%5X;Q9[RYMA#.C6Q4%WC*
MH^X9^5NC8[XZ&K% !1110 4444 %%%9D&O6=U<ZG;PK.\NF8$Z>2P))7< HZ
MMD>G7(Q0!IT5%;3BZM8KA4DC$J!PDBE67(S@@]#ZBI: "BBB@ HJAK.LVF@Z
M>;Z]\WR0ZH3'&7.6(49QTY(Y-7Z "BBB@ HIK,J*7=@JJ,DDX %4EUFT?7GT
M0>;]K2W^T',9"[-VWACUY]* +]%%% !15#2]9M-8-X+3S?\ 0K@VTOF1E#O
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M@Y C?:.,+CCDD_C5>S\%Z38:I)>VS7<:23>>;,7+?9_-SG?Y?3.>?3('' H
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M @O+8(FQ)F!\M@2NX*6!'7NM='<>&K*;4+F^CEN+66]C$=V()-HG4# W<'!
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MON!!V*3@<$C/)Y/J:M6OAVWMI()3=74TMM T%M),ZLT*-C.#CDG:O+9/'UH
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M**!  N" 1R<GGFK55;>P2VO+NZ6:=VNF5F224LB;5Q\BGA<]3CJ:M4 %%%%
M!1110 4444 %%%% &5X6_P"12T?_ *\(/_1:UJUE>%O^12T?_KP@_P#1:UJT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61X7_
M .1?M_\ >D_]&-6O61X7_P"1?M_]Z3_T8U &7\3-3O\ 1? U[J>FW3VUU;M'
ML=0#]Z15.000>":QO%5[XDA\%Z;J&C:I.EZ+'[5/E$;S@%5FX(XX+'CTQ6_\
M0-#O_$OA"ZT?3A%YURR?/,Y55"NK=@?2I++3M1ACT2&:T@:.TM3!<GSL\E57
MY1CYA\O?'6@#G/$GC6\N_AO%K>A7'V:XDMA<2NJAO*PP1DY!&=YQSV5JJ^)?
M$.LZ;X$\*:I!JTT5QJ$EL+J4A,.)(]S<$8'/I5I_AQ<:?X$UG0-+>.6;4;@M
M$TTA"Q1!PR+G!Z#/;JQIVO>#M<U3P?X:T>".U6?2'@>9GG(5O+3;\I"YYZ\@
M4 4_^$ZU32)_%<XF.KZ/ID2&SO'5<&5MJ^7N0 , S'/?Y>O-:41UA_AD?$;:
MQ<_VN;$Z@) W[L?+O$?E_=V[>.F>^:ZO6M(M_$.@W.E7RE8KN+8^TY*'J"/<
M$ _A7-KX>\2IX'/A,26!'D&T%_YC?ZD_+GR]OWMO&-V.^>U '/:SXZU*\\+>
M%-<L[UM/.HW@M[Q4V[,!BKGY@<<@G/H:VM'U[5+KX@7^CV&HG5=(2TW_ &DJ
MC"VF[+YB@!OH<G\C4.O> +LZ/X;TC0UA-OHURL[O/(5,F#DXP#R22?QJYI?A
M/5/#?C6XU#1OLXT74P'N[)Y"IAE_O1X!'X<=2.PH S]4O-<TSQ_X;\/_ -O7
M<L%[ YNF*QAG95;D?+QR.E=@'N]%T%S<W+:A=(SB)G 5I2SD1*< #/S*I./>
ML+7?#6K7_P 1-%\06T=N;338V217E(=]P8<#&.,]S6[J>GW>HZI9JZQ_V=#N
MD<I<R1R^;T4C:.@!;^+DD>G(!C?#GQ+<>)?#3IJ+%=3L97MKL=&# \'';CCZ
M@U@6'BW6O#7BHV'BB\:XT;5)9$L;YE53 RN5VL5 ]!D_0],XV-*\(:IH'CW4
M-9TYK8Z5J$8$]O)<R-*7'._)4Y.<]6_B/-:-SX83Q!X4GT;7;:.,R22.K1/O
M\MB[,K*<#D9_F.AH 2*VU*?3$N?[:NE6W%UOP$W2L'Q'D[>BA3TQG-8WPWO-
M;\1^&K'6;W6IY)5N9!-&R($E09 & N002#D'M70Z)H][I'@J'2'9+B[AMVBW
M;L*Y)/.3]<U2^'/AW4?"OA9=)U(0F6.5W#PR%E8,<]P,4 ;&AZY#KUK/<0VM
MW;"&X> K=1;&8KU('<<]?K7/_%35]1T+P<^I:7>/:W,<R*&4*003@@@@BN@T
M*/6X[68:[-:33FX<Q&U4A1%_"#GOU_2L?XC^'=1\5>%FTG31")9)4<O,Y55"
MG/8&@#)A\1ZB/'FCZ;I6J'5[*ZMR]_'A'%KQPV]0-N?0G^8JG-XIN;/XDZ_I
M6HZ[/!IUI;Q-:Q*8PS2.L9"@E23DN?\ (K2;PAJ^F>+;/Q)H(MHFGB$6JV<D
MI"2XQ\RD _-WZ#D>YIL7A35T\?ZYKTUG:7%CJELD"PFX*NNU4&3\I'\&?;B@
M#K+,3:1HSMJ=\]T;?S7>X=0&9-S%<A0!D+@<#M7.^ _%-]K%]K>DZS'Y&HV%
MVS"(XXA8Y4>^.F?0BM"6R\0:E;Q1:A%9I%)=^9<11W3@I$H^148)DG<%8GCN
M._&7<>#-2L_B%:^)=$D@6'R?)O8[JZE9YU]<E6Y'RXY_A% %+2K_ %K5?B%X
MET/^W+JWM[&-&M2B1L8RP!YRIW#GH:U?AUXLN_$^E7<>I)&-0TZX-O.T8PLF
M.C =NA_+\*J:;X=\1:9XWU[7X;:QD34T58$DN6785  +80\<=JU?!'A$>$M*
MFBEN1=7MY,9[J8+M#,>P'H/ZGZ4 9_Q6UC4M \(?VCI5X]K<I<(FY0I!!SD$
M$&JNC:_J5W\17TK3]3;5-&%D'NGD" V\IS@*R@%OX?7[Q]*TOB3X;U'Q7X8_
MLK31 )6G60O-(54!<^@//-5G\*:MJ/CS3O$MU]FLH].MC$(H)3)).<-PQV@!
M?F]^GOP 8OAKQ)=ZCK6N:5J7B.YCGCU1K.P2/R@^W+\X*G. N<G^M7/'&L:U
MX>/A.$:P\+W5Q';ZA*H0+(/D#-R/EZL<C%2^&_"VN:)?ZY=7%A8W7]H:@;VW
M4794QMN8@$[#C[V,CWIWB;PQXCUX^&IV%FUQIEV+NZS*54G<&V)\IR!C )QV
MH 36O%+Z'X:U#Q-INJR:I: &WMXYMA03!]N]2H!*]>_\/'6G:DVL:;\-U\0Q
MZO<OJT5LEW([MF*3.&9#']T+@D# !X'-=#KOA:PU[PY>Z-*GV>.\)D)0<I(3
MNW#_ (%R?7GUK&O/#WB34?!4?A:=[&+,26\M^LK,6B7'(CVCYB!@C..3S0!A
MZUXUOK@^"=0M+]]/M=:DVWJ KM !0-RP.,$MS6QX6UW4[_QOK6E)>MJFB6\2
MM#>[5^24[<QAT #=6]QMJ+7? ]X]YX3CT>*#[#X?D#.)I<-(N4Z8!Y^4DYQR
M:G\/^%-5\)^*;YM*,#^'K_\ >FT:0J]O+WV#&".W4<8].0#$\+^);S5-4UG2
M]2\1W,=PNIM9V"1^4'"C=S@J<X"]3_6O2;".XBT^VCO)1-<I$JS2 8#N -Q_
M$YKA_#'A77-!NM9N+BPL;HWU^;VW NROEMEL G8>S8R/>NUTQ;U=-@&I-&UX
M5S-Y1R@8\D+GL.@^E '#^)/%RZ'XY>S\127UGI,UNGV"YMF94$G.]GV\L<X&
M#D#'3G-0^--:U?1O#OAZ?3M>>9[N]6&2[B",)XVR0W3 .,=*ZB_TS4;V;4K:
M\L;#4],NF4P07$I5H_D4'/RD8W D$<CKSGCE=4^'6JCPCX?T+3I8)FTN[^U2
MRS2% >68JO!/5N_I0!HZCKU]J?Q'M_!UE=26MI:VWVB]FC.)9>!A W\(Y7)'
M/)Z5T0T>[M]5@FMM3NOL(C=9K664R?,1\KAFRW'/!..167J7A6Z'C"U\6Z28
M5O1#Y%W:SN529,=G .&''8@X'2J]MX1OG^(;^*[F*TBB%KY:6R.79I/[Y.T
M'WY- &+IGBW6O#GB<:=XIO&N-)U5F%A?LJKY+!BNUB !Z9/T/0G$GCO6]:T'
MP#::C8:M<+>-?>4TS*A+*2_!&W'\(Z"NDN_"T?B+PC)HNN6\<;,S,C1/O\MM
MQ*NI('(S_,=#6!XD\#:UJGPZTKPU;/;/=6<B-+-+*55MH8<<$G.0: +'CRZ\
M4:+/;:AX>NY)X;.$S7EE(JMYT:L 2#C(.#S@].1TYT=+\4V>L)'K]I>S&P&G
MR32VW'[MT(W \9W $]\=#6RL=^^N17#VL:VXMFC9O-RP8D'ICD<=<_A6)HO@
M.TT/Q)JUU:A?[,U2#:UKVC<GYP!_=(_+ITQ0!4\"7=_XST>7Q!JMY<1K<3NM
MK;6TS1) BG ^[@LV<\MGZ5U.C6=]8VTT-_?/?.9V:.9P WEG&T$  9'3@<]>
M]<WH?A34_#6C7N@6\=IJ6F2L[6S3RE'C#?PN-I! /.1^51^&/"7B'PKH&FZ=
M97FGM*+SS=1D=&/F1'JJ'&2<<#./PH [64.T3B-MKE2%)['M7GNJ7FMZ9X]\
M-:!_;UW+!?0R&Z8K&&=E4G(^7CD5Z+7&Z]X;U;4/B'HFOVT=N;334=9 \I#O
MN!' QCC/<T 4=?U76O#7B/PI8-J=S>1WD]TMPJQ(SSJ"#&,!1@@. 2,#C)K;
MM_'FC7.@Q:M$+C;-=BRCMV0"5IR<"/&<9[]<8[U#XF\/:EJOB_PWJMJL)M])
MDE>8/(59MX4?*,=MOK7,Q?#;6F\)M9/+91ZA;ZR=3MMS%X7X'R/\N?T- 'H&
MC:W:ZW%<- KQR6EP]M/%(!NCD7J."0>H((/0UC^+O%=UH&J:+I]KI\EP^IW(
M0NK)]T8W*H9A\QR.3@<]<UKZ'92V=FWVBRL+.:5MSQ6*_(#C'7 +'WP/3MDY
M7BWPW?:SJF@ZE826_F:3=F9HIV91(IQG! .#QZ4 277C?2[2[GAECN/+M9HH
M+J<!2D$DGW5;YLG'&2 0,CWQ"?'MB=8OM)ATO5;B[L)XXIDA@#@!SP^0WW1P
M3G!YZ=<9UMX*U"Q\6:I>+!I-]I^JRK.S7<9,MO)_%M7:0P/ID=O3G1\.^'-1
MTKQ?XBU>Y:U:WU9XFB$<C%TV CY@5 YSG@]J *UW\3=*LQJ3R:=J1BTJY6VO
M)1''MC);:#]_D9].?:KD7CO2S>:G:W%O=VCZ;:?;',T8_>0XSN4 D^G!P>>G
M7'-:C\/-=O=,\56:3:>IUR^2XA8S/^[57W8;Y.O3I6FGA+6E\5:CK)&G,EUH
M_P!B2%Y'<>8 OWALP4)!!]NW:@#H]#UZ'7H//M[::*)HTE1W*,LBMG&"K$9&
M"".QIVNZ_9^'[6&>[\QVN)TMX(8@"\LC' 49('YD5C>"O",OA:[U5D*P65Y(
MCP6,<[2K 0#N(9@.I/IT S[6?&'AJ;Q!%IDUK(B76EWT=Y$LA(23:>5) .,^
MN#0!E^)_'#1^#=<N](CFBU'39/L\R2!-ULQ(&\\X(P>",\XXZXV_"5O<QZ+%
M<W5Y>3M=HDVR[=6,65&0",\$\]3U[5S-YX!U.[T7Q0JS6JW_ (AN$?:TC>7#
M&C94;MN2<9SQW]J[?2K>:TTFTMIPGFPPI&_EL67( '!('IZ4 8$_BRZ'Q%C\
M,Q:;,\*V9GDE5DR<LJAN6&%7YL_Q$]!QS@^$?'[0VDD?B":[N&EUJ2P@NO)7
MRTX&Q6(Q[] ??%=!-X;U!/B-'XFMI+=[=[#[)-'(S!U^?=E< @YQCDC'OTKE
M%^'_ (B&AQ6)6R\U/$/]JD^>V/+QC;]W[WZ4 ;A\76>D^(?%,]]>ZBT.F1P,
M]J\2>7%D #RR&R=Q(/.,9Y]NITK5%U:"29+>6%4<*"Y5A("JL&5E)#*0W7/4
M&N5;P?JI\2>)=2>+3;BVUE((TMYI'(*IM5@_R<94'D9P<=:T? _A>;PK87EH
MTW^CRW32VUN)3(+="!\NX@9YR>GY\F@#4U;7K;2+BRM9(Y9KF_D:.WBC RY"
M[CRQ ''J:R8/B%HUSHMAJ4*7+G4;H6D%ML E,N<%3SM&/7.*G\5:3K>K3:8-
M+N[:.UAG+WL$Y8"=<# ^7DCKE> <\UP]UX<U/PKX6TG26M;34K\:UY]H()C%
M(0 SY1F&%;Y>0<C'KQ0!UD_Q&TRVTC4]3FT_4%ATNZ%K<@+$663.T@#?R 2.
M?<8SSBT?&]BL#326&H1![F*VM1+!L^V/(,KY>3R/4G&*Y#^R;SQ3X4U[PQ:Z
M&-$U)[J*XNGO+KSA*SMO+%T4Y;Y/NX  (KI?&/A2^\1:'IB6KVL6H:;<1W,:
M39:%V48*GC./P_G0!<7QMI;VZ%4G-T]^VGBTPOF>>I^9>NW '.<XQCZ57G^(
M6DP6EA<&VO9!?7IL0D<:LT4X;:48;O7TS6;KO@G4=4LM-N[6UT>SU&PO/M/V
M1$/V:0$ ,K':"2<==OM[U+K7A'5-230FM;?2K-M/U-+^>&)F1/E(^52$^8G'
MWB!]* 'S?$[2[>SOKF?3-2C&FW0MKU3'&3;DG )(?# G^Z2>.G3.IJWC/3=)
MN+B%XY[@VENMU=- JD0Q$X!.2,GO@9.!],\GJ7P\UV]TSQ39I-IZG7+Y+B)F
MF?\ =JK[L-\G7ITK1N/!>IQ^+CK4%OI5[#>6<<%W;WNXB-U  9#M.1@=#C/M
MV -#4?B%INGZA>V2V%_=26=E]N=H$0HT. =P)<=CWQ[9JOJOCQH[[PU#I=A/
M=1:X#,K@H&*!<E0&8 -RN<D#'3)Z5-3\$:O=:_K5[;O8+!J&BG38E+LA1B -
MQ4(0!P> 3VH7P1K$,/@^6*:R-SX>5XYD:1]DBLH7*G;G(VYP0.O6@#O0<@$C
M'L>U<U:>+[77K&[;3([E8UCG"70V;5:/C! 8E2<Y 8#(YKI:X.P\#7]EX@NM
M8@2ULVNK*2*Y@MIV,=U,WW6VE0$]3C//3OD ;X#\>B]T;0;36GNI-1U03B.Z
M>$+'*R.WR@C'(7;T&/?-;'_"?:/YY&V?[(+_ /L[[;M7RO/QG;UW8[;L8S^=
M<UI/@/7K&+P;'*+,_P!@S7#W!68_.)'R-OR]AZXJ8_#:]^PG0Q<0?V8=:_M+
MS][>;Y>/]7MQC.?XL].W:@#;O/B'I5BFN-+9WQ_L*2)+H*B'/F$A2OS\CCV/
M-59?$-V/B=86:WCII=SHYO'A<* &R?FSC(X [XK,UWX?ZY?7/BJ.PGL/LWB#
M[.X>>1PT31G)& IZ\\Y_#TNW/@[5+WQ3:7LWV=+--$;39BDI+AF#9905&1SW
MQ0!4U7QQ/?ZOX7GT62\@T_4-0,#/)$HCNHPV"1U8<YZ[2:]%(R".E>96G@GQ
M/%9^%[&2/3]GA^]:5I?M#?OTW9&!L^4XX[\^E>G4 >;>$_B ]KI=Y-XCENYX
MDUB2T2]\I?+A7"[0Y&#Z\@'KSVKJ-4\:Z7I-W>02I/(NG+$U]+&H*VPD.$W9
M()]> <"N27X=ZQ-X;O/#MPULL&H:L;Z6X24DQQ$C*A<<O\H]N>O'.K-X+OX/
M&NH:K:P:5>V&JI&)H[]2S0.@P&4;2&&.<9&?48S0!W ((!!R#WKE[/Q]8ZAJ
MDVG6NE:K+/;7HL[@I;AEA;)&]F#$!,@\_I74*H50HZ 8X%<MX1\-ZAH>I^(+
MF^:U:/5;UKF,0R,Q4$GALJ/7M0!8LO&^E7][:P1+.(;V2:*UNF"^7,T7W@.<
M^N"0,X/MF+3?'NDZIJ.G6D,5RJZHDK64[JNR7RR0PX.5Z'J!67X/\%:EX:#6
M$L.DSVMO,\EI?&,M<@'.%(*X!R>N[IQ[BGI?@3Q-%X@T/6M4OM/NKFPEG-U(
M&DWRK(" 02N. <!< #'O0 GC/QW*VEQ7/AV:[B6'5$LWNQ&AAE/\:C.3QQS@
M#K@FO2*\IE^'?B.+PS_PC=L+%X(-6%Y#<R7#*7CYPI4*<'U/->JKN*C< &QR
M <@&@#G9/&VG)J7V2.WNYXUOET^2YBC#1I.1G:>=W'0G& 341\?Z2-0@M1%<
MF.?4&TU;@*NS[0,?*1G=U.,XQ^'-5= \-Z]X<\0ZK]DFL9M(U.[-WF5G$L+,
M?F 4##9Z=1T!]CDWO@3Q1J&JP:A=W^G7$EKK27L+.T@/D*<B/IA<8Z ')))/
M'(!OR>/;%=9OM(BTO5+B\L)8TE2" /P_1QAONC@G.#STZXG'C;2SJ M@LQA:
M_P#[.%UA?+^T[<[.N[VSC&:@T'PYJ.F>-?$&M7#6K6VJ^5Y0CD8NFP8Y!4#G
M.>#Q[UGZ!X*O]#UN^5K?2;O3KB^-Y#<3(6N("3DJ!MQVX.X8Z^U &5I_BJ_F
MU;Q'K.IRZG#9Z#=D?98#$5,8!4HR[L%L_-D'MP>@KK+/QCIVIZO9Z/%#>13Z
MAIRW\,C*H41,..0Q(;VQVK$@\"ZH;'Q?:W,UHG]ORO+ T<C-Y9.<!@5'J.1F
MFZ%X0\06'B32=8O/[/*:?HRZ<8HIG+,5SALE .>/3&>^,D P-/\ &'B&;PGX
M6OY-4D:XO=<%I<-L3]Y$7Q@C'' ZBNZ@\;65Q=:Q:)I]^+G1]OGP,L8:3<?E
MV?/SGKVZCN<5R%G\/O$-MX:T#3&6R:;2]7%]*PG.UD!S@?+UY/Y5NKI=AK7Q
M&AUW2[Y72""2WU&*/HTD;KY8;W#9/_;,=J .U4EE!*E21G!ZC\J\YTGQU/I>
MH>*&UM[V[L-.U$0I+'"K"VC)(&[&"1G'3)KT>O.+KP-KDMOXILD^R^7XAO!*
MDQE/[A ^3N7')QT /7KB@#IM3\:Z7ILLR!9KH6]JMW</;A2L4+' 8Y(SGK@9
M.!GTS'J7CK2]/EN%2&ZO4LXX9;J2U0.(5E/R$C()R.> >.:QI/ =Y8>*4U'3
MH=-O[*6RBM)X-1!RGEJ%5UPISPHXX[_46H/"VN:+XTN]8T:6PDL]2ABCN89]
MT?E,BA0R!0<C /RY'7&1UH N:OX_TC1I[Q)XKF2.PEBBNY8U7;"9!E<@D$CU
MP#4]]XTL+#6=0TJ6UO&GT^P;4)"BIM>)2 =I+=>>AQT-<SXO\!^)?$\NKH^H
MV#V\YA-B)=X, 7[PP!A<_P![YB< <#I=UWPAK=]XEO-6LI+'&H:*^G3+-(X\
MIF.=RX4[AV[?TH TD\?:7-#I;06]U++JL#SV\&$5RJ]1\S %CV ))J74?&^F
MZ<\JO#<RFVM4N[KRU7_1XV( +9(Y[X&3@'VSS=[\/+^^\&:=H=S!82W%C;,D
M5RMPZ-!-GY64[.5(^\IQT&/6K+^!]5M?%*ZM%_9NK1W-E%;7BZD#G>BA?,7Y
M6SG&2..IY[@ [N*1)HDEB8.CJ&5AT(/0USEYX^TBRN+Q9$N&MM/N$MKN[55\
MJ&1N #SDX/!(!QFNCAC$,$<0"@(H4!5VC@=AV'M7GVI?#F_N;?7-+M[BW%AK
M>HI>/,S'S(1NW.H7&&Y''(Z\^X!LZK\0=/TK4=2L'T[49YM,@%Q.840KY9Q\
MP)<>O3K5#4/$UW)XY\)KIMU*VF:O:S3O %7]Z!$73KR#R.XJ+5? ^L7>L^(K
MJVDL5@U735LH!),X9" HRWR'T/3/:E@\(ZQ:ZQX0O9?LGD>'[)H+EEF;YB8]
MF5RHXZ'G% &UI'C:RUJS:XM-/OMT=]]AD@=8UD23N2-_0=^_!XXKI*XKPSI-
MC<>,M3\2:5>K/IE]%%*J)]S[00P9O8[?_1A]J[6@#*\+?\BEH_\ UX0?^BUK
M5K*\+?\ (I:/_P!>$'_HM:U: "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K(\+_ /(OV_\ O2?^C&K7K(\+_P#(OV_^])_Z,:@#
M1N[NWL+62ZNI5AAC&6=CP*H-XBLD\4)X=99A>R6WVE#M&PIDC.<]<@\5ROQC
MB#^%K%F+@+J4(;:Y48.<YP?ISVK*\1V=M)\2XH(KB=88_#<K*\=R^XX>0C+Y
MW'GW[>E 'JE%>2:/K6KZEI7@"UN[J=K74))UO)?,(:8QDA%9AR>G3OCVJ.VU
M#Q1J'A??8W#7;:?J]P(;::9E:^MD'W0X(+%=Q[\X[[: /7Z*\E/B*;5M0\.V
M"7$]KIVH:3*\)N[QXR9R67YI ,N5 R,]20>N*])T);D:#9I>WB7LZPA9+F/.
M)2.-P^O7- %N"[M[F2>."99'MI/+E"_P-M#8/OA@?QJ:O$;"[N=#\!^,K_39
MIDU"/5IH0WGN62,M&&;:3U&?OXR,]:VO$<UW:>!O$.HV.M*;:2.UGLH[6\DD
M>V)958^9P</UQZYH ]4HKRWQG:7.B?#*XU>#6M4:]NA:.TC7;#8W .P#&T$,
M<CZ>E5-6^T0>(/&-@FIZA]FM=%%Y$OVR3B8("&SG/4].GMP, 'KM(3@$\\>E
M>1:IJNN_\(SH6N">74+6+25.HVT=RT4RAN/M"D$98;<9YQSQR37J:R)=:0)
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M'_ DM]?WL<MWJ36\LL<[1M/$' &[!YXXSU[T >Q7%Q#:6TES<2+%#$A>1V.
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MS7M+%[<S6BV=O,L<\[2;7*KDC<3C.3TXZ>@J/XH01RZCX1,K2*C:S$CE960
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MFO;^ZDM([0,H*R1G#[FSC:.#D=<BJ?PVU&^OKCQ+'>3W,BVVK2Q0QW$ID:%
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M:+::0H06C.&! )/X_P#ZZF\)>*-0\0ZUKD$]@8+>PNVMD.]3L*\$''4DY/'
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M5X6_Y%+1_P#KP@_]%K6K65X6_P"12T?_ *\(/_1:UJT %%%% !1110 4444
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M=@3VJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_ "*6C_\
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M#^>@R_'.Y?4]Q7FNG/#8?#S0YX8HHK.ZU<1:E+&H7,'GR ;R/X<[0<]CCH:
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M"R,N""I((P2".Q_ UIZ7XTB::/2KNQO(]0_LY;R)9/+_ -*3')4AL Y!X;%
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MO:SJ#V935S$RQP.S&,H",<J,]3S[=!G F\5>&[[6-7T'4["6W632;EI&CG+
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MBBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\
M7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_
M "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM
M:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H
M UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_
M ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O
M_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO
M"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/
M"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG
M_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R
M+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_
MZ+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6
MC_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:R
MO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$
M'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?
M^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(
MI:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\
MR+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJ
MUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_
M +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"
M_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\
M7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_
M "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM
M:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H
M UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_
M ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O
M_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO
M"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/
M"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG
M_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R
M+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_
MZ+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6
MC_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:R
MO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$
M'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?
M^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(
MI:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\
MR+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJ
MUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_
M +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"
M_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\
M7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_
M "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM
M:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H
M UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_
M ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O
M_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO
M"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/
M"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R+]O_ +TG
M_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_Z+6M6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R/"_P#R
M+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6C_\ 7A!_
MZ+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:RO"W_ "*6
MC_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *R/"_P#R+]O_ +TG_HQJUZR/"_\ R+]O_O2?^C&H UZ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO"W_(I:/_ ->$'_HM:U:R
MO"W_ "*6C_\ 7A!_Z+6M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 9']AW/_0P:I^</_P ;H_L.Y_Z&#5/SA_\ C=:]% &1_8=S_P!#!JGYP_\
MQNC^P[G_ *&#5/SA_P#C=:]% &1_8=S_ -#!JGYP_P#QNC^P[G_H8-4_.'_X
MW6O10!D?V'<_]#!JGYP__&Z/[#N?^A@U3\X?_C=:]% &1_8=S_T,&J?G#_\
M&Z/[#N?^A@U3\X?_ (W6O10!D?V'<_\ 0P:I^</_ ,;H_L.Y_P"A@U3\X?\
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M_P"-UKT4 9']AW/_ $,&J?G#_P#&Z/[#N?\ H8-4_.'_ .-UKT4 9']AW/\
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MVEC6,B2;*C>HP -HSQN()'<#4U$8\::(P9ANM[H$;C@X\O''3N>: -ZBBB@
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M0X.,MC&?4CI[C(!I454TR_35-/BO8XI(DER0LF-W!(SP2,'&1@]*MT %%%%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit103-form147_716ba007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit103-form147_716ba007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK&IQZ-HU
MYJ<R-)':0M,R)U8*,X&:NUC>,+6>^\':Q:6L32SS6<J1QKU9BI  H BA\32I
M>6MOJ>C7>G+>/Y<$TCQR1L^,A248E2<<9&#6LM]9O=M9I=P-<H,M") 7 ]2O
M6N:NY;WQ))I=E#H]]:0VUY#=7%Q=HL8 B.X*HR226 '3&,UFV&DWBPZ3IO\
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M=1N!=PRVD8D(;RT1D89!'W 0>G/48J2YO-3FTFW36M$F>&\$GVF.PD8R6_S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L_4-"TG5I4EU#3[>Y=%VAI
M$!.WK@^H]CQ6A10 @ 50J@  8 ':EHHH **** "BBB@ J*WMH;2!8+>)8HES
MA$& ,G)_4U+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH.]/LM7L-06<VEP)6MCMFC"GS(SC.&3&X'VQS7FMA]H'@[P[L :(>)@+(.Q
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M^SJ?\\5UEDER\KW<MR[13Q1E+8HH$)P=V".3G(Z],4 7**** "BBB@ HHHH
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M%[&A$]RJ+*V\D,%SMXS@=3TJQ10 4444 %%%% !1110 4444 %%%% !1110
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M_N\9]\^U2:MX2U34[W5[A9K6W:Z:UFM'#L^R2 Y&\;1\I)['CWKLJ* .-O\
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M)/H7_06M?^_@H_X2?0O^@M:_]_!6K10!E?\ "3Z%_P!!:U_[^"C_ (2?0O\
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MK_W\%:M% &5_PD^A?]!:U_[^"C_A)]"_Z"UK_P!_!6K10!E?\)/H7_06M?\
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MC_A)]"_Z"UK_ -_!6K10!E?\)/H7_06M?^_@H_X2?0O^@M:_]_!6K10!E?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,CPU_R#KC_L(7G_ *425KUD>&O^0=<?
M]A"\_P#2B2M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,C5_^0QH7_7W)_Z(EK7K(U?_ )#&A?\ 7W)_Z(EK7H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &1X:_P"0=<?]A"\_]*)*UZR/#7_(.N/^PA>?^E$E:] !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&K_\
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M#(\-?\@ZX_["%Y_Z425KUD>&O^0=<?\ 80O/_2B2M>@ HHHH **** "BBB@
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M/(DM9C(C^6'!S&\; @\?=<]>,@<'I6??>!]$NE@-M;)8RP31RQR6Z ;"K!N
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MCS-7_P"?2R_\"7_^-T 7Z*H>9J__ #Z67_@2_P#\;H\S5_\ GTLO_ E__C=
M%^BJ'F:O_P ^EE_X$O\ _&Z/,U?_ )]++_P)?_XW0!?HJAYFK_\ /I9?^!+_
M /QNCS-7_P"?2R_\"7_^-T 7Z*H>9J__ #Z67_@2_P#\;H\S5_\ GTLO_ E_
M_C= %^BJ'F:Q_P ^EE_X$O\ _&Z/,U?_ )]++_P)?_XW0!?HJAYFK_\ /I9?
M^!+_ /QNCS-8_P"?2R_\"7_^-T 7Z*H>9J__ #Z67_@2_P#\;H\S5_\ GTLO
M_ E__C= %^BJ'F:O_P ^EE_X$O\ _&Z/,U?_ )]++_P)?_XW0!?HJAYFK_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^: $TWP]I6D2^;96OEN(Q"K-([E(P<[%W$[5SV&!6G5#^Q[7_GK>_P#@=/\
M_%T?V/:_\];W_P #I_\ XN@"_15#^Q[7_GK>_P#@=/\ _%U#<V.G64)EN;J[
MB3U:_GY[\?/['\J -6BLQ-/TZ2U6Z2[NF@9!(LHU"8J5QG=G?TQSFGKI-FZ*
MZ3WC*PR"+^;!'_?= &A15 Z/:CDRWO'_ $_3?_%U%:V6FWUNMQ:WEU/"Q(62
M/4)BIP2#@[_4$4 :E%4/['M?^>M[_P"!TW_Q=,&F6/G& 7-WYH7>4^WS9P3C
M/W^G!H TJ*H?V/:_\];W_P #I_\ XNH;NRTVQMVN+N\NH(4^\\FH3*!V_OT
M:M%9-W;:38(KWNH36RNVU6FU.5 Q/89?DTZVL=-O(O.M;VXGCR1OBU&9ER.H
MR'H U**H?V/:_P#/6]_\#I__ (NC^Q[7_GK>_P#@=/\ _%T 7Z*H?V/:_P#/
M6]_\#I__ (NC^Q[7_GK>_P#@=/\ _%T 7Z*H?V/:_P#/6]_\#IO_ (NC^Q[7
M_GK>_P#@=/\ _%T 7Z*S9=,L8$WRW%VB[@N6OY@,D@ ??[D@4_\ L>U_YZWO
M_@=/_P#%T 7Z*H?V/:_\];W_ ,#I_P#XNC^Q[7_GK>_^!TW_ ,70!?HK'\C2
M?MPLOMUS]I()$7]H39. "?X^H!!QZ$5'$V@3RB*'6#)(7,81-6D)+#JN-_7V
MH W**H?V/:_\];W_ ,#IO_BZ/['M?^>M[_X'3_\ Q= %^BJ']CVO_/6]_P#
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M_P#\71_8]K_SUO?_  .F_P#BZ +]%4/['M?^>M[_ .!TW_Q=']C6O_/6]_\
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M\#I__BZ/['M?^>M[_P"!TW_Q= %^BJ']CVO_ #UO?_ Z;_XNC^QK7_GK>_\
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MD>&O^0=<?]A"\_\ 2B2M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&U?WD+% 6Z;ONLS[LX&WT!KK%C1&9E15+'+$#&3[TGEQF02[%W@8#8YQZ9H
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M0 4444 %%%% !1110 4444 %%%% !1110!D:O_R&-"_Z^Y/_ $1+6O61J_\
MR&-"_P"ON3_T1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&1X:_P"0=<?]A"\_]*)*UZR/#7_(.N/^PA>?^E$E:] !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&K_\ (8T+_K[D_P#1
M$M:]9&K_ /(8T+_K[D_]$2UKT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!D>&O^0=<?\ 80O/_2B2M>LCPU_R#KC_ +"%Y_Z425KT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D:O_ ,AC
M0O\ K[D_]$2UKUD:O_R&-"_Z^Y/_ $1+6O0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &1X:_Y!UQ_V$+S_P!*)*UZR/#7_(.N/^PA>?\ I1)6
MO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &1J_P#R&-"_Z^Y/_1$M:]9&K_\ (8T+_K[D_P#1$M:] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 9'AK_D'7'_80O/\ THDK7K(\-?\ (.N/
M^PA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 9&K_\AC0O^ON3_P!$2UKUD:O_ ,AC0O\ K[D_]$2UKT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!D>&O\ D'7'_80O/_2B2M>L
MCPU_R#KC_L(7G_I1)6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &1J__ "&-"_Z^Y/\ T1+6O61J_P#R&-"_Z^Y/_1$M
M:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'AK_D'7'_ &$+
MS_THDK7K(\-?\@ZX_P"PA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 9&K_P#(8T+_ *^Y/_1$M:]9&K_\AC0O
M^ON3_P!$2UKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>&O
M^0=<?]A"\_\ 2B2M>LCPU_R#KC_L(7G_ *425KT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!D:O\ \AC0O^ON3_T1+6O6
M1J__ "&-"_Z^Y/\ T1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &1X:_Y!UQ_V$+S_ -*)*UZR/#7_ "#KC_L(7G_I1)6O0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J__(8T+_K[
MD_\ 1$M:]9&K_P#(8T+_ *^Y/_1$M:] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9'AK_ )!UQ_V$+S_THDK7K(\-?\@ZX_["%Y_Z425KT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D:O
M_P AC0O^ON3_ -$2UKUD:O\ \AC0O^ON3_T1+6O0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% &1X:_Y!UQ_P!A"\_]*)*UZR/#7_(.N/\ L(7G
M_I1)6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% &1J_\ R&-"_P"ON3_T1+6O61J__(8T+_K[D_\ 1$M:] !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 9'AK_D'7'_80O/_ $HDK7K(\-?\
M@ZX_["%Y_P"E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9&K_ /(8T+_K[D_]$2UKUD:O_P AC0O^ON3_ -$2UKT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?]A"\_P#2
MB2M>LCPU_P @ZX_["%Y_Z425KT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!D:O_R&-"_Z^Y/_ $1+6O61J_\ R&-"_P"O
MN3_T1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_P"0
M=<?]A"\_]*)*UZR/#7_(.N/^PA>?^E$E:] !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 9&K_\ (8T+_K[D_P#1$M:]9&K_
M /(8T+_K[D_]$2UKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!D>&O^0=<?\ 80O/_2B2M>LCPU_R#KC_ +"%Y_Z425KT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D:O_ ,AC0O\ K[D_
M]$2UKUD:O_R&-"_Z^Y/_ $1+6O0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &1X:_Y!UQ_V$+S_P!*)*UZR/#7_(.N/^PA>?\ I1)6O0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J_P#R
M&-"_Z^Y/_1$M:]9&K_\ (8T+_K[D_P#1$M:] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 9'AK_D'7'_80O/\ THDK7K(\-?\ (.N/^PA>?^E$
ME:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9&K_\AC0O^ON3_P!$2UKUD:O_ ,AC0O\ K[D_]$2UKT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!D>&O\ D'7'_80O/_2B2M>LCPU_R#KC
M_L(7G_I1)6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &1J__ "&-"_Z^Y/\ T1+6O61J_P#R&-"_Z^Y/_1$M:] !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 9'AK_D'7'_ &$+S_THDK7K
M(\-?\@ZX_P"PA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9&K_P#(8T+_ *^Y/_1$M:]9&K_\AC0O^ON3_P!$
M2UKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?]A"
M\_\ 2B2M>LCPU_R#KC_L(7G_ *425KT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!D:O\ \AC0O^ON3_T1+6O61J__ "&-
M"_Z^Y/\ T1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X
M:_Y!UQ_V$+S_ -*)*UZR/#7_ "#KC_L(7G_I1)6O0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J__(8T+_K[D_\ 1$M:
M]9&K_P#(8T+_ *^Y/_1$M:] !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 9'AK_ )!UQ_V$+S_THDK7K(\-?\@ZX_["%Y_Z425KT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D:O_P AC0O^
MON3_ -$2UKUD:O\ \AC0O^ON3_T1+6O0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &1X:_Y!UQ_P!A"\_]*)*UZR/#7_(.N/\ L(7G_I1)6O0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1
MJ_\ R&-"_P"ON3_T1+6O61J__(8T+_K[D_\ 1$M:] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 9'AK_D'7'_80O/_ $HDK7K(\-?\@ZX_["%Y
M_P"E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9&K_ /(8T+_K[D_]$2UKUD:O_P AC0O^ON3_ -$2UKT %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?]A"\_P#2B2M>LCPU
M_P @ZX_["%Y_Z425KT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!D:O_R&-"_Z^Y/_ $1+6O61J_\ R&-"_P"ON3_T1+6O
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_P"0=<?]A"\_
M]*)*UZR/#7_(.N/^PA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 9&K_\ (8T+_K[D_P#1$M:]9&K_ /(8T+_K
M[D_]$2UKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=
M<?\ 80O/_2B2M>LCPU_R#KC_ +"%Y_Z425KT %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!D:O_ ,AC0O\ K[D_]$2UKUD:
MO_R&-"_Z^Y/_ $1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &1X:_Y!UQ_V$+S_P!*)*UZR/#7_(.N/^PA>?\ I1)6O0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J_P#R&-"_Z^Y/
M_1$M:]9&K_\ (8T+_K[D_P#1$M:] !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 9'AK_D'7'_80O/\ THDK7K(\-?\ (.N/^PA>?^E$E:] !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&K_\
MAC0O^ON3_P!$2UKUD:O_ ,AC0O\ K[D_]$2UKT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!D>&O\ D'7'_80O/_2B2M>LCPU_R#KC_L(7G_I1
M)6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &1J__ "&-"_Z^Y/\ T1+6O61J_P#R&-"_Z^Y/_1$M:] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 9'AK_D'7'_ &$+S_THDK7K(\-?\@ZX
M_P"PA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 9&K_P#(8T+_ *^Y/_1$M:]9&K_\AC0O^ON3_P!$2UKT %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?]A"\_\ 2B2M
M>LCPU_R#KC_L(7G_ *425KT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!D:O\ \AC0O^ON3_T1+6O61J__ "&-"_Z^Y/\
MT1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_Y!UQ_V
M$+S_ -*)*UZR/#7_ "#KC_L(7G_I1)6O0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &1J__(8T+_K[D_\ 1$M:]9&K_P#(
M8T+_ *^Y/_1$M:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9
M'AK_ )!UQ_V$+S_THDK7K(\-?\@ZX_["%Y_Z425KT %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!D:O_P AC0O^ON3_ -$2
MUKUD:O\ \AC0O^ON3_T1+6O0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &1X:_Y!UQ_P!A"\_]*)*UZR/#7_(.N/\ L(7G_I1)6O0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J_\ R&-"
M_P"ON3_T1+6O61J__(8T+_K[D_\ 1$M:] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 9'AK_D'7'_80O/_ $HDK7K(\-?\@ZX_["%Y_P"E$E:]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9&K_ /(8T+_K[D_]$2UKUD:O_P AC0O^ON3_ -$2UKT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!D>&O^0=<?]A"\_P#2B2M>LCPU_P @ZX_[
M"%Y_Z425KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!D:O_R&-"_Z^Y/_ $1+6O61J_\ R&-"_P"ON3_T1+6O0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_P"0=<?]A"\_]*)*UZR/
M#7_(.N/^PA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9&K_\ (8T+_K[D_P#1$M:]9&K_ /(8T+_K[D_]$2UK
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?\ 80O/
M_2B2M>LCPU_R#KC_ +"%Y_Z425KT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!D:O_ ,AC0O\ K[D_]$2UKUD:O_R&-"_Z
M^Y/_ $1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_Y
M!UQ_V$+S_P!*)*UZR/#7_(.N/^PA>?\ I1)6O0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &1J_P#R&-"_Z^Y/_1$M:]9&
MK_\ (8T+_K[D_P#1$M:] !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 9'AK_D'7'_80O/\ THDK7K(\-?\ (.N/^PA>?^E$E:] !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&K_\AC0O^ON3
M_P!$2UKUD:O_ ,AC0O\ K[D_]$2UKT %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!D>&O\ D'7'_80O/_2B2M>LCPU_R#KC_L(7G_I1)6O0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J__
M "&-"_Z^Y/\ T1+6O61J_P#R&-"_Z^Y/_1$M:] !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 9'AK_D'7'_ &$+S_THDK7K(\-?\@ZX_P"PA>?^
ME$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 9&K_P#(8T+_ *^Y/_1$M:]9&K_\AC0O^ON3_P!$2UKT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?]A"\_\ 2B2M>LCPU_R#
MKC_L(7G_ *425KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!D:O\ \AC0O^ON3_T1+6O61J__ "&-"_Z^Y/\ T1+6O0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_Y!UQ_V$+S_ -*)
M*UZR/#7_ "#KC_L(7G_I1)6O0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &1J__(8T+_K[D_\ 1$M:]9&K_P#(8T+_ *^Y
M/_1$M:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'AK_ )!U
MQ_V$+S_THDK7K(\-?\@ZX_["%Y_Z425KT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!D:O_P AC0O^ON3_ -$2UKUD:O\
M\AC0O^ON3_T1+6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M1X:_Y!UQ_P!A"\_]*)*UZR/#7_(.N/\ L(7G_I1)6O0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J_\ R&-"_P"ON3_T
M1+6O61J__(8T+_K[D_\ 1$M:] !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9'AK_D'7'_80O/_ $HDK7K(\-?\@ZX_["%Y_P"E$E:] !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&K_ /(8
MT+_K[D_]$2UKUD:O_P AC0O^ON3_ -$2UKT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!D>&O^0=<?]A"\_P#2B2M>LCPU_P @ZX_["%Y_Z425
MKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!D:O_R&-"_Z^Y/_ $1+6O61J_\ R&-"_P"ON3_T1+6O0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &1X:_P"0=<?]A"\_]*)*UZR/#7_(.N/^
MPA>?^E$E:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 9&K_\ (8T+_K[D_P#1$M:]9&K_ /(8T+_K[D_]$2UKT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!D>&O^0=<?\ 80O/_2B2M>LC
MPU_R#KC_ +"%Y_Z425KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!D:O_ ,AC0O\ K[D_]$2UKUD:O_R&-"_Z^Y/_ $1+
M6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1X:_Y!UQ_V$+S
M_P!*)*UZR/#7_(.N/^PA>?\ I1)6O0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &1J_P#R&-"_Z^Y/_1$M:]9&K_\ (8T+
M_K[D_P#1$M:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'AK
M_D'7'_80O/\ THDK7K(\-?\ (.N/^PA>?^E$E:] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9&K_\AC0O^ON3_P!$2UKU
MD:O_ ,AC0O\ K[D_]$2UKT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!D>&O\ D'7'_80O/_2B2M>LCPU_R#KC_L(7G_I1)6O0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1J__ "&-"_Z^
MY/\ T1+6O61J_P#R&-"_Z^Y/_1$M:] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 9'AK_D'7'_ &$+S_THDK7K(\-?\@ZX_P"PA>?^E$E:] !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&K
M_P#(8T+_ *^Y/_1$M:]9&K_\AC0O^ON3_P!$2UKT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!D>&O^0=<?]A"\_\ 2B2M>LCPU_R#KC_L(7G_
M *425KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!D:O\ \AC0O^ON3_T1+6O61J__ "&-"_Z^Y/\ T1+6O0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &1X:_Y!UQ_V$+S_ -*)*UZR/#7_
M "#KC_L(7G_I1)6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %#4]+&I&V=;RXM);64R1RP!"02K*1AU88PQ[57_L:_\
M^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&
M:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\
MH9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QF
MC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[
M]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(
M_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\
MOW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\
M^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&
M:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\
MH9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QF
MC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[
M]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(
M_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\
MOW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\
M^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&
M:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\
MH9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QF
MC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[
M]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(
M_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\
MOW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\
M^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&
M:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\
MH9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QF
MC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[
M]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(
M_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\
MOW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\
M^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&
M:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\
MH9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QF
MC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[
M]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(
M_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\
MOW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\
M^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&
M:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[]VO_ ,9K7HH R/[&O_\
MH9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(_L:__P"AGU3_ +]VO_QF
MC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\ OW:__&:/[&O_ /H9]4_[
M]VO_ ,9K7HH R/[&O_\ H9]4_P"_=K_\9H_L:_\ ^AGU3_OW:_\ QFM>B@#(
M_L:__P"AGU3_ +]VO_QFC^QK_P#Z&?5/^_=K_P#&:UZ* ,C^QK__ *&?5/\
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MZW;*Q5Y-&C2S.< %FF#D>^?+S]!7/ZA:7U_I4 TR*=#:^'S;7*QJ0ZLS19C
M_OA8Y..HR/44 =]'J-I-:R74<P:"-2QE"G:0.I!Z,..HS34U:Q>[%HLX\XML
MVE2!NV[MN<8W;>=N<XYQ6#9M<S7MQIL<YNM+E> 6\A5<*H5FE3Y0 5PJ#V,A
M';%4(K.Y#0:=M;[9'XBDNW./^6)=Y _^Z48+GU.* .KLM:T_4+J:UM;@/-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#,E\1:3!=R6LUWY<D,BQ2%XV54=ON@L1M!.1CGG-:=<7_9,/B#Q!XET
M^>X9+26:V,J(!F4(BD@,>V1@XY[9%,75;QM?;[/<7D:-]NB<3H[A'0CRR5 V
M@<$J!R5Y))- ';TUF5%+LP55&22> *\\L]:NI-/GO;;49I62VM/.M?,>:5 '
M'VB4+P<;2.G(P<8)KKO#I$NG2L+V:^@DF9HI)HV7Y"!\HW$LR@YY/T[4 2:=
MXBTK5KDV]E<F241F3:8G7*@@9^8#/4?G44WBK18)5BDO,,P4C$3D?-]WD# S
MD?F*AD:6:XU.[CW*[LEA;,!TY^9Q]'=L^T=6+^!'N--TR&,+#Y@FD ' 2+!4
M?]]^7^ - &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M16-=:AJ3>(?[/LOLHB@AAFG\]6W.LDCJ0I!PI 0GD')(''6@#9HKF1X\TQHT
M=+6]<2+O ")GRR(R'^]T(E3WZ\#%17WCJVCL;A[6UG$\<;[?.0;!(JN=C8;.
M?W;]...O(H ZNBN9D\;Z=9@)=>:[E)I 8XU7(C,F0%+ELXB;GITY&0*F/C&Q
M19G>TO52VBEEN6\M2( AE4[L,>IA<#&1P.1D4 =!17/W'B.2Z\.C5-'BWYG\
MI]T?G&-0^UVV1M\^,$X5N1R,TVW\76HLU-S^_N$M?M$GV-2Z.H3<73)R5/09
MYSQ[T =%17+R^.[*W$DL]E<1P+##+&Y>+]X9#( !\V/^69.<X/;MF:/QKITL
M\<:6UV8Y'15FV+L.YUC!^]G&YU'3O[' !T5%8!\3K=>'8]7L8'59+J&$+<*
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M"18Y9(U4 .IW-M7G/4].> #H:*Y_7-:O]*M;94AADNG@:28[&9$"E%9@ <D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>cpix-20200630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20200630"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20200630.xsd" xlink:type="simple"/>
    <context id="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaafea39242fe45dfbb5917478334e41d_I20200810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="ic125e85e38194740b3b6e42596d48565_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id4cd51a619a04cf88ce903ca6be458df_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i93a8372917ee45d59a9761300b60915f_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3afa198dbba942a8a7bb26d3c8157c4d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4b29c2b729c047069c2f8e4ed4afac13_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i77939a55b3504e7ea9bf84d21f5ab999_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i614de951b5564e1aa4a9b1cd5dd0b630_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6b0a727080d249279283aba5d6854990_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie23c7a1f4a90472a8b17ffd7485c2576_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i43f01311cc044c44bc525d43248d6c74_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i79f88a5961fc427a9c998030dc46f114_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i3ea30b21c62f403ea68c6689d93cd21d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i974df3aa74f74bdda4d426ab248294a8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie2f525b0defd4b22ab5cb985179a3531_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2d2d8f136b4c4979a189712441c7cf09_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8c307de3b4e5439ebd106206ec278efd_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8b4d219a9d4941c3950eb19706eb7a5c_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3a8bcdfaca924879b5b43dd5bddd703a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i067cca3f781144dd860b28147290813f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iae43656c3c484911bf5d613a8a8e45be_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i555b1189aac24c028c9886b3795085a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4f2d546729f4a7388d0da7c59afeefd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0768144df9f74550ab2219166aa29003_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9594a27a8953498781fa2c5b518d8690_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4b35cee38dff4f04bdb57a8e96d4e329_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic6a024f6a04f4471a56faa5a162c173b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia9c893f1703e4ba7b7c6c8a4e8d3796d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i17bd2f5664584e4e961c165808307967_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iab2bd5c666b24aa0b832eb6b9d845d8c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i45bf4110d4a5466bb3c612fbfef3c696_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i66d5c13fd94d4f238dd81f8caf9f3403_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08c7c34335f54f47863478492f5a0e20_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2f61c1f6404247408b4f8f98b89594d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iabb40a61c7844cbe9615cb5fbe8dba63_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5f3a745bf4174278a74c0d5a8fa02da3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idea52a7e581244558e3b890ffe46b51c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia322c6d2a6df4e9fa5ed3bb2684d5ddc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9323653bab9c4287addb88df384f442e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0dd57a040d73460c9eb5b7058fff5111_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if41ac3abceec4ba59776f3a5132e11cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e21e374e0f74f1598291e91e92c3d51_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i92c97dcff25b433083d6b0f9f881f774_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia08b7430594741ebaab75913bbcae614_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id509d7930bbf4bd694189ff99605fa09_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5669834e215b45b99cc41e3d665e69a1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if68a865edbbc4fa68606bf229911a560_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i02b378ebb06a479bbf879faf98e19814_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifc949d2f070b4f25affead2a375d491e_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iddf47d357fe2412f8af2acff2342ebb6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc40475e1a9d4a6bb5ec18bfe4e3e1b3_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if6b3dd0ec548447582e12cdbcd66e63b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iffd0d5dd3b844bdaa5729899189c6770_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idd91fba54ac84e0a8c8bd5e8f448455f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib0a5687dc8d944909b67b606cb812cce_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7e3f32cd85cd4f9e996353f5f78ff1b7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06ca879e8d4a47f39f75644f1ed2d685_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iea199d488f3d4c6fbdc6df78ea63c963_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i285e24ce4de04744ab32c8c31fb15880_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i0fdbdea3b95045f39274bd68ed525b3e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i810c3828a9d245e9a17ec124b2f9b2e8_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="if6deafdc7c3545129085c07232f96d65_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9de4abd6721c4ddfae052da0cb09699a_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i566675b7d46442779736a5e02fec5bb6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4fe634f61a1e4a5a9ad7dcfe2f238132_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia147af4d03624f11ac640a8b4886b751_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i217c307695d149f3a072f507e80428e0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id1febb70c5d54883bd12e7f1136868a7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0aaf60aeada144d6b60fa49b4caff778_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7c1b0b04c6a4448c9bdd40023c85de9c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i410438689ecc46098ef7e58bf86b9e48_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i918c1048efdc4eeaa992c0bef857728b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia46fcc7519ab4d55866e429c4169b5c6_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i338997cfd24048679aea6c8ed87a43ce_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7262f7e4e1134261beeed2cb335a5dc1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i17b3c50fbe874b3196c15fa2ac7f84ee_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i798cb1e7aeb14bf4a99ccd87345abcd7_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i9476294995c8476c8cf46424d7813e1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c685386484241a88e1c0f981bdbb1c0_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i90f8ddce573e405db035f43203edac82_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i34205ca5f1bd40e4bc73ff67fce99b21_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i70788808c3514d7cb738bf570ee8ecab_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i326c4e1bbd4143b0991323596e8218e2_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i4932bbb650d149da92ef6f0570dbee67_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1abd143533634e079845141c8834cf0d_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2811f76482b0428a8411c4d8087350fc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i576c01f880e64cda9a7bae358c95e641_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ib3072a59195c43eb83bc07add8758654_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="if09748a76bfe44299df7ff1fe1acec07_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i69c8bad9e0024da2b5f4ecd513ca3279_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="ie23ab79d4c84449990786e49b3945c33_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icf877f310c4d446597ea48ad1a455784_I20181017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-17</instant>
        </period>
    </context>
    <context id="i9a59ea378ede42c9b6cecb1b250655ca_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i814c31ba70e6430d9e51bcc5840e4ac9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icc647785e8e346e4a56e83e0cc7fa9ca_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7363b185835a4fefb0d6e62a0ebf0dfc_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="ia8648009ac16482485d4df4b4a6b9fa6_I20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <context id="ie53b0f9aa7b34fdab1a8da61d4eedd27_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6a665abb669e4b8294fe2d11afdae64b_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i2c77d503275442c7bd85a5f3a65d371a_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id334b396a4b3435091868e865fabd32c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaf017760b38441c1af2d35a25e124e99_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib89bcb77f46a4517a75030c3a28c5b4f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if905a7f82f44495396e2179b4d0584ba_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ief4c0cae1876488cbb05cfd3be1ad10d_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="if3a989ff74234cd4a92b992a22f309d6_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i46ecb77eacf14a63afd0516b29399c0a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i575e7871cbfc48ecb68373ff71bde4cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i484fde4f0aac43cf954b8569b221802d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0967848cdd484daebc2c83c3e623f456_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibb806d70ebf248d28f3e9175478166e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8bb4e69141de4966aa42c82e466f9e01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGFibGU6YzBmZjJhZTk2NWEzNDhlMWE2YTE0ZjIxMjRmNzY0NjYvdGFibGVyYW5nZTpjMGZmMmFlOTY1YTM0OGUxYTZhMTRmMjEyNGY3NjQ2Nl81LTEtMS0xLTA_2ffdc9d7-cf6a-460b-a32b-5be67c58f44f">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGFibGU6YzBmZjJhZTk2NWEzNDhlMWE2YTE0ZjIxMjRmNzY0NjYvdGFibGVyYW5nZTpjMGZmMmFlOTY1YTM0OGUxYTZhMTRmMjEyNGY3NjQ2Nl82LTEtMS0xLTA_8cbcdc30-3385-447f-a85b-3e981243b978">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGFibGU6YzBmZjJhZTk2NWEzNDhlMWE2YTE0ZjIxMjRmNzY0NjYvdGFibGVyYW5nZTpjMGZmMmFlOTY1YTM0OGUxYTZhMTRmMjEyNGY3NjQ2Nl83LTEtMS0xLTA_0aab578f-e96d-42d4-b786-2a2cd91ef98e">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGV4dHJlZ2lvbjoxMWRiY2U4YjRjNjA0MjZjYWJkYTgxYTExMzcyYTQ1Zl83OQ_39c3d227-99c9-4a3e-9b81-11d4d3b34bba">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80L2ZyYWc6MTFkYmNlOGI0YzYwNDI2Y2FiZGE4MWExMTM3MmE0NWYvdGV4dHJlZ2lvbjoxMWRiY2U4YjRjNjA0MjZjYWJkYTgxYTExMzcyYTQ1Zl84MA_232b9f05-c017-4589-af8f-700ae47d624d">0001087294</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIz_8f7a5473-8676-4bb6-8de8-528197d11a85">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6NWIzNmM5ZDA2YTBhNDdjM2JmNWI3ZTFjZGIzYmQxN2YvdGFibGVyYW5nZTo1YjM2YzlkMDZhMGE0N2MzYmY1YjdlMWNkYjNiZDE3Zl8wLTAtMS0xLTA_8b7755ea-b1d1-433f-be8a-0ee65127bccd">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY183Njk2NTgxMzk2NDkw_481ea127-a63d-40a5-8627-16f24f7947fa">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6Y2JiYTkwYzc0NjcyNDFkNDhjZjhhZGFkYWNkYTM1OGMvdGFibGVyYW5nZTpjYmJhOTBjNzQ2NzI0MWQ0OGNmOGFkYWRhY2RhMzU4Y18wLTAtMS0xLTA_8d62b07a-872b-4891-b8d6-4a11e1080b48">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDE5_98424cee-fdbc-4819-a2af-b99b34fdeb2a">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIw_259c198b-a3d4-4ca2-b2b5-54f55b45f3fb">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8wLTAtMS0xLTA_bc122903-834d-4367-ab29-b46681ab1063">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8wLTItMS0xLTA_8dcbc135-6378-4045-88f4-8f93b37e3e67">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV81_eaa3b693-f336-4d8e-a55b-316f1be50bbc">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV85_1974e986-1a73-439d-a19d-7f52598a3471">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV8xMw_a39332c3-b251-4005-bd62-f120298ebbde">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo5NWY2NjkzNWM2ZDM0YzQyODBlMzgxMDE4Y2ZjYzNhNV8xNw_f498b3e4-57f9-447d-a34f-0a3c0ad7693d">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ZWM2Y2UyZDM0ZjNjNGRjOWI0ODZlMmVkOTUyODRkZTgvdGFibGVyYW5nZTplYzZjZTJkMzRmM2M0ZGM5YjQ4NmUyZWQ5NTI4NGRlOF8zLTItMS0xLTA_b03a056d-e70f-48ac-9798-74c4a1680c6e">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIx_1cd3885b-ef55-4e34-930d-a515573645c3">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDI1_6028160f-7285-4ef6-aa61-e2f11fd4e500">255-0068</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDI2_efa46a27-864b-48ab-9dd9-cd9fe775eb4c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDIy_9f712e0f-d252-4e5b-a171-b6d111bcb5b0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ODhkNTUxZDhmMTI4NGE3MzlhYzlmNTliNzQ1NjVjMDIvdGFibGVyYW5nZTo4OGQ1NTFkOGYxMjg0YTczOWFjOWY1OWI3NDU2NWMwMl8xLTAtMS0xLTA_4eb8eabd-1880-4681-ba12-98500bc36899">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ODhkNTUxZDhmMTI4NGE3MzlhYzlmNTliNzQ1NjVjMDIvdGFibGVyYW5nZTo4OGQ1NTFkOGYxMjg0YTczOWFjOWY1OWI3NDU2NWMwMl8xLTUtMS0xLTA_5fb8e25e-c134-452a-a9af-1e503904ffea">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6ODhkNTUxZDhmMTI4NGE3MzlhYzlmNTliNzQ1NjVjMDIvdGFibGVyYW5nZTo4OGQ1NTFkOGYxMjg0YTczOWFjOWY1OWI3NDU2NWMwMl8yLTItMS0xLTA_197ac007-1fc7-4504-96a0-3dcec352095e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGV4dHJlZ2lvbjpkODQ4N2IzYTE0NTU0NWMyYmQ4ZDQ5NWUwNWI5NGExY18yMDE2_b76d841b-fcf1-4a63-b117-ccdc9db9c540">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTAtMS0xLTA_ba2584f6-67cd-47df-9f9b-8a95a1c6f016">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTItMS0xLTA_5653a83c-689e-48c0-b8b9-637d6f3033a0">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTQtMS0xLTA_81de71d1-7c80-4826-a604-d21b12342df9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iaafea39242fe45dfbb5917478334e41d_I20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xL2ZyYWc6ZDg0ODdiM2ExNDU1NDVjMmJkOGQ0OTVlMDViOTRhMWMvdGFibGU6OTUyYWY2NGFiNDljNDM2OTkzNmYyZDQ3OTRmMWU0YWUvdGFibGVyYW5nZTo5NTJhZjY0YWI0OWM0MzY5OTM2ZjJkNDc5NGYxZTRhZV8xLTYtMS0xLTA_1bbffb76-e43d-4ec7-94d0-88967a844ea0"
      unitRef="shares">15138623</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMy0xLTEtMS0w_45a35764-059b-4f47-a497-975f8e4f263d"
      unitRef="usd">27373737</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMy0zLTEtMS0w_2788aabe-68e1-4a24-9b74-74f7b932f5a5"
      unitRef="usd">28212635</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNS0xLTEtMS0w_e6bbbba7-d974-4e6d-85ae-f55e884a7e77"
      unitRef="usd">7924338</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNS0zLTEtMS0w_6947ada6-43e3-4f7f-b018-a1f621027208"
      unitRef="usd">7843917</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNi0xLTEtMS0w_5f512f0d-085c-48aa-aceb-2b797505730e"
      unitRef="usd">7627270</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNi0zLTEtMS0w_a352cb8e-6cc3-4461-bcd7-1b76e49b9c6b"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNy0xLTEtMS0w_2f2da8ac-81f2-4c69-8769-dab1c02b376e"
      unitRef="usd">744403</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfNy0zLTEtMS0w_dc41afc1-9f9b-4af9-841f-920fab8d4ac7"
      unitRef="usd">2477813</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOC0xLTEtMS0w_abffb8bd-dcce-4938-8224-e7b9498b9b42"
      unitRef="usd">2085230</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOC0zLTEtMS0w_937f187c-9e42-452b-aa19-f1996b93fe93"
      unitRef="usd">2757456</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOS0xLTEtMS0w_c31522aa-23af-48d8-ac79-a4edcb59a615"
      unitRef="usd">45754978</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfOS0zLTEtMS0w_c2b8532d-3717-4877-967e-daa6eb3f38f4"
      unitRef="usd">50163075</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTAtMS0xLTEtMA_22cc3628-9703-4da6-b4a0-73abfc9b95f7"
      unitRef="usd">15640060</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTAtMy0xLTEtMA_6a37075b-7d70-42d7-9fb4-c14c1ecc28bf"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTEtMS0xLTEtMA_2db2048b-fc2f-4396-94fb-94028547558a"
      unitRef="usd">631534</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTEtMy0xLTEtMA_96c4a9b4-7d02-4974-ac9f-8fa710c965d9"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTItMS0xLTEtMA_04090e35-ee7e-4e6d-9186-d413888b631f"
      unitRef="usd">29151228</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTItMy0xLTEtMA_3082f3e8-7634-4e92-b553-8aeec4ebce1b"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTMtMS0xLTEtMA_7ec1bb0d-3b96-42cf-ba18-200693bf3091"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTMtMy0xLTEtMA_b859387c-1999-4931-843d-7f63fb676dd2"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTQtMS0xLTEtMA_ef56e9d2-2aa9-4119-9d5c-883232f6d03f"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTQtMy0xLTEtMA_8a321429-ad51-485a-b929-d3f358b9bdc7"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTUtMS0xLTEtMA_c54cc707-d4ee-4ee3-acf5-246af1343bc2"
      unitRef="usd">2502850</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTUtMy0xLTEtMA_3db1809b-d664-4ce0-a8a1-8238e56c2776"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTYtMS0xLTEtMA_8f53143c-651a-4f76-b5ec-d0af5b4ddb24"
      unitRef="usd">2939003</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTYtMy0xLTEtMA_a4c6a6d0-3192-4711-b44c-d6840916388a"
      unitRef="usd">3298725</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTctMS0xLTEtMA_84dd56cf-f2d2-4863-a78d-7254ec0c3dc0"
      unitRef="usd">97523455</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMTctMy0xLTEtMA_1928abf1-78f4-4426-bd19-7b7be419c91d"
      unitRef="usd">104549283</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjAtMS0xLTEtMA_ae940ed5-bcbf-4ada-aca1-ec843785170f"
      unitRef="usd">10829982</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjAtMy0xLTEtMA_4ffd2074-9d2a-4298-a17e-6c153277f1bc"
      unitRef="usd">9993578</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjEtMS0xLTEtMA_baa122eb-76f8-49de-89dc-bf5105b231a5"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjEtMy0xLTEtMA_574046c8-e08a-4d0b-9fb0-f837cfe605c9"
      unitRef="usd">1918868</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjItMS0xLTEtMA_1432e6f2-6556-4c39-8c53-06c625ac0309"
      unitRef="usd">967656</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjItMy0xLTEtMA_5a2e48b8-3813-44bc-9a01-7b2a88650a64"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjMtMS0xLTEtMA_4b7cca68-f79c-4d91-9ee5-0d2afc12e875"
      unitRef="usd">10866765</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjMtMy0xLTEtMA_2ce438e9-d8fe-4c44-b492-2d00a15d6c0e"
      unitRef="usd">11317358</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjQtMS0xLTEtMA_ad73d889-f5f3-42ef-81a1-00c895b9b873"
      unitRef="usd">22664403</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjQtMy0xLTEtMA_892fefdf-277b-4a97-9548-2cac2b0f9a62"
      unitRef="usd">24150235</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjUtMS0xLTEtMA_df59a5e0-bc88-4955-8c26-63a3793ca958"
      unitRef="usd">17000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjUtMy0xLTEtMA_759e868c-b9a6-471f-a589-dad8e9981bc2"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjYtMS0xLTEtMA_712ac865-6ed0-45a5-b17f-fdb01752e7c9"
      unitRef="usd">1580203</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjYtMy0xLTEtMA_0881241b-29f5-4b18-9bb0-df85b2ac52c4"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjctMS0xLTEtMA_9ab85973-4962-46cd-a1a1-e4e8cd883189"
      unitRef="usd">7867679</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjctMy0xLTEtMA_ee733389-0ec9-410e-8223-afa2ff31f479"
      unitRef="usd">8737323</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjgtMS0xLTEtMA_d35f8c3b-5d48-4bfc-8c1b-ddbf1823c23c"
      unitRef="usd">49112285</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjgtMy0xLTEtMA_d12c537b-adfa-47c1-83b4-12484990d9a5"
      unitRef="usd">53464030</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjktMS0xLTEtMA_61703df2-1a87-4e73-b2b1-0120a3a9dae8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMjktMy0xLTEtMA_be09bcdd-6cf3-4148-a609-68df3a1dd711"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzE3_2225b63b-9bcf-4af3-821e-0d2184f86880"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzE3_a4e4c83a-dbe7-4751-b5a0-3c1617e9db9e"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzMx_2b433daf-e9c7-4732-b8f8-4702168f5264"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzMx_d11eb078-a47a-4aef-8fb8-a6f464f68dc4"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzUz_1f14ce9e-c278-4a2e-b6f0-3c5b3e72c1f5"
      unitRef="shares">15181276</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzUz_e788bc35-c006-48a3-8c25-9d5b82af950b"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzYw_52748fb3-1ad4-4f3d-8641-a4d1d0d01574"
      unitRef="shares">15263355</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOmMyNGE1MTljODM4ZDQ5YjBhNmZmMDhiYzQ4ZDMyMWIxXzYw_b6212445-d447-4ac2-a7ef-5270a4a87225"
      unitRef="shares">15263355</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMS0xLTEtMA_8d8a0ef0-f72a-45a9-b396-de50a58d8301"
      unitRef="usd">49246129</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzItMy0xLTEtMA_2278584a-3891-4e6c-aa16-c1daee92834a"
      unitRef="usd">49914478</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzMtMS0xLTEtMA_926ff970-add8-4afb-8b82-3f3fc09775a8"
      unitRef="usd">-765500</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzMtMy0xLTEtMA_9cf7c9c0-5452-4166-9ac7-63da2a1d9360"
      unitRef="usd">1208395</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzQtMS0xLTEtMA_1716b61c-9999-494a-9dcd-b08adcb84ecf"
      unitRef="usd">48480629</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzQtMy0xLTEtMA_4a22e606-c812-41c0-97a7-ee4edb3c8577"
      unitRef="usd">51122873</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzUtMS0xLTEtMA_88bcf5bb-d9e7-42e6-bd1c-006aea399c7c"
      unitRef="usd">-69459</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzUtMy0xLTEtMA_5da19772-e335-4882-bbb3-44515b8c242b"
      unitRef="usd">-37620</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzYtMS0xLTEtMA_28e8f101-cb6f-42a2-8326-f9196ff219bc"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzYtMy0xLTEtMA_ddc62e8c-0369-4d3c-bcb6-33085831bad0"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzctMS0xLTEtMA_d8558806-143e-41d6-a341-bf41b10790ab"
      unitRef="usd">97523455</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xNi9mcmFnOjg2YTZmZDYyNDcxNjQ5NzM4YjQ0ZTdiYmM5ZmUyYzNjL3RhYmxlOjU2ZjY5OTRjZjhkYTQ5YjU4NjZkMGZhMWZhNWJmYzlkL3RhYmxlcmFuZ2U6NTZmNjk5NGNmOGRhNDliNTg2NmQwZmExZmE1YmZjOWRfMzctMy0xLTEtMA_e1770913-1cc4-4f6a-834a-77c887e75d4c"
      unitRef="usd">104549283</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi0xLTEtMS0w_ba7c553f-eed2-4cd4-a193-2044217e5336"
      unitRef="usd">9598177</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi0zLTEtMS0w_54af28d3-13b4-44d7-a883-d93cd0e5baa2"
      unitRef="usd">9417443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi01LTEtMS0w_9f4d465a-27bc-4a89-be96-e0dcf42cc456"
      unitRef="usd">17928911</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMi03LTEtMS0w_3e28b82d-549b-4bb1-95fd-d229e2f1adf0"
      unitRef="usd">18147303</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC0xLTEtMS0w_7eb6e345-2861-43f0-9cc5-5e21c29aa891"
      unitRef="usd">2609982</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC0zLTEtMS0w_415129b2-781c-483a-bdca-a3f685d52774"
      unitRef="usd">1792293</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC01LTEtMS0w_04741f64-78d4-47f5-8464-763bb8093049"
      unitRef="usd">4244163</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNC03LTEtMS0w_04b55b8d-7bab-4f6e-a24f-2707600164f4"
      unitRef="usd">3451082</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS0xLTEtMS0w_4a196e8d-05bb-493e-9812-0931009200bc"
      unitRef="usd">3865406</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS0zLTEtMS0w_9a99c557-6da5-41c0-8588-46128cdae033"
      unitRef="usd">3982379</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS01LTEtMS0w_d42a560b-402c-4c6a-9e03-76d77c0f6744"
      unitRef="usd">7573082</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNS03LTEtMS0w_675d85d8-abbc-4c3e-9f8c-5c604c3c61da"
      unitRef="usd">7419311</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi0xLTEtMS0w_05f4d381-db99-4309-b75a-51f2a80632fb"
      unitRef="usd">1421502</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi0zLTEtMS0w_72d43d51-7b8e-4879-8204-09b63022a5d7"
      unitRef="usd">1716169</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi01LTEtMS0w_c24d612c-4781-4bfb-8fc4-3f1d10dd299a"
      unitRef="usd">3144057</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNi03LTEtMS0w_57cdfa45-ae93-4514-a8be-be6c04126208"
      unitRef="usd">3115856</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy0xLTEtMS0w_5cd35ce2-6c5e-46c6-b644-9abed7a7070f"
      unitRef="usd">2190764</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy0zLTEtMS0w_a737bc78-3a8c-4546-bcb6-11121de635f8"
      unitRef="usd">2270318</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy01LTEtMS0w_a4fbbb29-6393-42f2-8c86-c4c42d7a693a"
      unitRef="usd">4227048</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfNy03LTEtMS0w_7ee15fdc-5906-483f-a8fc-4659a893e43a"
      unitRef="usd">4807057</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC0xLTEtMS0w_efea4058-0e06-41ff-aecd-c6f94ad43cec"
      unitRef="usd">1091485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC0zLTEtMS0w_173f34f1-2dca-4d8b-968a-e70c7701c82e"
      unitRef="usd">1029708</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC01LTEtMS0w_8b98ff6a-bbda-4dcb-aa4c-d30ad22def48"
      unitRef="usd">2167524</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOC03LTEtMS0w_d535a06f-4002-4e54-92a3-64fb99c104a3"
      unitRef="usd">2051353</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS0xLTEtMS0w_54ee58f1-13fe-42b0-8c04-e18a141fcd8d"
      unitRef="usd">11179139</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS0zLTEtMS0w_dc448f6f-79da-4ca1-b1ff-b4aa6bc36b98"
      unitRef="usd">10790867</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS01LTEtMS0w_512d6111-203b-45a6-a3a0-4136ecda27ff"
      unitRef="usd">21355874</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfOS03LTEtMS0w_a113c92b-4b73-4977-a2e3-6855dd6f0cad"
      unitRef="usd">20844659</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtMS0xLTEtMA_c22e8956-fcbb-4a9d-a2f5-e8f99da21779"
      unitRef="usd">-1580962</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtMy0xLTEtMA_bec90bed-3df2-426a-88b1-ad40d2b6adc8"
      unitRef="usd">-1373424</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtNS0xLTEtMA_f313fae4-55b9-4a4d-9179-50212dd36545"
      unitRef="usd">-3426963</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTAtNy0xLTEtMA_279e4c67-1595-42a4-b6e4-26554d2752ca"
      unitRef="usd">-2697356</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtMS0xLTEtMA_38f92c91-198c-4c80-a60a-438e8af8276c"
      unitRef="usd">28661</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtMy0xLTEtMA_6db2ab99-1ded-4498-9d69-7ea8649fb1ff"
      unitRef="usd">130565</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtNS0xLTEtMA_b132dac2-ea35-4b2c-8983-0cce54f1255e"
      unitRef="usd">58549</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTEtNy0xLTEtMA_81151ae9-b3f9-462a-becd-07a1905dfd22"
      unitRef="usd">246426</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItMS0xLTEtMA_5c9793b0-bee6-4ccf-8ce4-778cacef5e75"
      unitRef="usd">119455</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItMy0xLTEtMA_74edd79f-fa4b-4292-8178-aee81be87e68"
      unitRef="usd">91200</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItNS0xLTEtMA_b73230f7-5351-49d1-9e1a-36ae523d2277"
      unitRef="usd">152520</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTItNy0xLTEtMA_8a2b44b7-5fce-439b-8518-3ef3da3eef06"
      unitRef="usd">152111</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtMS0xLTEtMA_d40199fe-7bee-4a4c-81ab-b5cf46729bbd"
      unitRef="usd">-1671756</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtMy0xLTEtMA_0b05aca9-30fa-4863-b7c4-54818d68dc46"
      unitRef="usd">-1334059</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtNS0xLTEtMA_51ce4990-be53-4264-9391-8e78d528c9c3"
      unitRef="usd">-3520934</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTMtNy0xLTEtMA_1343216f-75b9-481f-8a1f-4b75e521b206"
      unitRef="usd">-2603041</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtMS0xLTEtMA_c3e62040-184d-4e13-ab62-0abc2846324e"
      unitRef="usd">7455</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtMy0xLTEtMA_ca879612-d404-4eee-863f-9a28b0b91610"
      unitRef="usd">4462</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtNS0xLTEtMA_fcd955f1-9949-4081-84f5-71353adb773b"
      unitRef="usd">41695</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTQtNy0xLTEtMA_f7596934-d280-406a-9e18-fc894cf45419"
      unitRef="usd">-76966</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtMS0xLTEtMA_fe5f238f-6cd6-4d6d-a14f-73d2c313fd5d"
      unitRef="usd">-1679211</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtMy0xLTEtMA_7022d629-37e8-4fc5-9ae6-73158992adb8"
      unitRef="usd">-1338521</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtNS0xLTEtMA_38fea491-9bd3-4479-855a-8ee560ecd7ce"
      unitRef="usd">-3562629</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTUtNy0xLTEtMA_0924735d-6ec3-43ee-9186-832222077ec3"
      unitRef="usd">-2526075</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtMS0xLTEtMjM5_3156a832-dc41-4c64-94eb-23879b385c9d"
      unitRef="usd">738622</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtMy0xLTEtMjM5_c259318c-0c67-462c-900d-7486e1c1cc01"
      unitRef="usd">771709</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtNS0xLTEtMA_ef9a550e-9843-4b82-a289-b1acc3baef2c"
      unitRef="usd">1556895</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTYtNy0xLTEtMA_dffa6539-d223-44ab-a29b-846f5c5e28d0"
      unitRef="usd">1918845</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctMS0xLTEtMjU1_c43c4214-2f8f-4427-8cd8-d621013b619a"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctMy0xLTEtMjU1_83fe752c-c574-473b-952b-f14514351e60"
      unitRef="usd">-566812</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctNS0xLTEtMA_c6e54a07-1487-44eb-82d3-97a81632a148"
      unitRef="usd">-2005734</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTctNy0xLTEtMA_ac5f50de-ca45-4991-8d76-2251dc1932d9"
      unitRef="usd">-607230</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtMS0xLTEtMA_9edcca95-ce25-466e-a31c-753c62a114c7"
      unitRef="usd">-22314</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtMy0xLTEtMA_a648f629-2831-4f27-b1f7-1026422b7c40"
      unitRef="usd">-17305</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtNS0xLTEtMA_16f50ad7-a515-44cc-8025-c644af4e00f7"
      unitRef="usd">-31839</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTgtNy0xLTEtMA_c41d323e-2291-4475-833e-3b9eaf2d0b29"
      unitRef="usd">16155</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktMS0xLTEtMA_f4630e2a-378a-41a3-91c2-93090749741b"
      unitRef="usd">-918275</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktMy0xLTEtMA_d0a9d967-fa20-40dd-9d9f-1304af105ed6"
      unitRef="usd">-549507</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktNS0xLTEtMA_8b777266-d406-423c-8476-0d6a4a3bcba6"
      unitRef="usd">-1973895</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMTktNy0xLTEtMA_4fb35814-c7d0-4e91-ab23-b7e5a9e76b90"
      unitRef="usd">-623385</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtMS0xLTEtMA_abd325e2-8252-43b1-86d1-b8749953d724"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtMy0xLTEtMA_09f73400-5315-4019-9d90-591667824f69"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtNS0xLTEtMA_3c9260d4-d934-4e76-b8b8-c88c2e95a79a"
      unitRef="usdPerShare">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjEtNy0xLTEtMA_eef66a90-6d77-4908-a7a2-7bca435b3569"
      unitRef="usdPerShare">-0.16</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItMS0xLTEtMjQ3_2beed848-5a31-4769-bd87-0ce5974c8b74"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItMy0xLTEtMjQ3_fd31ae8f-0e35-4eb0-bc70-84128c8ed65b"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItNS0xLTEtMA_add614b1-2f68-4955-8db4-0ab5b81ad401"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjItNy0xLTEtMA_35ed696a-07ea-4be7-b813-3a765aa63bca"
      unitRef="usdPerShare">0.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtMS0xLTEtMjUy_7035bc9c-9572-43a4-95a1-be683c97a164"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtMy0xLTEtMjUy_a1d5eb5e-44af-4cfe-96d0-d02247f5686c"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtNS0xLTEtMA_b65a6570-453a-4ac2-a93c-8f15e98a570c"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjMtNy0xLTEtMA_f22e42ed-b048-47f1-aa80-881ac2c731f1"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtMS0xLTEtMjU4_9d604fea-d417-42b3-b882-204ee1ada50b"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtMy0xLTEtMjU4_7bc1cf7e-13da-4c7b-b988-67de312cc0b4"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtNS0xLTEtMA_fcf701b2-529d-4f9c-8b3b-51573a0b983b"
      unitRef="usdPerShare">-0.23</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjUtNy0xLTEtMA_2efa0001-4e18-4a35-82f0-ba4a2b1e9a08"
      unitRef="usdPerShare">-0.16</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtMS0xLTEtMA_a9723415-7dc5-4252-bfb2-b453684de3f6"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtMy0xLTEtMA_e6f92aa5-9051-45c9-8f6e-2b05111a3875"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtNS0xLTEtMA_daaeb67b-9cd4-4d63-957f-9809bcbccbee"
      unitRef="usdPerShare">0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjYtNy0xLTEtMA_951c3169-494b-400a-a54b-dd0ce49448ee"
      unitRef="usdPerShare">0.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctMS0xLTEtMjU4_305f8ab3-a858-4549-bda8-9e53010c8676"
      unitRef="usdPerShare">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctMy0xLTEtMjU4_f2d44f11-028b-4534-9878-d44401fa3ccd"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctNS0xLTEtMA_9d5dd155-90a8-4941-919d-0ff48adc599b"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjctNy0xLTEtMA_bdff32ba-407d-46e2-9ae0-d7472a4853a4"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktMS0xLTEtMA_aa209967-83b2-48cd-86c7-e381f010e476"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktMy0xLTEtMA_74ef3cc9-dcdd-4f84-8f85-349fa4dff825"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktNS0xLTEtMA_90310ade-0d34-458f-ada0-d7e650387e0a"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMjktNy0xLTEtMA_cc409c1d-0df6-48bf-93e2-b996cfa4d47c"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtMS0xLTEtMA_72900226-7db4-4353-a385-f7512f61af53"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtMy0xLTEtMA_3d8a0b28-bba3-4c9f-8be6-2a3f8ba2b72e"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtNS0xLTEtMA_677426b1-99e7-4dae-a9cb-9ff74c8e3048"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8xOS9mcmFnOmY4NDZhNjFlZmVlMjQ5N2I5NzQwYjUyMjQ4ODZhZjhjL3RhYmxlOjU5NTIxMGM5NzM0ZDQ5OTk5NzQyZTdmNTc4NTdjYjhhL3RhYmxlcmFuZ2U6NTk1MjEwYzk3MzRkNDk5OTk3NDJlN2Y1Nzg1N2NiOGFfMzAtNy0xLTEtMA_41ec238e-8e09-4b53-9dc4-229c8376b150"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMy0xLTEtMS0w_f184c818-265e-46f4-845c-4030425906e8"
      unitRef="usd">-2005734</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMy0zLTEtMS0w_2bfe29f2-6ae5-466f-8fe5-3e33d0f0efb4"
      unitRef="usd">-607230</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNC0xLTEtMS0w_ae23e87c-d871-4e90-bef5-2c220ab36f5e"
      unitRef="usd">1556895</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNC0zLTEtMS0w_d0baef70-73dc-4372-95d7-d1170d8b8217"
      unitRef="usd">1918845</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNS0xLTEtMS0w_101ff3b3-2dcc-4d61-96d5-ce527717627f"
      unitRef="usd">-3562629</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNS0zLTEtMS0w_1d9c529e-70a1-412a-9943-ca29a29ba6a1"
      unitRef="usd">-2526075</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNy0xLTEtMS0w_5c494c6e-0076-4e34-8708-1ef753fcf886"
      unitRef="usd">2334669</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNy0zLTEtMS0w_efc71b37-996e-4f96-8836-f2360e0ba560"
      unitRef="usd">2174397</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOC0xLTEtMS0w_c608478e-9dbc-409c-b7e5-7607a7a574b2"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOC0zLTEtMS0w_ddb3eeff-3300-4257-898b-2f713dfcca14"
      unitRef="usd">43605</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOS0xLTEtMS0w_b4f65d58-148f-44f6-ad0c-bef418596b0c"
      unitRef="usd">542923</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfOS0zLTEtMS0w_21021b25-0cc7-4875-a10c-30f2675e6b66"
      unitRef="usd">760982</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTAtMS0xLTEtMA_a24eb312-3694-4523-895f-17d6bdc61e5d"
      unitRef="usd">645571</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTAtMy0xLTEtMA_9c75bfe2-25f6-4e32-a923-02cf88074737"
      unitRef="usd">321894</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTEtMS0xLTEtMA_f12bbdef-4a77-4425-aca7-4883885be455"
      unitRef="usd">22973</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTEtMy0xLTEtMA_8a973e41-ed73-4b6a-880e-c936735b3f1b"
      unitRef="usd">28111</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTItMS0xLTEtMA_521b07db-3b29-494d-9feb-01b4e0c24761"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTItMy0xLTEtMA_ef537131-f356-499a-9d64-168e72c0c2d7"
      unitRef="usd">125804</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTQtMS0xLTEtMA_0621ab25-4ad3-43f5-94a8-c16dcb15db1e"
      unitRef="usd">80421</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTQtMy0xLTEtMA_b19ebbe7-b4e0-4c4a-b3d4-25f240fcb5c0"
      unitRef="usd">652652</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTUtMS0xLTEtMA_3d2cc731-7f3e-4c19-be02-9f1ac7a3bf63"
      unitRef="usd">-1158916</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTUtMy0xLTEtMA_c45e2fe7-0d32-4d31-8a6f-e13b353f4433"
      unitRef="usd">-883545</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTYtMS0xLTEtMA_88efc2dd-f3e3-4c1c-aec9-34abe89f22f6"
      unitRef="usd">-1017650</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTYtMy0xLTEtMA_41ec1cd6-e399-412c-811d-106f5b7f2fe4"
      unitRef="usd">-141577</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTctMS0xLTEtMA_1bddaf13-636a-4c38-abbf-09f3a0952fd8"
      unitRef="usd">2413768</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTctMy0xLTEtMA_47ffe0de-ea3c-40c1-ad1d-6bb0f49dd5e4"
      unitRef="usd">-163530</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTgtMS0xLTEtMA_d4d1421d-9a9e-4b74-b31c-2f2aafe8bb39"
      unitRef="usd">-869644</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTgtMy0xLTEtMA_9cf40498-ded8-4d83-a630-949702efefb2"
      unitRef="usd">-342940</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTktMS0xLTEtMA_48b725f8-e8dd-4346-b438-9415f1e37234"
      unitRef="usd">2332634</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMTktMy0xLTEtMA_ae5b286f-8992-4bee-b0a9-5fa842687652"
      unitRef="usd">-100678</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjAtMS0xLTEtMA_f08ae70c-646c-4465-b6c2-e2dffb3ca5df"
      unitRef="usd">1371437</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjAtMy0xLTEtMA_6d100912-81fa-471b-896f-a851c9a671f9"
      unitRef="usd">1565604</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjEtMS0xLTEtMA_f8466796-03d4-4469-b8c4-fc4d7e8984a7"
      unitRef="usd">3704071</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjEtMy0xLTEtMA_feb5cdb4-94de-48c0-8226-ede36984fd21"
      unitRef="usd">1464926</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjMtMS0xLTEtMA_82543bfb-7419-48c3-94af-9a3a0d71688a"
      unitRef="usd">50883</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjMtMy0xLTEtMA_dbe5e46a-eee2-4107-a020-14ca7d2833ac"
      unitRef="usd">89070</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjQtMS0xLTEtMA_790d0af5-977d-4877-95d0-ca2961e8cd9d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjQtMy0xLTEtMA_dc7e408d-48ba-488f-af61-25f3d000ae7e"
      unitRef="usd">9627191</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjUtMS0xLTEtMA_1de798ea-8e17-4b8e-af96-975817c1d2e5"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjUtMy0xLTEtMA_731b6745-c90c-41f0-b45f-666425c7b505"
      unitRef="usd">8563988</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMS0xLTEtMTU5_eed5fb87-c4ea-4047-a64f-636778c85267"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMy0xLTEtMTU1_b5d5c844-f732-4a87-b6f9-698b2499d19b"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMS0xLTEtMA_99620e10-444a-4f2b-a20a-0ed4fdc52a58"
      unitRef="usd">722131</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjYtMy0xLTEtMA_4eb95868-0ce9-41b8-bf4b-260f13873a08"
      unitRef="usd">395005</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjctMS0xLTEtMA_c9e507ce-932d-4579-b553-eb465ec47ab1"
      unitRef="usd">-773014</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMjctMy0xLTEtMA_ba86d840-6a2c-45b7-8855-8b084a635558"
      unitRef="usd">-6547278</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzAtMS0xLTEtMA_7a26c7d2-2372-4ab8-ac4b-8eb1a7014932"
      unitRef="usd">35500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzAtMy0xLTEtMA_84ea42b8-4ab3-4b3c-8209-2607b3812ac6"
      unitRef="usd">36000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzEtMS0xLTEtMA_b31084d6-2307-41ed-8750-b89acfcd04ed"
      unitRef="usd">37000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzEtMy0xLTEtMA_6f477b12-fdb7-4ab9-8818-d6d0cf73da7b"
      unitRef="usd">36000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzQtMS0xLTEtMA_d187486d-80f2-4498-8e66-65362dd3a1e4"
      unitRef="usd">260735</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzQtMy0xLTEtMA_2c48ff4a-0fbf-4e7d-a81b-5dd92a3d4fec"
      unitRef="usd">684738</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzctMS0xLTEtMA_4e1b846d-ffca-4f6b-aa40-551adcedfbe2"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzctMy0xLTEtMA_d0b815cb-c825-4e12-8815-afc554d116c9"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzgtMS0xLTEtMA_f5774306-a3b7-4af9-9e2a-8ec3cbafd432"
      unitRef="usd">1209220</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzgtMy0xLTEtMA_4c5751d7-0dbd-4e27-ba11-aa0bf53cfcf2"
      unitRef="usd">1220690</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzktMS0xLTEtMA_93bf8cbb-6fda-4391-84cb-4b72c2609dde"
      unitRef="usd">-3769955</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfMzktMy0xLTEtMA_b5493b47-4983-41ae-8519-aa6ca5cc31db"
      unitRef="usd">-1905428</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDAtMS0xLTEtMA_eecabd6f-83b6-4b42-9f12-8f4fb97ddfc5"
      unitRef="usd">-838898</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDAtMy0xLTEtMA_87ddb0da-eb0f-49c4-9e5e-568c69203bc8"
      unitRef="usd">-6987780</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDEtMS0xLTEtMA_6105bab4-2857-484e-a6c2-5b5b6de5bab1"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDEtMy0xLTEtMA_8fbb827f-2492-40fe-bb93-db59b3fde792"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDItMS0xLTEtMA_c51ee85f-baff-4f91-bd60-0184d8c426bc"
      unitRef="usd">27373737</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3afa198dbba942a8a7bb26d3c8157c4d_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yMi9mcmFnOjRjYWM4OGVmNGJkYzRmZmQ4OTllMWEzYmVjNjIyNzEyL3RhYmxlOjFlNzBhNjc0N2ExYjQ3ZWVhNGU3YWFjMjVjZDNiMGZhL3RhYmxlcmFuZ2U6MWU3MGE2NzQ3YTFiNDdlZWE0ZTdhYWMyNWNkM2IwZmFfNDItMy0xLTEtMA_fc02f74d-d79b-4835-a795-608e899a618c"
      unitRef="usd">20951180</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4b29c2b729c047069c2f8e4ed4afac13_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi0xLTEtMS0w_18a73489-8cf1-43a0-b2de-7c57565e52dd"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b29c2b729c047069c2f8e4ed4afac13_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi0zLTEtMS0w_f1bf4610-7ee5-4d81-984e-5075e2e5c2e9"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77939a55b3504e7ea9bf84d21f5ab999_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi01LTEtMS0w_0a55e708-5a8b-4d64-85b4-ea207714e238"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i614de951b5564e1aa4a9b1cd5dd0b630_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi03LTEtMS0w_527c26de-c7bd-41ac-9535-576e7e260370"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMi05LTEtMS0w_b64fd22f-e8a7-43cd-8bfa-96d239ad3f78"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMy0xLTEtMS0w_a6fd185d-dfaf-4e22-abfa-d8c4e235791e"
      unitRef="shares">187486</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMy0zLTEtMS0w_e5c9ed1e-4207-4a93-814a-452594413aed"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfMy05LTEtMS0w_e0baed9d-042f-4f5e-88a7-f6107225bc28"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNC0xLTEtMS0w_ea310078-1a62-4f6f-9406-25a46753bc59"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6b0a727080d249279283aba5d6854990_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNC0zLTEtMS0w_473d6ef4-f3c2-4247-9c59-ddd48972be32"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNC05LTEtMS0w_032883bf-6076-4d92-a0c8-2a2781337968"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="ie23c7a1f4a90472a8b17ffd7485c2576_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNS01LTEtMS0w_08f68fc5-7755-440a-bf1d-113670b08e71"
      unitRef="usd">-73878</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i43f01311cc044c44bc525d43248d6c74_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNS03LTEtMS0w_612308b2-20f9-4ba6-a5e3-89bd21a7edd9"
      unitRef="usd">33460</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNS05LTEtMS0w_bd1eda36-0054-4d32-be12-9d39fac24198"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi0xLTEtMS0w_ac458db4-e765-414c-bb9a-2ab8dca89e61"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi0zLTEtMS0w_cf2e5cf8-e65d-4360-99c2-02e925f9e49e"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ea30b21c62f403ea68c6689d93cd21d_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi01LTEtMS0w_5e4e8e09-cd2a-4997-9e57-5ccebf9af18a"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i974df3aa74f74bdda4d426ab248294a8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi03LTEtMS0w_992b1cf8-544c-4cba-bccc-8615d524593a"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2f525b0defd4b22ab5cb985179a3531_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOjQ5MTcwMGVmODE4YjRlYTJiYWM5ZmZiM2I2YjQ2NmQxL3RhYmxlcmFuZ2U6NDkxNzAwZWY4MThiNGVhMmJhYzlmZmIzYjZiNDY2ZDFfNi05LTEtMS0w_38f4a3ec-d623-4d4e-adfb-fa3edfacf86e"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC0xLTEtMS0w_400e4cc6-7934-4d20-a4e6-1130efb352e9"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79f88a5961fc427a9c998030dc46f114_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC0zLTEtMS0w_25759df2-2df1-44fe-b85d-3072c0de2377"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ea30b21c62f403ea68c6689d93cd21d_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC01LTEtMS0w_7a126c70-b272-42d2-9d25-03f4b996b69b"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i974df3aa74f74bdda4d426ab248294a8_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC03LTEtMS0w_d7bfe884-5482-455c-950e-915feb131efe"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2f525b0defd4b22ab5cb985179a3531_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMC05LTEtMS0w_381f8e71-d1ca-48b6-8a8b-6a84c9d72232"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi0xLTEtMS0w_d7f16b24-e8e2-4987-933e-7cd3b8b71fa0"
      unitRef="shares">8000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi0zLTEtMS0w_79d82a04-69fd-44fd-ac07-b89ffe57216f"
      unitRef="usd">396548</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi05LTEtMS0w_f1c8041d-4fb5-42fe-ad2c-a55cafcb5fb5"
      unitRef="usd">396548</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi0zLTEtMS0zMDEw_88885973-2511-4dbe-a3fa-a325c0a322d3"
      unitRef="usd">685805</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i2d2d8f136b4c4979a189712441c7cf09_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi03LTEtMS0yOTk4_d3f7c132-9585-4817-9cbf-c749c26f4afb"
      unitRef="usd">114195</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMi05LTEtMS0zMDAw_1f31cb3c-5570-4ee2-9566-9c0632a12b6f"
      unitRef="usd">800000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMy0xLTEtMS0w_dc55abf5-a1f5-4b2e-a8e3-52643525136a"
      unitRef="shares">84447</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="id71f3b1b590e41788c2f36dd5ef0023c_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMy0zLTEtMS0w_bde2fe07-e06f-48d6-b694-bb345f319eff"
      unitRef="usd">531746</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfMy05LTEtMS0w_79ce3fdd-de6d-4657-934b-315783fa8436"
      unitRef="usd">531746</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i8c307de3b4e5439ebd106206ec278efd_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNC01LTEtMS0w_ab7ee01c-8c64-46a1-97df-0849ed2ac9ef"
      unitRef="usd">-549507</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2d2d8f136b4c4979a189712441c7cf09_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNC03LTEtMS0w_5f7bbe9d-f3af-45b5-8fda-b21e2878de42"
      unitRef="usd">-17305</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNC05LTEtMS0w_6a17b8cb-3537-41f3-ae14-e033756ad428"
      unitRef="usd">-566812</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8b4d219a9d4941c3950eb19706eb7a5c_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS0xLTEtMS0w_98a26d29-a139-4fb4-a2e6-6e882cb9ad8c"
      unitRef="shares">15471070</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b4d219a9d4941c3950eb19706eb7a5c_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS0zLTEtMS0w_0eb9f0b7-3244-44c2-8b1d-08920e28854c"
      unitRef="usd">49938254</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a8bcdfaca924879b5b43dd5bddd703a_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS01LTEtMS0w_a7a5a978-928f-48d9-9bcb-872d99d9d34f"
      unitRef="usd">4122769</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i067cca3f781144dd860b28147290813f_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS03LTEtMS0w_65397588-b585-438d-994a-d22fd0a2385d"
      unitRef="usd">-372306</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3afa198dbba942a8a7bb26d3c8157c4d_I20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY3NmQyMjMwMmJkOTRiNzNiMWE4YTRlOWVmZTMyYmZkL3RhYmxlcmFuZ2U6Zjc2ZDIyMzAyYmQ5NGI3M2IxYThhNGU5ZWZlMzJiZmRfNS05LTEtMS0w_a842e492-74c6-48f7-94ce-281cc0aa66c0"
      unitRef="usd">53688717</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iae43656c3c484911bf5d613a8a8e45be_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi0xLTEtMS0w_394b4751-f07f-4120-b625-405f8f20b041"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae43656c3c484911bf5d613a8a8e45be_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi0zLTEtMS0w_1ff1e977-92f0-410d-8b99-aac26818f0e7"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i555b1189aac24c028c9886b3795085a2_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi01LTEtMS0w_e62e6507-cde5-4333-a68e-9ec3e812d659"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4f2d546729f4a7388d0da7c59afeefd_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi03LTEtMS0w_652285ae-cc82-475f-9355-5f1ddf7d0ac0"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMi05LTEtMS0w_e5893db9-a5e4-4f07-8f9a-ca83a51a1403"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMy0xLTEtMS0w_430ac57f-65aa-4c25-af09-6c8af531de87"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMy0zLTEtMS0w_ea5fc642-bad8-4534-9506-4da14a2d9822"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfMy05LTEtMS0w_a730a6f7-9007-480d-b28d-9c9da1876c95"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNC0xLTEtMS0w_4db927ac-5473-4778-9bb0-1f813e7b874d"
      unitRef="shares">164866</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i0768144df9f74550ab2219166aa29003_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNC0zLTEtMS0w_8ee972b3-911d-490a-a3fe-dea87df39ea3"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNC05LTEtMS0w_a6e40a0e-8def-4d15-a18e-b0d4e524cc63"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i9594a27a8953498781fa2c5b518d8690_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNS01LTEtMS0w_30b53eb8-4de1-431f-8258-12e291908b49"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b35cee38dff4f04bdb57a8e96d4e329_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNS03LTEtMS0w_b94c795d-0e85-4d54-bac9-9416c57fdd79"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i96476f16f2d84f92af7d0682beb18a81_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNS05LTEtMS0w_08c4dd5f-6011-4586-bf14-6ff4574ef3fc"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi0xLTEtMS0w_22e6e5f1-60be-4416-bef5-1d2786817d31"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi0zLTEtMS0w_00806a6c-dac1-46ba-b36d-d6d2f190e3cc"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9c893f1703e4ba7b7c6c8a4e8d3796d_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi01LTEtMS0w_41672f51-1e4a-4f35-8af5-2d6e57951767"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17bd2f5664584e4e961c165808307967_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi03LTEtMS0w_bd68f069-ac48-4dd0-8bcf-a770f6822807"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab2bd5c666b24aa0b832eb6b9d845d8c_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmY5ZDVjZWFhYjhiNjRiMzhhZDMyMjM5ZjI2ZWY0M2QzL3RhYmxlcmFuZ2U6ZjlkNWNlYWFiOGI2NGIzOGFkMzIyMzlmMjZlZjQzZDNfNi05LTEtMS0w_7395ba81-da8d-48cd-aa7e-ca61a92a14f5"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC0xLTEtMS0w_3ab11a68-7ee7-466d-853c-6e445f55ec9f"
      unitRef="shares">15318539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6a024f6a04f4471a56faa5a162c173b_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC0zLTEtMS0w_23d3291a-5e38-4358-aa39-f260eafce729"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9c893f1703e4ba7b7c6c8a4e8d3796d_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC01LTEtMS0w_a9fcf70b-62ea-4d67-86c7-b83a70d81363"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17bd2f5664584e4e961c165808307967_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC03LTEtMS0w_e3f64020-2e73-4239-bfbd-3425a4b0162f"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab2bd5c666b24aa0b832eb6b9d845d8c_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMC05LTEtMS0w_b27e819a-bcef-4721-a84a-fe860ca122d5"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMS0xLTEtMS0w_bc95cf52-6fa0-4aa9-930d-1b1c112751dc"
      unitRef="shares">4200</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMS0zLTEtMS0w_93b434a0-7c32-42c3-960f-13fb47277801"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfMS05LTEtMS0w_015404c7-70a1-4d53-8dd8-d817a661dc06"
      unitRef="usd">278349</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNC0xLTEtMS0w_6a3dcbb5-3464-4879-970c-cf2afd67b739"
      unitRef="shares">141463</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i819d6eb107bb430f9b4eb890c824cb92_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNC0zLTEtMS0w_ca68a778-5826-4d55-9d9b-ba994d4a7131"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNC05LTEtMS0w_b04aba61-3ced-4852-b731-61b398706590"
      unitRef="usd">769648</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i45bf4110d4a5466bb3c612fbfef3c696_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNS01LTEtMS0w_07fd6fd1-4936-4e61-978c-3a406d4656e5"
      unitRef="usd">-918275</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i66d5c13fd94d4f238dd81f8caf9f3403_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNS03LTEtMS0w_8745eae6-0719-4842-8d8e-1099e8671998"
      unitRef="usd">-22314</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNS05LTEtMS0w_b022045d-addb-4e5a-8ab9-79043768d9cc"
      unitRef="usd">-940589</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i08c7c34335f54f47863478492f5a0e20_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi0xLTEtMS0w_b1a9f929-19f1-4884-b2d0-ef725832da01"
      unitRef="shares">15181276</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08c7c34335f54f47863478492f5a0e20_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi0zLTEtMS0w_33cf519f-4cfe-414e-ae3b-503c9a1b35d1"
      unitRef="usd">49246129</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f61c1f6404247408b4f8f98b89594d2_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi01LTEtMS0w_d39fd368-a65c-4419-974e-186aea0ab766"
      unitRef="usd">-765500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabb40a61c7844cbe9615cb5fbe8dba63_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi03LTEtMS0w_d08231fc-16a1-49dc-9a61-02ac0434bfa7"
      unitRef="usd">-69459</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8yNS9mcmFnOjQyZjIyOGJkZjZhMzRmNWU4NzgzN2U1MWM3MTY3OGFlL3RhYmxlOmU0MWE3MTk4N2E5ZjQ5NDk5OTQwOTllNDg1OTM0Mjg4L3RhYmxlcmFuZ2U6ZTQxYTcxOTg3YTlmNDk0OTk5NDA5OWU0ODU5MzQyODhfNi05LTEtMS0w_b6a4dc11-c6aa-4adf-ad1f-f158f09433b8"
      unitRef="usd">48411170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMTA_fa8d9a22-13f0-41f9-b2c9-84a17cb08f42">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#x201c;2019 Annual Report on Form 10-K&#x201d;). The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Reclassification of prior period amounts&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the condensed consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the condensed consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the 2019 periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's corporate, sales and Cumberland Emerging Technologies (&#x201c;CET&#x201d;) employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#x2019; safety and well-being, while also keeping its business operating.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMDM_1329f866-5f69-4dea-8145-34052f589e8a">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMDY_04dfacbe-1b81-4234-b737-41359699f08f">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTEwMDg_483af090-16d5-46ce-a2cb-06cd655f0282">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zMS9mcmFnOjBmZmIxYzA4YzQ5MTRiYWJiN2RhYzRlMTZjZjc5N2FlL3RleHRyZWdpb246MGZmYjFjMDhjNDkxNGJhYmI3ZGFjNGUxNmNmNzk3YWVfMTAyMDA_5e756bdc-3352-45a6-8547-51e8f0060456"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RleHRyZWdpb246MzhlYzgzNDVhODZhNDZlNDg0OWQ3ZDNiNjE0Y2MyMmVfMzQzNQ_dfafb04d-63f0-4303-866f-d734ee4b0df5">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of June 30, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of June 30, 2020 and December 31, 2019, all trading securities were investments with original maturities of less than ninety days and as a result, were classified as cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 -   Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.162%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RleHRyZWdpb246MzhlYzgzNDVhODZhNDZlNDg0OWQ3ZDNiNjE0Y2MyMmVfMzQ0MA_0bcf7712-877e-4eb0-aa4a-bf7ca0c92f26">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.162%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="i5f3a745bf4174278a74c0d5a8fa02da3_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC0xLTEtMS0w_774da53a-8b98-4433-9b5b-e69866bbe2e8"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idea52a7e581244558e3b890ffe46b51c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC0zLTEtMS0w_5a8b3e9f-47b5-444d-9bf6-8435ab0221d4"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia322c6d2a6df4e9fa5ed3bb2684d5ddc_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC01LTEtMS0w_cd194fc6-ad52-44f4-ae07-fdf76bcb800b"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i9323653bab9c4287addb88df384f442e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC03LTEtMS0w_771fa954-3f6a-4a4f-9cd8-5ee37f2d5827"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0dd57a040d73460c9eb5b7058fff5111_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC05LTEtMS0w_1ebfc308-6867-4b93-a789-34dbe117afca"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if41ac3abceec4ba59776f3a5132e11cf_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNC0xMS0xLTEtMA_88dc8203-c0d8-4e5c-947e-c9f5abaa42f6"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4e21e374e0f74f1598291e91e92c3d51_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi0xLTEtMS0w_3858d978-86d2-42a0-ab99-4a9519f5af5a"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i92c97dcff25b433083d6b0f9f881f774_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi0zLTEtMS0w_b55bb3a0-34a3-4e12-a69f-645b660fc50b"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi01LTEtMS0w_fe83860e-c2f5-4865-a624-891dbda27b83"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ia08b7430594741ebaab75913bbcae614_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi03LTEtMS0w_9ff39fee-40ed-4ecb-8a46-bd2544397d6e"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id509d7930bbf4bd694189ff99605fa09_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi05LTEtMS0w_ed59e4b8-d86b-4e73-84b6-626810f438dc"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNC9mcmFnOjM4ZWM4MzQ1YTg2YTQ2ZTQ4NDlkN2QzYjYxNGNjMjJlL3RhYmxlOjZkNTQyMTA4YjNkZDQwNGM4ZGIxMTcyYTI4Y2VlM2VjL3RhYmxlcmFuZ2U6NmQ1NDIxMDhiM2RkNDA0YzhkYjExNzJhMjhjZWUzZWNfNi0xMS0xLTEtMA_2bd1745a-261f-431a-88b1-b82305b2b094"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfNDI5_78945fbf-b839-48c9-bca1-280eb68a429a">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.087%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.446%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,679,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,338,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;771,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(918,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.087%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.446%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,562,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,526,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,918,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,973,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(623,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020 and 2019, restricted stock awards and options to purchase 199,210 and 13,500 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfNDMz_fa9e69b3-0dba-4236-88d5-c2c0cf1f281b">&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.087%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.446%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,679,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,338,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;738,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;771,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net (income) loss at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(918,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(549,507)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,523,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.087%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.444%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.446%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3,562,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,526,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,556,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,918,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(16,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,973,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(623,385)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,241,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,497,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMy0xLTEtMS0zMjc_fe5f238f-6cd6-4d6d-a14f-73d2c313fd5d"
      unitRef="usd">-1679211</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMy0zLTEtMS0zMjc_7022d629-37e8-4fc5-9ae6-73158992adb8"
      unitRef="usd">-1338521</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNC0xLTEtMS0zMjk_3156a832-dc41-4c64-94eb-23879b385c9d"
      unitRef="usd">738622</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNC0zLTEtMS0zMjk_c259318c-0c67-462c-900d-7486e1c1cc01"
      unitRef="usd">771709</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNS0xLTEtMS0zMzE_9edcca95-ce25-466e-a31c-753c62a114c7"
      unitRef="usd">-22314</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNS0zLTEtMS0zMzE_a648f629-2831-4f27-b1f7-1026422b7c40"
      unitRef="usd">-17305</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNi0xLTEtMS0zMzM_f4630e2a-378a-41a3-91c2-93090749741b"
      unitRef="usd">-918275</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfNi0zLTEtMS0zMzM_d0a9d967-fa20-40dd-9d9f-1304af105ed6"
      unitRef="usd">-549507</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfOC0xLTEtMS0zMzU_aa209967-83b2-48cd-86c7-e381f010e476"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfOC0zLTEtMS0zMzU_74ef3cc9-dcdd-4f84-8f85-349fa4dff825"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMTAtMS0xLTEtMzM3_72900226-7db4-4353-a385-f7512f61af53"
      unitRef="shares">15241463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjFjODgzNTRjYjRlYjQxM2RhODNjZjA3NjRkNmFjYzNiL3RhYmxlcmFuZ2U6MWM4ODM1NGNiNGViNDEzZGE4M2NmMDc2NGQ2YWNjM2JfMTAtMy0xLTEtMzM3_3d8a0b28-bba3-4c9f-8be6-2a3f8ba2b72e"
      unitRef="shares">15523628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMy0xLTEtMS0w_38fea491-9bd3-4479-855a-8ee560ecd7ce"
      unitRef="usd">-3562629</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMy0zLTEtMS0w_0924735d-6ec3-43ee-9186-832222077ec3"
      unitRef="usd">-2526075</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNC0xLTEtMS0w_ef9a550e-9843-4b82-a289-b1acc3baef2c"
      unitRef="usd">1556895</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNC0zLTEtMS0w_dffa6539-d223-44ab-a29b-846f5c5e28d0"
      unitRef="usd">1918845</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNS0xLTEtMS0w_16f50ad7-a515-44cc-8025-c644af4e00f7"
      unitRef="usd">-31839</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNS0zLTEtMS0w_c41d323e-2291-4475-833e-3b9eaf2d0b29"
      unitRef="usd">16155</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNi0xLTEtMS0w_8b777266-d406-423c-8476-0d6a4a3bcba6"
      unitRef="usd">-1973895</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfNi0zLTEtMS0w_4fb35814-c7d0-4e91-ab23-b7e5a9e76b90"
      unitRef="usd">-623385</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOC0xLTEtMS0w_90310ade-0d34-458f-ada0-d7e650387e0a"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOC0zLTEtMS0w_cc409c1d-0df6-48bf-93e2-b996cfa4d47c"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOS0xLTEtMS0w_65e54301-d1f5-465f-8653-a1929d7465d0"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfOS0zLTEtMS0w_5961758d-4fa7-440a-af53-d0c3ff2fb34d"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMTAtMS0xLTEtMA_677426b1-99e7-4dae-a9cb-9ff74c8e3048"
      unitRef="shares">15241020</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RhYmxlOjExYWVjNDhiMzkyMDRmNmU5MDg0MzczNDc1YjQ4ODhiL3RhYmxlcmFuZ2U6MTFhZWM0OGIzOTIwNGY2ZTkwODQzNzM0NzViNDg4OGJfMTAtMy0xLTEtMA_41ec238e-8e09-4b53-9dc4-229c8376b150"
      unitRef="shares">15497989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfMjUz_5ab50bd2-92ff-485f-9622-46019bce8116"
      unitRef="shares">199210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF8zNy9mcmFnOmZiNGJlOTBjMWVkMzQyOWI5Y2Y5MjM0MWFlNjI1YjAwL3RleHRyZWdpb246ZmI0YmU5MGMxZWQzNDI5YjljZjkyMzQxYWU2MjViMDBfMjYw_85e31b96-3e7a-471b-a83f-ed28ecdef599"
      unitRef="shares">13500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMjIwNg_0a4e55c3-6fc8-4d57-8b31-d0b2becd7adf">REVENUES&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.409%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.202%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.202%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.202%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;595,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;983,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,308,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,832,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;478,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;124,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,477,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,476,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,771,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,785,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;382,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;499,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,166,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,054,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,261,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,372,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,299,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,599,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,721,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,659,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;612,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,359,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,598,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,417,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,928,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,147,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1&#160;million and $0.2 million for the three months ended June 30, 2020 and 2019, and $0.3 million and $0.8 million for the six months ended June 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMjIwNQ_f4c108ad-c7c3-4d75-aa0f-9b1ef6ae0102">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:38.409%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.202%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.202%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.824%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.202%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.205%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;595,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;983,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,308,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,832,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;478,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;124,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,477,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,476,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,771,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,785,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;174,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;212,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;382,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;499,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,166,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,054,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,261,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,372,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,299,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,599,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,721,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,659,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;874,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;612,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,359,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,319,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,598,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,417,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,928,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,147,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5669834e215b45b99cc41e3d665e69a1_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy0xLTEtMS0w_7b598c76-4e7b-4d29-bb89-e73b6ba4aa48"
      unitRef="usd">595310</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if68a865edbbc4fa68606bf229911a560_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy0zLTEtMS0w_96aaf91c-be8f-450e-b666-3d499abd3879"
      unitRef="usd">983473</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02b378ebb06a479bbf879faf98e19814_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy01LTEtMS0w_94b70b0f-64b5-4cc1-824c-bd172fd26208"
      unitRef="usd">1308711</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc949d2f070b4f25affead2a375d491e_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMy03LTEtMS0w_5f143aa3-70b4-4d20-8c52-513fb98afa49"
      unitRef="usd">1832976</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddf47d357fe2412f8af2acff2342ebb6_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC0xLTEtMS0w_83e57bed-f84f-445f-8678-28b210900142"
      unitRef="usd">10948</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc40475e1a9d4a6bb5ec18bfe4e3e1b3_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC0zLTEtMS0w_444ad37f-95c8-46e4-8543-a6c323c84091"
      unitRef="usd">478604</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6b3dd0ec548447582e12cdbcd66e63b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC01LTEtMS0w_60030ab4-442f-4f33-9024-4176938f4764"
      unitRef="usd">124371</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffd0d5dd3b844bdaa5729899189c6770_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNC03LTEtMS0w_339e8c77-8598-4446-af4f-b3c242b530fb"
      unitRef="usd">678141</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd91fba54ac84e0a8c8bd5e8f448455f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS0xLTEtMS0w_d670cf34-b160-4dcd-986a-47d8d8a7a363"
      unitRef="usd">3477471</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0a5687dc8d944909b67b606cb812cce_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS0zLTEtMS0w_ab7824b2-9bd1-4b55-af88-476a34bc414f"
      unitRef="usd">3476807</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e3f32cd85cd4f9e996353f5f78ff1b7_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS01LTEtMS0w_75fcabec-e8c6-43d4-853c-df374d73c375"
      unitRef="usd">6771433</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06ca879e8d4a47f39f75644f1ed2d685_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNS03LTEtMS0w_5be3944f-e040-483f-ae91-fa24d26bc147"
      unitRef="usd">6785050</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea199d488f3d4c6fbdc6df78ea63c963_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi0xLTEtMS0w_1f3e8816-2a9e-4a4e-8592-6981f08e6b59"
      unitRef="usd">174159</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i285e24ce4de04744ab32c8c31fb15880_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi0zLTEtMS0w_150dea6a-6f89-40c0-87d1-10038705bd92"
      unitRef="usd">212526</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fdbdea3b95045f39274bd68ed525b3e_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi01LTEtMS0w_364a5bb1-e135-40b3-8c7b-46d58de6b4d4"
      unitRef="usd">382016</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i810c3828a9d245e9a17ec124b2f9b2e8_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNi03LTEtMS0w_08157a82-d9c3-4b2a-afe8-410e935de76d"
      unitRef="usd">499202</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6deafdc7c3545129085c07232f96d65_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy0xLTEtMS0w_06eb3c1c-005d-45d8-ab0b-c4b16f8eddd0"
      unitRef="usd">1166569</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9de4abd6721c4ddfae052da0cb09699a_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy0zLTEtMS0w_ce1fac6f-bbc9-452d-97e9-0516d8fd83e8"
      unitRef="usd">1054718</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i566675b7d46442779736a5e02fec5bb6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy01LTEtMS0w_95c78c9b-c275-4515-ac1b-a6c1f902ac76"
      unitRef="usd">2261286</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fe634f61a1e4a5a9ad7dcfe2f238132_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfNy03LTEtMS0w_f02a1466-598f-44b5-bd97-9fe096ad4d78"
      unitRef="usd">2372599</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia147af4d03624f11ac640a8b4886b751_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC0xLTEtMS0w_cb9b727b-9a82-4f86-82ee-f69eee92523e"
      unitRef="usd">3299507</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i217c307695d149f3a072f507e80428e0_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC0zLTEtMS0w_498892b3-252c-43c9-83ce-3ef09b979665"
      unitRef="usd">2599280</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1febb70c5d54883bd12e7f1136868a7_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC01LTEtMS0w_bea5d148-cdb3-41db-92d1-c3952a7480eb"
      unitRef="usd">5721708</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0aaf60aeada144d6b60fa49b4caff778_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOC03LTEtMS0w_a11fa1f4-74f6-4b06-a66f-055c7b21884f"
      unitRef="usd">4659471</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c1b0b04c6a4448c9bdd40023c85de9c_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS0xLTEtMS0w_81e68e15-f0bb-4501-a5ef-b714288137c6"
      unitRef="usd">874213</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i410438689ecc46098ef7e58bf86b9e48_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS0zLTEtMS0w_8571687d-ea54-40d6-90f6-a51815caa505"
      unitRef="usd">612035</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i918c1048efdc4eeaa992c0bef857728b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS01LTEtMS0w_2c21b533-58fc-463d-96ae-31465234821a"
      unitRef="usd">1359386</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia46fcc7519ab4d55866e429c4169b5c6_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfOS03LTEtMS0w_600411fc-2122-48ee-965e-661545e156bf"
      unitRef="usd">1319864</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtMS0xLTEtMA_bbdb38e9-520c-4345-a416-c244b47710bc"
      unitRef="usd">9598177</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic33260ae2f3e427ea877af8f0a5e48d1_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtMy0xLTEtMA_ed5c4504-6410-4988-baaa-a9a58a2c50d9"
      unitRef="usd">9417443</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtNS0xLTEtMA_841a106b-3f93-40a9-9d56-282f429d9cc7"
      unitRef="usd">17928911</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93a8372917ee45d59a9761300b60915f_D20190101-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RhYmxlOjkyZGYyZmU3YTlmZDQ4ZjliMDJiMmNiZDBhNTZhY2M1L3RhYmxlcmFuZ2U6OTJkZjJmZTdhOWZkNDhmOWIwMmIyY2JkMGE1NmFjYzVfMTAtNy0xLTEtMA_1076c2c2-c9ce-4d18-ae48-7ceb756c03e4"
      unitRef="usd">18147303</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i338997cfd24048679aea6c8ed87a43ce_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzI1Nw_4589d807-4bec-4f3c-b44e-3e66dfc65e1d"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7262f7e4e1134261beeed2cb335a5dc1_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzI2OQ_1a28d511-6229-49ad-a226-e757e1ad9a49"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17b3c50fbe874b3196c15fa2ac7f84ee_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzM3MQ_6586c077-4624-4356-be65-f9b004cc96c1"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i798cb1e7aeb14bf4a99ccd87345abcd7_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80MC9mcmFnOjMxMDA1Mzk2N2U5NzQ1NzhiYjUyMWI5YTU3OTNjZTAzL3RleHRyZWdpb246MzEwMDUzOTY3ZTk3NDU3OGJiNTIxYjlhNTc5M2NlMDNfMTA5OTUxMTYzNzM4MA_d194376b-a54b-4bc3-b797-1b5c2afdac00"
      unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMjAwOA_2dc766d3-9fd4-48e7-b34f-ddb34d933fee">INVENTORIES&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#x2019;s warehouses.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at multiple locations. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods inventory. Cumberland also maintains API for its Vaprisol brand which is classified as raw materials inventory.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The consigned inventory represents Authorized Generic product which is shipped to the Company&#x2019;s distribution partner and stored until sale.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  The Company also has obtained $0.4&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June 30, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $15.6&#160;million. The Company did not have any finished goods included in the non-current inventories at June 30, 2020 or December 31, 2019, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.531%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,660,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,387,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,267,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,640,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,627,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNoncurrent
      contextRef="i9476294995c8476c8cf46424d7813e1d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMTY2Nw_d40e0c83-547c-403d-8a79-1bc1e6275b34"
      unitRef="usd">400000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMTgzMA_110b0283-bbec-4fca-824b-6d899edddac5"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMTgzMA_850af5a8-40ec-493e-bdb8-a1a13d2de61c"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RleHRyZWdpb246ODBiMWQ1MDUxZjE2NDUxOThkOTk4NDcyMmQ2OWQ2Y2VfMjAwOQ_9c105609-bfe4-49d0-b4e3-a8c878cd0ef3">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.531%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,660,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;219,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,387,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,267,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,640,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,627,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMi0yLTEtMS0w_7fc567f6-7319-4576-9073-51e496f0a22e"
      unitRef="usd">19660890</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMi00LTEtMS0w_b8a382ef-9713-44c7-a4bb-e451e9167384"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMi00LTEtMS0w_e343d231-e1e1-4df5-97aa-fcc5ae2efee8"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMy0yLTEtMS0w_e578d5d0-04b3-4e57-840b-771ab5ce67b2"
      unitRef="usd">219228</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMy00LTEtMS0w_70ac0bc7-2024-4d5a-8bd0-3dc1526f07b9"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfMy00LTEtMS0w_70cd88c3-6f62-4279-806d-030381016f53"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNC0yLTEtMS0w_88ece921-cc2c-4252-8ce2-340df428c53f"
      unitRef="usd">3387212</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNC00LTEtMS0w_15cd3541-2225-4cc2-bc74-4e9a568c8946"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNC00LTEtMS0w_54385687-7a26-46ab-a16e-310757d9608d"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNS0yLTEtMS0w_5db88ec8-1422-4bad-814e-550bf2d7d300"
      unitRef="usd">23267330</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNS00LTEtMS0w_21ed4384-c1df-47c6-b43b-edd803f3d7d7"
      unitRef="usd">24426246</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNi0yLTEtMS0w_a9a5ff7b-f763-4af2-aa18-21ea84736f8f"
      unitRef="usd">15640060</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNi00LTEtMS0w_c5023be1-5fbf-4a3f-967e-b94d0d7ba2c4"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNy0yLTEtMS0w_62a55928-4162-458e-adec-c14ca881002c"
      unitRef="usd">7627270</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80My9mcmFnOjgwYjFkNTA1MWYxNjQ1MTk4ZDk5ODQ3MjJkNjlkNmNlL3RhYmxlOjNiZWYxMGY3ZjljYzQyMjA5M2NhNjYxOTZkNzgwODBmL3RhYmxlcmFuZ2U6M2JlZjEwZjdmOWNjNDIyMDkzY2E2NjE5NmQ3ODA4MGZfNy00LTEtMS0w_1b134590-94f1-4416-879c-bbf6e99954ff"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTgwNw_fd5fac62-9d3c-4d80-8dbb-1fa7878bbc3b">LEASES&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at June 30, 2020 is 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.399%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.399%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;967,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,580,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,547,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.971%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Maturity of Leases Liabilities at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;566,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,823,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(275,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,547,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTY0Mg_ed54b9dd-baf1-4e27-b716-ccefd81b351e"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTY5Nw_837ff8a1-8708-480e-be0b-5df563adddd6">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTgwOA_92a8bb7b-ebad-4b92-ad06-5c722af5c780">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At June 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.399%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,502,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.742%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.643%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.408%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:15.399%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;967,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,580,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,547,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmZiZWQ2MGIzZmQ4NDQxNTdhODk2ZGQ4MmNkZDhhMDhlL3RhYmxlcmFuZ2U6ZmJlZDYwYjNmZDg0NDE1N2E4OTZkZDgyY2RkOGEwOGVfMS00LTEtMS0w_c54cc707-d4ee-4ee3-acf5-246af1343bc2"
      unitRef="usd">2502850</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmZiZWQ2MGIzZmQ4NDQxNTdhODk2ZGQ4MmNkZDhhMDhlL3RhYmxlcmFuZ2U6ZmJlZDYwYjNmZDg0NDE1N2E4OTZkZDgyY2RkOGEwOGVfMS02LTEtMS0w_6230fc23-35f9-4bdf-90cd-6234d140e4e8"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfMi00LTEtMS0w_1432e6f2-6556-4c39-8c53-06c625ac0309"
      unitRef="usd">967656</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfMi02LTEtMS0w_49e9e429-5830-442e-870a-e41e6f69ff96"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNC00LTEtMS0w_712ac865-6ed0-45a5-b17f-fdb01752e7c9"
      unitRef="usd">1580203</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNC02LTEtMS0w_b8c6b5b9-3ff7-416b-a285-9b8d4fde3763"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNS00LTEtMS0w_17954716-2dd1-429e-8b84-5c8fbf1e92a9"
      unitRef="usd">2547859</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOmIyMzA1NTE5OWVjZjQ1YmU4ZTE1MjdjOGZiMGMwZDgxL3RhYmxlcmFuZ2U6YjIzMDU1MTk5ZWNmNDViZThlMTUyN2M4ZmIwYzBkODFfNS02LTEtMS0w_9ec86735-1e8b-4b9b-ac06-df015d402988"
      unitRef="usd">2996903</cpix:LeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RleHRyZWdpb246MzdjM2E0YjkzOWZkNGFjN2FiMTU0OWU3ZjY0NTk3NjVfMTgwOQ_292956c4-0541-46a8-bb22-d1deaf670914">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.971%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"&gt;Maturity of Leases Liabilities at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;566,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,823,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(275,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,547,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfMS0yLTEtMS0w_391c2b0b-7dde-45ba-9138-334bb5db4d58"
      unitRef="usd">566713</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfMi0yLTEtMS0w_adb33da0-38f6-448f-b4e4-86d68dbc4b9a"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfMy0yLTEtMS0w_9548c0d2-87bc-4635-8082-c08f612c0117"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNC0yLTEtMS0w_adf294ec-6d3a-4f17-b5e4-7abade5d2eaa"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNS0yLTEtMS0w_bfab4e4a-df7c-46fa-b103-d7e8dd43883c"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNi0yLTEtMS0w_decf3634-d155-4fbf-8c13-793b75d23e12"
      unitRef="usd">2823393</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfNy0yLTEtMS0w_188ed9a3-b129-439e-94c3-92ef7e0e6a6b"
      unitRef="usd">275534</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80Ni9mcmFnOjM3YzNhNGI5MzlmZDRhYzdhYjE1NDllN2Y2NDU5NzY1L3RhYmxlOjE1NjlhZTU1ZTU1YTRlMGU4MGJlN2EyMDkzYzdlYzNhL3RhYmxlcmFuZ2U6MTU2OWFlNTVlNTVhNGUwZTgwYmU3YTIwOTNjN2VjM2FfOC0yLTEtMS0w_f49e190f-a0e3-4a90-a4cd-3663f148a3e8"
      unitRef="usd">2547859</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNzY5NjU4MTQwNDU1NA_a54d6881-0aa9-412f-9e09-b9c9d9a6a31b">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2020 and June 30, 2019, the Company repurchased 306,329 shares and 205,913, respectively, of common stock for approximately $1.2 million during both 2020 and 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the six months ended June 30, 2020 or June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Restricted Share Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the six months ended June 30, 2020, and June 30, 2019, the Company issued 229,141 shares and 222,469 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cumberland Emerging Technologies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a $1&#160;million investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET common shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $0.8&#160;million that was funded during 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#x201c;Pinnacle Agreement&#x201d;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#x201c;Second Amendment&#x201d;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 2.92% at June 30, 2020).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of June 30, 2020 and December 31, 2019, the Company had $17.0 million and $18.5 million in borrowings outstanding under our revolving credit facility, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The PPP is administered by the U.S. Small Business Administration.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. Cumberland will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4c685386484241a88e1c0f981bdbb1c0_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTMx_7fd8d095-2609-4a17-b5c3-c7cd7287528e"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i90f8ddce573e405db035f43203edac82_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjky_d9193204-f279-4511-817a-6fb459a101d2"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i34205ca5f1bd40e4bc73ff67fce99b21_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzk4_3737717c-67e3-4226-8762-75f4ffadff74"
      unitRef="shares">306329</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i70788808c3514d7cb738bf570ee8ecab_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDEy_8ac3a402-41f3-4b0d-8b74-cfad6de933be"
      unitRef="shares">205913</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i70788808c3514d7cb738bf570ee8ecab_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDY0_886dc398-247f-4358-880e-6a38b36ead85"
      unitRef="usd">1200000</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i326c4e1bbd4143b0991323596e8218e2_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfOTcz_994e3ce8-1fff-4401-9f77-281650a48c32"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4932bbb650d149da92ef6f0570dbee67_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTY0OTI2NzQ0NjU1Ng_a99f2753-46b3-47fd-8441-c93cd00dfb63"
      unitRef="shares">229141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1abd143533634e079845141c8834cf0d_D20190101-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTMxNA_4d0c2bbd-b652-45ee-a49d-05febc13aef9"
      unitRef="shares">222469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2811f76482b0428a8411c4d8087350fc_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNzY5NjU4MTQwNDU1NQ_fdcac782-5db8-4a58-bbf4-a738562b0302">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i576c01f880e64cda9a7bae358c95e641_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTkyOA_336163ef-d63d-45ef-b9e3-d76b45467535"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="i576c01f880e64cda9a7bae358c95e641_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjIxNQ_2004345a-499a-4113-b7ec-eb2e852b3d05"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentCashContribution
      contextRef="ib3072a59195c43eb83bc07add8758654_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjMwNQ_ebf5987f-a179-4046-ae59-d46c144453ea"
      unitRef="usd">300000</cpix:SubsidiaryInvestmentCashContribution>
    <cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable
      contextRef="if09748a76bfe44299df7ff1fe1acec07_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjMzNg_b7a526fc-598a-4989-85c7-422bdd1c55af"
      unitRef="usd">700000</cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="i69c8bad9e0024da2b5f4ecd513ca3279_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMjUzOA_612a2db0-725f-450c-8a93-16a6f2f8033d"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie23ab79d4c84449990786e49b3945c33_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzc1NQ_46bbabef-9556-4543-8db1-0a4aaeb0d4e7"
      unitRef="usd">12000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="ie23ab79d4c84449990786e49b3945c33_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzgzOA_9c00adb2-0c10-4cc8-a789-50918ed89fb8"
      unitRef="usd">20000000.0</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icf877f310c4d446597ea48ad1a455784_I20181017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDA3OQ_b009f4e0-6be9-42bb-ba87-a9650cba8219"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9a59ea378ede42c9b6cecb1b250655ca_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDI2Ng_16922523-aced-48af-b145-a01c97663139"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i814c31ba70e6430d9e51bcc5840e4ac9_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDI3Mg_6fdac87e-d616-44c9-8538-c1a357cc4b4d"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie23ab79d4c84449990786e49b3945c33_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDMwOQ_e88bc2b7-07cf-46b1-a4e1-41a8121d5f95"
      unitRef="number">0.0292</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="icc647785e8e346e4a56e83e0cc7fa9ca_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDM0Mw_85c6e493-9547-4511-8876-fe43a1d48878"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfNDU3OQ_df59a5e0-bc88-4955-8c26-63a3793ca958"
      unitRef="usd">17000000.0</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="id4cd51a619a04cf88ce903ca6be458df_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTY0OTI2NzQ0Njc0NA_759e868c-b9a6-471f-a589-dad8e9981bc2"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i7363b185835a4fefb0d6e62a0ebf0dfc_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTA5OTUxMTYzMzAzNg_9a75751a-38ab-4433-8b31-b9fae997fc9d"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia8648009ac16482485d4df4b4a6b9fa6_I20200420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMTA5OTUxMTYzMzM0Nw_7c7353b7-2b57-43b3-b414-e16a4f5f0729"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i7363b185835a4fefb0d6e62a0ebf0dfc_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF80OS9mcmFnOmU0MTIxNmVjN2VhNzRmYTJiNTI5NTk1OTUxM2ExN2E1L3RleHRyZWdpb246ZTQxMjE2ZWM3ZWE3NGZhMmI1Mjk1OTU5NTEzYTE3YTVfMzg0ODI5MDcwNTc0Ng_9a75751a-38ab-4433-8b31-b9fae997fc9d"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81Mi9mcmFnOjM2Nzc2ZGRiY2U5MDQxZGQ5NjhjZTJiNzEyNmExMDA1L3RleHRyZWdpb246MzY3NzZkZGJjZTkwNDFkZDk2OGNlMmI3MTI2YTEwMDVfNzY5NjU4MTM5NzcwNg_92d0500c-5837-450e-b73f-10879bfded7b">INCOME TAXESAs of June 30, 2020, the Company has approximately $56.3 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie53b0f9aa7b34fdab1a8da61d4eedd27_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81Mi9mcmFnOjM2Nzc2ZGRiY2U5MDQxZGQ5NjhjZTJiNzEyNmExMDA1L3RleHRyZWdpb246MzY3NzZkZGJjZTkwNDFkZDk2OGNlMmI3MTI2YTEwMDVfMTA5OTUxMTYzMDk2NQ_67053f3e-dda7-4a10-8fca-a3f758795eec"
      unitRef="usd">56300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic125e85e38194740b3b6e42596d48565_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81Mi9mcmFnOjM2Nzc2ZGRiY2U5MDQxZGQ5NjhjZTJiNzEyNmExMDA1L3RleHRyZWdpb246MzY3NzZkZGJjZTkwNDFkZDk2OGNlMmI3MTI2YTEwMDVfMTM3Mw_dd031b47-53b6-4572-bed5-e17cced0be5a"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81NS9mcmFnOjBhYzMxZWE2ZGU2NDRhYWRhZDE1Y2UzOTk0NzNmMGI4L3RleHRyZWdpb246MGFjMzFlYTZkZTY0NGFhZGFkMTVjZTM5OTQ3M2YwYjhfOTc4_db92be01-c221-416c-b7f2-93ae6f872d4e">COLLABORATIVE AGREEMENTS&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 10 do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNjAxNw_7203ab7d-23b6-4420-b77a-07578befa81e">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  The Company expects to deduct the goodwill acquired in the acquisition for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.369%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(260,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(645,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;573,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,300,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration liability of $8.3&#160;million was classified as other current liabilities of $2.8&#160;million and other long-term liabilities of $5.5&#160;million on the condensed consolidated balance sheet as of June 30, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V.&#x2019; ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and is recorded as an other current liability at both June 30, 2020 and December 31, 2019.  During the three months ended June 30, 2020, Cumberland recognized $0.5&#160;million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#x201c;the Products&#x201d;)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first two quarterly installments totaling $1.5 million during the six months ended June 30, 2020 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;as discontinued operations and will record each future quarterly installment over the two year period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; As there are no expenses associated with these payments,  approximately $1.5 million in discontinued operations income was recorded during the period ended June 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Products provided $5.3&#160;million in revenue, with $3.4&#160;million in direct expenses resulting in $1.9&#160;million in discontinued operations income during the six months ended June 30, 2019. These direct expenses do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Those sales and marketing individuals who supported the Products have subsequently shifted their efforts to support other Cumberland brands.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December 31, 2019 current assets of discontinued operations included $0.5&#160;million in remaining &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;inventory for the Products sold and returned to Clinigen as part of the transaction. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of June 30, 2020, and December 31, 2019, &lt;/span&gt;the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6a665abb669e4b8294fe2d11afdae64b_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTIxNg_be37664a-1a78-4633-bc42-aa87218257d8"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i2c77d503275442c7bd85a5f3a65d371a_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTI1OQ_21a094a4-418a-4ad9-ad9d-3fb062c0b3e7"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i6a665abb669e4b8294fe2d11afdae64b_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTM2Mg_072e89ed-dee6-418f-8533-5f9dfb344fe8"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNjAyMQ_196accdc-78e4-43d3-af22-10988f92658c">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.369%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfMi0xLTEtMS0w_db173078-2e64-46f3-8750-2e8e99656624"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfMy0xLTEtMS0w_9d99b243-5e5c-453d-b2c7-a430bb8da810"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfNC0xLTEtMS0w_5ff4ebf2-d6b9-466c-bddc-0803a0f79f7d"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjgzNTc0ODMyMDcxYjRiMzM5M2RkZDRkY2RmYmY1NzgyL3RhYmxlcmFuZ2U6ODM1NzQ4MzIwNzFiNGIzMzkzZGRkNGRjZGZiZjU3ODJfNS0xLTEtMS0w_d515a442-6565-4001-826f-223330760f7c"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM1NA_9d54fa5d-8970-40d3-a08a-3b398638ba08">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMC0xLTEtMS0zMDIx_5e8bbbda-2daf-4012-82b7-998bad624b89"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMS0xLTEtMS0zMDIx_ee99872d-ae75-476c-a3b9-d156d3045dc0"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMi0xLTEtMS0zMDIx_d8bb1c0e-7f36-4162-8378-d8a1e733c867"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfMy0xLTEtMS0zMDIx_896c693e-bdf0-40d9-a7a8-4f01fc9dc022"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfNC0xLTEtMS0zMDIx_d90adcb3-cebe-46b9-894f-287de9d6ca99"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfNi0xLTEtMS0zMDIz_0061b7ba-4cc7-45e5-8b83-1ea2b6832660"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfNy0xLTEtMS0zMDIz_645cec66-4673-4447-8843-a30896ae42e0"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfOC0xLTEtMS0zMDIz_7ecb250e-adee-46e2-8c4e-222b765c302d"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOmYyMWIzNzQ5ZmU2ZjQwYzBhZTI3ZTMzMDI3ZGYzNTEyL3RhYmxlcmFuZ2U6ZjIxYjM3NDlmZTZmNDBjMGFlMjdlMzMwMjdkZjM1MTJfOS0xLTEtMS0zMDIz_1c2d4c2c-6a20-4c33-84cd-2feecea54425"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i0b7f8c80c52c49a296cee15864710502_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNjAyMg_6430a94b-f385-4213-b742-745affae06a7">&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(260,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(645,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;573,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,300,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iaf017760b38441c1af2d35a25e124e99_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfOS0xLTEtMS0w_22d2c679-c7ad-4a15-94f5-e2d5937ecb76"
      unitRef="usd">8633589</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTAtMS0xLTEtMA_d821a267-a3a6-471e-8158-c4a30267d135"
      unitRef="usd">260735</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTEtMS0xLTEtMA_1b77001b-0150-437a-841c-4678fa1491de"
      unitRef="usd">-645571</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTItMS0xLTEtMA_567d0a9c-bbf9-49f6-9492-214f759a46da"
      unitRef="usd">573279</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RhYmxlOjRmM2NmYjMzNTY0NDQ0ZjdiYjU2ZDBkZTVlMWUyNDNmL3RhYmxlcmFuZ2U6NGYzY2ZiMzM1NjQ0NDRmN2JiNTZkMGRlNWUxZTI0M2ZfMTMtMS0xLTEtMA_11f3ee84-d435-4ee1-ba1e-7c05460cdddd"
      unitRef="usd">8300562</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id334b396a4b3435091868e865fabd32c_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM5Nw_314973d0-cd01-4a93-a179-918b495d7a82"
      unitRef="usd">8300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib89bcb77f46a4517a75030c3a28c5b4f_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM1Ng_0c3bf241-57be-4aa9-96d2-1c7ebc8a0a55"
      unitRef="usd">2800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if905a7f82f44495396e2179b4d0584ba_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzM3MA_31809291-7706-41e9-ae88-157e5ce3c1b8"
      unitRef="usd">5500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ief4c0cae1876488cbb05cfd3be1ad10d_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMjk0NQ_0cefc811-286c-4a63-ae9d-8a2471c50423"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ief4c0cae1876488cbb05cfd3be1ad10d_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMjk5MQ_0b46feb6-5d65-4a77-88f3-e523e805c9a8"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="if3a989ff74234cd4a92b992a22f309d6_D20161101-20161130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzAxOQ_0209d9fd-dcae-4f23-b9a9-ed4289cce88d"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="if3a989ff74234cd4a92b992a22f309d6_D20161101-20161130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzQ3Mw_0209d9fd-dcae-4f23-b9a9-ed4289cce88d"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i46ecb77eacf14a63afd0516b29399c0a_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzU0Nw_fae2757a-f3d9-4aee-a962-e5d2802f4987"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i575e7871cbfc48ecb68373ff71bde4cb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMzY0OA_65b0d0ae-dcde-4db3-bb5a-eb21b2e4dcd4"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Revenues
      contextRef="i484fde4f0aac43cf954b8569b221802d_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMjc0ODc3OTA4MjQzMw_eb22077f-cf12-4f2f-b777-c9a8777bd5b3"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i0967848cdd484daebc2c83c3e623f456_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNDYwNA_931cac8f-fbc0-4cd3-953b-346f8343fc2b"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ibb806d70ebf248d28f3e9175478166e3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTY0OTI2NzQ0ODAxNw_cb4f5f74-f473-408c-b1fe-8b0cb779cea7"
      unitRef="usd">1500000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ibb806d70ebf248d28f3e9175478166e3_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfMTY0OTI2NzQ0ODA5Mw_cb4f5f74-f473-408c-b1fe-8b0cb779cea7"
      unitRef="usd">1500000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:Revenues
      contextRef="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNTExMA_ac04229b-d2c6-4789-aaa7-01aafe7f7640"
      unitRef="usd">5300000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNzY5NjU4MTQwNzQxMQ_89d720f1-8be5-480d-95c9-503c8251b034"
      unitRef="usd">3400000</us-gaap:OperatingExpenses>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNTE1MQ_b48896ce-d0f4-411a-bafc-2625723b28cb"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i8bb4e69141de4966aa42c82e466f9e01_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjYwYzc4OWFhNjk1ZTQ0MTQ5NGIwOWQ0OGEyMWU1Yzc0L3NlYzo2MGM3ODlhYTY5NWU0NDE0OTRiMDlkNDhhMjFlNWM3NF81OC9mcmFnOmNkODIyM2I4ZjBjYzRjNzRiY2RjOTk1MDI2OTQ5YWZmL3RleHRyZWdpb246Y2Q4MjIzYjhmMGNjNGM3NGJjZGM5OTUwMjY5NDlhZmZfNTU4Ng_18541aa5-07f0-4bb1-9099-4446e596e1ec"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382122217160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,138,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382120209688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,373,737<span></span>
</td>
<td class="nump">$ 28,212,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">7,924,338<span></span>
</td>
<td class="nump">7,843,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">7,627,270<span></span>
</td>
<td class="nump">8,871,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">744,403<span></span>
</td>
<td class="nump">2,477,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,085,230<span></span>
</td>
<td class="nump">2,757,456<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,754,978<span></span>
</td>
<td class="nump">50,163,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,640,060<span></span>
</td>
<td class="nump">15,554,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">631,534<span></span>
</td>
<td class="nump">747,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">29,151,228<span></span>
</td>
<td class="nump">30,920,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">21,802<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,502,850<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,939,003<span></span>
</td>
<td class="nump">3,298,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">97,523,455<span></span>
</td>
<td class="nump">104,549,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,829,982<span></span>
</td>
<td class="nump">9,993,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,918,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">967,656<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">10,866,765<span></span>
</td>
<td class="nump">11,317,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,664,403<span></span>
</td>
<td class="nump">24,150,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">1,580,203<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">7,867,679<span></span>
</td>
<td class="nump">8,737,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,112,285<span></span>
</td>
<td class="nump">53,464,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">49,246,129<span></span>
</td>
<td class="nump">49,914,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (deficit)</a></td>
<td class="num">(765,500)<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">48,480,629<span></span>
</td>
<td class="nump">51,122,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(69,459)<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">48,411,170<span></span>
</td>
<td class="nump">51,085,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 97,523,455<span></span>
</td>
<td class="nump">$ 104,549,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382123546888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,181,276<span></span>
</td>
<td class="nump">15,263,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,181,276<span></span>
</td>
<td class="nump">15,263,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119441688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 17,928,911<span></span>
</td>
<td class="nump">$ 18,147,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">2,609,982<span></span>
</td>
<td class="nump">1,792,293<span></span>
</td>
<td class="nump">4,244,163<span></span>
</td>
<td class="nump">3,451,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">3,865,406<span></span>
</td>
<td class="nump">3,982,379<span></span>
</td>
<td class="nump">7,573,082<span></span>
</td>
<td class="nump">7,419,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,421,502<span></span>
</td>
<td class="nump">1,716,169<span></span>
</td>
<td class="nump">3,144,057<span></span>
</td>
<td class="nump">3,115,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,190,764<span></span>
</td>
<td class="nump">2,270,318<span></span>
</td>
<td class="nump">4,227,048<span></span>
</td>
<td class="nump">4,807,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,091,485<span></span>
</td>
<td class="nump">1,029,708<span></span>
</td>
<td class="nump">2,167,524<span></span>
</td>
<td class="nump">2,051,353<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">11,179,139<span></span>
</td>
<td class="nump">10,790,867<span></span>
</td>
<td class="nump">21,355,874<span></span>
</td>
<td class="nump">20,844,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,580,962)<span></span>
</td>
<td class="num">(1,373,424)<span></span>
</td>
<td class="num">(3,426,963)<span></span>
</td>
<td class="num">(2,697,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">28,661<span></span>
</td>
<td class="nump">130,565<span></span>
</td>
<td class="nump">58,549<span></span>
</td>
<td class="nump">246,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(119,455)<span></span>
</td>
<td class="num">(91,200)<span></span>
</td>
<td class="num">(152,520)<span></span>
</td>
<td class="num">(152,111)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(1,671,756)<span></span>
</td>
<td class="num">(1,334,059)<span></span>
</td>
<td class="num">(3,520,934)<span></span>
</td>
<td class="num">(2,603,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(7,455)<span></span>
</td>
<td class="num">(4,462)<span></span>
</td>
<td class="num">(41,695)<span></span>
</td>
<td class="nump">76,966<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">(1,679,211)<span></span>
</td>
<td class="num">(1,338,521)<span></span>
</td>
<td class="num">(3,562,629)<span></span>
</td>
<td class="num">(2,526,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">738,622<span></span>
</td>
<td class="nump">771,709<span></span>
</td>
<td class="nump">1,556,895<span></span>
</td>
<td class="nump">1,918,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(940,589)<span></span>
</td>
<td class="num">(566,812)<span></span>
</td>
<td class="num">(2,005,734)<span></span>
</td>
<td class="num">(607,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">22,314<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">31,839<span></span>
</td>
<td class="num">(16,155)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (1,973,895)<span></span>
</td>
<td class="num">$ (623,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">(0.06)<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.23)<span></span>
</td>
<td class="num">(0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">15,241,463<span></span>
</td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,241,463<span></span>
</td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382195339176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,005,734)<span></span>
</td>
<td class="num">$ (607,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">1,556,895<span></span>
</td>
<td class="nump">1,918,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(3,562,629)<span></span>
</td>
<td class="num">(2,526,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,334,669<span></span>
</td>
<td class="nump">2,174,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">542,923<span></span>
</td>
<td class="nump">760,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(645,571)<span></span>
</td>
<td class="num">(321,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">22,973<span></span>
</td>
<td class="nump">28,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(80,421)<span></span>
</td>
<td class="num">(652,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,158,916<span></span>
</td>
<td class="nump">883,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">1,017,650<span></span>
</td>
<td class="nump">141,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">2,413,768<span></span>
</td>
<td class="num">(163,530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(869,644)<span></span>
</td>
<td class="num">(342,940)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="nump">2,332,634<span></span>
</td>
<td class="num">(100,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">1,371,437<span></span>
</td>
<td class="nump">1,565,604<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">3,704,071<span></span>
</td>
<td class="nump">1,464,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(50,883)<span></span>
</td>
<td class="num">(89,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,627,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,563,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(722,131)<span></span>
</td>
<td class="num">(395,005)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(773,014)<span></span>
</td>
<td class="num">(6,547,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">35,500,000<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(37,000,000)<span></span>
</td>
<td class="num">(36,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(260,735)<span></span>
</td>
<td class="num">(684,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(1,209,220)<span></span>
</td>
<td class="num">(1,220,690)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(3,769,955)<span></span>
</td>
<td class="num">(1,905,428)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(838,898)<span></span>
</td>
<td class="num">(6,987,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">28,212,635<span></span>
</td>
<td class="nump">27,938,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 27,373,737<span></span>
</td>
<td class="nump">$ 20,951,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382113956680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">$ 4,746,154<span></span>
</td>
<td class="num">$ (274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">364,434<span></span>
</td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(703,790)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(40,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,878)<span></span>
</td>
<td class="nump">33,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2019</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">4,746,154<span></span>
</td>
<td class="num">(274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(607,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2019</a></td>
<td class="nump">53,688,717<span></span>
</td>
<td class="nump">$ 49,938,254<span></span>
</td>
<td class="nump">4,122,769<span></span>
</td>
<td class="num">(372,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,471,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2019</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">396,548<span></span>
</td>
<td class="nump">$ 396,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Repurchase of subsidiary shares from noncontrolling interests</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">$ (685,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(531,746)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,447)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(566,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(549,507)<span></span>
</td>
<td class="num">(17,305)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2019</a></td>
<td class="nump">53,688,717<span></span>
</td>
<td class="nump">$ 49,938,254<span></span>
</td>
<td class="nump">4,122,769<span></span>
</td>
<td class="num">(372,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,471,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,263,355<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(441,624)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,620)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2020</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,263,355<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,005,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2020</a></td>
<td class="nump">$ 48,411,170<span></span>
</td>
<td class="nump">$ 49,246,129<span></span>
</td>
<td class="num">(765,500)<span></span>
</td>
<td class="num">(69,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">15,181,276<span></span>
</td>
<td class="nump">15,181,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Mar. 31, 2020</a></td>
<td class="nump">$ 49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">152,775<span></span>
</td>
<td class="num">(47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,318,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">278,349<span></span>
</td>
<td class="nump">$ 278,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(769,648)<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(940,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(918,275)<span></span>
</td>
<td class="num">(22,314)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Jun. 30, 2020</a></td>
<td class="nump">$ 48,411,170<span></span>
</td>
<td class="nump">$ 49,246,129<span></span>
</td>
<td class="num">$ (765,500)<span></span>
</td>
<td class="num">$ (69,459)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">15,181,276<span></span>
</td>
<td class="nump">15,181,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117820920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;2019 Annual Report on Form 10-K&#8221;). The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Discontinued Operations</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reclassification of prior period amounts</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has made certain reclassifications to prior period amounts to conform to the current-year presentation of the reporting of research and development expense and general and administrative expense on the condensed consolidated statements of operations. Certain costs and expenses related to research and development were previously reported as general and administrative expenses on the condensed consolidated statements of operations. These reclassifications have no effect on the reported operating loss or equity for the 2019 periods presented. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. The Company has implemented measures to address the impact of the novel coronavirus on the business and taken appropriate action to protect the employees, secure the supply chain, and support the patients who can benefit from its medicines.  All of the Company's corporate, sales and Cumberland Emerging Technologies (&#8220;CET&#8221;) employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland's sales organization has continued to interact with medical professionals, providing information and product samples as requested. However, much of their contact has shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.  Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on the future results as of the date of this filing.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company continues to monitor the COVID-19 pandemic situation both in the U.S. and internationally in order to maintain the employees&#8217; safety and well-being, while also keeping its business operating.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div>Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117830168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of June 30, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of June 30, 2020 and December 31, 2019, all trading securities were investments with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:27.368%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.162%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117813896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:justify;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.087%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.446%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,679,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,338,521)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">738,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">771,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,305&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(918,275)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(549,507)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:58.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.618%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.087%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.446%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,562,629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,526,075)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,556,895&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,918,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,155)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,973,895)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(623,385)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020 and 2019, restricted stock awards and options to purchase 199,210 and 13,500 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117827928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:38.409%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.202%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.202%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.202%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">595,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">983,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,832,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">478,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124,371&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,477,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,476,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,771,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,785,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">382,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">499,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,166,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,054,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,372,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,299,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,721,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874,213&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">612,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,359,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,598,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,417,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,147,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.1&#160;million and $0.2 million for the three months ended June 30, 2020 and 2019, and $0.3 million and $0.8 million for the six months ended June 30, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117789992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on the arrangements with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival at the Company&#8217;s warehouses.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company then holds such goods in inventory until distribution and sale. These finished goods inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company evaluates inventory for potential losses due to excess, obsolete or slow-moving goods by comparing sales history and projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At June 30, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at multiple locations. As that API is consumed in production, the value of the API is transferred from raw materials to finished goods inventory. Cumberland also maintains API for its Vaprisol brand which is classified as raw materials inventory.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The consigned inventory represents Authorized Generic product which is shipped to the Company&#8217;s distribution partner and stored until sale.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  The Company also has obtained $0.4&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $15.6&#160;million. The Company did not have any finished goods included in the non-current inventories at June 30, 2020 or December 31, 2019, respectively.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:56.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.531%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,660,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,345,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">219,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,387,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,664,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,267,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,426,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,640,060)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,554,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,627,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,871,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382196028824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As Cumberland&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at June 30, 2020 is 2.5 years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lease Position</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.742%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.399%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,502,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.742%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.399%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">967,656&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,580,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,547,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,996,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:76.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.971%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Maturity of Leases Liabilities at June 30, 2020</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">566,713&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,823,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(275,534)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,547,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117700360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the six months ended June 30, 2020 and June 30, 2019, the Company repurchased 306,329 shares and 205,913, respectively, of common stock for approximately $1.2 million during both 2020 and 2019.  </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, Cumberland filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the six months ended June 30, 2020 or June 30, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the six months ended June 30, 2020, and June 30, 2019, the Company issued 229,141 shares and 222,469 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cumberland Emerging Technologies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">an agreement whereby Hongkong WinHealth Pharma Group Ltd. ("WinHealth") made a $1&#160;million investment in CET through the purchase of shares of its common stock. As part of the agreement, WinHealth obtained the rights to name an individual for appointment to the CET Board of Directors  as well as the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, during 2019, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET common shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for $0.8&#160;million that was funded during 2020.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of June 30, 2020.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 2.92% at June 30, 2020).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of June 30, 2020 and December 31, 2019, the Company had $17.0 million and $18.5 million in borrowings outstanding under our revolving credit facility, respectively. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Paycheck Protection Program Loan</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The PPP is administered by the U.S. Small Business Administration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the condensed consolidated balance sheet. The Company intends to apply IAS 20 to the PPP loan forgiveness and has presented the amounts expected to be forgiven as deferred income. The Company will account for the anticipated forgiveness of the PPP loan under IAS 20 when the Company believes that the forgiveness is reasonably assured.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. Cumberland will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119938856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESAs of June 30, 2020, the Company has approximately $56.3 million in federal net operating loss carryforwards including approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options. These have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119214104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 10 do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117690632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  The Company expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.631%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.369%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,633,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(260,735)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(645,571)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">573,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance at June 30, 2020</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,300,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability of $8.3&#160;million was classified as other current liabilities of $2.8&#160;million and other long-term liabilities of $5.5&#160;million on the condensed consolidated balance sheet as of June 30, 2020.  </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RediTrex</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, the Company announced an agreement with the Nordic Group B.V.&#8217; ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As consideration for the license Cumberland paid a deposit of $100,000 at closing.  The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectible product and authorization to market them under the RediTrex brand name.  The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020 and is recorded as an other current liability at both June 30, 2020 and December 31, 2019.  During the three months ended June 30, 2020, Cumberland recognized $0.5&#160;million of other revenue in its condensed consolidated statement of operations for a collaborative payment due from Nordic. The payment was received during July 2020.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">   </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ethyol and Totect </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland is receiving $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first two quarterly installments totaling $1.5 million during the six months ended June 30, 2020 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as discontinued operations and will record each future quarterly installment over the two year period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> As there are no expenses associated with these payments,  approximately $1.5 million in discontinued operations income was recorded during the period ended June 30, 2020. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Products provided $5.3&#160;million in revenue, with $3.4&#160;million in direct expenses resulting in $1.9&#160;million in discontinued operations income during the six months ended June 30, 2019. These direct expenses do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Those sales and marketing individuals who supported the Products have subsequently shifted their efforts to support other Cumberland brands.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019 current assets of discontinued operations included $0.5&#160;million in remaining </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">inventory for the Products sold and returned to Clinigen as part of the transaction. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of June 30, 2020, and December 31, 2019, </span>the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382203296888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117850840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:27.368%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.162%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119211176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and six months ended June 30, 2020 and 2019:</span></div><div style="text-align:justify;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.087%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.446%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,679,211)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,338,521)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">738,622&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">771,709&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,314&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,305&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(918,275)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(549,507)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,523,628&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:58.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.618%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.087%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.444%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.446%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,562,629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,526,075)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,556,895&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,918,845&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,839&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,155)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,973,895)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(623,385)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,241,020&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,497,989&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117911816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:38.409%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.202%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.202%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.824%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.202%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.205%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Six months ended June 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">595,310&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">983,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,308,711&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,832,976&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,948&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">478,604&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">124,371&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678,141&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,477,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,476,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,771,433&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,785,050&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">174,159&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">212,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">382,016&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">499,202&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,166,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,054,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,372,599&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,299,507&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,599,280&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,721,708&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,659,471&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">874,213&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">612,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,359,386&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,319,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,598,177&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,417,443&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,928,911&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,147,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119363448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:56.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.531%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,660,890&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,345,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">219,228&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,387,212&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,664,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,267,330&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,426,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,640,060)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,554,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,627,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,871,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119028664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At June 30, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.742%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.399%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,502,850&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:61.742%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.643%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.408%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.399%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">967,656&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,580,203&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,547,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,996,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:76.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.971%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Maturity of Leases Liabilities at June 30, 2020</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">566,713&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,823,393&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(275,534)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,547,859&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119373288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.631%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.369%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,633,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(260,735)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(645,571)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">573,279&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Balance at June 30, 2020</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,300,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382119935480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382267576808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382222827304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (1,679,211)<span></span>
</td>
<td class="num">$ (1,338,521)<span></span>
</td>
<td class="num">$ (3,562,629)<span></span>
</td>
<td class="num">$ (2,526,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">738,622<span></span>
</td>
<td class="nump">771,709<span></span>
</td>
<td class="nump">1,556,895<span></span>
</td>
<td class="nump">1,918,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">22,314<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
<td class="nump">31,839<span></span>
</td>
<td class="num">(16,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (918,275)<span></span>
</td>
<td class="num">$ (549,507)<span></span>
</td>
<td class="num">$ (1,973,895)<span></span>
</td>
<td class="num">$ (623,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">15,241,463<span></span>
</td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,241,463<span></span>
</td>
<td class="nump">15,523,628<span></span>
</td>
<td class="nump">15,241,020<span></span>
</td>
<td class="nump">15,497,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382124235192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">199,210<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382113888696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 9,598,177<span></span>
</td>
<td class="nump">$ 9,417,443<span></span>
</td>
<td class="nump">$ 17,928,911<span></span>
</td>
<td class="nump">$ 18,147,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">595,310<span></span>
</td>
<td class="nump">983,473<span></span>
</td>
<td class="nump">1,308,711<span></span>
</td>
<td class="nump">1,832,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">10,948<span></span>
</td>
<td class="nump">478,604<span></span>
</td>
<td class="nump">124,371<span></span>
</td>
<td class="nump">678,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,477,471<span></span>
</td>
<td class="nump">3,476,807<span></span>
</td>
<td class="nump">6,771,433<span></span>
</td>
<td class="nump">6,785,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">174,159<span></span>
</td>
<td class="nump">212,526<span></span>
</td>
<td class="nump">382,016<span></span>
</td>
<td class="nump">499,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,166,569<span></span>
</td>
<td class="nump">1,054,718<span></span>
</td>
<td class="nump">2,261,286<span></span>
</td>
<td class="nump">2,372,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,299,507<span></span>
</td>
<td class="nump">2,599,280<span></span>
</td>
<td class="nump">5,721,708<span></span>
</td>
<td class="nump">4,659,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">874,213<span></span>
</td>
<td class="nump">612,035<span></span>
</td>
<td class="nump">1,359,386<span></span>
</td>
<td class="nump">1,319,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117637816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 15,640,060<span></span>
</td>
<td class="nump">$ 15,554,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382220805400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 19,660,890<span></span>
</td>
<td class="nump">$ 19,345,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">219,228<span></span>
</td>
<td class="nump">416,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,387,212<span></span>
</td>
<td class="nump">4,664,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">23,267,330<span></span>
</td>
<td class="nump">24,426,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(15,640,060)<span></span>
</td>
<td class="num">(15,554,992)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 7,627,270<span></span>
</td>
<td class="nump">$ 8,871,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382203096680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382117639256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,502,850<span></span>
</td>
<td class="nump">$ 2,960,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">967,656<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease noncurrent liabilities</a></td>
<td class="nump">1,580,203<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,547,859<span></span>
</td>
<td class="nump">$ 2,996,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382124149480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Leases Liabilities at June 30, 2020</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 566,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">1,144,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,823,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(275,534)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,547,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382114690808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentCashContribution', window );">Contribution of cash</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment through purchase of shares of CET Stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Cash payments for return of shares</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,141<span></span>
</td>
<td class="nump">222,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,463<span></span>
</td>
<td class="nump">164,866<span></span>
</td>
<td class="nump">84,447<span></span>
</td>
<td class="nump">121,466<span></span>
</td>
<td class="nump">306,329<span></span>
</td>
<td class="nump">205,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (769,648)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (531,746)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentCashContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Cash Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentCashContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Conversion Of Intercompany Loans Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382123152232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Second Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382195562328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382115249960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Clinigen | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300,562<span></span>
</td>
<td class="nump">8,300,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ | Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382123768792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382195846536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="nump">6,624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="nump">3,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="nump">1,827,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="nump">9,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="nump">21,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="nump">11,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="nump">12,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">$ 34,182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382120189112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vibativ<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 8,633,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(260,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(645,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="nump">573,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 8,300,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>61
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MOX5GCC>?%9MS0EN;?X,3U$$*G%Z !NGOV4H;!?/N'T3RHI:\<)(7)R3?R;"
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M"8GL#.#[J=;VY<8=YN]^>3/Y#U!+ P04    "  &B0Y1&'1P[H0"  #0!@
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M0>604+WS8^/6[\.!.'FSSY&W($JE[PK4#K#0BIW%2*H@,&ACW)< @X%G4+X
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M0 *9?QZI,Q#)&T \36G8^,).31@N>B%.'%Q+"<'46O$.0YJ#;L\&A,P )&$
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M SG43C\ZU_+7M@! M+3\Y]J "'MZ /?IW#/]H WRY]<O_P-02P,$%     @
M!HD.46:D?CAR!P  *Q,  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6RM
M6&USVS82_BL8]>::S,B2+"=ISK$]8SNZJ>^23!HYZ8=./T#D2D0, @P 2E%_
M_3T+D#1E2^Y=Y[[HA>"^/;O[[))G&^ON?$$4Q/=2&W\^*$*H3L=CGQ542C^R
M%1F<+*TK9<!?MQK[RI',HU"IQ]/)Y-6XE,H,+L[BM8_NXLS602M#'YWP=5E*
MM[TB;3?G@^-!>^&36A6!+XPOSBJYHCF%S]5'AW_C3DNN2C)>62,<+<\'E\>G
M5R_X_GC#%T4;W_LM.)*%M7?\YR8_'TS8(=*4!=8@\;6F:]*:%<&-;XW.06>2
M!?N_6^W_C+$CEH7T=&WUKRH/Q?G@]4#DM)2U#I_LYF=JXGG)^C*K??P4FW3O
M2]R<U3[8LA&&!Z4RZ5M^;W#H";R>'!"8-@+3Z'<R%+U\*X.\.'-V(QS?#6W\
M(X8:I>&<,IR4>7 X59 +%S=F33X Y>"%,N):^D+,OM5J+76\)DTNWDMW1T$N
M-(DY9;5309$_&P>89R7CK#%UE4Q-#YAZ)=Y;$PHO9B:G?%=^#+<[WZ>M[U?3
M)Q7^JS8C<3(9BNED.GE"WTF'Q4G4=_+G6 S%6UJ$&#VC$;:]R,5OEPL?'.KI
M]R>,ONB,OHA&7QPR^N'+;'[[?O;A=BYN/HCKR_G/8O;+YYLOE^_BM<L/;\7[
MRT__GMU>7KV;B?GL^O.GF]N;V7Q? IXTQ?U]ZBN9T?D #>S)K6GPU^V+VX+$
MM2TK:;8H'88NEE!Y7RW^'C,<6)>3$\%R^:I2_4%"0<)1J!T.C<A0>Z-^L?7$
M,PL:\$'8I?"%=>$HD"NC1&.ZR=KGT7PD;L%.OG9;86R@5,(+:W(<9]95ULE
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M!IPO+:BL^<,&NO=C%_\!4$L#!!0    (  :)#E$P^Y ='@0  %8*   8
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M1ERR.Z*JU,26 >1=&VZ* 3U38T<2%, >4@ @"QZO<'=6KR%UAJ!:X;\WS=<
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MUTR@T!^!PJ2F,!E&$\A]$+[BZ<HETKR(=OD<)/D!2",==E_08#B,1KV$ESW
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M1 Z]JNYD6<N8)GG3+%( XJ_QZ2<%:CL:#J-U$6C[V!'ZMI-E+^P4$ I&40_
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M+<ES^XN?)?]OT(8-O)X3^=T@!.C^8-/?4$L#!!0    (  :)#E&\>HXK[0,
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M\'YI4.3#%SJ@^9\3WOX74$L#!!0    (  :)#E''.4#Y9PH  .<:   9
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*U9:V\;N17]*X06V-J 7I8=)YLX
M!FQWL\VB:8PXV451] ,U0TEL9L@)R;&B_?4]]Y*<&3E^9(M^L35#\C[//?=2
M.MM:]]EOE KB:UT9_WJT":%Y.9OY8J-JZ:>V408K*^MJ&?#HUC/?."5+/E17
ML\5\?CJKI3:C\S-^=^W.SVP;*FW4M1.^K6OI=I>JLMO7HZ-1?O%!KS>!7LS.
MSQJY5C<J?&JN'9YFG912U\IX;8UP:O5Z=''T\O*4]O.&W[3:^L%G09XLK?U,
M#V_+UZ,Y&:0J5022(/'O5EVIJB)!,.-+DCGJ5-+!X><L_0W[#E^6TJLK6_VN
MR[!Y/7HQ$J5:R;8*'^SV;RKY\XSD%;;R_%=LT][Y2!2M#[9.AV%!K4W\+[^F
M.'S/@44ZL&"[HR*V\J\RR/,S9[?"T6Y(HP_L*I^&<=I04FZ"PZK&N7#^WJVE
MT7_(&")3BDOIM1=V):Z=\LJ$N')P;2M=:.4/SV8!:NGPK$@J+J.*Q0,J3L4[
M:\+&BY]-J<K]\S.8V]F\R#9?+AX5^&MKIN)X/A:+^6+^B+SC+@;'+._X.V(P
M%E?6>#A;]B'9BP0B\T8;:0HM*W&#EPH0#5[\ZV+I@P/(_OV(12>=12=LT<D#
M%GU0!82*BZ*PK0G:K,4O+2PRA;HO_/^K+)&72ML$50ZW7#MK\+E@Y\1;(_YA
M;U6]5 XQ/WHQ%F&CQ)N+FTNAO6_IZ,TG;)GRZH0V_/C#B\5B_@K%4LFE=3%V
M%\Y)LXX!>RFN*NGT:D?J2-Q;$Q3%CS8N5=@J9<1'V^A"O)B_X#S$I]/Y*0L_
M>B4.2&U2>3@5'R&%[&'?D*>T>C*9_R2<U!YV?FF5)PU>P*HVL&)]CV)ZO\YA
MPONB]^-6"3GP@RUSZE:95N%_8==&DZBI&!@G9%D"1%YY2$9Y461= &6&G5CN
MQ,'1H2B&T9!!I T"F#(^6N<[\QXT1S32!11J(\DTO[%M5>(4R(]3BPB QX7T
MG<4M:M+M16J[2?X7>[E[0 D"+F0B*N7&XF!Q2,Z2&RT"06E(NOMX!@L+$ M/
MNJ#)/:&.+&:=)(VV#A>A?ZO#9F $9^3@^%"@2Q55R[9@U=:P=R=6SM:T0A7-
MP1[&ER5]E]\^9DDZ)8P-HM30%:H=XEI)"C-\]+*B?%M*N2OC87ZQCDZSLIP'
M-JL 3Q(2LR')(3\55RT57T6>R52M% @?\$9"N%JM%/<W\:LT+;JK.(KT&"49
M*S3<+P)AF0Y>Q6C\Q9/.1'<$CH[9?,=L4RK_+!4@>?YH]3^?S$^ZZK^!TFI0
MXA]1? S 7ZPMM[JJQ%N8H1WIN5O3)"C5= <<IVK0D ?MJD8L,AK669CNA(D
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M6#0_[3CG+6>TAW,,UU*80L.ER#![;N^3_WT0T3:(>700\$LCCF 8#" *HN
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M*PG*7L#S2DIS-*R#\;N[^A=02P,$%     @ !HD.4;W@4[-_!   3 L  !D
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M?)D)( L+2I@?!D'73PA-O?'0GMV+\9"O%:,IW LDUTE"Q-]K8'PS\K#W>O!
M5[$R!_YXF)$5S$ ]9O="[_R*94$32"7E*1*P''E7^'*"^P9@(WY2V,C&&IE2
MYIP_F<W-8N0%1A$PB)2A(/J2PP08,TQ:QW-)ZE4Y#;"Y?F7_9HO7Q<R)A EG
MO^A"Q2.O[Z$%+,F:J0>^^0YE01W#%W$F[2_:%+$]'1RMI>))"=8*$IH65_)2
M&M$ X/8>0%@"PH\"6B6@90LME-FRID21\5#P#1(F6K.9A?7&HG4U-#6/<::$
MODLU3HUOTARDTL]%2413-"$R1E^?US0GS)Z1=(%^$/$$BLP9H!E$:T$5!8E.
MIOJ,,GF*SM'C;(I.OIP.?:4E&6(_*M-?%^G#/>EOU^D%:@5G* S"8 =\XH9/
M(=)P;.!XL WWM1&5&V'E1FCY6GOYYJI1XQFZRG6)IO)S_<6<2VT*^GVG0>A&
M02+_.%*VJI0MF[*])V7#7%DEWF5D0=.U-.;CS,?:L+SIU=N($.-!-^A5<5L*
MVY7"ME/AA"<)B(@2AC*2@7 4W:DH.\?RN5NE[![&YX*FX_#Y;833YUZEL.=4
M> <Y,(0=M?8KIOZQ[!U4*0>'L7?PKKVNB"UM.*B;7/ 1:]$_](F7&3=Z*#Z6
MW[AN53@\C.,EC\MR9\BVOKJO87=C*SP/7;76'0BWCV9PW:-PYT &=]XW^&V(
MLV?@NJUA=U\K;?[DJUWW)-P[FO-U^\+] SG??_=/<4?(;N?]QA!E)E@M8D53
MB1@L-3*XZ.F')XJAL-@HGMFY:LZ5GM+L,M:#- @3H.\O.5>O&S.J5:/Y^#]0
M2P,$%     @ !HD.4;>UJ:;H P  )0T  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&ULK5?;;N,V$/T50BV*!&@BB;JGMH&-Y45;=(M@@^T^TQ9M$RN1
M+DG%V[_OD%*TMDS;Z>7%%JDS9SB'P^%HLA?RB]I2JM'7IN9JZFVUWCWXOEIM
M:4/4O=A1#F_60C9$PU!N?+63E%36J*E]' 2IWQ#&O=G$SCW)V42TNF:</DFD
MVJ8A\J]'6HO]U N]UXF/;+/59L*?379D0Y^I_K1[DC#R!Y:*-90K)CB2=#WU
MWH4/B] :6,0?C.[5P3,RH2R%^&(&OU13+S KHC5=:4-!X.^%SFE=&R98QY\]
MJ3?X-(:'SZ_L[VWP$,R2*#H7]6=6Z>W4RSU4T35I:_U1['^F?4")X5N)6ME?
MM.^P6>2A5:NT:'IC6$'#>/=/OO9"'!@ C]L ]P9X;!"?,8AZ@^BM'N+>('ZK
MAZ0WL*'[7>Q6N))H,IM(L4?2H('-/%CUK37HQ;A)E&<MX2T#.SU;$,D9WRAT
M\YM0ZA8]48F>MT12=%-235@-<W?HTW.);KZ_G?@:7!I#?]73/W;T^ Q]A#X(
MKK<*+7A%*X=]>=D^O6#O0ZA#O/@UWD=\D?#7EM^C*/@1X0 'CO7,WVP>%JYP
M_IOWQ;_V?B1&-&Q^9/FB,WR_MPV51 OY<($L'LAB2Q:?(X.JQOA*-) ZM<VE
MM10-6L'^,=Y"CB&H;N -RH-R)5+'GEIV4]Y>9G=AFA4X#"?^R^$.N8!1E"=X
M!"P=P"A)<8J+8^#" <0)3H,L&8!'DB2#),E%24JF^O!I=27ZCB@Y6$(6Y2G&
MH]@=L"S,@E% Y2DL3)(T+Y)1X Y<$>9Y?";N=(@[O9H*-UTNW"*3"XAHN(J6
MBE4,;B,8:<F6K2;+FB(M$!?<Z"1%79L\85Q3295V"I6>+!GC*(Q'.IVBPBP*
M1N&7IZ@HS*-Q=IRB(#%!3[=&V:!1]@^/RU@5>-? 5:I,-=Z*NJ+2*4AVFKRP
MAS@;!3MWX)*X2()L)(H#%Q:0C"?)XP"FV!Q$MS#Y($Q^L2B5E NXZ*Z5I6*@
M*R[J_-FV"K2Z(R]P_C:TTU,A:)J4)KPR"??#=SF4F9],Q\%6)G-[D//"*QQG
M"\=AG$8CP5W !$<ISD>*GV&T5\21XBY@7&1%7K@E#X-O74!PI5+5K>G8$%VO
MH85#8HV$WD(OH.BJE4PS4.RR+F7OX7!UX_5?A!RO_*!_"?^W_:U,E%"*K^QP
M[_$-6^Q$.O?X'.?I)CN1SEWV#]H^N,@WMM]64#=:KKLF8)@=>OIWMI,=S3^&
M#_/0,5^:;P#;9GZC[SX@/A"Y85RAFJ[!57"?P7)EUY-W RUVMNE<"@TMK'W<
MPG<,E08 []="Z->!<3!\&<W^!E!+ P04    "  &B0Y1FEMRSUL"  !0!0
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M.?5\A18V?*$;;),(BM8Z+0<P*9!<]7_V..1A#T \AP'I $B? Z8O +(!D(5
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MH_)Z<RM%(G4%L.>?E/WD:7>J ;H5K,5_4$L#!!0    (  :)#E%DR5L'+0(
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M0\ A,Y:!XF</,^#<$F$;/UM.KSO2 H_7!_:/3CMJ65,-,\F_L8W93;WW'ME
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MV4G<;V6I0,)?H@U]\S>H#YQUP"0C<9P?V=J\Q><G\0_,F$MT7X)G9FP?..^
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M7+9$PT*R;[0PU2QX%Z "2M(P\RC;#]#G,W5\N63:OU';^<9)@/)&&\E[L%7
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M183> .M+SM5NH@/8!F[X#U!+ P04    "  &B0Y11I>X\$ #  #\"0  &0
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MC\CY:-7X^"1ELF.<GQ(K1W8<TE[.[:C7@\L*RFRKHOSQV!MBK9)8JY'8 UM
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MC/Z'-7_%FN9)G)\Y^$&'.KB(BK?O'Q4W>%UQ212E6?Q7X/"H)56@U[[Q&MR
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M-^X6QI7G5.0+3>I#NV\T'-7+N'4EQ)4KNY5S15GWH:;[R'3Q&U!+ P04
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MUZ1697/T9]WOB?DG4$L! A0#%     @ !HD.40=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  &B0Y1
MEV7>F.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  &B0Y1F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  :)#E'EH=VD2@4
M  $6   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  &B0Y11Q7U#H<&  #(&0  &               @(&-
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ !HD.41AT
M<.Z$ @  T 8  !@              ("!2A0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    (  :)#E$[)*IHB@<  #XB   8
M  " @007  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  &
MB0Y1"V9,@BX'  "2'0  &               @('$'@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ !HD.42C]AG6V!P  3RT  !@
M         ("!*"8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   (  :)#E&TBG\)3A$  (HM   8              " @10N  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  &B0Y19J1^.'('   K$P
M&               @(&8/P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ !HD.43#[D!T>!   5@H  !@              ("!0$<  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  :)#E'KQ:"<W 8
M ),/   9              " @91+  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ !HD.44DMZ:8$!@  M0T  !D              ("!
MIU(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  &B0Y1
MTB'HN*X%  ",#0  &0              @('B6   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    (  :)#E',@41D:PT  !LB   9
M      " @<=>  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ !HD.49[&Q.L7 P  S08  !D              ("!:6P  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  &B0Y1O'J.*^T#  !W"
M&0              @(&W;P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    (  :)#E'ZYEN=3PP  *@@   9              " @=MS  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ !HD.4<<Y0/EG
M"@  YQH  !D              ("!88   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  &B0Y1QHO+M*\"   Z!@  &0
M@('_B@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (  :)
M#E%3!\IKM@,  &0)   9              " @>6-  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ !HD.47*#JH55 P  NP8  !D
M         ("!TI$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  &B0Y1@4V(=M "  #.!0  &0              @(%>E0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  :)#E%""ER4,P,  (,'
M   9              " @668  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ !HD.4;W@4[-_!   3 L  !D              ("!SYL
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  &B0Y1D.,/
M+"<"  "@!   &0              @(&%H   >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    (  :)#E'* <D0U0(  *8+   9
M  " @>.B  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M!HD.4;>UJ:;H P  )0T  !D              ("![Z4  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  &B0Y1FEMRSUL"  !0!0  &0
M            @($.J@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    (  :)#E%/WW-Z1 0  ,T2   9              " @:"L  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ !HD.463)6P<M @
MC 4  !D              ("!&[$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  &B0Y1"OOX_LH"  "_!P  &0              @(%_
MLP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (  :)#E$A
MZ;3R P(  (,$   9              " @8"V  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ !HD.42]6PO]N @  9P8  !D
M     ("!NK@  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  :)#E$V-?ZMR@4  "(:   9              "
M@9_)  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ !HD.
M4:6C$)$I P  S D  !D              ("!H,\  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  &B0Y11I>X\$ #  #\"0  &0
M        @($ TP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   (  :)#E%@Q:_NU0(  /T&   9              " @7?6  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ !HD.49KJ+'TK @  ?0D
M  T              ( !@]D  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  &
MB0Y1EXJ[',     3 @  "P              @ '9VP  7W)E;',O+G)E;'-0
M2P$"% ,4    "  &B0Y1G<>%#((#  #H&@  #P              @ '"W
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ !HD.43QA]1J- 0  3Q@  !H
M             ( !<>   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ !HD.49C$(26B 0  IA@  !,              ( !-N(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     #  ,  '#0  ">0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20200630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20200630.htm">cpix-20200630.htm</File>
    <File>a2020q2-exhibit311.htm</File>
    <File>a2020q2-exhibit312.htm</File>
    <File>a2020q2-exhibit321.htm</File>
    <File>cpix-20200630.xsd</File>
    <File>cpix-20200630_cal.xml</File>
    <File>cpix-20200630_def.xml</File>
    <File>cpix-20200630_lab.xml</File>
    <File>cpix-20200630_pre.xml</File>
    <File>exhibit101-amendment2l.htm</File>
    <File>exhibit102-amendment2d.htm</File>
    <File>exhibit103-form147_716ba.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20200630.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 122,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20200630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20200630.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 319,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 5
   },
   "keyCustom": 19,
   "keyStandard": 247,
   "memberCustom": 15,
   "memberStandard": 18,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Investments in Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Investments in Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i5669834e215b45b99cc41e3d665e69a1_D20200401-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i9476294995c8476c8cf46424d7813e1d_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i90f8ddce573e405db035f43203edac82_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i90f8ddce573e405db035f43203edac82_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ia8648009ac16482485d4df4b4a6b9fa6_I20200420",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "if4c1e41af6694cc8bfe181c41dfd667b_D20190101-20190630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "ic125e85e38194740b3b6e42596d48565_I20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
     "shortName": "Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "id334b396a4b3435091868e865fabd32c_I20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "idb4dceb96ca1441caa16db008ee7093f_D20200401-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "iaf017760b38441c1af2d35a25e124e99_I20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i1bda28049d3e4ce59f41b85641882c9b_D20200101-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "idcf4bbaf2ef74a4b84a7cc379f11980e_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "iab68a01528bb4af289eae255fa7a48dc_D20190101-20190331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities",
     "shortName": "Investments in Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200630.htm",
      "contextRef": "i0b7f8c80c52c49a296cee15864710502_D20200101-20200630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "totalLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Clinigen"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "xbrltype": "stringItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicGroupBVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "terseLabel": "Nordic"
       }
      }
     },
     "localname": "NordicGroupBVMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentCashContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Cash Contribution",
        "label": "Subsidiary Investment, Cash Contribution",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "SubsidiaryInvestmentCashContribution",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "label": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "SubsidiaryInvestmentConversionOfIntercompanyLoansPayable",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Cash payments for return of shares"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment through purchase of shares of CET Stock"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20200630",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r218",
      "r221",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r388",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r218",
      "r221",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r388",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r157",
      "r206",
      "r207",
      "r354",
      "r387",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r157",
      "r206",
      "r207",
      "r354",
      "r387",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r208",
      "r218",
      "r221",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r388",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r208",
      "r218",
      "r221",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r353",
      "r388",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r198",
      "r219",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r162",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r29",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r64",
      "r80",
      "r312"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r80",
      "r191",
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r137",
      "r147",
      "r153",
      "r176",
      "r286",
      "r291",
      "r302",
      "r358",
      "r375"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r54",
      "r86",
      "r176",
      "r286",
      "r291",
      "r302"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r10",
      "r12",
      "r194",
      "r196"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r224",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r217",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r217",
      "r220",
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r269",
      "r270",
      "r272"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r267",
      "r269",
      "r270",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r79",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r268",
      "r271",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 1.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r14",
      "r39",
      "r82"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r82",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r303"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r8",
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r197",
      "r363",
      "r380"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r66",
      "r354"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r359",
      "r360",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r80",
      "r87",
      "r247",
      "r253",
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r80",
      "r135"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r61",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r63",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r105",
      "r107",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r368",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r63",
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r107",
      "r110",
      "r111",
      "r112",
      "r116",
      "r117",
      "r368",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r104",
      "r119",
      "r177",
      "r202",
      "r203",
      "r230",
      "r231",
      "r232",
      "r249",
      "r250",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair value of marketable securities, by type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r301",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r209",
      "r210",
      "r215",
      "r216",
      "r301",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r209",
      "r210",
      "r215",
      "r216",
      "r301",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r192",
      "r355"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r189",
      "r190",
      "r357"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails": {
       "order": 2.0,
       "parentTag": "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r90",
      "r137",
      "r146",
      "r149",
      "r152",
      "r155"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r95",
      "r137",
      "r146",
      "r149",
      "r152",
      "r155",
      "r176",
      "r283",
      "r302"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r58",
      "r63",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r110",
      "r111",
      "r365",
      "r366",
      "r368",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r58",
      "r63",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r107",
      "r110",
      "r111",
      "r112",
      "r368",
      "r381",
      "r384",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r11",
      "r12",
      "r258",
      "r382"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r61",
      "r63",
      "r108",
      "r110",
      "r111",
      "r368",
      "r382",
      "r384",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r108",
      "r110",
      "r111",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r241",
      "r242",
      "r244",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r243",
      "r245",
      "r251",
      "r256",
      "r259",
      "r260",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r103",
      "r104",
      "r136",
      "r238",
      "r252",
      "r257",
      "r386"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r134",
      "r311",
      "r312",
      "r369"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r34",
      "r187"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r15",
      "r51"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r35",
      "r187"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r68",
      "r133"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r356",
      "r373",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r317"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r86",
      "r148",
      "r176",
      "r287",
      "r291",
      "r292",
      "r302"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r86",
      "r176",
      "r302",
      "r362",
      "r378"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r86",
      "r176",
      "r287",
      "r291",
      "r292",
      "r302"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r9",
      "r10",
      "r12",
      "r194",
      "r196"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r42",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r42",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r47",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r86",
      "r176",
      "r302",
      "r361",
      "r377"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r203",
      "r284",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Repurchase of subsidiary shares from noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r76",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r56",
      "r57",
      "r62",
      "r81",
      "r86",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r103",
      "r104",
      "r109",
      "r137",
      "r146",
      "r149",
      "r152",
      "r155",
      "r176",
      "r302",
      "r367",
      "r383"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r57",
      "r103",
      "r104",
      "r289",
      "r294"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r203",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Direct expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r137",
      "r146",
      "r149",
      "r152",
      "r155"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturity of Leases Liabilities at June 30, 2020"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease noncurrent liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r44"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during 2019"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r70",
      "r273"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for acquisition",
        "terseLabel": "Payment to acquire business upon closing",
        "verboseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r56",
      "r57",
      "r75",
      "r86",
      "r95",
      "r103",
      "r104",
      "r137",
      "r146",
      "r149",
      "r152",
      "r155",
      "r176",
      "r283",
      "r288",
      "r290",
      "r294",
      "r295",
      "r302",
      "r370"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r22",
      "r23",
      "r195",
      "r379"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r235",
      "r397"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r203",
      "r233",
      "r376",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings (deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r104",
      "r177",
      "r230",
      "r231",
      "r232",
      "r249",
      "r250",
      "r391",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r145",
      "r150",
      "r151",
      "r157",
      "r158",
      "r160",
      "r205",
      "r206",
      "r354"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r86",
      "r131",
      "r132",
      "r145",
      "r150",
      "r151",
      "r157",
      "r158",
      "r160",
      "r176",
      "r302",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r167",
      "r168",
      "r171",
      "r172",
      "r173",
      "r174",
      "r371",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r21",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r224",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r129",
      "r130",
      "r137",
      "r138",
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r222",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r104",
      "r119",
      "r177",
      "r202",
      "r203",
      "r230",
      "r231",
      "r232",
      "r249",
      "r250",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r391",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r119",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r27",
      "r28",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r202",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r49",
      "r202",
      "r203"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r27",
      "r28",
      "r203",
      "r223",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r27",
      "r28",
      "r202",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r28",
      "r202",
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r31",
      "r32",
      "r86",
      "r165",
      "r176",
      "r302"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r92",
      "r93",
      "r94",
      "r96",
      "r102",
      "r176",
      "r177",
      "r203",
      "r230",
      "r231",
      "r232",
      "r249",
      "r250",
      "r281",
      "r282",
      "r293",
      "r302",
      "r304",
      "r305",
      "r309",
      "r392",
      "r393"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r203",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r310",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r310",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r310",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r106",
      "r112"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r105",
      "r112"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11374-113907"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r398": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r399": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r401": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r402": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r403": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001628280-20-012738-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-012738-xbrl.zip
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M+&D+^+>7F[,QX_ P$*!;V9QO*%+]L ;;'%!TWIMA0AL\73LCPSQ5-C',[$J
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MZ[).%2_#FU_ <17!N$)5ULXYI'+[Z4K,:$!ES6A6TH#97W_=T@P&@VV<S?K
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M(K3S(0Q##TS\UQ3WGH#6I3HN!Y(<FU:I>K+@1M:OZM[V%SUI.;=Z>[5<#E9
MY6.[KA=,0SB#&]C4Y'D?+6+6Y--4;SX$TY<A W_+9G()D4P5"(#3>L*UY0#0
MB\56#A:*[]G#(@-13%#KP%E&=.^$Q8R=8",')@&Z:"EX8'_=T^E0\X!3Q=$
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MQ>#6:F]A'O&LZ)PE+O'A4UX#:.CAROLZ#2D86C5?8Z,Y6&DP0WLD].!L27A
M7)H*AA43&(:N H?2U-.#5KVNF584Q"1<9U^Z^;P*)$$O/IK=M&]*W91CU(!,
M2)/VI;LDX8+BXAX$+$DD%OS)DAY& K"DG&(CMIWDN+[X&%:AK[Q6X _RF06L
M"M:2T3D:1D>"75 8S^?,17S2W1N&[J@/+R5SO"Q[PD(2N@RY*,NB2^FQP%,%
M3!-LCB]QRI.4X*@0D80BN=_,H;+6E/ 9"6E2&U_Z= U]5\@<.?3@\(OH)$7/
M2;U!%&))$%.S9?YH>,XB(:*@<Y2/4$%F/MT,T8A[E,OAZ9,XH9WRQ?18$OMD
MW6%A-I"R2N:%Q(3]6,QN'/9%2--N*\?:<1;5" QEA%?:+R(>)8]X5.%]FVDH
MK:/FS=G?K?O=S#9&&<:NEM6LW7G;D80$._%%Q:B4-6+B>1A?9C.]'E^:Y7=!
MK4S:<;9OJ:-/Y^(Z3DOC,K^C8Z^5"3R?S=\JS0^T8&=-N2I%.R*J]+X$<P7/
M]X/!30"^?X*=;Q$<E(9"D^>ICP+MHKKX4@@WXLCIIY1Q*K<PB=2,*PJC&X?D
M>?Z* JXW#[WR:_ZULFY4M= >O6TT4%S:IA3!K_8FF_FB9K*P)3PW[F<>1>E1
ME.Y8E.J/HO2_B1(+,2(,2!:-8$@I"!;S,#53E5*Q"),Q9<QI(L6I*K.)[P-6
M0\\8.6%&C&J55(O0LHRHT*"7'1)E\1>62OU<VZ*8\LQG\E6TI=Q2H.Z:VO9N
M\7FNS;OLJ_(CH#M34J.EM%JM?Z:D[9:B:;NJY0\$KZ1+GJ7]-_,RYV['J?FH
MR?]6DY\>-([-)'OB#@PV6[ K4KTO#!=CHYA#TAT2"DGD,P]*Y/>N![;VO?M,
M^KWC]88CA)_.<;Y2/!"2^^DB303HC?RLZ3;DEDN'L;]+QV,3'Q?@NUR KYYL
M_G2E^F66X/O#^[VC]H;#^9_.\:^U"C_L77=EET/..,KON70X]8D,"+?O?FQ?
M":E<7XW,4.120<UBV&FWOCM2//-[+-F-FM[?4$L#!!0    (  :)#E$]8/+B
M]X$!  UL%  1    8W!I>"TR,#(P,#8S,"YH=&WL?6E76\FRY??W*]3<U]U5
M:REQS@.NHA?%5-2SA W"ON*+5XYPL :N!@S\^L[4 &*PS2@=B5.KBI)TICP9
MD3MV1$9&_O'_SIN-TIGO=+-VZ\\EM R72O]O]8__!<"__]K[4-IHVW[3MWJE
M]8[7/>]*W[/><>F+\]UOI=!I-TM?VIUOV9D&8'#->OOTHI,='?=*&&)XZV!G
M)5@)=4 6& X]H%1HH 4* %*&-?*"0FG+1RM6($08BZ<A'P!EA@"M,8N?H(-0
M,,VY*+L5#JV02FNNF*<4444-5(Y*C9%G5M#TV.->?+OXAJWN2G;>^W/IN-<[
M77GW[OOW[\OGIM-8;G>.WF6M1M;RZ77?]3JZU0WM3E/W8G>\PQ Q #' ?&EX
MDQLW^$X&ER.EU+OS]*"EZR>!KK<W3H[?EX_:9[]\F 0$C>^36IC=WV8,(8GW
MZO9TR_KQ^?'.WWYR>CIL=/?J]/-N=M_[Q'/1NW]7/NS;8]_4X/9#LO,?/0*1
MB;<;G][M7/=ZT%TS.#?^^"XI"(!HXG7MZ:U[1]4SOM/0+7=ZK&,W+=MV<W =
MY 1.=I*[?I')5^;OA@>O3KW303=$F(Z.3^UWP9'6IW>;/CIP3_.=O]6*L<CC
M@=0[ZN;I6;=-,1(_$^_PC,$%*[$7COY<\BUPL+\4U=IKM_I'T_=T*5T._'_Z
MV=F?2^OM5B\.5E"[.(WRLL-O?R[U_'GOW4!!WZW^UW_]UQ^]K-?PJZF[P;@W
M_W@W_/&/=\-;F[:[6/W#96>E;N^BX?]<<EGWM*$O5EKMEH\-R,Y7THF^,_R8
M.>=;@X_Q>#4B1B>SP^>?]_9\^',I@T8$&8>_9=A2I;'BUGO$)*<"00;QUXU!
M4U#LHVL)MW0S/=IG*V,<VLJZ5C?J7G>VXB_=I5+FXLT=^7QA-MIG'_#>69U4
M^NYD\^QP6YWLGM2_UR\MW?VR=5P]^88.:Y]@I?:)5;=WON]^^01WMS<O*E\.
M4#P'?B#51OVRC2O;%;*[T3BNU^JL^N4 5C<VX6YM+ZML-+Y5-XZ/*R=;C>J7
M"JEN2?@!'U[4OUA>J6U]JS>KC=WM'5B_K'^O;NS@.M[*#K<W:>7+YGFE5B&5
MYB:L?JF?N>VMS&P?\/KE7\W#DW^.#VO?</7+YF6\=R.>B^NU37AXLG->.=EK
M5B_KL'HRON9S?!9K'=9.3RK;A\U*<ZNQ6ZNC>JT2W^/@O%X[/*[4]IJ5D\V+
MZG:=5$\^X6I#H@^US5YE'YY_J*U]Q2$XJYP -G -*(<&:((-8,9S89D,E(:E
MU=3_?[R[(<OIB?9CO'_;%<)]D'#QI'"E-=99 @$ADB7C&H"6S #BE428$J.$
M7%K]A%]=M$.3%J\^[ZV8=KOA=2OH1K([UT)?BQ)W ZDW]%$AZ%\)FDP*&FIM
MF) !>,4=H-A18(3D &MLG8J42<D(T5MK'_8WISB,U_N=S@V WFRYC4@9YU*X
MGZG[^Y_&(6Z<F9/V>>7+7E;'![1^LG=2/5F#E9/#D_J7?[[5:T=18/':2WM1
MKWU"AU%0NY^^$F6)PU@ I:P"5!,/E)$((.2H(X908_32*@ (1SHP10EMMJ*-
MOUB/0NKHQD[+^?/_\1=O2SRT$HU@M'@J0 8L1"+Z%%(!'>)H$A!J3X7CF+JE
M59CZ40JLZ!T)O;O)>#H^^*CYUG?O(6J)4ZYT!TPZRK TX)@KO4C/_ESJ9LW3
M1J+5@]^..TG$-SC9\GDW-N2/=S?O,7S^]4-';>BV^YW!MX'3L#+2FZ%PGZ(W
MXQOY@=*,OV4N?0^9[Y0&#?+W^CCK._]SLP-O7[PZ_NGFW4\'MG_\+;H=G5Y"
MD-4QUX9H?-WUL:MFNHE3.4B,]N:1\??Q0][=Z*CQ??JM;-AIW>AQ^.Y5-S2]
M[O8[?G7T^,'!\2W&Q\;?TSWNE8/6P6NB,,7!4^:",4PA084DA'J*W->=0?=+
ME(?N'_I]O5&/2H"N>G1\Y)$]VA]H\\TN&[DX*P?[&X_N38LP\Y)Y(I&B@D)#
M#/<4LV@4J62<C7HS'\I\LS<G]?-QO7FC!QRUCB'-D=*0VB"E]0H2J[F)ZB5=
M2#V %,+1Z<Q3#T1/>&3ZGJM/T5G83T/QZO6BPQJ;-7GJ +5UK]UYHNK=N3[]
MN.%;[6;6NN^V#P6(&[=X=[/UO])\9ZBSWD08UXA29+5&W)D('-X+J$@8X3G-
M-Y[3:>#Y3<0@!/-HY'$@$2B$UU*(9/JA9IY*AU*_(37JM_@A?_V6@D@/[+=T
MZ@OUFR):DO@&2/ADMYC22G!$(#0<*L3"J-]0OOOM@?SA!?O-V9"X?L ^"*JI
MD50+:XE0 2$EH1_@L\P?/LOGX/.-'B ZZ/BJ+O:"HEA++8S!W!$K$1.6NJ&%
MRHG"W+!0+V6CJ<'*8A.;92$5D,<O07KJ'8U=8Q&9G@Z,--\?I;#+\*N+#SL_
M;60VZU5\BK677!:/#J>"1I'NE?U>5/]TS>9_^LE_;#=/VZWXM;MVGD6"/#XM
M_MYLM_9[;?MM>*\_WMW[B*M>NVK)K)13"$649LP0!JF/YD"9(*G#*#!ME%(+
M(YH]W]-9R[M-W6EEK:/NG,B'(^J\8L@PQJE'6M,H(10IKW/1\A"X,/*IMEOI
MQ3OM1G3UCW9B%T3RV)L7*1FH!1900H>IPD)A2;31S'')J%+P-CD@<R^N5T6Z
M9[ 6,B'09[ 6;;C4$#$LC8E&"DOE(V5F+&BA(TNV,Q#H7/2;Q\0*C4)$J6CI
M(]DQ2(3@!)7,8B;XX@V$U[<KLY<J)0$B@I"-](U:2HUEF#E*<!P*W JZ>%*=
MEC6:O6RC(R:E9HJC8"D66ED5W3("G:4\NFATY)W,OTBGQ<UOB>8YCJ/7!!J,
M+,>!POB-2\NY5$X1&QFZ6QC13)6;OYQ\E* N$*T%#8(:YS1U%'-M(BS&?M1R
M8>0S V[^<E+R.$1K9:#SP5&#L3;,&B49$DH31M#TI#2K'G "!6*B"ZF@ITA(
M:7$@W#GF X21L,T@Y#O/6#_[6#1VV,F "#>1C:FHQT@J@7":!A$V0+5X IT5
M'YN^;*4E4#A/#/6,$N6-0Y!CR+W%0D8(6SS93M^#FH%438JI*JT<57&4$L6@
M-TB)*%<C-+/3FP.89^1]E<D)HJ6Q+FBK521N0AEF*(G&,1(Z)R#1"R.::;/L
M%Y(/Y,):38*0T1NESDD>?2*):.Q%*!$)"R.?V;#L%Y*2]I1PQBVQ5%*%D G,
M<13'EI:>,N.GEX:S, #W4I,3C#&#4%HD9C&U$$NKI.2&B&B$)--X840S98![
M*?D8&K!CE,=>"U0+(J6#3@O+E X^,;Y%D<], .ZEI 0%E\G^!!4$90QJ@R.A
M0YQK'0T1)+?SA^<_ZC,U)_J1B<TO%/A6G H>$(^#3]*@L ["02ZQB<0\6BTT
M X'.1[\Q13466BI&J)*1E@6-+3,,R<C-AG/=BS40INN@SD:JU!!FO2?2A4 #
MI,89%F6<5E=13[!:/*G.(J0T&]E:KB&F(?ZE@5*!-.-!:Z81QQ8)8D:+!.9?
MI%/BYK=%\QRW25FI2$ "$D^-%D98;J6F7KK(S[E;&-%,DYN_H'R0, X'QCEE
MDGH:X1!9Q)F$DL H'[$P\ID^-W_)462P<<QRS@VF6D,C"?:&&Q69'7/23D]*
ML^H!B93CD;A"80PE,"A#O9$*6AE=?J/P#%;#S#/6SWZ9#F4F4(2@HYK1J->&
M6(YP,,&'^$GQQ1/H]%GV]*7*>80I1()3U-& (]MVT7V25@<5"+T*(BR05&?%
MLJ<O6RBML(02P@*+/%M(3N(?JB)]T-!C.+VEN/.,O*^R1AB'1-L"IY#BM$I:
M&AID4#):2!9'(EX8T4R;9;_4Y%$D+5!'&<7Q$NE*8MG,&A9,=(.,YF1AY#,;
MEOUT*5U7@A@^_$[M@E2K8V5_>'!\CP<7+V"!:#$D.H)B(>,7"QW3,FB(G9X#
ML6_IK/-9-_K^KXNKCW_'.^J./;[XX,]\XZ;\KT[::9WV>]W!&>@7XG]X8[*6
M;MDLE;7I]CJ#<F)W@=MWTAD?=91[?M7N9O:BUPQKX5DJX$49DYXDSR8$3[EA
MR+X-+<&%EOS<A!",+7=8<Q>H5T$S[TA:9RUI6BLY#UJRF()1!!/.B-%&68JE
MT,X9*5T@,@6C\1PDAA0@/X79=>>8T-'Q=8)0#JWRAAD!F0PA,(30V]"2A03Y
M%]222!2U)=I8[RTUFBDA>.20#!'L$;)3K/6T""#_@H*A'B-/!/4P"!H04Q(K
MY-._V!+'T!Q8WRF ?&Y,,K9*.!L"3JG.!$KBN($A+01%00CZ-J3U*[#-B[0T
ME$90 EDJ\(>\T=H(IE DMU9[/EZ@FVO0R_O8>D$D= PJ)Q2!Q@1J'%<4216"
M4ARRH*%Z&])ZU;'UDJG1G"M)DO6*2,B,4M;&(1;AD#//E49S,!_3[?16/G;:
MKF][NYU]WSG+K!\*:!";6[.^IUV[YQ=QRB5PJ644E8M82(/FDD-N L9*H93D
M!.=@K5P^Q#>;17$0&R*D-P9R386*B"F%"CJ5;D=*(CJ#DLSS*;ZI58:^.?JL
MHLKA  5,2QB8#L%KAS41S-'(_6=0$7,^Q3>CPIPN4.$($\%CBG"0.F"=G )"
M<1R3\Y!A\@OQ[3:];>AF^_RC7L@<H6CT(!7,H[2L6'-CF+=(FN"I)QX9,O_F
M;WH2G(T%#-P0YZ"WC$H:12FQ1]@Z8R,#]9R8^;> TQV#,S""P<$TP41,%*!Q
M6K/8L3(24*DL%^).Y<="@OFS@PH%HQG55E(/M;32..;3/F"2,C:+0O(O+,'_
MZ62Q*QOM[D(Z@09&5T\*9Z53E"JH#!<F.H+6R(BEUL^_%9R6_&9C X4G@42C
M)YEU-"BO%">,!!:$# $9,?\V<)KC;_H6,(XT'?UV+R,'I2(0%03CE ;D'4[U
MC^?? DYS_$W?_GF-5-HQ6 ;BJ.7!.,M=''Q><V+C6)Q_^_=9GT8)MAN+:/VP
M9-%]MYXZ'WU!2K6)6"HMB90&,2D7( 0Z'>G-* (:G'%>$Z,8I"QB)TZ%1+GT
M+I6L)'[^;=_TQM[T+9]$T!*)I58.4^:51L);A*G!01GLY?Q;ONF-O>G;O<#C
MR LN+=IAE*%438Q9*#")TN..L_FW>^NZX=J-]BLD$<W>[BGGHZUS7&!DJ7-!
M>\BPT] :J+A2>O[MWG2D-QN[QSCG@AGA:/04L!!*$*Z9ASAXRZ[G'N;8[DUO
M[$W?[M'@.:&!(XWB(&1::9?2R3Q.*UH1P?-O]Z8W]J9O]S2B0@?J(.$X>NE(
M6TZAEH:FHH""+4#.R^>=O]9J.Y\7T>QA)%)]:*Z80U0%HB-A"0P*+R'%TB^"
MNS<-X<W&ZCD4O#$"6N98'&W$.(2]B$.0<,FE7H!(Y]1&W@S"G%J'M&^N=FF_
M8<<-AT%39:C5(0BQ",[>M$;>]&V>L,A  ZGEFE(JK3+.T<'>%Y(YK^S\V[S=
MWK'OC(XO9.D4BB E$2:5MY9RJ*0/:4VP"9&U*$_E_%N^*8IP1EMH(VFC%-,N
M%I9ZK[52V$+C@V1"8+D(V2[3'873MX*:\F!M]!*4-M0Q)CGW%"M+$5>&V3O[
M.Q8BS)TM)$0J)6QPF,:QR(6*G(9;Z9T4FA+KY]H6CA>E;'=T:R&K3 G,<31\
MU$>O@6*.C/?>86L(89HYB^;:#$Y1>K.Q@$@88AE,A8T$-00I;A$+&FLK@HPF
M<:XMX)3'WO2-GU#2&N2%]@91D_8X5M9&V"24:6.=F&OC-^6Q-WV[IZC@L1>5
M8E;&CU;:0#G%U F)B$=SL,W&7_UNUO+=[IK]3S_K9KUX<(*X[ 3?Z[2-;JTW
MLE9F]2M,VK[4&LRKLF*M?FK+G:IBHWO$C^,;/+BF6'3Q)8M^(I51M$A+Z9&%
M04EDG#'QXT#*$#)$<E4*&$648@"1I_7G33V'03IG/1/$4\B<@80%2C DWFDK
MA]O]\+2?=[YZ@"=0>)E]DRF&S&H6HM I]-1804+@(EBOE,%W=O;((4[GJ21G
M#@PO%%)**"UA*.*U-8)($YB WDMOM9D#PYM7@<[(!\7<1A?&Q/&)*#%0*40P
M88I[B9'TPQED@48"C1]>7Z"/[3<!T$/[;7#JRP1!%<'&&,Y@FOYS6F$?>(!Q
M)+CH"/)YF$$::_C:=]UQM8O36_1SSW=[G<SVO%M8-$/:1.D11@@GU,/H5= (
M:\A*2:@-T,T1FN5!B+-!,"P1"B+23&S2S+N6%*5$M&BD!(D.OGUK(_&73TN>
M9RWK-?QNV&FY["QS?3VJ)),.;60=;WN+F2_%HK<)48@,QG-J(VIK8;0G3%K%
MXB^CXH:0YD]%DF36V_U4I_HT]M1%53<G8^5_MUM'_Q/_^Y*U_O:ZT3O^>*P[
M3;W=:?=/U]L?LF86M>>5W5!(7Z;,EB%08,T44LQ2XHTDQL)4K50*)CFCMP.K
M4Y#6ZX8TZ0NE44,EJ-2"I[H#%"OE@@@!!8^T];$'IZ?<L](<KJPTVBD/(:9.
M8Q/=;6\=0\1J@H6:@>:\\#C?;K0[F1X.;NO[O11=RM<,]0LIL\=$&Z$<M9)2
MJI2*CB?W5!FB*+-D#BK2?\A:T<*N=[S+>EO:9HW8N E)?LQ:+6T;_B_=>K9%
M'S]RPYO>C\J93C;GI9YWW\M=DY:S=N,L:QW=/.DU;= +EGJT00H1"(*125+*
MF1)>1VQU2%/&A!R6>I214XI"_7ZJ?J-M*6+GNK7XJTM'%E3]D 0( B1>(G(<
MZ8_7J22;\Q1;97BTX 89S"!GS.H"_6:(?LE$[^G6D;_VF2I9*VOVFPNJV"^(
MJQ)12Y#1(CE@!$:JQI"QELDT.Z"MRJ]BWR=U??Z24E_@(;/XBFTMIT)(YJ4G
ME*?%6-Q+XJ&U(FAE]1Q%H0H]G(X>SCX<)@@G!DDF"=,T^&"@XYYC#;T)T%V%
M3FE\Y/C#XBOM"TB2QNYZH"0G3WU.-G#*LX!0:8M2))Q*YJ@+U*1BE"IH/K*K
MA0 ?8A(F9?(,D^ 927LY:"T,H<%I@[1TFB-'O7<.B_QRG;%,=EJVW?0U?;[6
M[QVW.W>@<B,>[?8R.PA8=>;%5'/-.=/&<*X\-3+V6?#8(:2CC"(K'>8PR/&4
MMYS&E/=3!?3S/+3I+".3#Y]^ER\V_8ZM$(Y!@@6CT4$6QDFFTRZ6G#DBT)VB
M$SF,].9)AC,)\2+C-):0*D<\M9ZI0)&1C%,D98IYS!%ESH$,9\,@'2'4$,5U
M_$L)@PI)+KWD+&CC")Z#S1YG)+K7V: H0"0$AX9(2I&-%@V[2.TQ\PA3K^9@
MRYN92^,%M[0Q4AEKA @T#@^&A!;18$%+(NA99FB8@[&A&[IE_?ZQ][T/;:NO
MQ3$^8[!&;[W?Z<0;?\BT2;0]\[^:D9P?=7C!P1D49%H$B4.:T&01-#U&0AGJ
M()/4S$%,_R6D\=*ZE_9Q?ZSZY44C?* 66NV13.EKTAH#F0V.&(^T0Z/T0SYV
M1/C\.B(5']W'7L>?ZU??P(4_W!OA+^:-1+]#I;WE!,6$6D>UPD8IK#$.!"K'
MYTB0TTE!+-1FD$/.?>('7MN J.9$AV@*$#=8$:4LG*<Y@[P(<E9II<P+*9 U
MP5(9A<HE20N=1'1QHVMKAJ8]S[Q[OV^Z_C_]>-'F6?QS%P!NG; ( '##IK_8
M_LN2ABCS +6VE-B@&$TQ#64P1A)B-R<U'7Z2@EAM=UQF!YG%?RUD93^HN)!4
M6N>B,)WVQF(KB26>8Q(H&U5607 H0@15/D5XM;YMW_J6CF]_G;@P_F6KW?%6
M=U\D(^8G&C-8!GWD1YGI5G?\JR6DWXIJIL6\#]*>:#/4"VV"8R3D3J0I5$RE
MPS(0KY!@5$C$N2=S8-3S*<X9[2I&+?(4Z<"YHM:F/?V01)8B%QSG8AX6O.93
MG+-9+":-H9XK%.7GJ>)<:QK!'7O*>5 >HOQ&2/,CQ><'2]_%!G=\M]WO6-\=
M?CWVV@W:X[*SU3_BG]%<+;1"*JVY8IY21!4U,&V1HS'RS KZ-<GI^IIN[Z(1
M)=+,6N#89T?'O17*3GOOOV>N=[P2+?;_?K]T\T3=.8KG]MJG*PC'$T??3;O7
M:S=7>/PEGM\]U:W5/TSG77S2\//P@7<>FUX.Z$9VU%J)!C8*ZOW$_4F\&8CZ
M >))'6U[*]U^,QZ^&#]A?!.C[;>C2*Y:#MA4^'JE<V1^PXR5Q_^5X#+\_?WP
MV+_@X)_W(?8L"+J9-2Y6_F\M*DVW5/7?2WOMIF[]WW)7M[KQT9TL#$_L9I=^
M!<G8H,'7[\.>$O$^48G\N.<0'G37076GMKE1VJ^MU3;W;W; 3U\]YZ^UO[E^
ML+=3V]G<+ZU5-TJ;_U[_>ZVZO5E:WZU4=O;W=W:K<_"N^&'O^F5M_^^=ZG9M
MMUHN;:R7,&14C=]N)NV&M]I-[V_W__D7XO#](^1P:[CE7 6W=O<JI3\B]K7:
MK6J_&>]B2R.(W/,A.2)&!&DEM Q;JC16W'J/F.14(,@@OH]*EEHZV23GLY6-
MMAVD4R9G?FD\7?OYPFRTSS[@O;,ZJ?3=R>;9X;8ZV3VI?Z]?6KK[9>NX>O(-
M'=8^P4KM$ZMN[WS?_?()[FYO7E2^'*!X#OQ JHWZ91M7MBMD=Z-Q7*_56?7+
M :QN;,+=VEY6V6A\JVX<'U=.MAK5+Q52W9+G'_#A1?V+Y8<;1W!WPV45O'E>
MW3A U8W/)Y7F/]]VM^,S:I\;E8W/6;S'<>5+Y<QM?Z;N[W\:A[AQ9DY.O^UN
M?*)5O'-9KVW":BT^[TOEHM[\1 \W/J7G?Z]^V8GMW3RO(WE1V=BY_"J#T)%V
M$R"YX( :PX%T7@*&)5(B)?Q(MK0:781/ PMT+875T@]U;D+#V PU[/8 ^H&&
M_5;1G6^EW9;__5<O=-/B];1I^*N7BOZ^[Z07:NC3KE\9?WCOLNYI0U]$JS]X
M]."B]V>^,UB4.!J8L:-&UE>I90'%P #WHIWON?']1\9Y>6B<W_7<W8-D67+V
MX\,_O?:G!Q5>1N2A=WXW:/>P[;$34H?^N426QE><:N>RUM% -_#I^?OQ]U'7
MII\>J!\3P-;PH7=?GXYOGHZOH"BU\0^=H?SOZN9/S :]K85?XIW2W;HW].^F
MVC[P76(K7AKA0KO3U+UX]7EOQ;3;#1\I9Z?O[X.^3_U(E7VG<;'G3]N=WERB
MX%9FM@]X1+?+:K/"#C?6<+WVUW%UPYU4\#_-^#LYK&V='&Y'9&Q^.J_B^NB:
MS_%9K'58:Z-Z/+-^V?A6V3@\KFQ'],25>&X]_NX:E2_5;_63:G:XL4D.&_+[
MA]I:K[(/S^/_OTHC!&-> X,< I20 (R7&D#O.4-8&&M=LM)*4/[^-H9>(<YH
M7,W'B!G XTP@'?T*TH?>RZ>#M;W:YMZ'>FEO\^/N7JWT\6!O_V"M6BO5=DN1
MU-8B<RTA4MK=*R'VF_N]M+M5JOV]69K@NU=<=VV]E@XC1>@MS^8*[MX-4/VQ
MY$OEWS1NM3NEWK$O_6>,$*6ALUKR+>?=R].R2=!R*3 ;[WCL],6%CZYZZS[L
M^CAHS^8PUC&7R/5D_D;B.^!J[>B\<AG_O_'M^U<JD=<1<H#FQ $*-8NL+GY%
M/& :A*(BZ*75?_HM7R*P7$K]_G!2-^^ZO+M7T+N"WBTPO0NZT;V7W]4ZL?V#
M6>.Y)WAU_$]6KWU+[8/5$WM1W=A*]S\Y/#D^/MS>^E9/1*U60;O;E5L$[_2D
MWOSG>+?VUTGU\A.N7N[ RN!=JLW=P75[QW4<GW5Y0".TWB1XCF,#A0928 .H
M5 B8^!N@&B&/H(2&RA'!HP7!FP[!J^VM5?=W!C0NQPQO#H(?8X;7N\*(,<4+
MG79S&%M\_M]2KUUZJ7LM+RQ#245TLVZ:R"J%+'*/8;7QE=>,?FX.9K"VXM.J
MP]+F\V@:GA,!W61?52J]'GL-!&=LQ'>D@,8Z>O%*#9:D>H-UFJ=$(%5 %3]"
M^%QHUBO,$<P0Q/ #!\ZK#Y ]?Y1U$T3VTH3RFQLD.]^_8J8L4M( 31P%U&H,
M##8,,!H8,Y0%$DQ$L &(-'3+E6Y5WROMM.SR<YS-G&/W;YOGVO9*23U*[5"Z
M5IB2[I;V3[U-"0TN]D)II]<MK1\/XBGYF'!@'#W-(Z5BF1/\1*\3+J,?'\3+
ME)(G7OOS)K-E@1?7UYW/$01?!\0G7.244I)RIWK^M-,^2^A^,YHX1/E4R*$3
M'>3!*JI!8NBH9,-ZV\TGZ ^=YL,O%5S'!Q>'&Q5X>%(]J6[OG>Q^V8GW.6Q4
MFI^_[=8.+G8W]KX=UHYN.\VQG8<GA[5_OE4N]YH5'*_?KK#Z230>S7B_+_']
M:CLTWJ^QNW73:3868:P@ 9)0!RCA FB#%3"4<XFT05%&T8WSK937[OT/W>9K
M/^S^0?@R(VPX9!\XR.;.E2\@X4>\KJ;/=T;9AL.UDW/L!4U[K.],!,AL'.Z$
M@>@=24 A94#*0($,BA@B//%<+*UR#)#@C&#U@,&>%]/[*&#(XU#[99;5<*3]
M-C!WI7:G-%@O7/JGW\FZ+K.#@% [Y)^G/_ ];YCXP>MVCG0KNQQ\_[VP.L5H
M&(R&G>6]Y?WETF;SM-&^2'GABZ+^-XQ=J=I>OD_G?P&^XYSQ^,@\C .>UX9=
M]]C8)8\VS^?.NYS[09T;-KGF7">MTAW^+Y5J1 63_!63O)SP&F^%*=OQ_>HX
M]LME?!^<VE&__!2?^5>C<GET7MG8I'5\>%*_K!Y7/TOTU6M-#%<$!$(XH$YZ
MH!DS@" >D/$,&F.75C'#K/3%=WNES98KK9WY5O^.]UE^_2F7N[J""UV9EJZP
MKT@)ZI7D &E! "7* 8WB'Q&B>BBI293ETNI^/XND6+$[65+E_#."O*'B>ORX
MVZFUO[<*/9^6GI]7OG_51!&"+0$&,Q2=<\B <=$7#RB*3$EOC/-+JU7=/3[+
M&HUI0.&CX[(C#1JXJ+N=C_',K&6+@.STU*CZ_6N@2AKB*6 B*$"IB(!): !0
M$PNU$]'NNB*>^Z &C^S"<YK\@YS&^R#_P:8C+YF-/QC]']L1)QJ'V6DQ&?/
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MUHYR*X&',G)E!TW:WPN"((FPP7/(K%I:166%9%GR:7#EA<?((L[_N"Z\7<K
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M_OJ8_R+C+*^ ]70>/(-YP (OYSQ>6N#E2^'E=;PTNC3*,B8 =YH-M\"63$I
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M;AS4V>,B):D5JG'G;Z&K_7E5TD;X2?A)^'E+_+Q[8)?P<R7X.;4_A7$9HS;
ME5/5_O0(05<X%5HI3,)49O2-)%@[TY77E*LE_&QS2/?A2(5W*RP-\G TB>^V
M42&\;DS03A'P[O%?=9J;4N5G!' ^\40"<Y' L]D@KK3%B>@X<-<48*P>$7C-
M/*"TV?IBA=&QDH#M:DU]&TDK06"Y+H)> LO[ LNIQ5R)3?BF[2%/.0&BL^"2
M=M!,I$97&IWOUG;U@KI*+Z' #*$EH>4FH^42U;F$EO>$EC/QV<"E2#X*R%XJ
MP" B6&<EL.KK*RR\KHJ\M:UL5V';)60$E@26+0?+)2IM"2SO"RRGIJ7E7'&?
M'019'* 6'D)3O9 97R=+I9*$J'XXZB:=16BY!@'83=;47H1<)V49VB&F73=T
M7ZY>=@YX/YM<*CE^&U3?G8VNJNB,DX%5+,\:,,8"-F8$8VST,1>5C6J*+;@N
MJJL!@Q4FV-H.0*1!>!BPM]2 *<'>G6!O:LP:S"D95^HJP@ HG #+C06?L^4A
M6Y.UW=IVO%N)BE"/4(]0;X6!3T*]NZ#>;+S32"%9,:"DXH N<7"9>Y#:9R5D
M=>"-J<:>$ETE"/8(]@CV5AG")-B[$^S-1"Z]"(BAPEZ)&5"Z %9Q"S(7F;RL
MBYOI,]CC_*J$B&!O,W2BZ]!1:W?V_'^G#/I'8_SI'9\TU0'Z9^KR_O&P$W(%
MDGQ>+V#D_Z:ZLZTBBE44#YB>.?BE+IPG%^OF^<6R^7F\:LZ>][I9,WN]X_Z@
M-SH])YN=XW3Y79[][TF]O)='!_TT3:K1H8;YV&AO-N*:ZJ0[5S*8D'-S*"R"
MY3Y 4+&@KL9%"$UYVZXVO&L6?*B!JM:0'H$0O#7E"PC!6XS@4W^"!:9\] XD
M*Q[0:@G!1 2%EMND;8JHQV41)';9-<7'",$)P5LVR9N(X*LHH$ (WEX$GPF$
M*QXS.M>H'I1L"ML@..DXV&QL4L)&%V53F$$)UG5RL85M",$)P0G!6U/"@1"\
MQ0@^M<&Y1"EXT\-B7%K'\@+6UQ\8C,I*\"":F+[H:B:[#!<;U2<$)YWR'2/^
M(_]WYX>)5/E?G9"/<^F-2+/<_C#]G+Q2^6*2T/WY;(Z) ^;B@-\OE?>568LZ
M.< M)L#,)?B@!3 ?HK"HI<"\M6U(N4QB%@*_%2N7"?SN!?RF!G"LT^4T%Y"0
M806_G,%J6<!Y80,+CFO.MK:QB^VJ:T[@1^#7!O!;JH"9P.\^P&^VL&Y,3JG"
MP3FLWC^S'"P6!89+)7T*QLA0P8]WM2/3C]#O0:#?6L15"07OC()3$[ 8Y;23
M"$E85E%0^^8XAX42K<-84"%WU?]M:HLOH2##YD,A:9OO<D/W\^AR?[.OZ)M)
MR]PB4[F=6N;ZC,.3YA:_Z ^:!W9&HT$OG(Q\.,RO^_O]X^8[#/J'A[VF&CN5
M_[D%V;R9#;:6K(J0MH".20,FG: NAP)&)A&;/A=)363+KBL6?(R&$FXDF2"P
M7B/9,H'U,L!ZIKP%$R)IX4":; %+5.!\UA6LN;+."9_"6>,V:;M*$%@36!-8
MKV40FL!Z3<%Z_U*#B^S1<7 A24 T#JQ2'JI_I33+,9F8QV)D+;H5TPFL":P)
MK$F,3&"]/+">.?OG!!JI$N@<*UC+G,%QJ\%*4?]CQN3FY$A30$EWF5EL\I'
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M8#Y(751S JBKE.Y:1TWO2=].N+@0BY=PL06X.#6%$PL^%\/ R!0!Z]R"4\E
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MY^$P#W\=](<$]O.!_4P_IM=OU)^55U4)UD#$:CHC0P->8VG*S!M3)U<);2C
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M,KJ:7T(S:5A34P&[0FLJ!4L\3#Q,/$P\O"%5!(E]5\&^ZH)]@\:2A"B0K3>
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M!)@$F&L'F*3 I,U FX$V VT&V@QK$80F4_J>36DU<U0T9EE2@I1U M2J*4J
M 217QLKB+4I-IO2:!*(W67F\GT>=P_YP47'F#<\NDJ*($NBTQ&F)TQ)?YR4^
MCWENHV0F91DP*Y0NA\29%DSG*(S-)7W;/)^_*/&+0;_T1K]5EB:#? Z#?'^V
M,K\/)F?&(]BHL1KDGH,SJ0"SZ'(2/KK<Q+;1=15;;#*0@(^ KR5SMURU, '?
M\H!O6E%=%1-"=@F*] 50!06V) ]!\"RLL2FCV-KFIBOI(!#A'N'>_<=C"?>6
MAWO3"&RU\$RP,8!4T@#R(L%GCI"9E$9IGU#8:O!IW;5<$/"U+>;Z<,2_%^W>
M_W-RG#N2+;3;^YVR :$_2'DP_KQZ&SO#_F$O=9KONW8$,)\@V 9,@COO$KIJ
M[LJF(TW@SE2O/QBOXJ2QQ)UTP-05_KY(X-6, MA9+W02#CR7KBD%A.!%UJ"S
MM2(&YY.-XZ[P:'B7F;87"/_V!FPKR*V#LF'9;#4_JK9K3N^S:=%2ML7ZT- U
M<>=;<1 U-VH[5TW5UW4^76'!@!2(@!@%V, 3,.L$R\):A96KT'6=M'45(7$5
M<15Q%7%5^[A*>AMB*CYZ)] :%U1 F9(**27#I">N6D^NFLFF5I/#.V/!"3L^
M*>3 A1C &I&<2RY)+$V?<RY$UVA'5$54151%5-7"] [3)D8OB[&<(Z9D-0O"
M<C3",<MEN9&KJ+?X>I#6-!.NE71&60MA7!]+V@3.H8<D1$G,"VE5VMJ61G3E
M@GN+$UL16Q%;$5O-[U@5SYU-(7B'PEMO0A ZR6BY,A$3.5;KR5%3U8*W*#(Z
M 0:CKHY5,> P9J@F28S,>ZTC:\Z-=;6U7<.7T.&<N.H[50X'9X/CHH[VJ@:D
MC/];K.9K(6.9F4)9IS#U3^K&_ZZL_U*'V::QT"VC6T:W;&-OV9@'?AP;0/7?
MU/MK^]_C'^-'+ER8LX^JHSSTGX;Y\?DO/Z7>\-.A/WW<.ZX64X;QBZ[3L7WN
MI='!8V<?.:/')NN$>2;O?W:9/SHS9__!\V<7)7N$3M]\_:LO_OI%]LBJV[Z8
M/>)?NRC=;5]+0U[]D/DC(\UZ#;FYR]\[Y&^8@.=[NQKD^1NH1D]=XE-IVM;R
MJ31M:_E4FK:U?"I-VUH^E:9M+9]*T[:63Z5I6\NG?E_H7ET785I!94T:& V,
M!D8#HX'=X\"NC]J?#_#(#][WCL\3X?KL=130;WO<EH9, ?U%!O3;@*)NL04?
M8FY$6W<:\G?*=LP29#M/)KWS&AG;=PA-%^."M&'5U-$,^I_/?E]PR9#-6D$O
M\\A7'D^=[ ?'=:##S@\IEU[LC:XHP&GJ-VOJ+XM9.[V)FO7FVN@T[QLQ[Z_[
M(W_8R6.Y\SR*SY9,^LHF^D9U[_<+JEJT"EY]O=_N@J;]'NXAK8F%K8F=H_JD
MT?K@_]K:JALY<&I%<[M"B$]SS$<A#SJ2+[08XIR%.>\";>MSZNS:"H@^H]1*
M1QG1HN,\%)4TE]YZFU&%?';PC O)J0+BUPZ4J7=/__OA71W;VP\'O?T/]3.^
M'!R\>[K7'#)3]?W$NS_>LCWQ^Y>K!\KJ6/ZHX_WCE][S7W=%_3Y?ZGM_W/O2
M'#([/-K[\.[PW8??O[Q[NE_V>C,5$*7#@$9Q*,P40"X8!"T4(%/%%L$"0SZN
M@"BT["IUM03XJAN_?->N:RNDW6N1\.4Y74L!H#:-Y7R"%KG([\T):->]N\\#
MX(N#AO7AWZNGOF]'OG3JN^TD/2W]R$OAV1D#3A1629HEL,$Y\#X*;;DM+)NS
MTH\<NV@LD71K2?K.3N9M;\S.H.</5TK,]S<"HF.BX];2<762 N?6->",D0D;
MG;4Z2.,4L\H+HN/UI.-I=<NL1=:*&8@I-X7"I 2O;0:7H\R6BZ25JSYS5S#;
ME8Y<9F)C8F-B8V+CE13P#%A$4JB-< 6]D=8FEKR)ROF2FX:\-]$Q%?!<#UZ>
M+> I1+6P,L1H!:!1!9Q4"E3A*163F&^*HTG3U>)J)Y\5=G0C/FY3F<Y[8A^B
MG@==BC-A3(I[S9UG&(NU,3LFH]<AH[*ID!>XGFPS+<69E74R!0=-HU? 4OU!
M6YR'Z*WT=>HY,KFUK7BW>OUU%<GU<0/7D7.HQ>A=I8T0_# W-^_H4SX>^F:)
MMK')Z&8+:9C1MNDS4%PQJ!3S08A*$UI[+QQCLNDF+1CCXV[2]1=Y%T7-F$%V
MA\.3G)Z>#!K>J%^TG\[4->.?/S=+XLG,BB"ZF(<N3F>$-BBK^Z%, :V\!XQ"
M@2_,@8[6%R5YRM9L;=?)[EK5]CZC;<>S-C<2:-%M:M58KH\B$N,LU$NY(]W,
M[:Y<)9O_^L.33%QS'UPSU8MDKTK4**I)ERR@D@A.,0V8JE?B17)6B,HU&KO*
MM+U/:-M!E+B&N.;A<LW__7^LX.(G@@R"#((,@@R"C <(&;09EN*K.8U&%ZZ+
M2!:+$[[):&LK0@[<>LO)5ULC7VVFHYN1S.NFCQMC!M"R!$$TK4>CJ]Z:-3HZ
M1;[:.N6--OD,]LO\Z600#^KV[_1+DRL:5]/Z>F6,I1["7C<"N%G*UI+\T'3&
MKTD2$>S/ ?O[3V;302DX87P$A48"&F/!A<" %\ME-L$:3%O;O,*^U8MM-GW+
M#=96A&J7'JU%-Z958UFH._U@*6/U"9X;V&+L.1!9S$<6TWR.S=D9$20XSA.@
M8QZ\+!E2]M:D(EWV<FL;D7>UN.HC$%D061!9/%"R6%2TE8" @(" @(" @& 9
MQYEHB=^W8[3L; HY1O?G&,TD3W1&YED&FW(!3%R!YS9#8 FS$ABC)L>HQ9F2
M,OYO(S,E^WG4.>P/%Y86N7KK-@G*%V:MW.ZVM761W<%:^;ZM1VY+Z]T6 @("
M @(" H(-!X*YG#OET OCK5,2G366%R^B"HK;9+5CWW;NYB_^\V+0+[W1;]7B
M(W=N'G?NU4QA/<F"DCG8ZLEE#BAY 2N4!2ZR<-PQ&W!<6(_5=;'P&CY$$$00
M1!";21 8I(HY2YM*P<(PI* J762G$V8I'!%$FPAB6N$M.(S&J00L6U590B'4
M]>' (==-<8643"4(UU7B:M55(H<U(0<Z3[(N*1 "P>6!X#3IP6S$E%0!S7BU
MDI75$ I'T)7+E,%<9(EC*UFK+L?% B$=%Z'C(E^Y@Q<M^_;\(!Y,^O4UCEL;
M%!PWU[^;7)E\EJP74_\D'.8;"GNVG!/F.V$2M6<"2_V)!=%PKW3Q7GFN1>1&
MAJ9PY5T/EE KO_OBA=E6?D)DG57AE1="!JPF,81<%/ DC-66FR3/6OE);KM*
MNC4J2/E]&[*M*+@L3=&" *U]I97G_#KM6@VM++P\SP9;'X*[ZO/<CMVH+'/;
M67!Z5H8QR[37$9*/U3O2P4.0.D'2213N6)8QCGOE&6FZ*-:H5QZQ(+$@L6!;
M-M@ZLZ!WT3I9N&$R8_ FF-B4(<9LDS1.)V+!]63!:2:].G]&%,6!9_2 12IH
MRDR#2-5%-$YQHTWC"XJN,6O4H(XHD"B0*+ M&ZQU%#A/]HN;4!T"I34JBQFS
MTSQRK2RSDE4.-#=R(/6%6P\RG%$-)&T+TPY\Q$9;EAC8$ MX8UC15@C+FO;I
M9N'9,J)!HL$6?)UVK0:BP55Z@D&$I*+6.@CTG@4K10XZN&11)1O)$UQ/\INJ
M18QT*GC+(7F; &U,X+W)$+WFW@G/L:AQ/-2B[#)%\=!5JTM^'&^$^F_J_;7]
M[_&/LZ>$P8]3:?#TXOCI%XQY=DOJ)Q_Z3\/\^/R7GU)O^.G0GS[N'==ME6'\
MHNLD)I][:73PV-E'SN@QKDW$+I/W/[O,'YUAWC\6P]E%R1ZATS=?_^J+OWZ1
M/;+JMB]FC_C7+DIWV]?2D%<_9/[(2+->0V[N\O<.F51GFZ,Z(_48J<>^:2>^
M87M_/*N/?\1]\:S:A75<3S^JYZ]___S\]>'A_M/W_/GK/;;WX3U>L1-?__[W
MV]?Q[^>OW\NWKP^/ZNOJ&#_6U^^HYW7,SY^^47M??C]]_O2@[,T6))8^<.ZU
M!9.S =0Z@54R@LZ(JBB5HRNM5H^U'97:55GJMC=F9]#SARL]=W=_([C^M-W2
MXCD4E_F^K;P^E$AZLX?"FU.]F9!)"L<]J"PMH%06O)<.BM L^Q*S$:[5>C/B
M3>)-XDWBS5;Q)BG4-I,WIPHU[THLA@70(GO I U8'0T$*[UAR7+9E.YLJT*-
M2)-(DTB32),T;42?2Z3/J:8MRZ*Q3B:(W/2/$]7C#"4DD"B4Q\"X%J6-FC8B
MSMN4PB&:()H@S1>1PU?)8:KY"L)DRYV'$)NV"$9P\!8]E&PUBYX+D=JM^5I#
MEJ#V"'/=P7'F'D+3#Z5I(WW12)YJ7RY>I%&A(>D<.#,AH&3%!<S!.A:MP!B<
MF!1^P_/";UJR.S:1WAT.3Z[K'SW^^7.S")[,K $"_GF _]6,B"-$IV)1 G3Q
M#"JY.W"2)>"A.H)<&,534_R@6R=U"9A/13+GPG$*J=U+2(T8XY[]A3O2Q=R.
MPU6R&'=)(ZZX#ZZ8"A><K+.)E29,E )01 E.LP)<EE!=!F,LXUO;PMBNQ&6H
M_8@MB"V(+=K)%M2%B38];7K:]+3IV[[I:8DOR M* 5/,P>GH.2*/WG.= F,V
M9\.<+.0%K9$7---,@2MD& T8YGG344:"3<E"LMQXK7F*3),7U/(\R0:?99WV
MC>_T2Y,I.:HP=1;5I_.L]ZNG:DFN9#KCUR1,".CG /K]V?.MVLL40U @42.@
M-0Z<81%B$;XD;8*136])Y%W4DA13ZZJ86KW+N?H1+-;I?:CTL/K$R W,,/8+
MB!CF(X9I'B1Z;;TQ%I05NO$ %+CD @3O'";TAC=M<XQV78U7E5)$#$0,1 P/
M@!@6%@VE34^;GC8];7K:]"U-@6SV$I_'X5EV#H0<GOMS>&9.AS#TP6L.,N:F
M(K 2$(SDH'F0SAJFE6/D\+0WV['!IT+V\ZASV!\N++6QV=EL$FRLH6!C]0["
MZD= *BW:]+3I:=/3IE^ TX8J%.2<)?0*M0Y!1LU%"267^IO3WW;:YJ\.\V+0
M+[W1;]62(S=M'C?MU4R!-&9*TB5Q0"<U8*X.FS,V@O3(=$*M=%9;VX[;KKBF
M0-J]NFE$!40%1 7K3P5:)Q6Y+*E);!<A&Z4K+S;ZXHI$)HD*VD0%TV)?UJ#*
M/FM@ACM BP)LLADX<RY;71]T=FM;B*[D2$RPKDQ N-?>O 7AWO)P;S93(01#
ME: NQ5!-8.7!^N# .(;2:)M<C-4$1M95]NKA# *^56<J-OA<QD6/L?^<'.>.
M9&UJ,79SQ\QU _GYSFHP&TV4**4J"@L:JV7]@4X4Y5D6;%+8\$Y'-*CYV'T!
M?6^V;A7WKCCA@+O"JX%K$8)(#'(Q0EDIDF]JD7#5Y99WA=&M*UCX[2W75B!;
M?3/V^:SCI97"G6/ [9K15C947U>BN>I,W(YEJ'QNV]EH>B)$REA492+ 6#(@
MQPP^RP"*R>@\#U(E/BZ?*U!WN6A?*TQB(V*CMLPHL=%B8UNB-$T^FF80*- @
MLP&++<X&ZY3#)&ZD(^KYL1Z\-,T()^E*DMJ"URH"(F^.L%=RXE;[[)D/1NM&
MN*NZZIKZOBL4[A(?$1^U94:)CQ;+1SX$9+YR4O6),(:F!Y6*0960;0I>2^*C
M->>C:5HZ,2LD+Q&X;FIGN13!->=*F/"1H<10O-G:UJZ+:L'9&:(CHB.BHX="
M1W.P4>1"9=NT9N>N\8Z"##JC4$XGM$HK"M:M)PG-: 2TQQ0YAZB]!_2I@$^\
M0.'*%N90RF"WMM%VD?,N-\OH>_* V>@;*H*#L\'9.MC52*H6,929"91U E/_
MI&[TV[ EC9)&2:.D4=(HOV.48Z;Y<6Q4U7]3[Z_M?]<?YZ,]\H/WO>/Q9^@I
M;V[_.PQ^G)XSN.%%$VZ?O&[\"1=NU=G0Z[<^])^&^?'Y+S^EWO#3H3]]W#NN
M5EV&\8NNT[E][J71P6-G'SFCQV;UA"LG[W]VF3\Z,[G_88N<793L$3I]\_6O
MOOCK%]DCJV[[8O:(?^VB=+=]+0UY]4/FCXPTZS7DYBY_[Y"_8;2>[^WJ-.1O
M@"0]=8E/I6E;RZ?2M*WE4VG:UO*I-&UK^52:MK5\*DW;6C[U^FEC=SJS=7W0
M_#Z#V]\,=]R8#+Y^;)>S -^=//A&$F(<#YD$CS@;>UVO<N[X&/M'=8RG]6MU
M]ONC^O:C?N?-L3])O5%.G2?]XY2/AV>_C7,BOGGXE]ZQ/XX]?]AY-:H/'.7C
MT?#1Y8!..Y84/74! ;I/_6&OR=D]'N1#/^K]E7\Z]_;KNIJL,6&N[(Z+E_E0
M5]+)*/\TV;AL]O677S.S46-NDK0_U>4>H3[:Y T?#T^.ZC<X;>].$^-OA/_8
M&C,_F^\ZSC1K%HUUWFNG,B)'AX&YA-8+GE4T^*>P6^<O.AA,(?%]AC#(_B/X
M4F_/8W_XV9\.MWZ\/,MUBB<C4EB'?./MGED.7-0G7AN*O6F%7%DG:S9YYOK)
M>_)F[^=G+W_;V7_:>?$_.R_W=IX\>_-Z]\G.;Z\ZN_M/'G6:"Z_>_/QJ]^GN
MSLO=9Z]NW#97;T?+O_D%'\S! IOS[7^X8,%_7?U2W[=EFXXUW\3<JWML'7?)
M#_Q?G8D@:/_DJ+Y)_,=QO6"*C99%)2(Z+YR..7-E-1K.%#MOTL0OU?ZX+/%Y
M/GCOCWM?QIU6I^NP4?8<IQ>#/*RK:OSG\W*Q,*?K\FEO& _[PY-!?EW']/-A
M/WY<K<3GR]Z%Q.?GHW='NW^__;*#;[_\KO;J\]_^\9_>OGAY\/;+R\.]U^\^
MO/L0U;X82WP.\_^\/'WW1_H4!.J]7]\=O?WPRX>]IP<?]I]^_'O_U_\<O#W:
ME>]^_>7#_J]O_MX_JO_WY:-\^\=_R][K9Y_W7N_\6;Q-=0($<%D8("\.@H@.
M+'IN8F"VH#B3;_6.3W+::=177$D5=2@V&8_9QE!7=W9)"8_*UH6_U<G#Z#\U
MVWQPDK>VG[_\=6=_]]W.Z]WG^V. _'GGU>ZKSO-?.B]>/GOU;/_U^,JY!FBR
M8/Y!)_7:9!#C63V;K&\/Y/+ ,S?"ZL#0"D03C#7HF(K(,FH4LMQH;7PX&8YZ
MY?2G;V[6MNS+&TR/)R='(0\._7'JO#CP@R,?\\G8U1EV=H_CH\X/3>%:P7Z:
M/J\[?H3_U!D=Y,[YU3,GX>)2?]#QP\Y)PPB]X_$3)YN]Z8XZ><WG?/'TR2,G
MP]DWF#S8/QE,'OQ7IS?L^,[P4VZV[NBT\^G2@#L33Z53^G'\R?VS3_;Q?T]Z
M9Y9EMY/R7_FP_ZG9\IWF.S>=6O.@>;\)<#0##(-ZJ;[!IPH:<=#[-'[\TZ"?
M3F)U8SJ=U_5=)]_X_QW6"[T&@#NC.O5YU*F_?\RC.M!![ASTAY]ZHSHT'ZLY
MVXG-8\VGOO?#T: _9KDZS^]/'S5O.<R=HYS&W^3\*_;RV?O$^D4KUM<I_E*'
M%4X[YX;UX6ES8QN^'(P9=S+B.E.=X(<-.1_XT?@N3,;;"?FP5^_!L [FN/[1
M^92/\__/WILNMW$L:<.WTL&9^<:.0.ETK5TESZ<(6I1UY#%!2Z*L(/\H:B6;
MPL+!(HJ\^C>KN@$TN$@DQ06@^L2Q30"]U)+YY%J9]<T^!&_KI\([QGW=ZW7J
M:<'/8]V#V\)P9#TL0H-N8%=<&GB\"K0!6*DO9;2#8>\'PR]IH//EJT94]N-%
M/ON_*2P\[&3LF1LG"D_/CN&&B,AII<"@ABD!*0WZL+;QU^%P!..+GV:K-?#>
MG;<NO\VTZ\.3%2V/LQ+6 Q8"F %6/U)V7W\M^^597.6*O69T#"LT@>6+?\&J
MQOMF2]^)/'GB>[WXWYH1XOT#&'9]3:0*E[2W>#6\_Q N!3 [A*T$\AO 0Z_F
M(+CY6)L2-K2,%-+@DE3\NOAM,91$U;!0TP!D#3(W$?7DL!P!">M1O+^3G1R6
M]C!=")0R&GL_B!<MUF;^T!D1U?FZ:52+9\<9PFL#4!&P,>#:TLBRD^'H,S #
MB/Y(]B=EG&JB4A@+BF,YS<!LKC*#$PS 5P,83B3TOO[LEU8XTU]TV4N9*#7L
M?1@D-TG2,VY&H^LN6-Y4"Q!)K(95>"98HY%P.C4P-WQ+T[E+R<Z-"=LT)L+<
MF!C/E;;XU":X'6K %!,I!8 0=JH2 CIB(8!4?!QL923<M,_QSBUO?22HC.)8
M&@JKK#&,[[P\85]*(H>Y1*YR<>_2;YW9R^+48)## 1#7(.:J]X"-[724R'+I
MA@&,9#Q.@F28!5U&E#NNM-8TTG)0Y;K'Q1P#^L$GF,.A'_ER $8FO#^>S"H#
M0"+<D=AU)A#C0D]G(P:P'XRKG.IQ8\% +/1ADI-*8MNF^EPQS.TVZ)(=@<?'
M 8U<+,RUV(F1/YCV=#6L>EO?QY4J*RD((W_U%>3@X"!M=[],[)S]TE!"WK]Z
M.=,4*O"R?C31\+KFTL7OW5S7;PYP,2T0,\-^.8F3 O@[]J/Z0\(H&-:KETE0
MI34N^_&"<NAFF[58LO%M%VU\.)SV7)3.(Z]G^W$T'53'*.8K=C-*'21CO:;7
M]% 0)MGF -3G7O;.'P,Y16;Y U8JPSGZWS3%^)I3KT>93PK116YIKG_ZXNH'
MSO:F(B=8K&FOXN A+&"]\;-W3@Y'OE*5QN77K ]H<SBNQ[!4R"V)!YC9G'L
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MQG.AL9CALQH:YU-)80@899W*[*_(<NK4";_G(S)I7G&CHRX%^M'GV9K,SE(
MRE=YL %TQ?*@K!Q1%T@Z98;-"?/"*'5RAL:I ,LU#X& ,*Q,ADK5[4^K" BJ
M4SL6B?$P@1 3_#I5ILJD"AO#R 8I&K-P.1H/@QS4B3=5_MD(QKF0F'5NSU)>
MY5PW*.?R[3:ZV4ID]5XI)^;:\SG8:Z3"@F[^Q4=::62^7@::\1>4 YIO7 ,J
MLU\JZY(2\>OS;'=VC&PW6@<5W[^+KOVP46](%3N,8+JX(CG_0R*[^OUIY.:T
M$6F,5L<"!2*']6K/:<4BY0B4+U#.#)!BB@W.%,J%AI0-C^?D#6\\**/O^P)J
MU_ 10X3G&79Z'.T:5S]FEB0 6[@,-3.%:I&:5;VM3#Q7@W EOOM 8A%3XD&W
M66YF-?IX^*O^<:9;I=!E ^.1.46+3]7QETJMFS\BI>M.&@>6TMRK)-M+$!=^
M_)[06;NDVAJCXJY5+O@FB<4U;Y!\7.)E#9=FU8HV=_U;#YC9M7/I":294#P*
MGY2MV[M<&Y[CYDWMRO.GIV]28N#1];N;^EF;BG#TQ0-!/G_(",&'L=\)KT L
MQ,T<_Y3^_[U/.7-!6^,1-A(C1BA#IJ %8IAR)90*N0S?\O^O,5E>"C=)97"@
M%5:>K^>5;S!>!C/Y,$XNU3G-_(!]]NC+\GW,K8[_+>5*W^1(7'4&+BJP4?(D
M29\BI0M;0]NHFT?IO$""XQ&HOV7*-YK[<1:G4,^?'IV=Z/6S':GR@4#]Z1_7
MB>+)05GIJ$NYQ[.,\6C)+$R\7CD_#GWNW&&5)YH&&0>R=.'D7 C=7_. WU4#
MJOVAYQ+ ZY-.*96P.MV699MV,M6]>3S?)E>W*T,\55&?/(FFQF)]*E=W=44Z
M#]Y8J^IL^*"R2BY634A61//$ZN*I]1G%Y\F)'UU9YXS#6 WAP$<BKW?(VM$T
M%JR(/X[@A]G6S7+.JF-3X^1)3];6\O.&,9$*0*EVC$\'U3&D^A@W+%Y*TXWN
M[^;\9L4MZG$G7]JBTD2U?TT-<T$9MK:UX>9Y\!TL55,;6=78?V&_ICOG'-,@
MEUE";/7;C'A.XPN&MDQ4DCCDTJ=_1TEH4];N$OG$>J:LK9?PN4.9?'FRWG>3
M[\XEZW%>V)PHC8TS#*XRABM>*$6P,]A*LW'?RNA[?Q#EPKN9\Z/-49GIJ >?
MF*0ZY"I'6#B.&"PNTL0:E OK!.<A)_)">2M6&)X;XTE1!*8]UD1SBYG-L8=M
M<.)">:OY4:1Z)\;7P-DGFQ]W.5-=CTDNWO?=O;AP^N_*/I3C:G,V[H#_%DTI
MWW3_6&I+&<56;$UY,ARYL1]<R"Q+L;2=,">9&<6L2JO)1V#4S=/MK<U/W!=<
M&&<1I9P@QK5 DK,"<>QE@&7/&8?-'@[\A5:1C:. ]1;7+L9R?'7UL$7V[_;"
M0DBG(*+2FPX:U$G'?KF@EF[4&IN<'OOJN&U]/!OT'="L=\Z/ISJP CI<3*TM
MJWC!(E,Y*8N#JN  F##1NY]2:ZI)C"M#JCH5#:IMTU/9]/'#9'VE02Y.N]C#
MZ$Y=+$\DVU1')1H^HTY4?V=?(?@J7A*1Y#CYANLO9A=$F^I CUQ]/#R5IFK$
MP6?&4SP=4KG?T]! ZU[*KY[%V=,1N2L,G:59@6KM8VF",CG[#X<G*?FE>JUO
MU,A:O+[Y[L[L8$M=!B59=+$0RG?IHBXQD"H[S<)$H$4,AC&7=U[T+54LJ7ZT
MY<A.^]'EFPJF9>^G)GZ(Y]:BN7KA1-;<SS>S$T8QP&1G)7DNGG-+1M]PDBRV
MF8F73NS&>G2Q$(IN=+1-9;O!8JZ:@2[R8"X31.>_N234?LWZINSGJ6]*[KV^
MZ1NP1>MR46\&6]Y,-@=N>VZJ5DV-%R63X,<ZR+ [TI%)-Q-9K5Z=T^[+F7S9
M9OL?M]GVV5N\MWM ]G;?$G@7Z\9[R-NSO:,]D!O=H^VC/R_*E[-#>._!67?K
MG\.=K?W#[M9^;&.<P_CH_E:W[!Z]RO?(]NEV'^3+V=NS[MM/+NA@<N:02&5.
M:4Z1%"(@5U#F/5"R"_R\'IA+["07@3!MF&!&D<))!1JC*CS1DI_7 ]]T_WGU
M?G?[57<WUH+.7FZ^_W?VZNV'-_]L_I6^BY5/MS??_>^KW<W?_WH5"TM]>/=F
M-]6(OG'ET^^.[:D7G%LZM)-895Q)K;DSIY$QL'R:(I52]'61Q>@K2@FJ>GP8
ME8'+;J^KNZ5C-(=@8Z$HD=(=]:OK3(ODH]P=I<#A:5V"*\*V&0Y<RD^H3^!6
M7YROIW@,I#2*?KG*)9A.$47EHDX]6SZT,Z_&,KYBRB#WZOC>I *$YH^7YUDT
M,TJ</_:#=%NMZ\0DW^CSF^5#P.BJW#<8XKDB78-+2H=UKAAFJCH19>TH)<Q%
MUUPO%0B]..KJ0.?YJ:2"J7HT*JM(;<,'=SY-Y # L?;45O'9<PD<"Y4LE=*L
M>\!'_R3(SD9AV^L4M;C)PD3=X)(]2BO3(*]J/G5Z1B^KX[)I-T/6JPZN [N"
MGA2/ [G9X;/&&;-.O=J+0CY1.8I4'+WEL&@_DJVZ[B#RW\T<REGPOUKXJD!$
MY4MNG.X?3>N3S;,BJ^>R#$#Y'L6"%*<5QZ2:,V7,(AA?J/"8O,LQOZ>JQY)^
M;PX!".K-I([_IZ3O03P_72=[-5)>ZZ#'+U5QFSX@W*\S_3*F637B#E5IA6:.
M0V/DJ5!-^:4>Z"&L6&2$>@(I<C(=5$D[Z43 L*I%7-HZO:K*$)TIR:EV8C)]
M["*YXMQH?ODK3CS#2Y/^=1[G@-6_.("A@5W_4KOMCZ>3^5/H\E/NL.++&E#T
M9E9KT//$J&L19&,QXZ)?MKHS&IVEU34>G&KD544<S6BH 6#C1HRK4M%5A>IX
MB *V\?FW]Z*,(<+)<Y2B"DO]EB1>[,;:;LZ,RE&696^7V&:921KIFQ<9ZCL
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M:_" EF8#H"RFG?;Y(-5.^'E63@KA#(/_OP-,I)WJ-C 42%^BX/VW&BO+/,Y
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MS./(C"S7\%PW9M>HKS8GHJ5:IU&J#K,G6%2!:4C)!UZ@ 0@F4L6'NO7L&/'
M.CK_:GJA9;F6K;.8)SJ(Q%2/3,?5F6'&H>]YMFF'6#3INPN,^%\HA.]VPH'I
MQ+89,1\#X+:1A-PUHSAV ZRF9W'8G?##GK!]>/[52[%%AL_U!.QJW7%BC#79
M@1Z;S';].'8B)P%1N_R$7Q9<I@7*,I<Y"717%O\)A-H1P-T)X/ 2="T/@BBV
M(E\W_#C%S'M39PXW=>SN8UIFXJ:ABP00+A9&_Q<6);5<!;^!VCVH$V!Z@!!3
M?@]"B&//\?W Y0&W':  YGH\L+D1QW[*0I#UMRCUN!E^?1I-,3E9@BY N,.,
M0GSO..\(A C$.+S\&K@Q\J -9J_CRZ8N@>_I*7=L9B8._!)@6,]:)B'&@-$Q
M'QG10]S'8$"B@,F4=G_.V4+T(V6( A?-+R(U42&T"&+7WG*XL(+1S:*W.5\.
M7@N8#,,(!0# 'W#?B'S_Y82-9"0 _D59R-,"ZTOYI*2TMWFO&"UOC\>BFE4$
M8^;#4GW .7>R0QZ_SWD^.C_CQ;#)#L_8VOB$UD:2NH MP=J(XB#0G=!U]2"V
M/-VS 6V&=LQ"%PC<]*_SZR QW.6D0<4EKLD\,V2& ^9G$//0@$>!P>.X09**
MU!O3:K>LZD[Z08K-8N-H]ZL/UD3@!;$>A0R CV^F.G.#4$]8$O 0.]K%6#@<
M["R*M6;E<%0+G7PZ02F2U-X)%"&U6UF*H%1JG_EBH4WVLM\UC>$#F\5]'G_7
M/A3Y1*;?RI9J%(#?Y+VX,8U!E3&H6ME&2+H ?0+D(/0>IK\@W5"8&7.WM+3(
MAW-I!U5,67G.[A=K\&W/CLS #6R7.2E/(R/QN&<Q@T>ID52E8(YEZ.J'NPHF
M<A&?]?G;O,A'["(KIN5NEISP0<;3W5&R#^O)AUDL&QO,=N,)4H)J@7 B=^89
MES7NNG2OL\\_#G_L8IY@R'S7!RVBVP&+P':S;3V(;!,D6LI A/EI'*+MUC,#
MOV<Z2[17LT<,^8JN8<N7^ 65X_+A0^7/K:'6.YY0%5CC@#4XX9XFSE@4A:MC
M5@UH9M1UYN6+M[LG^Z?X,Y;L"!\QAM8XD#IF?,C..KZ,2&ZTL+S9D0?[BX!9
ME=*1PUUVT_FT<[JCG0X1H[Z9EEC. )O<*+G+1SNW*F)ZK+>T;O>6VNU*K=;@
M+$CP#JE/1RE%MTC#L2Q!T1&8-V7M^0"3F-W3_<&PKZYAA"PVL2@7('_B)*D3
M.0 +@:4]"?_G9&_G_G@ >7IH'%U^]6/?=NW(UZW(!4O7CFP]<DQ'YZ8'2M%-
M#=\B;^>B)*T-W5YEFE)[#*SJSH=P"N08EYFLC1Y(*,N0RD8@;X'*9D!-6&D[
M9EE"E(1]8("D9=?322XH$<4F19)'N?@VI23#&D9L(%K78%)6*?#"1!$QVKYP
M!W@"V=-T,R!;# +"'0JPBGM5/W'MG(H(^R+=.\9+(S[B*29R4PD++!6]^X5*
M8YM.Y#R<;9;-=6IA*X\2Q'6OBJ<*_%5])L4''2QLV#E@&+ ;Z+,9G0B=!6[E
M?Z:P->D,"40639<:=1HJXR*+ZB2@2E,V4S0;%\NSA*,L,8T3,WM0?]!)J2FO
M0G*IC^JSZU3'0Y'*.\5ZJLI>H?FV?ZB4O%CQJ$#O2 ^40KJ$*'::!@/>@0]X
M++-B61Q7UXML$H&>6]1(]?OG>/8C$ANB@X3 <>NQM7<U)TG#C9@L6MD5FX![
M=HKV.!:26@9@S(/=4_@! 6;C*[A5[^O-D&V=R+E7#=/ [6M\9[<L,[3T8[ZS
M)AMV,XP98Y+QA-HWP![EY_F42 _?3!/[@OX+O!BI8Y@G?%!1$6OO5H-T6+43
M36$DY!PI02HY(O\I()#I8#+O'\6_QSAG1_! 9[)N%<3Z<6X<[QVXAWOQY=%9
M;#R$R4K"*^$I+T06$J"K>AS?3)F.62G)<6F[DIQRU]6D@<8L/Q6:6-&E)&(#
M2JLM^QRKQYNYMY0<GU"=.QN/ ?5)GE*&-1ATPH,C(0":;4I^UYU5B-DD?D!Q
MK\1Z$SL0)&B]?GLEEQF6@LSI 8QM8#K51&"-:@DU@!'+$TI KOVRS^<:NB+A
M7U!E,IO(]D3UO3+D95;FV,MPAI(!!&>RQ;G#S>I_./),PKA)'S9"Z%G,K"?L
MG$ZIO1/04@;["R)25A AFH[8Z+N0BK"[YYE,"P7(!Q=G#$\?&R[(TQ,8D+KQ
MD%>FURHA$? "CJ:QM"&GDP))KV[9)A>.DRV9T N)RMQ!RA+"479?14>VPI7X
M/<%!RQ KK+>J:&G0,U(:4EDZ;7$)/.3>]L(&)&7- 37LSSE RRY/4RR22:?%
M .NY:/-GS:9B*+*$PJS:.Q__=;"GFR$< _ H.M"H\+;*XZHU<6WU*;9N*]UZ
M5E"2<[$H. :@$,"J.9YEF;<@)@F4RBY$JS$'I4R974E%/IHHY2V%P*L)5/;J
MP)?CQ3G7JAM.V'<NNN>#:4M^ZUAD#(!M-.(X8YD5LYW;5 K=;OJ<:]UK^MPU
M=2M;/\0N>/0A=@>DO\[8U=K-K3,/ZSF<UM&/V/KR_B3[;'T"+//QZLM[>,ZW
M_K<OB)E^[,^.AOM7AWN["UCI\,=G^^C'E^]?WO\!W_U^>;3W[ON7O>_6\?NC
M 6 F&S"8!5CI\G"OV?'MT(7G72)6LA+81R/6 >)BXH7!]<BW4]TT C^,4A#3
M_L($.)^[S+4L([4C[MB!'07<<9D71W'D)X[KS\^M.SAZ>WRXKYWM_G_[I]</
MJ-ON]-GE]6<W[V9[]\/0=BS/\<+0Q<:E46C%8(X89N2:?AQ;[,7K)8DDBR;1
M_8>*<->.C!3DH!_93IJPR&1!PCPS<< @22Q_>0+)K1HB+ [0S<OR+2N*&5R*
M#1O7IE[CE_-NRY4,WSGZ^-7S#==.;:XG"?-Q/)NA!VG,=&:GO@OLZW(>OWCM
M>DMZO32S"U(94AMA#;7:>-#I +?CYM8WFXW?FWA^Y?#ECG8JVCFT#R^_)HEA
MFY'CZ\# 6%OF6WK$$U?G*#AX8D0@B5Z\=IR=)7V/&P/];J03 2K)2:-0(K_B
M19P)5Q#<5X#ZK&I9FX]E<9 8"-)G%_ O@)IY@3U>L$R=@YFH(@HX'X2J]@E@
M LXM^419Z1-VI>41J U6W[&V0\C<!4*>+ ).##90Q0%UI%'W NG?Z PB0W&S
M'%%QL[-=):&%F_L':_0P@/>Y:<=Z!*XQ#,.NR*,E%R!:GI(]C1N)!E*C;:FV
M;)CR.K:67*[W;M9CK=$#RHP <LACPO+P5^S*UQ@SV: !U1+VI8PH43N"!!!@
M=5*M!K#S&[G$7KRE"> ^I0FPB;?INB_<M?N"M9G=%[;>E@T?W99]BUGE42[:
M7C>:G*^?:7NDP@#?WO0!L%Y]^7L?8,XGZVCOI/_Y[Y/^E[U]$R#/C^.S[\;1
MCZ/AX?L#9P'BO'_W[?#'N\'G,X Y9Y^-H_?O^E_>O_M^>/870)Y#@,,?[4,+
MWN-;'^?T.%\34"(1J! ]MBPL+O%B,&932P]MQKTT\"TP4>;-*6[;$5@O1FK&
ML6.:(-UAZWT_"F/;C:+ GC=FWQ[_^>?NF^.3W;.#O_:UW?<G^_N'^T=GCV[8
M+M6A-RY^33CF9M<E9J*1$UK.)!*#[.(FO6NL)OA2^+;1HTA)>]D(=G(R%6V<
ML-U!@O5BZ4R3K5!Q7A&8+,.LI.R%5@M!U<(7,-DHH2B,A(TJFBX#'/6XX%+T
MJ@>L6,"NU YM!0E5DN*U*73:R],W!R?_.CT[._FMX>^6HQ8(%[;1:Y^B,E4C
M)Q4?*?G\-E5C^WIU*PA^%?-QL[-6^QJ5W8,(:5J6(A'D"/.%3 .P%R&O(1=N
M_CIN0*6W==Q6!'9V3]]J9_D8I%]@!+TUB5W?N2E^:W>JJN9R/=[F^K4+JFD,
M;Y3GAW4 9#:A026F+"*.Y@SXAS@/TVU-_U6I^FD34=:V%$T4P2\+0JUS<E=S
MZ0[.?02Z(TK!V!*2&$\)F<O4H2JH ^!]6L@D5&R.)H0!9B_AX@O^GVE65)'*
M@F?#"-BZSED5BZ*+=C1X[/Q=J^5>PR_TM"JFFXUJ^2(B8!=\D(]E0SV5/(4S
M4:2<J!+KR5H[ETD>U%).IA]@?(;CRUQP4$#E3P^L6+3_[FJN!#]CKCPY!ZQ"
M8J;QZ%!,2760SE$FTH+6#X4=OU7)&$??C_<.9H?6@?/EVYMOGW^<?#OZ@4ZG
MDV^ P,S#O0,+T)3[^>\OPWD4]MGZZ!Q^._@!* M0VM&W(WC^$3J=WB,"^W1Y
M^ W6 >OY,OR2'GW;O<(<5\O &NM$M\C1A-DQD>\SW?!=/XAXR@)S 8?9@<N
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MD?3!@Z"33CO<1SM0'*8Q=/UM10TM=T>G'.Z@'([>-I2#FZ8.CU)+3[PH!%L
M*S.2)-:-P+"9D?IAZB<O7H<],[ Z4V!#5,4VFP)G^83*3YJ:X'&AR37^+QGI
MH-J[,>@B3!#7_D'O(SZ1C[+APR2?8HR$/GU&?K,[8KV?W=%.J=[!Y%J2*=_2
MJF=UX-OL-.Q=-.QIT]OFFBYS'$OW7,_5@=I,/;"\5+<LV[8-WP,E&[]X;3N_
M3L4^"4^NGYA;I8S_18'I9MNQ9IW"?3K4+2N]_E7I(2=55LR!*+W,>+)+@ZVD
MBR79'25_UETPX3-84W*&>_!L,T>J=EP?@=>![W>_AHGKI,Q-]"#T#>!BS"(Q
M J;;D1T&GAU$\-MU620;G_=\B\22-,,&S+(/2*.BM<ZYJI*\Q&BU.J]\+A>K
MF; ,?Y(I\XN9)W?BQ'5,4@DM^Y&25 S??Y@DE<X"F7-/83T-=NW$Z@@L=L%R
MEKQ8<#[],BNDLR:V/^Z>V+8#FL9C\&_'=HW0#+R !YZ;LBBQK?C^W=G(P[;$
M$EC$#2@);X$<%'^\1_8X4-RQ'?;#\#,\^^ 'V 'NE^$GZ\NWC[#6-_TO9P?V
MES.P)/;@O^\_@XVQOV _?/EV /8&K&%O,/QR]F5XM/?FV^'[=X/#;\D K@3\
MD7S_\NW0/#S[(SVL/71XSZNO+@^B" Q#W4I8"NC#M,"&B'P]# %X))[E1$'X
MXK77@Y_6TH18=YG^B_QRLK_;-FK%O_."QA'2S)&RU'209@,6\0$HRHL,I-%C
MQ>H7]_291F,V2$4@L1R(21EEK2(^*8+Y"^FE4QAW41BG<PJ#XQ!;WTITQGU7
M=WPOUID=A7IBNEYB&XZ;Q,:+UW8/C-E?I##NQZ?K*NZZ0,[#*XP+1OUU4,P]
MJL;HLKNV16/\55%,IS+NK#*R.961@(EAQ@;7_=3&:DX/; S;#_0D8";W;3L.
M//_%:[,76'YG8ZRORMAB&^.$7>($5&K;TMD3G7:HM ,0QJ&BB\[C="]M,)O3
M!D'HQ5YH<SU*4HIWA3KS6: [J6'BF+[8L"S*"[/"SH!87VUP7P/"V@!U(%+!
MGC[^LCH_HHO,W'_/.@5ZKP2N>^O03F_>1V\>S4=JDM!@21S9>LPCKCN85!V$
M3JI;@9_P,/%B%H8O7EMFSW77L]KFMIRY?N+L[BKUVBX7M[2D?DG'C;NMI7&$
M-V8>=^TW'HCZ< K]8,#CR50,+AASZI(^Q$%(/^3LJ D;G6?4:I7D<>?@[#1P
M2P,K^N@\F7?2P6U/YH^O<*)FY$=,=^(81Z=R5P^BP-9-SJS("VS+\XP7KTVS
MYZ^I#EYW6=>Y,G]V!]_+SLJ=%W/C58 ZRDYFWT5FS^9DMN>X,8\]#TPFW]8=
MQ_'U('!LG=E& *?''8N#S Y^68E,YVWLO(U+O8T51J.VF>>/+,<?VG;O)/Q3
MIT9/^)\XBJH!]N&KG0ZYAPXY?CNG0WP>1Y9K<)TE''UOW-*#V.&Z95F1[[FQ
M;5@)3FGM>?:F55JNNW1<;XO <C9&P<P5QCTNI.E:&_Q"C-BU-M@L=YSX2J>1
M[Z*13^<TLAE;B1-;L>XQR]"=V+;UP(D3W4HYCSG#(3#N+^Y]\!1,NWYR\&E[
M'UQ_GPTHA%_9E&X@Q<A,*_@8A]3B?(5)/<=DH65=/86AGO#,HOR"MZ?'P;W&
MC$:=P+VPE%[.^KII=DF]'C55;"$*I4TG\(T?6-6/DX=I$#'<9SK*(]BB"QFZ
M&D]I9MPNC=2CL6.]^;70H+P!W)1Z3&!)_Y\XF%>SFT-7AISA'%8YA+A-%HM3
M<QN$(@;=Y<"N?$#C@>L*_/]Z)4_(<07=+;N,1<"\TPE_)3G6:%Z_LE<#COKA
MQ;J3I&G/;63CW_VB%I?G7(\*SK[K+(6W^IT-+MFL?/&O]K@38&%Y=Q=A\\I=
M:K [.7!6#B->)@&N&_-ZT]C6N3&O@6>9(?< .IC<,3TG,M+8"/TT2#%U,>8O
MUF@4SXKVA<^VSPI.Z#G_ZCFVP4(GTE,[<'7',FT]\AU+]QV7I2GCAL?\^_=6
M6:>QV'?HK=+2'G$?IYA68\G35H?46RH &F::@>+A4@:+L;@X-FM:4$OMB)69
M&@RZ\H:<%2,YQY7%,9P%#<6JYXO68^-+,;5"SJ L,3NBT/XS907(GL%L9P$2
M=!U:?G*,D+.V8X3NMS*I?']F;;>$W/ZO,)37:2V*]V[OKU-<!XJ4WW#J2[_:
MW;Z[_2;>OLMS;(N.-VQ (ZL!3.SQF*.%JMEF;^D\CJX%UI,76FR/]YBEANG[
MGA'9@>.8L<E2*[%=9KG<M!P>AN@]-D/3LLV'[8>[S&!3WN(M*9;X=C(\M(Z&
MG[\=_C@Z^PS/^6A\^99DG[]]LK[LO?G^Y>RO :QM=K1W-)QW#Q^]__SCL_4%
MV^B:1]\^PK4GPR/KC^SH[,OWP_<GL+Y/5U_.#HQ#ZTO3/7SYU;(2*_;\4(]]
MEN@.,UT]=%)7YU;BAC:&<GWOQ>N@Y]EVSPW"M8O5KKN<7N^(["9HNM;4*;"S
ME<=6#J"B6=5P_WPA2-LE<=YF>U^N9U/TQK 1,?D]VY9T_%\DY0_/=B=5/ZK=
MKTE@F<SR?)W9S-,=W^1Z8+J!'CO,-N#OB6F[+UY;GM'S;7=!RO_6Y71N:$[G
M)@AX\JJB^S*]W<BI;!0/ILDJC^=ZY(!V:N Z-8 1SO]]H3^*4;!;%$A/I#T$
M:1V,=H>P!9/C]"8[8EOF:_PJ%;/?5#%FY/MPZI%NF*ZA.[;/]  L1"PE"%)F
M.J&9\!>O/<?MN;[YN"JFLR$Z&Z*E8GXVC-;9%H_L5OI50PQOKT?VB31V1\FN
M((R#T;$BBWU)%9VVN).V.&AJ"Q=L#H.%L1Y%::@[8>KIH1-:NF4ZJ>^&S/$2
M]N*UZ]L]R_\5;J?.*ED#JX32#]8S143D+C3"+G],1URS#0RY6,9<6E77^VK]
M0S)=[ZM'2O7O@C4/JC4/6S:6F=J<!XZ>P''J#N>F'C&3ZWYLN(YGQ G\#\,U
MMF'T7,]:NW#-<RJM4^F[Z]/5:KV:6CU0D<.&#.V[16IHGFK_?'3AKKN_2+I[
MFRG='VI:I7MT^=4VG="W$T./$[!;'1;:.C/]4(>3BIS037P66""M=^P5<AIH
M<8!$<,G*N9*.?-+GA889PTA0@[IJ[JY$% 5A%$>^GSI 1Z[I,]\U;".VP1B/
MW<A).R)ZVI&GYU_A,*+4<DS=];&5)6- /UYBZ6;L\R@.F,%<C-SM!#<0$?JX
M!-D,<E3RO!C^#.&DH>$R/PVLU'& ED$.<0MH.W(2PPV<B'6$\Y2$8P-6M,W
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MC%W#L>P7KTUC>9=/]*7& Z"!T;DL>E/2!5CY(L,\CW4EC.4 I5%06@ SI1Q
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M0.P;SJ*5Z2OB"GC!X<GI+@U@'XED(/0=@90&\P7[/N;G_%$;'_YR!EB /+7
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M]545-U1JIWK:RS(F86741"C=)3-9>2VJ9O"&$^H LU"JVD,5,N*8_89C7+:
M#E98P >+;5VK##AICFVQ1U=50E/]Y.TGL6K4=@H?*MQ$\[,7ZQ+KNO'1I%\
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MUB(4VG 68??"7.AMRAZE7G,5@5)2;#EI=CFD(.M(QEFQ=V)>4*O:A/-A/9.
M:^=5$\(X*^+I4(0  =Y^P!LJ,$!-)\C-3[X9)D4,KJ*Q^91V3K=B14'2#:$%
MOV:3U?PR#"=&O$85LDI>K+Z$Q]"2=L7\3K4H,<5:#/ZL<GS*!F6H60BW(A6$
M0\,<WKE2%42P<@R.FF+5H%.1]R-Z26)I/'9M)(,F95E1O[E(JA<(LAKIT"-O
MZ4C,U)%M4$M5AHX#/X8 K-@5?M:^6X,&51* 8$VUJ[.>F,FAB\ N#4D=E=+4
MJ@8CBEA_#<SJ3!OANF>C<S+8Q+&M%O>=8^:.$M4R5CMF[H"#[1<;YLVY41.N
M]6&NG!-P^NE/ -W'[[3C#_LGNV<'QT>K0??&@($5;WM&H7%*5,4L;#2/_\ @
MH2WSTT61B^Q_3LF!UUX  '/SM^JZ-@CUR #9U:DQ^WDZ8M,D$\V^,!8Y; (%
M5*SU #+4"#+>0N&1]B<W[S,<#,5>8<-__ZD-ESI,[CC%A7&W!VQ<\M_5#Z^P
M]&; 9K]G(]H7NFA9MZ]*[NP84O9,"O@G40^0G^^(S_XU218_=/P=W_!7?W[M
MQ==_:.]XCGW/BXT=\[H/7?N^UUZ_9&?'LH)NR=62G=M?"\2+?/&_+^P7ZHN*
MC$?YB%=?_1>1:+'JFEM*H0:0&?!T,L\<@NE>C=%//3K7\2N_F\"!Z@^%$#2"
M)Q?>P RJY:@+D*FM\55U \G5^*>[KUA"KY]9<U-PWZ"%;BVBVY+]EJ]UK4JK
M1.4=:61+O[H!I&\_(>5+=4A@>3S1R"^B*7+<.+9 T' +^G_00W^ '>PHXA$I
MHI%1\(LHHCOT)S[TMY2DOUV"X#[*[3YT](\XYCQ-;WIGM(0>E"Z<7T 71WQ2
M.:SGJ>/QM^Q>9+)>&_C/Q]TUHIN?V39!>,+X6J-M"WMN&/1,W__O?YB>\6HC
M-G']B&_YYMU&JM^-0>\FJCNYT<F-QY,;CNGW',?NY$8G-SJYL:XDOW9RPPR,
MGF\[G=38.JGQA(;AO4SCC303WV+CE59"T^\;YT+J5M.M9O-7TSF]'D::-7N-
MHAY.5LHSZZ'W\3J <,->KAVNLGJ>$?;"P'IJ9+7N-+?FX*DC\NN,AYX?6CTK
M?'*G0T?D'9$_UMD%IM_S@K C\8TF\<X(?KRC/^4#FA!)#135>(5'@HTW[NHV
MB1Z[%WANSS&\!Q<^#[*-ZTJ/]Q=%3V#!=NQP!W8 >ZIG^P^OBSMVZ-AAX]CA
MI6EZO="W?^L880L9H?-L/N31GZPH"NZ<F_?S^SB6V7.-SKFYV49Q1^37.S=!
MOYI>Y_GIB'QKB?RE%3H]S_,?$D-VY-TY-K<#-;X7/9Q$&YW&M+F+U05#G?UZ
MAQ"Y&1H]WWOXY,/.BET7*[9CASNP@^4;/=L,.G;HV*%CAY=^V'-=IW-N;B,?
M=,[-ASSZW2$.3/]!';,ZA^;]?#U&:/:<P.U\/1MM#'=$?CV16V'/-QX>8'9$
MWA'YFIR=9_;\IV^>T%'XAL'#Y^/3/,LG3 Z,;]4MKJ-'\V?:)*V=9#+-G@DV
MK6FO6?K:,RV]?E[>G^WB)*/GAT8O\!Y>SW><U''2,^(D.PAZEO_P:5P=&VT$
M&W5NV(<\>CEH#&?9B^$V+P=Y62X$,)[&CM\JL?72[+F!T0L]ZPGSEIZIF-H^
M%]>VL8;MVSW'>M#(:<<:'6ML/FM8AM]S[:!CC*UDC,YI_'A'?X#S '@YD<AV
M'7W%FR:-K*#G>>9Z6=[K3H8;95QWO'![AZYM]%SOX9-O.F;HF&'CF.&E:9B]
MT.@R7[>2$3J7ZZ/@4IG%L!Z^ULV3.&;8<URW*P+=5-NW(^_KR#LT>Y9A=-3=
M4?<V4K<5X.\==6\J=7=^R\?$AXU O)86^1#V<#3)1E,,T^<B8)^/2BWB:5YP
M%;B?L*LN(?97A"H]W^SYKK<VINXSC<\\+X?0MC&1;3L]PPT[)NJ8:,T.>6.8
MR+;]GA<^:!>LCH4V@H4Z?^PCX&W S]I+Z9+]#;#UB*=9UVKU?J+)[SRSFVS=
M=\1]'7$[/>=)<[@[XNZ(^_$<L[TP?-#F_!UQ=W[9[<")1WS2+I*ZQC?[*VVR
M:ZAHI4FVN/OKM=?_7'NC=NTE.3JJPYYEFNOO(%A[UM\$[T G8CH1\P1N_*#G
M6IV(Z41,)V(Z$?,800['Z'GA@^;!=0)F;07, ]FQ?;&K+MQ\O5[FL1;6H$H;
MJ#+)I]& KQ"1Z[+FM5U8MYE;L)EKXVW[UX3!&\-_D^SB]?^#?ZE+AJPXST:T
M,Q[<7_XJ%9>WJ#YN>2QM[7!KI7*#<AID(Z[+_38M@@EG?:ZE^6"07Z+KB]Y2
M*Z=#> ^X2ZF-^$0K^ 4?3>&7:*:-BSR9QA.XI- F<.D8'ILG)?R=EWPTX<GO
M6J6;[K-5<@%RKP35P5X,V+CDOZL?7JESRD;T1G31,N?D999,^K^'X4[@VH2)
MI+*1]Q<?FSL"+\UA$O&AX^_XP36?7WOQ]1\Z.Y9KWO-B8^>:*XT=U[;N>>U6
M+MFYY<4WX)%U$/6F^[AN_AB9N/BI-=\2+/N_ "R?]0O.M2$\I5]J?)3P1/MC
M.N*:;?1N@:"7:H,G_^H&$.DCAZ*NI=&?20Y</P*V#,OXU;;> ^Q@1Q&/2!%F
MN''6?W?H/W?H;_ML=-ZN,.^R0^^T@Q^$W5+^_O@Y'X\K/Y_:1.XV9_TW9WWS
M@ZP-$!6[,9^P))\L=/1XHKA9%QV[3\[AVL7 W-#MV:;1-1K;MFA7)Q8ZL7#_
M?0H#N^?X=B<6.K'0B85.+-09,T'0,[T'K>%X;B)AG5PDFV#X' ]Y/&##_$K_
MP+YW);/WV4+3Z(5.-^1XLZNO.@J_YNP</^AYAM.1>$?BVTKB+QW/[WD/VQIL
M^\F[<SK_S(;^7Y&5$S;('ZV/]+/J8X\N%1_^Z6:<;)U;I6.'^[&#UPN,-9M9
MW;%#QPY/<:Z>]_#FRW-CA,ZW=K<M_(N- >'E@\ZM=B^WFN_T3#?LG Z=TV%;
M2=PRK9YK>1V)=R2^K23^T@YZMO>@G8ZWG[H[M]I/)<ZS08)?Z)QJ#P#">J;G
M]5SOX6'8<S.>.B_"5K"#X3H]WWSX:'_'#AT[;!X[F&8O<+N RQKBO>UVK&41
MFV07G5_M?H$A*PQ[[B,$AK;?,.O<#AM"Y%;/!2*W@H<OO>J(O"/R-3D[WS!Z
MEM7)\;4 7 _D8 LV 'X=3_J\4!WB.B_;SV]HX#L]R^SJ 3NG0L<,KSW3ZAFV
MVS%#QPP=,UB>U3/]SMV\AH!OFSMGG>43-FCU 7Y<\^)>$R3D)_)1<RVJC67=
MD]9KDQ^R+/Z.)ML#;.J:"LRPYX8!B,PGMXH?;(O7CW#7TV?T]!*I$TJ/PS';
M(9<<T^\YSL,;^4^XR^M'OIUHZD33FC/-VHDF,S!ZOOWDW1V>G6"Z?L9,8]>^
M3<M)ELY>-6:I4)K&&LZ=H0?_GH'UF,4+>[QD$LW1_]_>UW:WB20+_Y4^N9EG
MG>=@!A!Z<W;G',5Q=KR;V%[;F=G]M*<E6A8W"#0TV-'\^EO5W2#0FV5'LD'J
M/3LSMH&FNMZKNJ@JA)AFAIW7W<)Z@$D1XGPB3K)ZY@3!=OX&>6 Q(V^[9HL
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M3QA2+C=W*C=:C.D+M%J5)9UI*;EABNZ #V)-\<$@$$<711V#C^>F5ISF,4\
MS > G $C@4]]CNZ&7 G5Q;(PHJ18<!T:ABDL\^ECCZ3 MV3(A((Z>/LI,@94
M<B#UQL 7/(D%8]1#DY#5&WBZ*<7#:Z<8FF.*!?_4*)S;K3ULP)BSG $IL3?U
M[H%[XZD4^#@:,LYE4(W\6)2*N:@UC,+C >4C($0T^*94D#CO#+D\JBP 5CS-
MX,7#ZY51]Z(=EB#V4PY(Y[RD@P)V)PY*>:)#Y]X8S<B?@@3U*/DH0IQ+B*\2
M0%1Z?BG/JRD&="*P\:<\YX?@Q1<E&1PXAZM$)O)=9HV0:\HG]1C2)&C8#'00
M/8:N+L\L'O*3QX;B]HRC2A ^Y?35>S2N Q#P8Q L8I@ Q-_!:B40G:+O8,]'
MLM:J2/:P.?X\!+6#E3G?9]_15)GAL<@D@WC!(FQ0ZD2SLZ@L)E(Q^?.6%*F%
M_6*@1Q2D\.06ZL?(B"[(H#MS]U462!6R@'H)(C!" QK'4\#S XT]KDPL7A1F
M6A9882F5.DJ,0K#,@:Q0DE8SFLB2I&1$$P  / 2(A),H1@<3 .@S%J+J$WY
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MEUP@3#RLPI5<YPH4,+<@_0+3&U#OY(=PJ"!32)3?)P&2 CKA["3[X;WG\TE
MIR=^*+8J'EK6($)Z5MVNZ=I-X5RI5A5J?>5XF=+QFOLX2UYLMLU.TUE]?>W#
MZR^VS6:S\\R'+=->=['C=)_Y[*,@MS9]^)'6(%7HE[/CYG0JW/D1D#?\UJ[]
M M_:E42_)@V1-(&?0. %3?Z43C_*VK0![FH1?E> K?VPMK)05Q:P;:%3-Z1Z
MDLR?H@,LG/4Y3_C5^E+I5@F;M8>K7+,#IVTTV@VCK7LGZU8J6L+W4L([AF,[
M1JO1U!+^O+XDE>R.7@,WY<NRU*5NDKX-1NV 2+_7?7!U3V@M#%H8*FOJ]CD&
METVA,0 W%L+PPF<PCUB_:G1"U+[]#Z&MHHJQ.J']$[!8/>X[\+A?*X[#4QR5
MR1CLF^+8[#C.;E3U &G[D!4HO$D'YLK 75W(MH91'1 \2=Q_GRN].@*?/\8"
M2?7QD"AWR_X6^+3O!R(DV'&;:9W2W\.4?L.PNI;1;+^Z@:ZZ4!ZX\ZXEO*X2
MWC(L<,$[KJ4EO J9S,,YM#M5'HKXV(8<C=,@\2>!_'2D[-!@2_H-W!E]IO$,
M\3>W+_>'=IZA#_?V0A"V/[GPT 3A1Y).N_2"-2P5AZ4J?M0N/LUX"5F\9MB*
M#'-"\]\2R\^-T6.:OJ1B>SQKJ(?A_:B!J/OTNX8!M^,_U;*[^SCTKG(>JM8]
M6O>\ZE1@HZEU3Q4&;A9;&.%V]K%Q O9EERW,19^-P:IOZC;LFR:>+34OV[BE
M@FZ@H!LHO&3^J:N_K]]<=]ZLDOH-7+E,7L,H9(]$^$MOK0$OO6:OABU\?5XA
M1GN-!AV[;8=0,8XHNW%[P3'/ZO;1JD@M7'?G@.V6O7>LW75]79G;<?Q\UGPQ
M[PQYE'+10?'=2=5J? [Z_54Y.:@EHU_*3J<X34D.!-GN=V-;U?35PEQE$G$5
MS[,UC+;E&E9;GZWK%+Y6#%HQ%!+P;LLUNDY+*X;JU:#NLW-_+EI&K_=YME0_
M]\SZY[I4S!VUVPW#LMT=?U:T9^+ZV@&39N]-V;ME--VVX;0[FL'U-Q$OA,]/
M8O[%BUBG@ZKN/H) M-4UNLWF-H7YT%S-RL6@6A2>(0JVT;6:ANMLU:X=FBB\
M7M15UQIU/%4I3J)>6095O<YENFYT!XUU:E]#>M1I=(Q.]S7#@ZTAMWHL6\W0
M6>LBK8LJJ8M:1K?3-MH=2VNC2M2UKY\E*:;UUJ"P'2O7WUIF)Q_COI$#M_'\
M;YQ.*B>U OR$)DGL]U-9H(XM'W!9576C)CV*Q @._ER2)C$).9TOVHF6%#C@
MUY%O&V8[WY. 0@RNQE'TQ!]/X&;Y?+9=4;<O8 B3*)Z*)>S9='LQR?R!!6(*
MHAC]ZL'C0$^\,8S"8XDA.2== ."Q2<P&OA@S:^"D6)"G/\5O8G]\1&-VW*>X
M>1S?"L_)B]FL]01[ N.^WCIF-P,CPX# &4#O+SGJ$+M%$-702X %14\.5P>D
M^V%"PSL?2" 19140A9 AF>4T5GG5+KP<!^\NHXR:(<KD6%ODJ9A-Z#1?Q3:;
M^3OP_[!,O.*#5CE9MXC[G!/%KF$'L'8:#T;(I *-/!]X6IR..T>P$I.+E3(>
M+BP'Z_"TSWW/%Z.%Q>(_-$ZV+AJ@;5H[T !V5S#C#XJ]028TQH'( 8KED .\
MP/J*2U37LGE6>4Q%/$F5%+EWC2I!B(JX*RL38+\RJ-53*&5JK!#NM\VLGTRV
MD4S0@;+ 3S&]%_.=$4] -H1<;&\ O,/];#SQ;WX?QSR;&[R=!CR:@1!FE9OR
M7OG<\KG&DG1V2;D]H@G=371=S(8!$T3?CJ9ZMH*Q"U[4+W_MQS__LK#0CB[F
M+F<D27H2LT",[5:?B]D6J!>E:MRFA'+98[0/+F2:L/?*;[2*S[]9A0I5M@]:
M;W ,?XV!-B?R@[QIU16NTRSCLOCO43SSY.] E$&1?#NF0]CJ"0T>Z)2_^;G\
MY1^P@5J]Z<+K5Z)NWBU=^07F,FK/,<2K([:]'+$?63\AO;N8,=1%SQ2H3O4M
M]F5(OM IL:UL4/H#(T(<A"8$E4-!*_DQ:#K @R?T\M&;6_&77O:7-^]0-Z'R
MFG45.97=1#Y'L/4<C0;Q:"),.I@ZIR->V897^LF(7/EA2 >@<3_0\!LYPLDI
MCO4^_VN^AKA@OW]GHG$@<Y" <4JDUX#0B,'SREXL+@1_!CK<C20T<D*M8Y<<
M\W'DR<'N XA>J8^N#&API?!1_>,;>/8*]MV7QD9I>1S!$8')IC@&'O1_2"X'
M283C<''3L/7.,FR#$HK"$KH5*F[DA7RO&2+(P\@?H/V2GH+<^IA^]\?IF- [
MV.X=(!VC)H!I@G/798>7@ F?"P+M6'Z)##S)XI7(BL#.6S.O#C;T"9ZFZLOE
M:8:$,;PKQJV74+.XH,"SV"3S#-@T(Q<10-G..(D.T.F@X51"1E/@)N&)P .A
M]$E"D2X0##7#.$_@#_@";OZ FUV[;\J_KJ&=X+('X#$B>%?XO1"5_"_X'(CM
M"-SK18XU%#6!*_'W@8AE*/F4"ND2VO$:_4$3^;J7W@$>B>T6V%K1=A4_';WY
MY,?PS)P2 0<GH/ R&0F$=\$RV*3"6 (?@[\K-"P 2@2WWBH'#?Q$V0E;7!/,
M*&1;^G]B@3)XP._+]$VN(:2SGFF'C.\7H1!: ZX@=P>^ #P!9F.Y8[L<0I-\
MB&#/RU\_H%(C"1H+STEZB[B<<HP)>#7@P \2*;J_YPQ1!"1'ZW(8EE&""A$O
M)6E,7!V#!,E>@D3TAU\$"PS3) 68(:KR(^_Y872GTO*]PAVYHM/!B$$T=Q6#
MFA1DQ!_O8CH6-G8O<;':9>F!-0N(DZ<%3U,<,Q^@<$%,RR!PD%(V!*#1@ C=
M%: O,HRC\9ROH01^9BHA%DY5HLDQ[$[;L%V+0.#%4RHMH=!I:RARA#=D'LS5
M56ZI9Q;V$X.?@+]/HS@*Z;T?IYST?+"$URSPV= 0>N(,;%PT]@?D1@:A4](;
MH.8\[5V?W>#/;]X9ROIC&@$$14217RB$B,1I9^+X%#N]9E.(OFI9ZAJXUU]G
MAKF,Z*LK(_<J);_EUP2?CL$I[PL/[0ZX.22^N#8E$/3/LHU_I(";H4!\GMD1
MEHP/8K\_LV4YPQ@J\8%/%!Z>T&D<!:AM><(-H731(Q7MDU4VADN6S"ZEB6JI
MG-/N5:C@;$8%0EX5R@UYY1.J)N%'H!("9LBT%WA3(WJOZ)YSB-)2R <\!8%?
MP@Q+!,OW_O;&;UF#=J=+::O;9*YKNUVW;W4]MT,=FS4';?>_'>?-(YV7EL?]
ME4ZAK#"MEY\^'7_H?>Y=G)Z1FU_/SFY)[_JZ=_'WLR]G%[<WF_9)JIT5_0@6
M!=M/;=8\*L\->+Y'P@@"[?".W@D'$C0_IM&/^S00SAT?,?!F:1QC^ZI5^GU#
M-FP^PH;+,5]'+CP'6RC3X V3_ L=#?"',0,JT/\OE&WU^T>?#X*(IYC]I?TH
M38B<94VN??ZM_NRZ"C\B2\)%&,76;W4/PWN(J-#P@UZ/U$F /*(@,2"B&/(5
MFL;Y&<9BN,BS8U)QG" .Y432'&\<P9N"Z7'@_Y&"<(,B #=#+8^^79H-C2V?
MLJIVP4,Z$*V"1=3G14(W".?@3XR'8_]>,NW,[?-#GL2IT L8DD<B8B_L!G 4
MRN.PTJUBRR&J'($$# 3EB<MLC]GF9680XTX2B2P'KI6=D\R.>D0 73R5$B^9
MP'(LOB_FR\###E1&S?\3MYZ_%>Z(QBQ/) ;1P[$@R.P%/W;:6T<^[6, <X](
MH8E >9E&\PR;$V7IH3#0!!DJ"U8D9>>7F&-T=9#,V8Q['Z(T\/!LUDO!0(EA
M9SGI:*B2%>@N#S-.G%^3!O#R#R*]"L*3C18IWR7MHQ2!# L/"X++@=XB9Q-B
M2=,#\+JWN"6J>+DDQTJ"EPJHQ,RI#,1R(RV\1OQ#@2')(*"<RZ05IKB7'G4"
MZ<HYG4-BXI<C\VHBEU24(O$AT0"Y>;WBR,\MN$JK(-KF>MF#^NAGQ/Q\_N'R
MFDR"%(W9W-H<M#[U9(H7LZ*H==0#8S^4!RDJ;ZN6B7UQBJ_*/:326;$LPF.;
M[>9/"+4C?CB*F; SH:I3F7L.'G#,KO/3@AB^,TEO,>%JR #1(V_M8MD-<%4!
M1^ G\H3*>'*&KS7F?&\]R;/O2NP.TY,4S@PPC*Q.8H5J2I4L^AJ*_-U-DBN[
M.=4&O Y+9NIQ,!6BB84_4ET&TZ*&S'S!Y0X@K#9BWIQ3M[#^,$@'22H/.>3A
M1:9WD8<W?13%6D@S%6>[^&A63"/\Y85GI?7,CU+S]X#\=2WBT6E!NX"^COQ!
MEN03YQN43+"D:G88E"_09[),<>PK7=:87TYD@=)9)B@1ZE"\0AZ\EB%E&4O?
M@=,KG76($'%?\I1GG&=[G] O&D-^>-F%.E2C0,)[<?HRD#91%::%L&)>I2:R
MZYG9S*&2/I1TPG*D*H#8<(@'1<KLS4KF9+&I"!&*IT&A++=:;0MU!=%3*XA:
MJRN(GI"IZ;S90MF1(,R.RXX.)(ODFA -A$D<!5(?7,71@'F8--KOZF,5 N&1
MF]U^SU720)5!9,?.HOX7@_NB>IY_\G3DLR$Y^PY1D<@@7 [!G4=%"-B4US[E
MBDE=,T"]@4*%Z#6E63VG5'!XAH-AYXIW>7E.#W7<C&J3G&KD"%86>7Y1U>27
MZA6N4RPYM1OTV&X>L7?B4;OIJ=]FIXZYZ],;)._4V;V ,?2R'^7I>G[.(\J0
MX67_2@%E+ 8OX9JA64.%#69H3&SK^%^%R%A J! @ZHJ7[79&$X$OV'%>#TQE
M85 9+K&H!&SY@AN@3QC"G!:(M)@-HAC]84/>Q[GX.9O$D%60QV*_XA+6_)($
M6!;0 *;:YWB<!A9U+/DHQLQ%K*(3E@$UJ^7.HG/E9\F%N4R4H.OMB[IA/,WI
M@V? 5]#MH,+ PB%%,HH96_MM4"*"-^0H&9HS>38Q"[+S;%0H?0ED%(*,7G Q
M<G)+NHQ$BD3Z*OC!D6 @K%@#.H%8!/XW9 :1G)R[R7C:Z]8$7-JE>:I+T]Z&
M2].UZ^;2U(QZJTJ=>M>WY/Q<U,_8]GMR>?OKV34YO_AT>?VE=WM^>?'<T\2N
M^]BAMEM[M\\VR6=V!XI%^'L,S=MS';YF]<W#112R9Q\N=]N;U#C4G!UZILAP
MD4\ ?A3OL>]_'N;?8F6%:?)HL>BAX:=^\%LRDCX8&/ _<K]66F)#9F,Q^8Z>
MV$CD++" S<]\,9&''DITSCXCPQ0^N&R],$RQBG7!1_YGGGF9,AHK_^4C&S"L
M6U0?'V"%!2ZRUM?.UUGB#\G"/_4E@R4+MB022KYF5EH&_N:\;_IL80+;MO_2
MY)CD:QBS.Y_++S9NJ/K2[PP<_V2:E6F* S1 _5?Y ;#2Q*MEKZ(Z=Y5YSG.F
MRS:^O[;F=Y8E-H,\-2R^P2Q^E#E1M;)82)#]+9V(CV?LV<G,LJ_+B^7%&,Z#
ML/>/[4X6"9<B0 +*[A\4-$T\56H#E_L0T5B$RQ\A")7J";08[0<^'ZE<1):9
M+0*S'/KB=Q@3"+QC0M-D%,7J"V%YX#5[-/\.M7C,5/XF=:,#I1KPP2/3&V5%
MM"@JF1JH786&-HBW>22[.)OQ=3#2W0PA<XU.5E"W'-+L8J0DF"#34B'6DV=*
MVFW3==T=S93<U<IFJ[F;A9NF;35W,P:SV7CNL[O#\BN"O&8FZ%,F=[[Z2(VJ
M=V.Z$MGC#7K#51.3:Y,\KV0P.X_YBU(7WV*;D$W<PEKLYD)\:"9-7C3<FVW=
MR&8B1U&\-UO",A;^;F^VDX5='CFRYW95\4;;6K?NC"EZL&]ZQ_:'R6-_P*1R
MO:*^MS?[FF0F0^C9O=D6F M1+:CUD=9',U]/<OK>.TID7QT,23/*,ST<;]3]
MJA9[Q&Q\V@_\03#=FSWUPA!@&8!C>!7 ,GNS+Y PU7F":_.BS0NRQ!=9B5\T
M,'O#[FA1>I-)',$6:;(_/N)'3.;'Y#<:I.P=V3M/0/(B$$_^L&<^@2@7P/:0
M_V$)^; _3#GGZX@>/7NS.=%>"%T!LD?9/$FHS?^=N0ZSQC_IY*6WUC*;FVQN
MR8$FCEQ#+9).2DZ/GMO\I#,?T21N1T<^2_"FY.B)@TXL:\GXG:ICMF49MNOJ
M24L;$;-:I*OB+*4BVBHZ+:EA=EO+YXM5$G_5X[MJ#F?3UD!; VT-JJ[-*F<-
MVH9MMXUFIZE-0N5G)#\KHUK+>.<+G>XHVGD4AVNM7>T0Z38,J]W1<^SW;8Y]
MP^S86]?8AS;&OKJ2H'6<UG$'K^-:1K?9 -?4T8JN>K[H/F?;\1.VBB3;:X>[
M1L=P7/OEL+=/7_84R^&W:S>>&(O7S5(T3-=Z[?Q%U9E+9ZWKK!HV5JNO0SVM
MG=;ZL1VG8;1=5ZNH*GBNAY-%+7^O6J4<P]IDO[JHWMZ8X-2!%)LLU/98T79M
MPVTU:I*BT-!4,S&GA:86C/%:T A3^;/H++.J2M;'.:;)R;'=*:PDERZ,S\U;
MG%6\?1&$R^1R*)O?R0F2!FD83J,IFUGE0Z0G^??FGF@GA5UNU9BKB9CJQ0K3
M$VBB&ANQ\#CK,36D?C[7"_M!R[DLQ990S^TUUVS,FLVO;NA>%3H\VE6N:9(;
M[/C,N>H-]H4FH,^XG /U6R0G0.0C@'^- M!9/]+)L79=H'N)Z(LX9DPT9@8L
MX3<)336K8D7O,X]AHW31(1VGC #6L@'B802;]V6/,L'T(X%20KU[GT?QE-Q'
M:F >RYN_XXAC%G+91I*!VIFJ-E[8SA%;=2=^(&0@!/27WE!:-9OM,<1>X6)T
M![8W+\#PR*NS<<\@O,5NX]$ F -G%N%TI%AV>2QT=?P+1TRU")7=*7,\EE[-
MD0UAZ0QO^<P4T?V2)RC3LP;Z,;OWHY2+)NIC'$=?:J6_A!S9_"1X<LAP:HG@
MZJPE>A$.T0 ^'Y"4MZCT,^2HO:W?S!R35'1>2,7ESNF4T?:\/MJVU:A;(^W]
M:EO:,LG9]Y'?!QU:\RY]+;-MMW?32L]M/;N/V[J+[4:^VVV#;)D=Q]E.^[B,
M<U#$JA47:,CJ"5E54I!U/;JXB,S:Q?":J(\0]2/C@]B?H-]88>)N:"L:E=5[
M&K)Z05856U'+XRIP ^W_7V%M4B=3L85.Z\/A;@)RC"'$5CV<6B>2+2=R0!S>
MAL#3V@%=BJJ9C%#?OR&CF W_]D;];EOV,<7\$DX+= )SE(S?_-+[Z\_TH#8,
M/Q_:EL4OY"(]M'V+>4 .2:)#VSA)#FW'HT/;,".'J+EQO@N>?ESC-!X\SW L
MJTT^1^!]W.(HW_,03P/PI.?TX(2^<*B&+:O,0]L_$1NN>GM+G1'0D%6)X71&
MX)&,@*,S CHCL+=VU"G844]E!+(_$-D66$10HDRDM](#RVI3_L)++MA2ET1;
MZ#VV-AHR;:%?VD(WM(76%GIO+73C&&>NVV[[OVV[U:?21E_1J;#05W&4@.$5
M!E9V:=[KJ'\I+LA%A#W^#V[;'KI?![COP]NR:+X-CO;A[5Q6G!N'MW$LU,<P
MJ\^2!\;" V3Z4Q%\!HB$P]O\U8C&8SHXO(VS5'BO(HU@'B#A#Y3=_3"D@X"1
M#S3\=GC;UWFQO<_Q:,AT7NQE^S79NI9U*S352;'JF%&*T> ?SK'Z>\.V5:R
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M6EW6^',_\J;PGU$R#G[Y/U!+ P04    "  &B0Y1U#7\,!H,  #'>   $0
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M4#M@'9*=L"^3OET*^JJNX>&RQ>KXTB^?/]21O!AQ&S,OM  &RQDM@-Z!QR2
M5L5L/$8KG>UC15X&<D<[ 1X4/?:2>L.T^[/.G/&4?#?JY-=9^V<LLSF>'_[
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M8([*QL+(<N9<@&+DXW@B%J"1UDN/EJDN+OJ]V8)#-Y:ZCY]OYY5ALJWQG$7
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M,2N(1E*_8A%.:YY\G[M<-V 9Y%)\5]U?R^X=9=Z>S>L1&W7".CKK01\$I;0
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M][,)J6"Q+E]!'WJ.<;G+RGI]8RU7R"TAMPO]7_O ;_^P1W1_AZ<<1*I;=O(
MXE[_UU[ %]L]B$BO[4C+1.73&TIV36S_^O6V"<?7P.K2\_V/0%W?6">I'.;
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MS8ZF]8+O7S/1<%S&X;P._^F,E9].\X4M4/K;R3&]N2[5[[R.,84(4AD/*H8
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M[L8G'G;#=OO.7\Q^/%55_1'# O_QM_\/4$L#!!0    (  :)#E%:3-=GSBX
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M[5I;DM%-EI9SXTP5>[\COL>M5S5(NJU+:I"UZWWZ<MZ&ST7/;RVY(]RN 5C
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MVCO06M'0H]*GE@^&==0OP=",'WY'!N^OO<=J>KO]9I;]93Y#*&*2)U!_/6@
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MUG$=9@+S*5M^3844;UY^S:6X6VP.8U_S5?JUC"RN/>H@22*D* 52)1 @S'U
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MRO14]:M#.JQ]III?N&[V#_S*5;C:%#+?Y\ A'UAK+D9*!E;AZRD5V$EK&_.
M[=\Q7A*PDTCW,H"=OJ*=;_]9KFBZD.*69B8G3Z[]A_73>F[.)KR5*N7I:B9E
M("1#/N!0Q  )*+6?'R+ $@B59"%GH6.&T\N=3L_GKS%[L@+M?2]*K(ZU+BT8
MMYL*],OBP JWH>]V0]\.7N_M)2J=)PGV[/0Y8;#H==3)@ST+AQ,)ASO[R*SV
MV60N^JA^S<ML\#,.8X$YBH"@)HT:%!C0)!$ :;U!"8EQ@GG[-&H'O4W-$]I&
M@Y4ITC(#%RP56.N_E 4SNR1).^3:3FYZ8W!@I3D*I?M<LZ?!EG4NALIT=H:4
MX=*:'7;XBCG,SMC>G+#LW$W=UBD_2R[3KV;YPR3@J9;7(BI$*&("A P3<VS;
M!U0B"""F@6",!1B'[58K3W4W/?]ELRZ7;>!>>8N&=\&=8K<5S*ZTC;6.^7F'
MKW('_7H^7_Y)]3M2G N]R:1(5YZI,SW@6F<36T.L>)[L[U76/9LL/[?ZV7C/
ML <)9C'FS">1 E+$"""3[I!!&@ >X"@D*HPX<TIR:-NQDQ,S6C7+_1ROPQP<
MZ/FLP(1$R.UXP/BG 890(.N^)QGS?TZ9G.]OL7#\5BZ63R:L<KG=__<3CC@.
M!-#S)090HA1@*A8@PLJ/XT1H*HA#C8D374S/U=D!Z5)IXA1]%FO*'2D9>C-G
MBZY=R8E3K#BL,G=D9Z2UYAV4?=6>:#"\<=GYU'WC+3XWH-Y;@FZZKH5RW>A_
M2!_DXJ^2SE>/G&9:&Y_2E135MD841(S%B -(E  HA!B0B'#@^Q1*2I' U"KG
MEDUG4UL,JN$ZO+.7Z+10M1Y)&ECA:J3>%JI786VSGW:).P?MZY'#D72P@<N>
M9-&2DT:)O-3&>')I:<V>=-K>TW*:NLSS;>;#%STASM9T_GDYG[];9N9T_0SR
M@%!,$Q"$(0=(80RP5 P0%5$1QG%$L%4,CW6/4Q-4 W@G6Z?))%Q ]GXWH+T*
MM6,6Y\N\6TY2^V1SZ-EI1R+=IZ6VY/0Z'[W8Z;@345L.CF:@UC=V.#6W5X+I
MKCB&;$ZG++/B3-]JE:5LO3+K<E^6'[2]&HZV73?Z<+?0K[[,5]LYAA(HQC0$
MH4^U3,&0 DRURR=1Y"<DDI*RQ&V]OE^ TYOVEC99SG@'&C4[D7N]D1A8$4_5
MD+OR-L9YE77>KGEF 6_?0*^V<*#R<T.0W_LYOOX0CG_&KW=V3Y[_Z[^787=&
MBN0E^E6;)=J?#W@L 8DYU!XH(X#Y,0=<8L9P!'F,G0Y+NP*8FD,Z7$JE#>7]
M[I"T(7)2.R5750HEW?WXFR:'[+W&YLD&PR0W40X9:KN9<M1..X'3VKI\DL9_
M?J=-.E6JZ9/,WJ;SM9[$%Z>O9Q3[2 2(@1A!#!")!" 2*H 5":&(:8BY4RDE
M9P13D[AMU.=<&_&#2?]9YB'WZ($KM)NDO/K">6"W>-JVQ)W^O2AM]KY/%Y[0
M7S>JK]ZT[1B8ZS[,=JHZZ. -+*LE=N_[]\6H%=4&3]:Q*XJ(>I4192:*_H2U
M-8%]*JL[B%&EM35'A]K:OJ&6I5662_%G.I_/5!0+QJ0$6CSUA-_'"6!<F:-?
M@1(XB7R%L5-=E:KAJ4EAC<NQKDI-DYWFM#%^8"FY:+=[+94#(WLMI%*W/6X5
ME0.+CDJH'/Y[R_HIV9)+*8HW_)Z:VFMZ2JC'*M7?X#+_^BR*"4X0BT @,#*U
MS/4<30D* AP%/D]8'"9.\?>7NYS:>_HN7= %3^G\(+EB&3];)E>4WWB98<\$
M@CYG2['F*V^><I-GL8S:=ZVS<GED[ 2@7[X'EH8:;.E@&+@F4>$6<!FUWV-1
M-7MV>JVS<KG7<>NL6+-P5&?%_LZNQ6NOO])T;B8'[Y:9Z>I>\G56U,Q]GR[D
MW4H^Y3,5B#!!. 8T\25 @H1:K#@&*HQI3%D04N)4N-&I]ZGIUEO)5MX6YY6W
ML0%HE0*Y>;M^-^B] G[K:K4V V.Y'3 4W0/+5F],=RA/Z\#8,+5I;0"\4F%:
M!V[.5Z5U::3C0<C;*D'SS)=8Q)1($(0P "@(?8"UWP4H#83 OD*^<)H*'?4P
M.<U*M5>U:IFA^I@_.]GIQ,K TK)=QKZ]Q$G[,XN'=@]R3G'3R>N<33RT\>QY
MQ*,+^U@K?IOF99+VM13;!90/<O51?:'?#I<3)94!%H$/I"DDAT(2:#<FHD!
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MR4:7]L8[Y=C"RKT3CVWN;[?Z]E8JF652E%-#/>\K-R/U+' &A: \)@BP2/D
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MQ[YB]&WI:([7O]C*B+'[MA;MQ_%;W]6R *]^1J1Y5-YO0M$YX3PD(@1)$%"
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M! #'@9ZHQ$K+ :,<0!+[21A@S)'OEL+'$<'T%HWV*UZW<EI<1R'2,\.(13%
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M)T)V6S733@_?T;0\Z;1SAC3?_/*OJ?;&,OY8E\O#1!C!\P%1$3<YW1%@L9"
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MB^FC6-%O46UTF'&T^S2\^N@,_&DX587HZE0<2A%:8AF),DA)TT%'8N#R1ST
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M/F7+KZF0XLW+K[D4=XLJS\7BX9JOTJ]EH9#Z4 [!0BK)?2#BT-003WS (IJ
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M#^(R2;WZSN=[&]=]OFCUD0=]^8ZV'H">K,NL*/,BW](5W<1H">F+F$5 $8@
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MYM=^C_2OMW(IU7QKJDOEM%-O=4?B;O5DF ;RA6U_AWAKJ"J+G".&,28ASX"
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M=L49@[J=<7_9$\O00TE9^Z"_+]O;I3"1/,_FD9G(."=I& $ND*$!5H:I/$M
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M=$H9TDB*S.YYX<%BD-A))Y4D72'5KQ\#2=_I+CIYX1?*Z3@*EV^ZUY8/!C/
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M^AE_"NNP8VN2)4L%F0'&+ 55K*88H&>0$Y(_5)@/.-QYQGX:#@/*=W!0>K*
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M+5,NSM4#%@U!&0$BHU4B%1]"DS97CZ9TW'O>\3;<H[75@2U[I-&^P2J*$EU
M#=;6)@V"18B!)8A.,:$D9M%F%OD)-(][4=O#MGNT!CL ZVWY[7B9V! DLTH#
M#])0&$>>A&?)@1<B)B:2PS:=$.ZA9]R;UR?9?(^1?!?;[]]P^N$C4?Z,'AH^
MX&^;FN[7Y4[E_=6 K:R$EEF!T%Z 2CZ!,R0_IY,(WOMJUEM@Z[&$'A;M?E>)
M>4UU]5VA<>OKUO8T(<?:]+74:@Q%UGHS7@OK39NO!61-]MM'43GNJ4M;R!R)
MS\=KKV=P7G<@;O0J$4R*%'0$'1/M!2(JB*@RB""B+<5SZYKLPH^D<]R3EQX
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M=:$T:8A[,(7?C4E]#*KNG-HVT5<'UU27>\7SKY>?_L<4ET34QZ^O\#/.-LW
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MV)[G-[,P_RV<7<S8"I(KYJ0EK]'66VQ:GB'3"N-12*^CM[[-)/$6S(SK\I^
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M'7=U]PQ[0]G!W3!MU-3G1>%U0$NB%<3U5!+(=-X#J8*C"E8Q,.T  /&B($\
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MO;PX+HSE9YK<B[K)O?A<D_NI\2>9Y-I_^%9@>DDPOH7X_P!02P$"% ,4
M"  &B0Y1RLK&I]T(  #C/P  %@              @ $     83(P,C!Q,BUE
M>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    (  :)#E''H0%YV0@  .P_   6
M          "  1$)  !A,C R,'$R+65X:&EB:70S,3(N:'1M4$L! A0#%
M  @ !HD.4>(+5NB$!0  K",  !8              ( !'A(  &$R,#(P<3(M
M97AH:6)I=#,R,2YH=&U02P$"% ,4    "  &B0Y1/6#RXO>! 0 -;!0 $0
M            @ '6%P  8W!I>"TR,#(P,#8S,"YH=&U02P$"% ,4    "  &
MB0Y1U#7\,!H,  #'>   $0              @ '\F0$ 8W!I>"TR,#(P,#8S
M,"YX<V102P$"% ,4    "  &B0Y1B8D7$(\=  "!- $ %0
M@ %%I@$ 8W!I>"TR,#(P,#8S,%]C86PN>&UL4$L! A0#%     @ !HD.45I,
MUV?.+@  MML! !4              ( !!\0! &-P:7@M,C R,# V,S!?9&5F
M+GAM;%!+ 0(4 Q0    (  :)#E$U&_660(X  (KE!0 5              "
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M;F1M96YT,F0N:'1M4$L! A0#%     @ !HD.4>7[(_T&&0  C%@  !P
M         ( !$.0" &5X:&EB:70Q,#,M9F]R;3$T-U\W,39B82YH=&U02P4&
2      P #  P P  4/T"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
